<SEC-DOCUMENT>0001564590-21-012588.txt : 20210311
<SEC-HEADER>0001564590-21-012588.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311172547
ACCESSION NUMBER:		0001564590-21-012588
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncternal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		21734353

	BUSINESS ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 434-1113

	MAIL ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GTX INC /DE/
		DATE OF NAME CHANGE:	20030822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>onct-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9417954+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:onct="http://www.oncternal.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
onct-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:EntityCentralIndexKey" contextRef="C_0001260990_20200101_20201231">0001260990</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:AmendmentFlag" contextRef="C_0001260990_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001260990_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001260990_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000293" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231">P3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000437" name="onct:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20190101_20191231">P4M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20201231" decimals="-6">0</ix:nonFraction>
			<ix:nonNumeric id="F_000319" name="onct:ResearchAgreementTerm" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000517" name="onct:PeriodForCumulativeChangeInOwnership" contextRef="C_0001260990_20200101_20201231">P3Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="C_0001260990_20200101_20201231" decimals="INF">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000405" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20180101_20181231">P3Y9M</ix:nonNumeric>
			<ix:nonNumeric id="F_000406" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20190101_20191231">P2Y9M</ix:nonNumeric>
			<ix:nonNumeric id="F_000407" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20200101_20201231">P4Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000423" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231">P8Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000424" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231">P8Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000425" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231">P8Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20200101_20201231">P6Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000456" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20190101_20191231">P6Y</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="onct-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001260990_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20210303">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_deiLegalEntityAxis_onctGTxIncMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">onct:GTxIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:MergerAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">onct:OncternalTherapeuticsIncAndGTxIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:MergerAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_onctsegment">
				<xbrli:measure>onct:segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-22</xbrli:startDate>
					<xbrli:endDate>2019-05-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:ChiefFinancialOfficerSonMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-05-01</xbrli:startDate>
					<xbrli:endDate>2016-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-01</xbrli:startDate>
					<xbrli:endDate>2017-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_onctCVR">
				<xbrli:measure>onct:CVR</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtConsolidatedEntitiesAxis_onctGTxIncMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:GTxIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;<ix:nonNumeric id="F_000002" name="dei:DocumentType" contextRef="C_0001260990_20200101_20201231">10-K</ix:nonNumeric></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="width:4.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:40%;text-indent:0pt;;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:95.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:40%;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.08%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.92%;">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000003" name="dei:DocumentPeriodEndDate" contextRef="C_0001260990_20200101_20201231" format="ixt:datemonthdayyearen">December&#160;31,<ix:nonNumeric id="F_000005" name="dei:DocumentFiscalYearFocus" contextRef="C_0001260990_20200101_20201231"> 2020</ix:nonNumeric></ix:nonNumeric></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="width:4.18%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:95.82%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(D)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000018" name="dei:EntityFileNumber" contextRef="C_0001260990_20200101_20201231">000-50549</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0001260990_20200101_20201231">Oncternal Therapeutics,&#160;Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.22%;"></td>
<td style="width:0.97%;"></td>
<td style="width:48.81%;"></td>
</tr>
<tr style="height:11.15pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001260990_20200101_20201231">62-1715807</ix:nonNumeric></p></td>
</tr>
<tr style="height:17.35pt;">
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or <span style="font-size:8pt;">other jurisdiction</span> of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine1" contextRef="C_0001260990_20200101_20201231">12230 El Camino Real</ix:nonNumeric>, <ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine2" contextRef="C_0001260990_20200101_20201231">Suite 300</ix:nonNumeric><br /><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001260990_20200101_20201231">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001260990_20200101_20201231">CA</ix:nonNumeric> <ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001260990_20200101_20201231">92130</ix:nonNumeric><br />(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001260990_20200101_20201231">858</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001260990_20200101_20201231">434-1113</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)<span style="font-size:3pt;font-weight:normal;">&#160;</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:8.65pt;">
<td valign="top" style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title&#160;of&#160;Each&#160;Class</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:25.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol (s)</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7pt;">&#160;</p></td>
<td valign="top" style="width:35.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name&#160;of&#160;Each&#160;Exchange&#160;on&#160;Which&#160;Registered</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:Security12bTitle" contextRef="C_0001260990_20200101_20201231">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:25.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:TradingSymbol" contextRef="C_0001260990_20200101_20201231">ONCT</ix:nonNumeric></p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:35.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000029" name="dei:SecurityExchangeName" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001260990_20200101_20201231">No</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001260990_20200101_20201231">No</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric id="F_000014" name="dei:EntityCurrentReportingStatus" contextRef="C_0001260990_20200101_20201231">Yes</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric id="F_000027" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001260990_20200101_20201231">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntitySmallBusiness" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr style="height:9.9pt;">
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span> &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000031" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined by Rule&#160;12b of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;Yes <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June&#160;30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000017" name="dei:EntityPublicFloat" contextRef="C_0001260990_20200630" decimals="-5" scale="6">27.2</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June&#160;30, 2020 of $2.84 per share.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of outstanding shares of the registrant&#8217;s common stock as of March 3, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000016" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001260990_20210303" decimals="INF" format="ixt:numdotdecimal">49,281,327</ix:nonFraction>.</p><ix:nonNumeric id="F_000210" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December&#160;31, 2020.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics,&#160;Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;10-K &#8212; ANNUAL REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the Fiscal Year Ended December&#160;31,&#160;2020</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:none;">PART I</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM1_BUSINESS"><span style="text-decoration:none;">Business</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:none;">Risk Factors</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:none;">Properties</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGSFROM_Q3_FORM_10Q"><span style="text-decoration:none;">Legal Proceedings</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART II</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA_MAY_NOT_B"><span style="text-decoration:none;">Selected Financial Data</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 8.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENT_OR_SUPPLEMENT"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9A.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9B.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:none;">Other Information</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:none;">PART III</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 10.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 11.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 12.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"><span style="text-decoration:none;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART IV</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p></td>
</tr>
<tr>
<td valign="top" style="width:10.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:84.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:94.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:none;">Signatures</span></a></p></td>
<td valign="top" style="width:5.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART&#160;I</p>
<p style="margin-top:11pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form&#160;10-K, or this Annual Report, including the sections entitled &#8220;Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business,&#8221; contains forward-looking statements. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes, to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain regulatory approvals for our product candidates</span><span style="color:#000000;">, including cirmtuzumab and TK216&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">our ability to identify and advance into the clinic product candidates from our ROR1-targeted CAR-T therapy program</span><span style="color:#000000;">&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the expected timing for achieving key milestones, including </span><span style="color:#000000;">commencing, </span><span style="color:#000000;">completing and announcing clinical trial results of </span><span style="color:#000000;">our product candidates</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing or likelihood of regulatory filings and approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the estimated size of the patient population and anticipated market potential for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the impact of products that compete with our product candidates that are or may become available&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain favorable regulatory designations for our product candidates and preclinical programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing upon the intellectual property rights of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">our commercialization, marketing and reliance on third-party manufacturing capabilities and strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the impact the COVID-19 pandemic has had on our business and the U.S and global economies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the plans and objectives of management for future operations and future results of anticipated products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing. </span></p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We qualify all of the forward-looking statements in this Annual Report by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SUMMARY OF RISK FACTORS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing in our common stock is subject to numerous risks and uncertainties, including those described in Part I, Item 1A, &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K. The principal risks and uncertainties affecting our business include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The COVID-19 outbreak may adversely impact our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We depend heavily on the success of cirmtuzumab and TK216, which are in Phase 1 or Phase 1/2 clinical trials, as well as our ROR1 CAR-T program, which is in preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not be able to maintain orphan drug designations for certain of our product candidates, and may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fast Track designation by the FDA for TK216 or our other product candidates may not actually lead to a faster development or regulatory review or approval process.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to good laboratory practices, GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM1_BUSINESS">Business.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Our development efforts are focused on promising, yet untapped, biological pathways implicated in cancer generation or progression. Our pipeline includes cirmtuzumab, an investigational monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance. Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma, or CIRLL) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma, or MCL, and chronic lymphocytic leukemia, or CLL, and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. We are also developing a chimeric antigen receptor T cell, or CAR-T, therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, we are developing TK216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins. ETS alterations have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. TK216 is being evaluated in a Phase 1 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Food and Drug Administration, or FDA, has granted orphan drug designations for cirmtuzumab for the treatment of MCL and for the treatment of CLL/small lymphocytic lymphoma, and has granted rare pediatric disease designation, as well as orphan drug and fast track designations for TK216 for the treatment of Ewing sarcoma.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab is an investigational, humanized, potentially first-in-class, ROR1 monoclonal antibody that is designed to bind to a specific functionally important epitope of ROR1. ROR1 is a protein expressed on many tumors, and is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, a protein typically expressed during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 overexpression in multiple tumor types, including MCL, CLL and breast cancer, has been associated with more aggressive disease, resistance to therapy and shorter progression-free survival, or PFS, and overall survival, or OS. In preclinical models, inhibition of ROR1 has shown anti-tumor activity, and we believe may have additive or synergistic effects when combined with either targeted therapy or chemotherapy. Preclinical data indicated that when cirmtuzumab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Cirmtuzumab was developed in the laboratory of one of our scientific advisors, Professor Thomas Kipps, M.D., Ph.D., Professor of Medicine and Evelyn and Edwin Tasch Chair in Cancer Research at the University of California San Diego, or UC San Diego, with support from the California Institute for Regenerative Medicine, or CIRM. We have an exclusive, worldwide license to develop cirmtuzumab for certain therapeutic uses from UC San Diego. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we presented updated interim data from the CIRLL trial in patients with MCL and CLL at the American Society for Hematology 2020 Virtual Meeting, or ASH 2020 annual meeting. The combination of cirmtuzumab plus ibrutinib has been well tolerated, with adverse events consistent with those reported for ibrutinib alone. To date, there have been no dose-limiting toxicities and no serious adverse events attributed to cirmtuzumab alone.&#160;&#160;As of the data cut-off date of October 30, 2020, 15 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of this clinical trial were evaluable for efficacy. The objective response rate, or ORR was 87% (13 of 15 evaluable patients), improved over the 83% ORR reported at the <span style="color:#000000;">ASCO Annual Meeting in May 2020, or </span>ASCO 2020 annual meeting. The complete response rate, or CR, determined by Cheson </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">criteria, remained 57% (7 of 12 evaluable patients) for Part 1 of the study, and was 47% (7 of 15 evaluable patients) for Part 1 + Part 2, including three patients from Part 2 who had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been on the study for a relative</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> brief time</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as compared to other patients</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. One of the seven patients </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with CR </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had a complete metabolic response as assessed by PET scan, with an indeterminate bone marrow biopsy on blinded review. All complete responses</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> durable, ranging from 5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 months as of the cutoff date, with no progressions reported after achieving a CR. Six patients (40%) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">achieved a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partial response, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PR.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In addition</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, two patients had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stable disease, or SD</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, for a total best clinical benefit rate (CR, PR and SD) of 100%. Median</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PFS was not reached, with the 95% confidence interval above 17.5 months, after a median follow-up of 12.1 months. Patients had received a median of two prior therapies (range 1-5) before participating in this clinical trial, with 73% of patients </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">having received</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> two or more prior lines of therapy. Four patients had received prior treatment with ibrutinib and all four achieved clinical responses in this clinical trial, with two CRs and two PRs. Fourteen of the 15 evaluable patients (93%) had high or intermediate MIPI-b risk score at study entry. Historical data for 370 patients with relapsed/refractory MCL</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from three clinical trials</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> who had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received a median of two prior therapies</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Rule et al., 2017, British Journal of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Haematology</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">showed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an ORR of 66%, CR rate of 20%, and median PFS of 12.8 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95% confidence interval </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.5 &#8211; 16.6 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) for single agent ibrutinib in patients with MCL. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, as of the data cut-off date of October 30, 2020, 56 evaluable patients with CLL were enrolled in the dose-finding, dose-confirming and randomized cohorts of this clinical trial, 49 of whom were treated with the combination of cirmtuzumab and ibrutinib. Forty-five of the 49 patients achieved a clinical response, for an overall best ORR of 92%, including one patient who achieved a CR. In addition, four patients had SD, for a total clinical benefit rate (CR, PR, and SD) of 100%. The median PFS was not reached for patients with treatment-na&#239;ve CLL (n&#61;19) after a median follow-up of 16.6 months, and median PFS was 29.5 months for patients with relapsed/refractory CLL (n&#61;30) after a median follow-up of 17.1 months. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to announce a data update from this Phase 1/2 clinical trial in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab is also being evaluated in an investigator-sponsored Phase 1b clinical trial in combination with paclitaxel in patients with HER2 negative breast cancer. We expect to announce interim data from this Phase 1b clinical trial in the second quarter of 2021.&#160;&#160;We are also supporting a new investigator-sponsored Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL in collaboration with UC San Diego, which is open and enrolling patients. Additionally, we plan to further explore clinical combination strategies for cirmtuzumab for patients with hematologic malignancies. We also continue to evaluate the use of cirmtuzumab in additional ROR1-expressing tumors and expect to announce data from additional preclinical studies in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also developing a ROR1-targeted CAR-T cell therapy candidate utilizing the binding domain of cirmtuzumab as a single-chain variable region fragment, or scFv, as a potential treatment for patients with aggressive hematological malignancies or solid tumors. Because cirmtuzumab has been shown to bind to multiple cancers but not to normal adult tissues in preclinical studies, we believe that a cirmtuzumab-based CAR-T may be selective in distinguishing cancer from normal tissues. Our preclinical ROR1-targeted CAR-T cell therapy candidate was developed in collaboration with UC San Diego, with funding support from CIRM, and is being further developed in collaboration with the Karolinska Institutet in Stockholm, Sweden and under a manufacturing agreement with Lentigen Technology, Inc., or Lentigen, to produce clinical-grade lentivirus. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shanghai Pharmaceuticals Holding Co., Ltd., or SPH, has the right to develop a ROR-1 targeted CAR-T therapy in greater China, and we are collaborating with them in this effort. SPH recently announced breaking ground on a 3.2 million square foot biotech park in Shanghai that will include R&#38;D facilities and manufacturing facilities for CAR-T.&#160;&#160;We expect the first-in-human dosing of our ROR1-targeted CAR-T cell therapy in China in the second half of 2021 in collaboration with SPH. In parallel, we are continuing preclinical development activities in the U.S. and Europe.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216 is an investigational, potentially first-in-class, targeted small molecule that is designed to specifically inhibit the biological activity of the ETS family of oncoproteins. Tumorigenic gene fusions involving ETS factors are frequently found in tumors such as Ewing sarcoma and prostate cancer, and ETS proteins are often overexpressed in other tumors, such as acute myeloid leukemia, or AML, and diffuse large B-cell lymphoma, or DLBCL. Researchers in the laboratory of Professor Jeffrey Toretsky, M.D., at </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Georgetown Lombardi Comprehensive Cancer Center, identified the precursor to TK216 using a novel chemical screening assay they developed based on a deep understanding of the underlying biological mechanism of ETS factors. Following this early work, TK216, which is designed to be a specific inhibitor of ETS factors, was created by us through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction. In preclinical models, TK216 inhibited the interaction between ETS family members and RNA helicase A, or RHA, and by doing so, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inhibited</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> excessive cell proliferation. We own intellectual property related to TK216 and have an exclusive license to product candidates targeting ETS oncoproteins for therapeutic, diagnostic or research tool purposes from Georgetown University.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating TK216 as a single agent and in combination with vincristine in <span style="color:#000000;">an open-label, multicenter</span> Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma. <span style="color:#000000;">Ewing sarcoma is a rare pediatric cancer that has historically been very challenging to treat effectively, particularly for recurrent and metastatic disease. ETS fusion proteins have been shown to be present in over 90% of Ewing sarcoma cases. </span>The dose-finding portion of the study was completed in 2019, and we <span style="color:#000000;">continue to enroll</span> patients in the Phase 2 expansion cohort to evaluate the clinical response of treatment with TK216 in combination with vincristine using the recommended Phase 2 dose<span style="color:#000000;">, or RP2D, regimen. The RP2D has been established to be 200 mg/m2/day of TK216 for 14 days, with vincristine 0.75 mg/m2 on the first day of each 28 day treatment cycle. In November 2020, we announced updated interim clinical data from our ongoing open-label, multicenter Phase 1/2 clinical trial evaluating TK216 in patients with relapsed or refractory Ewing sarcoma. Patients entering the trial had previously been treated with a median of three, and as many as eight prior lines of systemic therapy. The presentation included interim data for 50 evaluable patients, including 23 evaluable patients treated at the RP2D as of the October 16, 2020 efficacy cut-off date. Two of the 23 patients treated at the RP2D (9%) achieved a CR, including one surgical CR. Both patients achieving CRs remain on treatment, with no evidence of disease, at 1.5 years and 8 months on study as of the cutoff date. The best ORR was 9%. Eight additional patients treated at the RP2D had SD, for a disease control rate (CR, PR or SD) of 43%. The median progression-free survival for patients treated at the RP2D was 1.8 months.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216 has been generally well tolerated in this trial. As of the October 2, 2020 safety cut-off date, the most common drug-related adverse events included myelosuppression, fatigue, alopecia, nausea, pyrexia and decreased appetite. Dose limiting toxicities consisted of transient and manageable myelosuppression, primarily neutropenia. No unexpected off-target toxicities have been observed. We expect to announce interim data from the Phase 1/2 expansion cohort as well as preclinical data in additional ETS-driven tumors in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmacokinetic data from the clinical trial showed that TK216 drug levels at the RP2D exceeded plasma levels associated with anti-tumor activity in preclinical models.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have assembled a management team, board of directors and scientific founders who have significant experience in successfully developing and commercializing therapeutics in oncology and orphan diseases, having worked or served on the Board of companies such as Amgen, Inc., Bavarian Nordic, Inc. (lead cancer asset acquired by Bristol Meyers Squibb Company), Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt plc), Dynavax Technologies Corporation, Elan Corporation (acquired by Perrigo), Eli Lilly and Co., Gilead Sciences, Inc., Innocrin Precision Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck, Micromet, Inc. (acquired by Amgen, Inc.), Pfizer, Inc., Roche Holding AG, Sorrento Therapeutics, Inc., Tracon Pharmaceuticals, Inc., and Zavante Therapeutics, Inc. (acquired by Nabriva Therapeutics plc).</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our strategy</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs. We believe our investigational agents target novel cancer pathways and have unique mechanisms of action. Our current pipeline is derived from our ability to identify therapeutic candidates that have generated promising, late-stage preclinical results or early clinical data, and in-license them for further development. We are particularly focused on therapeutic approaches for which there is a genetic or protein biomarker that can be used to identify populations of patients most likely to respond. We prioritize targets that we believe have the potential to transform the treatment paradigm of difficult-to-treat cancers with either single agent or combination therapy. As is the case for many oncology products, we believe that potential efficacy in one indication suggests the potential for application in other indications that carry the same target.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key elements of our strategy are as follows:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">advance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">cirmtuzumab</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">through</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">development in multiple indications,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">with a primary focus</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">MCL</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.15pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0.15pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">advance our ROR1-targeting CAR-T cell therapy candidate into clinical development, initially in hematological cancers and then in solid tumors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">evaluate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cirmtuzumab preclinically</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">additional</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">ROR1-positive</span><span style="letter-spacing:-0.1pt;color:#000000;"> solid </span><span style="color:#000000;">tumors</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">lung,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">ovarian and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">prostate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cancers, as well as in additional hematological malignancies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance TK216 in combination with vincristine for the treatment of relapsed/refractory Ewing sarcoma through clinical development, including completion of the ongoing Phase 1/2 clinical trial&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:0.15pt;color:#000000;">evaluate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">TK216</span><span style="letter-spacing:0.05pt;color:#000000;"> preclinically </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">additional</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tumors</span><span style="letter-spacing:-0.3pt;color:#000000;"> with ETS fusion proteins or overexpression, </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">prostate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cancer, lymphoma and AML.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pipeline</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following figure summarizes our current programs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000001.jpg" title="" alt="" style="width:508px;height:262px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken action in an effort to slow the spread of COVID-19, including issuing and modifying varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have put restrictions on employee travel and working from our executive offices, with many employees continuing their work remotely. To date, we have been able to continue to supply cirmtuzumab and TK216 clinical trial sites for patients enrolled in our ongoing clinical trials and do not currently anticipate any interruptions in the supply of cirmtuzumab or TK216. While we are continuing the clinical trials we have underway in sites across the U.S., we expect that COVID-19 precautions may continue to directly or indirectly impact the timeline for some of our clinical trials. For example, some of our clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Patients with MCL or CLL may be at increased risk of severe disease if they develop COVID-19 because of advanced age and/or immunosuppression, and so may be unwilling to travel to our study centers to enroll in our clinical trials. For our existing patients, we are actively working with all of our clinical trial sites to minimize disruptions and address concerns on an individual site or patient basis in order to allow participating patients to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to receive treatment at home or in alternative healthcare settings while minimizing their potential exposure to the virus that causes COVID-19. If restrictions related to the COVID-19 pandemic continue for a prolonged period of time or if additional clinical trial sites pause patient enrollment or treatments, our clinical trial milestones would be negatively impacted. Any delays in the completion of our clinical trials and any disruption in our supply chain could have a material adverse effect on our business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the success or failure of vaccination programs, the emergence of new variants of COVID-19, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as well as the economic impact on local, regional, national and international markets.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab - monoclonal antibody targeting ROR1</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab scientific background: inhibition of ROR1 as a therapeutic strategy in cancer</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROR1 is an onco-embryonic protein essential for normal fetal development whose expression is suppressed in adults unless reactivated as a survival factor by many different cancers. The switching-on of ROR1 is consistent with a pattern in cancer, in which normal cells lose their highly differentiated functions and return to a more primitive state, where they exhibit a greatly increased capacity for invasion, metastasis and resistance to treatment. This de-differentiation is associated with expression of a number of genes normally restricted to fetal development, one of which is ROR1. Cancer cells with the highest potential for self-renewal are sometimes referred to as tumor-initiating cells or cancer stem cells and are capable of invading other tissues or metastasizing to form tumors in distant sites in the body. These tumor-initiating cells are also the cells that have been found to be the most resistant to standard cancer therapies including chemotherapy and radiation therapy. Cancer cells that overexpress ROR1 have been shown to have increased survival, migration and resistance to chemotherapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over-expression of ROR1 has been reported in multiple hematological and solid tumor types. Histological staining of over 350 human tumor samples identified that a majority expressed ROR1, including 90% or more of uterine cancers, lymphomas and prostate cancers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cancer type</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expressed (%)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cancer type</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expressed (%)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uterus</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adrenal</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCL</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#62;95%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLL</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphoma</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Testicular</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Colon</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Skin</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovarian</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54%</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pancreas</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bladder</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43%</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High ROR1 expression on patients&#8217; tumor cells in a variety of cancers is associated with the development of metastases, and early relapse after therapy. ROR1 expression levels on patients&#8217; tumor cells is higher in cancers that are more advanced or poorly differentiated. For example, whereas Grade 1 or 2 ovarian tumors were found to be 21% positive for ROR1, Grade 3 or 4 tumors were found to be 62% positive for ROR1. Similar patterns in the percentage of ROR1-positive tumors were seen in pancreatic cancers, with 54% of Grade 1 or 2 tumors and 100% of Grade 3 or 4 tumors testing positive for ROR1 by immunohistochemistry. High expression of ROR1 has been associated with more aggressive disease and shorter patient survival in multiple tumor types, including CLL, breast cancer and ovarian cancer. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inhibition of ROR1 signaling or silencing ROR1 in multiple preclinical cancer models, including breast cancer, ovarian cancer and glioblastoma, was associated with suppressing the expression of genes characteristic of tumor-initiating cells, and with repression of cancer migration and metastasis. Preclinical models have also demonstrated that inhibition of ROR1, or blocking of Wnt5a-induced signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells &#8211; resulting in fewer metastases and improved survival. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inhibition of ROR1 has been demonstrated in preclinical models to be additive to, or synergistic with, chemotherapy agents such as paclitaxel, and with targeted therapy agents such as ibrutinib and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venetoclax</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, inhibition of ROR1 has been shown to enhance sensitivity of cancer cells to targeted therapy with agents such as erlotinib and may increase apoptosis and decrease proliferation. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In summary, we believe that ROR1 is an attractive therapeutic target in oncology for several reasons:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ROR1 is widely expressed </span><span style="letter-spacing:0.15pt;color:#000000;">on </span><span style="color:#000000;">many tumors, </span><span style="letter-spacing:0.2pt;color:#000000;">including </span><span style="letter-spacing:0.15pt;color:#000000;">hematological malignancies </span><span style="letter-spacing:0.1pt;color:#000000;">and solid </span><span style="color:#000000;">tumors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Expression of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">high</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">levels</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">ROR1</span><span style="letter-spacing:0.1pt;color:#000000;"> on patients&#8217; tumors is </span><span style="color:#000000;">associated with</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rapid</span><span style="letter-spacing:0.05pt;color:#000000;"> disease </span><span style="color:#000000;">progression, resistance to therapy</span><span style="letter-spacing:0.1pt;color:#000000;"> and</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">shorter</span><span style="letter-spacing:-0.45pt;color:#000000;"> patient </span><span style="letter-spacing:0.1pt;color:#000000;">survival&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Blocking of ROR1 in preclinical models inhibited tumor cell proliferation, migration and survival, and induced differentiation of the tumor cells&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Inhibition of ROR1 has been observed in preclinical models to be synergistic with chemotherapy and targeted therapy&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Clinical data presented for a ROR1-targeting antibody-drug conjugate (ADC) presented at the ASH 2020 annual meeting did not reveal any unusual off-tumor organ toxicity.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two notable acquisitions in 2020 involved companies developing product candidates targeting ROR1: Merck &#38; Co. acquired VelosBio, Inc. and its ROR1-targeting ADC, and Boehringer-Ingelheim acquired NBE Therapeutics and its ROR1-targeting ADC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab development in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MCL disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MCL is an aggressive form of non-Hodgkin&#8217;s lymphoma. There are approximately 4,200 new cases of MCL each year in the U.S., with the average age at diagnosis in the mid-60s. MCL is an aggressive lymphoma and carries a poor prognosis, with a median survival of about two to five years. The 10-year survival rate is only approximately 5-10%. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are several therapeutic options available to treat patients with relapsed or refractory MCL, none of these options offers long-term benefit, with most patients relapsing in less than 20 months. Inhibitors of Bruton&#8217;s Tyrosine kinase, or BTK, such as ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) are emerging as a standard of care in patients who have failed other therapies. These therapies are given continuously for prolonged periods of time, and their use can be associated with significant toxicity. The majority of patients with MCL are older, and remissions are not durable for most patients treated with continuous ibrutinib therapy. As a result, we believe that more effective and better tolerated therapies with shorter treatment periods represent a significant unmet need.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CLL disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CLL is the most common form of leukemia in adults, accounting for 25-30% of all leukemias in the U.S. An estimated 20,720 new cases of CLL were expected to occur in the U.S. in 2019, and in 2016 the prevalence of CLL in the U.S. was estimated to be 178,000 patients. CLL is primarily a disease of older adults. The median age at diagnosis is 71 years of age. Most patients are diagnosed as a result of routine blood work when elevated levels of lymphocytes are detected.</p>
<p style="margin-top:10pt;margin-bottom:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BTK inhibitor therapy has also emerged as a standard of care for CLL, and is increasingly used as first-line therapy. Patients with CLL can enjoy a substantial period of disease control, but the disease eventually recurs, and is more likely to do so for patients with previous CLL therapy, and if certain risk factors such as high simplified MCL international prognostic index (sMIPI), presence of bulky disease, and blastoid histology. The trade-off of these newer targeted therapies is the paradigm of continuous treatment required for BTK inhibitors, resulting in accumulating costs and toxicities. Adverse events have been shown in a real-world analysis to limit ibrutinib treatment duration for almost half of all patients. An acceptable safety profile may be particularly important for patients with CLL who are older (the median age at diagnosis is 71) and have multiple co-morbidities.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market for CLL therapies in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, France, Germany, Italy, Spain, the UK, and Canada is estimated to be approximately $8 billion, largely driven by recently approved therapies, including ibrutinib, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">venetoclax</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">idelalisib</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We believe that CLL represents an attractive clinical and commercial opportunity for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab preclinical summary in MCL and CLL</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROR1 is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, which is a protein typically expressed during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 is over-expressed in many different cancers, including MCL, CLL and breast cancer, and has been reported to be associated with more aggressive disease, resistance to therapy and shorter PFS and OS. In preclinical models, inhibition of ROR1 has shown anti-tumor activity and we believe may have additive or synergistic effects when combined with other agents.<sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab is an investigational, humanized monoclonal antibody, or mAb, designed to bind to a specific functionally important epitope of ROR1. The ligand for ROR1 in hematologic malignancies is Wnt5a, a secreted glycoprotein that has a critical role in embryonic and fetal development. Researchers at the UC San Diego School of Medicine discovered that targeting a critical epitope on ROR1 was key to inhibiting Wnt5a activation, specifically targeting ROR1 expressing tumors. This led to the development of cirmtuzumab, which binds this critical epitope of ROR1.  Cirmtuzumab was developed in the laboratory of one of our scientific advisors, Thomas Kipps, M.D., Ph.D., Professor of Medicine and Evelyn and Edwin Tasch Chair in Cancer Research at UC San Diego with support from CIRM. We have an exclusive, worldwide license to develop cirmtuzumab for certain therapeutic uses from UC San Diego. Unlike antibodies that bind to other epitopes of ROR1, cirmtuzumab was not observed to bind to normal adult tissues in a Good Laboratory Practice, or GLP, tissue cross-reactivity study.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Studies in mice have shown that ROR1 expression on tumor cells accelerated the development and progression of leukemia in models of CLL, and that Wnt5a enhanced CLL cell viability, migration and proliferation in a ROR1-dependent manner. Patients with high levels of ROR1 on their CLL cells have more aggressive disease and have a significant reduction in survival. An analysis of MCL and CLL patient samples has shown that ROR1 surface expression, as well as secreted Wnt5a levels, were comparable between patients with MCL and CLL. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies showed that when cirmtuzumab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Preclinical studies with cirmtuzumab showed that treating MCL or CLL patient&#8217;s tumor cells with a combination of cirmtuzumab and ibrutinib led to reduced proliferation.  <span style="font-style:italic;">In vivo </span>studies conducted in mouse CLL models have shown that ibrutinib and cirmtuzumab exerted antitumor activities through independent pathways&#59; that is, inhibition of BTK by ibrutinib did not alter ROR1 signaling nor did it impair the rate at which cirmtuzumab blocked ROR1 signaling. The combination of both drugs reduced the size of the spleen, the primary site of leukemic disease in these mice, as well as the number of CLL cells in these spleens. Further preclinical studies suggested that cirmtuzumab was synergistic with venetoclax <span style="font-style:italic;">in vitro</span>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab clinical development in MCL and CLL </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cirmtuzumab Phase 1 clinical trial in patients with CLL</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 dose escalation clinical trial of cirmtuzumab, which was funded jointly by us, CIRM, and others, was conducted in 26 patients with actively progressing CLL who had relapsed or refractory disease. Patients received four doses of cirmtuzumab administered every two weeks in cohorts of three, with each patient receiving escalating doses from 0.15 to 20 mg/kg/dose. Cirmtuzumab infusions were generally well tolerated. There were no dose-limiting toxicities, no serious adverse events, and no discontinuations related to adverse events. The most common adverse events included anemia, thrombocytopenia, and neutropenia, which were primarily attributed to the underlying CLL. Pharmacokinetic data showed a plasma half-life of approximately 32 days following four doses of cirmtuzumab at 16 mg/kg. In this clinical trial, 22 patients were evaluable for response assessment&#59; four patients who discontinued cirmtuzumab early without meeting criteria for progressive disease were not considered evaluable. No patients met criteria for complete or partial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remission following this brief treatment. Seventeen of 22 evaluable patients had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SD</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Five patients had progressive disease. Most patients experienced reductions in their leukemic lymphocyte counts and were able to delay initiation of further treatments for an average of 262 days, at which point plasma levels of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were undetectable. Although </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapy was limited to four doses, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one patient who received </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at 20 mg/kg had a greater than 50% reduction in lymphadenopathy. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Analysis of blood samples from these patients </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to treatment </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">showed significantly higher plasma levels of Wnt5a compared to healthy matched controls. Patients also had high levels of expression of ROR1 on their CLL cells. In addition, when compared to baseline, cells from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> treated patients showed a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduction</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expression of a panel of genes</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> identified as being highly correlated with stem cells and oncogenic dedifferentiation. These results were consistent with other preclinical observations that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">induced ROR1 inhibition </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may drive</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cells away from a stem-cell-like profile.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cirmtuzumab Phase 1/2 clinical trial in combination with ibrutinib in patients with MCL and CLL </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and UC San Diego, with major funding from the California Institute for Regenerative Medicine, or CIRM and a donation of ibrutinib product from Pharmacyclics LLC, are conducting a Phase 1/2 trial of cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory MCL, or patients with CLL who are either relapsed/refractory or treatment-na&#239;ve (the CIRLL Study). This clinical trial was designed to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of cirmtuzumab in combination with ibrutinib in adult subjects with adequate performance status and organ function. The&#160;study has three parts:&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 1</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;">is a Phase 1b, open-label, sequential allocation, dose-finding evaluation of the administration of cirmtuzumab monotherapy followed by cirmtuzumab/ibrutinib combination therapy in subjects with CLL or relapsed/refractory MCL&#59;&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 2</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;">is an open-label dose-confirming or expansion evaluation of the concurrent administration of cirmtuzumab and&#160;ibrutinib in CLL or MCL using the recommended cirmtuzumab dose regimen derived from Part 1&#59; and&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.2%;text-indent:-6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Part 3</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;">is a Phase 2 open-label, randomized, controlled evaluation of the clinical activity and safety of cirmtuzumab plus ibrutinib versus ibrutinib alone in patients with CLL.</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We have completed enrollment of patients with CLL in Parts 1 and 2, and those patients are completing therapy or are in long-term follow-up. Following an evaluation of safety and PK data from Part 1, the recommended dose regimen, or RDR, of cirmtuzumab for Part 2 was determined to be 600 mg of cirmtuzumab administered intravenously every two weeks for three doses, followed by dosing every four weeks until disease progression or intolerance develop. This cirmtuzumab regimen was designed and chosen to be used in combination with 420 mg of ibrutinib administered once daily for patients with CLL, or 560 mg of ibrutinib once daily for patients with MCL, which are the FDA-approved doses of ibrutinib in these indications. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab CIRLL clinical trial Part 1 interim data in MCL</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In June 2020, we announced an updated clinical strategy for cirmtuzumab that prioritizes development in MCL, based on encouraging interim clinical results from the CIRLL Phase 1/2 clinical trial that were presented at the ASCO 2020 annual meeting. As a result, we amended the CIRLL study to increase the number of patients with relapsed/refractory MCL to be enrolled in the Phase 2 expansion cohort to at least 20 patients and to allow the enrollment of patients with a broader range of prior Bruton&#8217;s tyrosine kinase inhibitor treatments. In addition, we limited the total enrollment of CLL patients in the randomized Part 3 of the CIRLL study to 28 patients, in order to focus resources on the MCL portion of the study. In September 2020, we met with the FDA to discuss potential accelerated approval pathways for cirmtuzumab plus ibrutinib in patients with relapsed/refractory MCL, and are in an ongoing dialogue with them.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we presented updated interim data from the CIRLL trial in patients with MCL and CLL at the ASH 2020 annual meeting. The combination of cirmtuzumab plus ibrutinib has been well tolerated, with adverse </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-top:10pt;margin-bottom:0pt;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">events consistent with those reported for ibrutinib alone. There have been no dose-limiting toxicities and no serious adverse events attributed to </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> alone.</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of the data cut-off date of October 30, 2020, 15 patients with relapsed/refractory MCL enrolled in the dose-finding and dose-expansion cohorts of this clinical trial were evaluable for efficacy. The ORR was 87% (13 of 15 evaluable patients), improved over the 83% ORR reported at the ASCO </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">annual meeting. The CR rate, determined by </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cheson</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> criteria, remained 57% (7 of 12 evaluable patients) for Part 1 of the study, and was 47% (7 of 15 evaluable patients) for Part 1 + Part 2, including three patients from Part 2 who had </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">been on the study for a relative</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> brief time</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> as compared to the other patients</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. One of the seven patients </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">with a CR </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">had a complete metabolic response as assessed by PET scan, with an indeterminate bone marrow biopsy on blinded review. All complete responses remained durable, ranging from 5</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> to </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25 months as of the cutoff date, with no progressions reported after achieving a CR. Six patients (40%) achieved a PR. In addition, two patients had SD, for a total best clinical benefit rate (CR, PR and SD) of 100%. Median</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PFS was not reached, with the 95% confidence interval above 17.5 months, after a median follow-up of 12.1 months. Patients had received a median of two prior therapies (range 1-5) before participating in this clinical trial, with 73% of patients </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">having received</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> two or more prior lines of therapy. Four patients had received prior treatment with ibrutinib and all four achieved clinical responses in this clinical trial, with two CRs and two PRs. Fourteen of the 15 evaluable patients (93%) had high or intermediate MIPI-b risk score at study entry. Historical data for 370 patients with relapsed/refractory MCL</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> from three clinical trials</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> who had </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">also </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">received a median of two prior therapies</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Rule et al., 2017, British Journal of </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Haematology</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">showed</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> an ORR of 66%, CR rate of 20%, and median PFS of 12.8 months</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">95% confidence interval </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.5 &#8211; 16.6 months</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">) for single agent ibrutinib in patients with MCL. Results from the ASH 2020 annual meeting poster presentation for patients with MCL treated with </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> plus ibrutinib are shown in the two figures below. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000002.jpg" title="" alt="" style="width:623px;height:336px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 1. Individual patient response over time in the MCL cohort, based on investigator assessments, in the CIRLL clinical trial of cirmtuzumab in combination with ibrutinib as of October 30, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note: Bars represent response status of patients on treatment&#59; arrows indicate that a patient continues on treatment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000003.jpg" title="" alt="" style="width:362px;height:344px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 2. Progression-free survival in the MCL cohort in the CIRLL clinical trial of cirmtuzumab in combination with ibrutinib, as of October 30, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab CIRLL clinical trial interim data in CLL</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combination of cirmtuzumab plus ibrutinib has been well tolerated, with adverse events consistent with those reported for ibrutinib alone. There have been no dose-limiting toxicities and no serious adverse events attributed to cirmtuzumab alone.&#160;&#160;As of the data cut-off date of October 30, 2020, 56 evaluable patients with CLL were enrolled in the dose-finding, dose-confirming and randomized cohorts of this clinical trial, 49 of whom were treated with the combination of cirmtuzumab and ibrutinib. Forty-five of the 49 patients achieved a clinical response, for an overall best objective response rate of 92%, including one patient who achieved a CR. In addition, four patients had SD, for a total clinical benefit rate (CR, PR, and SD) of 100%. The median PFS was not reached for patients with treatment-na&#239;ve CLL (n&#61;19) after a median follow-up of 16.6 months, and median PFS was 29.5 months for patients with relapsed/refractory CLL (n&#61;30) after a median follow-up of 17.1 months. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000004.jpg" title="" alt="" style="width:298px;height:282px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3. Progression-free survival in the CLL cohort in Phase 1/2 clinical trial of cirmtuzumab in combination with ibrutinib, as of October 30, 2020.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-right:1.3%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:3pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to announce a data update from this Phase 1/2 clinical trial in the second quarter of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab development in breast cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Breast cancer disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast cancer is the most common type of invasive cancer among women and the second leading cause of cancer deaths among women. There are approximately 266,000 new diagnoses and 41,000 breast cancer deaths in the U.S. each year, and 12.4% of women will develop breast cancer in their lifetime. The Centers for Disease Control and Prevention, or CDC, estimates that there are approximately one million women in the U.S. living with breast cancer that has been diagnosed within the past five years.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast cancers can be segregated into subtypes based upon the presence of three protein receptors: estrogen receptor</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ER, </span><span style="letter-spacing:0.1pt;">progesterone </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receptor</span><span style="letter-spacing:-1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.1pt;"> human</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">epidermal growth</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factor</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">receptor</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">2</span><span style="letter-spacing:0.15pt;">, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HER2. Therapies have been developed that target tumors containing one or more of these receptors. Approximately 10% to 15% of breast cancers, however, do not express any of these three receptors and are referred to as triple-negative breast cancers, or TNBC. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. The five-year survival rate for patients with breast cancer other than TNBC has been reported to be 80.8%, but only 62.1% for patients with TNBC. One hypothesis for the high rate of metastasis and poor response to chemotherapy for patients with TNBC is that these tumors contain a high number of tumor-initiating cells, or cancer stem cells, that are highly migratory and insensitive to standard chemotherapy. Treatment options for TNBC are limited and include chemotherapy, targeted therapy (such as PARP inhibitors), surgery, radiation, and immunotherapy. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or Her2-negative aggressive breast</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancers, an unmet medical need exists for new breast cancer therapies that can target rapidly</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proliferating cancer cells and target cancer stem cells, with minimal damage to normal tissues.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ROR1 Expression and Historical Clinical Outcomes in Patients with Breast Cancer</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approximately 75% of breast tumors have been shown to express ROR1. In a retrospective analysis, patients with TNBC with high levels of ROR1 were found to have a significantly reduced disease-free survival (p&#60; 0.00015) as well as OS (p&#60;0.026) compared to patients with low ROR1 levels. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000005.jpg" title="" alt="" style="width:257px;height:137px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 4. TNBC patients with high levels of ROR1 expression had lower disease-free survival.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:2.59%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Another retrospective, long-term analysis that included all breast cancer types showed that patients with tumors expressing high levels of ROR1 were at a statistically significantly higher risk of developing metastases within the first several years. Over 60% of patients with high ROR1 developed metastases, compared to only 35% of patients with the lowest levels of ROR1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000006.jpg" title="" alt="" style="width:266px;height:147px;" />&#160;&#160;&#160;&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 5. High levels of ROR1 in breast cancer were associated with shorter metastasis-free survival.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical experiments have shown that treatment of breast tumors with paclitaxel increased the percentage of cells with high levels of ROR1. In these experiments, immunodeficient mice were implanted with patient-derived xenografts, or PDX, then were treated with paclitaxel. While paclitaxel either slowed tumor growth or reduced the size of tumors in these mice, the surviving cells were enriched for expression of ROR1. This increased expression of ROR1 was also associated with a shift in the properties of cells from these </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tumors towards a more metastatic and more tumorigenic phenotype. Cells from tumors that had been treated with paclitaxel were more likely to form spheroids in tissue culture and were enriched for cells with the ability to form new tumors when transplanted, both properties that are correlated with tumor aggressiveness.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a preclinical model, cirmtuzumab reduced the growth rate of primary human breast cancers in immunodeficient mice and led to complete suppression of tumor growth for twenty days when used in combination with paclitaxel. Even after tumors did eventually grow, they lacked the ability to form new tumors. All tumor samples isolated from control mice, most of the tumor samples from paclitaxel-treated mice, and some of the cirmtuzumab-treated mice were able to establish new tumors when transplanted into other mice. No tumors, however, were formed when equal numbers of tumor cells from mice treated with the combination of cirmtuzumab and paclitaxel were introduced into other mice.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000007.jpg" title="" alt="" style="width:352px;height:126px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 6. Combination of cirmtuzumab and paclitaxel suppressed growth of primary human breast tumors in a mouse model.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together, these clinical and preclinical data are consistent with a model of the natural disease progression in breast cancer centered on the critical role played by tumor-initiating cells or stem-like cancer cells that express high levels of ROR1:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">TNBC</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">initially</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">responsive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">chemotherapy</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">paclitaxel,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">because</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">chemotherapy</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">kills</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">the</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">majority</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cancer</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">cells,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">leaving</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cells </span><span style="color:#000000;">with stem-like properties </span><span style="letter-spacing:0.15pt;color:#000000;">that </span><span style="color:#000000;">express</span><span style="letter-spacing:-0.7pt;color:#000000;"> </span><span style="color:#000000;">ROR1&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">TNBC</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">recurs</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">often</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">other</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">types</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">breast</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cancer</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">part</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">because</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">the</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">initial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">chemotherapy</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">enriches</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cells</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">higher </span><span style="letter-spacing:0.1pt;color:#000000;">propensity </span><span style="color:#000000;">to form</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tumors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">site</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">recurrence</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">often</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">site</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">body</span><span style="color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">remote from</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">the</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">original</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">tumor</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">because</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cells</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">stem</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cell-like</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">properties</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">able</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to metastasize&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">recurring</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">tumor</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">may </span><span style="letter-spacing:0.15pt;color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">resistant</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">therapy</span><span style="color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">because</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">contains</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.2pt;color:#000000;">high</span><span style="color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">percentage</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.15pt;color:#000000;">of</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cells</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with stem</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">cell-like</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">properties.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cirmtuzumab clinical development in breast cancer</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An investigator-sponsored single-arm, open-label, Phase 1b trial of cirmtuzumab in combination with paclitaxel in patients with locally advanced, unresectable or metastatic HER2-negative breast cancer is underway at UC San Diego. The objectives of the trial include the evaluation of safety, tolerability, pharmacokinetics, and clinical activity of cirmtuzumab plus paclitaxel. The treatment regimen is cirmtuzumab at a dose of 600 mg on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle, and paclitaxel weekly at a dose of 80 mg/m. In December 2019, an interim clinical data update for this clinical trial was presented by the investigator at the 2019 San Antonio Breast Cancer Symposium. As of the data cut-off date of November 27, 2019, a total of eight patients with HER2-negative, metastatic or locally advanced unresectable breast cancer was enrolled in the study. Seven of the eight patients were evaluable for safety and efficacy. Four of the patients had TNBC at study enrollment. Four of the seven evaluable patients achieved a PR, for an ORR of 57%, including one patient who had a PR that continued on cirmtuzumab alone for 30 weeks after discontinuing paclitaxel. It was reported that the combination of cirmtuzumab and paclitaxel was well tolerated in this trial, with no study discontinuations for toxicity and no dose-limiting toxicities observed </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">as of the cutoff date. Adverse events were consistent with the known safety profile of paclitaxel alone. Pharmacokinetic analysis of serial plasma samples for free unbound antibody from two patients provided results similar to those observed in previous studies of patients with CLL, consistent with a projected half-life of 30 days. No abrupt decline in antibody concentration over time was observed, consistent with the absence of anti-drug or neutralizing antibodies. In the </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">second quarter</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> of 2021, we expect to announce additional </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">interim </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">data from this study of patients with HER2-negative, metastatic or locally advanced unresectable breast cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential additional clinical opportunities for cirmtuzumab in solid tumors</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Lung cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 77% to 93% of lung cancers. In adenocarcinoma of the lung, higher levels of ROR1 expression were correlated with advanced stages of disease and with positive lymph node metastases. In addition, Kaplan-Meier survival analysis indicated an association of high ROR1 expression with worse OS in lung adenocarcinoma patients. ROR1 expression has been shown to be correlated with the presence of other negative prognostic factors such as phosphorylated AKT, or p-AKT, or phosphorylated CREB, or p-CREB. Inhibition of ROR1 in lung cancer cell lines induced apoptosis and cell cycle arrest and led to a reduction in levels of p-CREB and p-AKT. Notably, a recent preclinical study has shown that downregulating ROR1 expression re-sensitizes erlotinib-resistant lung cancer cells to an EGFR inhibitor drug.&#160;&#160; </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Ovarian cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 54% of ovarian cancers, which is the most lethal gynecologic malignancy among women worldwide. Analysis of ROR1 expression on ovarian cancer patient samples revealed that disease-free survival and OS rate in patients with high ROR1 expression were significantly lower than in patients with low or no ROR1 expression. In a preclinical study, it was shown that a ROR1 antibody inhibited growth of ovarian cancer cell lines in vitro and slowed tumor growth in a mouse model.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Prostate cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 90% of prostate cancers, and the Wnt5a signaling pathway is activated in patients with advanced prostate cancer that is progressing while on treatment with an androgen receptor, or AR, inhibitor. Treatment of prostate cancer cell lines with an AR inhibitor was found to increase the expression of Wnt5a, and the addition of Wnt5a attenuated the antiproliferative effect of AR inhibition. The expression of Wnt5a in patients with metastatic castrate resistant prostate cancer, or mCRPC, has been associated with poor OS. We are collaborating with academic investigators to investigate the potential effects of cirmtuzumab on this disease.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pancreatic cancer<span style="font-style:normal;">. ROR1 is expressed by approximately 83% of pancreatic cancers. A recent preclinical study has shown that blocking ROR1 led to apoptotic cell death, which was further enhanced in combination with chemotherapeutic drugs such as erlotinib and ibrutinib, when tested against a panel of pancreatic cancer cell lines.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are undertaking further preclinical studies with cirmtuzumab in several cancer types, and expect to identify one or more indication for potential clinical development in the second quarter of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ROR1 CAR-T Cell Therapy Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We are developing CAR-T cell therapy candidates based on the ROR1 binding domain of cirmtuzumab to treat patients with aggressive hematological malignancies or solid tumors. We believe that the selective expression of ROR1 on tumor cells and its absence on normal cells make it an ideal target for a CAR-T cell therapy approach. In addition, we believe that ROR1-negative relapses might be less likely to develop after ROR1 CAR-T therapy, because the survival benefit imparted on cancer cells by expressing ROR1 may limit the development of ROR1-negative tumors, such that any tumor cells that lose or mutate ROR1 to escape CAR-T treatment may be less aggressive than the original cells. Our ROR1 targeted CAR-T cell therapy candidate is in preclinical development. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We are pursuing a two-pronged development strategy for our ROR1 CAR-T cell therapy program. The first part of the strategy is to demonstrate evidence of safety and activity of a ROR1 CAR-T cell therapy in humans - while seeking to reduce the development risks by using an autologous CAR-T approach and selecting a hematological indication that is known to be susceptible to CAR-T cell therapy. The second part of the strategy </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">would be</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> to develop next-generation cell therapies targeting ROR1 by introducing more advanced cell therapy technologies, </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">which could include CAR-T bearing additional features to overcome the solid tumor microenvironment, or </span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;off-the-shelf&#8221; allogeneic CAR-T and/or CAR-NK (Natural Killer) therapies</span><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We expect partnerships and collaborations to be essential for implementing our strategy. In January 2021, we announced a research and development collaboration with Karolinska Institutet to advance novel ROR1-targeting cell therapies focused on CAR-T cells and CAR-NK cells from the laboratory into the clinic. In addition, in January 2021, we announced an agreement with Lentigen, a wholly-owned subsidiary of Miltenyi Biotec B.V. &#38; Co. KG, to manufacture lentiviral vectors for our investigational ROR1-targeting CAR-T cell therapy program.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">We are also collaborating with SPH for our CAR-T cell therapy program, through its U.S. subsidiary Shanghai Pharmaceutical (USA) Inc., or SPH USA. SPH USA has entered into the SPH USA License Agreement with us to develop ROR1 targeted CAR-T cell therapy product candidates in greater China. We and SPH USA also intend to collaborate by conducting one or more initial clinical trials of our CAR-T cell therapy candidate at hospitals in China that have experience with processing cellular immunotherapy materials and conducting CAR-T clinical trials. In the second half of 2021, we expect to announce first-in-human dosing of our ROR1 CAR-T therapy candidate in China by our partner SPH USA. In parallel, we are continuing preclinical development activities in the U.S. and Europe. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Scientific background: CAR-T cell therapy overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immuno-oncology approaches to treating cancer involve redirecting one of the pillars of the immune system, the adaptive immune system, so that it specifically and efficaciously recognizes cancerous cells that might previously have escaped immune recognition. A key element in the adaptive immune response is the T cell. T cells are white blood cells that can recognize and kill infected and abnormal cells. T cells also act to signal other immune cells to respond to threats. T cells recognize their targets because they are created in a way that allows them to specifically recognize foreign antigens on the surface of other cells.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T cells are ideally suited for immuno-oncology applications based on several characteristics. They are created to be exquisitely specific and avid killers. One T cell can eliminate numerous target cells. T cells are extremely specific, able to recognize a cancer cell and kill it, while ignoring an almost identical healthy cell. T cells are thought to be active all the time, eliminating cancer cells from the body before they can form tumors. However, tumor cells sometimes evolve to escape killing by T cells by activating a number of pathways that suppress T cell function. Adoptive T cell therapies, and specifically CAR-T cells, were developed to provide a method to generate large quantities of T cells capable of specifically recognizing and killing tumor cells despite tumor suppressive mechanisms.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapeutics are created by isolating T cells from patients and modifying them to recognize specific antigens on tumors. T cells have potent cell killing activity that is directed to target cells that are recognized by specific T cell receptors, or TCRs, that are expressed on the surface of these T cells. While some T cells have TCRs that can recognize cancer cells leading to their killing, potent T cells do not develop to all targets. In some cases, the potential cancer cell target is also a protein that has an essential role in other tissues or at other stages of development, and TCRs that recognize these targets are eliminated during normal T cell development.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapy has emerged as a way to engineer T cells to recognize specific targets, such as those that are selectively expressed on cancer cells. A gene encoding a chimeric protein is constructed that contains a single antigen-binding domain of an antibody that recognizes the target, which is coupled to a T cell costimulatory domain and a portion of the T cell receptor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAR-T cell therapies are typically produced from a patient&#8217;s own T cells which are isolated by leukapheresis. These cells are then genetically modified with the chimeric antigen gene construct which can be delivered by various mechanisms such as lentiviral gene delivery vectors. Transduced cells are then expanded and undergo quality testing before being reintroduced into the same patient.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000008.jpg" title="" alt="" style="width:251px;height:154px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 7. CAR-T production and patient treatment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TK216 - ETS oncoprotein inhibitor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.48%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216 is an investigational, potentially first-in-class, targeted small molecule that was designed to specifically inhibit the biological activity of the ETS family of oncoproteins. Tumorigenic gene fusions involving ETS factors are frequently found in tumors such as Ewing sarcoma and prostate cancer, and ETS factors are often overexpressed in other tumors, such as AML and DLBCL. Researchers in the laboratory of one of our scientific advisors, Jeffrey Toretsky, M.D. of Georgetown Lombardi Comprehensive Cancer Center, identified the precursor to TK216 by using a novel chemical screening assay that they developed based on a deep understanding of the underlying biological mechanism of ETS factors.&#160;&#160;Following this early work, TK216, which is designed to be a specific, high-affinity inhibitor of ETS factors, was created by us through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction. In preclinical models, TK216 has inhibited the interaction between ETS family members and RNA helicase A, or RHA, and by doing so, shut down excessive cell proliferation. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating TK216 as a single agent and in combination with vincristine in a Phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma. The dose-finding portion of the study was completed in 2019, and we are currently enrolling patients in an expansion cohort to evaluate the clinical response of treatment with TK216 in combination with vincristine using the RP2D regimen. Ewing sarcoma is a rare pediatric cancer that has historically been very challenging to treat effectively, particularly for recurrent and metastatic disease. ETS fusion proteins have been shown to be present in over 90% of Ewing sarcoma cases. TK216 has received an Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of patients with relapsed or refractory Ewing sarcoma.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TK216 scientific background: ETS transcription factors and oncogenesis</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216 targets the ETS family of oncoproteins known to be associated with both solid tumors and hematological malignancies. In normal development and physiology, ETS transcription factors govern processes such as cell cycle control, differentiation, proliferation, apoptosis, tissue remodeling and angiogenesis. However, when alterations in the functions of ETS factors develop, through overexpression, gene fusion or modulation, they have been shown to lead to tumor initiation, progression, and metastasis. Fusion proteins are a well-known category of targets for small molecule cancer therapy that have been cited in the scientific literature as providing a number of diagnostic and therapeutic advantages because of their tumor-specific expression. ETS overexpression or fusion proteins incorporating an ETS factor have been observed in multiple tumor types:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:38.19%;">
<tr>
<td style="width:29.06%;"></td>
<td style="width:9.14%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma*</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">98%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Prostate cancer*</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">55%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Diffuse Large B Cell-Lymphoma</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">52%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Head &#38; Neck cancer</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">33%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Acute Myeloid Leukemia*</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Breast cancer*</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Melanoma</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ovarian cancer</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">23%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lung cancer</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">21%</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Glioblastoma multiforme</p></td>
<td valign="top">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15%</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">* Fusion identified</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fusion proteins involving ETS factors have been implicated in various solid tumors, including Ewing sarcoma and prostate cancer. For example, approximately 85% of Ewing sarcomas contain a genomic rearrangement between chromosomes 11 and 22. DNA is exchanged between these chromosomes in a pathological manner, and this exchange results in a fusion of two genes: the <span style="font-style:italic;">FLI1</span> gene, an ETS family member, and the <span style="font-style:italic;">EWSR1</span> gene, an unrelated transcription factor. This gene fusion, known as <span style="font-style:italic;">EWS/FLI1</span>, functions as a transcription activator that is no longer controlled by the relevant regulatory machinery in the cell. In addition to escaping regulation, the dysregulated function of the resultant EWS/FLI1 fusion protein causes a series of abnormalities in RNA processing including aberrant mRNA expression and splicing, where it leads to defects in the synthesis of proteins such as BRCA1, a DNA repair protein. EWS/FLI1 fusion proteins also cause the formation of abnormal and potentially deleterious DNA and RNA structures known as R-loops that are associated with replication and transcriptional blocks as well as being prone to increased DNA damage.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple other tumors contain gene fusions of other ETS factors. For example, over 50% of metastatic prostate cancers carry a <span style="font-style:italic;">TMPRSS2-ETS</span> gene fusion. Other tumors have genetic changes that result in overexpression of ETS factors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="4" valign="bottom" style="width:47.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ETS Fusions</p></td>
<td valign="bottom" style="width:8.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:44.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ETS Overexpression</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing<span style="letter-spacing:-0.55pt;"> </span>sarcoma</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AML</p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EWS-FLI1</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLI1, ERG, ETV5,<span style="letter-spacing:0.75pt;"> </span>ETS2</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLBCL</p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TMPRSS2-ERG</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV1, FLI1, ETV4,<span style="letter-spacing:0.65pt;"> </span>SPIB</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AML</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prostate<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-various<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">(20+)</span></p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ERG, <span style="letter-spacing:0.1pt;">ETV1, ETV4,</span><span style="letter-spacing:0.8pt;"> </span>ETV6</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALL</p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-RUNX1</p></td>
<td valign="top" style="width:8.06%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV5, ETV1, FLI1,<span style="letter-spacing:0.7pt;"> </span>ETS1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;width:2%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:43.92%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secretory breast<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
<td valign="top" style="background-color:#CFF0FC;width:8.06%; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="background-color:#CFF0FC;width:2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="background-color:#CFF0FC;width:42.34%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breast<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">cancer</span></p></td>
</tr>
<tr>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.36%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:42.56%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6-NTRK3</p></td>
<td valign="top" style="width:8.06%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top" style="width:40.34%; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;letter-spacing:0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETV6, ETV4, SPIB,<span style="letter-spacing:0.65pt;"> </span>ETV5</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:3.15%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the genetic associations between ETS factors and tumorigenesis and the reported correlation between high levels of ETS factor expression and survival, there are currently no approved therapeutics available that target these factors. It had been widely considered that transcription factors are difficult to target due to their non-enzymatic mechanism of action. Researchers in the laboratory of Jeffrey Toretsky, M.D., Professor at Georgetown University, identified the precursor to TK216 by using a chemical screening assay that they developed based on a deep understanding of the underlying biological mechanism of ETS factors. TK216 has been observed to inhibit the interaction between ETS family members and RNA helicase A, or RHA, a critical component of the human transcriptional complex, and by doing so, shuts down excessive cell proliferation in preclinical tumor models. We believe that our approach of inhibiting protein-protein interactions is novel and that our product candidate TK216 targeting ETS factors could fill an important gap in the treatment landscape for both solid tumors and hematological malignancies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">TK216 development in Ewing sarcoma</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Ewing sarcoma disease overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma is the second most common bone tumor of children, and it occurs most often in adolescents, accounting for approximately 2% of all childhood cancer diagnoses. The incidence of Ewing sarcoma for all ages is approximately 1.3 cases per 1 million people in the U.S., corresponding to approximately 430 new patients diagnosed per year in the U.S. The median age at diagnosis of patients with Ewing sarcoma is 15.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nearly all Ewing sarcoma cases are driven by translocations of <span style="font-style:italic;">ETS</span> family oncogenes, including 85-90% of cases driven by the <span style="font-style:italic;text-decoration:underline;">EWS-FLI1</span> fusion, and approximately 10% by <span style="font-style:italic;">EWS-ERG</span>.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma typically develops in the pelvis, femur, and bones of the head and trunk, but its diagnosis often takes months as other causes for non-specific symptoms such as localized pain, fever, fatigue, weight loss, or anemia are ruled out. The five-year survival of patients who are diagnosed with non-metastatic disease is between 50% and 70%. Patients diagnosed with metastatic disease have five-year survival between 18% and 30%. The prognosis for patients with recurrent Ewing sarcoma is particularly poor, and five-year survival after recurrence is approximately 10 to 15%.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ewing sarcoma is usually treated systemically due to the fact that local treatments, even in patients without overt metastases, have an 80% to 90% relapse rate. The current standard therapy for patients with localized Ewing sarcoma in the U.S. is a combination of chemotherapy agents, including vincristine, doxorubicin and cyclophosphamide, with alternating cycles of ifosfamide and etoposide &#8211; a therapy known as VDC/IE. Patients that respond to this therapy may be candidates for tumor resection and continued treatment for a total of 14 to 17 cycles. This therapeutic regimen, however, is associated with significant toxicities. Patients with metastatic disease are often treated with VDC/IE or variations of this therapy with higher or more compressed dosing. This may also be supplemented by local radiation therapy or systemic radiation followed by autologous hematopoietic stem cell transplant. We believe that more effective therapies are needed for this rare and severe pediatric disease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TK216 preclinical data in Ewing sarcoma </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TK216 was the product of a novel approach based on developing small molecule inhibitors of a critical protein-protein interaction linked to the ETS family of transcription factors. Researchers at Georgetown University identified YK-4-279, the precursor to TK216, by using a novel chemical screening assay. Following this early work, TK216, a specific inhibitor of ETS factors, was then created by Oncternal through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction linked to the ETS family of transcription factors. TK216 is a structural analog of YK-4-279 that has shown increased potency in biochemical, cellular and xenograft tumor models. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000009.jpg" title="" alt="" style="width:615px;height:151px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-weight:bold;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 8. TK216 inhibits interaction of ETS fusion protein EWS/FLI1 with RNA helicase A.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In Ewing sarcoma, a key heterodimer between EWS/FLI1 and RHA forms the core of a transcriptome complex causing activated oncogenes, inhibited tumor suppressors, abnormal RNA transcription and abnormal RNA splicing. TK216 was developed to disrupt that heterodimer, thereby potentially preventing transcription and leading to inhibition of the oncogenic activity of EWS/FLI1, by decreasing oncogene expression, increasing tumor suppressor function, and apoptotic cell death. In preclinical models, TK216 inhibited the interaction between ETS family members and RNA helicase A or RHA, and by doing so, shut down excessive cell proliferation and caused apoptotic cell death.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TK216 clinical development in Ewing sarcoma</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are evaluating TK216, as a single agent and in combination with vincristine, in an open-label, multicenter Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma. The dose-finding portion of the study was completed in 2019, and we continue to enroll patients in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Phase 2</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expansion cohort to evaluate the clinical response of treatment with TK216 in combination with vincristine using the recommended Phase 2 dosing, or RP2D, regimen. The RP2D has been established to be 200 mg/m2/day of TK216 for 14 days, with vincristine dosed at 0.75 mg/m2 on the first day of each treatment cycle. In November 2020</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at the Connective Tissue Oncology, or CTOS meeting</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, we announced updated interim clinical data from our ongoing open-label, multicenter Phase 1 clinical trial evaluating TK216 in patients with relapsed or refractory Ewing sarcoma. The objectives of the clinical trial include the evaluation of safety, tolerability, pharmacokinetics, and tumor response. Patients entering the trial had previously been treated with a median of three, and as many as eight prior lines of systemic therapy. The presentation included interim data for 50 evaluable patients, including 23 evaluable patients treated at the RP2D as of the October 16, 2020 efficacy cut-off date. Two of the 23 patients treated at the RP2D (9%) achieved a CR, including one surgical CR. Both patients achieving CRs remain on treatment, with no evidence of disease. The first patient </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a CR was</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on treatment in this clinical trial for over 1.5 years and the second patient </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a CR was on study </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for over 8 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of the cutoff date</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The best ORR was 9%. Eight additional patients treated at the RP2D had SD, for a disease control rate (CR, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PR</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or SD) of 43%. The median progression-free survival for patients treated at the RP2D was 1.8 months</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, with some patients enjoying extended PFS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000010.jpg" title="" alt="" style="width:442px;height:198px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 9. Overall best clinical response in Phase 1/2 clinical trial of TK216 in patients with relapsed/refractory Ewing sarcoma, as of October 16, 2020.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: Patients were considered evaluable for efficacy if they completed 2 planned cycles of treatment and follow-up tumor assessment studies or had documented or clinical PD following a complete first cycle of therapy.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="genzerafbudl000011.jpg" title="" alt="" style="width:338px;height:264px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Figure 10. Progression-free survival in Phase 1/2 clinical trial of TK216 in patients with relapsed/refractory Ewing sarcoma, as of October 16, 2020. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216 was generally well tolerated. As of the October 2, 2020 safety cutoff date, the most common drug-related adverse events included myelosuppression, fatigue, alopecia, nausea, pyrexia, and decreased appetite. Dose limiting toxicities consisted of transient and manageable myelosuppression, primarily neutropenia. No unexpected off-target toxicities were observed.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmacokinetic data from the clinical trial showed that TK216 drug levels at the RP2D exceeded plasma levels associated with anti-tumor activity in preclinical models.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second quarter of 2021, we expect to announce additional interim clinical data from this Phase 1/2 clinical trial in patients with Ewing sarcoma.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential additional clinical opportunities for TK216</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acute myeloid leukemia (AML).<span style="font-style:normal;"> AML is a hematologic malignancy characterized by dysregulated maturation of myeloid or blood stem cells and failure of the bone marrow to properly function, leaving patients with anemia and immune deficiency, and at high risk of infections and bleeding. AML is the most common type of acute leukemia in adults. Approximately 21,450 new AML cases and 10,920 AML associated deaths occur annually in the U.S. The average age of an AML patient is 68 years. The National Cancer Institute estimated in 2018 that the five-year survival rate for adult patients with AML was approximately 27%.&#160;&#160;We believe that there is a need for more effective and less toxic therapies for AML.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ETS overexpression or fusion proteins incorporating ETS family member have been observed in about 30% of AML cases. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ETS family member ERG is overexpressed in many cancers, such as AML. In a retrospective analysis of patients with AML, the quartile of patients with the highest levels of ERG expression had a significantly higher rate of relapse and poorer </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OS</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> than patients with lower levels of ERG expression. Those with the highest levels of ERG had a five-year survival rate of 20%, while those with lower levels of ERG had a survival rate of approximately 50%. ERG overexpression was an independent negative prognostic factor. Similarly, AML patients with high levels of ETS2, another ETS family member, had a significantly lower five-year survival rate of approximately 15% compared to 40% for patients with lower levels of ETS2. ETS2 overexpression was an independent negative prognostic factor. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="genzerafbudl000012.jpg" title="" alt="" style="width:551px;height:120px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure<span style="letter-spacing:-0.45pt;"> 11</span><span style="letter-spacing:0.2pt;">.</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.1pt;">Survival</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:-0.15pt;">the</span><span style="letter-spacing:-0.45pt;"> </span>quartile<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.75pt;"> </span><span style="letter-spacing:-0.15pt;">AML</span><span style="letter-spacing:-0.35pt;"> </span>patients<span style="letter-spacing:-0.55pt;"> </span>with<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:-0.15pt;">the</span><span style="letter-spacing:-0.4pt;"> </span>highest<span style="letter-spacing:-0.75pt;"> </span>ERG<span style="letter-spacing:-0.6pt;"> </span>(left)<span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span>ETS2<span style="letter-spacing:-0.25pt;"> </span>(right)<span style="letter-spacing:-0.75pt;"> </span>expression<span style="letter-spacing:-0.6pt;"> </span>was<span style="letter-spacing:-0.6pt;"> </span>significantly<span style="letter-spacing:-0.25pt;"> </span>lower<span style="letter-spacing:-0.4pt;"> </span>than<span style="letter-spacing:-0.65pt;"> </span>those<span style="letter-spacing:-0.45pt;"> </span>with lower<span style="letter-spacing:-0.15pt;"> </span>expression.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:1.48%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiple AML cell lines have been shown to be sensitive to being killed by TK216, with sensitivity proportional to ETS expression. TK216 may provide a novel therapeutic strategy for the treatment of patients with relapsed and refractory AML, a patient population known to express, in certain cases, fusion proteins involving ETV6, and to have overexpression of ETS family members including FLI1, ERG, ETS2, and ETV5.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Prostate cancer.<span style="font-style:normal;"> Approximately 174,650 new cases of prostate cancer are diagnosed annually in the U.S. The incidence of metastatic prostate cancer is increasing, causing an estimated 31,620 deaths per year in the U.S. New therapeutic options are needed after failure of androgen antagonism and prior to chemotherapy. Approximately 55% of men with advanced prostate cancer carry the ETS family fusion gene </span>TMPRSS2-ERG<span style="font-style:normal;"> that is related to androgen resistance.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:1.48%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe TK216 may provide a novel therapeutic strategy for the treatment of patients with advanced prostate cancer, in particular those who carry the ETS family fusion gene <span style="font-style:italic;">TMPRSS2-ERG</span>. In a preclinical in vivo study, YK-4-279, which is an analog of TK216, showed anti-tumor activity against a prostate cancer cell line harboring the ETS-family translocation, while growth of a prostate cancer cell without the translocation was not inhibited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><img src="genzerafbudl000013.jpg" title="" alt="" style="width:525px;height:133px;" /></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure<span style="letter-spacing:-0.45pt;"> 12</span><span style="letter-spacing:0.2pt;">.</span><span style="letter-spacing:-0.7pt;"> </span><span style="letter-spacing:0.1pt;">Prostate cancer sensitivity was associated with an ETS-family fusion protein in human prostate cancer xenograft models.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the second half of 2021, we expect to announce additional preclinical data for TK216 in ETS-driven tumors.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SARD and SARM Technologies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger as defined below, GTx had been developing selective androgen receptor modulators, or SARMs, under an exclusive, worldwide license agreement with the University of Tennessee Research Foundation, or UTRF.&#160;&#160;GTx&#8217;s SARM product candidate, enobosarm (GTx-024), was evaluated in post-menopausal women with stress urinary incontinence, or SUI<span style="color:#000000;"> in a Phase 2 clinical study.</span> During 2018, GTx announced that the <span style="color:#000000;">study</span> failed to achieve statistical significance on <span style="color:#000000;">its</span> primary endpoint and determined that there was not a sufficient path forward <span style="color:#000000;">and</span> discontinued <span style="color:#000000;">the </span>further development of enobosarm<span style="color:#000000;">. Effective in March 2020</span>, we <span style="color:#000000;">terminated</span> the SARM License Agreement<span style="color:#000000;"> with UTRF</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, under an exclusive worldwide license agreement with UTRF, GTx had been developing UTRF&#8217;s proprietary selective androgen receptor degrader, or SARD, technology, to provide compounds to degrade or antagonize multiple forms of androgen receptor, thereby potentially inhibiting tumor growth in patients with progressive castration-resistant prostate cancer, including those patients who do not respond to or are resistant to current androgen targeted therapies.&#160;&#160;We are performing additional mechanistic preclinical studies in order to determine if one or more of these SARD compounds should be advanced into the additional preclinical studies required to submit an investigational new drug application, and whether we should advance one of the SARD compounds into a first-in-human clinical trial. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are intensely competitive and characterized by rapid technology evolution. Our potential competitors include large pharmaceutical, specialty pharmaceutical and biotechnology companies, as well as government, academic and other research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. <span style="color:#000000;">These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs. </span>Our commercial opportunities may be reduced or eliminated if our competitors develop and commercialize similar products that are safer, more effective, have fewer side effects or are less expensive than any products that we or our collaborators may develop. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In particular, we compete with other companies that are developing and commercializing treatments for patients with cancer. Competing therapies include chemotherapies, targeted therapies and immunotherapies and may represent various therapeutic modalities including small molecules, antibodies, cell therapies, gene therapies, and cancer vaccines. These companies may compete with us for clinical trial sites and eligible patient populations, scientific and management talent, outsourced manufacturing capacity and healthcare budgets for commercial-stage products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;" id="ca74401_sards_for_the_potential_">Cirmtuzumab competition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are several therapeutic options available to treat patients with relapsed or refractory MCL, none of these options offers long-term benefit, with most patients relapsing in less than 20 months. In an open-label Phase 2 clinical trial, ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), a BTK inhibitor that is approved by the FDA for the treatment of patients with relapsed MCL, demonstrated an ORR of 67% and a CR rate of 23%, with a median duration of response, or DoR, of 17.5 months, median PFS of 13 months and median OS of 22.5 months. In an open-label Phase 2 clinical trial, acalabrutinib (Calquence<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), another BTK inhibitor approved by the FDA for the treatment of patients with relapsed MCL, demonstrated an ORR of 80% and CR rate of 40%. Another BTK inhibitor approved in 2019, zanubrutinib (Brukinsa<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), demonstrated an ORR of 84% and CR rate of 59%, with a median DoR of 19.5 months in an open-label Phase 2 clinical trial. These therapies are given continuously for prolonged periods of time, and their use can be associated with significant toxicity. The majority of patients </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with MCL are older, and remissions are not durable for most patients treated with continuous ibrutinib therapy. As a result, we believe that more effective and better tolerated therapies with shorter treatment periods represent a significant unmet need.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant progress has been made in the treatment of CLL since the advent of targeted therapies and FDA approval of ibrutinib for CLL in 2014. A treatment paradigm shift has taken place, from chemotherapies to targeted therapies. Three classes of targeted therapies have been approved for the treatment of patients with CLL: inhibitors of BTK, a key component of cell signaling in B-cells, such as ibrutinib, which is marketed as Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AbbVie, Inc., and Johnson &#38; Johnson, and acalabrutinib, which is marketed as Calquence<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AstraZeneca PLC&#59; inhibitors of the protein B-cell lymphoma-2, or Bcl-2, such as venetoclax, which is marketed as Venclexta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Venclyxto<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AbbVie, Inc., and Roche/Genentech&#59; and inhibitors of Phosphoinositide 3-kinase, or PI3K, which include idelalisib, which is marketed as Zydelig<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by Gilead Sciences, Inc., and duvelisib, which is marketed as Copiktra<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by Verastem, Inc. These targeted therapies are now the core of the recommended treatment regimens for patients with both first-line and relapsed or refractory CLL, and have achieved objective response rates of 85-90%, two-year PFS of 65-90%, and two-year overall survival of 75-95%. The outcomes are worse for patients with certain prognostic factors, such as 17p or 11q chromosome deletions&#59; for such patients with relapsed or refractory CLL treated with ibrutinib, the reported PFS is 50-75%.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved products targeting the ROR1 receptor, we are aware of therapeutics in clinical development that target ROR1, including an ADC being developed by VelosBio, Inc. (acquired by Merck in 2020), an ADC being developed by NBE-Therapeutics (acquired by Boehringer Ingelheim in 2020), and a ROR1 CAR-T therapy being developed by Juno Therapeutics, Inc., a subsidiary of the Bristol-Myers Squibb Company.&#160;&#160;VLS-101, the ADC being tested clinically by VelosBio was originally designed and had its early development at Oncternal, it binds to the same epitope on ROR1, and it utilizes cirmtuzumab to target ROR1. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">There are numerous companies developing or marketing treatments for the same oncology indications that we are targeting with our cirmtuzumab program. Therapies approved or in clinical development for the treatment of patients with treatment-na&#239;ve or relapsed/refractory CLL and relapsed/refractory MCL include BTK inhibitors, Bcl-2 inhibitors, PI3K inhibitors, anti-CD20 antibodies, and cell therapies that are being marketed or developed by companies including AbbVie, Inc., AstraZeneca PLC, BeiGene, Ltd., Eli Lilly and Company, Gilead Sciences, Inc., Johnson &#38; Johnson, MEI Pharma, Merck, Novartis Pharmaceuticals Corporation, Roche Holding AG&#8217;s Genentech subsidiary, TG Therapeutics, Inc., and Verastem, Inc.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ROR1 CAR-T competition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved cell therapy products targeting the ROR1 receptor, we are aware of an autologous CAR-T cell therapy that targets ROR1 in clinical development for solid and liquid tumors by the Fred Hutchinson Cancer Research Center and Bristol-Myers Squibb.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">There are numerous companies developing or marketing cell therapy treatments for the same oncology indications that we may target with our ROR1 CAR-T program including AbbVie, Inc., Adicet, Allogene Therapeutics, Atara Biotherapeutics, Inc., Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Therapeutics, Fate Therapeutics, Gilead Sciences, Inc., Johnson &#38; Johnson, Legend Biotech, Merck, NantKwest, Nkarta Therapeutics, Novartis Pharmaceuticals Corporation, Poseida Therapeutics, Roche Holding AG, and others.<span style="font-weight:bold;font-size:15pt;"> </span>Four CAR-T cell therapies, Yescarta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup>and Tecartus<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, developed by Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc., and Kymriah<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>, developed by Novartis Pharmaceuticals Corporation, have been approved by the FDA. All of these therapies target the CD19 protein, a protein expressed on the surface of the majority of B cells, including B cell tumorigenic cells. Yescarta has been approved for the treatment of relapsed or refractory large B-cell lymphoma, Tecartus for the treatment of mantle cell lymphoma and Kymriah for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia. These therapies have shown high response rates with prolonged treatment effects for a subset of patients. No CAR-T therapies have been approved for use in patients with solid tumors. Despite the high response rates and prolonged treatment effects observed for a subset of patients, we believe that novel CAR-T cell therapy approaches have the potential to improve efficacy, duration of response as well as safety.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TK216 competition</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">While there are currently no approved drugs targeting ETS oncoproteins, there are numerous companies developing or marketing treatments for the same oncology indications that we are targeting with our TK216 program. Investigational therapies in clinical development for the treatment of patients with relapsed/refractory Ewing sarcoma include kinase inhibitors,<span style="font-weight:bold;"> </span>LSD1 inhibitor and other targeted therapies, therapeutic antibodies and cell therapies that are being developed by companies including Bayer AG, Bristol-Meyers Squibb Company, Eisai Co., Ltd., Epizyme, Inc., Gradalis, Inc., Eli Lilly and Company, Johnson &#38; Johnson, Exelixis, Inc., NantCell, Inc., Pharmamar S.A., Pfizer, Inc., Salarius Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and others.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licenses and Collaborative Relationships</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UC San Diego</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, we entered into a license agreement with the Regents of the University of California, or the Regents, represented by UC San Diego, which was amended and restated in August 2018, and amended on March 25, 2019, May 15, 2019&#160;&#160;and February 5, 2021 (the &#8220;UC San Diego License Agreement&#8221;), for the development, manufacturing and distribution rights to naked antibodies, including cirmtuzumab and genetically engineered cellular therapy products, including CAR-T products that are covered by licensed patents for all human therapeutic, diagnostic and preventive applications in all indications. Under the UC San Diego License Agreement, we paid an upfront license fee of $0.5 million and issued 107,108 shares of common stock. Commencing in 2017, we also pay UC San Diego an annual license maintenance fee and reimburses to UC San Diego its annual patent costs for the licensed patents. The UC San Diego License Agreement also requires the payment of certain development and regulatory milestones, aggregating from $10.0 million to $12.5 million, on a per product basis, certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, low single-digit royalties including potential future minimum annual royalties on net sales of each product, reimbursement of certain annual patent costs, and requires certain minimum diligence efforts to advance the licensed assets, including spending at least $1.0 million in development annually through 2021. Unless terminated earlier, the UC San Diego License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the 15th anniversary of the first commercial sale of a licensed product. UC San Diego may terminate the UC San Diego License Agreement if a material breach by us is not cured within a reasonable time, we file a claim asserting the licensed patent rights are invalid or unenforceable, or we file for bankruptcy. We may terminate the agreement at any time upon at least 90 days&#8217; written notice. In July 2016, we entered into a research agreement with UC San Diego (the &#8220;UC San Diego Research Agreement&#8221;), for further research on the ROR1 therapeutic development program. Under this five-year agreement, UC San Diego will have an aggregate budget of $3.6 million, with $125,000 payable quarterly. The costs paid to UC San Diego under the UC San Diego Research Agreement are included as part of our annual diligence obligations under the UC San Diego License Agreement. As of December 31, 2020, we believe we have met our obligations under the UC San Diego License Agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CIRM</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance our Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. We are conducting the trial in collaboration with UC San Diego, and we are responsible for study conduct and data management. We estimate we will receive approximately $14.0 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022. We are required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. As of December 31, 2020, we believe we have met our obligations under the CIRM award and UC San Diego subawards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $5.8 million grant to the researchers at UC San Diego to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, we agreed to provide up to $1.0 million in contingency funds if required during the grant period. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CIRM may suspend or permanently cease disbursements of funds under the research subaward agreements, or pursue other remedies as allowed by law, if CIRM determines that UC San Diego has not complied with the terms and conditions of the award, or if there are unexpected, substantial manufacturing failure leading to delayed enrollment in the clinical trial, failure to enroll the trial, or if FDA issues a clinical hold order with respect to the clinical trial.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Georgetown University</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, we entered into an exclusive license agreement (the &#8220;Georgetown License Agreement&#8221;), with Georgetown University, or Georgetown, pursuant to which we licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes. Under the Georgetown License Agreement, we are solely responsible for all development and commercialization activities and costs in our respective territories, and are also responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights. Commencing in 2015, we are obligated to pay Georgetown an annual license maintenance fee until the first commercial sale occurs, make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and will be required to pay low single digit royalties based on annual net product sales. The term of the Georgetown License Agreement continues until the expiration of the last valid claim within the patent rights covering the product, but may be terminated by either party upon material breach, or by us as to one or more countries with 90 days written notice of termination. Additionally, Georgetown may terminate the agreement in the event we fail to pay any amount and fails to cure such failure within 30 days after receipt of notice, defaults in our obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or declares insolvency or bankruptcy. We may terminate the agreement at any time upon at least 60 days&#8217; written notice.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into the SPH USA License Agreement, with SPH USA under which we granted exclusive rights to SPH USA to manufacture, develop, market, distribute and sell in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (the &#8220;SPH USA Territory<span style="color:#000000;">&#8221; or "Greater China"),</span> our product candidates under the Georgetown License Agreement and the UC San Diego License Agreement. Under the SPH USA License Agreement, SPH USA is solely responsible for all pre-clinical and clinical development activities specific to obtaining regulatory approval for such product candidates in the SPH USA Territory, any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the UC San Diego License Agreement, and paying us a low single digit royalty on net sales of licensed products in the SPH USA Territory. The SPH USA License Agreement will expire on a licensed product-by-licensed product and country/region-by-country/region basis on the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country/region. The SPH USA License Agreement may be terminated by SPH USA, on a country/region-by-country/region or product-by-product basis with 180 days written notice following the first anniversary of the effective date of the agreement or at any time on a product-by-product basis for a safety concern with respect to such product. Either party may terminate the SPH USA License Agreement in its entirety or on a licensed product-by-licensed product basis upon material breach that is not cured within 90 days, or in its entirety the event the other party becomes insolvent or enters into bankruptcy proceedings. We may terminate the agreement with 60 days written notice if SPH USA or its affiliates or sublicensees commence an action challenging the validity or enforceability of any licensed patent, or with 10 days written notice if SPH USA fails to own at least 20% of the voting securities of any assignee of the SPH USA License Agreement. Upon termination of the agreement for any reason all rights and licenses granted to SPH USA under the agreement will terminate, and in the event of termination for reasons other than our material breach, SPH USA would grant us non- exclusive, royalty-free, worldwide license to any intellectual property rights controlled by SPH USA or its affiliates to exploit the terminated program in the SPH USA Territory.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selexis</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> S.A.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, ROAR Therapeutics, Inc., our predecessor company, entered into a commercial license agreement (the &#8220;Selexis License Agreement&#8221;), with Selexis, S.A., a Swiss company, as amended in February 2020, pursuant to which we obtained a world-wide, non-exclusive license under certain of Selexis&#8217; patents and technology rights to use a recombinant cell line produced using the Selexis technology to produce cirmtuzumab. Under the terms of the Selexis License Agreement, we will pay Selexis milestone payments totaling, in the aggregate, CHF 1,235,000, and a royalty in the low single digits on net sales of cirmtuzumab to third parties. The Selexis License Agreement remains in effect until the last to expire of the licensed Selexis patents, but may be terminated by either party if the other party materially breaches the agreement and fails to cure the breach within sixty days after receipt of a notice of default from the other party, or in the event the other party becomes insolvent or enters into bankruptcy proceedings. Additionally, we may terminate the Selexis License Agreement and the license granted therein at any time upon sixty days prior written notice to Selexis. In May 2015, Selexis&#8217; rights to receive future milestone payments and royalties under the Selexis License Agreement were assigned to Ligand Pharmaceuticals, Incorporated.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we entered into a license agreement with UTRF (the &#8220;SARD License Agreement&#8221;), pursuant to which we were granted exclusive worldwide rights in all proprietary selective androgen receptor degrader, or SARD, technologies owned or controlled by UTRF, including all improvements thereto. Under the SARD License Agreement, we are obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development. We are also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. Unless terminated earlier, the term of the SARD License Agreement will continue, on a country-by-country basis, until the expiration of the last valid claim of any licensed patent in the particular country in which a licensed patent is granted. UTRF may terminate the SARD License Agreement for our uncured breach or upon its bankruptcy. On January 30, 2020, the SARD License Agreement was amended to extend certain diligence milestones.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2007, we entered into a consolidated, amended and restated license agreement with UTRF (the &#8220;SARM License Agreement<span style="color:#000000;">&#8221;) which granted us</span> exclusive worldwide rights in all existing selective androgen receptor modulator, or SARM, technologies owned or controlled by UTRF<span style="color:#000000;">. In 2018, we ceased the development of the SARM technology following the failure of a Phase 2 clinical study of enobosarm to achieve statistical significance with respect to the primary endpoint of the study. Effective on March</span> 31, 2020, we <span style="color:#000000;">terminated</span> the SARM License Agreement, <span style="color:#000000;">and we no longer have any obligation to make further payments under the SARM License Agreement, including payments for patent prosecution and maintenance. We no longer have any rights to develop or sublicense the SARM technology. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a manufacturing strategy of contracting with third parties to manufacture drug substance and product in accordance with current Good Manufacturing Practices, or cGMPs, and additional manufacturers are used to label, package and distribute investigational drug products. This strategy allows us to maintain a more flexible infrastructure while focusing our expertise on developing our products.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on third parties for the production of clinical and commercial quantities of any product candidates. There are no unusually complicated biochemistries or unusual equipment required in the manufacturing process for either cirmtuzumab or TK216.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or acquired or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the U.S and in jurisdictions outside of the U.S. related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trade secrets and know-how relating to our proprietary technology, continuing innovation, and acquisition and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of cancer therapeutics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success may depend in part on our ability to (i) obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements&#59; (ii) preserve the confidentiality of our trade secrets&#59; (iii) defend and enforce our proprietary rights, including our patents&#59; and (iv) operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed, licensed and acquired numerous patents and patent applications and possess substantial know-how and trade secrets relating to the development and commercialization of healthcare products and services. As of February 19, 2021, our owned and in-licensed patent portfolio consisted of approximately <span style="color:#000000;">3</span>9 issued U.S. patents and <span style="color:#000000;">18</span> pending U.S. patent applications related to certain of our proprietary technology, inventions, and improvements, and <span style="color:#000000;">50</span> issued patents and <span style="color:#000000;">72</span> pending patent applications in jurisdictions outside of the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ROR1 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an exclusive, commercial, worldwide, transferrable license to a portfolio of patents and patent applications directed to ROR1 antibodies and CAR-T therapies for all therapeutic indications. This portfolio is licensed from the Regents of the University of California. We have know-how and trade secrets related to compositions of matter for treating cancers, methods for treating cancer, and methods of screening for additional compositions of matter used for treating cancer, as well as to additional antibodies and molecules that modulate ROR1 signaling. We have also developed certain patents and patent applications directed to ROR1 based therapies, which are owned by Oncternal.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;letter-spacing:-0.15pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 22, 2021, our licensed patent portfolio included patents related to our clinical candidate currently in phase 1/2 clinical trials, cirmtuzumab. Cirmtuzumab is a humanized monoclonal antibody that specifically binds to the ROR1 receptor. We have two issued U.S. patents directed to the cirmtuzumab composition of matter: U.S. Pat. No. 9,217,040, with a patent term not due to expire before 2032&#59; and U.S. Patent No. 9,758,591, with a patent term not due to expire before March 2033. We have one patent issued in the U.S. directed to methods of using cirmtuzumab to treat cancer, U.S. Pat, No. 10,344,096, with a patent term not due to expire before March 2033. We have one patent application pending in the U.S. related to single chain variable region fragments derived from cirmtuzumab which, if issued, would have a patent term not due to expire before 2033. We also have patents issued in Australia, China, Europe, Israel, Japan, Korea, Macao, Canada and Mexico directed to cirmtuzumab compositions of matter. In Europe patents directed to cirmtuzumab compositions of matter have been validated in jurisdictions including France, Germany, Italy, UK, Spain, Turkey, Belgium, Poland, Netherlands, Greece, Switzerland, Sweden, Austria, Denmark, and Ireland. We have approximately 13 pending applications in foreign jurisdictions related to cirmtuzumab compositions of matter and methods of use in treating cancer, including Australia, China, Europe, Japan, Korea, Malaysia, Mexico, Philippines, and Thailand. Patents, if issued from these pending foreign applications, would not be due to expire before 2033.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 22, 2021, we have licensed patent applications pending in the U.S. and in approximately 22 jurisdictions outside the U.S. related to methods of treating cancer using a combination of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and small-molecule chemotherapeutics. Patents, if issued from these pending non-provisional applications, would not be due to expire before dates ranging from 2037 to 2041. </span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 22, 2021, we have licensed patents and patent applications related to additional ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-cirmtuzumab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors. We have six issued U.S. patents directed to non-cirmtuzumab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-cirmtuzumab ROR1 binding antibodies, polypeptides, and chimeric antigen receptors: U.S. Pat. No. 8,212,009, with a patent term not due to expire before November 2026&#59; U.S. Patent No. 9,242,014, with a patent term not due to expire before June 2031&#59; U.S. Patent No. 9,938,350, with a patent term not due to expire before June 2031&#59; U.S. Patent No. 9,217,040, with a patent term not due to expire before January 2032&#59; U.S. Patent No. 10,627,409 with a patent term not due to expire before January 2032&#59; U.S. Patent No. 10,900,973 with a patent term not due to expire before January 2032.&#160;&#160;We have two patent applications pending in the U.S. related to additional non-cirmtuzumab ROR1 binding antibodies, polypeptides, chimeric antigen receptors, and nucleic acids encoding such non-cirmtuzumab ROR1 binding antibodies, polypeptides and chimeric antigen receptors, which, if issued, would have a patent term not due to expire before dates ranging from 2031 to 2032. We also have patents issued in Europe and Canada directed to additional ROR1 binding antibodies. We have one patent application pending in Europe related to additional ROR1 binding antibodies specific for ROR1. Any patent issued from this pending foreign application, would not be due to expire before 2032.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 22, 2021, we have licensed patents and patent applications related to methods of screening for antibodies that specifically bind to ROR1. We have two issued U.S. patents, U.S. Pat. Nos. 9,523,695, and 9,933,434, with patent terms not due to expire before January 2032, directed to methods of screening for antibodies that specifically bind to ROR1. We additionally have one issued U.S. patent and one patent application issued in Japan directed to methods of screening for modulators of ROR1 signaling&#59; additionally, we have applications pending in the U.S., Australia, Canada, China, Hong Kong, and Europe directed to methods of screening for modulators of ROR1 signaling.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 22, 2021, <span style="letter-spacing:0.15pt;">we also own one patent application filed </span>under the Patent Cooperation Treaty directed to methods of treating cancer using a combination of cirmtuzumab and small molecule cancer chemotherapeutics. We also own two U.S. provisional applications directed to ROR1 targeted cell-based therapies.&#160;&#160;Patents, if issued from these pending applications would not be due to expire before 2041.  </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">TK216 Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to small molecules, including TK216, targeting EWS-FLI1 for use in therapeutics and companion diagnostics. We hold a portfolio of patents and patent applications, the Oncternal Portfolio, related to TK216, analogs thereof, and uses thereof, as well as the Georgetown Licensed Portfolio, which is licensed from Georgetown University.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of February 19, 2021, the Oncternal Portfolio consisted of approximately </span>eight<span style="Background-color:#FFFFFF;"> U.S. issued patents and </span>two<span style="Background-color:#FFFFFF;"> pending applications in the U.S., as well as approximately nine patents and approximately 24 pending patent applications in jurisdictions outside of the U.S. As of February 19, 2021, we had two U.S. patents directed to TK216: U.S. Pat. No. 9,604,927, with a patent term not due to expire before October 2035, and U.S. Pat. No. 9,987,251, with a patent term not due to expire before October 2035. We also had a patent with claims directed to methods of inhibiting proliferation of a cell that overexpresses an ETS gene or comprises an ETS fusion gene, or inhibiting growth of or killing neoplastic cells: U.S. Pat. No. 9,895,352, with a patent term not due to expire before October 2035. We had approximately one pending U.S. application and approximately 19 patents or pending applications in jurisdictions outside the U.S., including Australia, Canada, China, Eurasia, Europe, Hong Kong, India, Israel, Japan, Korea, </span><span style="color:#000000;">Macao, </span><span style="Background-color:#FFFFFF;">Mexico, New Zealand, and Taiwan. These patents have a patent term not due to expire before October 2035, and patents, if issued from these applications, would not be due to expire before October 2035. We also had a patent with claims covering compositions of TK216 in combination with venetoclax </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">and associated methods of inducing apoptosis in cells in AML and DLBCL: U.S. Pat. No. 10,159,660, with a patent term not due to expire before July 2037</span><span style="Background-color:#FFFFFF;">, and a patent covering TK216 in combination with lenalidomide and associated </span><span style="Background-color:#FFFFFF;">method</span><span style="Background-color:#FFFFFF;">s</span><span style="Background-color:#FFFFFF;"> for inducing apoptosis in a lymphocyte produced in mantle cell lymphoma</span><span style="Background-color:#FFFFFF;">: U.S. Pat. No. </span><span style="Background-color:#FFFFFF;">10</span><span style="Background-color:#FFFFFF;">,</span><span style="Background-color:#FFFFFF;">646</span><span style="Background-color:#FFFFFF;">,</span><span style="Background-color:#FFFFFF;">470</span><span style="Background-color:#FFFFFF;">, with a patent term not due to expire before July 2037</span><span style="Background-color:#FFFFFF;">. We had approximately one pending U.S. application and approximately </span><span style="Background-color:#FFFFFF;">10</span><span style="Background-color:#FFFFFF;"> pending applications filed in jurisdictions outside the U.S., including Canada, China, Europe, Hong Kong, Japan, Korea, Mexico, Singapore, and Taiwan. Patents, if issued from these applications, would not be due to expire before July 2037.&#160;&#160;The Oncternal Portfolio further contained additional patents and pending applications related to </span><span style="Background-color:#FFFFFF;">indoline</span><span style="Background-color:#FFFFFF;"> derivative compounds, which are analogs of TK216. We had two issued U.S. patents directed to compounds and methods of inhibiting proliferation of a cell expressing an ETS gene or comprising an ETS fusion gene: U.S. Pat. No. 9,822,122, with a patent term not due to expire before March 2037, and U.S. Pat. No. 10,351,569, with a patent term not due to expire before March 2037. </span><span style="Background-color:#FFFFFF;">We also </span><span style="Background-color:#FFFFFF;">had</span><span style="color:#000000;"> </span><span style="color:#000000;">an </span><span style="Background-color:#FFFFFF;">issued U.S.</span><span style="color:#000000;"> patent with claims directed to killing or inhibiting the growth of a neoplastic cell and methods of treating specific cancers by administering an analogue of TK216:</span><span style="Background-color:#FFFFFF;"> U.S. Pat. No. 10,711,008, </span><span style="Background-color:#FFFFFF;">with a patent term not due to expire before March 2037. There was </span><span style="Background-color:#FFFFFF;">also </span><span style="Background-color:#FFFFFF;">approximately </span><span style="Background-color:#FFFFFF;">six</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">patents or </span><span style="Background-color:#FFFFFF;">applications pending outside the U.S. in</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">China, Europe</span><span style="Background-color:#FFFFFF;"> </span><span style="color:#000000;">(including a European patent validated in Austria, Belgium, Denmark, France, Germany, Great Britain, Ireland, Italy, Spain, Sweden, and Switzerland)</span><span style="Background-color:#FFFFFF;">, Japan, Korea, and </span><span style="Background-color:#FFFFFF;">Taiwan</span><span style="Background-color:#FFFFFF;">. Patents, if issued from these applications, would not be due to expire before March 2037.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 19, 2021, the Georgetown Licensed Portfolio contained patents directed to other EWS-FLI1 inhibitor compounds. We had three U.S. patents directed to compounds and methods for treating Ewing sarcoma or pancreatic cancer: U.S. Pat. No. 8,232,310, with a patent term not due to expire before November 2028, U.S. Pat. No. 9,045,415, with a patent term not due to expire before August 2028, and U.S. Pat. No. 9,758,481, with a patent term not due to expire before December 2027. We had four issued patents in jurisdictions outside the U.S., including Australia, Canada, Europe (validated in Germany, France and Great Britain), and Hong Kong. These patents are not due to expire before December 2027. We had two issued U.S. patents directed to compounds and methods for treating pancreatic cancer or Ewing sarcoma: U.S. Pat. No. 9,290,449, with a patent term not due to expire before April 2033, and U.S. Pat. No. 9,714,222, with a patent term not due to expire before April 2033. There are approximately 18 patents or pending applications outside the U.S. in Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, Macao, Mexico, and New Zealand. These patents have a patent term not due to expire before April 2033, and patents, if issued from these applications, would not be due to expire before April 2033.&#160;&#160;The Georgetown Licensed Portfolio contained additional patents and pending applications related to methods of treating cancers. We had one issued U.S. patent directed to methods of treating lung cancer or glioblastoma multiforme: U.S. Pat. No. 9,511,050, with a patent term not due to expire before October 2034. There were approximately two patents issued outside the U.S. in China and Japan. These patents have a patent term not due to expire before October 2034.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SARD Program</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have exclusive worldwide rights to a portfolio of patents and patent applications related to Selective Androgen Receptor Degrader (SARD) compounds for use in therapeutics. We hold a portfolio of patents and patent applications related to SARDs and jointly owned with <span style="color:#000000;">UTRF</span><span style="Background-color:#FFFFFF;">, including 10 issued U.S. patents directed to SARD ligands and methods of use thereof: </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,814,698, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,017,471, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,035,763, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,441,570, U.S. Pat. No. </span><span style="color:#000000;">10,865,184, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,815,776, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">9,834,507, </span>U.S. Pat. No. <span style="Background-color:#FFFFFF;">10,093,613, U.S. Pat. No. </span>10,597,354, and U.S. Pat. No. <span style="color:#000000;">10,806,720, as well as four</span> issued patents in Australia, Japan, and Russia,<span style="Background-color:#FFFFFF;"> with a patent term </span>not due to expire before April 2036. <span style="Background-color:#FFFFFF;">We also have a portfolio of </span>patents and patent applications licensed from <span style="color:#000000;">UTRF</span><span style="Background-color:#FFFFFF;"> including three issued U.S. patent directed to SARD ligands and methods of use thereof: </span>U.S. Pat. No. 10,314,797, U.S. Pat. No. 10,654,809, and U.S. Pat. No. 10,806,719 with a patent term not due to expire before June 2037.&#160;&#160;A third portfolio for the SARD program includes 10 patent applications licensed from UTRF.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patents if issued from these applications will have a patent term not due to expire before May 2039. Individual patents extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. Generally, patents issued for applications filed in the U.S. are effective for 20 years from the earliest </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective and non-provisional filing date. The patent term may be adjusted to compensate for delayed patent issuance, when such delays are caused by the patent office or successful appeals against patent office actions. There is no limit on this patent term adjustment. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The extended restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following the date of FDA approval of the applicable drug product. The duration of patents outside of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective non-provisional filing date. Our issued patents are due to expire on dates ranging from 2026-2037. If patents are issued on our pending patent applications, the resulting patents would be due to expire on dates ranging from 2026-2040. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most countries require a patent owner to pay maintenance fees or annuities in order to extend the patent to the full length of its term.&#160; If these fees and annuities are not paid timely, our patents will expire prior to the expiration dat</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record&#8209;keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process and a new biologic must be approved by the FDA through the biologics license application, or BLA, process before it may be legally marketed in the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Drug Development Process</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under the Public Health Service Act, or PHSA, and their implementing regulations. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with GLP requirements and other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of an Investigational New Drug Application, or IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of adequate and well&#8209;controlled human clinical trials in accordance with Good Clinical Practice, or GCP, requirements to establish the safety and efficacy of the proposed drug, or safety, purity and potency of the proposed biologic, for its intended use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of an NDA or BLA after completion of all pivotal clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a determination by the FDA within 60 days of its receipt of an NDA or BLA whether to file the application for review&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential review of the product application by an FDA advisory committee, where appropriate and if applicable&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug</span><span style="color:#000000;"> or biologic</span><span style="color:#000000;">&#8217;s identity, strength, quality and purity</span><span style="color:#000000;">, </span><span style="color:#000000;">and audits of selected clinical trial sites to ensure compliance with GCP</span><span style="color:#000000;">&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval of the NDA or BLA.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls, or CMC, information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin.  The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA, supervision of certain human gene transfer trials may also require evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to the public health or the environment, and such assessment may result in some delay before initiation of a clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of a product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, patient selection and exclusion criteria, and the parameters to be used to monitor patient safety, including stopping rules that assure a clinical study will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations including GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical study must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical study will be conducted. The FDA, the IRBs, or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk or if a trial is unlikely to meet its stated objectives. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;1</span><span style="color:#000000;">:&#160;&#160;The product candidate is initially administered to healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life&#8209;threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;2</span><span style="color:#000000;">:&#160;&#160;The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine the appropriate dosage for further clinical trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;color:#000000;">Phase&#160;3</span><span style="color:#000000;">:&#160;&#160;The product candidate is administered to an expanded patient population at geographically dispersed clinical study sites. These clinical trials are intended to establish the safety and efficacy of the product and the overall risk&#8209;benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling and commercial use of the product.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;approval trials, sometimes referred to as Phase&#160;4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA or BLA.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a new drug or biologic, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase&#160;2, and before an NDA or BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase&#160;2 trial to discuss Phase&#160;2 clinical results and present plans for the pivotal Phase&#160;3 clinical trial that they believe will support approval of the new drug or biologic.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <span style="font-style:italic;">in vitro</span> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are also requirements governing the reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of FDA&#8209;regulated products are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">United States Review and Approval Process</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development, preclinical and other non&#8209;clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The NDA or BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of an NDA or BLA is subject to the payment of user fees&#59; a waiver of such fees may be obtained under certain limited circumstances.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews all NDAs and BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the submission is accepted for filing, the FDA begins an in&#8209;depth substantive review. The FDA&#8217;s goal is to review standard applications within ten months after the filing date, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP&#8209;compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may refer the NDA or BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates an NDA or BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA or BLA identified by the FDA and may require additional clinical data, such as an additional clinical trial or other significant and time&#8209;consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase&#160;4 testing, which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness after NDA or BLA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS.&#160;The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for non&#8209;compliance with regulatory requirements or if problems occur following initial marketing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Food and Drug Administration Safety and Innovation Act, or FDASIA, made permanent the Pediatric Research Equity Act, or PREA, which requires a sponsor to conduct pediatric clinical trials for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non&#8209;compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the U.S. or, if it affects more than 200,000 individuals in the U.S., there is no reasonable expectation that the cost of developing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and making a drug or biologic product available in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA or BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug or biologic also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user&#8209;fee waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs or biologics are eligible for Fast Track designation if they are intended to treat a serious or life&#8209;threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. With regard to a Fast Track product candidate, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product candidate submitted to the FDA for approval, including a product with a Fast Track designation or Breakthrough Therapy designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A BLA or NDA for a product candidate is eligible for priority review if the product candidate has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of a BLA or NDA designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&#160;months of the filing date as compared to ten&#160;months for review of original BLAs and new molecular entity NDAs under its standard review goals.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a product </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be eligible for accelerated approval. Drug</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and biologic</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> intended to treat serious or life</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;controlled post</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;marketing clinical trials. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA currently requires as a condition for accelerated approval pre</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug or biologic that meets the following criteria: (i) the drug or biologic qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions&#59; (ii) the drug or biologic is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition&#59; and (iii) preliminary clinical evidence indicates that the drug or biologic has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides all the benefits of Breakthrough Therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Product candidates granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of clinical trial sites, including through expansion of trials to additional sites.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation, Breakthrough Therapy designation, RMAT designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rare Pediatric Disease Priority Review Voucher Program</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#201F1E;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#201F1E;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#201F1E;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents&#59; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any Rare Pediatric Disease Priority Review Voucher.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Post</span><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8209;approval requirements</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug and biologics manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any drug products we or our partners manufacture or distribute pursuant to FDA approvals will be subject to continuing regulation by the FDA, including, among other things, record&#8209;keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug and biologics manufacturers, such as those related to direct&#8209;to&#8209;consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off&#8209;label use&#8221;), industry&#8209;sponsored scientific and educational activities, and promotional activities involving the internet. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and consistent with the provisions of the approved label. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications or supplements to approved applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Drug Product Marketing Exclusivity </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. For example, the FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section 505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of marketing exclusivity available in the U.S. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA&#8209;licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being addressed by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12&#8209;year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well&#8209;controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FDA Regulation of Companion<span style="font-weight:bold;"> </span>Diagnostics<span style="font-weight:bold;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may require use of an <span style="font-style:italic;">in vitro</span> diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the U.S., the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA, approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&#160;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;<span style="font-style:italic;">In Vitro</span> Companion Diagnostic Devices.&#8221; According to the guidance, for novel candidates such as our product candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of <span style="font-style:italic;">in vitro</span> companion diagnostic devices on issues related to co-development of these products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these <span style="font-style:italic;">in vitro</span> companion diagnostics in conjunction with the review of therapeutic candidates such as those we are developing involves coordination of review by the FDA&#8217;s Center for Drug Evaluation and Research and by the FDA&#8217;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Approval Process Outside of the United States</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. In addition, ethical, social and legal concerns about gene-editing technology, gene therapy, genetic testing and genetic research could result in additional regulations restricting or prohibiting the processes we may use.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product candidates in those countries. The requirements and process governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. Failure to comply with applicable foreign regulatory requirements, may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, or EU, for example, a clinical trial authorization, or CTA, must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved by the national health authority and the ethics committee has granted a positive opinion in relation to the conduct of the trial in the relevant member state(s), in accordance with a country&#8217;s requirements, clinical study development may proceed. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials of medicinal products in the European Union must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on Good Clinical Practices, or GCP, as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.&#160;&#160;Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products, or ATMPs. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to commencing a clinical trial, the sponsor must obtain a CTA from the competent authority, and a positive opinion from an independent ethics committee. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, CTAs must be submitted to the competent authority in each EU member state in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect by early 2022, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have only limited involvement. Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees.&#160;&#160;Medicines used in clinical trials must be manufactured in accordance with GMP. Other national and European Union-wide regulatory requirements may also apply.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorizations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, medicinal products can only be placed on the market after obtaining a Marketing Authorization, or MA. To obtain regulatory approval of an investigational biological product under European Union regulatory systems, we must submit a marketing authorization application, or MAA. The application used to file the BLA in the U.S. is similar to that required in the European Union, with the exception of, among other things, country&#8209;specific document requirements. The process for doing this depends, among other things, on the nature of the medicinal product. The centralized procedure results in a single MA, issued by the European Commission, based on the opinion of the EMA&#8217;s CHMP, which is valid across the entire territory of the EU. The centralized procedure is compulsory for human medicines that are: (i) derived from biotechnology processes, such as genetic engineering, (ii) contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii)&#160;&#160;designated orphan medicines and (iv) advanced therapy medicinal products, or ATMPs, such as gene therapy, somatic cell therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used in certain other cases. It is very likely that the centralized procedure would apply to the products we are developing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Data and Marketing Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight&#160;years of data exclusivity and an additional two&#160;years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic or biosimilar application. During the additional two&#8209;year period of market exclusivity, a generic/biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic/biosimilar product can be marketed until the expiration of the market exclusivity. The overall ten-year market exclusivity period may be extended to a maximum of eleven years if, during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies is approved. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be a new chemical entity, and products may not qualify for data exclusivity. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Medicinal Products</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the European Union are similar in principle to those in the U.S. A medicinal product may be designated as orphan if (1)&#160;it is intended for the diagnosis, prevention or treatment of a life&#8209;threatening or chronically debilitating condition&#59; (2)&#160;either (a)&#160;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&#160;the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment&#59; and (3)&#160;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. The application for orphan drug designation must be submitted before the application for marketing authorization. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a MA, entitled to ten&#160;years of market exclusivity for the approved therapeutic indication. During the ten-year market exclusivity period, the EMA cannot accept a MAA, or grant a MA, or accept an application to extend a MA, for the same indication, in respect of a similar medicinal product. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the MAA is submitted. An orphan product can also obtain an additional two&#160;years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 10&#8209;year market exclusivity may be reduced to six&#160;years if, at the end of the fifth&#160;year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, MA may be granted to a similar product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior&#59; (2) the applicant consents to a second orphan medicinal product application&#59; or (3) the applicant cannot supply enough orphan medicinal product.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the U.S. federal and state governments and by authorities in the foreign jurisdictions in which they conduct their business. At the federal level, such laws include, without limitation: the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program&#59; federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent and civil monetary penalty laws&#59; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59; and the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to physicians, certain other health care professionals beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies are also subject to U.S. state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or that apply regardless of payor&#59; laws which require pharmaceutical companies to comply with the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, laws which require pharmaceutical companies to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and information related to drug pricing, and laws requiring the registration of pharmaceutical sales and medical representatives. Violation of these laws or other governmental regulations may result in penalties, including, without limitation, significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform policy for coverage and reimbursement exists in the U.S., and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that may require companies to provide scientific and clinical support for the use of a product to each payor separately. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. Lastly, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The U.S. and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In March 2010, the Affordable Care Act, or ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the U.S., and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular importance to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA. For example, the Tax Act, was enacted on December 22, 2017, which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health insurance for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well.&#160;&#160;The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule.&#160;&#160;It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the law. </span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May 1, 2020 through March 31, 2021, and reduced payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The likelihood of these and other proposals initiated by the former Trump administration is uncertain, particularly in light of the new Biden administration. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Data Privacy and Security Laws</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical companies may be subject to U.S. federal and state health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the U.S. Department of Health and Human Services, or HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.&#160;&#160;Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain state laws <span style="color:#000000;">govern the privacy and security of health information in certain circumstances, some of which </span>may be more stringent, broader in scope or offer greater individual rights with respect to protected health information, or PHI, than HIPAA, and many of which differ from each other, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation.&#160;&#160;For example, California enacted the California Consumer Privacy Act, or the CCPA, on June 28, 2018, which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> California Privacy Rights Act, or CPRA, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, the General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes stringent data protection requirements for controllers and processors of personal data of individuals within the European Economic Area, or EEA. The GDPR applies <span style="color:#000000;">to any company established in the EEA as well as to those outside the EEA if they collect and use personal data in connection with the offering of goods or services to individuals in the EEA or the monitoring of their behavior</span>. The GDPR allows EU and EEA member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU and EEA member states may result in fines of up to &#8364;20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the European Union and the U.S. remains uncertain. For example, in 2016, the European Union and U.S. agreed to a transfer framework for data transferred from the European Union to the U.S., called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union. Further, from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 6, 2019, we, then operating as GTx, Inc., or GTx, entered into an Agreement and Plan of Merger and Reorganization, as amended, or the Merger Agreement, with privately-held Oncternal Therapeutics, Inc., or Private Oncternal, and Grizzly Merger Sub, Inc., our wholly-owned subsidiary, or Merger Sub. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as our wholly-owned subsidiary (the &#8220;Merger&#8221;). On June 7, 2019, the Merger was completed.&#160;&#160;GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as our wholly-owned subsidiary, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;&#160;&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.073386 shares of our common stock (the &#8220;Exchange Ratio&#8221;), after taking into account a one-for-seven reverse stock split of our then-outstanding common stock (the &#8220;Reverse Stock Split&#8221;). Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately 77.5% of the outstanding common stock of the combined company. The par value and the authorized shares of our common stock were not adjusted as a result of the Reverse Stock Split. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America, or GAAP. Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#8217;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#8217;s senior management holds all key positions in the senior management of the combined company. As a result, as of the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">closing date of the Merger, our net assets were recorded at their acquisition-date relative fair values in our consolidated financial statements and the reported operating results prior to the Merger are those of Private Oncternal. &#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Human Capital</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March <span style="color:#000000;">5, 2021</span>, we had twelve full-time employees, <span style="color:#000000;">two</span> part-time employees, and a number of consultants, most of whom are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, and incentivizing our management team and our clinical, scientific and other employees and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and motivate personnel through the granting of stock-based and cash-based compensation awards, in order to align our interests and the interests of our stockholders with those of our employees and consultants<span style="font-family:Arial;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in San Diego, California, where we currently sublease 4,677 square feet of office space used primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the name Genotherapeutics, Inc. in Tennessee in September 1997.&#160;&#160;We changed our name to GTx, Inc. in 2001 and reincorporated in Delaware in 2003.&#160;&#160;On March 6, 2019, we, then operating as GTx, Inc., entered into the Merger Agreement with Private Oncternal and Merger Sub. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as our wholly-owned subsidiary. On June 7, 2019, the Merger was completed and GTx, Inc. changed its name to Oncternal Therapeutics, Inc.&#160;&#160;Private Oncternal, which remains as our wholly-owned subsidiary, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located at 12230 El Camino Real, Suite 300, San Diego, CA 92130, and our telephone number is (858) 434-1113. Our website address is www.oncternal.com. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form&#160;10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. We make available on our website at www.oncternal.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing. Further, our references to the URLs for these websites are intended to be inactive textual references only. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />

<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS"><span style="color:#000000;">Risk Factors.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should consider carefully the following risk factors, together with the other information contained in this annual report on Form&#160;10-K, including our financial statements and the related notes and &#8220;Management Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations or financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring and&#160;in-licensing&#160;our product candidates and conducting preclinical studies and early-stage clinical trials. Cirmtuzumab and TK216 are in clinical development, while our ROR1 CAR-T program is in the preclinical stage. We have not yet demonstrated an ability to successfully obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or embark on sales and marketing activities necessary for successful post regulatory approval product commercialization, and have not developed any companion diagnostic test for our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant operating losses since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. Our net losses were $<span style="color:#000000;">17.2 million and $</span>34.2 million ($18.1 million related to nonrecurring Merger costs) for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of $82.8 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and anticipate these losses will increase substantially as we continue to develop, seek regulatory approval for and potentially commercialize any of our product candidates, and seek to identify, assess, acquire, in-license or develop additional product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress our value and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in our company&#8217;s value could also cause stockholders to lose all or part of their investment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of cirmtuzumab and TK216, continue research and development and initiate clinical trials of our other development programs<span style="color:#000000;">, including our preclinical ROR1 CAR-T program,</span> and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, as our product candidates progress through development and toward commercialization, we will need to make milestone payments to the licensors and other third parties from whom we have in-licensed or acquired our product candidates, including cirmtuzumab, TK216 and ROR1 CAR-T. If we obtain regulatory approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution<span style="color:#000000;"> and we will need to make royalty payments to the licensors and / or other third parties from whom we have in-licensed or acquired our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, following the completion of the Merger, we have incurred additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based our estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through a combination of equity financings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our&#160;day-to-day&#160;activities, which may adversely affect our ability to develop our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs incurred as a result of the COVID-19 pandemic, including clinical trial delays&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the type, number, scope, progress, expansions, results, costs and timing of, our clinical trials of cirmtuzumab and TK216, and preclinical studies or clinical trials of </span><span style="color:#000000;">our ROR1 CAR-T program or additional indications of cirmtuzumab or TK216 as well as </span><span style="color:#000000;">other product candidates that we may choose to pursue in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of obtaining ibrutinib, for which we currently obtain supply at no cost under our clinical supply agreement with Pharmacyclics LLC, and vincristine to conduct our clinical trials of cirmtuzumab and TK216, respectively&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">the costs and capacity for CAR-T development and lentivirus </span><span style="color:#000000;">manufacturing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs, timing and outcome of regulatory review of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our efforts to evaluate, develop or partner the SARD assets&#59; our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the costs associated with hiring additional personnel and consultants as our clinical and other development activities increase&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of the milestone or other payments we must make to the licensors and other third parties from whom we have in-licensed&#160;or acquired our product candidates or technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of establishing or securing sales and marketing capabilities if any of our product candidates are approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs associated with any products or technologies that we may&#160;in-license&#160;or acquire.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conducting clinical trials and preclinical studies is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, our Form S-3 registration statement expired and we do not currently have an effective shelf registration statement on Form S-3. Future sales under a Form S-3, if any, will depend on a variety of factors including, but not limited to, the effectiveness of a Form S-3, prevailing market conditions, the trading price of our common stock and our capital needs. If we are successful in filing a Form S-3 in the future, there can be no assurance that we will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate<span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, government funding or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect stockholders&#8217; rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 outbreak may adversely impact our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental authorities in impacted regions are taking action in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have put restrictions on employee travel and working from our executive offices with many employees continuing their work remotely. In addition, while we are currently continuing the clinical trials we have underway in sites across the U.S., we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trials. For example, some of our clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients traveling from out of state, have implemented a 14-day self-quarantine before appointments. Patients with MCL or CLL may be at increased risk of severe disease if they develop COVID-19 because of advanced age and/or immunosuppression, and so may be unwilling to travel to our study centers to enroll in our clinical trials. For our existing patients, we are actively working with all of our clinical trial sites to minimize disruptions and address concerns on an individual site or patient basis in order to allow participating patients to continue to receive treatment at home or in alternate healthcare settings while minimizing their potential exposure to the virus that causes COVID-19. If restrictions related to the COVID-19 outbreak continue for a prolonged period of time or if additional clinical trial sites pause patient enrollment or treatments, our clinical trial milestones would be negatively impacted. Additionally, our expectations for the timing of first-in-human dosing of our ROR1 CAR-T therapy in China has been delayed</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to the second half of 2021.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the present time, we believe we have sufficient quantities of our cirmtuzumab and TK216 clinical trial materials to continue to treat patients in our clinical trials through at least the end of 2021. However, if our third-party manufacturers, including those located in China, experience additional manufacturing difficulties due to the COVID-19 outbreak or as a result of natural disasters, labor disputes, unstable political environments, or other public health emergencies, our ability to provide our product candidates to patients in clinical trials, or to provide product for treatment of patients if approved, would be jeopardized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business, clinical trials and manufacturing and supply chains, including:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruptions or delays in the operations of the FDA or other regulatory authorities, which may delay receiving feedback or approvals from the FDA or other regulatory authorities with respect to future clinical trials or regulatory submissions&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">further delays or difficulties in enrolling patients in our clinical trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limiting our ability to interact with our clinical trial investigators, present our data in person at scientific and investor conferences, develop and renew contracts due to travel limitations or cancellations of scientific or investor conferences&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, including interruption of supply cirmtuzumab or TK216&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:10pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and interruption in global shipping that may affect the transport of clinical trial materials&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">changes in local regulations as part of a response to COVID-19 which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether&#59;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59; and</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the spread of COVID-19 may have impacted, and may continue to impact, the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis, or at all, or enter into partnerships with pharmaceutical companies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to rapidly evolve. The extent to which the COVID-19 may impact our business, including our clinical trials, manufacturing and supply chains and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We depend heavily on the success of cirmtuzumab and TK216, which are in Phase 1 or Phase 1/2 clinical trials, as well as our ROR1 CAR-T program, which is in preclinical development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our two clinical-stage product candidates, cirmtuzumab and TK216, are in Phase 1 or Phase 1/2 clinical development. Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL and in an investigator-sponsored Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. We are also developing TK216, an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. TK216 is being evaluated in a Phase 1 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. In addition, we are developing a chimeric antigen receptor T cell, or CAR-T, therapy candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. None of our product candidates have advanced into a pivotal or registrational study for the indications for which we are studying them. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on various factors, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful completion of preclinical and clinical studies with favorable results&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of investigation new drug applications, or INDs, by the FDA, or similar regulatory filing by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed designs for future clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">demonstrating safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receiving marketing approvals from applicable regulatory authorities, including Biologics License Applications, or BLAs, or new drug applications, or NDAs, from the FDA, and maintaining such approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">making arrangements with our third-party manufacturers for commercial manufacturing capabilities and manufacturing process optimization for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing sales, marketing and distribution capabilities and launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the demonstration of an acceptable safety profile of our products following approval, if any&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing, in-licensing or acquiring companion diagnostics to our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintaining and growing an organization for people who can develop our product candidates and technology.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business, including our ability to finance the company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any of our product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early<span style="color:#000000;">-</span>stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials or receive regulatory approval on a timely basis, if at all.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while cirmtuzumab was well tolerated and showed favorable results in the Phase 1 portion of our ongoing Phase 1/2 clinical trial as well as the inhibition of ROR1 signaling in patients with CLL in early clinical trials, we do not know how cirmtuzumab will perform in the Phase 2 portion of the clinical trial and one or more of the reported clinical outcomes may materially change as patient enrollment continues in such trial, and such results may not be replicated in any other future clinical trials, including as a result of any differences in the target population, drug interactions or other differences in our trial design.&#160;&#160;It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, this and any future preclinical and clinical data may be susceptible to varying </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot assure you that we will be able to successfully progress our preclinical programs from candidate identification to Phase&#160;1 clinical development.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. We are conducting a Phase 1/2 clinical trial of cirmtuzumab in combination with ibrutinib in patients with treatment-na&#239;ve or relapsed or refractory CLL and previously treated patients with MCL. Additionally, we are evaluating TK216 as a single agent and in combination with vincristine in a Phase 1 clinical trial in patients with relapsed or refractory Ewing sarcoma.&#160;&#160;We will have to follow the same procedure for our other preclinical product candidates that we plan to advance to clinical development, and would also be required to submit regulatory filings to foreign regulatory authorities if we decide to initiate clinical trials outside of the U.S.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties in recruiting clinical trial investigators with the appropriate competencies and experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in obtaining approval from one or more institutional review boards, or IRBs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes to clinical trial protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical sites deviating from trial protocols or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">challenges in manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment&#160;follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">lack of adequate funding to continue clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjects experiencing severe or unexpected drug-related adverse effects&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">occurrence of serious adverse events in clinical trials of the same class of agents conducted by other companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current Good Manufacturing Practices, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any changes to our manufacturing process that may be necessary or desired&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials in a timely manner or consistent with applicable clinical trial protocols, good clinical practices, or GCP, or other regulatory requirements&#59; third-party contractors not performing data collection or analysis in a timely or accurate manner&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. We could also encounter delays if our clinical trials are suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial, or by the FDA or comparable foreign regulatory authorities. Regulatory authorities may suspend or terminate clinical trials due to a number of factors, including failure to conduct clinical trials in accordance with regulatory requirements or the applicable clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, if we decide to conduct clinical trials of our product candidates in foreign countries additional risks may arise that may delay completion of those clinical trials. These risks include the failure of enrolled patients in other countries to adhere to clinical protocol as a result of differences in healthcare practices or cultural customs, managing additional administrative burdens associated with the regulatory schemes of other countries, as well as political and economic risks relevant to other countries.&#160;&#160;Under our license and development agreement with SPH USA, SPH USA has the right to manufacture, develop, market, distribute and sell our cirmtuzumab, ROR1 CAR-T, and TK216 product candidates in the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan, or Greater China, and the obligation to perform all preclinical and clinical development activities required to obtain regulatory approvals for such product candidates in Greater China. In the event that SPH USA&#8217;s preclinical studies or clinical trials of our product candidates raise new safety or efficacy concerns, the prospects for obtaining regulatory approval of our product candidates in the U.S. and other countries, and our business, could be adversely impacted.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays in the completion of, or termination of, clinical trials of our product candidates, the commercial prospects of such product candidates may be harmed, and our ability to generate product revenues from such product candidates may be delayed. Moreover, delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many of the factors that cause, or lead to, the termination, suspension or delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. If we make formulation or manufacturing changes to our product candidates or revise the route of administration or dosing regimen for our product candidates, we may be required to conduct additional preclinical or clinical studies to bridge our modified product candidates to earlier versions or to bridge the new dosing regimens to dosing regimens used in our clinical trials. The need to conduct additional preclinical or clinical studies could result in delays in the approval or commercialization of our product candidates, which could shorten any period during which we may have the exclusive right to commercialize our product candidates and enable our competitors to bring products to market before we do. In such an event, the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the availability of competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, a limited number of patients are affected by CLL, MCL and particularly Ewing sarcoma, which are our initial target indications for cirmtuzumab and TK216. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required&#160;follow-up&#160;periods. For certain of our product candidates, including cirmtuzumab and TK216, the conditions which we currently plan to evaluate are orphan or rare diseases with limited patient pools from which to draw for clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. If patients are unwilling to participate in our clinical trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of approved therapies, or if we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure stockholders that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of the label for an approved product candidate, or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with oncology drugs generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence, or unexpected characteristics of side effects. For example, our ongoing clinical trials of cirmtuzumab in combination with ibrutinib, and TK216 in combination with vincristine, and the ongoing investigator-initiated clinical trial of cirmtuzumab in combination with paclitaxel, may reveal adverse events based on the combination therapy under evaluation. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials, result in a more restrictive label for the product candidate, or delay or cause the denial of regulatory approval of the product candidate by the FDA or comparable foreign regulatory authorities. The drug-related side effects could also affect patient recruitment for our clinical trials, or the ability of enrolled patients to complete the trials, or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial prospects for the product candidate if approved. We may also be required to modify our plans for future studies based on findings in our ongoing clinical trials.&#160;&#160;Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as the use of our product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw, suspend or limit approvals of such product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to recall a product or change the way such product is administered to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we could be sued and held liable for harm caused to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of the product may decrease significantly or the product could become less competitive&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation could suffer.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to maintain orphan drug designations for certain of our product candidates, and may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the U.S. and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of greater than 200,000 individuals in the U.S., but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the European Union, the EMA&#8217;s, Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. In June 2020, we announced that we had obtained orphan drug designations in the U.S. for cirmtuzumab for treatment of MCL and for treatment of CLL/small lymphocytic lymphoma. We have also received orphan drug designation in the U.S. for TK216 for patients with Ewing sarcoma. We may seek additional orphan drug designations for cirmtuzumab or TK216 or for certain of our other product candidates. There can be no assurance that the FDA or the EMA&#8217;s Committee for Orphan Medicinal Products will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a NDA or BLA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The regulatory landscape that will apply to development of gene therapy or cell-based therapeutic product candidates by us or by our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory requirements governing products involving gene therapy treatment have changed frequently and will likely continue to change in the future. Approvals by one regulatory agency may not be indicative of what any other regulatory agency may require for approval, and there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of gene therapy products, cell therapy products and other products created with genome editing technology. For example, in addition to the submission of an IND to the FDA, before initiation of a clinical trial in the U.S., certain human clinical trials for cell therapy products and gene therapy are subject to the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. The NIH Guidelines call for the supervision of human gene transfer trials including an evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. We will therefore be subject to significant regulatory oversight by the FDA, and in addition to the government regulators, the applicable IBC and IRB of each institution at which we or our collaborators conduct clinical trials of our product candidates, or a central IRB if appropriate, would need to review and approve the proposed clinical trial.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar requirements apply in the European Union. The European Medicines Agency, or the EMA, has a Committee for Advanced Therapies, or CAT, that is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products. Advanced-therapy medical products include gene therapy medicine, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Similarly complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any of our gene therapy product candidates such as CAR-T, but that remains uncertain at this point.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for product candidates involving gene therapy can be more lengthy, rigorous and expensive than the process for other better known or more extensively studied product candidates and technologies. Since we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or comparable regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. This may be a particularly significant risk for many of the genetically defined diseases for which we may develop product candidates alone or with collaborators due to small patient populations for those diseases, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene therapy in a timely manner or under technically or commercially feasible conditions. Even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene therapy, either of which could materially harm our business. Furthermore, regulatory action or private litigation could result in increased expenses, delays or other impediments to our research programs or the development or commercialization of current or future product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a product candidate to market could decrease our ability to generate sufficient product revenue to maintain our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As an organization, we have limited experience in the process of enrolling patients in our clinical trials, have never conducted later-stage clinical trials or submitted a BLA or an NDA, and may be unable to do so for any of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are early in our development efforts for our product candidates, and will need to successfully complete later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market cirmtuzumab, TK216, ROR1 CAR-T, or any future product candidates. Carrying out later-stage clinical trials and submitting a successful BLA or NDA is a complicated process. As an organization, we are in the process of conducting a Phase&#160;1/2 clinical trial for cirmtuzumab in combination with ibrutinib and a Phase 1 clinical trial for TK216, alone and in combination with vincristine. We have not yet conducted any clinical trials for our other product candidates. We have not previously conducted any later stage or pivotal clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submitted a BLA, an NDA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, TK216 or any other product candidates will be required or how such trials should be designed. We may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in our planned clinical trials could delay or prevent us from submitting BLAs or NDAs for, and commercializing, our product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. We are not permitted to market any of our product candidates in the U.S. until we receive approval of a BLA or an NDA from the FDA.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses, and in the case of biological products, that such product candidates are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may disagree with the design or execution of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">such authorities may disagree with us regarding the formulation, labeling and/or the product specifications of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">approval may be granted only for indications that are significantly more limited than those sought by us, and/or may include significant restrictions on distribution and use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which we contract for clinical and commercial supplies&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failure to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical trials and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials, and/or the implementation of a REMS, which may be required because the FDA believes it is necessary to ensure safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there are a greater likelihood of success.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we are focused on specific product candidates, indications and development programs. As a result, we may forgo or delay the pursuit of opportunities with other indications or other product candidates that could have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we could relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements, when it might be more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fast Track designation by the FDA for TK216 or our other product candidates may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted a Fast Track designation for TK216 in the U.S. for the treatment of Ewing sarcoma and may seek Fast Track designation for cirmtuzumab or our other product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing new product candidates that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended, alone or in combination with one or more drugs, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. With a Fast Track product candidate, the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA or BLA, the FDA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining a Fast Track designation does not change the standards for product approval, but may expedite the development or approval process. Even though the FDA has granted such designation for TK216, it may not actually result in faster clinical development or regulatory review or approval. Furthermore, such a designation does not increase the likelihood that TK216 or any other product candidate that may be granted Fast Track designation will receive marketing approval in the U.S.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may conduct certain of or portions of our clinical trials for our product candidates outside of the U.S. and the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may in the future choose to conduct one or more of our clinical trials or a portion of our clinical trials for our product candidates outside the U.S. Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCP requirements, and, and FDA must be able to validate the data from the study through an onsite inspection, if required. In general, the patient population for any clinical studies conducted outside of the U.S. must be representative of the population for whom we intend to label the product in the U.S. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trial conducted outside of the U.S. If the FDA does not accept the data from our clinical trials of our product candidates, it would likely result in the need for additional trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or topline data from our clinical studies, which are based on preliminary analyses of then-available data. Such preliminary results and related findings and conclusions are subject to change following more comprehensive reviews of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.&#160;As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated.&#160;Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may also disclose interim data from our clinical studies, such as the positive interim data we announced from our Phase 1/2 clinical trial of cirmtuzumab in combination with ibrutinib in <span style="color:#000000;">May and </span>December 2020. Interim data from this clinical trial and future clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects<span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses of data from preclinical studies or clinical trials of its product candidates, or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or prospects for commercialization of the product candidate, or our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Information that we decide not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the interim, topline or preliminary data that we disclose differ from actual results, or if others, including regulatory authorities, disagree with the conclusions we reach based on our analyses of such data, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">B</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">reakthrough </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">T</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">herapy designation that we may receive from the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek Breakthrough Therapy designation for some of our product candidates, including cirmtuzumab and TK216. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. The designation also includes the same program features as Fast Track designation, including eligibility for priority review. Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as Breakthrough Therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification and rescind the designation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek a rare pediatric disease designation for TK216, however, there is no guarantee that we will obtain such designation, and even if we do, there is no guarantee that FDA approval of TK216 will result in a priority review voucher.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor.&#160;&#160;The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek a rare pediatric disease designation for TK216 for the treatment of Ewing&#8217;s sarcoma, however, we may not be able to obtain such designation. If we are able to obtain rare pediatric disease designation, there is no guarantee that we will be able to obtain a priority review voucher, even if TK216 is approved by the FDA.&#160;&#160;Moreover, Congress included a sunset provision in the statute authorizing the rare pediatric disease priority review voucher program.&#160; On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any rare pediatric disease priority review vouchers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a third-party to conduct the clinical trials according to good laboratory practices, GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on third parties to conduct our clinical trials and preclinical studies, including our ongoing clinical trials for cirmtuzumab and TK216 and preclinical studies for ROR1 CAR-T and our other development programs. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and applicable regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of its clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no guarantee that any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any BLA or NDA we submit to the FDA. Any such delay or rejection could prevent us from commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates and related raw materials for clinical and preclinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA or other regulatory agencies pursuant to inspections that will be conducted after we submit a BLA or an NDA to the FDA or their equivalent to other regulatory agencies. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of our drug products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency and pure compounds or other products, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if regulatory authorities withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our or a third-party&#8217;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms, or to comply with cGMP could adversely affect our business in a number of ways, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to initiate or continue clinical trials of cirmtuzumab, TK216 or any future product candidates under development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">requirements to cease development or to recall batches of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">breach of the manufacturing agreement by the third-party&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to manufacture our product according to our specifications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure to manufacture our product according to our schedule, or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">misappropriation of our proprietary information, including our trade secrets and&#160;know-how&#59;&#160;and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">termination or nonrenewal of the agreement by the third-party at a time that is costly or inconvenient for us.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we currently rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements with our advisors, employees, consultants and contractors prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our&#160;know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered into and may seek to enter into additional collaborations, licenses and other similar arrangements, and we may not be successful in doing so, and we may not realize the benefits of such relationships.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints, in addition to our collaboration with Shanghai Pharmaceutical Holding Co., Ltd. and SPH USA. We may not be successful in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, we entered into a clinical trial and supply agreement with Pharmacyclics, LLC, an AbbVie Company, in support of our clinical trial to evaluate the combination of cirmtuzumab with ibrutinib. Ibrutinib is an<span style="color:#000000;"> inhibitor of Bruton&#8217;s tyrosine kinase, a key component of cell signaling in B-cells,</span> and is marketed by Pharmacyclics for treatment in patients with CLL and MCL. We initiated a Phase 1/2 clinical trial in May 2018 to assess cirmtuzumab in combination with ibrutinib in patients with CLL and MCL. Pursuant to the agreement, Pharmacyclics has supplied ibrutinib up to a maximum aggregate amount at no cost to us for part 1 (a dose-finding arm) and part 2 (dose expansion arm) of the ongoing Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib.&#160;&#160;Under the clinical trial and supply agreement with Pharmacyclics, we are required to provide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periodic reports to Pharmacyclics, including safety data reports, and to collaborate with Pharmacyclics in relation to any interactions with regulatory authorities regarding ibrutinib. The agreement includes no upfront costs, milestone or royalty payment commitments. In August 2019, Pharmacyclics agreed to provide additional quantities of ibrutinib at no cost to us for part 3 of the clinical trial, and so that patients who participated in parts 1 and 2 of the study may continue to receive ibrutinib in combination with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for as long as their disease is responding. In the event the clinical supply agreement is terminated, we would likely incur substantial additional costs in order to obtain and purchase ibrutinib from a source other than Pharmacyclics and the Phase 2 part 3 of the Phase 1/2 clinical trial may be delayed.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we would. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Commercialization of Our Product Candidates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following potential approval of any of our product candidates, the FDA may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications we filed or suspension or revocation of approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention, or refusal to permit the import or export of our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-2.81%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such&#160;off-label&#160;uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses, and a company that is found to have improperly promoted&#160;off-label&#160;uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in&#160;off-label&#160;promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. For example, the results of the 2020 U.S. Presidential Election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these orders will be implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of the new administration are unknown and could materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics, or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities and products, and on March 18, 2020 the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities.&#160;&#160;Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">demonstration of clinical efficacy and safety compared to other more-established products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the indications for which our product candidates are approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the limitation of our targeted patient population and other limitations or warnings contained in any&#160;FDA-approved&#160;labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of a new drug for the relevant indication by healthcare providers and their patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of patients to pay all, or a portion of,&#160;out-of-pocket&#160;costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any restrictions on the use of our products, and the prevalence and severity of any adverse effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential product liability claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of market introduction of our products as well as competitive drugs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effectiveness of our or any of our potential future collaborators&#8217; sales and marketing strategies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unfavorable publicity relating to the product.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be limited to patients who are ineligible for or have failed prior treatments and may be small or different from our estimates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, including targeted therapy, immunotherapy, chemotherapy, hormone therapy, surgery or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. In markets with approved therapies, there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive later stage therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. In addition, the potentially addressable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first- or second-line therapy.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty, and any processes adopted by the FDA to implement the BPCIA could have a material adverse effect on the future commercial prospects for our biological products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of&#160;off-label&#160;uses. If we are found or alleged to have improperly promoted&#160;off-label&#160;uses, we may become subject to significant liability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we are found to have promoted such&#160;off-label&#160;uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in&#160;off-label&#160;promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion and avoid off-label promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require&#160;co-payments&#160;that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the U.S., the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require&#160;pre-approval&#160;of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we or our collaborators may develop companion diagnostic tests for use with our product candidates as we are targeting certain defined populations for our treatments. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement sought for our product candidates, once approved. While we, or our collaborators, have not yet developed any companion diagnostic test for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain approval, coverage and adequate reimbursement for the same reasons applicable to our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the U.S, the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do, or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the fields of immunology, inflammation and oncology. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and&#160;in-licensing&#160;new product candidates. Smaller or early<span style="color:#000000;">-</span>stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved in oncology indications such as CLL or MCL, they will compete with small molecule therapies, biologics, cell-based therapies and vaccines, either approved or under development, that are intended to treat the same cancers that we are targeting, including through approaches that may prove to be more effective, have fewer side effects, be less costly to manufacture, be more convenient to administer or have other advantages over any product candidates we develop. In addition to competing with other therapies targeting similar indications, there are numerous other companies and academic institutions focused on similar targets as our product candidates and/or different scientific approaches to treating the same indications. We face competition from such companies in seeking any future potential collaborations to partner our product candidates, as well as potentially competing commercially for any approved products. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant progress has been made in the treatment of CLL since the advent of targeted therapies and FDA approval of ibrutinib for CLL in 2014. Three classes of targeted therapies have now been approved for the treatment of patients with CLL: inhibitors of BTK a key component of cell signaling in B-cells, such as ibrutinib, which is marketed as Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AbbVie, Inc., and Johnson &#38; Johnson, and acalabrutinib, which is marketed as Calquence<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AstraZeneca PLC&#59; inhibitors of the protein B-cell lymphoma-2, or Bcl-2, such as venetoclax, which is marketed as Venclexta<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Venclyxto<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by AbbVie, Inc., and Roche/Genentech&#59; and inhibitors of Phosphoinositide 3-kinase, or PI3K, which include idelalisib, which is marketed as Zydelig<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by Gilead Sciences, Inc., and duvelisib, which is marketed as Copiktra<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> by Verastem, Inc. These targeted therapies are now the core of the recommended treatment regimens for patients with both first-line and relapsed or refractory CLL, and have achieved objective response rates of 85-90%, two-year PFS of 65-90%, and two-year overall survival of 75-95%. The outcomes are worse for patients with certain prognostic factors, such as 17p or 11q chromosome deletions&#59; for such patients with relapsed or refractory CLL treated with ibrutinib, the reported PFS is 50-75%. While CLL is treatable, it generally remains incurable, and patients with CLL will generally experience a recurrence of their cancer. <span style="color:#000000;">Additionally, clinicians are investigating their potential in earlier stage disease in multiple clinical trials.&#160;&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several therapeutic options available to treat MCL. Newly diagnosed patients are typically treated with rituximab combined with a chemotherapy regimen known as CHOP, comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone. Alternative chemotherapy regimens include bortezomib or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bendamustine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Patients with clinical responses to chemotherapy may become candidates for another therapeutic approach, autologous stem cell transplantation, a procedure in which radiation and/or chemotherapy is used to eliminate the patient&#8217;s immune cells, including residual MCL cells. Recently, ibrutinib was granted accelerated approval by the FDA for the treatment of relapsed MCL. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, two other BTK inhibitors, acalabrutinib (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Calquence</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zanubrutinib</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brukinsa</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) have</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> been approved by the FDA for the treatment of patients with relapsed MCL. These therapies are given continuously for prolonged periods of time, and their use can be associated with significant toxicity.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current standard therapy for patients with localized Ewing sarcoma in the U.S. is a combination of chemotherapy agents, including vincristine, doxorubicin and cyclophosphamide, with alternating cycles of ifosfamide and etoposide &#8211; a therapy known as VDC/IE. Patients that respond to this therapy may be candidates for tumor resection and continued treatment for a total of 14 to 17 cycles. This therapeutic regimen, however, is associated with significant toxicities. Patients with metastatic disease are often treated with VDC/IE or variations of this therapy with higher or more compressed dosing. This may also be supplemented by local radiation therapy or systemic radiation followed by autologous hematopoietic stem cell transplant.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of products we may develop, if approved, could be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the market opportunities for our products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The precise incidence and prevalence for all the conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases, the number who have the specific indicated stage or treatment history we believe will be the approved indication, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the indication approved by regulatory agencies and the diagnostic criteria included in the final label for each of our product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the U.S. and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for any of our product candidates. To obtain separate regulatory approval in most other countries, we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, manufacturing, pricing and distribution of our product candidates. If we receive regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">different regulatory requirements for approval of drugs in foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced protection for intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the existence of additional third-party patent rights of potential relevance to our business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unexpected changes in tariffs, trade barriers and regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">economic weakness, including inflation, public health emergencies, or political instability in particular foreign economies and markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign reimbursement, pricing and insurance regimes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce uncertainty in countries where labor unrest is common&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions, including war and terrorism, public health emergencies, such as the outbreak of a novel strain of coronavirus affecting the People&#8217;s Republic of China and elsewhere or natural disasters including earthquakes, typhoons, floods and fires.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business Operations and Industry</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our product candidates, which may change from time to time&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and any manufacturing issues or challenges requiring additional manufacturing activities, and the terms of our agreements with third-party manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters such as earthquakes, typhoons, floods and fires or public health emergencies or pandemics such as the recent coronavirus (COVID-19) outbreak&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of any milestone or other payments we must make to the licensors and other third parties from whom we have&#160;in-licensed&#160;or acquired our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the level of demand for any approved products, which may vary significantly&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">future accounting pronouncements or changes in our accounting policies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a&#160;period-to-period&#160;basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are dependent on the services of our management and if we are not able to retain these individuals or recruit additional management or other key personnel, our business will suffer.</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned operations, planned clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter difficulties in managing our growth and expanding our operations successfully.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 5, <span style="color:#000000;">2021</span>, we had twelve full-time employees and two part-time employees. As we continue research and development activities and pursue the potential commercialization of our product candidates, as well as function as a public company, we will need to expand our financial, research, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for the company. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to various foreign, federal, and state healthcare laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, CMS, information related to payments and other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, such reporting obligations will also extend to payments and other transfer of value made during the prior calendar year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiology assistants and certified nurse midwives&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">analogous U.S. state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by&#160;non-&#160;governmental third-party payors, including private insurers, or by the patients themselves&#59; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources&#59; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities&#59; and state and local laws that require the registration of pharmaceutical sales representatives. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting arrangements with physicians and other healthcare providers, some of whom received stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, referred to collectively as the ACA, was enacted in the U.S. Among the provisions of the ACA of importance to our potential product candidates, the Affordable Care Act: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents&#59; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59; expands eligibility criteria for Medicaid programs&#59; expanded the entities eligible for discounts under the Public Health program&#59; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program&#59; created a new Medicare Part D coverage gap discount program&#59; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research&#59; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. For example, the Tax Cuts and Jobs Act, or the Tax Act, was signed into law, which included a provision repealing, effective January&#160;1, 2019, the&#160;tax-based&#160;shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well.  The U.S. Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule.&#160;&#160;It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA or our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August&#160;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-top:10pt;margin-bottom:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. The likelihood of success of these and other proposals initiated by the former Trump administration is uncertain, particularly in light of the new Biden administration.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients with life-threatening diseases or conditions to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. There is no obligation for a drug manufacturer to make our drug products available to eligible patients as a result of the Right to Try Act.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by HITECH. Any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or<span style="letter-spacing:-0.4pt;"> </span>conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In addition, the CCPA went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states. Further, the CPRA, was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January 1, 2023, and become enforceable on July 1, 2023.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, or EU, the GDPR went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S., and the efficacy and longevity of current transfer mechanisms between the EU and the U.S. remains uncertain. For example, in 2016, the EU and U.S. agreed to a transfer framework for data transferred from the EU to the U.S., called the Privacy Shield, but the Privacy Shield was invalidated in July 2020 by the Court of Justice of the EU. Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. Currently there is a four to six-month grace period agreed in the EU and United Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when) an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to the United Kingdom long term without additional measures. These changes may lead to additional costs and increase our overall risk exposure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. If we or our third-party CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our historical operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain workers&#8217; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injury to our reputation and significant negative media attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs to defend the related litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a diversion of management&#8217;s time and our resources&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to trial participants or patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product recalls, withdrawals or labeling, marketing or promotional restrictions&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant negative financial impact&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decline in our stock price.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold $10.0&#160;million in product liability insurance coverage in the aggregate. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We and any of our potential future collaborators will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR or the CCPA), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and&#160;follow-up&#160;actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a&#160;man-made&#160;or natural disaster or other business interruption. In addition, our corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (1)&#160;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2)&#160;manufacturing standards, including cGMP requirements, (3)&#160;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the U.S. and abroad or (4)&#160;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and&#160;out-licensing&#160;or&#160;in-licensing&#160;of intellectual property, products or technologies, similar to our approach in&#160;in-licensing&#160;and acquiring our current product candidates. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired&#160;in-process&#160;research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by licensing or filing patent applications in the U.S. and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our or our licensor&#8217;s patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our or our licensor&#8217;s patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we own and license issued patents in the U.S. and foreign countries, we cannot be certain that the claims in our or our licensor&#8217;s other U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent and Trademark Office, or USPTO, courts in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our or our licensor&#8217;s issued patents will not be found invalid or unenforceable if challenged.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we, our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patent applications may not result in any patents being issued&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is also expensive and time consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license,&#160;and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, although we enter into&#160;non-disclosure&#160;and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensees, collaboration partners, and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including with respect to cirmtuzumab and TK216, or otherwise experiences disruptions in our business relationships with our licensors, we could lose license rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to several license agreements under which we are granted rights to intellectual property that are important to our business and we may enter into additional license agreements in the future. For example, in March 2014, we entered into an exclusive license agreement with Georgetown University, or Georgetown, to obtain an exclusive license to certain intellectual property rights to develop and commercialize compounds targeting EWS-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLI1.&#160;&#160;In March 2016, we entered into an exclusive license agreement with the Regents of the University of California to obtain an exclusive license to certain intellectual property rights to develop and commercialize </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other ROR1 related naked antibodies.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These license agreements impose, and we expect that any future license agreements where we&#160;in-license&#160;intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be&#160;non-exclusive,&#160;thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope of rights granted under the license agreement and other interpretation-related issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to sublicense patents and other rights to third parties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our right to transfer or assign the license&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ownership of inventions and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our and our licensor&#8217;s patent rights are highly uncertain. Our and our licensor&#8217;s pending and future patent applications may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own or license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be able to circumvent our or our licensor&#8217;s patents by developing similar or alternative technologies or products in a&#160;non-infringing&#160;manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our and our licensor&#8217;s patents may not cover our product candidates or may be challenged in the courts or patent offices in the U.S. and abroad. Our and our licensor&#8217;s patents may be subject to a third-party&#160;pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and&#160;inter partes&#160;review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our or our licensor&#8217;s patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors or our licensor and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our or our licensor&#8217;s patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our or our licensor&#8217;s patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we or our licensors may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our or our licensor&#8217;s patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our or our licensor&#8217;s patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. If we or our licensors, whether current or future, fail to establish, maintain or protect our patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a licensee of third parties, we rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to our assuming control over patent prosecution.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical&#160;in-licensed&#160;technology, we may be unable to successfully develop, out-license,&#160;market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop,&#160;out-license&#160;or market and sell our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some of our intellectual property has been discovered through government funded programs and thus may be subject to federal regulations such as&#160;&#8220;march-in&#8221;&#160;rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with&#160;non-U.S.&#160;manufacturers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government funding and may therefore be subject to certain federal regulations. For example, some of the research and development work on cirmtuzumab and TK216 was funded by government research grants. As a result, the U.S. government may have certain rights to intellectual property embodied in our product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a&#160;non-exclusive,&#160;non-transferable,&#160;irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or&#160;non-exclusive&#160;licenses to any of these inventions to a third-party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention&#59; (ii)&#160;government action is necessary to meet public health or safety needs&#59; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as&#160;&#8220;march-in&#160;rights&#8221;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the U.S. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the U.S. or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with&#160;non-U.S.&#160;product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply. With respect to state funding, specifically funding via the California Institute of Regenerative Medicine, or CIRM which has granted funds for the study of cirmtuzumab in combination with ibrutinib and a novel anti-cancer stem cell targeted therapy, the grantee has certain obligations and the state or CIRM&#160;has certain rights. For example, the grantee has an obligation to share intellectual property, including research results, generated by CIRM-funded research, for research use in California. In addition, the California government can exercise march-in rights if it determines that action is necessary because we or the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grantee </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to achieve practical application of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CIRM</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-funded technology, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because we failed to comply with agreed to access and pricing requirements, or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because action is necessary to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">address a public health emergency declared by the governor of Cal</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fornia.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications that we own or license&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our licensors or predecessors might not have been the first to file patent applications covering certain of our inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">it is possible that our or our licensor&#8217;s pending patent applications will not lead to issued patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may not develop additional proprietary technologies that are patentable&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patents of others may have an adverse effect on our business.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, it could significantly harm our business, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on licensee relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including milestone payments and future royalty revenues.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully, our product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. Such disputes or litigation could adversely affect our rights to one or more of our product candidates and could delay, interrupt or terminate the collaborative research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. In addition, a significant downturn or deterioration in the business or financial condition of our collaborators or partners could result in a loss of expected revenue and our expected returns on investment. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our or our licensee&#8217;s research, development and commercialization activities may be subject to claims that we or our licensee infringes or otherwise violates patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our or our licensee&#8217;s ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">result in costly litigation that may cause negative publicity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">divert the time and attention of our technical personnel and management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">cause development delays&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subject us to an injunction preventing us from making, using, selling, offering for sale, or importing our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require us to develop&#160;non-infringing&#160;technology, which may not be possible on a cost-effective basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subject us to significant liability to third parties&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be&#160;non-exclusive,&#160;which could result in our competitors gaining access to the same technology.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although no third-party has asserted a claim of patent infringement against us as of December 31, 2020, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially reasonable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or our licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third-party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our or our licensor&#8217;s patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or&#160;non-enablement.&#160;Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to our or our licensor&#8217;s intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We or our licensor may not have sufficient financial or other resources to conduct or participate in such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we or our licensor can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derivation or interference proceedings provoked by third parties or brought by us or our licensors or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions with respect to our or our licensor&#8217;s patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensor&#8217;s defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the U.S. transitioned in March 2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third-party was first to invent the claimed invention. A third-party that files a patent application in the USPTO after March 2013 but before we could therefore be awarded a patent covering an invention of our even if we had made the invention before it was made by such third-party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensor was the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our or our licensor&#8217;s patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensor&#8217;s patent applications and the enforcement or defense of our or our licensor&#8217;s issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other countries may diminish the value of our intellectual property rights and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our or our licensor&#8217;s patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensor&#8217;s ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensor&#8217;s ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.&#160;non-provisional&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not obtain patent term extension for our product candidates, our business may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our or our licensor&#8217;s U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our or our licensor&#8217;s patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we and our licensors have issued patents and pending patent applications in the U.S. and certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we or our licensor has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our and our licensor&#8217;s patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensor may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our licensor&#8217;s efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensor is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our and our licensors&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent office&#8217;s require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we rely on the protection of our trade secrets, including unpatented&#160;know-how,&#160;technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented&#160;know-how,&#160;including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An active, liquid and orderly market for our common stock may not be maintained.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our common stock is listed on the Nasdaq Capital Market, or Nasdaq, an active trading market for our common stock may never develop or, if it develops, <span style="color:#000000;">it may</span> not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The trading price of the shares of our common stock may be highly volatile, and purchasers of our common stock may incur substantial losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above their purchase price. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="color:#000000;"> or our collaborators</span><span style="color:#000000;"> ability to enroll subjects in our ongoing and planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of our clinical trials and preclinical studies, and the results of the trials of our competitors or those of other companies in our market sector&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the U.S. and foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success or failure of our efforts to acquire, license or develop additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">innovations or new products developed by us or our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">announcements regarding the results of discovery efforts and preclinical, clinical and commercial activities by us, or those of our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing, supply or distribution delays or shortages&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">achievement of expected product sales and profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our financial results or those of companies that are perceived to be similar to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trading volume of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establishment of short positions by holders or non-holders of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to obtain additional funding&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our stock by insiders and stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, industry and market conditions or other events or factors, many of which are beyond our control&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">intellectual property, product liability or other litigation against us.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our executive officers, directors and principal stockholders, if they choose to act together, will continue to control or significantly influence all matters submitted to stockholders for approval. Furthermore, two of our directors have been appointed by one of our principal stockholders.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our executive officers, directors and greater than 5% stockholders, in the aggregate, owned approximately 9.70% of our outstanding common stock. Furthermore, two of our directors have been appointed by our largest stockholder, SPH USA. As a result, such persons or their appointees to our board of directors, acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock by our stockholders in the public market could cause our stock price to fall.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. As of December 31, 2020, 44,077,016 shares of our outstanding common stock are freely tradable, without restriction, in the public market, unless they are purchased by one of our affiliates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, up to 8,195,327 shares of common stock that are either subject to outstanding warrants, options or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the exclusive right of our board of directors, unless the board of directors&#8217; grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prohibition on removal of directors without cause due to the classified board of directors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the required approval of at least&#160;66-2/3%&#160;of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal certain provisions of our amended and restated certificate of incorporation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to the anti-takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the Merger does not qualify as a &#8220;reorganization&#8221; for U.S. federal income tax purposes, U.S. Holders of our common stock will be required to recognize gain or loss for U.S. federal income tax purposes upon the exchange of their Private Oncternal common stock for our common stock in the Merger.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal income tax consequences of the Merger to U.S. Holders will depend on whether the merger qualifies as a &#8220;reorganization&#8221; for U.S. federal income tax purposes.&#160;&#160;Our and Private Oncternal&#8217;s obligations to effect the Merger were subject to the satisfaction, or waiver, at or prior to the effective time of the Merger, of the condition that each company receive an opinion of counsel, dated as of the closing date of the Merger, to the effect that the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code.&#160;&#160;If, contrary to the opinions from counsel, the Merger fails to qualify as a reorganization within the meaning of Section 368(a) of the Code, a U.S. Holder of Private Oncternal common stock would recognize gain or loss for U.S. federal income tax purposes on each share of Private Oncternal common stock surrendered in the Merger for our common stock and any cash received in lieu of a fractional share.&#160;&#160;For purposes of this discussion, a U.S. Holder is a beneficial owner of Oncternal common stock that, for U.S. federal income tax purposes, is or is treated as: an individual who is a citizen or resident of the U.S.&#59; a corporation created or organized under the laws of the U.S., any state thereof, or the District of Columbia&#59; an estate, the income of which is subject to U.S. federal income tax regardless of its source&#59; or a trust that (i) is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code) over all of its substantial decisions or (ii) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use net operating loss (&#8220;NOL&#8221;) carryforwards and other tax attributes may be limited.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all). As of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020, we had federal and state NOL carryforwards of approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively. Approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.4</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of NOLs do not expire and the remaining federal and state NOL carryforward will begin to expire in 2033</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 2032, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, unless previously utilized. </span><span style="color:#000000;">As of December 31, 2020, we had federal and state research and development credit carryforwards of approximately $</span><span style="color:#000000;">1.3</span><span style="color:#000000;"> million and $</span><span style="color:#000000;">0.9</span><span style="color:#000000;"> million, respectively. The federal research and development credit carryforwards will begin expiring in 2034, unless previously utilized. The state research and development credits do not expire.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Tax Act, federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely but federal NOLs generated in taxable years beginning after December 31, 2017 may only be used to offset 80% of our taxable income annually. Under Sections&#160;382 and 383 of the Code, our NOL and research and development tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including changes resulting from our Merger. We have not yet determined the amount of the cumulative change in our ownership resulting from the Merger or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Tax Act has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes became effective beginning in 2018, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury Department and the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. There may be other material adverse effects resulting from the legislation that we have not yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stockholders prior to the Merger who hold CVRs may not receive any payment on the CVRs and the CVRs may otherwise expire valueless.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and certain other parties have entered into a <a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex101.htm"><span style="text-decoration:none;">CVR Agreement, dated as of June 7, 2019, or </span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the CVR Agreement, pursuant to which, for each share of GTx common stock held, stockholders of record as of immediately prior to the Merger received one contingent value right, or CVR, entitling such holders to receive in the aggregate 75% of any net proceeds received during the 15-year period after the closing of the Merger from the grant, sale or transfer of rights to our SARD or SARM technology that occurs during the 10-year period after the closing of the Merger (or in the 11th&#160;year if based on a term sheet approved during the initial 10-year period) and, if applicable, to receive royalties on the sale of any SARD products or SARM products by us during the 15-year period after the closing of the Merger.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we announced that we had ceased development of the SARM technology following the failure of a Phase 2 clinical study of enobosarm to achieve statistical significance with respect to the primary endpoint of the study. Effective March<span style="color:#000000;"> 31, 2020, we </span>terminated<span style="color:#000000;"> the amended </span>and restated license agreement with UTRF for the development and production of the SARM technology, and we no longer have: (i) the obligation to make further payments to UTRF under the SARM license agreement, including payments for patent prosecution and maintenance, and (ii) any rights to develop or sublicense the SARM technology.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CVRs are not transferable, will not have any voting or dividend rights, and interest will not accrue on any amounts potentially payable on the CVRs. Accordingly, the right of any stockholder of record as of immediately prior to the Merger to receive any future payment on or derive any value from the CVRs will be contingent solely upon the achievement of the foregoing events within the time periods specified in the CVR Agreement and if these events are not achieved for any reason within the time periods specified in the CVR Agreement, no payments will be made under the CVRs, and the CVRs will expire valueless. In addition, we (as successor in interest to GTx) have agreed only to use commercially reasonable efforts to develop SARD products, subject to certain limitations, which allows for the consideration of a variety of factors in determining the efforts that we are required to use to develop SARD products, and we are not required to take all possible actions to continue efforts to develop SARD products. Accordingly, under certain circumstances we may not be required to continue efforts to develop SARD products, or may allocate resources to other projects, which would have an adverse effect on the value, if any, of the CVRs. Furthermore, the CVRs will be unsecured obligations of our company and all payments under the CVRs, all other obligations under the CVR Agreement and the CVRs and any rights or claims relating thereto will be subordinated in right of payment to the prior payment in full of all of our current or future senior obligations. Finally, the U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS, would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action we take to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future&#160;non-compliance&#160;with Nasdaq&#8217;s listing requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements that apply to us. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. If these requirements </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our common stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;404 of Sarbanes-Oxley, we are required to report upon the effectiveness of our internal control over financial reporting. Additionally, our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade our information technology systems&#59; implement additional financial and management controls, reporting systems and procedures&#59; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="color:#000000;"> may become involved in the future, in securities class action litigation that could divert management&#8217;s attention, adversely affect our business and subject us to significant liabilities.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been brought against a company following volatility in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future lawsuits to which we may become a party are subject to inherent uncertainties and will likely be expensive and time-consuming to investigate, defend and resolve, and will divert our management&#8217;s attention and financial and other resources. The outcome of litigation is necessarily uncertain, and we could be forced to expend significant resources in the defense of future lawsuits, and we may not prevail. Any litigation to which we may become a party may result in an onerous or unfavorable judgment that may not be reversed upon appeal or in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments of substantial monetary damages or fines, or we may decide to lawsuits on similarly unfavorable terms, which could adversely affect our business, financial condition, results of operations or stock price.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Unresolved Staff Comments.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES">Properties.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are <span style="color:#000000;">located in San Diego, California, where we currently sublease 4,677 square feet of office space used primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Our sublease for this facility expires on March 31, 2021, and we are actively negotiating an extended lease arrangement for the same office space.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGSFROM_Q3_FORM_10Q">Legal Proceedings.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Mine Safety Disclosures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART&#160;II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT&#8221;. As of March 3, 2021, there were approximately 130 holders of record of our common stock.&#160;&#160;<span style="color:#000000;">This number was derived from our stockholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_SELECTED_FINANCIAL_DATA_MAY_NOT_B">Selected Financial Data.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reserved.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and future financial performance, includes forward-looking statements that are based upon current beliefs, plans and expectations and involve risks, uncertainties and assumptions. You should review the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that could cause our actual results and the timing of selected events to differ materially from those described in or implied by the forward-looking statements contained in the following discussion and analysis. Please also see the section within Part&#160;I of this Annual Report entitled &#8220;Forward-Looking Statements.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated or as the context otherwise requires, the historical financial information included in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is that of Private Oncternal prior to the Merger because Private Oncternal was deemed to be the accounting acquirer in the Merger for financial reporting purposes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Our development efforts are focused on promising, yet untapped, biological pathways implicated in cancer generation or progression. Our pipeline includes cirmtuzumab, an investigational monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance. Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma, or CIRLL), for the treatment of patients with B-cell lymphoid malignancies, including <span style="color:#000000;">mantle cell lymphoma, or </span>MCL, <span style="color:#000000;">and chronic lymphocytic leukemia, or </span>CLL, and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. We are developing a chimeric antigen receptor T cell, or CAR-T, therapy candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, we are developing TK216, an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. TK216 is being evaluated in a Phase 1 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">U.S. Food and Drug Administration, or </span>FDA, has granted orphan drug designations for cirmtuzumab for the treatment of MCL and for the treatment of CLL/small lymphocytic lymphoma, and has granted rare pediatric disease designation, as well as orphan drug and fast track designations for TK216 for the treatment of Ewing Sarcoma.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:4.44%;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2020, we announced an updated clinical strategy for cirmtuzumab that prioritizes development in MCL, based on encouraging interim clinical results from the CIRLL Phase 1/2 clinical trial that were presented at the ASCO 2020 annual meeting. &#160;As a result, we amended the CIRLL study to increase the number of patients with relapsed/refractory MCL to be enrolled in the Phase 2 expansion cohort to at least 20 patients and to allow the enrollment of patients with a broader range of prior BTK inhibitor treatments.&#160; In addition, we limited the total enrollment of CLL patients in the randomized Phase 2 CLL cohort of the CIRLL study to&#160;28 patients, in order to focus resources on the MCL portion of the study. In September 2020, we met with the FDA and are in dialogue with the FDA regarding potential accelerated approval pathways for cirmtuzumab plus ibrutinib in patients with relapsed/refractory MCL. Additionally, we are supporting a new, investigator-sponsored Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL in collaboration with the UC San Diego School of Medicine, or UC San Diego.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since Private Oncternal&#8217;s inception in 2013, we have devoted most of our resources to organizing and staffing, business planning, raising capital, acquiring product candidates and securing related intellectual property rights and advancing our </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cirmtuzumab</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and TK216 clinical development programs.&#160;&#160;Under research subaward agreements between us and UC San Diego, we are eligible to receive approximately $14.0 million in development milestones throughout the award project period, estimated to be from October&#160;1, 2017 to March&#160;31, 2022.&#160;&#160;Through December&#160;31, 2020, we have funded our operations primarily through: </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gross proceeds of $125.0 million from the issuance of common stock, (ii) </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gross proceeds of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0 million from the issuance of convertible preferred stock, (ii</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;receipt of $11.6 million in subaward grant payments received from UC San Diego, and (i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) cash proceeds of $18.3 million received in connection with the closing of the Merger described</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in Part I, Item 1, &#8220;Merger&#8221; of this Annual Report</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;As of December&#160;31, 2020, we had cash and cash equivalents of $116.7 million.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each year since inception.&#160;&#160;Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates.&#160;&#160;Our net losses were $17.2 million and $34.2 million (including $18.1 million related to nonrecurring merger costs) for the years ended December&#160;31, 2020 and 2019, respectively.&#160;&#160;As of December&#160;31, 2020, we had an accumulated deficit of $82.8 million.&#160;&#160;Substantially all of our net losses have resulted from costs incurred in connection with: (i) advancing our research and development programs, (ii) general and administrative costs associated with our operations, including the costs associated with operating as a public company, and (iii) in-process research and development costs associated with the Merger.&#160;&#160;We expect to continue to incur significant and increasing operating losses for at least the next several years.&#160;&#160;We expect that our expenses and capital funding requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance cirmtuzumab through clinical development in multiple indications, with a primary focus in MCL&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>generate clinical proof-of-concept data with TK216 in Ewing sarcoma, an orphan pediatric cancer indication&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance our ROR1-targeting CAR-T therapy candidate to clinical development, initially in hematological cancers and then in solid tumors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>respond to the impacts of the COVID-19 pandemic, which has slowed enrollment into our clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate cirmtuzumab in additional ROR1-positive solid tumors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate TK216 in additional tumors with ETS fusion proteins or overexpression&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue to develop additional product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acquire or in&#8209;license other product candidates and technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintain, expand and protect our intellectual property portfolio&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek regulatory approvals for any product candidates that successfully complete clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>add operational, financial and management information systems and personnel, including personnel to support our planned product development and future commercialization efforts, as well as to support our transition to a public reporting company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.73%;text-indent:-2.81%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate product sales revenue unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates.&#160; If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution.&#160; In addition, we expect to incur additional costs associated with operating as a public company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we believe we will need substantial additional funding to support our continuing operations and pursue our business strategy. Until such time as we can generate significant product sales revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements.&#160;&#160;We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.&#160;&#160;If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in licenses or acquisitions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable.&#160;&#160;If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months.&#160;&#160;We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Beyond that point, we will need to raise additional capital to finance our operations, which cannot be assured.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing and modifying varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have put restrictions on employee travel and working from our executive offices, with many employees continuing their work remotely. To date, we have been able to continue to supply cirmtuzumab and TK216 clinical trial sites for patients enrolled in our ongoing clinical trials and do not currently anticipate any interruptions in the supply of cirmtuzumab or TK216. While we are continuing the clinical trials we have underway in sites across the U.S., we expect that COVID-19 precautions may directly or indirectly impact the timeline for some of our clinical trials. For example, some of our clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. For our existing patients, we are actively working with all of our clinical trial sites to minimize disruptions and address concerns on an individual site or patient basis in order to allow participating patients to continue to receive treatment at home or in alternative healthcare settings while minimizing their potential exposure to the virus that causes COVID-19. If restrictions related to the COVID-19 outbreak continue for a prolonged period of time or if additional clinical trial sites pause patient enrollment or treatments, our clinical trial milestones would be negatively impacted.&#160; Additionally, our expectations for the timing of first-in-human dosing of our ROR1 CAR-T therapy in China has been delayed. Any delays in the completion of our clinical trials and any disruption in our supply chain could have a material adverse effect on our business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not and do not expect to generate any product sales revenue in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate product sales revenue in the future. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. Our grant revenue has been derived from a California Institute for Regenerative Medicine, or CIRM, grant subaward with UC San Diego.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance our Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. Oncternal is conducting this study in collaboration with UC San Diego and estimates it will receive approximately $14.0 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022. In addition, we are committed to certain co-funding requirements and are required to provide UC San Diego progress and financial update reports throughout the award project period. We received subaward payments of $1.4 million and $6.2 million in the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we believe we have met our obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for the preclinical and clinical development of our product candidates, cirmtuzumab, TK216 and our ROR1-targeting CAR-T therapy candidate, which include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>expenses under agreements with third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs related to develop and manufacture preclinical study and clinical trial material&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>salaries and employee-related costs, including stock-based compensation&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs incurred under our collaboration and third-party licensing agreements&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>laboratory and vendor expenses related to the execution of preclinical and clinical trials.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue all research and development costs in the period for which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred and then expensed as the related goods are delivered and as services are performed. Any unearned advances would be refunded when known. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially for the foreseeable future as we: (i) invest in additional operational personnel to support our planned product development efforts, and (ii) continue to invest in developing our product candidates preclinically, advance them into later stages of clinical development, and as we begin to conduct larger clinical trials. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, contract research organizations, or CROs, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by product candidate unless </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we can include them </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as subaward costs.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development, including any potential expanded dosing beyond the original protocols based in part on ongoing clinical success and the potential effects of the COVID-19 pandemic. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments of each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related costs, insurance costs, facility costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. Personnel-related costs consist of salaries, benefits and stock-based compensation. We expect our general and administrative expenses will increase substantially as we: (i) incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs, (ii) hire additional personnel, and (iii) protect our intellectual property.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Income (Expense)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Preferred Stock Warrant Liability</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with Private Oncternal&#8217;s Series B-2 preferred stock financing in 2017, Private Oncternal issued warrants to purchase shares of its Series B-2 preferred stock. We classified these warrants as a liability on our consolidated balance sheets and remeasured them to fair value at each reporting date, and we recognized changes in the fair value of the warrant liability as a component of other income (expense), net in our consolidated statements of operations. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the closing of the Merger, all outstanding warrants to purchase Private Oncternal Series B-2 preferred stock were converted into warrants to purchase our common stock. As a result, such warrants no longer require liability accounting and the fair value of the warrant liability has been reclassified to stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received a loan under the Paycheck Protection Program, or PPP, a program implemented by the U.S. Small Business Administration, or SBA, under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. The loan forgiveness was recorded as other income in the consolidated statement of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash equivalents, which consist of money market funds. Our interest income has not been significant due to low interest earned on invested balances.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31,&#160;2020 and 2019</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December&#160;31,&#160;2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,375</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,425</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,544</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,159</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,385</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,088</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,088</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,373</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,286</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,087</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,917</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,533</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,616</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,542</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,108</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,566</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,268</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,268</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(172</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">317</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,080</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,397</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,225</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,188</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,963</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue for the year ended December 31, 2020 was $3.4 million, compared to $2.4 million for the year ended December 31, 2019. The increase of $1.0 million was primarily due to an increase in the revenue recognition rate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the periods indicated (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase/</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,359</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,156</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,101</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,239</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">408</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,542</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,494</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,048</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,544</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,159</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,385</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the years ended December 31, 2020 and 2019 were $12.5 million and $10.2 million, respectively, an increase of $2.4 million. The increase was primarily due to: (i) a $1.3 million net increase in direct product candidate costs, and (ii) a $1.0 million increase in unallocated research and development expenses.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for cirmtuzumab increased $0.2 million for the year ended December 31, 2020, compared to the year ended December 31, 2019, primarily due to the following partially offsetting factors: (i) a $0.2 million increase in preclinical study costs, (ii) a $0.7 million increase in manufacturing development costs, and (iii) a $0.7 million decrease in license and milestone fees under the Regents License Agreement, as defined below. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for TK216 increased $1.2 million for the year ended December 31, 2020, compared to the year ended December 31, 2019, primarily due to an increase in clinical trial costs related to our ongoing Phase 1 clinical trial of TK216 in refractory Ewing sarcoma.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated expenses increased $1.0 million for the year ended December 31, 2020, compared to the year ended December 31, 2019, primarily due to higher personnel costs, including higher share-based compensation expense of $0.3 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In-Process Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development expenses decreased $18.1 million for year ended December 31, 2020, compared to the year ended December 31, 2019, due solely to the completion of the Merger in 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the years ended December 31, 2020 and 2019 were $8.4 million and $7.3 million, respectively, an increase of $1.1 million. The increase is primarily due to the following partially offsetting factors: (i) higher personnel and professional related costs of $1.3 million, <span style="color:#000000;">including higher share-based compensation expense of $0.7 million,</span> (ii) higher director&#8217;s and officer&#8217;s insurance costs of $0.6 million, (iii) lower patent costs of $0.3 million, and (iv) lower public company and other expenses of $0.5 million.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Income (Expense) </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income of $0.3 million in 2020 was primarily related to the forgiveness of the PPP loan. Other expense of $1.3 million in 2019 was primarily related to the change in fair value of warrant liability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and negative cash flows from operations since inception. As of December 31, 2020, we had an accumulated deficit of $82.8 million and anticipate that we will continue to incur net losses for the foreseeable future. <span style="color:#000000;">As of December&#160;31, 2020, we had $116.7 million in cash and cash equivalents. We believe we have sufficient cash to</span> fund our projected operating requirements into 2023<span style="color:#000000;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our net cash flow activity for each of the periods presented (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,495</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,746</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,137</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,181</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,686</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(594</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, operating activities used $17.5 million, resulting from our net loss of $17.2 million, which included net non-cash charges of $1.4 million related to stock-based compensation, lease expense, and forgiveness of the paycheck protection program loan, offset by a $1.7 million change in our operating assets and liabilities. The $1.7 million change in operating assets and liabilities primarily consisted of the following partially offsetting activities: (i) a $2.0 million decrease in deferred revenue, (ii) a $0.7 million increase in prepaid and other assets and operating lease liability, and (iii) a $1.0 million increase in accounts payable and accrued expenses.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, operating activities used $16.7 million of cash, resulting from our net loss of $34.2 million, which included non-cash charges of: (i) $18.1 million related to the acquisition of in-process research and development in connection with the Merger, (ii) $1.3 million related to the change in fair value of warrant liability, and (iii) $0.5 million related to stock-based compensation charges&#59; partially offset by a $2.4 million change in operating assets and liabilities. The net $2.4 million change in operating assets and liabilities primarily consisted of a $6.0 million decrease in accounts payable and accrued liabilities and a $3.6 million increase in deferred revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was none for the year ended December 31, 2020. Net cash provided by investing activities was $16.1 million for the year ended December 31, 2019, primarily resulting from cash received in connection with the Merger. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities provided cash of $114.2 million for the year ended December 31, 2020, which primarily consisted of $113.9 million in net proceeds received from various public offerings. Financing activities provided cash of $15,000 for the year ended December 31, 2019, consisting of option and warrant exercises. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 21, 2020, we completed a registered direct offering pursuant to which we concurrently sold: (i) 1,943,636 shares of our common stock, and (ii) warrants to purchase up to an aggregate of 971,818 shares of common stock, at a combined price of $2.5725 per share. The net proceeds to us from this offering were $4.4 million, after deducting placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 21, 2020, we completed a registered direct offering pursuant to which we concurrently sold: (i) 2,581,867 shares of our common stock, and (ii) warrants to purchase up to an aggregate of 1,290,933 shares of common stock, at a combined price of $2.3825 per share. The net proceeds to us from this offering were $5.7 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2020, we completed an underwritten public offering pursuant to which we sold 2,428,886 shares of our common stock at a price to the public of $2.10 per share. The net proceeds to us from this offering were $4.4 million, after deducting the underwriter&#8217;s discounts and commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the underwriter&#8217;s warrants. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 20, 2020, we completed an underwritten public offering pursuant to which we sold 7,725,065 shares of our common stock at a price to the public of $3.10 per share. The net proceeds to us from this offering were $20.4 million, after deducting the underwriter&#8217;s discounts and commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the underwriter&#8217;s warrants. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 14, 2020, we completed an underwritten public offering pursuant to which we sold 19,161,667 shares of our common stock at a price to the public of $4.50 per share. The net proceeds to us from this offering were $79.0 million, after deducting the underwriter&#8217;s discounts and commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the underwriter&#8217;s warrants. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Capital Requirements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the research and development of, and seek regulatory approvals for, our product candidates and conduct additional research and development activities. Our product candidates have not yet achieved regulatory approval and we may not be successful in achieving commercialization of our product candidates.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash and cash equivalents as of March 11, 2021 will be sufficient to fund our projected operating requirements into 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our planned operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. For example, the FDA or other regulatory authorities may require us to generate additional data or conduct additional preclinical studies or clinical trials, or may impose other requirements beyond those that we currently anticipate. Additionally, it is possible for a product candidate to show promising results in preclinical studies or in clinical trials, but fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals. As a result of these and other risks and uncertainties and the probability of success, the duration and the cost of our research and development activities required to advance a product candidate cannot be accurately estimated and are subject to considerable variation. We may encounter difficulties, complications, delays and other unknown factors and unforeseen expenses in the course of our research and development activities, any of which may significantly increase our capital requirements and could adversely affect our liquidity.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital for the research and development of our product candidates and to perform our research and development obligations under our collaboration agreement with UC San Diego, and we may be forced to seek additional funds sooner than expected to pursue our research and development activities. We expect to finance our capital requirements in the foreseeable future through a combination of the sale of public or private equity or debt securities, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements. There can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. Any of these events could significantly harm our business, operations, financial condition and prospects.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our forecast of the period of time through which our existing cash and cash equivalents and investments will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the type, number, scope, progress, expansions, results, costs and timing of our preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future&#59;<span style="font-size:7pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs incurred as a result of the COVID-19 pandemic, including clinical trial delays&#59; the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of obtaining ibrutinib, for which we currently obtain supply at no cost under our clinical supply agreement with Pharmacyclics LLC, and vincristine to conduct our clinical trials of cirmtuzumab and TK216, respectively&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs, timing and outcome of seeking and obtaining regulatory approvals our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements, including milestone or other payments under our existing in-license agreements and any in-license agreements that we may enter into in the future&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs associated with any products or technologies that we may in-license or acquire&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the cost of establishing sales, marketing, manufacturing and distribution capabilities for, and the pricing and reimbursement of, any products for which we may receive regulatory approval.</p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot continue or expand our research and development operations, or otherwise capitalize on our business opportunities, because we lack sufficient capital, our business, operations, financial condition and prospects could be materially adversely affected.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into the ATM Sales Agreement, pursuant to which we were able to offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million.&#160; In August 2020, we terminated the ATM Sales Agreement and can no longer offer and sell shares under the ATM Sales Agreement. In connection with our sale of common stock and common stock warrants in July 2020, we agreed not to enter into other variable rate transactions prior to July 21, 2021, other than pursuant to an at-the-market offering facility with the placement agent. We do not currently have an active at-the-market facility available to us.  </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under current SEC regulations, if at any time our public float is less than $75.0 million, and for so long as our public float remains less than $75.0 million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of our public float, which is referred to as the baby shelf rules. As of December 31, 2020, our calculated public float exceeded $75.0 million. In January 2021, our Form S-3 registration statement expired and we no longer have an effective Form S-3 shelf registration statement available. Future sales of our common stock, if any, will depend on a variety of factors including, but not limited to, the expected timing for achieving key milestones, including completing and announcing results of clinical trials of cirmtuzumab and TK216 and announcing the first-in-human dosing of our CAR-T product candidate targeting ROR-1, currently in preclinical development, prevailing market conditions, the trading price of our common stock and our capital needs. There can be no assurance that we will be successful in consummating future sales of our securities based on prevailing market conditions or in the quantities or at the prices that we deem appropriate or that we will enter into a new at-the-market offering facility.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a number of license agreements, pursuant to which we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. As of December 31, 2020, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. See Note 4 to our consolidated financial statements included elsewhere in this Annual Report for a description of these agreements. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable contracts.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates are based on our historical trends and other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our significant accounting policies are described in more detail in Note 1, &#8220;<span style="font-style:italic;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</span>,&#8221; in the notes to our consolidated financial statements as of December 31, 2020 and 2019 and for each of the years ended December 31, 2020 and 2019, appearing elsewhere in this Annual Report. However, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for our own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. We record accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, we analyze progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from our estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation of Warrants to Purchase Convertible Preferred Stock</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, we classified outstanding warrants to purchase shares of our Series B-2 convertible preferred stock as a liability on our consolidated balance sheets as these warrants were free-standing financial instruments exercisable into contingently redeemable shares. The warrants were initially recorded at fair value on the date of grant, and were subsequently remeasured to fair value at each balance sheet date while the instrument was outstanding. Changes in the fair value of these warrants were recognized as a component of other income (expense) in our consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase our common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#8217; equity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently generate revenue from a research subaward agreement with UC San Diego, which provides us with payments for certain types of expenditures in return for research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying costs are incurred and services are rendered, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-</span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">B</span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">ased </span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">C</span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">ompensation </span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">E</span><span style="font-style:italic;color:#000000;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">xpense</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the estimated grant date fair value of stock option awards and employee stock purchase plan rights amortized over the requisite service period of the awards (usually the vesting period) primarily on a straight-line basis. We estimate the fair value of all stock option grants using the Black-Scholes option pricing model and recognize forfeitures as they occur.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the fair value of equity awards as of the grant date using valuation models, such as the Black-Scholes option pricing model, is affected by assumptions regarding a number of complex variables, including the expected stock price volatility, the risk-free interest rate, the expected term of stock options, the expected dividend yield and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Quantitative and Qualitative Disclosures About Market Risk.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENT_OR_SUPPLEMENT">Financial Statement and Other Supplementary Information.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Consolidated Financial Statements and supplementary data of Oncternal Therapeutics, Inc. required by this Item are described in Item 15 of this Annual Report on Form 10-K and are presented beginning on page F-1.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORTINDEPENDENTREGISTEREDPUBLICACC">Report of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders and Board of Directors </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Oncternal Therapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-align:justify;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Accruals</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Notes 1 and 2 to the consolidated financial statements, the Company has recorded $1.0 million for accrued clinical trial expenses for the estimated costs incurred but not yet billed or paid as of December 31, 2020.&#160;&#160;When payment terms under the related contracts do not align with the pattern of costs incurred, the Company is required to make estimates of the outstanding obligations as of period end.&#160;&#160;When evaluating the adequacy of the accrued clinical trial liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs, which could involve significant judgments, estimates and specialized knowledge. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified clinical trial accruals as a critical audit matter due to the application of significant management judgement over the estimate of services provided as of year-end. Specifically, the amount of accrued clinical trial expenses recognized is sensitive to the availability of information to make the estimate, including the estimate of the progress of the clinical trial and the level of effort expended including patient enrollment and follow-up activity as of the balance sheet date and the associated cost of such services. Auditing these elements involved especially subjective auditor judgment due to the nature of the audit evidence available to address these matters. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary procedures we performed to address this critical audit matter included:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Reviewing the Company&#8217;s contractual agreements with third parties and any change orders to assess the impact to the amounts recorded including changes in scope and timing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Testing clinical accrual cutoff and evaluating the completeness and valuation of clinical accruals by comparing invoices received by the Company subsequent to December 31, 2020 to the amounts recognized by the Company as of that date.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Testing clinical accrual for completeness and accuracy by confirming amounts due at December 31, 2020 directly with clinical research organizations (CROs) including total expenses incurred for all services provided by the CRO during 2020. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ BDO USA, LLP</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2016.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except par value)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20191231" decimals="-3" scale="3">190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">767</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:Assets" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:Assets" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, net of current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000057">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000058">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000071" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000072" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000073" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000074" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">none</ix:nonFraction> at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December&#160;31, 2020 and 2019, respectively&#59; issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000075" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000076" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000059">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000060">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000079" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000080" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20191231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">60,000</ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; at December&#160;31, 2020 and 2019, respectively&#59; issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000083" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">48,802</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000084" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">15,387</ix:nonFraction></ix:nonFraction> at December&#160;31, 2020 and 2019,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(thousands, except per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:Revenues" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:Revenues" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,533</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">33,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,080</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000106" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20200101_20201231" decimals="2" sign="-">0.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000107" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20190101_20191231" decimals="2" sign="-">3.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000108" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20200101_20201231" decimals="0" format="ixt:numdotdecimal">20,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000109" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20190101_20191231" decimals="0" format="ixt:numdotdecimal">10,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on forgiveness of payroll protection program loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of preferred stock warrants liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,268</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">529</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">44</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">272</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="onct:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" scale="3">150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="onct:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">16,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash acquired in connection with the Merger</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:CashAcquiredFromAcquisition" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition related costs paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from payroll protection loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options and common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="onct:ProceedsFromStockOptionsExercisedAndWarrantExercises" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="onct:ProceedsFromStockOptionsExercisedAndWarrantExercises" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock and common stock warrants,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,181</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" scale="3">594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,645</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of 2019 bonus awards with stock options in lieu of cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockIssued1" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued to placement agent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="onct:FairValueOfWarrantsIssuedToPlacementAgent" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,325</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on forgiveness of payroll protection program loan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="onct:ConversionOfConvertiblePreferredStockToCommonStock" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to GTx stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:StockIssued1" contextRef="C_0001260990_deiLegalEntityAxis_onctGTxIncMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of preferred stock warrants liability to additional paid-in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="onct:ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net liabilities assumed in Merger</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF">Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000153" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" format="ixt:numdotdecimal" scale="3">8,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">3,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">29,631</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000160" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to repurchase liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to former stockholders of GTx</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; upon Merger</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000167" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">3,458</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock upon Merger</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000171" name="onct:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">8,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="onct:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000173" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">8,148</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="-3" scale="3">8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,588</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of convertible preferred stock warrant</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,942</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">34,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000183" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">15,387</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000191" name="onct:ExerciseOfCashlessWarrantShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to repurchase liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of issuance cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000194" name="onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">33,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">113,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of 2019 bonus awards with stock option in lieu of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000204" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">48,802</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">Notes to<span style="color:#000000;"> </span>Consolidated Financial Statements</p><ix:nonNumeric id="F_000211" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000211_dcnt_68eb9a05-ac6c-44d6-b8d2-fb4f213c5440">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Business,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">Basis</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Presentation<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>Summary<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.45pt;"> </span>Significant<span style="letter-spacing:-0.5pt;"> </span>Accounting<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">Policies</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.</p><ix:nonNumeric id="F_000222" name="us-gaap:BusinessCombinationsPolicy" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000222_dcnt_3b8205fa-0884-4fe6-96d5-c052d23595a2">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221; &#8220;the Company,&#8221; and the &#8220;combined company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000252" name="onct:StockExchangeRatio" contextRef="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607" decimals="6">0.073386</ix:nonFraction> shares of Company common stock (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split, as defined below. Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000253" name="onct:OwnershipPercentageOfStockholdersUponClosingOfMerger" contextRef="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607" decimals="3" scale="-2">77.5</ix:nonFraction>% of the outstanding common stock of the combined company. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#8217;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#8217;s senior management holds all key positions in the senior management of the combined company. <span style="color:#000000;">As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the Merger are those of Private Oncternal. &#160;</span></p>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_68eb9a05-ac6c-44d6-b8d2-fb4f213c5440" continuedAt="F_000211_dcnt_2cd19f47-68bf-48ca-bf90-48e58d1b2458"><ix:continuation id="F_000222_dcnt_3b8205fa-0884-4fe6-96d5-c052d23595a2">
</ix:continuation><ix:nonNumeric id="F_000223" name="onct:ReverseStockSplitAndExchangeRatioPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split and Exchange Ratio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, in connection with, and prior to the completion of, the Merger, GTx effected a one-for-<ix:nonFraction unitRef="U_xbrlipure" id="F_000254" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607" decimals="0" format="ixt-sec:numwordsen">seven</ix:nonFraction> reverse stock split of its then outstanding common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company&#8217;s issued and outstanding common stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All issued and outstanding Private Oncternal common stock, preferred stock, options and warrants prior to the effective date of the Merger have been retroactively adjusted to reflect the Exchange Ratio for all periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000224" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000225" name="onct:LiquidityAndGoingConcernPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20201231" decimals="-5" scale="6">116.7</ix:nonFraction> million in cash and cash equivalents. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20201231" decimals="-5" sign="-" scale="6">82.8</ix:nonFraction> million as of December&#160;31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p></ix:nonNumeric><ix:nonNumeric id="F_000226" name="us-gaap:UseOfEstimates" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>preferred <span style="letter-spacing:0.1pt;">stock, </span>preferred <span style="letter-spacing:0.1pt;">stock</span> warrant <span style="letter-spacing:0.15pt;">liability</span> and stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000227" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000227_dcnt_4522a812-9077-4f3c-b931-69e4a15d9889">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_2cd19f47-68bf-48ca-bf90-48e58d1b2458" continuedAt="F_000211_dcnt_79d44c66-b013-4731-ac83-300cded88fc8"><ix:continuation id="F_000227_dcnt_4522a812-9077-4f3c-b931-69e4a15d9889">
</ix:continuation><ix:nonNumeric id="F_000228" name="onct:ConcentrationRiskCreditRiskPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></ix:nonNumeric><ix:nonNumeric id="F_000229" name="onct:PatentCostsPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p></ix:nonNumeric><ix:nonNumeric id="F_000230" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2020, the Company&#8217;s clinical trial accrual balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">12.5</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric id="F_000231" name="onct:PreferredStockWarrantLiabilityPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000231_dcnt_c69241b7-98d6-40a1-b56c-5538818e0fa1">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, Private Oncternal had outstanding freestanding warrants to purchase shares of its Series B-2 convertible preferred stock (the &#8220;Series B-2 warrants&#8221;). Private Oncternal adjusted the carrying value of such Series B-2 warrants to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as a change in fair value of warrant liability in the consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase the Company&#8217;s common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#8217; equity.</p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_79d44c66-b013-4731-ac83-300cded88fc8" continuedAt="F_000211_dcnt_af199b31-a398-41a0-a16d-89c557ee9ebb"><ix:continuation id="F_000231_dcnt_c69241b7-98d6-40a1-b56c-5538818e0fa1">
</ix:continuation><ix:nonNumeric id="F_000232" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000233" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2020 and 2019, the Company had deferred grant revenue of <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> </span>million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20191231" decimals="-5" scale="6">3.6</ix:nonFraction> million, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000234" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p></ix:nonNumeric><ix:nonNumeric id="F_000235" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000235_dcnt_c976a9ae-057a-49fe-879b-084eb70ec4ea">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_af199b31-a398-41a0-a16d-89c557ee9ebb" continuedAt="F_000211_dcnt_3a65696f-de82-4503-b784-2f2d8002bed5"><ix:continuation id="F_000235_dcnt_c976a9ae-057a-49fe-879b-084eb70ec4ea">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p></ix:continuation><ix:nonNumeric id="F_000236" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="U_onctsegment" id="F_000261" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment in the United States.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000237" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of <ix:nonFraction unitRef="U_xbrlishares" id="F_000262" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">25,000</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000263" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">56,000</ix:nonFraction> shares from the weighted-average number of common shares outstanding for the years ended December<span style="color:#000000;">&#160;</span>31, 20<span style="color:#000000;">20</span> and 201<span style="color:#000000;">9</span>, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p><ix:nonNumeric id="F_000239" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares&#59; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000265" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20190101_20191231" decimals="INF">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000266" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000267" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">1,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000268" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231" decimals="INF">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000269" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20190101_20191231" decimals="INF">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000270" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">7,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000271" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">2,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000238" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000238_dcnt_f1b6d60b-67a1-48da-a101-e1963fe8e6c8">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.</p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000211_dcnt_3a65696f-de82-4503-b784-2f2d8002bed5"><ix:continuation id="F_000238_dcnt_f1b6d60b-67a1-48da-a101-e1963fe8e6c8">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes: Simplifying the Accounting for Income Taxe</span>s, which is intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company adopted this standard effective October 1, 2020, the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued <span style="color:#000000;">ASU </span>2018-13, <span style="font-style:italic;">Fair Value Measurement: Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement, </span>which modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard effective January 1, 2020, <span style="color:#000000;">the adoption had no impact on the consolidated financial statements</span>.</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000212" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div><ix:nonNumeric id="F_000240" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20201231" decimals="-3" scale="3">412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20191231" decimals="-3" scale="3">582</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20201231" decimals="-3" scale="3">980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20191231" decimals="-3" scale="3">624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">424</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="onct:AccruedUnvestedShareLiability" contextRef="C_0001260990_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="onct:AccruedUnvestedShareLiability" contextRef="C_0001260990_20191231" decimals="-3" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20191231" decimals="-3" scale="3">252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,731</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000213" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000213_dcnt_95d63f27-dc7e-425c-a415-135323663d9d">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001260990_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively. On May 22, 2019, the Company entered into an office sublease agreement for <ix:nonFraction unitRef="U_utrsqft" id="F_000288" name="us-gaap:NetRentableArea" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522" decimals="0" format="ixt:numdotdecimal">4,677</ix:nonFraction> square feet in San Diego, California (&#8220;San Diego Lease&#8221;) which expires on <ix:nonNumeric id="F_000289" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric>. Base rent is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="onct:AnnualBaseRent" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522" decimals="0" format="ixt:numdotdecimal">166,000</ix:nonFraction> annually and the monthly rent expense is being recognized on a straight-line basis over the lease term. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a <ix:nonFraction unitRef="U_xbrlipure" id="F_000291" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231" decimals="3" scale="-2">10.0</ix:nonFraction>% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and a lease liability of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231" decimals="0" format="ixt:numdotdecimal">40,000</ix:nonFraction> that matures in March 2021, as of December&#160;31, 2020, in the accompanying consolidated balance sheet. The weighted average remaining lease term was 0.25 years.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000213_dcnt_95d63f27-dc7e-425c-a415-135323663d9d">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#8217;s Chief Financial Officer, acted as the Company&#8217;s agent at Newfront Insurance. During the years ended December 31, 2020 and 2019, the Company paid total related policy premiums of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:GeneralInsuranceExpense" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:GeneralInsuranceExpense" contextRef="C_0001260990_20190101_20191231" decimals="-5" scale="6">1.2</ix:nonFraction> million, respectively, for which Mr. Vincent&#8217;s son received a commission of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:InsuranceCommissions" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million in each respective period. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2020, the Company recorded amounts receivable from SPH USA related to statements of work totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AccountsReceivableRelatedParties" contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million (see Note 4).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter (see Note 7).</p></ix:continuation><ix:nonNumeric id="F_000214" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000214_dcnt_33e561a0-c03e-4f20-b0fa-f0aad8f6e500">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration and Research Subaward Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="onct:LicenseMaintenanceFeeToBePaidAndPaymentMade" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> until the first commercial sale occurs, (ii) is required to make up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231" decimals="INF" scale="6">0.2</ix:nonFraction> million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2020, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with <ix:nonNumeric id="F_000301" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231" format="ixt-sec:durday">90</ix:nonNumeric> days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within <ix:nonNumeric id="F_000302" name="onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231" format="ixt-sec:durday">30</ix:nonNumeric> days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within <ix:nonNumeric id="F_000303" name="onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231" format="ixt-sec:durday">60</ix:nonNumeric> days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least <ix:nonNumeric id="F_000304" name="onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;<span style="font-weight:bold;font-style:italic;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231" decimals="-5" scale="6">1.0</ix:nonFraction> million based on net product sales. In July 2020, the </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000214_dcnt_33e561a0-c03e-4f20-b0fa-f0aad8f6e500" continuedAt="F_000214_dcnt_34a119c6-b7f8-4642-98cc-fd3f9ca864a2">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731" decimals="-3" format="ixt:numdotdecimal" scale="3">293,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The amount recorded as research and development expense for the year ended December 31, 2020 was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">122,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the amount was insignificant for the year ended December 31, 2019.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018 in connection with the spin-off transactions described below, the Company entered into a license agreement (as amended, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement was amended on March 25, 2019 and May 15, 2019, to update the patents covered under the agreement.&#160;&#160;The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="onct:UpfrontLicenseFeesPaid" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">0.5</ix:nonFraction> million was paid and <ix:nonFraction unitRef="U_xbrlishares" id="F_000309" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="INF" format="ixt:numdotdecimal">107,108</ix:nonFraction> shares of common stock were issued, (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="onct:AnnualLicenseMaintenanceFees" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531" decimals="INF" scale="6">12.5</ix:nonFraction> million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">75.0</ix:nonFraction> million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="onct:AdvanceLicensedAssets" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">1.0</ix:nonFraction> million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: <span style="letter-spacing:0.15pt;">(i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></ix:nonFraction> in </span><span style="letter-spacing:0.1pt;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">maintenance</span><span style="letter-spacing:-0.3pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>research<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">expense for each of the</span> years ended December 31, 2020 and 2019, and (ii)<span style="letter-spacing:-0.6pt;"> approximately</span> $<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction> million<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">costs</span> as general <span style="letter-spacing:0.1pt;">and administrative </span><span style="letter-spacing:0.15pt;">expense </span>for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company believes it has met its obligations under the Regents License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000319">five-year</span> agreement, the Regents will have an aggregate budget of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="onct:ResearchAgreementResearchFundingAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231" decimals="-5" scale="6">3.6</ix:nonFraction> million, with $<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="onct:ResearchAgreementResearchFundingAmountPayable" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction> payable quarterly. The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20190101_20191231" decimals="-5" scale="6">0.5</ix:nonFraction></ix:nonFraction> million in research and development expense under this agreement&#160;for each of the years ended December 31, 2020 and 2019. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. <span style="color:#000000;">The Company may terminate the agreement at any time upon at least <ix:nonNumeric id="F_000324" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20200101_20201231" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2015, the Company and UTRF entered into a license agreement (the &#8220;SARD License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#8220;SARD&#8221;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20190101_20191231" decimals="-5" scale="6">0.4</ix:nonFraction> million for each of the years ended December 31, 2020 and 2019, respectively. <span style="color:#000000;">As of December 31, 2020, the Company believes it has met its obligations under the SARD License Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company believes it has met its obligations under each of the UTRF agreements.</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000214_dcnt_34a119c6-b7f8-4642-98cc-fd3f9ca864a2">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award<span style="font-size:6pt;font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017,<span style="color:#000000;"> and as amended and restated in December 2020,</span> CIRM awarded an $<ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">18.3</ix:nonFraction> million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">14.0</ix:nonFraction> million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231" decimals="-5" scale="6">6.2</ix:nonFraction> million in the years ended December 31, 2020 and 2019, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2020 and 2019, the Company&#8217;s grant revenue was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231" decimals="-5" scale="6">2.4</ix:nonFraction> million, respectively. Related qualifying subaward costs for the years ended December 31, 2020 and 2019 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231" decimals="-5" scale="6">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231" decimals="-5" scale="6">5.4</ix:nonFraction> million, respectively. As of December 31, 2020, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="-5" scale="6">5.8</ix:nonFraction> million grant to the researchers at the University of California San Diego School of Medicine (&#8220;UC San Diego&#8221;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="onct:AmountAgreedToBeProvidedInContingencyFunds" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="INF" scale="6">1.0</ix:nonFraction> million in contingency funds if required during the grant period. The Company recorded <ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20200101_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20190101_20191231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction> research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018,<span style="color:#000000;"> and as amended in August 2020, </span>the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) <span style="letter-spacing:0.15pt;">either</span><span style="letter-spacing:-0.5pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">event</span> <span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">other</span><span style="letter-spacing:-0.5pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>declares<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">insolvency</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">bankruptcy.</span></p></ix:continuation><ix:nonNumeric id="F_000215" name="us-gaap:DebtDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000215_dcnt_c228acf0-8741-4e43-835d-d5723cc48544">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531" decimals="-5" scale="6">0.3</ix:nonFraction> million unsecured loan, bearing interest at <ix:nonFraction unitRef="U_xbrlipure" id="F_000340" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531" decimals="INF" scale="-2">1</ix:nonFraction>%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. <span style="color:#000000;">The loan forgiveness was recorded as other income of $</span></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000215_dcnt_c228acf0-8741-4e43-835d-d5723cc48544">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200101_20201231" decimals="-3" scale="3">301</ix:nonFraction></span><span style="color:#000000;">k in the statement of operations.</span></p></ix:continuation><ix:nonNumeric id="F_000216" name="onct:MergerDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000216_dcnt_4deef3a1-2690-47e9-8f7a-2dd69652027c">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Merger</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger, which closed on June 7, 2019, was accounted for as a reverse asset acquisition, as substantially all of the fair value of the assets acquired were concentrated in a group of similar non-financial assets, and the acquired assets did not have outputs or employees. Because the assets had not yet received regulatory approval, the fair value attributable to these assets of $18.1 million was recorded as in-process research and development expenses in the Company&#8217;s consolidated statement of operations in the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Merger Agreement on June 7, 2019, the Company, a representative of holders of the contingent value rights (&#8220;CVRs&#8221;), and Computershare, Inc. as rights agent entered into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;). Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received <ix:nonFraction unitRef="U_onctCVR" id="F_000342" name="onct:ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger. CVR holders are entitled to receive <ix:nonFraction unitRef="U_xbrlipure" id="F_000343" name="onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607" decimals="2" scale="-2">75</ix:nonFraction>% of the aggregate amount of any net proceeds received by the Company during the <ix:nonNumeric id="F_000344" name="onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607" format="ixt-sec:duryear">15</ix:nonNumeric>-year period after the closing of the Merger from the grant, sale or transfer of rights to the Company&#8217;s SARD or SARM technology that occurs during the <ix:nonNumeric id="F_000345" name="onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607" format="ixt-sec:duryear">10</ix:nonNumeric>-year period after the closing (or in the 11th year if based on a term sheet approved during the initial 10-year period) and, if applicable, to receive royalties on the sale of any SARD or SARM products by the Company during the 15-year period after the closing. Effective in March 2020, the Company terminated the SARM license agreement with UTRF and no longer has any rights to the SARM technology. The CVR Agreement will continue in effect until the payment of all amounts payable thereunder. As of the years ended December 31, 2020 and 2019, no milestones had been accrued as there were no potential milestones yet considered probable. The total purchase price paid in the Merger has been allocated to the net assets acquired and liabilities assumed based on their fair values as of the completion of the Merger. </p><ix:nonNumeric id="F_000241" name="onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td valign="bottom" style="background-color:#CFF0FC;width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of shares of the combined organization owned</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; by the Company&#8217;s pre-Merger stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000346" name="onct:CommonStockSharesOutstandingPriorToStockSplit" contextRef="C_0001260990_20190607" decimals="INF" format="ixt:numdotdecimal">3,458,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiplied by the fair value per share of GTx common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock (1)</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000347" name="us-gaap:SharePrice" contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctGTxIncMember_20190607" decimals="2">8.40</ix:nonFraction></p></td>
<td valign="bottom" style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td valign="bottom" style="background-color:#CFF0FC;width:55%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of consideration issued to effect the Merger</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:12%; border-top:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">29,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.12%; border-top:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.45pt;">
<td valign="bottom" style="width:55%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:NoncashMergerRelatedCosts" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">2,154</ix:nonFraction></p></td>
<td valign="bottom" style="width:1.12%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td valign="bottom" style="background-color:#CFF0FC;width:55%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:12%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="onct:AssetAcquisitionPurchasePrice" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">31,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.12%; border-bottom:solid 1pt #CFF0FC;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" style="width:55%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-bottom:solid 1pt #000000;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.12%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Based on the last reported sale price of the Company&#8217;s common stock on the Nasdaq Capital Market on June 7, 2019, the closing date of the Merger, and gives effect to the Reverse Stock Split.</p></td></tr></table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000242" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000242_dcnt_27a2f824-866e-4059-8f10-22516ea5673c">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price is as follows:</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td valign="bottom" style="background-color:#CFF0FC;width:78.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash acquired</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:16.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:CashAcquiredFromAcquisition" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">18,292</ix:nonFraction></p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="bottom" style="width:78.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net liabilities assumed</p></td>
<td valign="bottom" style="width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:16.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="C_0001260990_20190607" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,177</ix:nonFraction></p></td>
<td colspan="2" valign="bottom" style="width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.45pt;">
<td valign="bottom" style="background-color:#CFF0FC;width:78.6%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&#38;D (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;width:16.64%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">18,088</ix:nonFraction></p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;width:1.92%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td valign="bottom" style="width:78.6%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td valign="bottom" style="width:1.42%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1.42%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="width:16.64%; border-bottom:solid 1pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="onct:AssetAcquisitionPurchasePrice" contextRef="C_0001260990_20190607_20190607" decimals="-3" format="ixt:numdotdecimal" scale="3">31,203</ix:nonFraction></p></td>
<td colspan="2" valign="bottom" style="width:1.92%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" style="width:78.6%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td valign="bottom" style="width:1.42%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td valign="bottom" style="width:1.42%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:17.14%; border-bottom:solid 1pt #000000;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td valign="bottom" style="width:1.42%; border-bottom:solid 1pt transparent;">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Represents the research and development projects of GTx which were in-process, but not yet completed, and which the Company plans to advance, consisting primarily of GTx&#8217;s preclinical SARD technology. Current </span>accounting standards require that the fair value of IPR&#38;D projects acquired in an asset acquisition with no </p></td></tr></table></div>
</ix:nonNumeric></ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000216_dcnt_4deef3a1-2690-47e9-8f7a-2dd69652027c"><ix:continuation id="F_000242_dcnt_27a2f824-866e-4059-8f10-22516ea5673c">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000217" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000217_dcnt_56903bde-a048-4b2b-a3da-28335194cdff">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amended and Restated Articles of Incorporation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company&#8217;s certificate of incorporation was amended and restated to authorize <ix:nonFraction unitRef="U_xbrlishares" id="F_000355" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20190607" decimals="INF" format="ixt:numdotdecimal">60,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20190607" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of undesignated preferred stock, each with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000357" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20190607" decimals="INF">0.001</ix:nonFraction> per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;<span style="font-weight:bold;font-style:italic;">Convertible Preferred Stock</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger, all of the then outstanding shares of Private Oncternal&#8217;s convertible preferred stock were converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000358" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607" decimals="INF" format="ixt:numdotdecimal">8,148,268</ix:nonFraction> shares of the Company&#8217;s common stock. As of December 31, 2018, Private Oncternal&#8217;s convertible preferred stock was classified as temporary equity on the accompanying consolidated <span style="color:#000000;">statements of convertible preferred stock and stockholders&#8217; equity (deficit) </span>in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of Private Oncternal&#8217;s control, including liquidation, sale or transfer of control of Private Oncternal. Private Oncternal did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because the occurrence of any such change of control event was not deemed probable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase Agreements <span style="color:#000000;">and </span>Underwritten Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors) for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000359" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="INF" format="ixt:numdotdecimal">1,943,636</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="-5" scale="6">4.4</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000361" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">971,818</ix:nonFraction> shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000362" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">2.5725</ix:nonFraction>. In addition, the Company<span style="color:#000000;"> issued </span>warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000363" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">116,618</ix:nonFraction> <span style="color:#000000;">shares of </span>common <span style="color:#000000;">stock at </span>an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000364" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">3.2156</ix:nonFraction><span style="color:#000000;"> per share </span>to the placement agent, H.C. Wainwright &#38; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on <ix:nonNumeric id="F_000365" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" format="ixt:datemonthdayyearen">May 21, 2025</ix:nonNumeric>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000366" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">2,581,867</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="-5" scale="6">5.7</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000368" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">1,290,933</ix:nonFraction> shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000369" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.3825</ix:nonFraction>. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000370" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="2">2.32</ix:nonFraction> per share and expire on <ix:nonNumeric id="F_000371" name="onct:CommonStockWarrantsExpirationDate" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">January 21, 2026</ix:nonNumeric>. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000372" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">154,912</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000373" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.9781</ix:nonFraction> per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000374" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">July 21, 2025</ix:nonNumeric>. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#8217;s largest stockholder, Daniel L. Kisner, a member of the Company&#8217;s board of directors, and Hazel M. Aker, the Company&#8217;s then General Counsel.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;August Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000375" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="INF" format="ixt:numdotdecimal">2,428,886</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000378" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="2">2.10</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="-5" scale="6">4.4</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000377" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="INF" format="ixt:numdotdecimal">145,733</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000379" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="3">2.625</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000380" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" format="ixt:datemonthdayyearen">August 27, 2025</ix:nonNumeric>. An investor participating in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_56903bde-a048-4b2b-a3da-28335194cdff" continuedAt="F_000217_dcnt_b902a674-8d9b-40c9-b460-db8b004e5ef7">

<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="INF" format="ixt:numdotdecimal">7,258,065</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000384" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="2">3.10</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="-5" scale="6">20.4</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000383" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="INF" format="ixt:numdotdecimal">435,484</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000385" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="3">3.875</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000386" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" format="ixt:datemonthdayyearen">November 17, 2025</ix:nonNumeric>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000387" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">19,161,667</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000390" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="2">4.50</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="-5" scale="6">79.0</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000389" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,149,700</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000391" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="3">5.625</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000392" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" format="ixt:datemonthdayyearen">December 9, 2025</ix:nonNumeric>. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">other than pursuant to a new at-the-market offering facility with the placement </span>agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The<span style="color:#000000;"> Company does not currently have an active at-the-market facility. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p><ix:nonNumeric id="F_000243" name="onct:ScheduleOfWarrantActivityTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2018</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000393" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20181231" decimals="INF" format="ixt:numdotdecimal">841,620</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000399" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20181231" decimals="INF">37.97</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">3.75</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000394" name="onct:ExerciseOfWarrants" contextRef="C_0001260990_20190101_20191231" decimals="INF" sign="-">196</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000400" name="onct:WarrantExercisedPricePerShare" contextRef="C_0001260990_20190101_20191231" decimals="INF">6.13</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000395" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal">841,424</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000401" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20191231" decimals="INF">37.97</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000406">2.75</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000396" name="onct:ExerciseOfWarrantsIssued" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,265,198</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000402" name="onct:WarrantIssuedPricePerShare" contextRef="C_0001260990_20200101_20201231" decimals="INF">3.47</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000397" name="onct:ExerciseOfWarrants" contextRef="C_0001260990_20200101_20201231" decimals="INF" sign="-" format="ixt:numdotdecimal">74,781</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000403" name="onct:WarrantExercisedPricePerShare" contextRef="C_0001260990_20200101_20201231" decimals="INF">3.22</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000398" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal">5,031,841</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000404" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20201231" decimals="INF">9.25</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">4.40</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, all warrants met the criteria for classification in stockholders&#8217; equity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted <span style="color:#000000;">Common Stock and Unvested Share Liability</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, the<span style="color:#000000;"> Company issued restricted common stock subject to vesting and repurchase by the Company. For employee and non-employee awards, the issuance date fair value is recognized over the requisite service period of the award (usually the vesting period) on a straight-line basis. In addition, the Company has outstanding unvested shares related to the early exercise of stock options. The Company has the right, but not the obligation, to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The consideration received in exchange for unvested shares is recorded as an unvested share liability on the accompanying consolidated balance sheets and is reclassified into common stock and additional paid-in capital as the shares vest. At </span>December&#160;31, 2020 and <span style="color:#000000;">2019, the unvested share liability was $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" contextRef="C_0001260990_20201231" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> and $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" contextRef="C_0001260990_20191231" decimals="0" format="ixt:numdotdecimal">24,000</ix:nonFraction></span>, respectively.</p><ix:nonNumeric id="F_000244" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000244_dcnt_97418b2a-2429-4ede-8896-e054b9f1e847">
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_b902a674-8d9b-40c9-b460-db8b004e5ef7" continuedAt="F_000217_dcnt_e6f9837e-9c17-4c7f-812b-0f075dd5a072"><ix:continuation id="F_000244_dcnt_97418b2a-2429-4ede-8896-e054b9f1e847">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested shares is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000410" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_0001260990_20191231" decimals="INF" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000411" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001260990_20200101_20201231" decimals="INF" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000412" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="C_0001260990_20201231" decimals="INF" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) <ix:nonFraction unitRef="U_xbrlishares" id="F_000413" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal">1,678,571</ix:nonFraction>&#160;shares of common stock, (b)&#160; up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal">275,579</ix:nonFraction> shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;) as of&#160;&#160;June 7, 2019, that are subsequently cancelled will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) <ix:nonFraction unitRef="U_xbrlipure" id="F_000415" name="onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607" decimals="2" scale="-2">5</ix:nonFraction>% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, <span style="color:#000000;">2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">937,837</ix:nonFraction></span> shares remain available for future issuance under the 2019 Plan (see Note 10).</p><ix:nonNumeric id="F_000245" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000417" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,107,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000420" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF">4.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000423">8.3</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000418" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,107,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF">4.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000424">8.3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000419" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">965,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="INF">3.61</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000425">8.1</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 under the 2013 Plan, there were: (i) <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">111,145</ix:nonFraction></span> outstanding and fully vested options with a weighted average exercise price of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000431" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231" decimals="2">63.58</ix:nonFraction></span> per share, and (ii) <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">145,652</ix:nonFraction></span> cancelled options that were added back to the 2019 Plan as of December&#160;31, 2020. As of December&#160;31, 2020, the former GTx stock option plans had an aggregate of <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231" decimals="INF" format="ixt:numdotdecimal">118,024</ix:nonFraction></span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000436" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231" decimals="2">75.16</ix:nonFraction></span> and a weighted average remaining contractual term of 0.4 years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000430" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731" decimals="INF" format="ixt:numdotdecimal">631,120</ix:nonFraction> shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire <ix:nonNumeric id="F_000433" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant and vest over a <span style="-sec-ix-hidden:F_000434">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan allowed for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019.</p><ix:nonNumeric id="F_000246" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000246_dcnt_26a8d781-f42f-42bf-bbf1-396a59ccd0de">
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_e6f9837e-9c17-4c7f-812b-0f075dd5a072" continuedAt="F_000217_dcnt_d535cb55-a631-4d61-846d-8a6bed7956b3"><ix:continuation id="F_000246_dcnt_26a8d781-f42f-42bf-bbf1-396a59ccd0de">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal">1,662,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000443" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_20191231" decimals="2">4.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000439" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">624,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000444" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20200101_20201231" decimals="2">3.37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">173,753</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000445" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20200101_20201231" decimals="2">2.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">5,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000446" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20200101_20201231" decimals="2">0.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal">2,107,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_20201231" decimals="2">4.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about the Company&#8217;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the years ended December 31, <span style="color:#000000;">2020 and </span>2019 was $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231" decimals="2">2.53</ix:nonFraction></span> and $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20190101_20191231" decimals="2">3.69</ix:nonFraction></span> per share, respectively.&#160;&#160;The aggregate intrinsic value used in the above table of options at December&#160;31, 2020 is based on the Company&#8217;s closing market price per common share on December&#160;31, 2020 of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000450" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20201231" decimals="2">4.90</ix:nonFraction>. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, <span style="color:#000000;">2020 and </span>2019 was not material. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p><ix:nonNumeric id="F_000247" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20200101_20201231" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20190101_20191231" decimals="3" scale="-2">1.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20200101_20201231" decimals="3" scale="-2">91.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000454" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20190101_20191231" decimals="3" scale="-2">77.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">6.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.0</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><ix:nonNumeric id="F_000248" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000248_dcnt_1c9b5b31-d343-4e89-8f82-8ae968352f9b">
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000217_dcnt_d535cb55-a631-4d61-846d-8a6bed7956b3"><ix:continuation id="F_000248_dcnt_1c9b5b31-d343-4e89-8f82-8ae968352f9b">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" scale="3">544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" scale="3">237</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the total compensation cost related to nonvested awards not yet recognized was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001260990_20201231" decimals="-5" scale="6">3.4</ix:nonFraction> million and the weighted-average period over which it is expected to be recognized was <ix:nonNumeric id="F_000464" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_20200101_20201231" format="ixt-sec:duryear">2.5</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p><ix:nonNumeric id="F_000249" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000465" name="onct:CommonStockWarrantsReservedForFutureIssuance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000466" name="onct:CommonStockWarrantsReservedForFutureIssuance" contextRef="C_0001260990_20191231" decimals="-3" scale="3">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000467" name="onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000468" name="onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000469" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231" decimals="-3" scale="3">938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000470" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20191231" decimals="-3" scale="3">495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000471" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">8,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000472" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">3,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000218" name="onct:COVID19PandemicAndCARESActDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000218_dcnt_56e31a9a-3c3a-4c2b-9ff0-3ab70332127c">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#FF0000;"></span>COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#8217;s income tax provision for the 12 months ended December&#160;31, 2020.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000218_dcnt_56e31a9a-3c3a-4c2b-9ff0-3ab70332127c">
</ix:continuation><ix:nonNumeric id="F_000219" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000219_dcnt_a3de1851-a53f-4c18-91c2-19c8036e3ce7">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div><ix:nonNumeric id="F_000250" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,617</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">7,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001260990_20190101_20191231" decimals="-3" sign="-" scale="3">968</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="onct:IncomeTaxReconciliationPermanentItems" contextRef="C_0001260990_20200101_20201231" decimals="-3" sign="-" scale="3">65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="onct:IncomeTaxReconciliationPermanentItems" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="onct:IncomeTaxReconciliationInProcessResearchAndDevelopment" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_0001260990_20200101_20201231" decimals="-3" scale="3">226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="C_0001260990_20190101_20191231" decimals="-3" scale="3">265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000251" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001260990_20201231" decimals="-3" scale="3">367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" contextRef="C_0001260990_20191231" decimals="-3" scale="3">214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,688</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001260990_20201231" decimals="-3" scale="3">393</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001260990_20191231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,551</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,599</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,540</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="C_0001260990_20191231" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="onct:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="C_0001260990_20191231" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001260990_20201231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001260990_20191231" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the Company&#8217;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December&#160;31, 2020 and 2019.&#160;&#160;As a result of the Merger in 2019, the Company recorded deferred tax assets of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">13.1</ix:nonFraction> million which are fully offset by a valuation allowance. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="onct:ValuationAllowanceDeferredTaxAssetChangeNetAmount" contextRef="C_0001260990_20200101_20201231" decimals="-5" scale="6">13.1</ix:nonFraction> million net deferred tax assets do not include federal and state net operating loss carryforwards and federal research and development credit carryforwards that are estimated to expire under Internal Revenue Code Sections 382 and 383 as a result of the Merger.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">69.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">47.7</ix:nonFraction>&#160;million, respectively. Of the federal net operating losses at December&#160;31, 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="onct:OperatingLossCarryforwardsNonExpirePortion" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">43.4</ix:nonFraction> million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in <ix:nonNumeric id="F_000511" name="onct:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2033</ix:nonNumeric> and <ix:nonNumeric id="F_000512" name="onct:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2029</ix:nonNumeric>, respectively, unless previously utilized. At December&#160;31, 2020, the Company also had federal and state research and development credit carryforwards of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million, respectively. The federal research and development credit carryforwards will begin expiring in <ix:nonNumeric id="F_000515" name="onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2034</ix:nonNumeric> unless previously utilized. The state research and development credits do not expire. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000516" name="onct:CumulativeChangeInOwnershipPercentage" contextRef="C_0001260990_20200101_20201231" decimals="2" scale="-2">50</ix:nonFraction>% occurs within a <span style="-sec-ix-hidden:F_000517">three-year</span> period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study and the </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000219_dcnt_a3de1851-a53f-4c18-91c2-19c8036e3ce7">
<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December&#160;31, 2020 and 2019, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001260990_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2013 through 2020 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000220" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001260990_20200101_20201231" escape="true" continuedAt="F_000220_cnt_1">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Inducement Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:continuation id="F_000220_cnt_1">In February 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Equity Incentive Award Plan (Inducement Plan) and initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000521" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20210228" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction> shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan.</ix:continuation> </p>
<p style=" clear:both;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES">Controls and Procedures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosures. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2020, the end of the period covered by this report. Based on the evaluation of these disclosure controls and procedures, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management's Report on Internal Control Over Financial Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, as management of Oncternal Therapeutics, Inc., are responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Securities Exchange Act Rule&#160;13a-15(f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with United States generally accepted accounting principles. Any system of internal control, no matter how well designed, has inherent limitations, including the possibility that a control can be circumvented or overridden and misstatements due to error or fraud may occur and not be detected. Also, because of changes in conditions, internal control effectiveness may vary over time. Accordingly, even an effective system of internal control will provide only reasonable assurance that the objectives of the internal control system are met. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2020 using the criteria for effective internal control over financial reporting as described in "Internal Control&#160;&#8212; Integrated Framework," issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, we concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting during the fourth quarter of 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OR_INFORMATION">Other Information.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The information set forth below is included herein, by our option, for the purpose of providing disclosure under &#8220;Item 8.01 &#8211; Other Events.&#8221; of Form 8-K.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 26, 2021, Igor Bilinsky, Ph.D. resigned from his position as the Chief Business Officer of the Company effective as of March 12, 2021.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART&#160;III</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Directors, Executive Officers and Corporate Governance.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2021 Annual Meeting of Stockholders or the Proxy Statement, which is expected to be filed not later than 120&#160;days after the end of our fiscal year ended December 31, 2020, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; and &#8220;Delinquent Section&#160;16(a) Reports,&#8221; and is incorporated herein by reference.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">Executive Compensation.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation&#8221; in our Proxy Statement.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in our Proxy Statement.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by Item 201(d) of Regulation S-K is incorporated by reference to the information set forth in the section titled &#8220;Executive Compensation&#8221; in our Proxy Statement.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Certain Relationships and Related Transactions, and Director Independence.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding certain relationships and related transactions and director independence is incorporated by reference to the information set forth in the sections titled &#8220;Transactions with Related Parties&#8221; and &#8220;Election of Directors &#8211; Independence of the Board of Directors,&#8221; respectively, in our Proxy Statement.&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC">Principal Accountant Fees and Services.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled &#8220;Principal Accountant Fees and Services&#8221; in our Proxy Statement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART&#160;IV</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Exhibits and Financial Statement Schedules.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Documents filed as part of this report.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Financial Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements of Oncternal Therapeutics,&#160;Inc. listed below are set forth in Item 8 of this Annual Report for the year ended December&#160;31,&#160;2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:92.31%;"></td>
<td style="width:1.92%;"></td>
<td style="width:5.77%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORTINDEPENDENTREGISTEREDPUBLICACC"><span style="text-decoration:none;">Report&#160;of&#160;Independent&#160;Registered&#160;Public&#160;Accounting&#160;Firm</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:none;">Consolidated Notes to Financial Statements</span></a></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Financial Statement Schedules</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These schedules have been omitted because the required information is included in the financial statements or notes thereto or because they are not applicable or not required.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Exhibits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this annual report on Form 10-K and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;16.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Form_10_K_Summary"><span style="font-weight:normal;"></span>FORM 10-K SUMMARY</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:8.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:38.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:5.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:8.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No</p></td>
<td valign="bottom" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:17.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="top" style="width:0.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:8.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed/</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:18.45pt;">
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312512413983/d420023dex21.htm"><span style="text-decoration:none;">Asset Purchase Agreement dated as of September 28, 2012 between the Registrant and Strakan International S.&#224; r.l.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October&#160;3,&#160;2012</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2.7pt;">
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2*</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465919013252/a19-5973_1ex2d1.htm"><span style="text-decoration:none;">Agreement and Plan of Merger and Reorganization, dated March 6, 2019, by and among the Registrant, Oncternal Therapeutics, Inc. and Grizzly Merger Sub, Inc.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 7, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465919025348/a19-9089_1ex2d1.htm"><span style="text-decoration:none;">Amendment No. 1 to Agreement and Plan of Merger, dated April 30, 2019, by and among the Registrant, Oncternal Therapeutics, Inc. and Grizzly Merger Sub, Inc.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 30, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex101.htm"><span style="text-decoration:none;">CVR Agreement, dated as of June 7, 2019, by and between the Registrant, Marc S. Hanover, as the Holders&#8217; Representative, and Computershare Investor Services, as Rights Agent</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095013405014821/f11069orexv4w1.htm"><span style="text-decoration:none;">Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-127175</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 4, 2005</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095012311046639/c16700exv3w2.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 6, 2011</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465914037092/a14-12275_1ex3d3.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 9, 2014</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465915036849/a15-7744_1ex3d4.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 11, 2015</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465916160637/a16-22576_1ex3d1.htm"><span style="text-decoration:none;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 5, 2016</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex31.htm"><span style="text-decoration:none;">Certificate of Amendment of the Restated Certificate related to the Reverse Stock Split of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex32.htm"><span style="text-decoration:none;">Certificate of Amendment of the Restated Certificate related to the Name Change of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex33.htm"><span style="text-decoration:none;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex42_392.htm"><span style="text-decoration:none;">Specimen of Common Stock Certificate</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465917063137/a17-24206_1ex4d9.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Purchase Agreement, dated September 25, 2017, between Registrant and the purchasers identified in Exhibit A therein</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-221040</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 20, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex411.htm"><span style="text-decoration:none;">Form of Warrant to purchase shares of Series B-2 Preferred Stock of Oncternal Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex41_414.htm"><span style="text-decoration:none;">Form of Amendment to Warrant to Purchase shares of Series B-2 Preferred Stock of Oncternal Therapeutics, Inc</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex41_7.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement, dated May 19, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex42_8.htm"><span style="text-decoration:none;">Form of Placement Agent Warrant, issued by Registrant pursuant to the Securities Purchase Agreement, dated May 19, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex41.htm"><span style="text-decoration:none;">Form of Common Stock Warrant, issued by Registrant pursuant to the Securities Purchase Agreement, dated July 17, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex42.htm"><span style="text-decoration:none;">Form of Placement Agent Warrant, issued by Registrant pursuant to the Securities Purchase Agreement, dated July 17, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520236278/d32449dex11.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement, dated August 27, 2020, between the Registrant and H.C. Wainwright &#38; Co., LLC</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 31, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520298237/d76696dex11.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement, dated November 17, 2020, between the Registrant and H.C. Wainwright &#38; Co., LLC</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 19, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520315323/d67428dex11.htm"><span style="text-decoration:none;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement, dated December 9, 2020, between the Registrant and H.C. Wainwright &#38; Co., LLC</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 11, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.12</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex45_1133.htm"><span style="text-decoration:none;">Description of Securities of Oncternal Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1046.htm"><span style="text-decoration:none;">Commercial License Agreement between Selexis SA and ROAR Therapeutics, LLC (predecessor to Oncternal Therapeutics, Inc.), dated May 19, 2014</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex102_765.htm"><span style="text-decoration:none;">Amendment No. 1 to Commercial License Agreement between Selexis SA and Oncternal Therapeutics, Inc., dated February 7, 2020</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3&#8224;</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1047.htm"><span style="text-decoration:none;">Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1048.htm"><span style="text-decoration:none;">Amendment to Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 17, 2016</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.48</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1049.htm"><span style="text-decoration:none;">Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated December 15, 2014</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.49</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1050.htm"><span style="text-decoration:none;">Amendment #1 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated January 24, 2016</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1051.htm"><span style="text-decoration:none;">Amendment #2 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated May 1, 2016</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.51</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1052.htm"><span style="text-decoration:none;">Amendment #3 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated September 17, 2018</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1053.htm"><span style="text-decoration:none;">Research agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, on behalf of its San Diego Campus, dated November 3, 2016</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.53</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1054.htm"><span style="text-decoration:none;">License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC, dated February 6, 2018</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.54</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1055.htm"><span style="text-decoration:none;">Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and The Regents of the University of California, dated August 31, 2018</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.55</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1056.htm"><span style="text-decoration:none;">Amendment #1 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated March 25, 2019</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.56</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13&#8224;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1013_766.htm"><span style="text-decoration:none;">Amendment #2 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated May 15, 2019</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex1014_496.htm"><span style="text-decoration:none;">Amendment #3 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated February 5, 2021</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1057.htm"><span style="text-decoration:none;">Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.57</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1058.htm"><span style="text-decoration:none;">Form of Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.58</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1059.htm"><span style="text-decoration:none;">Form of Early Exercise Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.59</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1060.htm"><span style="text-decoration:none;">Restricted Stock Purchase Agreement dated May 22, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.60</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1061.htm"><span style="text-decoration:none;">Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.61</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1062.htm"><span style="text-decoration:none;">Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and William R. LaRue</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.62</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex1063.htm"><span style="text-decoration:none;">Restricted Stock Purchase Agreement dated May 9, 2018, between Oncternal Therapeutics, Inc. and Charles Theuer, M.D., Ph.D.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.63</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex101_210.htm"><span style="text-decoration:none;">Employment Agreement dated August 26, 2019 between Oncternal Therapeutics, Inc. and Frank Hsu, M.D.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex102_215.htm"><span style="text-decoration:none;">Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Gunnar F. Kaufmann, Ph.D</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex103_213.htm"><span style="text-decoration:none;">Employment Agreement dated September 9, 2019 between Oncternal Therapeutics, Inc. and Igor P. Bilinsky, Ph.D.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex104_212.htm"><span style="text-decoration:none;">Employment Agreement dated September 12, 2019 between Oncternal Therapeutics, Inc. and James B. Breitmeyer, M.D.</span></a><span style="text-decoration:none;"> </span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex105_211.htm"><span style="text-decoration:none;">Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Richard G. Vincent</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex106_214.htm"><span style="text-decoration:none;">Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Hazel M. Aker</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519139911/d722331d424b3.htm#rom722331_39"><span style="text-decoration:none;">Registrant&#8217;s 2019 Incentive Award Plan effective June 7, 2019</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.29</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019041983/onct-ex107_307.htm"><span style="text-decoration:none;">Amended Oncternal Therapeutics, Inc. Annual Incentive Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 8, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.30</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex1023_440.htm"><span style="text-decoration:none;">Sublease by and between Oncternal Therapeutics, Inc. and Host Hotels &#38; Resorts, L.P., dated May 22, 2019</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9, 2019</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1031_767.htm"><span style="text-decoration:none;">Form of Indemnification Agreement</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32#</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex1032_768.htm"><span style="text-decoration:none;">Consulting Agreement dated September 20, 2019 between Robert J. Wills. Ph.D. and Oncternal Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.34#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021006178/onct-ex101_8.htm"><span style="text-decoration:none;">Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan and form of stock option agreement thereunder</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 17, 2021</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex101_9.htm"><span style="text-decoration:none;">Form of Securities Purchase Agreement, dated May 19, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex101.htm"><span style="text-decoration:none;">Form of Securities Purchase Agreement, dated July 17, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.37</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex1037_578.htm"><span style="text-decoration:none;">Engagement Letter between the Registrant and H.C. Wainwright &#38; Co., LLC, dated as of December 9, 2020</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.38#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_6.htm"><span style="text-decoration:none;">GTx, Inc. 2001 Stock Option Plan, as amended through November 3, 2009, and Form of Stock Option Agreement</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.39#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_7.htm"><span style="text-decoration:none;">GTx, Inc. 2002 Stock Option Plan, as amended through November 3, 2009, and Form of Stock Option Agreement</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.40#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000089161804000126/g85196a3exv10w5.txt"><span style="text-decoration:none;">GTx, Inc. 2004 Equity Incentive Plan, as originally adopted, and Form of Stock Option Agreement</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-109700</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 15, 2004</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.41#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095013408008543/f40503exv10w6.htm"><span style="text-decoration:none;">GTx, Inc. 2004 Equity Incentive Plan, as amended effective April 30, 2008</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 6, 2008</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_10.htm"><span style="text-decoration:none;">GTx, Inc. 2004 Equity Incentive Plan, as amended effective November 4, 2008 and Form of Stock Option Agreement</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.43#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000089161804000126/g85196a3exv10w6.txt"><span style="text-decoration:none;">GTx, Inc. 2004 Non-Employee Directors&#8217; Stock Option Plan and Form of Stock Option Agreement, as originally adopted</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-109700</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-6</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 15,2004</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.44#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095014406004016/g01123exv10w1.htm"><span style="text-decoration:none;">Amended and Restated GTx, Inc. 2004 Non-Employee Directors&#8217; Stock Option Plan, effective April 26, 2006</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 27, 2006</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.45#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095014406007655/g02832exv10w35.htm"><span style="text-decoration:none;">Form of Stock Option Agreement under the Amended and Restated GTx, Inc. 2004 Non-Employee Directors&#8217; Stock Option Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.35</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9,2006</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.46#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_14.htm"><span style="text-decoration:none;">Amended and Restated GTx, Inc. 2004 Non-Employee Directors&#8217; Stock Option Plan, as amended effective November 4, 2008</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.47#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465913037597/a13-11497_1ex99d1.htm"><span style="text-decoration:none;">GTx, Inc. 2013 Equity Incentive Plan, as originally adopted</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-188377</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 6, 2013</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.48#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_16.htm"><span style="text-decoration:none;">GTx, Inc. 2013 Equity Incentive Plan, as amended effective May 6, 2015</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.49#</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465913055542/a13-12577_1ex10d2.htm"><span style="text-decoration:none;">Form of Stock Option Grant Notice and Option Agreement under the GTx, Inc. 2013 Equity Incentive Plan (Standard Form</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 22, 2013</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.50#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465913083462/a13-18507_1ex10d3.htm"><span style="text-decoration:none;">Form of Retention Stock Option Grant Notice and Option Agreement under the GTx, Inc. 2013 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2013</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.51#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465913083462/a13-18507_1ex10d4.htm"><span style="text-decoration:none;">Form of Retention Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the GTx, Inc. 2013 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 12, 2013</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.52#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465915036849/a15-7744_1ex10d5.htm"><span style="text-decoration:none;">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the GTx, Inc. 2013 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 11, 2015</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.53#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000104746917001982/a2231118zex-10_21.htm"><span style="text-decoration:none;">GTx, Inc. 2013 Non-Employee Director Equity Incentive Plan, as originally adopted (refiled to reflect reverse stock split effected on December 5, 2016)</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 24, 2017</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.54#</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465913055542/a13-12577_1ex10d4.htm"><span style="text-decoration:none;">Form of Stock Option Grant Notice and Option Agreement under the GTx, Inc. 2013 Non-Employee Director Equity Incentive Plan</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jul 22, 2013</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020011213/onct-ex211_764.htm"><span style="text-decoration:none;">Subsidiaries</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 16, 2020</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex231_826.htm"><span style="text-decoration:none;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:none;">Power of Attorney (see Signature Page)</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex312_15.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer Pursuant to Rules 13a-15(d) and 15d-15(e) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex322_16.htm"><span style="text-decoration:none;">Certification of Principal Financial Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex311_7.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer Pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex321_8.htm"><span style="text-decoration:none;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</span></p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following financial statements from the Oncternal Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Stockholders&#8217; Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:8.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:38.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:11.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:17.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
</table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">These&#160;certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. <br />Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and <br />are not subject to the liability of that section. These certifications are not to be incorporated by reference into <br />any filing of Oncternal Therapeutics, Inc., whether made before or after the date hereof, regardless of any <br />general incorporation language in such filing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Management compensatory plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"> Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not <br />material and (ii) would be competitively harmful if publicly disclosed.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">Signatures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Section&#160;13 or 15(d)&#160;of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:48.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics,&#160;Inc.</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:44.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 11, 2021</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:44.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;James B. Breitmeyer, M.D., PH.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:44.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS<span style="font-weight:normal;">, that each person whose signature appears below constitutes and appoints Dr.&#160;James B. Breitmeyer, M.D., Ph.D and Richard G. Vincent, and each of them, as his or her true and. lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Member of the Board of Directors</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard G. Vincent</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David F. Hale</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David F. Hale</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael G. Carter</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael G. Carter, M.D., ChB, FRCP</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Man Cho</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Man Cho</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Daniel L. Kisner</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daniel L. Kisner</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William R. LaRue</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William R. LaRue</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rosemary Mazanet</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosemary Mazanet, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:6.3pt;">
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Xin Nakanishi</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xin Nakanishi, Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Robert Wills</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert Wills, Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="top" style="width:35.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Charles P. Theuer</p></td>
<td valign="top" style="width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p></td>
</tr>
<tr>
<td valign="top" style="width:35.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charles P. Theuer, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:21.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>onct-ex1014_496.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex1014_496.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.14</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENT NO. 3 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TO THE AMENDED AND RESTATED LICENSE AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BETWEEN ONCTERNAL THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FOR UC CASE NUMBERS SD2005-212, SD2020-036, SD2011-178,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SD2012-143, SD2012-403, SD2015-027, SD2015-200, SD2018-253 AND SD2019-278</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Amendment No. 3 (&#8220;Amendment No.3&#8221;) is made as of the Amendment No. 3 Effective Date by and between Oncternal Therapeutics, Inc. having an address at 12230 El Camino Real, Suite 300, San Diego, California 92130 ("LICENSEE") and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (&#8220;UNIVERSITY&#8221;), represented by its San Diego campus having an address at University of California San Diego, Office of Innovation and Commercialization (&#8220;OIC&#8221;), Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (&#8220;UC San Diego&#8221;). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-style:normal;">, LICENSEE and UNIVERSITY entered into an Amended and Restated License agreement, UC Control Number 2019-03-0137, effective August 31, 2018, which was amended by Amendment No. 1 (&#8220;Amendment No. 1&#8221;), UC Control Number 2019-03-0137(R501) effective March 25, 2019 and further amended by Amendment No.2 (&#8220;Amendment No. 2&#8221;), UC Control Number&nbsp;&nbsp;2019-03-0137(R502) effective May 15, 2019 (collectively, &#8220;Agreement&#8221;); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">WHEREAS<font style="font-style:normal;">, LICENSEE and UNIVERSITY wish to further amend the Agreement to make certain changes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">NOW THEREFORE<font style="font-style:normal;">, in consideration of the foregoing premises and the mutual covenants set forth below, the parties amend the Agreement and otherwise agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">All capitalized terms used but not defined in this Amendment No,. 3 have the meaning ascribed to them in the Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Section 3.3(a)(A)(v) of the Agreement is hereby deleted and replaced with the following:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">dose the first patient in the first Phase I/Phase II clinical trial treating any solid tumor with Licensed Product within three (3) years from the Effective Date;&#8221;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Section 3.3(a)(A)(ix) of the Agreement is hereby deleted and replaced with the following:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">dose the first patient in the first Phase III clinical trial for treating any solid tumor with Licensed Product within six (6) years from the Effective Date; and&#8221;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">In consideration for this Amendment No. 3, LICENSEE shall pay an amendment fee in the amount of twenty-five thousand dollars (US $25,000).  Payment shall be made within thirty days after the Amendment No. 3 Effective Date.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;font-size:12pt;font-family:Times New Roman;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">All other terms and conditions of </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">the </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">Agreement shall remain unchanged and in full force and effect.&nbsp;&nbsp;This Amendment </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">No. 3 </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">constitutes an integral part of the Agreement and sets forth, together with the Agreement, the entire agreement between the Parties in respect of the subject matter of this Amendment </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">No. 3 </font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">and the Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">This Amendment No. 3 shall be governed by, and construed in accordance with, the laws of the State of California, which govern the Agreement.  This Amendment No. 3 is effective as of the date of the last signature below (the &#8220;Amendment No. 3 Effective Date&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:12pt;font-family:Times New Roman;color:#000000;">The parties agree that this Amendment No. 3 may be executed electronically and in one or more counterparts each of which shall be deemed an original and all of which together shall constitute but one and the same document.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF<font style="font-weight:normal;">, the Parties hereto have caused this Amendment No. 3 to be executed by their duly authorized representatives, as of the latest date written below.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.<font style="color:#000000;">:</font></p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE REGENTS OF THE </p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNIVERSITY OF CALIFORNIA<font style="font-weight:normal;">:</font></p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James Breitmeyer</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: </p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Victoria Cajipe</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:47%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James Breitmeyer, M.D., Ph.D.</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Victoria Cajipe, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President &amp; CEO</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Associate Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:46%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/5/21</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style="width:47%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/5/21</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.37
<SEQUENCE>3
<FILENAME>onct-ex1037_578.htm
<DESCRIPTION>EX-10.37
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex1037_578.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.37</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvndnkt0ksj3000001.jpg" title="" alt="" style="width:517px;height:49px;"></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Execution Version</font></p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 9, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">STRICTLY CONFIDENTIAL</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12230 El Camino Real</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 300</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California 92130</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Dr. Breitmeyer:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.34%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter agreement (this &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) constitutes the agreement between Oncternal Therapeutics, Inc. (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;) and H.C. Wainwright &amp; Co., LLC (&#8220;<font style="text-decoration:underline;">Wainwright</font>&#8221;), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an &#8220;<font style="text-decoration:underline;">Offering</font>&#8221;) of securities of the Company (the &#8220;<font style="text-decoration:underline;">Securities</font>&#8221;) during the Term (as hereinafter defined) of this Agreement.&nbsp;&nbsp;The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities.&nbsp;&nbsp;It is understood that Wainwright&#8217;s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connection with an Offering.&nbsp;&nbsp;The Company expressly acknowledges and agrees that Wainwright&#8217;s involvement in an Offering is strictly on a reasonable best efforts basis and that the consummation of an Offering will be subject to, among other things, market conditions.&nbsp;&nbsp;The execution of this Agreement does not constitute a commitment by Wainwright to purchase the Securities and does not ensure a successful Offering of the Securities or the success of Wainwright with respect to securing any other financing on behalf of the Company.&nbsp;&nbsp;Wainwright may retain other brokers, dealers, agents or underwriters on its behalf in connection with an Offering.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compensation; Reimbursement</font>.&nbsp;&nbsp;At the closing of each Offering (each, a &#8220;<font style="text-decoration:underline;">Closing</font>&#8221;), the Company shall compensate Wainwright as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Cash Fee</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Company shall pay to Wainwright a cash fee, or as to an underwritten Offering an underwriter discount (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Cash Fee</font><font style="font-family:Times New Roman;">&#8221;), equal to 7.0% of the aggregate gross proceeds raised in each Offering, excluding any proceeds raised from any of the investors listed on Exhibit A hereto (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Excluded Investors</font><font style="font-family:Times New Roman;">&#8221;).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Warrant Coverage</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;The Company shall issue to Wainwright or its designees at each Closing, warrants (the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Wainwright Warrants</font><font style="font-family:Times New Roman;">&#8221;) to purchase that number of shares of common stock of the Company equal to 6.0% of the aggregate number of shares of </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="font-family:Times New Roman;">common stock (or common stock equivalent, if applicable) placed in each Offering (and if an Offering includes a &#8220;</font><font style="font-family:Times New Roman;">greenshoe</font><font style="font-family:Times New Roman;">&#8221; or &#8220;additional investment&#8221; component, such number of shares of common stock underlying such &#8220;</font><font style="font-family:Times New Roman;">greenshoe</font><font style="font-family:Times New Roman;">&#8221; or &#8220;additional investment&#8221; component, with the Wainwright Warrants issuable </font><font style="font-family:Times New Roman;">only </font><font style="font-family:Times New Roman;">upon the exercise of such component).&nbsp;&nbsp;If the Securities included in an Offering are convertible, the Wainwright Warrants shall be determined by dividing the gross proceeds raised in such Offering by the Offering Price (as defined hereunder).&nbsp;&nbsp;The Wainwright Warrants shall be in a customary form reasonably acceptable to Wainwright, have a term of five (5) years and an exercise price equal to 125% of the offering price per share (or unit, if applicable) in the applicable Offering and if such offering price is not available, the market price of the common stock on the date an Offering is commenced (such price, the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Offering Price</font><font style="font-family:Times New Roman;">&#8221;). If warrants are issued to investors in an Offering, the Wainwright Warrants shall have the same terms as the warrants issued to investors in the applicable Offering, except that such Wainwright Warrants shall have an exercise price equal to 125% of the Offering Price</font><font style="font-family:Times New Roman;">.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Expense Allowance</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Out of the proceeds of each Closing, the Company also agrees to pay Wainwright (a) a management fee equal to 1.0% of the gross proceeds raised in each Offering; (b) $35,000 for non-accountable expenses (to be increased to $40,000 in case of a public Offering); (c) up to $50,000 for reasonable and documented fees and expenses of legal counsel and other reasonable and documented out-of-pocket expenses (to be increased to $100,000 in case of a public Offering); plus the additional amount payable by the Company pursuant to Paragraph D.3 hereunder and, if applicable, the costs associated with the use of a third-party electronic road show service (such as NetRoadshow); provided, however, that such amount in no way limits or impairs the indemnification and contribution provisions of this Agreement.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.26%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Tail</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Wainwright shall be entitled to compensation under clauses (1) and (2) hereunder, calculated in the manner set forth therein, with respect to any public, registered direct or private offering of Securities for capital raising purposes (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Tail Financing</font><font style="font-family:Times New Roman;">&#8221;) to the extent that such financing or capital is provided to the Company by investors whom Wainwright had contacted during the Initial Term or Extension Term, as applicable</font><font style="text-decoration:underline;font-family:Times New Roman;">,</font><font style="font-family:Times New Roman;"> or introduced to the Company during the Initial Term or Extension Term, as applicable, other than any Excluded Investors, but only if (a) Wainwright had presented to the Company terms for a potential Offering during the Initial Term following receipt of investors&#8217; input (irrespective of whether the Company accepts such terms), and (b) such Tail Financing is consummated at any time within the 12-month period following the first Closing during the Term.&nbsp;&nbsp;Upon the Company&#8217;s request, Wainwright shall as promptly as practicable provide a list of any such investors who are subject to this tail provision.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, in the event that Wainwright is offered the right to participate in a transaction, any fees payable by the Company to Wainwright shall be governed by the definitive engagement or transaction agreement with respect to such transaction, and no Tail Financing fee shall be payable by the Company under this Paragraph A.4, irrespective of whether Wainwright accepts such engagement. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term and Termination of Engagement; Exclusivity</font>.&nbsp;&nbsp;The term of Wainwright&#8217;s exclusive engagement will begin on the date hereof and end forty-five (45) days thereafter (the &#8220;<font style="text-decoration:underline;">Initial Term</font>&#8221;); provided, however, that if an Offering is consummated within the Initial Term, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the term of this Agreement shall be extended by an additional forty-five (45) day period (the &#8220;</font><font style="text-decoration:underline;">Extension Term</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#8221; and together with the Initial Term, the &#8220;</font><font style="text-decoration:underline;">Term</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Notwithstanding anything to the contrary contained herein, the Company agrees that the provisions relating to the payment of fees, reimbursement of expenses, tail, indemnification and contribution, confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or expiration </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this Agreement.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the Agreement for cause in compliance with FINRA Rule 5110(</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)(</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)(</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)(</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). The exercise of such right of termination for cause eliminates the Company&#8217;s obligations with respect to the provisions relating to the tail fees</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything to the contrary contained in this Agreement, in the event that </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an Offering pursuant to this </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement shall not be carried out for any reason whatsoever during the Term, the Company shall be obligated to pay to </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> its actual and accountable out-of-pocket expenses related to an Offering (including the </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fees and disbursements of </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s legal counsel</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not to exceed the limits set forth in Paragraph A.3 above</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and, if applicable, for e</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lectronic road show</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> service used in connection with an Offering</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. During </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s engagement hereunder: (</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the Company will not, and will not permit its representatives to, other than in coordination with </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, contact or solicit institutions, corporations or other entities or individuals as potential purchasers of the Securities</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (other than the Excluded Investors), provided that this shall not prohibit the Company from engaging in discussions with respect to any potential strategic transaction or merger or acquisition,</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and (ii)</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company will not pursue any </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity or equity-linked </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing transaction which would be in lieu of an Offering</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, other than a financing solely with the Excluded Investors</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Furthermore, the Company agrees that during </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s engagement hereunder, all inquiries</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from prospective investors </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(other than the Excluded Investors) </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will be referred to </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, except as set forth hereunder, the Company represents, warrants and covenants that no brokerage or finder&#8217;s fees or commissions are or will be payable by the Company or any subsidiary of the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other third-party with respect to any Offering.</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, nothing shall prohibit the Company from filing one or more registration statements on Form S-8</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or a shelf-registration statement on Form S-3 (but not any takedown therefrom)</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Information; Reliance</font>.&nbsp;&nbsp;The Company shall furnish, or cause to be furnished, to Wainwright all information reasonably requested by Wainwright for the purpose of rendering services hereunder and conducting due diligence (all such information being the &#8220;<font style="text-decoration:underline;">Information</font>&#8221;).&nbsp;&nbsp;In addition, the Company agrees to make available to Wainwright upon request from time to time the officers, directors, accountants, counsel and other advisors of the Company.&nbsp;&nbsp;The Company recognizes and confirms that Wainwright (a) will use and rely on the Information, including any documents provided to investors in each Offering (the &#8220;<font style="text-decoration:underline;">Offering Documents</font>&#8221;) which shall include any Purchase Agreement (as defined hereunder), and on information available from generally recognized public sources in performing the services contemplated by this Agreement without having independently verified the same; provided that Wainwright shall keep in confidence and shall not provide to investors or potential investors any material non-public Offering Documents that have not been approved in advance by the Company for such use (b)&#160;does not assume responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal of any of the assets or liabilities of the Company.&nbsp;&nbsp;Upon reasonable request, the Company will </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet with </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or its representatives to discuss all information relevant for disclosure in the Offering Documents and will cooperate in any investigation undertaken by </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> thereof, including any document included or incorporated by reference therein.&nbsp;&nbsp;At each Offering, at the request of </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company shall deliver such legal letters (including, without limitation, negative assurance letters), opinions, </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comfort letters, officers&#8217; and secretary certificates and good standing certificates</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, all in form and substance </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">satisfactory to </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and its counsel as is customary for such Offering.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be a third party beneficiary of any representations, warranties, covenants</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> closing conditions </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and closing deliverables </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">made by the Company in any Offering Documents, including representations, warranties, covenants</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> closing conditions</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and closing deliverables</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> made to any investor in an Offering.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Related Agreements</font>.&nbsp;&nbsp;At each Offering, the Company shall enter into the following additional agreements:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Underwritten Offering</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;If an Offering is an underwritten Offering, the Company and Wainwright shall enter into a customary underwriting agreement in form and substance reasonably satisfactory to Wainwright and its counsel.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Best Efforts Offering</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;If an Offering is on a best efforts basis, the sale of Securities to the investors in the Offering will be evidenced by a purchase agreement (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Purchase Agreement</font><font style="font-family:Times New Roman;">&#8221;) between the Company and such investors in a form reasonably satisfactory to the Company and Wainwright.&nbsp;&nbsp;Wainwright shall be a third party beneficiary with respect to the representations, warranties and covenants, closing conditions and closing deliverables included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial affairs will be available to answer inquiries from prospective investors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">Escrow, Settlement and Closing</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;If each Offering is not settled via delivery versus payment (&#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">DVP</font><font style="font-family:Times New Roman;">&#8221;), the Company and Wainwright shall enter into an escrow agreement with a third party escrow agent pursuant to which Wainwright&#8217;s compensation and expenses shall be paid from the gross proceeds of the Securities sold.&nbsp;&nbsp;If the Offering is settled in whole or in part via DVP, Wainwright shall arrange for its clearing agent to provide the funds to facilitate such settlement. The Company shall pay Wainwright closing costs, which shall also include the reimbursement of the out-of-pocket cost of the escrow agent or clearing agent, as applicable, which closing costs shall not exceed $12,900.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-family:Times New Roman;">FINRA Amendments</font><font style="font-family:Times New Roman;">.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, in the event that Wainwright determines that any of the terms provided for hereunder shall not comply with a FINRA rule, including but not limited to FINRA Rule 5110, then the Company shall use commercially reasonable efforts to agree to amend this Agreement (or include such revisions in the final underwriting agreement) in writing upon the request of Wainwright to comply with any such rules; provided that any such amendments shall not provide for terms that are less favorable to the Company than are reflected in this Agreement.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Confidentiality</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the event of the consummation or public announcement of any Offering, </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall have the right to disclose its participation in such Offering, including, without limitation, the Offering at </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright&#8217;s</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cost of &#8220;tombstone&#8221; advertisements in financial and other newspapers and journals.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Indemnity</font>.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">In connection with the Company&#8217;s engagement of Wainwright hereunder, the Company hereby agrees to indemnify and hold harmless Wainwright and its affiliates, and the respective controlling persons, directors, officers, members, shareholders, agents and employees of any of the foregoing (collectively the &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Indemnified Persons</font><font style="font-family:Times New Roman;">&#8221;), from and against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses incurred by any of them (including the reasonable fees and expenses of counsel), as incurred  (collectively a &#8220;</font><font style="text-decoration:underline;font-family:Times New Roman;">Claim</font><font style="font-family:Times New Roman;">&#8221;), that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company&#8217;s engagement of Wainwright, or (B) otherwise relate to or arise out of Wainwright&#8217;s activities on the Company&#8217;s behalf under Wainwright&#8217;s engagement, and the Company shall reimburse any Indemnified Person for all expenses (including the reasonable fees and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified Person is a party.&nbsp;&nbsp;The Company will not, however, be responsible for any Claim (including any related expenses incurred by an Indemnified Person) that is finally judicially determined to have resulted from the gross negligence or willful misconduct of any such Indemnified Person for such Claim (and, to the extent that the Company has made any payments to an Indemnified Person under this Paragraph F with respect to any such Claim, such Indemnified Person shall, and Wainwright shall cause such Indemnified Person to, promptly return any such payments to the Company following such final judicial determination).&nbsp;&nbsp;The Company further agrees that no Indemnified Person shall have any liability to the Company for or in connection with the Company&#8217;s engagement of Wainwright except for any Claim incurred by the Company as a result of such Indemnified Person&#8217;s gross negligence or willful misconduct.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">The Company further agrees that it will not, without the prior written consent of Wainwright, settle, compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any Indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.&nbsp;&nbsp;No Indemnified Person may, without the prior written consent of the Company, settle, compromise or </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="font-family:Times New Roman;">consent to the</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">entry of any judgment in any pending or threatened Claim in</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">respect of which indemnification may be sought hereunder (such</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">consent shall not be unreasonably delayed, withheld or</font><font style="font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">conditioned).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses.&nbsp;&nbsp;If the Company is requested by such Indemnified Person, the Company will assume the defense of such Claim, including the employment of counsel for such Indemnified Person and the payment of the fees and expenses of such counsel,</font><font style="font-style:italic;font-family:Times New Roman;"> </font><font style="font-family:Times New Roman;">provided, however, that such counsel shall be reasonably satisfactory to the Indemnified Person and provided further that if the legal counsel to such Indemnified Person reasonably determines that having common counsel would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it or other Indemnified Persons different from or in addition to those available to the Company, such Indemnified Person may employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. If such Indemnified Person does not request that the Company assume the defense of such Claim, such Indemnified Person may employ its own separate counsel (including local counsel, if necessary) to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable fees and expenses of its counsel and all amounts paid as a result of such Claim or the compromise or settlement thereof. Notwithstanding anything herein to the contrary, it is agreed that the Company shall not, in connection with any proceeding or related proceedings, be liable for the fees and expenses of more than one separate firm for all Indemnified Persons (including local counsel, if necessary). In addition, with respect to any Claim in which the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then (whether or not Wainwright is the Indemnified Person), the Company and Wainwright shall </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="font-family:Times New Roman;">contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and Wainwright on the other, in connection with Wainwright&#8217;s engagement referred to above, subject to the limitation that in no event shall the amount of Wainwright&#8217;s contribution to such Claim exceed the amount of fees actually received by Wainwright from the Company pursuant to Wainwright&#8217;s engagement.&nbsp;&nbsp;The Company hereby agrees that the relative benefits to the Company, on the one hand, and Wainwright on the other, with respect to Wainwright&#8217;s engagement shall be deemed to be in the same proportion as (a) the total value paid or proposed to be paid or received by the Company pursuant to the applicable Offering (whether or not consummated) for which Wainwright is engaged to render services bears to (b) the fee paid or proposed to be paid to Wainwright in connection with such engagement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.27%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Cambria;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;">The Company&#8217;s indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Person may have at law or at equity and (b) shall be effective whether or not the Company is at fault in any way.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation of Engagement to the Company</font>.&nbsp;&nbsp;The Company acknowledges that Wainwright has been retained only by the Company, that Wainwright is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company&#8217;s engagement of Wainwright is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto as against Wainwright or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221;)), employees or agents.&nbsp;&nbsp;Unless otherwise expressly agreed in writing by Wainwright, no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of Wainwright, and no one other than the Company is intended to be a beneficiary of this Agreement.&nbsp;&nbsp;The Company acknowledges that any recommendation or advice, written or oral, given by Wainwright to the Company in connection with Wainwright&#8217;s engagement is intended solely for the benefit and use of the Company&#8217;s management and directors in considering a possible Offering, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose.&nbsp;&nbsp;Wainwright shall not have the authority to make any commitment binding on the Company.&nbsp;&nbsp;The Company, in its sole discretion, shall have the right to reject any investor introduced to it by Wainwright.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Limitation of Wainwright&#8217;s Liability to the Company</font>.&nbsp;&nbsp;Wainwright and the Company further agree that neither Wainwright nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out of or relating to this Agreement or the services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and that are finally judicially determined to have resulted solely from the gross negligence or willful misconduct of </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Representations Warranties and Covenants of Placement Agent</font>. Wainwright hereby represents and warrants to the Company that the following representations and warranties are true and correct as of the date of this Agreement:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Cambria;margin-left:36pt;color:#000000;"></font>Wainwright is a member in good standing of FINRA and is registered as a broker-dealer under the Exchange Act. Wainwright is in compliance with all applicable rules and regulations of the SEC and FINRA, except to the extent that such noncompliance would not have a material adverse effect on the transactions contemplated hereby. None of Wainwright or its affiliates, or any person acting on behalf of the foregoing (other than the Company or its affiliates or any person acting on its or their behalf, in respect of which no representation is made) has or will engage in general advertising or general solicitation or has taken nor will it take any action that conflicts with the conditions and requirements of, or that would make unavailable with respect to the Offering, the exemption(s) from registration available pursuant to Rule 506 of Regulation D or Section 4(a)(2) of the Act. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Neither Wainwright nor any Wainwright Related Persons (as defined below) are subject to any Disqualification Event.  Any prospectus related to the Offering will contain a true and complete description of the matters required to be disclosed with respect to Wainwright and Wainwright Related Persons pursuant to the disclosure requirements of Rule 506(e) of Regulation D, to the extent applicable. As used herein, &#8220;<font style="text-decoration:underline;">Wainwright Related Persons</font>&#8221; means any predecessor of Wainwright, any affiliated company, any director, executive officer, other officer of Wainwright participating in the Offering, any general partner or managing member of Wainwright, any beneficial owner of 20% or more of Wainwright's outstanding voting equity securities, calculated on the basis of voting power, and any &#8220;promoter&#8221; (as defined in Rule 405 under the Act) connected with Wainwright in any capacity.  Wainwright agrees to promptly notify the Company in writing of (i)&#160;any Disqualification Event relating to any Wainwright Related Person and (ii)&#160;any event that would, with the passage of time, become a Disqualification Event relating to any Wainwright Related Person.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">J.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Governing Law</font>.&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein.&nbsp;&nbsp;Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York.&nbsp;&nbsp;The parties hereto expressly agree to submit themselves to the jurisdiction of the foregoing courts in the City of New York, State of New York.&nbsp;&nbsp;The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New York.&nbsp;&nbsp;In the event Wainwright or any Indemnified Person is successful in any action, or suit against the Company, arising out of or relating to this Agreement, the final judgment or award entered shall be entitled to have and recover from the Company the costs and expenses incurred in connection therewith, including its reasonable attorneys&#8217; fees.&nbsp;&nbsp;Any rights to trial by jury with respect to any such action, proceeding or suit are hereby waived by Wainwright and the Company.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">K</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Notices</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;All notices hereunder will be in writing and sent by certified mail, hand delivery, overnight delivery</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or e-mail</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if sent to </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, at the address set forth on the first page hereof, e-mail: </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notices@hcwco</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.com, Attention: Head of Investment Banking, and if sent to the Company, to the address set forth on the first page hereof, e-mail:&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JBreitmeyer@oncternal.com, </font><font style="color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Chief Executive Officer.&nbsp;&nbsp;Notices sent by certified mail shall be deemed received five days thereafter, notices sent by hand delivery or overnight delivery shall be deemed received on the date of the relevant written record of receipt, notices sent by e-mail shall be deemed received as of the date and time they were sent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Conflicts</font>.&nbsp;&nbsp;The Company acknowledges that Wainwright and its affiliates may have and may continue to have investment banking and other relationships with parties other than the Company pursuant to which Wainwright may acquire information of interest to the Company.&nbsp;&nbsp;Wainwright shall have no obligation to disclose such information to the Company or to use such information in connection with any contemplated transaction.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">M.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Anti-Money Laundering</font>.&nbsp;&nbsp;To help the United States government fight the funding of terrorism and money laundering, the federal laws of the United States require all financial institutions to obtain, verify and record information that identifies each person with whom they do business.&nbsp;&nbsp;This means Wainwright must ask the Company for certain identifying information, including a government-issued identification number (e.g., a U.S. taxpayer identification number) and such other information or documents that Wainwright considers appropriate to verify the Company&#8217;s identity, such as certified articles of incorporation, a government-issued business license, a partnership agreement or a trust instrument.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.34%;text-indent:7.34%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Miscellaneous</font>.&nbsp;&nbsp;The Company represents and warrants that it has all requisite power and authority to enter into and carry out the terms and provisions of this Agreement and the execution, delivery and performance of this Agreement does not breach or conflict with any agreement, document or instrument to which it is a party or bound.&nbsp;&nbsp;This Agreement shall not be modified or amended except in writing signed by Wainwright and the Company.&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of both Wainwright and the Company and their respective assigns, successors, and legal representatives.&nbsp;&nbsp;If any provision of this Agreement is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect, and the remainder of the Agreement shall remain in full force and effect.&nbsp;&nbsp;This Agreement may be executed in counterparts (including facsimile or electronic counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*********************</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.34%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In acknowledgment that the foregoing correctly sets forth the understanding reached by Wainwright and the Company, please sign in the space provided below, whereupon this letter shall constitute a binding Agreement as of the date indicated above.</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:44.04%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="margin-bottom:24pt;margin-top:0pt;margin-left:44.04%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">H.C. WAINWRIGHT &amp; CO., LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:44.04%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;<font style="text-decoration:underline;">/s/ Mark W. Viklund</font><font style="text-decoration:underline;margin-left:450pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:48.62%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Mark W. Viklund</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:48.62%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:48.62%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp; December 9, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted and Agreed:</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;<font style="text-decoration:underline;">/s/ Richard G. Vincent</font><font style="text-decoration:underline;margin-left:180pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.59%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Richard G. Vincent</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.59%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Chief Financial Offer</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.34%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>onct-ex231_826.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex231_826.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-221040, 333-204932, 333-201132 and 333-197911) and Forms S-8 (Nos. 333-233288, 333-223742, 333-210220, 333-208744, 333-188377, 333-165507, 333-149661, 333-136527, 333-118882, and 333-112576) of Oncternal Therapeutics, Inc., of our report dated March 11, 2021, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">/s/ BDO USA, LLP</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;text-indent:0%;color:#000000;font-size:10.5pt;font-family:Trebuchet MS;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>onct-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, James B. Breitmeyer, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 11, 2021</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>onct-ex312_15.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex312_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard G. Vincent, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Annual Report on Form 10-K of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 11, 2021</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>onct-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex321_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James B. Breitmeyer, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>onct-ex322_16.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex322_16.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Richard G. Vincent, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard G. Vincent</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:53.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: March 11, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\109979343.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>genzerafbudl000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -T Z8# 2(  A$! Q$!_\0
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M@U_R3;3/^N?]37H% 'R=_P 77_Y[ZO\ ]\G_  H_XNO_ ,]]7_[Y/^%?6-%
M'R=_Q=?_ )[ZO_WR?\*/^+K_ //?5_\ OD_X5]8T4 ?)W_%U_P#GOJ__ 'R?
M\*/^+K_\]]7_ .^3_A7UC10!\G?\77_Y[ZO_ -\G_"C_ (NO_P ]]7_[Y/\
MA7UC10!\G?\ %U_^>^K_ /?)_P */^+K_P#/?5_^^3_A7UC10!\G?\77_P">
M^K_]\G_"C_BZ_P#SWU?_ +Y/^%?6-% 'R=_Q=?\ Y[ZO_P!\G_"C_BZ__/?5
M_P#OD_X5]8T4 ?)W_%U_^>^K_P#?)_PH_P"+K_\ /?5_^^3_ (5]8T4 ?)W_
M !=?_GOJ_P#WR?\ "C_BZ_\ SWU?_OD_X5]8T4 ?)W_%U_\ GOJ__?)_PH_X
MNO\ \]]7_P"^3_A7UC10!\G?\77_ .>^K_\ ?)_PH_XNO_SWU?\ [Y/^%?6-
M% 'R=_Q=?_GOJ_\ WR?\*/\ BZ__ #WU?_OD_P"%?6-% 'R=_P 77_Y[ZO\
M]\G_  H_XNO_ ,]]7_[Y/^%?6-% 'R=_Q=?_ )[ZO_WR?\*/^+K_ //?5_\
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M_GOJ_P#WR?\ "C_BZ_\ SWU?_OD_X5]8T4 ?)W_%U_\ GOJ__?)_PH_XNO\
M\]]7_P"^3_A7UC10!\G?\77_ .>^K_\ ?)_PH_XNO_SWU?\ [Y/^%?6-% 'R
M=_Q=?_GOJ_\ WR?\*/\ BZ__ #WU?_OD_P"%?6-% 'R=_P 77_Y[ZO\ ]\G_
M  H_XNO_ ,]]7_[Y/^%?6-% 'R=_Q=?_ )[ZO_WR?\*/^+K_ //?5_\ OD_X
M5]8T4 ?)W_%U_P#GOJ__ 'R?\*/^+K_\]]7_ .^3_A7UC10!\G?\77_Y[ZO_
M -\G_"C_ (NO_P ]]7_[Y/\ A7UC10!\G?\ %U_^>^K_ /?)_P */^+K_P#/
M?5_^^3_A7UC10!\G?\77_P">^K_]\G_"C_BZ_P#SWU?_ +Y/^%?6-% 'R=_Q
M=?\ Y[ZO_P!\G_"C_BZ__/?5_P#OD_X5]8T4 ?)W_%U_^>^K_P#?)_PH_P"+
MK_\ /?5_^^3_ (5]8T4 ?)W_ !=?_GOJ_P#WR?\ "C_BZ_\ SWU?_OD_X5]8
MT4 ?)W_%U_\ GOJ__?)_PH_XNO\ \]]7_P"^3_A7UC10!\G?\77_ .>^K_\
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M67RCA\=C6#/KNE'P9'%_:%MO^R(-OFKG.T>]>>_!34[*SEUDW5W%%NF!7S)
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M(2_F*]GHKT_]8<Q_Y^$>RAV/&/\ A0]O_P!!"7\Q1_PH>W_Z"$OYBO9Z*/\
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MMR_9!)Y@BYW9SGK]:WPG$=/V]=UI^[]G04J+LK(JK\"+<J#_ &A+S[BJ]_\
M!""TL)K@7\I\M<XR*]O4;5 ]*BN[=+NUDMWSMD7!Q7SDN(,QMI4.B%*GS+F6
MA\Y>#OAE%XDDNU:Z>/R#C@]><5UG_"A[?_H(2_F*[WPEX2?PS<WKF=9$G.5
M!R.<UU59T>(,SY%SU-?D=>8TL+]8E]67N:6^X^;O'OPPB\)Z$M^EW)*3($VL
M:TO#7P>AUO0X+]KV1#(,X!'%>J>/?"<OC#0UT^*X2!A('W."1^E:?AC1GT'0
MX-/>19&C&"RC@UZTN(:_U&-JG[R[OIT//]DN;;0\P_X4/;_]!"7\Q7FGCKP@
MGA36[>Q2=I1("<D].<5]95YWX[^&0\6ZE;WT-VL$L7!W@D$9SVJ,OXAQ"JOZ
MS4TL^G6VA:I0YE=:71\WBQ!U**VW<.V,U[+;_ ^":PBN/M\HWQ!\9'<9K2?X
M)6_]J6=TEX D9!F4DY;UQZ5ZO% L-FENGW4C"#/L,5IB^(JWU:BJ-3W[>]IU
M-:]*B\1-TU[E]/0^:_#_ ,.8]8\03Z<;IU$9/S ^E=G_ ,*'M_\ H(2_F*[3
MP]X*FT7Q!-J3W22+(20H!R,UV=>/1X@S3E]^IK\CKS*E@_;+ZM\-E]_4\8_X
M4/;_ /00E_,4V3X%0)$[_P!H2_*">HKVFH[C_CVE_P!P_P JV_UAS'_GX<"H
MPOL?-?ASX=)K>NSZ>UVZB+/(/H*['_A0]O\ ]!"7\Q5OX>?\CM??\"_E7KE<
M^&XCS*<+RJ?D>KG6!H8?$J%*-E9,\8_X4/;_ /00E_,5P?Q%\!1^#%LRERTO
MGY^\>F*^HZXKQ_X"3QK;VX^T"&6 _*3G&#UZ5ZV6\0XA8F/UJI[G70\:=)<O
MNH\Q\)?"*'Q#X;L]3:]D0SINV@]*P?'G@"/PG-;(ER\OFL!\QZ5]%>&M#C\.
M:%;:9$Q98$VY)ZU@^._ 8\7I T=P(9HFR"V2/TK;#<15?KS=2I^ZN^G3H)T5
MRZ+4\\?X+P+H*W_VZ3)@63&1CD9KF/A_\/H_%YOP]T\7V:3:-IZU](#3@VB1
MZ=(V0L*Q%AWP,5S/@;P(W@ZYU%A<K+'=.&4 '*_7-32XAK?5JJE4]^ZY=//4
M;I*ZT.-_X4/;_P#00E_,4?\ "A[?_H(2_F*]GHKS?]8<Q_Y^%^RAV/%I/@3
MD;-_:$O )ZBN!\-^!8]:\:7&B-<,BQ!CO!Y.!FOJ61=\3I_>4BN'\+_#X:%X
MIO-<FN5EEF)$:KD;01@YKT,)Q#75&K[:I[UO=TZD2I*ZLCP;Q_X13PCK4-BD
M[2B2/?DGIS7H>B?!>&ZL+*_^WR@R(LF 1QD9IOQUTF!9K/4P6\XD1XSQCK7K
M?A;_ )%C3?\ KW3_ -!%=F.SC$K+J%6G+WG=,F--<[3-.WB\BVBBSG8@7/T%
M2445\4W=W.D****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7C?[0G_ "+5I_O-_2O9*\;_ &A/^1:M/]YOZ4 :'P'_ .1('U']
M:*/@/_R) ^H_K10!ZI1110 4444 %%%% !1110 4444 %%%% !7F7QS_ .2?
M7/U'\Z]-KS+XY_\ )/KGZC^= %WX,_\ )-M,_P"N?]37H%>?_!G_ ))MIG_7
M/^IKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.X_X]I?]P_RJ2H[
MC_CVE_W#_*ACCNCR?X>?\CM??\"_E7KE>1_#S_D=K[_@7\J]<KEPG\/YL]SB
M+_?%_AB%%%%=1X04444 %%%% !1110 4444 >.?'?_D&V?\ UU']:],\+?\
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M_A? _P"@%<_]]#_"O1S/A_$>U7U:G[MEU6_4B%56]YGL]%>,?\+X'_0"N?\
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MK:-I=GI=Q.MA$S+&2!M]J^<O"PCU#XAQM) !')+G9C@<BNVN_B+X@N;62&2
M!'!!.37':7<OINJ)>V\8,ZG(KV<!Q)]3]HFG+F5O1G%'A"O4I>])*2?KH?2O
M_".Z3_SY1?\ ?(KF/B%H>G6_@?4I8;2-9%08(7GK7$_\+,\1_P#/N/S-4=6\
M>:YJFF36=S !#(,,<FN.CG/LJD:EV[.]C!<*8N3LVDO47X'Z=:WMQJ(N;=9
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MS_R3;3/^N?\ 4UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?/'QN_Y&ZV_X!_*O:_!_P#R*MC_ -<Z\4^-W_(W6W_ /Y5[
M7X/_ .15L?\ KG7U.:?\BG#&$/XC-RBBBOEC<**** "BBB@ HHHH *\;_:$_
MY%JT_P!YOZ5[)7C?[0G_ "+5I_O-_2@#0^ __(D#ZC^M%'P'_P"1('U']:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/'QN_Y&
MZV_X!_*O:_!__(JV/_7.O%/C=_R-UM_P#^5>U^#_ /D5;'_KG7U.:?\ (IPQ
MA#^(S<HHHKY8W"BBB@ HHHH **** "O&_P!H3_D6K3_>;^E>R5XW^T)_R+5I
M_O-_2@#0^ __ ") ^H_K11\!_P#D2!]1_6B@#U2BBB@ HHHH **** "BBB@
MHHHH **** "O,OCG_P D^N?J/YUZ;7F7QS_Y)]<_4?SH N_!G_DFVF?]<_ZF
MO0*\_P#@S_R3;3/^N?\ 4UZ!0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'SQ\;O\ D;K;_@'\J]K\'_\ (JV/_7.O%/C=_P C
M=;?\ _E7M?@__D5;'_KG7U.:?\BG#&$/XC-RBBBOEC<**** "BBB@ HHHH *
M\;_:$_Y%JT_WF_I7LE>-_M"?\BU:?[S?TH T/@/_ ,B0/J/ZT4? ?_D2!]1_
M6B@#U2BBB@ HHHH **** "BBB@ HHHH **** "O,OCG_ ,D^N?J/YUZ;7F7Q
MS_Y)]<_4?SH N_!G_DFVF?\ 7/\ J:] KS_X,_\ )-M,_P"N?]37H% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/'QN_Y&ZV
M_P" ?RKVOP?_ ,BK8_\ 7.O%/C=_R-UM_P  _E7M?@__ )%6Q_ZYU]3FG_(I
MPQA#^(S<HHHKY8W"BBB@ HHHH **** "O&_VA/\ D6K3_>;^E>R5XW^T)_R+
M5I_O-_2@#0^ _P#R) ^H_K11\!_^1('U']:* /5**** "BBB@ HIDDL<*%Y'
M"*.I)P*KPZG8W'^INX9,''RN#0!;HHHH **** "BBB@ KS+XY_\ )/KGZC^=
M>FUYE\<_^2?7/U'\Z +OP9_Y)MIG_7/^IKT"O/\ X,_\DVTS_KG_ %->@4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ-QJ?AR&:Y.9 2N[UP<5T=4-&2R32H!88-OM^4BK]7/XF90V"BBBI*"BBB@
MKS+XY_\ )/KGZC^=>FUYE\<_^2?7/U'\Z +OP9_Y)MIG_7/^IKT"O/\ X,_\
MDVTS_KG_ %->@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\\?&[_ )&ZV_X!_*O:_!__ "*MC_USKQ3XW?\ (W6W_ /Y5[7X
M/_Y%6Q_ZYU]3FG_(IPQA#^(S<HHHKY8W"BBB@ HHHH **** "O&_VA/^1:M/
M]YOZ5[)7C?[0G_(M6G^\W]* -#X#_P#(D#ZC^M%'P'_Y$@?4?UHH ]4HHHH
M**** //O',$MKKVG:O+"TUE"0)%4%L<]<5Q6F>*-*$NN1FWGD-T"(H_(/)W9
M_"N[\=>*O^$<U"S^U%#83$+*I/8U#;>(_ ,<B7,(LTE/(8$9%*.JMTU*<FO7
M0W/ UC<6/AJ&.Y!#DE@I[ G(KI:KV5Y!?6J7%NP:)A\I%6*N3N[F<59!1114
ME!1110 5YE\<_P#DGUS]1_.O3:\R^.?_ "3ZY^H_G0!=^#/_ "3;3/\ KG_4
MUZ!7G_P9_P"2;:9_US_J:] H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^IKT"O/_@S_ ,DVTS_KG_4UZ!0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'SQ\;O^1NMO^ ?RKVOP?\ \BK8_P#7.O%/C=_R
M-UM_P#^5>U^#_P#D5;'_ *YU]3FG_(IPQA#^(S<HHHKY8W"BBB@ HHHH ***
M* "O&_VA/^1:M/\ >;^E>R5XW^T)_P BU:?[S?TH T/@/_R) ^H_K11\!_\
MD2!]1_6B@#U2BBB@ J"\NEL[62X<,50$D*,FIZ:Z*ZE74%3U!H8(X7Q-KN@:
MCHD1U.PN)89AE,19*^]<%;IX02X5I8M4GA4\0O;C;7H/B[4VL[^QTC3[&"2>
M9A]],A5KF-1U'4KW5Y[;1[&R$=A$KSEHL[FZ$#\:2T][^M!M.UOZU/3]%GMK
MC2H7M(FB@QA488(KDOBA!(^F6,RCY(KJ,M[#-=%X4U5=7T*&X6,1GE64# !'
M%:5]8P:C:/;7*!XW&"#5334K]F*#5C@?'L\=YX0L((7#27!"H >N178QPNOA
MB.#I(+51CWVUFV'@?3K*[CG:6><1',:2ON5/H*V&TM6U(7GGS   >4&^3\J)
M6<6NXE=-/L>7^ /#FCRZ/JK7\,<ER"Q;S.J=:W_AZ+J;1=3M$N'$22[+:4?P
MKCJ*V;[P/87=X]Q'-<6QD/[Q87VAOK6YINF6VDV:6MK&$C48^M/F_*P-=N]S
MF3X7\0$G'BB__-?\*X'XN:'J]CX*N);O7;N[B!&8Y",'GV%>X5YE\<_^2?7/
MU'\ZD9=^#/\ R3;3/^N?]37H%>?_  9_Y)MIG_7/^IKT"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 5YE\<_^2?7/U'\Z]-KS+XY_\D^N?J/YT 7?@S_R3;3/^N?]37H%>?\
MP9_Y)MIG_7/^IKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ^>/C=_P C=;?\ _E7M?@__D5;'_KG
M7BGQN_Y&ZV_X!_*O:_!__(JV/_7.OJ<T_P"13AC"'\1FY1117RQN%%%% !11
M10 4444 %>-_M"?\BU:?[S?TKV2O&_VA/^1:M/\ >;^E &A\!_\ D2!]1_6B
MCX#_ /(D#ZC^M% 'JE%%% !1139)%BC:1R JC))["@#CO&D6D:C<VVF7[-%/
M*1Y,P'W3VYK'3X;W,["*\\023V8_Y9X R/KFL3Q[K>B^)=0AMHM2NK8V[_Z^
M%1M!'N:U;+P7KUS:12VWBZ]DA*C:P9>1^5$=KCEO8]'T^QM].LH[6V4+$@P
M*M52TJTFLM/C@N)VGD4<R-U-7:;W)6P4444AA1110 5YE\<_^2?7/U'\Z]-K
MS+XY_P#)/KGZC^= %WX,_P#)-M,_ZY_U->@5Y_\ !G_DFVF?]<_ZFO0* "BB
MB@ HHHH ***K7>HV=@ ;NYB@!Z&1L9I-I:L<8RD[15V6:*RO^$ET3_H*6G_?
MT5/:ZQIM[)Y=K?03/_=1P324HO1,T>'JQ5W%_<R]1115&04444 %%%1-<PK,
M(FE02'D*3S0-)O8EHHHH$%%%% !1110 4444 %%1"YA,QA$J&0<E<\U+0-IK
M<**J76J6-E*D5U=PPR/RJNP!-6E974,I!4C(([TDT]AN$DDVM&+152+4[&>X
M-O%=Q/,.J*P)%6Z$TU=!*,HZ25@HHJJVI6*WBVC740N&Z1%AN/X4[A&,I;*Y
M:HHHH)"BBB@ HHHH **** "BBB@ HHJ.:>*VB,LTBQQCJS' %#:6K&DV[(DH
MJ&VNK>\B\VVF26,_Q(<BHKO5+"P8"[NX82>@=P*3:6K*5.;ERI:ENBH;>Z@N
MXO,MYDE0_P 2'(J:F2TT[,****!!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?/'QN_Y&ZV_P" ?RKVOP?_ ,BK8_\ 7.O%/C=_R-UO_P
M_E7L'A/5;"/PQ8H]Y"&$?(+BOJLSC*64X:R,(?Q&=/15+^V--_Y_8/\ OL4?
MVQIO_/[!_P!]BOF/93[,VNBU)+'"A>1U11U+' IEM=P7D0EMYDD0]T8&N"^*
MNKP?\(+>?8[^,2Y481QD\US7P+U1(]'U!+R]55290BR-C V]J]2GE4I8"6+O
MJG:UB'/WN4]HHJ*"XAN4WP2K(N<94YJ6O)::=F:!1112 *\;_:$_Y%JT_P!Y
MOZ5[)7C?[0G_ "+5I_O-_2@#0^ __(D#ZC^M%'P'_P"1('U']:* /5**** "
ML7Q8[1^&;YE8@^4W(^AK:JKJ-E'J-A-:2_<E4J?Q&*F:O%I%1=I)L\PT+2]&
ME^%LLDL$#3O;[F=E^;./6NA^&=Y$/"2(\X.V9U&3T QBLL?!S35B,2WMTL1X
MV"9L?SHA^#NGVZ;(;ZZ1<YP)W _G6CE=OSL9VT2[7/2U977<IR#WI:I:5IZZ
M7I\=HKLX0?>8DFKM)[Z#6VH4444AA1110 5YE\<_^2?7/U'\Z]-KS+XY_P#)
M/KGZC^= %WX,_P#)-M,_ZY_U->@5Y_\ !G_DFVF?]<_ZFO0* "BBB@ HHHH
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M9/BIHJ:FMFB/(K,%\Y6&VNKO=8L;#3?M\TZ"W(RK9X;Z5YQ\0M+M;#PE9^1
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MHK$85XW^T)_R+5I_O-_2O9*\;_:$_P"1:M/]YOZ4 :'P'_Y$@?4?UHH^ _\
MR) ^H_K10!ZI1110 4444 4=3U>QTB#SKV=8E[9(R:P_^%A^'?\ GZ?_ +YK
MF?B2=.AU_3)]8E0V 8!HW/&<]:NI+\-FC5@FF<@$=*2U5QO1V.\L[R&^MEN(
M&+1MT)%3U3TPV1L(SI^S[-CY-G2KE4]R5L%%%%(84444 %>9?'/_ ))]<_4?
MSKTVO,OCG_R3ZY^H_G0!=^#/_)-M,_ZY_P!37H%>?_!G_DFVF?\ 7/\ J:]
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MT)P&4_C7DWB_Q1<Z1X;TRRM9?*\] '<#) P*XMK^WT?RM0T[Q'/=7089A=&
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M*3U0T><:RVH)!::?'XG\F\P ["1/F^M9DNF>(K:)IG\8X5>21+'_ (5!XF\
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MCSUVC/Y5P7A;X=2Z5J@U+5[T7MVARC@GC\Z] I)*--0!^]/F^14U/_D%7?\
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MP4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\;_:$_
MY%JT_P!YOZ5[)7C?[0G_ "+5I_O-_2@#0^ __(D#ZC^M%'P'_P"1('U']:*
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ML@+%%<AX.\6R>)9KHNJQQQL553C/6NN+*OWF ^IK6O0G0J.G/=$QFI*Z%HI
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M@ HHHH **** "BBB@ KQO]H3_D6K3_>;^E>R5XW^T)_R+5I_O-_2@#0^ _\
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MA\![.LK2<VUZ6W'3DISIJ/1:G0T445\\=P4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\;_:$_
MY%JT_P!YOZ5[)7C?[0G_ "+5I_O-_2@#0^ __(D#ZC^M%'P'_P"1('U']:*
M/5**** "BBB@ HHHH ***Q/%&NC0=)-R%W2.PCC'^T>E)L:5S;HKSJ;Q!X@T
M)+'4-3F2:SNG :-4"F,'GK7?K<JUDMR.5:/>/RS5-65Q7U)J*\\@UGQ'X@-Y
M=Z=.MG:VQ.U)(LE\?_JK>\&>(Y/$.FR-.FVXMW\N7'<XS0DV@>ATM>9?'/\
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M@:U$+=_OV\[_ #M^ HI^^DQU/=/::***0!1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>-_M"?\BU:?[S?TKV2O&_VA/^1:M/\ >;^E &A\!_\ D2!]1_6B
MCX#_ /(D#ZC^M% 'JE%%% !1110 4444 %%%% !1110 4444 %>9?'/_ ))]
M<_4?SKTVO,OCG_R3ZY^H_G0!=^#/_)-M,_ZY_P!37H%>?_!G_DFVF?\ 7/\
MJ:] H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O&_VA/\ D6K3_>;^E>R5XW^T)_R+5I_O
M-_2@#0^ _P#R) ^H_K11\!_^1('U']:* /5**** "BBB@ HHHH **** "BBB
M@ HHHH *\R^.?_)/KGZC^=>FUYE\<_\ DGUS]1_.@"[\&?\ DFVF?]<_ZFO0
M*\_^#/\ R3;3/^N?]37H% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9  R3]!0!>HK,TC7['6E8VC/E>JR+M(_"M.BU@"BBB@ HHHH **** "BBB@
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M=V\'VC:I,L0Z@]*[6L+0?#JZ07EFF:XN7X,C$GCMUK=JF]B5N%%%%(84444
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M>H5XW^T)_P BU:?[S?TKV2O&_P!H3_D6K3_>;^E(9H? ?_D2!]1_6BCX#_\
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MKQ2=5#J5R/QKH*X34]DGB_1S:%2%*[MO]WFN[JFDDF2%%%%2,**** "BBB@
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MI:K;ZZT6&9_)C92#[&NR\-ZC+JFC1W$Z[9,E3[X[TTKQN)WN:]%%%(84444
M%%%% !1110 4456O[DV=C-<*A<QKN"@9)I-V5P2N4=2\1V&EZA:V,\G[^Y;:
MB@9[9K6!RH([BO%+S6+*?Q!IVHWD5V;S[0RX>+A0!QBO:+=Q);QNN<%0>:I+
MW;@][(DHHHI %%%% !1110 4444 %5KZ^ATZTDN;AML:#)-6:Y;QWG^QES_J
MMWS_ $XI,?F3:1XOL]5N_LX22)S]S>A&[\ZZ.N&UEH9=5T06Q5I G&T]!QFN
MYJNA/4*\;_:$_P"1:M/]YOZ5[)7C?[0G_(M6G^\W]*0S0^ __(D#ZC^M%'P'
M_P"1('U']:* /5**** "BBB@ HHHH ***I:KJ=OI%B]W<MA%Z>Y]*+V!*Y=H
MKC;;QV#<6XO=/DM;>Y8+#,S ALUV =3'Y@/RD9S[4[:7 =17(7?CC;=SQV&G
M27D-N?WTJN %K?T;6+77-.CO+5LHXSCTI)75P>CL:%>9?'/_ ))]<_4?SKTV
MO,OCG_R3ZY^H_G0!=^#/_)-M,_ZY_P!37H%>?_!G_DFVF?\ 7/\ J:] H H:
MKI%KK%KY%RO'\+#JI]JHZ;X4L-.+-NEN'(QNF.X@>U;M%"T#<YRV\&:=;:@;
MI7F89R(F;*+]!71  # Z4M%'2P=;A1110 4444 %%%% !1110!D:SX=L]:"F
M8R12)]V2(X8?C4,'A/3H;&2U(>7S/O2R'+Y]<UNT4=+ 8FC^&++1Y#)$\LSG
M@-*V2/I6W111< HHHH **** "BBB@ HHHH Y:]\#6-YJ4M^+N[@FE.6\J3%6
M)O"-I/8I;/<W)*'*R[_G'XUT-%'2P=;F5H^@VFC(PA+R.WWI)#EC^-:M%%-N
MX6"BBBD 4444 %%%% !3)(Q+$T;=&&#3Z* .17X?6$<TLD-_?1>8Y=E27 R:
MWIM(@N-,%C,SO'QRQY.*T**.E@ZW(K:W2UMTAC^X@P*EHHH;N"5M HHHH **
M** "BBB@ HHHH SO[%M/[6;4L'SV4*?3 K-O?!MA>WAN!-<0[CETB;"M]171
MT4#;;(+2TAL;9(($"QH, "IZ**&[B"BBB@ HHHH **** "BBB@#"U;PK9:K<
M>>TDT$O=X6VEOK6AIFEV^E6P@MP<=V/5OK5VBA: ]=PHHHH **** "BBB@ H
MHHH *0C(P>]+10!SEYX,L+R]-RT]PFXY:-'PK?45O6UO%:0+#"H5%& !4M%&
MRL#U=PHHHH **** "BBB@ HHHH *0@,,$9!I:* ,N\\/Z=?302RVZ;X6+*0.
M]::J%4*!@ 8%+11Y %%%% !1110 4444 %%%% !5>]LH-0M7MKA T;C!%6**
M ,+2O"ECI-QYZ/+,X^Z96SM^E;M%%%P"O&_VA/\ D6K3_>;^E>R5XW^T)_R+
M5I_O-_2@#0^ _P#R) ^H_K11\!_^1('U']:* /5**** "BBB@ HHHH *X'XH
M3.NG6$0)V/=Q!O\ OJN^K \6Z$=>TCR4($T;B2,^XZ4GHTRHG,?$2)(_!=FR
M* T9RA'8XKK8Y77PG%)SO^RJ?_'17'MIFO>(ELM-U"W6&VM7!D?G]X!Q78%[
MA;I=,%MFU$03S,>V*J2O%I=6R(NS7DCE/AVJR^$KZ1P"T@DW$]^M1_#BX:TT
MO6V"LT<%Q\B@9X"]J2'3==\-/>:=86ZS6MT2$?GY,]?YUU/A#0&T#2!#*0UQ
M(0TK#NU5=-N7DD#_ )?.YDGQ\P)']EW7_?E_\*X+XM>+#JO@NXMC83Q9(^=X
MV '/O7N=>9?',D?#VZ&>I'\Z@9=^#/\ R3;3/^N?]37H%>?_  9_Y)MIG_7/
M^IKT"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_?0H W**P_\ A+]"_P"@C#_WT*/^$OT+_H(P_P#?0H W**P_^$OT+_H(P_\
M?0H_X2_0O^@C#_WT* -RBL/_ (2_0O\ H(P_]]"C_A+]"_Z",/\ WT* -RBL
M/_A+]"_Z",/_ 'T*/^$OT+_H(P_]]"@#<HK#_P"$OT+_ *",/_?0H_X2_0O^
M@C#_ -]"@#<HK#_X2_0O^@C#_P!]"C_A+]"_Z",/_?0H W**P_\ A+]"_P"@
MC#_WT*/^$OT+_H(P_P#?0H W**P_^$OT+_H(P_\ ?0H_X2_0O^@C#_WT* -R
MBL/_ (2_0O\ H(P_]]"C_A+]"_Z",/\ WT* -RBL/_A+]"_Z",/_ 'T*/^$O
MT+_H(P_]]"@#<HK#_P"$OT+_ *",/_?0H_X2_0O^@C#_ -]"@#<HK#_X2_0O
M^@C#_P!]"C_A+]"_Z",/_?0H W**P_\ A+]"_P"@C#_WT*/^$OT+_H(P_P#?
M0H W**P_^$OT+_H(P_\ ?0H_X2_0O^@C#_WT* -RBL/_ (2_0O\ H(P_]]"C
M_A+]"_Z",/\ WT* -RBL/_A+]"_Z",/_ 'T*/^$OT+_H(P_]]"@#<HK#_P"$
MOT+_ *",/_?0H_X2_0O^@C#_ -]"@#<HK#_X2_0O^@C#_P!]"C_A+]"_Z",/
M_?0H W**P_\ A+]"_P"@C#_WT*/^$OT+_H(P_P#?0H W**P_^$OT+_H(P_\
M?0H_X2_0O^@C#_WT* -RBL/_ (2_0O\ H(P_]]"C_A+]"_Z",/\ WT* -RBL
M/_A+]"_Z",/_ 'T*/^$OT+_H(P_]]"@#<HK#_P"$OT+_ *",/_?0H_X2_0O^
M@C#_ -]"@#<HK#_X2_0O^@C#_P!]"C_A+]"_Z",/_?0H W**P_\ A+]"_P"@
MC#_WT*/^$OT+_H(P_P#?0H W**P_^$OT+_H(P_\ ?0H_X2_0O^@C#_WT* -R
MBL/_ (2_0O\ H(P_]]"C_A+]"_Z",/\ WT* -RBL/_A+]"_Z",/_ 'T*/^$O
MT+_H(P_]]"@#<HK#_P"$OT+_ *",/_?0H_X2_0O^@C#_ -]"@#<HK#_X2_0O
M^@C#_P!]"C_A+]"_Z",/_?0H W**P_\ A+]"_P"@C#_WT*/^$OT+_H(P_P#?
M0H W**P_^$OT+_H(P_\ ?0H_X2_0O^@C#_WT* -RBL/_ (2_0O\ H(P_]]"C
M_A+]"_Z",/\ WT* -RBL/_A+]"_Z",/_ 'T*/^$OT+_H(P_]]"@#<HK#_P"$
MOT+_ *",/_?0H_X2_0O^@C#_ -]"@#<HK#_X2_0O^@C#_P!]"C_A+]"_Z",/
M_?0H W**P_\ A+]"_P"@C#_WT*/^$OT+_H(P_P#?0H W**P_^$OT+_H(P_\
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M/'AZZ_W:@\%G/A.Q_P!T_P S0!X#_P * \5?\]X?^_XH_P"% >*O^>\/_?\
M%?3M% 'S%_PH#Q5_SWA_[_BC_A0'BK_GO#_W_%?3M% 'S%_PH#Q5_P ]X?\
MO^*/^% >*O\ GO#_ -_Q7T[10!\Q?\* \5?\]X?^_P"*/^% >*O^>\/_ '_%
M?3M% 'S%_P * \5?\]X?^_XH_P"% >*O^>\/_?\ %?3M% 'RCK'P8\1Z-!%+
M//%MDE6(8FSRQP*T?^% >*O^>\/_ '_%>V?$$@:=8Y_Y_H/_ $.NQH ^8O\
MA0'BK_GO#_W_ !1_PH#Q5_SWA_[_ (KZ=HH ^8O^% >*O^>\/_?\4?\ "@/%
M7_/>'_O^*^G:* /F+_A0'BK_ )[P_P#?\4?\* \5?\]X?^_XKZ=HH ^8O^%
M>*O^>\/_ '_%'_"@/%7_ #WA_P"_XKZ=HH ^8O\ A0'BK_GO#_W_ !1_PH#Q
M5_SWA_[_ (KZ=HH ^4)?@SXCBUQ-+,\7G-'Y@_?<8SBM+_A0'BK_ )[P_P#?
M\5[5?$?\+,MQG_ET'_H5=G0!\Q?\* \5?\]X?^_XH_X4!XJ_Y[P_]_Q7T[10
M!\Q?\* \5?\ />'_ +_BC_A0'BK_ )[P_P#?\5].T4 ?,7_"@/%7_/>'_O\
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M%?3M-D_U3_[IH ^4=*^#7B+5GN$AGBS"VULS8K3_ .% >*O^>\/_ '_%>T>
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MODGKSFKU5Y+ZVBM?M+S((L9W;ABJUAKFGZD[);7"LR]03@T :-%%% !1110
M4444 %%%% !2$9!![T,RHI9B HZDFLN+Q%I<UW]F2Z3S,XZC'YT>0%BPTJTT
MUI6MD*F4Y;)ZU=JI>ZE::?#YMS,J+VYY--L-5L]30M:S*^.HSS^5 %VBBB@
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M?'(_ D ':M)?%=_R_P"0K:.W?_,Z/P&NGK:7)T^>389,F!P!Y1Q]T"NPK@_
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M[>Y-:+25UMK\S-_#9[Z?(ZZBBBH*"BBB@ HHHH **** "BBB@ HHHH ****
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MVUC;68(MX4CSUVJ!3Y+>&617DB1G4Y5BH)%2T4 %%%% !1110 4444 %%%%
M".BR(5=0RD8((ZU0.AZ83G[#;_A&O^%:%% $"V5LD'D+!&(O[FT8_*FV^GVE
MH2T%O%&3U*H :LT4 %%%% !1110 4444 %%%% "$!AA@"#U!JJFEV,<OFI:0
MJ_7(C%6Z* *D^EV-R^^:TA=_[S(":(-+LK63?!;11MZJ@%6Z* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFD<YN+ES))CH":Z"JE:^A*"BBBI&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>genzerafbudl000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &M R0# 2(  A$! Q$!_\0
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M 4444 %%%% $0MH%NFN1$HF90C/CDCKBHXK"UAO)KN.!%N)@!)(!RV/6K-%
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M-A+E]I&WNZ_<5'L=$K!E##H1D4M5=.NXKRQCEA)*X Y&*M5V1DI)-$A1115
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M10 4444 & .@IHC16+*B@GJ0*=10 F >HZ4O6BB@! JA=H  ] * H484 #T
MI:* $90PPP!![$4BHJ#"J%'H!BG44 ,\F+:5\M-IZC:*!%&,8C48Z8'2GT4
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MII[G2+K3&CDV".Y'+# .1P..:F5*45=C4TW9&W116;K\T4&B7+SRSQ1[0I:
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M\Q0P!4(!2EB915W!V^7^86.IHIL9)C4GJ13JZA!1110 4444 %%%% !1110
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M%/6_6!X@_P"0MX>_Z_C_ .BGK?H **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=$8_+^5<M6%2%3GI1OI8I6MJ=(K!E##D$9%0O=P1W4=LSXED&57'6L4>%V
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M97;*US:6\S*,*9(@V!^(JS10!S&L:?96FL^'WMK.WA8WI!:*)5)'E/Z"NGK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH AN[=;JTD@>1XU=<%HVPP^AK E\,6D<+O_ &MJ*[1G
M)N!@?I5K5M6M/MT6BFW-Y/<C]Y"I^Y'W9O0=*I:MH>E:=:>?#H"78!^=$8Y
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M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M65M=D&X@20@8!8=*GHI <OJ^GVEIK/A][>!(V-Z02OIY3UU%8'B#_D+>'O\
MK^/_ **>M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-GX?@O(;Z4RLT;W.]LB;<P)^G)[>E=]0,****0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 8'B#_D+>'O^OX_^BGK?K \0?\A;P]_U_'_T4];]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110!@>(/^0MX>_P"OX_\ HIZWZP/$'_(6\/?]?Q_]%/6_0 4444 %%%%
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M*S<.-@&#Z#-5K"QN'U.SG&EKIRVZ$2;67$N01CY3V//-='11< HHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !61K6F7=Y)9W5A<)#=6KEE\P95P>
M&![]*UZ* ,6PTJ[_ +7DU74W@:X\ORHEA!VHO7OSGDT_4=+N=5T=K:>:..X#
MB2.2,9"E6RO7Z#-:]%%P.>CTK5+W4+.XU:6U,=GED2 'YWP1DY'OVK=EMX)R
M#+#')CIO4'%244 <WK=M!#K'A]HH(XR;X@E$ _Y9/725SWB21(=2\/R2NJ(M
M\<LQP!^Z?O6M_:FG_P#/_:_]_E_QH MT54_M33_^?^U_[_+_ (T?VII__/\
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M%']B:3_T"[+_ ,!T_P *OT4 4/[$TG_H%V7_ (#I_A1_8FD_] NR_P# =/\
M"K]% %#^Q-)_Z!=E_P" Z?X4?V)I/_0+LO\ P'3_  J_10!0_L32?^@79?\
M@.G^%']B:3_T"[+_ ,!T_P *OT4 4/[$TG_H%V7_ (#I_A5;4=%TI=+NV73+
M,,(7((@7(^4^U;%17$(N+66 D@2(4)';(Q0!CZ)HVER:#ISOIMFS-;1DL8%)
M)VCVJ]_8FD_] NR_\!T_PJQ96PLK"WM58LL,2QACU.!C-3T 4/[$TG_H%V7_
M (#I_A1_8FD_] NR_P# =/\ "K]% %#^Q-)_Z!=E_P" Z?X4?V)I/_0+LO\
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M Z?X59M+<6EE!;*Q80QK&&/? Q4U %#^Q-)_Z!=E_P" Z?X4?V)I/_0+LO\
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M/"$#6_A73U8$,8@Q!&",BA@C<HHHI#"BBB@ KG/%&OW>E6\L=C:/),(?-,Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>genzerafbudl000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Y!",# 2(  A$! Q$!_\0
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M6G_?1_PH_P"%A>$O^@]:?]]'_"@#IJ*YG_A87A+_ *#UI_WT?\*/^%A>$O\
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M6G_?1_PH_P"%A>$O^@]:?]]'_"@#IJ*YG_A87A+_ *#UI_WT?\*/^%A>$O\
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M6G_?1_PH_P"%A>$O^@]:?]]'_"@#IJ*YG_A87A+_ *#UI_WT?\*/^%A>$O\
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M^M1_PHGPUZS_ /?UJ]4HH \K_P"%$^&O6?\ [^M1_P *)\->L_\ W]:O5**
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M2J:7_P!=E_\ 0EI#/HJS_P"/.+_=J>H+/_CSB_W:GH **** "OGJS_Y+</\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449HH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .#^+_P#R3V\_WUK&^ G_ ")#_P#70?RK9^+_ /R3V\_WUK&^ G_(D/\
M]=!_*@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[
MXM?\E4TO_KLO_H2U](U\W?%K_DJFE_\ 79?_ $): /HJS_X\XO\ =J>H+/\
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MP_(U['6;-H5A/J'VZ2,F<#&<T)>]?U+C*R:[GC5Y?OXOLFTV3</L1PP]<?\
MZJJWNJZA8VMGIMI&YLBOS;1[U[1;^%]*M7F>*W"M-]\^M-G\*:5<6?V5H2$[
M%3AA^-#_ .']10:6G;;R5CQN+5O$NDP2-IUNYM67YC@Y6K]W8Z<?#ZZB-4>2
M\D;+QEAP<UZCIW@_2],1TA\]U<8(EDW"JJ_#[05G:7RILL<E3)\OY52:O]VO
MZ&;3?^7ZG*:3JL5O:H+ZX?R&C(X/2N1UZZCTW4([K29IF1FSO[5[2_A;2G@,
M+090C'6LV'X>:# K*(YV5NSR9 J&FVGV&DU!Q[GFOAG2G\365[>WNHW&8P2H
M5NG-=_\ #JYFET5XY9FE$;$ L>>IK>TWPSIFE6\D%K$523[P)JUIVDVFEQ-'
M:H55CD\UJY1U4=F5*TE?K?\  \SU^UU>[\;!-)O1;O@YRV,\U=N?!VJ-9W%W
MKU]]I\M,J V<5WO]C67V_P"V^6?.]<U<G@2Y@>&091Q@BLDK4U%;HFUYMRV;
M1Y+X<TCQ5=0E[#55CM@^ F\\#-=1K4%@8+6#6;G%VF")2>,@UU=CIMMIT9CM
MDVJ3FHM4T6QU>$Q7<08'^(<$?C3;=E;H-)-N_F<%)J5WI]ZCO?0:A;%L)$'W
M$5VM]<N_AUYHT*DQYQZ51TWP)HNEW G@6=V!X$LFX5T,UNDMLT. %(QBB6L+
M=1*_/?H>4EIG\*J8YFBEDDP6!YZU6?P^;*\L(TU&X)N5'F9([FNWL/#;174E
MM<1%K0-N0BMR31+&26&1HR6B&$YZ4WNY=VG\K;#=[M>3^_N>17MQ>>%M7NK.
MPNII(WB#'<>A)I+BVM+/P^=9MM8D?5"?]7O'K7K4OAW39KMKF2#=(R[23Z5E
MQ?#_ $&*]-TL4I8G.QGROY4T^_W_ *#E;F36W;N^YYKX?TVZ\6"6YU.^N$*H
M2%4]Z=J6GQW6BO:W-S*T4!(5B:]?MM"L+1G,$.S>,$"H)O#&F3VLMN\1\N7[
MV#S4=K;+\[DV>NO5_=8\ETWPY:7OB&UMH;U_)\L9*D9^[5DV-^EW?:39:DZP
M1Y^^W)XKTW3/".E:3.)K6-]XX!9LTMSX4TNZEED=)%>7[S(^#53::MY?C<44
MT[^9YOX(OX=,UA+"X65YGXWXX-;0"GQU=6YD*0/$N[';DUTECX*TK1R\]FDT
MDX'RF5]]1Z9X;,ES<7=^K"67Y>#C@'BK4DW=]$4M$_/^KF[IEM!:VHCMY?,3
MUS7->.=.LY+-;B6%6D##!(Z5U-E8Q6$ AAW;1_>.31>V%OJ$7EW"[ESFL:B<
MMBHNSU,WP[-'#H4+.X50.I-<1XI,EWXH5]/O$LYPH_?,VT'CUKT.72+66R%H
M0ZQ 8^5L&J&I>$-*U6!(KA)1LZ,C[6_.KF[SYB*=X1Y3E_ TK)KMU#<R"ZNA
M]ZX4Y!X]:]&K,TC0+#1(?+LXS_O.<L?QK3JIR3M845:X4445!04444 %%%%
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M!I'A?4GU"._UNXADN(S\OD@@?K79T4XOE=T3)*2LP' Q1112&%%%% !1110
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MF=7TT2>6;^V#]-OFKG^=9GC"\DL]$E,;%688R/>N$L/!MA/X8;5)7=KPKO\
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MZG[OWE32O%)\4>&+RX,"Q;488!)KSOX)?\C'JG_70_UKH?AY_P B7?\ T?\
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M7\T<=/K&KWGV"!+_ ,OSBP9N?7ZUM64>I:+K/]GOJ1N8[A3SN)*]NI-0^(/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X/XO_P#)
M/;S_ 'UK&^ G_(D/_P!=!_*MGXO_ /)/;S_?6L;X"?\ (D/_ -=!_*@#U6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF[XM?\E4TO_KL
MO_H2U](U\W?%K_DJFE_]=E_]"6@#Z*L_^/.+_=J>H+/_ (\XO]VIZ "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!VIZ@L_P#CSB_W:GH **** "BBB@ HHHH IZK_ ,@NX_W#7EGPI_Y#=_\
M[Y_K7J>J_P#(+N/]PUY9\*?^0W?_ .^?ZUR5OXT#Z++?^19BOD>IZK_R"KK_
M *YFO$/A%_R/VL?7_P!FKV_5?^05=?\ 7,UXA\(O^1^UCZ_^S5];E7_(OQ7H
MOS/EY_'$][HHHKYTV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@_B__ ,D]O/\ ?6L;X"?\
MB0__ %T'\JV?B_\ \D]O/]]:QO@)_P B0_\ UT'\J /5:*** "BBB@ HHHH
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MR/4]5_Y!5U_US->(?"+_ )'[6/K_ .S5[?JO_(*NO^N9KQ#X1?\ (_:Q]?\
MV:OK<J_Y%^*]%^9\O/XXGO=%%%?.FP4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\7_ /DG
MMY_OK6-\!/\ D2'_ .N@_E6S\7_^2>WG^^M8WP$_Y$A_^N@_E0!ZK1110 44
M44 %%%% !1110 &O,O&6D^(8_$,.I:-"TX4$%",@\UTGC74KC3K".2W;:Q;%
M1:AK]SIO@RWU)0'F8J#GWS4I_;71V^\I:R5/NCF4UKQZC;AX?4'U$*_XUZ'H
ML]]<Z<DFH0^5<'[RXQBFZ#?OJ>D0W4J@.Z@D5IUH]/=9FM=4%%%%24%%%% !
M1110 5\W?%K_ )*II?\ UV7_ -"6OI&OF[XM?\E4TO\ Z[+_ .A+0!]%6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!1110 4444 %?-WQ:_Y*II?_ %V7_P!"6OI&OF[XM?\ )5-+_P"NR_\ H2T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <'\7_P#DGMY_OK6-\!/^
M1(?_ *Z#^5;/Q?\ ^2>WG^^M8WP$_P"1(?\ ZZ#^5 'JM%%% !1110 4444
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MZFUB;XCZ8VLQ0QS^<N!#G'WAZU]3U\W?%K_DJFE_]=E_]"6I*/HJS_X\XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#@_B_P#\D]O/]]:QO@)_R)#_ /70?RK9^+__ "3V\_WUK&^ G_(D/_UT'\J
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M110 4444 %8?B[_D6KO_ '?Z5N5A^+O^1:N_]W^E14^!G3@_]XAZHXOX/?\
M(.N_^NG]*]0KR_X/?\@Z[_ZZ?TKU"L<)_!1Z'$'_ ",:G]=".X0R6TJ+U9"!
M^5?.4ESJ_P -?&-SJ4UBLJ2[@K'.WGCK7TC7E7QS5?\ A$T.T;O-3G'/4U]-
MD%=+$?5IQO&IHSP:JTOV.Y\)ZZ_B+0H=0>)8VD .U>E;E<7\+O\ D2+/_='\
MJ[2O,QU.-/$SA#9-EQ=TF%%%%<I04444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *VH6,6I6$UG-GRY5VM@X-?.?Q(\':=X3UC3QIYD_?2Y;>V>XKZ5KPOXW_\
M(:TC_KI_45]%PU7J1QBI)^Z[W7R,:R7+<]A\._\ (OV7_7,5IUF>'?\ D7[+
M_KF*TZ\*O_%EZLU6P4445D,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M7CU_XLO5FBV"BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3V'P[_R+]E_US%:=9GAW_D7[+_KF*TZ\>O\ Q9>K-%L%%%%9#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X/XO_P#)/;S_ 'UK
M&^ G_(D/_P!=!_*MGXO_ /)/;S_?6L;X"?\ (D/_ -=!_*@#U6BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .#^+_P#R3V\_WUK&^ G_ ")#_P#70?RK9^+_ /R3V\_WUK&^ G_(
MD/\ ]=!_*@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '!_%_\ Y)[>?[ZUC? 3_D2'_P"N@_E6S\7_ /DGMY_OK6-\!/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4M6_Y!5S_N5X?\&/^1PU?_KH?_0C7N&K?\@JY_W*\/\
M@Q_R.&K_ /70_P#H1KZ/*_\ D6XKT1C/XXGOM%%%?.&P4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 <'\7_\ DGMY_OK6-\!/^1(?_KH/Y5L_%_\ Y)[>?[ZUC? 3
M_D2'_P"N@_E0!ZK1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7S=\6O^2J:7_UV7_T):^D:^;OBU_R532_^NR_^A+0!]%6?_'G%_NU/4%G
M_P ><7^[4] !1110 4444 %%%% !1110!6U#_D'7'^X:\G^&W_(XZG]?_9J]
M8U#_ )!UQ_N&O)_AM_R..I_7_P!FKDK_ ,6!]%E7_(OQ7HOS/8:***ZSYT**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** *6K?\@JY_W*\/^#'_ ".&
MK_\ 70_^A&O<-6_Y!-S_ +E?/7PU\1:=X>\4:I-J$NQ7D(4_\"-?2Y/3E4R_
M$Q@KMV,:CM.)])45Q'_"U?#'_/V/S%'_  M7PQ_S]C\Q7D?V;C/^?;^XTYX]
MSMZ*XC_A:OAC_G['YBC_ (6KX8_Y^Q^8H_LW&?\ /M_<'/'N=O17$?\ "U?#
M'_/V/S%'_"U?#'_/V/S%']FXS_GV_N#GCW.WHKB/^%J^&/\ G['YBC_A:OAC
M_G['YBC^S<9_S[?W!SQ[G;T5Q'_"U?#'_/V/S%'_  M7PQ_S]C\Q1_9N,_Y]
MO[@YX]SMZ*XC_A:OAC_G['YBC_A:OAC_ )^Q^8H_LW&?\^W]P<\>YV]%<1_P
MM7PQ_P _8_,4?\+5\,?\_8_,4?V;C/\ GV_N#GCW.WHKB/\ A:OAC_G['YBC
M_A:OAC_G['YBC^S<9_S[?W!SQ[G;T5Q'_"U?#'_/V/S%'_"U?#'_ #]C\Q1_
M9N,_Y]O[@YX]SMZ*XC_A:OAC_G['YBC_ (6KX8_Y^Q^8H_LW&?\ /M_<'/'N
M=O17$?\ "U?#'_/V/S%'_"U?#'_/V/S%']FXS_GV_N#GCW.WHKB/^%J^&/\
MG['YBC_A:OAC_G['YBC^S<9_S[?W!SQ[G;T5Q'_"U?#'_/V/S%'_  M7PQ_S
M]C\Q1_9N,_Y]O[@YX]SMZ*XC_A:OAC_G['YBC_A:OAC_ )^Q^8H_LW&?\^W]
MP<\>YV]%<1_PM7PQ_P _8_,4?\+5\,?\_8_,4?V;C/\ GV_N#GCW.WHKB/\
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M&^ G_(D/_P!=!_*MGXO_ /)/;S_?6L;X"?\ (D/_ -=!_*@#U6BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH X/XO_ /)/;S_?6L;X"?\ (D/_
M -=!_*MGXO\ _)/;S_?6L;X"?\B0_P#UT'\J /5:*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'RO^-']E_&#_GI'_P!\K_C0![S17@W]E_&#_GI'_P!\K_C1_9?Q@_YZ1_\
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MF_P]E33+VXTF9=UUG+R#H<"O2*UFEHX[,S3U:[!1114%!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>genzerafbudl000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ', T # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO98V\P!NU1)6T)D2<TZF@G..U.I %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** &GH17AWC*^:V\47#WI/EQ/F'G'->Y' !->=>.[+PY/MD
MU-(S(#D!C@DT >:6UE:ZA;ZKJEZI9V3= <XYXKU;X:RSR:#'YF=BH-N:XZWU
M+PO=Q6^GB%(H4^7YFX(KU?0K:RM]-A2RV^2%^3:>U &F,'G&#0?>CG.#2D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTF>YH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO8!TH **** &$'<3BCMR*=2&A(%N9.MV/VRQ< [2 >E<OX;OA873V<LI.!@
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M6_MO35NON9/05N$C'K7RWIGC#4O"FJ/"'9X8V*[6;CK7>6?QF\V2)9HHT4D
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M\;P_\)!;-97#^1Y1W8XYXJU\-];N-3U5O-ED9=QQDF@#UQ2W\0IU-7..:=0
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M(4 T"- VX* ?I0 V./RXEC7HHP*>.#CM2GFCO0 4444 %%%% !1110 4444
M%%%% !1110!Y5\7)"ITMFQM2;)S6+XDUS3;SPE;VRE?,52" !Q7I'B?PC:>*
M(TBNF<",Y!4XKE?^%-:1M :>Y(';S#_C0!G^ ;OP[I&CQ2R%6F9?F+*"17J>
MG7\&H6ZRVYRA&17GR_!S24&Y;BZ'L)3_ (UVVB:)#HUFD$+N0HP-S9H V"><
M'O1C'>D7WI<?E0 UNFX=17GVO?$6'3[PVEH&>4'#?+G!KMM2=HK&1XS\P'%?
M/VDW^JG7=2^Q0132>>?]:F['YT >P>%_&4&NP2%U99$.#E<5AZG\3!;WDD5F
MA=(V*N=N<&LK0O$4<MC=QRQ+'=JV"$3:,TWX>VEM<VVJO<('S.QRPR>] '?^
M&?$UMXBM#+"<LIVL",<UNS?ZB0'KM/\ *O(_AS(+;7+V&,G9YSG'XUT&I_$S
M2[.:6W>.Y+@%>(SB@# \*X/Q(<DD?*_ ^M>OCFO$O &IQZIX_-S&&"E&QD8K
MVX<4 +2=Z6B@ H--[TM)@(><BFXRF#UIW>CWI[@CCO%FD2WL8DC'*'-9WA*[
M:&=X)V(8< $UWLB+,I&.*X+7K:.PUFVFCRN9/FQP*S>C.V%52AR,[Y>F1U-/
M3'/KWJI93K<6R2 YXS5M5&"P[U:.-QL[#J.U Z49IDBXHHHI6&'44T<<=Z4Y
M[48YI@,.!]:1DW1D-WXI_!:CMS2U X?7OAWIVJ;I4W+*?[O%<:?A-=PR.\1(
MP#@[J]J^;'04TXQSTK15&E8#P?3!K?A/4)\Q;OW;#)R?6K_A7X@31:FT5\V
M?6O7[K3X9X77R8R64C)45XQXF^'.H6]X]W;*/)!W<'FM(RC):@>R0:E#/9?:
M@1Y>,Y%45\2:9.RJ) =QP,XKRRQ\3W]EH#:88920",E#G\ZY"2;4HHHI=LR^
M6^[D$4E33 ]MUWP'H^NSFXN"59CGY*R1\(="=1AY0>]<Q_PGUY::5I]PSH=T
MF)!U.*[[P[XZTS77>.%RK(,G?Q4NFT!E_P#"H-"Z;I/K0?@_H0P5>7([UWL-
MU!/N"2JV/1@:G4J!WK-II@>?-\(]%D4;I)C]33?^%0:"/XY0:]$!/7M0<=:
M/._^%.Z"3DR2TG_"GM!+#:\O'6O1<#'7K2*W8=NN: . 'PGT=5PL]P!_O?\
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MD P<>M  H[TZD&:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9E*1D_YZU[E%#'&H5$50/08J.6PMIVW/"A8=RHH \Z^&VBW,?VF_N$*M+*6
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MQ$3Z!Q0U[; _-/&OL7 KYST;4]8M]6BEN([DQ <C:U3>(=7U6ZU**2VBN5C
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M4U1S',,G^X?Y4 >1^%-@^([X'\+_ ,Z]@[5X]X27_BXLG/9_YU[#VH ****
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MGH: '@'K2T@X[]:6@ HHHH **** #WJ*4_N)./X3_*I#TJ.8_N9./X#_ "H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ7"WE6[E"4;TK.\!ZI:1Z1J5I#(1+)+F-0.HK;^&S1+9:LQP6\]LY_&@#IO
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 - ()!Z=C1CWIU%
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M[I_E0!Y+X49?^%C/Z[7_ )UZ_7CWA3CXDOD<;7_G7L- !1110 4444 %%%%
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MN9"8[F+!VMG%8FC>"VN? )CG@ N4A^7Y<'-:W@.75-+T"\@G0[K6,;,@\]*
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M[ MECG.>E>L\ XKRCPKHMW;>/7N9$(B^?G'O7JXXX- "T444 %%%% !1110
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M;KF(%5PW&*[I(HT(VHH^@IWMVHP!P* &^5&&WA%!]0*<#DTOL*!US0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#*<6\
MI']T_P JE-,EP+>3']T_RH \C\)-_P 7&DR#]U_YU[!7CWA9BOQ'?<PQM?C\
M:]=65<?>% #Z6F"1<_?%+YB9^\* '44TRH/XQ1YJ8^\* %SSBC-1^:I&0XH\
MZ,C[PS0!)FEJ(.G\+#WIWF)_>% #Z*9YB?WA09(^NX4 /S[4F<_A4?F@D_,!
MZ4>8!P7&: )*7M49E0=Q3A(A'WA0 ZBF[T'\0H\Q/[PH =36; SVH\U/[PII
M>/&-PH XWXA3N-'6&$$.TBXK+M]$UZ2QBL_M,8C;#D[>WYUV]]I]IJ!'VC#X
M((Y]*N)Y2*$5@% P* *6DZ7%IMBMNJ@]S]:9?Z#87I#SPDMG^$XK3WH!PPI"
MZ_WQ0!Q&O>%;A)$N='<12!AG=SQ4>F>'-4N]4^VZK,DJ#!50,$$5W.0&R)%Q
M2^8H;[X'O0!DB"_EU"X1Y5^QLN%3'(KEKKP_K>G7]T^FW$:0S#:J[<XKO1(F
M[E@?>GY3JK#WH X_1/"TT.GW7V]E>ZNX]LCCH:QSX>\0VD4NFVUW$MHPV ;>
M@_.O1V=3QD4?N\8W"@#D8O"6WPX]GE?M)CVE^V:Q[+PSK4T]K;W=S&]K;'&T
M#J/SKT9F3& P [TBF-1\I% $2VXBLEAC& JX%<[X7\/W.EZCJ$\[JRW$NY0!
MT%=07']\"@2(I^\!_6@"1>N/RIPJ'S$/1@#VJ02+CEQ0 [-':F^8O]\4>8G]
M\4  .>>E*33#(AX)&*3S5QG< !QS0!+24SS(^NX4@D /+#% $F:7(J,.H_C&
M*7S$_OB@!^12$TWS%_OBD+IC)8<4 /SFC-1^:A7.X4"5,<L#F@9)VHZ4P2(.
M PI?,7^\* '4O:F>8G]X4>8G #"@0[IUHZ<TTRH, L,TWSEW8) H DS24P2#
MDEQBEWI]X,*!CZ6FB1,??%'F)_?% AU-W>U(9$QRP-()%Z;Q0 \>]+VJ/S$/
M(8$4"6/LPH ?C!HI/,3^\*-Z?WA0 H%+30Z?WA2&5,_>% #STI,\4TRIC[PH
M!# &@!V<8!I:0G)Z4M !BBBB@ HHHH 0C(Q2]L444 %%%% !1BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  G%07 _T
M>11W0_RJ8]*BE7="X!Y*D T ?/J6NM2^-I4TZZ,-S\Q$F.V>E=-_9?CW_H,-
M_P!\FMC0/#UY;^-&OY581X89(KTA1A<=: /'_P"R_'O;5V_[Y-']E>/C_P Q
MAO\ ODU[%QCBD)Q0!X]_97CTG']L-_WR:/[+\>]/[7;_ +Y->P=_0^M(I(X/
M/O0!X?K7_"<:):"XEU=F7TVFC13XWUK3H[^#5719!TVUZ1XWT^?4](\J%2S<
M\"G^!=.FTSPM:VTP*R(/F4]: .%&E>/P-W]LMS_LFC^R_'W_ $&&_P"^37L.
M>!VI: /'?[+\??\ 08;_ +Y-+_9/CX\_VPW'^R:]AH^E 'CO]F>/>^L-[':>
M*P=6U'QKI%_;VDNK,[S]"!TKWUNF,]:\]\8Z'=:CK^G3V\3%(L[B!0!ST-AX
M\GA20:PV&&1\IJ4Z9X^ _P"0PW_?)KU6Q5HK"%&7!5<&K0QCGF@#Q_\ LOQ_
MU_MEO^^32_V7X^_Z##?]\FO7N:7/KS0!X]_97CX'_D,M_P!\FFRZ;X\BC:5M
M88JHSC::]C.,X/)JO>!Y;&554Y*D ?A0!X/HNJ^,]9N9+>#4W5U8@G'I6_\
MV3X\V_\ (7;K_=-;G@C0+K3-4FFFC90TCD9'J37HOL>E 'C_ /9?CU1N75V_
M[Y- TKQ]NS_;#<_[)KV%>E*.E 'CO]E>/0-O]KM]=IH;2?'; 9U=@!_LFO8N
MU,(XY- 'B.K#QSIEJT[ZLVU1DC::9H<OCC6M.CN[?5V57'3::]0\7Z?-J&CR
M0Q9+E2..]5_ 6FSZ7X<M[6>,HZ+SF@#BO[+\?XP=98_\!-)_97CT?\QAN?\
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M ]X219$!1L@\@T$X'7)]*XOX<:M+J>BR><Y9HF";C6KXJU6XTK2Y)[: R2=
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M\.*Q4^;(X^>1AR: .D#9/ IPSSD4BJ.2#UIW:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MQ110 4444 %%%!QWH 3^'F@8/(JI?RFWM)I\_P"K0L/?%>9Z5\5GO=;^P2QQ
MJ=V!CZT >K=SFC@CUKC/&GC(^&M/BG149W."&JKX"\=2>*YIHY(T3RUW?+0!
MWIZ#BC//\JC\R,,?W@SZ$T/*%0N<;!WH D!/.>!02,8]:Y6V\86=WK4FG6\H
M=T;:^>U=.9%0#)'MDT .)].U 8$?SIOF @XVDGI@TGFH@^8@>N: ),C'/2CH
MI.<U&7R1LVLI]ZP-7\5V.DZA%932@32C*K0!TF,\TBD,?I5>&99(8Y=PVL,Y
MS4C2QXP'7\#0!+GYL4#UJ,OA>2!2+*K' 8$?6@!P#%LGBG#U-<QXDUN^TO9]
MCB60E@#N/8UNV-P9K5)'P&*@D4 6^W%)QG(-1K*K'[PSZ TX<MN7GVH ?GCV
MI,C&0:HZMJ"Z;8RW)QA%)Y]J\YT;X@:KK>JXL[:)[0MC=GF@#U3D\]J7CUJN
MLBLB@L PY(S4@E7&210 \#OVHXYJ-9 7X8$'T-/)49YZ4 +GIS2\YZ5 LBY.
MU@3Z9J93Z]30 9!^M'6HVDQNZ#%'FQ_+EQGT!H EI#C</6H]X5OO<'U-+E5Z
MMUZ&@"3DCFD#*W0]*C#*,LKY^II!* ISM!^M $ASNR.:=D$]:B#KG"-N8]J&
M<;220"!ZT 2BDY_'TKD(O$%^_B'["\*"#;G<#S75I(#]YAN(Z"@"09/48H/O
MTJ/<%&';'XT.T?=\?C0!)NR/EYI<]Q4+R 0NZD$*,\&N%L?',EWXLGTG8N(P
M#G\Z .^)S_2@<'F@<*!VKE/$GBR'1K^UM(V#S32;-I[4 =92@^E5+:X9[=6E
MPKL.1FI?-7A0P]^: )O6CI4)DB7@R#/UI^1LZ\=C0 _:,YSTI,$\8X-1-(JE
M<N./>G%L+N!^E #B PQGI2CCKV[TPRJ%ZKGZTBNI!PP/KS0!(S #=FCG;QS7
M,7_BVPLM8BTXRCSI!D*:KZMXI-AK-M:#;MECW?RH Z\ DY- !)S5>&X22%&W
MCY@#UJ0'!W,<"@"08Q2$@=*9YJ[MNY<?6N=\4^(+C0K>.>.)&5I%4Y[ F@#I
MCQS0IR.F*I:7?1:A9K<Q-N1A^M7?]V@!U%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %':BB@#/U<!M&O#G_EBW\J^8(%-MK<-VG7SN
M?IFOI_6,_P!DW:CG,38Q]*^>[+0;J[2\8Q.#&K,.#0!>\<:@WB&6*WB;<(V#
M'!JY\.[A=&N-5D''E0[JQ_ FB7EW)J$UW&_RPDKN!ZUM>%M(N[DZQ&8F7S(,
M(2,9-  -<UOQ+/-<V[JD2#<F'QFMKP_XIO\ 4;'4M*GP+B&/ (/4\=ZY'2M+
MLM&66UU:2]CD"X'DAL9KM/!^@64BW-S:&;E<J9 03]: ."\,V>JMXUF5/OK*
M-_S5W7B23Q"]S';1E$C!PQ\S!K TN9M"\>WLMW%)B27Y-JDBJ^N74U_XGDDU
M W,=FTG[LQ YQ0!H^%/%6I6GB==+NGWJTFW);-2^-/%^I/KD6G0CRXB2I8'%
M<_I&G"T\:V<\*SM;M)D,ZG.*ZOQA%97%U&=0BD2,9VO"G.* #PC?:[%K4$+N
MDEO(>2TF37+>.;/4V\7P1L?GD)*?-VHT>UN(O$UJVAM<R+NY\_./UK=\=07%
MMKVEWMS&Q5(_WFP$\T ;UVVOZ?X52* (9&08+/7&7NL:YX?GBO)I@YXRGF9'
M-:WC#5[^\TVV-FDGV41@.0I#5R>KZ7;76EI)8O>2S97>) V >] ';>+?&5_'
M:6JQ#;YL2L6'8D5G:-J6OP7\+0R+)&^"=\GK5[4XK6;P_;Q744GE+&H9E3Y@
M<5RDMC#]MA_L62\:8$<2;@,4 =W\1]:N-/BM"JJ6<Q[OQQ57QAXOU'3=*MH+
M>, NJ$L/<"J7CZUO)=/L?,C9I 8LX!/I6MXBMU_L*W%S"6@V)EE3+#@4 <]I
M>I:_%<0W$$BR!V 8/)V->PQ:HD%G'+=NJ,0,@'BO ;RPM!-"VBRWS3>8N5DW
M =:]//A*YU[088[Z:6*8<GRW(XH =X]NVU30)%T^0,5!+X;M7 ?#BQOTL[B\
MC4>6J$CGTKKW\%'0=)NY8YIY=\3+AW+=JJ_#FVE@\-7<<D; F-\ B@#G(?$/
MB35M;GLK!595')W$5J:GXHUC3K6VT7Y?M9;9(2W3\:F^&]C-!XMU%YH2%9!M
M++[FJOQ \-W"^(_[1F#BW>3),><@4 1IK>O>&;^S^T,LD,KX8E]V!6[XM\>3
M^5:0:?MW7)VY/%<Y#9Z-J-Y;16\E](0__+4-Q^=2>,_"$\%Q87 #_94?)*DY
M YH &U?7?#DUM=S.KQR'+@R9P*]BT+4DU728+P?\M%W=*\66RT>_DA@MY+Z2
M1CAA*&P*]FT"Q%CH]M GW53'- 'G?Q'\4W]AJ-M9VPVI+D%AQ6;X>U#7H-3M
MW5TEA<Y;?)G%;_Q CADN(OMT+>0,Y>-,L!7GBV2KJUN=!DNW)/(FW "@#O/'
M/B&]L+ZP6(A1(F6P:T_%VLW%CX&6]A8^=Y8/6N6\=:;J!M=.NVC+>5%^\QSS
M3?$VOIJ_@@:=:PRF41A3F,]: -.?Q+?#X=7%^#B=2N#GZUSN@W?BWQ)"T\*C
MR4X)#D&M&6UF_P"%6W,1B;?E>-IST-=;\+[9HO#LBO'M8L.",>M &%X+\37L
M.JR:9J1PPW').3Q3XO$-]J_C(V]N?]&5&R0>XK*^(FEWFD:ZNJZ?&2-FT@#N
M:VOAEX?N+>QFU"^4B=RQ&?0YH I6VO73^/&L?+3;Y!Y[YQ5C0O$=W8^,I-/O
MVQ%Y9<$FLRRLYC\33)Y;[=AYP<5:^)VBW<+KK%@F9"%C.V@"Q?>([[4_'1L;
M(YB5 QP:?XKN/$%QJ)MK?RTMD0-O$F#FH_AMHMV89-6NX_WS(R#/7I7.^(7N
MI?%DL6K&XCM\#:8,]?PH V?!>OZA_;5YI=T^](X=P);//-9FBG_BZ5Z0.JK_
M #-'A6Q2S\6WDMN)VMWA 5I <D\U-H]G<+\3;R3RF$95>2I]30![5*_DP,Y^
MZHS7BGVAM9^*%PI^:.&4,N>U>TW$?F6;HO5EQ7BVE1-I?Q.ODE&-[@ F@#3\
M?>(]2T[7[6TL #NEVXSCUK"US5O$VASVU[(!^^;(7><5L>.+.9O&6FND99/M
M')QGL:E^)-K<31Z:(8BP#'.!]: ,;4M2\3)80ZXZA8B/,P'.*Z^3QPUKX+AO
MY,?:&BW*.Q-4/$5O,WPYMHUC.\0= *RKKP[?ZKX#LEBCP\<&-IX[F@!L(\5Z
MM:-J\(X(WHN\@&MGP[XVN;S2[V"["K=6QV8'K4&C>+X-)\/KIEQ#*+F)-F!&
M2":SO#WAZ]"ZGJDL>V.:3>@'<?2@"KH>L>(_$-Y?6ML 8A+M+;R"*N^%/$>K
MV_B?^QKW!#L1DMD\5:^%MM)'J6I&6-DS/D9&*IVMK/\ \+2@?RF$89LMM]Q0
M!SGB.SU)O'T$2D^8^2GS=LBMOQ3%J%KJ=CM :X\D  GZ5)XO1M-\=V6H31R&
M!$()12>XK2UF0:EXBT^>&.0Q>2,DJ?:@#%U2\\1^&_L]]/\ ZL[1@N<<UT'B
M[QK>6OAZ%[=?GD"9(]Q3OBC!)+H-NL4;,1Y?09]*COXL>%(4G@W1[5R=F6'%
M '.:?J.O>;%-;3"3<P)#R>O6O1O$$4FI^$BUP )$7=\OJ!7D=[86&U'TB6^-
MSO'RN&"]:]-@ENK;P&ZZB-LI4@?EQ0 SX4:BUSHQ@=B2LC=37I/3I7EGPEL9
M(]/><@A3(_\ .O40Q(XH =1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2'I2T4 0M&=NS (/7-1I8VZ HL$8'^X.:M 8HH JI96\7*
M01J6X(5 *5;2&-B1$BY_NJ!5F@C- %"32K2=]SV\1([E!4T5K% FV.-4]E7%
M6>]!H H2:9:R2"5X(BX.2=@HETNSFP6MXCCI\@J]@4N!0!373[90I6WB!7H=
M@XI9M/M[E<2PQMCU4&K6!@^]*!B@"G#IMI P,4$:D=P@%.N+*WN1B:)']-R@
MU:H[4 4O[.M_*V&"(CL"@I$TRTC4HMM#@\GY!5['-% %0V-NT9C>",J>VT5'
M#I-E;MOCMX\YZ[!5\4M %26SBE8;XHV4?WE!H-K$PV&)&7'1E!JT1D4F!NS0
M!0BTFTB;>+:'=_N"K:KLY  %2T$9H C9$D4AE!4]B*BCM(81MCB15] H%6,#
M.:7'% %=+>)&)2*-6/4JH%)+:QS+MDC1Q_M+FK.*#TH H1:99Q'Y;>(,.X05
M*]JLJ>7)&C+VW &K0 Q1@4 4$TJTBYCMX@WKL%6@NT*I[=,5+0 ,T 5YK:*X
M0I+$CY_O*#5>'2+*W;*6\88]P@K0HH KS6L,T>R2-&7T*@U#'IEF@^6VBY]4
M%7<#(-+0!5^QPE"IACV_W=HQ^52)"L"[8D55/4*,5,1Q0!B@"O-:Q3D>9$C_
M .\H-*(408"A5]%&*GH% %86D"R>8L,>[^]M&:26WC;Y7C5U]&&:M4=J *Z6
MZPC$**J^@&!4-QIEK<2!W@C9QW*BKPI" 10!52T@5N((E([A *46D*RF588P
MYZMM&:LA1C%+B@!H!'!K@/%?A6XO-<M=1L@!(DN^3G&17H..<TUD4]10!0MK
M59HHY;F*-G7D':#5F2VBEY:)&]-R@XJ8* .*=B@"NUK')&(Y(T*CH-HQ2)!'
M"A41KL[*!5FC H H'2;*202-;19Z_<%3_9X@AC2-0I[8XJQ2T 5(K.&(G9$B
M9ZE5 H6R@2;S!%'N_O;1FK.!2@8% %*:PMISEX8W_P!Y0:>EE;J.(8^/]D<5
M9P-V:7O0!6>UCECVR1(X[!E!H^R0NFQXD(]-HQ5FEH RQI%G&_F?9HMV>R"L
M'QIIM_J=A%:6:HH\Q2W;C(S78X%-9%88(H R-!T==&TJ.VC !ZM6LH(7Y?UI
MV!C%+WH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>genzerafbudl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,S!C8# 2(  A$! Q$!_\0
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M= 'T1_:EC_S\Q_\ ?5']J6/_ #\Q_P#?5?.^YO[S?G1N;^\WYT ?1']J6/\
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MU1_:EC_S\Q_]]5\[[F_O-^=&YO[S?G0!]$?VI8_\_,?_ 'U1_:EC_P _,?\
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MYOSH ^B/[4L?^?F/_OJC^U+'_GYC_P"^J^=]S?WF_.C<W]YOSH ^B/[4L?\
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MYOSH ^B/[4L?^?F/_OJC^U+'_GYC_P"^J^=]S?WF_.C<W]YOSH ^B/[4L?\
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M?,?\UKCJ['3/^28:Q_U\Q_S6N.H **** "BBB@ HHJUI^GW.J7BVEI'OF;)
MSB@"K16QJ7A;6-*A66ZM&$9ZLGS ?7'2JD^DWD&E6^I21JMK.Q6-MP))&>W;
MI0!2HI,C.,C)[4>O!.* %HI<9 /3/2D/RGD&@ HH/&<]J5$>5U2-&=V. JC)
M)^E "45LR>%-9BTT7[V3B$C./XA]5ZUC$X8J001V- !1110 4444 %:.@?\
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M?QK;O4TT?#:^DTWS!#)*C&-SRAW#BLW2=9TFYT>_T;5KAH(9)S+',H)SSD8
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M9RB6!U0!@".B@=Z .?HHHH **** "BBB@ HHHH **** "NO^&W_(VK_UP?\
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M_D9+_P#Z[-_,U9\$?\CEIG_71O\ T%JK>*/^1DO_ /KLW\S0!D4444 %%%%
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M,I'8^M=1J$>F"TO#'XEN[G<I,<!+_,?1LC&*YFU2![N%+ES' SJ)&'55SR:
M/4/"UK>:;;7][/?IJ320[Q;I)N([UYA=G=>3N4V,TA)7TR>E=[HUSX6\-2S7
MMEK$UU(8R!"R$ _I7!7=Q]JO)I]NT2.6Q]30!#1110 4444 %:.@?\C#I_\
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M<YIN 3D@?E2T4 "#9TI,#<3W-+10 I)SG)S]:0\G)Z_2BB@ _I1110 4444
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MTI:* "D  8L.II:* %)).32'D8).*** #Z<4H.#D?RI** %!(.>](>1BBB@
MHHHH **** "BBB@ K1T#_D8=/_Z^$_G6=6CH'_(PZ?\ ]?"?SH Z'XE?\C''
M_P!<!_,UQM=E\2O^1CC_ .N _F:XV@ HHHH **** "BBB@ HHHH *3 SG'-+
M10 # Z48 /%%% !V^M%%% "@D'.31FDHH 1AN&&YYI1QTHHH 0@,<D<U>TO5
M;O1[AI[*01R,AC)*@\'ZU2HH 4LS,68EF)R23DDTE%% !1110 4444 %%%%
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M#I;?]^__ *]>344?4(]P^LR['K/]C^#_ /H=+;_OW_\ 7H_L?P?_ -#I;?\
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M_OW_ /7KR:BCZA'N'UF78]9_L?P?_P!#I;?]^_\ Z]']C^#_ /H=+;_OW_\
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MR#_H,-_WX'^-=[10!P7_  JR#_H,-_WX'^-'_"K(/^@PW_?@?XUWM% '!?\
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MG3_A/?%/_09N/R7_  H_X3WQ3_T&;C\E_P */J%3N'UN/8^B\^QHS[5\Z?\
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M4HX8$;UQ@CCI67XC_P"0#X9R?^7)_P#T:]5K76H+?PWJFE"%]UW*C(PQA0K
M\_E4.J:I'?:=I-LD3H;*!HF+8^8EV;(_.G&$E--_UH)R5C+HHHKL,@HHHH *
M*** "BBB@ HHHI %%%%, HHHH **** "BBB@ HHHH *<GWJ;3E^]0!/11109
ML****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?O"@">BBB@S84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%3?8[G_GWE_[Y-'V.Y_Y]Y?^^36W-'N19D%%3_8[G_GWE_[Y-'V.Y_Y]Y?\
MODT<T>X69!1^%3_8[G_GWE_[Y-'V.Y_Y]Y?^^31S1[A9D%%3_8[G_GWE_P"^
M31]CN?\ GWE_[Y-'/'N%F045/]CN?^?>7_ODT?8[G_GWE_[Y-'-'N%F045/]
MCN?^?>7_ +Y-'V.Y_P"?>7_ODT<T>X69!14_V.Y_Y]Y?^^31]CN?^?>7_ODT
M<T>X<K(..N!S14_V.Y_Y]Y?^^31]CN?^?>7_ +Y-'-'N%F045/\ 8[G_ )]Y
M?^^31]CN?^?>7_ODT<\>X69!14_V.Y_Y]Y?^^31]CN?^?>7_ +Y-'-'N.S(?
M7W&*2I_L=S_S[R_]\FC['<_\^\O_ 'R:.:/<5F045/\ 8[G_ )]Y?^^31]CN
M?^?>7_ODT<T>X[,@HJ?['<_\^\O_ 'R:/L=S_P ^\O\ WR:.:/<+,@HJ?['<
M_P#/O+_WR:/L=S_S[R_]\FCGCW"S(**G^QW/_/O+_P!\FC['<_\ /O+_ -\F
MCGCW"S(**G^QW/\ S[R_]\FC['<_\^\O_?)HYX]PLR"BI_L=S_S[R_\ ?)H^
MQW/_ #[R_P#?)HYH]PLR"MOPC$DWB_28I%#(]T@((ZC-9?V.Y_Y]Y?\ ODUN
M>#;6X3QEH[-#( MTA)*GCFLZLER/4J"?,CZ%_L73#S]BA_[YI?[$TS_GRA_[
MYJ\.E+7A\\NYZ*BNQ0_L33/^?*'_ +YH_L33/^?*'_OFK]%'/+N'+'L4/[$T
MS_GRA_[YH_L33/\ GRA_[YJ_11SR[ARQ[%#^Q-,_Y\H?^^:/[$TS_GRA_P"^
M:OT4<\NX<L>QG_V)IG_/E#_WS1_8FF?\^4/_ 'S6A11SR[ARQ[%#^Q-,_P"?
M*'_OFC^Q-,_Y\H?^^:OT4<\NX<L>Q0_L33/^?*'_ +YH_L33/^?*'_OFK]%'
M/+N'+'L4/[$TS_GRA_[YI/[$TS_GRA_[YK0HHYY=PY8]C/\ [$TS_GRA_P"^
M:7^Q-,_Y\H?^^:OT4<\NX<L>Q0_L33/^?*'_ +YH_L33/^?*'_OFK]%'/+N'
M+'L4/[$TS_GRA_[YI/[$TS_GRA_[YK0HHYY=PY8]C/\ [$TS_GRA_P"^:7^Q
M-,_Y\H?^^:OT4<\NX<L>Q0_L33/^?*'_ +YH_L33/^?*'_OFK]%'/+N'+'L4
M/[$TS_GRA_[YH_L33/\ GRA_[YJ_11SR[ARQ[&?_ &)IG_/E#_WS1_8FF?\
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MXG9&91117JG&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !75_#;_ )*#I/\ OM_Z U<I75_#;_DH.D_[[?\
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M /79J^K9?]6WT-?*7B'_ )&&_P#^NS5WX#XF<N)V1F4445ZIQA1110 4444
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MZ<U@X)^U+(VQ>V#QG.?:I=>%[7&H2.4HK;U;PQ>:1?6-K+-;2_;5#02Q.2K
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MC?\ 0/OO_'/\:/\ A<6C?] ^^_\ '/\ &O%Z*/J5,/K-0]H_X7%HW_0/OO\
MQS_&C_A<6C?] ^^_\=_QKQ>BCZE3#ZS4/:/^%Q:-_P! ^^_\<_QH_P"%Q:-_
MT#[[_P <_P :\7HH^I4P^LU#VC_A<6C?] ^^_P#'?\:/^%Q:-_T#[[_QS_&O
M%Z*/J5,/K-0]H_X7%HW_ $#[[_QS_&C_ (7%HW_0/OO_ !S_ !KQ>BCZE3#Z
MS4/:/^%Q:-_T#[[_ ,=_QH_X7%HW_0/OO_'/\:\7HH^I4P^LU#VC_A<6C?\
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M4$9\QXY,)N]A[?TJ9XF,78J-)L\BHKU^U\"^"H=9C\/W5[<7&JE2S>7)M7U
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MH/ /:G[*<FN9[!S);'H E#ZAX&9Y<L%BW-GG[YK-UB=4^*S3RRC8E_$S,3T
M*Y-<@7<[?F(*_=(ZBD=FD8LY))ZDTE0#G.YN?#6LR>.Q=S(T]N+I;@W9;*E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$HLCQ$,RC@%6[YK"\,'_ (O;K&?^>4O_ *$M>=7'C?Q)<2Q/)K%TS0L'0DC
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M** "BBB@ HHHH **** "BBB@ IR?>IM.3[PH GHHHH,V%%%% @HHHH ****
M"BBBF 4444@"BBB@ HHHI@%%%%( HHHH ****8!1112 **** "BBBF 4444@
M"BBB@ HHHI@%%%% !1112 **** "BBBF 4444 %%%%( HHHH ****8!1110
M4444@"BBBF 4444@"IK2TFOKN.VMHVDF<_*J]2:+2TGOKN.VMHFEF<X55[U[
MMX(\$0^'+3[1<A9+^4?,V.%]A6%>NJ4?,VI4G48O@;P7'X;LO.GPU]*!O..%
M]A794@I:\2<W.7,STXQ459!1114E!1110 4444 %%%% !1110 4444 %%%%
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M@HKU_P#X4U9_]!*?\A_A1_PIJS_Z"4_Y#_"CZY2[A]6GV/(**]?_ .%-6?\
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MO^APMO\ OAO\*/;Q#V<CB/PHKM_^$6\+?]#A;?\ ?#?X4?\ "+>%O^APMO\
MOAO\*/;Q#V<CB**[?_A%O"W_ $.%M_WPW^%'_"+>%O\ H<+;_OAO\*/;P#V<
MCB.?2CGTKM_^$6\+?]#A;?\ ?#?X4?\ "+>%O^APMO\ OAO\*/;Q#V<CB/PH
M_"NW_P"$6\+?]#A;?]\-_A1_PBWA;_H<+;_OAO\ "CV\0]G(XCGTH_"NW_X1
M;PM_T.%M_P!\-_A1_P (MX6_Z'"V_P"^&_PH]O$/9R.(Y]*/PKM_^$6\+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%=7\-O\ DH.D_P#71O\ T!JY2NK^&W_)0=)_WV_] :L:_P##94/B1<^+0_XN
M%>?]<HO_ $ 5P^VNX^+7_)0;S_KE%_Z *XBC#_PHA4^-B;?\YHVTM%;$";?\
MYHV_YS2T4 )M_P YHVTM% ";:-O^<TM% ";:-O\ G-+10 FW_.:-O^<TM% "
M;:-M+10 FW_.:-M+10 FW_.:-M+10 FW_.:-M+10 FW_ #FC;_G-+10 FVC;
M_G-+10 FVC;_ )S2T4 )MHV_YS2T4 )MHVTM% ";?\YHV_YS2T4 )M_SFC;2
MT4 )M_SFM[P6/^*TT?D_\?<?\ZPJV?"<\=OXNTB65PD:W499F. !FLZOP,NG
M\2/IX=*6L<>*-"Q_R%+;_ONE_P"$GT+_ *"EM_WW7@N$NQZ7,C7HK(_X2?0O
M^@I;?]]T?\)/H7_04MO^^Z.278.=&O161_PD^A?]!2V_[[H_X2?0O^@I;?\
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MY<:@ %5\X\S_ .O7B-.BD>&9)8V*R(<J0<8K&M0C5C;J:TJLH,^K!Z4M>?\
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M7[U-IR?>H GHHHH,V%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,-__ -=FKOR_XF<F)V1F4445ZIR!1112 **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?]^/_KT?\+(U;_GRTS_OQ_\ 7HY<3_*'UK#]SS"BO3_^%D:K_P ^6F?]^/\
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M;_GRTS_OQ_\ 7HY<3_*'UK#]SS&BO3O^%D:M_P ^6F?]^/\ Z]'_  LC5?\
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M%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH
M2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%
M'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2
MBE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'
MVEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2B
ME^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'V
MEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE
M^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2BE^TM_=%'VEO[HH 2K$/W/QJ#[2W
M]T5/"Y=,D8YH DHHHH CD'[M_I7S9K7_ "&KS_KJ:^E)?]6WTKYKUK_D-7G_
M %U->OE'Q2/%SCX8E"BBBO>/!"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KHO G_(ZZ9_OM_P"@FN=KH_ ?
M_(ZZ;_OM_P"@FN?%?P9>AMAOXT2U\2?^1UNC_P!,X_\ T$5R5==\2?\ D=+K
M_<C_ /017(T83^!'T'BOXTO4****Z# **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M;P
MO_R->E?]?2?SK)J6WNI;*XCN8&VS1,'1L="*SJP<X.*ZFE*2C--GT=1^->$_
M\)]XFS_R$F_[]K_A1_PG_B7_ *"3?]^T_P *\'^RZW='T*S.BELSW;\:,UX3
M_P )_P")?^@DW_?M/\*/^$_\2_\ 02;_ +]I_A1_95;NA_VI1[,]WS25X3_P
MG_B7_H)-_P!^T_PH_P"$_P#$O_02;_OVG^%']E5NZ#^U*/9GNU%>$_\ "?\
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M3_Q+_P!!)O\ OVG^%'_"?^)?^@DW_?M/\*/[*K=T']J4>S/=J7->$?\ "?\
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MDW_?M/\ "C^RJW=!_:E'LSW:EKPC_A/_ !+_ -!)O^_:?X4?\)_XE_Z"3?\
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MYX73TW*1FF4DTP:MN%%%%, HHHH$%%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK_=-.I&^[0"(****9J%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.MGM+5Y \BF3<6P,8)P*R%R.AP1W%)11"G&"LARFY:L4LS$[B2>V31N?& [
M>F:2BJLB;L4DDY).: 2#244[(0I9CC+$X]306;&-QQZ9XI**5D%V*"0>#@4G
M3H3113L@N+SMQDX]*-S8QN;\Z2BE9#NP_&BBBF(**** "BBB@ HHHH ****
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M445[IX(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %='X$_Y';3/]]O\ T$USE='X$_Y';3/]]O\ T$USXK^#
M+T-\-_&B6_B3_P CI=?[D?\ Z"*Y&NN^)/\ R.EU_N1_^@BN1HPG\"/H&*_C
M2]0HHHKH, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *T-"M8;[Q!I]K<)OAEN%1U/0@
MFL^M?PO_ ,C7I7_7TG\ZRKMJE)HUHJ]2*9ZU_P ()X9_Z!47_?3?XT?\()X:
M_P"@5%_WTW^-='17RKKU?YF?6+#4K?"CG/\ A!/#/_0*B_[Z;_&C_A!/#/\
MT"HO^^F_QKHZ*/;U?YF'U:C_ "HYS_A!/#/_ $"HO^^F_P :/^$$\,_] J+_
M +Z;_&NCHH]O5_F8_JU+^5'.?\()X9_Z!47_ 'TW^-'_  @GAG_H%1?]]-_C
M71T4>WJ_S,/JU+^5'.?\()X9_P"@5%_WTW^-'_"">&?^@5%_WTW^-='11[>K
M_,P^K4OY4<Y_P@GAG_H%1?\ ?3?XT?\ "">&?^@5%_WTW^-='11[>K_,P^K4
MOY4<Y_P@GAG_ *!47_?3?XT?\()X9_Z!47_?3?XUT=%'MZO\S#ZM2_E1SG_"
M">&?^@5%_P!]-_C1_P ()X9_Z!47_?3?XUT=%'MZO\S#ZM2_E1SG_"">&?\
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M">&?^@5%_P!]-_C1_P ()X9_Z!47_?3?XUT=%'MZO\S#ZM2_E1SG_"">&?\
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M.M_X0N#_ *&#3_S;_"C_ (0N#_H8-/\ S;_"N2_&C\:/8U?YQ>UI_P IUO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I#2T4 <_J.IZ@UVUG86IR.LK]!45MH ED$]_*UQ-U(/W1_C71E :4
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M_B3G_A-;K']R/_T$5C^'-*EUC68((T+ -N?:,X4=_P \5L?$G_D=;K_<C_\
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M3:N<X&*KR:OI%]:6 OK68W5H@C+1. '4=,\'G@54\1ZPFN7<,Z0>2$A5"@/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>AK0B_:1/?**6BOD7N?8K83%&*6B@8F*,4M% "8HQ2T4 )BC%+10 F*,4M%
M"8HQ2T4 )BC%+10 F*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRT[_ ,!__KT?\)A??\^6G?\ @/\ _7KGZ*/JU+L'MZG<Z#_A,+[_ )\M._\
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M^$POO^?+3O\ P'_^O1_PF%]_SY:=_P" _P#]>N?HH^K4NP>WJ=SH/^$POO\
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M_P#D:]*X_P"7I/YUE7P]-4VTC2A7FZBNSWVEI/UHY]#^5?+V9]8FK"T4G/\
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MLVNH7=G=31"*7R7P& Z<>M6M%\+V&AV5Q!;^8\ERQ>XGE;=)*Q[L>_4UMT4
M<M8>"+:U\/W>AS7UW<:?<0^0(WD_U2\_=].M6=/\-W-E);^9KNHSQ0CA'E^]
MZ9]:Z"B@#&A\/10ZYJ&K"XF:YNX1#DGB-1DC'XDT6GAZ&S\,-H<<KF%XY(V=
MN20Y8M^/S&MFB@"KIUC%ING6]E#GRX8PBY] ,5GP>'((3K#^=(TFJ$&5R>5
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MV\RWLTD$C;#\TA!S\Q[Y/)KI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "KEM_JOQJG5RV_U7XT 34444 ,E_U;_2OFO6O^0U>?\
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M_OX:AHH]G'L'M)=R;[7=?\_,W_?PT?:[K_GYF_[^&H:*/9Q[![27<F^V7/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "KEM_JOQJG5RV_U7XT 344
M44 ,E_U;_2OFO6O^0U>?]=37TI+_ *M_I7S7K7_(:O/^NIKV,H^*1XN<?#$H
M4445[IX(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %='X$_Y';3/]]O_ $$USE='X$_Y';3/]]O_ $$USXK^
M#+T-\-_&B6_B5_R.EU_N1_\ H(IWPWF6#Q#<2NZ+BTDP6/?(IOQ)_P"1UNO]
MR/\ ]!%<@0#G/>LJ5/VF%4.Z-*E3V>)<NS-/4M?U/5<_:[@F/ _=Q_*F?]T<
M5IZY,G_"*Z"%<97S,@'IPM<UVQ2$9K9X>/N\O0R]L[N_4ZZ[M'UOPUI3::_F
MSVB>5-"6 ([@C/UJQ=3W-O#HFDV=RJ:A:!I7<R':&/\ !^@XZ<UQ)4,<D9I>
MM8_5'LWH7[?MN=AK2))X;$^I6<%KJ@E*)Y 4><.I8@=.I_*I_%42:G!I%]"Z
M26,-K&DT@;H<@$>M</@4  =.#GJ*<<+)6=]@==.^FYZ/:VLFG>(;9-.M[)=(
M"HZW$R*S'<H)PQ^;J:QX(OMFM>)[>$JTDR2A!N W?O :Y# HQ41P;5W?4IXE
M62L==H+2V>GZGIJ+;'4#+'(D-PJNKA0P(&>,\BJ^LW>N#1A:WT-M;VKRAA%%
M$B$L._RUS.T9'H.U  '08JUA;5.<EU_<Y4;OA.^M+#7D>_ -K)&T+Y&0 W&3
M[58D\)7[WCR"2V-ONR)1)\NWU]:YOZ\_6D"J.PK25*7/S0=KD1J1Y>62.KTN
MSD72&FTVV@NKXW!CE,P5E5 !@@-QS6L9O^*C\-M-):F1(&#F !44[VXQQBO/
M^V,FDQCH3S6+PC<KMFBQ"2LD=+I4BKX[=BRA?/N.<\'AZ2PLSJFC:A913QBZ
M%X)DC=L%U 8''YUS9 -+5O"]4^WX$JOT9V/AJ%O#FNK]O>-9+R!HD4D,$.1C
M?V[>])>S>(+"WNV>TTV*(*8W>.WC^=3V&.<5Q_8CUI,8QCM4O"N4N:3&L1:/
M*CIM:D5O".A(&!8&3(STX6N:HQSFBNBE3]FK&52?.[A1116IF%%%% !1110
M4444 %%%% !1110 4444 %-?[M.I&^Z: 6Y!1113-0HHHH$%%%% !1110 44
M44 %%%% !1110 4458L;&XU"\CMK:)I)9#@**F4E%7948N3LA;&PN=3NX[6T
MB,DKG"@5[;X2\)V_AZR5G DO''[Q\?H*7PIX3M_#UF-ZK)>.!YDF.GL/:NDK
MYW'8UUGR0V/H,%@E27//<6BBBO./2"BBBD 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %7+;_5?C5.KEM_JOQH FHHHH 9+_ *M_I7S7K7_(:O/^NIKZ
M4E_U;_2OFO6O^0U>?]=37L91\4CQ<X^&)0HHHKW3P0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z/P)_P C
MMIG^^W_H)KG*Z/P)_P CMIG^^W_H)KGQ7\&7H;X;^-$M_$G_ )'2Z_W(_P#T
M$5R-==\2?^1TNO\ <C_]!%<C1A/X$?0,5_&EZA111708!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4C=*6M#0;:*]\0:?:SKNAFG5'7U!-3.:A%R94(\TDD8]%>Z_\
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MABTS_OK_ .O1]>H]P^IUNQPU%=S_ ,*W;_H8M,_[Z_\ KT?\*W;_ *&+3/\
MOK_Z]'UZCW#ZG6['#45W/_"MV_Z&+3/^^O\ Z]'_  K=O^ABTS_OK_Z]'UZC
MW#ZG6['#45W/_"MV_P"ABTS_ +Z_^O1_PK=O^ABTS_OK_P"O1]>H]P^IUNQP
MU%=S_P *W;_H8M,_[Z_^O1_PK=O^ABTS_OK_ .O1]>H]P^IUNQPU%=S_ ,*W
M;_H8M,_[Z_\ KT?\*W;_ *&+3/\ OK_Z]'UZCW#ZG6['#45W/_"MV_Z&+3/^
M^O\ Z]'_  K=O^ABTS_OK_Z]'UZCW#ZG6['#45W/_"MV_P"ABTS_ +Z_^O1_
MPK=O^ABTS_OK_P"O1]>H]P^IUNQPU%=S_P *W;_H8M,_[Z_^O1_PK=O^ABTS
M_OK_ .O1]>H]P^IUNQPU%=S_ ,*W;_H8M,_[Z_\ KT?\*W;_ *&+3/\ OK_Z
M]'UZCW#ZG6['#45W/_"MV_Z&+3/^^O\ Z]'_  K=O^ABTS_OK_Z]'UZCW#ZG
M6['#5K^%_P#D:]*_Z^D_G71?\*W;_H8M,_[Z_P#KU>T3P ;/7+*Z.NZ?+Y,J
MOL1OF;!Z#FLZV-I2IM)FE'"5543:/3:*G^S_ .T!1]F_VQ7S9]2MB"BI_LW^
MV*/LW^V*0R"BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@"
M"BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/
MLW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G
M^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[
M8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_
MMBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@"
M"BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/
MLW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G
M^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[
M8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_
MMBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@"
M"BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/
MLW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G
M^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[
M8H @HJ?[-_MBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_
MMBC[-_MB@""BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@"
M"BI_LW^V*/LW^V* (**G^S?[8H^S?[8H @HJ?[-_MBC[-_MB@""BI_LW^V*/
MLW^V* (*N6W^J_&HOLW^V*GA38F,YYH DHHHH C?[C?2O!=8)_MB[^8_ZPU[
MW)]QOI7@>L?\AB[_ .NIKT\LUE(\K,_A12R?4_G1SZG\Z**]CE1XUV&3ZG\Z
M,GU/YT44<J'=BY/J?SI,GU/YT44<J"[%Y]3^=)D^I_.BBCE0KL7GU/YTF3ZG
M\Z**.5#NPR?4_G1D^I_.BBCE0789/J?SHR?4_G111RH+L,GU/YTO/J?SI**.
M5"NPR?4_G1D^I_.BBCE0[L,GU/YT9/J?SHHHY4%V&3ZG\Z,GU/YT44<J%=BY
M/J?SI,GU/YT44<J'=AD^I_.C)]3^=%%'*@NPR?4_G1D^I_.BBCE0789/J?SK
M?\&9_P"$ML.3C<W_ *":P*WO!?\ R-MA_O-_Z":QQ"7LI&V';]JBQX_R/%MQ
M@G[B=_\ 9%<UD^I_.NE\?_\ (VW'^XG_ *"*YFC#)>QCZ!B&_;2#)]3^=&3Z
MG\Z**VLC&[#)]3^='/J?SHHHY4*[#)]3^=&3ZG\Z**.5#NPR?4_G1D^I_.BB
MCE0789/J?SHR?4_G111RH+L,GU/YT9/J?SHHHY4%V&3ZG\Z7)]3^=)11RH+L
M,GU/YT9/J?SHHHY4*[#)]3^=&3ZG\Z**.5#NPR?4_G1D^I_.BBCE0789/J?S
MHR?4_G111RH+L,GU/YT9/J?SHHHY4%V&3ZG\Z,GU/YT44<J"[#)]3^=&3ZG\
MZ**.5!=AD^I_.C)]3^=%%'*@NPR?4_G1D^I_.BBCE0789/J?SHR?4_G111RH
M5V&3ZG\ZU/#9/_"2Z<,GFX7^=9=:.A31VVNV4\SA(XYE9F(Z &LZT5[-V1K1
MDU43;/;L4M8O_"5Z)_S_ *?]\M_A1_PEFB?\_P"G_?+?X5\Y[*?8^D]O3[FU
M16+_ ,)9HG_/^G_?+?X4O_"6:)_S_I_WRW^%'LI]@]O3[FS16-_PE>B?\_Z?
M]\M_A1_PEFB?\_Z?]\M_A1[*?8/;T^YLT5C?\)7HG_/^G_?+?X4?\)7HG_/^
MG_?+?X4>RGV#V]/N;-%8W_"5Z)_S_I_WRW^%'_"5Z)_S_I_WRW^%'LI]@]O3
M[FS16-_PE>B?\_Z?]\M_A1_PE>A_\_Z?]\M_A1[*?8/;T^YLT5C?\)7H?_/^
MG_?+?X4?\)7HG_/^G_?+?X4>RGV#V]/N;-%4K'5[#4]WV.X67;]['!'YU=J'
M%IV9I&2DM HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BDS2Y% !1110 4444 %%%% !1110
M 4444 %6(?N?C5>K$/W/QH DHHHH 9)]QOI7@>L?\AB[_P"NIKWR3[C?2O ]
M8_Y#%W_UU->GEGQ2/*S3X8E*BBBO:/&"BBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5O>"_\ D;;#_>;_ -!-
M8-;W@O\ Y&VP_P!YO_036.)_A2-L/_%B6/'_ /R-MQ_N)_Z"*YFNF\?_ /(V
MW'^XG_H(KF:,-_!CZ!B?XT@HHHK<Q"BBBD 4444 %%%%, HHHI %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.3.\
M<GK3:=']\4 61E1C)P/>CG^\?SI:*D!.?[Q_.CG^\?SI:* $Y_O'\Z.?[Q_.
MEHH 3G^\?SHY_O-^=+10 G/]X_G1S_>/YTM% 6$Y_O'\Z.?[Q_.EHH 3G^\U
M'/\ >:EHH"Q8LK^?3YTEMW*,ISD=_8^U>IZ!KT&MVF[(6=1\Z9Z?3VKR2K&G
MZA<:9>+<6S[67MV/L:Y,3AE55UN=>%Q3HRUV/;**QM U^WUJU4@A+A1\\>>G
M_P!:MG\*\*<'!V9]#":G'F04445)04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !112&@ )P<4M8U[.WVE-KG"^AQ5RSNQ(F&//K
M5<NER5)-V+M132B*,L3TIQD55))&*S;Z_M?(<RL!&."322;8Y-(CCUG==FW,
M; ]F[4S^V5:_%N@^8'YL^E<Y<ZE-87F0@>%@-GEKS^/MBJ-KK*S^(I9(8=Y8
M!3+C[I]/TKKCA[J]NAQ2Q2B[-ZW/3 <C-+6*=9BB$"22(LDV?+4]6J6WU=)6
M(/\ #UKF<)'6JD>YJT5'',D@R&ZU)4%A1110 4444 %%%% !5B'[GXU7JQ#]
MS\: )**** &2?<;Z5X'K'_(8N_\ KJ:]\D^XWTKP/6/^0Q=_]=37IY9\4CRL
MT^&)2HHHKVCQ@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %;W@O_ )&VP_WF_P#036#6]X+_ .1ML/\ >;_T
M$UCB/X4C;#_Q8ECQ_P#\C;<?[B?^@BLS0='DUJ^FMQ((PD+29(SR,<?K6GX_
M_P"1MN/]Q/\ T$5-\/=O]N3[\[?LKYQZ9%8*;AA$UV-914\4XON<[I=F-1U2
MWLS)M\U@N[&<4R\MC:7\UMN\SRVQG&,UV.BIX4&L6OV.6\-R'&P,.,^]06=O
M VHZQ=N(#)!(!']HD"HI.>3^5+ZTTVV-8:ZLGJ<>0PZ@BDVL>@/%=5J<=O+X
M?9KFXL7U!)!L\B0'*GKFM+4[M++Q!IMG;VL*I((Q(2N=V3@U7UIM:(3PVNK.
M#PWI2+\S$#K7>0R00^+VT5+6$VI)#%ERS97/)_&J>E:='%%JUZAMD>&<PP_:
M#A4YZ_EQ1];LKM"^JZZ,Y#!%2VUM->7"06Z%Y'. !70ZO'&^C(\US9/=))@-
M!("60@Y_6F^"X_\ B97+ (TB6[F+/8\?TJ_K%Z;FEJ3[&U10Z#'\-621['UJ
M 7JC#0Y^7=W&<U@/&R.ZD<H><&FL7+EY.6)SG/6M_2(;XZ6TD M8(V?'VB<[
M23Z FCFE3CS-W!14Y<J5CG\D''KTI<'&<<5V=S:0GQ'H<CI"7N"AE\DY1CGJ
M*E?5(%\7R:;)90_8Y'\K:J\DGC.:CZTW:R*^K6;NSAADYQ2D'=C%=1:^1IFD
M:A?);1O<?:FAC9Q]Q>/UYIFB?\3S58S=+$/L\3,>,!L9(W?0U7UBZ<K:(GZO
M9J+>IS1!7J#S0 3P.]=D(XIK.^34KO37!7=!Y4HW*WH/;&:9'<)I?@BQO(;2
M"2<W#C,J;L#)J8XIM:+6XWAK/5Z'(8)[''K28P<5UEE.VHZ2%L6M(]1DF9Y8
MW&TN,\!3GI[5SE]YJWTPN(A#-N)>,# 4^E:TZSG*S5C.K244G<KT445N9!11
M10 4444 %%%% !1110 4444 %%%% !1110 4Z/[XIM.C^^* +5%)14C%HI**
M %HI** %HI** %HI** %HI** %HI** %H[4E'% %BROI]-O$N8'(D4\>_P!:
M]5T+7[;6;;Y"$G4#?'Z?_6KR+MT)^E=+X.TJ^N-22[B=H8(V^9_[W^R/6N'&
MT82AS/1G;@:U2,^5:IGJ%%%%>&?0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 (QP,U7-S&48[NG6II&4(2:XW6]0:Q^U31+YI$
M>%11\Q;L/>M*<.=V,JE3V:N17,EVVJ!4F&6;S"/[J=A^AK#\1ZI?V-Q(=/N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4445SG2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6\TZ*.6,']X%&3@9ZUYD\?ES.%^[G@UZD]RNI^#)YM 6.U?&98D0?B/RKD-
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M/Y#_  H_X2RR_P"A=L?R'^%'M*O\@>RI?S'+9]J,^U=3_P )99?]"[8_D/\
M"C_A+++_ *%VQ_(?X4>TJ_R![*E_,<MGVHS[5U/_  EEE_T+MC^0_P */^$L
MLO\ H7;'\A_A1[2K_('LJ7\QRV?:C/M74_\ "667_0NV/Y#_  H_X2RR_P"A
M=L?R'^%'M*O\@>RI?S'+9]J,^U=3_P )99?]"[8_D/\ "C_A+++_ *%VQ_(?
MX4>TJ_R![*E_,<MGVHS[5U/_  EEE_T+MC^0_P */^$LLO\ H7;'\A_A1[2K
M_('LJ7\QRV?:C/M74_\ "667_0NV/Y#_  H_X2RR_P"A=L?R'^%'M*O\@>RI
M?S'+9]J,^U=3_P )99?]"[8_D/\ "C_A+++_ *%VQ_(?X4>TK?R![*E_,<MG
MVHS[5U/_  EEE_T+MC^0_P */^$LLO\ H7;'_OD?X4>TJ_R![*E_,<MFM7PW
MSXDT\]A.I_6M3_A+++_H7;#_ +Y'^%7M&\2V=QK5G"NA6<1DE"B1 ,KD]1Q6
M=6I5Y&G$UHTZ:FK2/2:6DI:\ ^A"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!KG"$FN%\2O:IJEE<R$J5EPNQ06)P1CZ5VEV<0-CJ>*\L\73-=:A#;V\
M;-/'* R#NH[UV8.GS2;.''5.6"7<Q?%'ANVT*:0BP:Z9V(1W?DGM^%<&FL(M
M[:W5K#';B&7S&C/(;'J._P"->N_$>2":RA<SE8V'53U)[8]Z\BGT9)718+<A
MV^\5<GCUQ7>E.<$<"Y(R=SHM8O!<RS7#QK)$HXD'RLZ$=?YUE:;J+6%E/+8Q
MQRQS,$/F(-^?KU/6I]9FBL;6S9UCG>.%86B;N<G(QV.".:R[YK*&[$]FIB50
M'*YSS6DFON)@KKU-I%U'466S>Y<F/#$-N/)[ ]_IZU3U_P"V6FK7-K=!UCBC
M0J .IVCK[U5;Q/K(BMXC<%5R#&Z<<YX_SZ5:N==U+4K@K>M&)HAEV*#YU]JA
M3NRW3LB;PZ+:32R9;*X>[:0J9T;C;G/(SSVJ#5(3<ZFQM )"BCS!CY1^'UI_
M]HS6KP1FY:"&=&SM)4*<\<?2EMC%I=K*'Q(URV%"2$N._3'/YU=TERF3BW+G
MN9J7MXFHQ02Q"&X5PK./E"C\*OZ[86=UIZ.!@I&[(5^\<8Y-+,+JZ;[1)"5N
M #YN5Z'V_6I8M/%Q:QW<@5H5.&^;!]Q5JG[KCW(E5M-373L.T2*YD\,3-/=.
MT<$+.L;'@'' _2J>APV5YJ\44ZS7$EPP61L?<]\T^]U*%4N[2%W*[>G12%Z?
MSJAI6IW#7,8TL/!("-P4\/6<K)J)<%*2<GI<]%ATNZ\+:E#->W+WD<SF.TC&
M2JX&03Z<UD6.L7!URXN50PA9"69SN:0_CV[8KLM7U::[@M$@8Q3VB'SOEY.5
MZ+]<XKG)K&?6M*2]L8S \4FR7*CY^>F?KVHI]YDU&MHGKGAZ_74;))TC,89?
MNGU[UM5RGA(B*QCB1BRA0"<\[N_ZYKJZ\:LDIM(]W#R;IJX4445D;!5B'[GX
MU7JQ#]S\: )**** &2?<;Z5X'K'_ "&+O_KJ:]\D^XWTKP/6/^0Q=_\ 74UZ
M>6?%(\K-/AB4J***]H\8****0%[1]0_LK5K>^\O>86W;<XSP1U_&I]=UDZUK
M)U#R3$2%PH;."!651BLG1@Y\_4T562AR(Z36O%8UO2K>&:T"W$6/WX;)/KV[
M\5=T[QOLTQ+#4;)+N-0$RS=5]^.:XZBH^J4^7E+^M5+W.RG\<16D<D&BZ9#:
MJQYD['\*PM$UI]'UG^TFC\YL-E<XZCUK*HQ36&IJ+CW!XB;:DWL:.I:O)?:Z
M^JQIY3F19%7.0,8Q]>16EKOB>+7'M)9+)%FA(WMOSO'4CIZUSF**?U>%T^Q/
MMYV?F=G9>.+"P5Q;:!!$77:Y1\;A[\5@:WJ=GJDL<EII\5GM4AA&<[CGZ5ET
M4H8:G"7,BIXF<X\K%5WB9&C;#*P8'OD5VD?CJ&[M8K?5M+CNL<.S'OZXQ7%4
M556C"I\2)I5I4MCK9?&5L;ZRF71HUCM Q2,/P"<8/3CI6%K6JOK.J2WCJ8]Y
MP%#9P*SZ*F&&IP=TM1SQ%22LWH=%HOBHZ9I-QIL]L;B";(Y?:0",<<5(?%H'
MAHZ*MJH0#"OOY W9Z8KF:*3PM-RYK#6)J)<MS=\-^)&\/B=#%]HBF'S1E\#/
MK^58]S,L]S+*D8C#N6"CH!GI45%:QI1C-S6[,W5DXJ+V0#J#S^%=._BYF\,?
MV/\ 9!_JPADW_P!,5S%%*I2C4MS= A4E"]NH4445H0%%%% !6]X+_P"1ML/]
MYO\ T$U@UO>"_P#D;;#_ 'F_]!-8XG^%(VP_\6)8\?\ _(VW'^XG_H(KF:Z;
MQ_\ \C;<?[B?^@BN9HPW\&/H&)_C2"BBBMC$**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "M3PW_R,NF_]?"?SK+JWI=T+'5+:Z*%_)</M!QG%9UDW!I&E)I339[K17#_
M /"QD!P-/?\ [^__ %J/^%C)_P! ]_\ O[_]:O!^IUK['O?7J/<[BBN'_P"%
MC)_T#V_[^_\ UJ/^%C)_T#V_[^__ %J/J=;L'UZCW.XHKA_^%C)_T#V_[^__
M %J/^%C)_P! ]_\ O[_]:CZG6[!]>H]SN**X?_A8R?\ 0/;_ +^__6H_X6,G
M_0/;_O[_ /6H^IUNP?7J/<[BBN+A^(4$DRI+9O&I/S/OSC]*Z^">.YA26)PR
M.,JP[UE4HSI_$C:E7A5^%DM%%%9&P4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %/43MMF;ICOZ5P6L36BR3
MLLR0M< (+@)ELUZ!>1&6!E'I7E'B"WOK5GLY8$^SW$JGSVX2,#^M=N$:UN>?
MCE)I60GB#4K6&Y2SOQMCA&'D'W58] #[<XKEM-N91>6:VHCA1+K<&=]S@''4
M=AQ6]XBT.>/4]4U&Z0&)5W.K?ZHGGD^U>?:39SKK46"K,P\Q$#8!],'T-=Z:
MTL>?RZ.Y-J4<UQ>I&ZI,LGR*P&6.2>]/N_#\5NRVY8QMT\QGQG\*J:=>74FN
MFSN;W8()/,5E')8>A]:V+PW"H6U6)HI%D!C;;]]3[^M7&4975A3C.%M2C;Z+
M9K8>=/=+"X=I(8_O!P!CD>N0?TK%FFGN]74K(VYL#)Z\#T_"MO499=)OKE(X
MXOLY*E&=?51R/Y5H:7ILD^RY+0*5ZEEX)Z^O6E[/F^$IUN1<TCEKPS7U_'%)
M-/))GYV<=/PJ]:S6^GY697GC1LJQ'(JW/9K>ZE).I9Y%;K >#SZ=^:U1I]M;
MF2XND6;?'\\(ZX[?3M51IR5WU(G6@[1>Q4^V1W6F_:$4*,G 4\^U3>';W2]4
MO(+2XLWW28M]S39P#Z#'!]ZP/L%[!'+'#G<OSF-N"!ZXJ[H=N-/T:YN77;=1
MQ^9 Z<EF;[OX<4IU92LF%.C"*;7<<FDPRVMY?6\I$?F>6 X['IDUT.DV.E:+
M]GN(P':4AH@S<[O?VK.TVV%GX?:2^>&"9CD*!^\..Q7^M0/I]Q,MKJEXQ%K.
M^P;%X0^X_&J2BEKN3)R<FKZ'?ZA.+WQ!:PE(/(EM7$NU?F#!2>#Z8Q5OP_J5
MFFER016206BL5+N.&/K7/^'=!U6XUD3H8RD9+?:<<.A7;BMIHX$G$5CL8J6,
MKYX'7D5FU&7NA=Q]X[?1S']GA>(!8R<!0O%=!7#Z US<S1SHPV ;&R<[O>NW
M7[M>5B8\M2Q[>$ES4TQ:***YSI"K$/W/QJO5B'[GXT 24444 ,D^XWTKP/6/
M^0Q=_P#74U[Y)]QOI7@>L?\ (8N_^NIKT\L^*1Y6:?#$I4445[1XP4444 %%
M%%( HHHH ****8!1110 4444@"BBBF 4444@"BBB@ HHHI@%%%%( HHHH **
M** "M[P7_P C;8?[S?\ H)K!K>\%_P#(VV'^\W_H)K'$_P *1MA_XL2QX_\
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MO^- %ZBHH[JWFEDBBN(I)8QET5P2H[9%.66-F8++&Q0[6"G)4^A]* 'T444
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M6(?N?C5>K$/W/QH DHHHH 9)]QOI7@>L?\AB[_ZZFO?'^XWTKP/6/^0Q=_\
M74UZ>6?%(\K-/AB4J***]H\8****0!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !6]X+_Y&VP_WF_]!-8-;W@O_D;;
M#_>;_P!!-8XC^%(VP_\ %B6/'_\ R-MQ_N)_Z"*YR.62%Q)$[(XZ,IP171^/
M_P#D;;C_ '$_]!%<S2PRO1C?L&(_C2))YYKER\\KRL1C+L2:?#>W5O$8X;F6
M.,G)5'('Y5!16W)&UK&7,[WN.61T9F5V4L,$@]12^;)Y7E;V\O.[;GC/KBF4
M4<J"[)_MMUY'D_:9O*_N;SC\JB=VE??(Q9L8RQR:;10HQ3ND#DWHQR2/$X>-
MV1AT*G!%)D[MV3NSG.:2BG9,5WL66U"]=P[7<[, 5#&0Y /45 TCM&(V=B@.
M0I/%-HJ5"*V13G)[L<\CRJJR.S*HPH8Y 'M2R323/OED9V P"QR<4RBGRH5V
M32WES/&L<UQ+(B]%9R0*8)9!$8A(PC)R4SP3]*910HQ2L@<F]R>"\N;92L%Q
M+$&.2$<C-0L[.Y=V+,3DDGDTE%"BKWZAS.U@HHHIB"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *=']\4VG1_?% %JBBBI&%%%% !1110 4444
M%(3@<T5O>'/#LNL72NX*VBGYG_O>PK.I4C3CS2+ITY5)<L1/#WAR;69PT@*6
MJ'+M_>]A7J=O;Q6L$<$*A41< "BW@BM8%@A4(B# "]JEKP<1B)5I:['T.&PT
M:*\PHHHKG.GH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/0;62ZMK2(81H)BD@^8M]\<]36?8> =,TV_:]@O]7,TCB23??NPD8# +#//
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"K[K_H)Q?\ ?H_XUZ=BC%'UVMW#ZC1['F/_  J^Z_Z"<7_?H_XT?\*ONO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>genzerafbudl000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W!KH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8WQZX8 XK9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2O+-%NO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@C3M7\+66A/>V]X66"Y3H <\T =/^S]-(V@ZM$6)C2\;:/3@5TOQ@72W\!7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[CP9X[E\5WDT#Z5/9B--VZ1< ].*!G:T444""BBB@!,#.<4M%% !1@#H***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:)H]WJ]WKWVJU:<8M]I&,GCO7MGP\_Y$#1O^N'_LQH Z>BBB@ HHHH ****
M*VH?\@ZY_P"N3?RKRKX6?\C#J7U;^=>JZA_R#KG_ *Y-_*O*/A<Z)X@U(NP7
MENI]ZRG\:/1PJOAZOR/8**16#+E2"#W%+6IYP4444 %%%% $<T0F@>(G <8R
M*\;\0^'Y/#>MQR6*R2QQ!9=[+QG.?Z5[14%W:17MK+;RCY)%*MCK@TT[&56G
MSHY#PAXT&KLUM?.B7!;;$HXR,5VU>->(?"%]HFIK+IZRS1L=R;$)*_7%7X_%
M7B^.-4%@Q"C S;M3:,H57'W9H]6HKR:X\;^*;1 ]Q:K$I.,O"P'\Z]"T#5#J
M&C07-Q)&)7'.#BE8UA5C)V->BH_/B_YZI_WT*//B/_+5/^^A2-+HDHHHH&%%
M%% !7FWQC\5:MX5T*TN=)F6*624JQ90W''K7I->-_M#<^&-/Q_SW/]* *MK#
M\9+RTAN8K_3O+E0.N5&<'_@-=%J6J>+O#?PLOK_5[B ZQ$6*R1J"H'..,5S>
ME^"_B7+I5K);^+?+A:)2B?W1C@=:W_&]EJFG_!>^MM8N_M=ZJ'?-Z\&@#E?#
M^H?%OQ)I$6J6%]8FWE&5WH ?_0:Z'X=?$/7-1\3W?AGQ+%&+V!2PD10.AQC
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MNW_ZU=?\.O%6G>(;VZ2QT!M/\M?FD['D<=*!GHE%%% @KG/'/B8>$O"MWJN
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M:[G5+J0#>BKP#74JP= RG((R*FQT1DI;"T444%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #7C21<2(K#T89KQ2^\6O9ZS?:7X)\.QW&V7=/+
MMSEN^,U[8PW(5Z9%>&Z!XG7X8ZUJVG:W8RB.XN#-'.BYW _S% '2>"O'TM]K
M:Z)KVDQV&HD9C8(!N]OK7I]>*V.JO\1/B9I>IZ?9R16.GG<TS#[W(X/Y5[50
M 4444 1S1)/!)#(,I(I5A[&O&KOX.Z[:3WUIH.NI;:3?$^;"^<@'/ X]Z]IH
MH XRU\"_V3X ?P[I-VT%PR\W.<$MGD\4D'@9KOX?_P#"-:Y>-=R'=FXR203T
M(SZ5VE% 'BB_!_Q+/:QZ+>^(U?08W!$2YW$ ].G]:]@TS3X-*TVWL;9<0P($
M7\*MT4 >:?'3_DF\_P#UWC_F:Z3X>?\ (@:-_P!</_9C7-_'3_DF\_\ UWC_
M )FND^'G_(@:-_UP_P#9C0!T]%%% !1110 4444 0W41FM98@<%T*C\17@OB
MGPCJ?A=&OVO %FEVXB=@><FOH"O-_C!_R+UO_P!=U_D:RJQ3C<]#+:TH55!;
M,Z?P0[R>#=,>1F9C",LQR370UY/X;^)>DZ1X>LK":.8R0QA6PO&:ZOP]X^TW
MQ%J!L[5)1(%W?,N*<9QLE<C$82LI2GRZ'6T445H<04444 %%%% "$ ]11M7T
M%+10!SWBS09M>TU+:W=$8-G+=*XY/AUKD:A4U)%4= )& KU*BG<RE1C)W9Y=
M_P *]U[_ *"@_P"_KUB:OHFN:%>PH;B:?(W@QNQ'!Z5[928S3YB'AUT/,%\>
M>(%4#^RE./9J7_A/O$'_ $"E_(UZ=@48%*Z'[.?\QYC_ ,)]X@ _Y!2_D:VO
M!_C&ZU^_G@NH8HA&@(P>2:[*1-T;*.XQ7B=[;2^%?%">9(7 82-LXR,]*>C(
MGSTVFW='M]<!\5/!5_XVT:UM-/FACDBDW$RDX[>@]J=_PLZR_P"?1_S_ /K5
M;T[XAV.H7J6QB,6X_>9N!2LS7VT'U.'@\&?%6V@C@B\26BQQJ%4;>@'_  &N
MAE\(>*=4^'-_HNL:C!<ZC.3LEY"@<^U=[_:NG_\ /Y#_ -]BC^U=/_Y_(?\
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M,&QZ&I.I23V'4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\&@!]%%% !1110 4444 %%%% 'FGQT_Y)O/_ -=X_P"9KI/AY_R(&C?]</\
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M_P#K4?\ "LI?^@F_Y_\ UJ]%HHNP]A \Z_X5E+_T$W_/_P"M1_PK*7_H)O\
MG_\ 6KT6BB[#V$#SK_A64O\ T$W_ #_^M1_PK*7_ *";_G_]:O1:*+L/80/.
MO^%92_\ 03?\_P#ZU'_"LI?^@F_Y_P#UJ]%HHNP]A \Z_P"%92_]!-_S_P#K
M4?\ "LI?^@F_Y_\ UJ]%HHNP]A \Z_X5E+_T$W_/_P"M1_PK*7_H)O\ G_\
M6KT6BB[#V$#SK_A64O\ T$W_ #_^M1_PK*7_ *";_G_]:O1:*+L/80/.O^%9
M2_\ 03?\_P#ZU'_"LI?^@F_Y_P#UJ]%HHNP]A \Z_P"%92_]!-_S_P#K4?\
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MR,_<XI6'"LG+E>AT]%%%(V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$?68]5)@LM2"S07!4E2P !''XT[29E\6?%IM;L0SZ9I]J85F*D!W.0<9^@H
MLZE*/#7Q;L)8OEM];B,<X[&09(/Y*!7H]>:>-D-]\3O"=G#S)&6F?'\*X<9_
M.O2Z "BBB@ HHHH **** .6US0=7O_$FG7UGJ+P6ENP,T(8@.,BN#UCP;XF@
MO)9IO&#VT<CDHK3D8'IUKV1B0I(&2!TKPO0O"$_Q%U?5M0UG4[B(P7)B6%&P
MP Z<>E '0^$_"/B.#6;74)O$[WMG&^702E@P].M>J5XM8:'>> ?B1I.GZ=J$
MUU9W^1+$QW% ",D_G7M- !1110 4444 %%%% !1110!YI\=/^2;S_P#7>/\
MF:Z3X>?\B!HW_7#_ -F-<W\=/^2;S_\ 7>/^9KI/AY_R(&C?]</_ &8T =/1
M110 4444 %%%% !1110 4444 %%%% !1110 R9#)"Z#JRD5Y _PMUM;R6:"]
M2/><Y5L5[%142@I;G10Q52A?DZGCW_"M/$O_ $%#_P!_#1_PK3Q+_P!!0_\
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M$BW*OO/I@5MZ9XUU/1?@0FK73,;W/D0._4@@!6H ]6OM?TG39/+O=0MX'/\
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M\\^'?@.]TF^U_P#MZRMY;:\G$D2M\X(^;J"/>O4Z* *]K8VEC;^1:VT4,/\
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MXMCL)<;@^WHW-;\UK!<6Y@FA22$@ HRY'Y5+10 U$2*-8XU"HHP% X IU%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1116APA1110 C(KC#*&'H1F@  8 P*6B@ HHHH **** "BBB@ HHHH ****
M"BBB@ IKQI(NUT5AZ,,TZB@ HHHH **** "BBB@ IKQI( '16P<C(S@TZB@
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M011#+$7!)I/#7Q.N-)L6AOTENY2V0[R'I3]JKV>A/]G2E'FIR4O0]NHKRO\
MX7'#_P! YO\ OO\ ^M1_PN.'_H'-_P!]_P#UJ?M8]S+^S\1_*>J45Y7_ ,+C
MA_Z!S?\ ??\ ]:C_ (7'#_T#F_[[_P#K4>UAW#^S\1_*>J45Q?A7Q_!XENI8
M?L_D>6,Y+YS77?:X/^>J?G5*2:NCGJ4*E.7+):DU%'4451D%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z[Q_S-=)\//^1 T;_KA_[,: .GHHHH **** "BBB@ HHHH **** "BBB@
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M*.S,S_A'M)_Y\(?^^:/^$>TG_GPA_P"^:TZ*.5%>UGW9F?\ "/:3_P ^$/\
MWS3)?#FEM$ZK8P@D$ [>E:U%'*@]K/NSR"3X1ZA]IDDAU**,,> H85S'B3P]
MJ/A*]M?-O'N V)/D+8X/_P!:OH:LW6=*AU2PFA:&)I60JC.H.VLI45;0[Z.9
M5%->TU1B>"O%L7B&P=FC$!AVIAF'/^<5UM?.VL:-?^"]3MXVN797^<K$Y X_
M_77;Q_%V!(U7[!(< #-*%6VDB\1@')\]#5,]2HKR_P#X7!!_T#Y*/^%P0?\
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MN99YD.'%NH8(??F@#NJ*Q=%\5:1X@TIM1TZZ66!!E\=5^M<Y/\8/",-I)/\
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M:C<7#WM^1@2MT7Z"N[KS'PX/B0-=M?[8=#8;QYORJ./P%>G4 %%%% !1110
M445C^)O$MAX5T:34M0<B). J]7/H* -BBO+] ^-&G:KJ\-C>Z?<Z>+D@02S+
MA6)Z=Z]0!!&1T- 'FGQT_P"2;S_]=X_YFND^'G_(@:-_UP_]F-<W\=/^2;S_
M /7>/^9KI/AY_P B!HW_ %P_]F- '3T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M57_A5?A[_GE)_P!]'_&C_A5?A[_GE)_WT?\ &C]X%L%W9:_X65X;_P"?M_\
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M1S:5J'F6R7YW<#YE&[_ZU=M8>#K:P\$R>&5N)&@>)HC*0-V"* .4^!#$^!)
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M=2BG(_=V_P O^\ <5:TN>^_LBRX/^H3_ -!%9WQ&+:Y+IOA*WRTE[,'N"O\
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MDO%NWM8FN%&%E*_,/QJU10 4444 %%%% !1110 4444 %%%% !1110 4444
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M'\J .._X7]_U+\WYG_"C_A?W_4OS?F?\*]D^PVG_ #[1?]\"C[#:?\^T7_?
MH \;_P"%_?\ 4OS?F?\ "C_A?W_4OS?F?\*]D^PVG_/M%_WP*/L-I_S[1?\
M? H \;_X7]_U+\WYG_"C_A?W_4OS?F?\*]D^PVG_ #[1?]\"C[#:?\^T7_?
MH \8_P"&A(_-\K^PY/,_N[CG^5/_ .%_?]2_-^9_PK?D^'U\WQ<7Q*([?^S1
M#L*<9S]*]%^PVG_/M%_WP* /&_\ A?W_ %+\WYG_  H_X7]_U+\WYG_"O9/L
M-I_S[1?]\"C[#:?\^T7_ 'P* /&_^%_?]2_-^9_PH_X7]_U+\WYG_"O9/L-I
M_P ^T7_? H^PVG_/M%_WP* /&_\ A?W_ %+\WYG_  ILG[021+NDT*55]2Q_
MPKV;[#:?\^T7_? KD/B5X.F\4>$GTW2XH$N3,KY( X&<_P Z .)7]H .H9=
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MK'Q);B%+&!2& (!Z'M^- 'IM%%% !1110 4444 %%%% !1110 4444 %%%%
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MDKHD1/'R]*E^&LO_  C?Q:USPU:NWV GY(R> < YH ]WHHHH **** "BBB@
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M= 'HVFZSIVL)(^G7<=RL;;6*'H?2KU>,?L](T>A:JC<LMT03[X%>ST %%%%
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MB_%C7/[:5I[:UC(BC)X7!"UH_":X;0_B'K_A:*1S9I([1(3PNTF@#W"BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7HM5K"PMM,L8K*TC$=O$-J(.PJS0 4444 %%%% $%ZTRV4S0#,P0[![U\]>
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M896&017)1_"_PC%J/VY=)B\T-N (&T'Z4 >->++2_LO#'@O5[Z.0K;#:Y(Z
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M2_A_IL$ZE9&3S,'MNYKL*15"*%4 *!@ =J6@ HHHH **** /'OCV?]"\/_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>genzerafbudl000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &@!FD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#F?'FOW7AKPG=:G9A#/'@+O&1S7EVB^,/C#XATY
M-0TW3M+EMG)"L4 Z>Q:N\^+_ /R3N_\ JO\ .O,?A_=_%*/PW:IH%GI\FE^8
M<-*%W=L]6J8:MCEI%'7ZUJ_Q<M8TEL]-TXQI 'F+!>&QEOXJYCP_\0/BQXF:
MX&EV.ES?9VVRYC"X/XM7M=R;EO#,IO HN3:MYH7H&V\UY?\  K_6:]_UW_\
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M*=2!.Z"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ-1532[Z/4M,MKR,@K-$LG';(!JW3>@)W"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#EOB%H=YXB\'W>G6"JUQ(05#-@''O7E_A_2?C+X9TJ/3=.L=+%M&25\QD8
M\^^:]YHI)6=QMW5C#LH]8NO"ICU9(QJ4D#*ZQXV[BO\ C7)?"OPCK'A=M6.J
MP)%]HEW1[9 V1DGM]:])HI]6^Y-M$>8^)M/^)=EKT]YX8N;6YMI@ (;C&$QZ
M9-9_A7X?>(KSQB/%/C&2'[6J;5AAQCVZ$UZ]11'W1RU*FI0/<:9<PQC+O$RJ
M,]R*\[^%/@W6O"UQK#ZK D2W,NZ+;(&R,GT^M>GT4+1M]P:NK'.^-?#@\4^%
M[K2\A6D&Y"?[PZ?K7DD/@7XGW7AN;PY<W%I;Z=&"8V5@7DQT7(/ ->^T4DK,
M=]+'E&D^#_%ND_#*WTRPF2TU>"<R!0X*L,YP2#CFN>/@+Q_XL\1:==^*(=/M
M8K.0/YMN%W/@@X.#GM7O%%5?WKBZ6/*_%/@C6M1^(NDZM9P(]C:A [M( 1C'
M;\*K>.OAYX@D\61^*?"DL?V\*JM%(0 <>Y->NT4@/$[/P#XU\5^)[+5/&KVT
M,=FP9(H"""1CT/M6UK?@K6;OXJV.N6UO&=.AC56?S ", =NO:O4J*%HTUT$U
M=,\M^(?@O6_$'C/0-2T^W22VLY0TS-(%(&5/0]>E>B:E:&\T>YM,X,L+)^8Q
M5Z@\BDU[O*/K<\5^"-TUEJ.NZ#/A9(;AB@(P6&YLFJ5WX.^(VD>.K[7/#EG9
ML)B0K3R*<@^Q->I6G@;1K+Q5)XCMTG2_D0HV)/D(_P!WUKI:?9]@[KN>476E
M?$'Q)X&U/3_$%K9_;I&7[.L+*H(YSDY^E=+X+\,7%AX!CT/6(5#LK)*@8,,'
MWKLJ*'U%;8\#TGX4>)M,\?6MSMC?1[68O$YE&54MG&,YKK?B/\-;KQ%J%OKF
MB3K;ZK;XY/&_&,<_A7I]%*VB78?5ON>-VUG\8[]X;#4'L+2S! :XB*[\#Z-F
MJWB'P#XTTWQO'XC\+_9;J=H%B<SD#!  )P3SG%>VT4V"TT/&/!G@/Q=I_P 2
MSXAUT02I+;LLDL;@88@<;<YXK4\)^"M;TKXE:EK-W;HEE.&$;B0$G/M7J=%-
MO5/L)J]Q.U>%ZL!XI^/5G;0@-'IRB1GZCC::]T/-<[H?@C1O#^J7>HV23&ZN
MF+2/+)O/T'H*2TFI#?PM'1 8&!2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV2AKJXCA5C@%VQF@"Q13(IHYXEDB=71N0RG(-5[C4[&TE6*XNHHI&Z*S8)H
MMT4@(8 @Y!Z&JO\ :EA]J^R_:X?/Z>7NY_*@"W111T% !16?::YIE]>S6=K>
MPRW,/$D:."R_45H4 %%%% !1137=8T+NP50,DGM0 ZBJ*:QILLRPI>P-*PR$
M#C)JZS!5+,0 .IH 6BN4UWQS9Z5=):6T,E[<%2[)"N[:H&23CVK8T/6[77M*
MCU"U)\MN&##!4CJ#1<#3HKB+OXD6-MJ4D(M+A[2*40R7(3Y%<G&,_6K.J>.$
MLM5-A::?<WKB-9"T*%@ W3I2N!UU%5K.Z-Q8QW,L30EDW,CC!7ZUS#^/;2*S
MO;UX'-K!-]GB91DRR9Q@#ZXIW ["BN<\.>+8->N)K1[::UO(0&:&5=IVGH?T
MJ/Q%XQ@T.]CL8[::[O'4N8HER0H&23^% '3T5RY\>:.GAP:S)(R1'<NQA\V\
M=5Q]:>OC734\-)K=RQAA<$JIZFBX'2T5RZ>-[ ^%/[?D218&?8BX^9B3@#'O
M5.Q\?)>K=1?8)H;R&'SQ#*I7<F"<C\!1<#M**S]%U:#6M*AOK<_+(.1_=/<5
MH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,EEC@B:65P
MD:#+,3P!0 ^BN(D^+7@^.^^R'4@6SC>,;?SS75G5K :9_:1NH_L>W?YV[Y<?
M6@"Y17'Z;\3_  IJNI"PMM17SF.%W8 8^QS70:QK6GZ#8M>:E<I!"O=CU^E
M&A17,>'_ (@>'/$UT;;3KX-..B/@$_3FKGB'Q;HWA>%9-5NUAW_=7(W'\* -
MNBL/P[XNT7Q3"TFE7:R[/O(<;A]16Y0 45@^+/%=CX0TH:A?B0Q%MOR+DU;T
M#7;/Q'H\.IV)8P2C(W#!H TZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M!PNE_"?PUI&I0WUK XFB.5)<_P"-7?$WPZT'Q1=+=W<)2Y'!EC)!(_ UUM%
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MCP9I)T3PI863#YTCRWU)S_6MZDZ<#H*6@ HHHH **** "BBB@ HHHH ****
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M_A?<R^1%M^Q!L;!C.P<UZE7F<?\ R7Z;_KQ'_H H ],Z4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?#'_ )*]XK_ZZ?\ LS5[C0 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0#NQ72>"O!NI>/\ 6VUG6'D^QA]S,_\ 'ST'M7>:?:06'QS:UMHQ'#'IX55
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M-?V=!N(/R(/QR*[[1/A[IND^"9/#AQ)'*"97]6(Z_I7"CX->(/LZZ,WB-6T
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MTA-.O(=L<7^J9.L9]J /+/B]-'J7C/P]:VLBRR>:KX0YXI'9=,_:'1[E@B3
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M  K6^#W_ "3G3_\ =_H* .]HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI=>6^%/#'B&P\06]Q>^,8[^!2=UN),[N/K7J5 !1110 4444 %%%% !1110
M4444 %-?_5M]#3J:_P#JV^AH \0^&/\ R5[Q7_UT_P#9FKW&O#OAC_R5[Q7_
M -=/_9FKW&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***BN(WEMI(XWV.RD*_]T^M $M%>->'(/%$WQ(O
M-,N/$LTMO9E9&0EL.#SCK7LM !1110 5Y'X]U2TT;XH:+?WL@C@BMI6)]?N\
M5V/BGXA:#X3@9KRZ62;^&&,Y)/X=*^9_&GBB]^(OBE)8K>18S\D$6-V!T)XH
M W+N;5_C'X[$4>Y;"-B%_NH@/7ZD5])^'M!LO#>CP:=8QJD<:C.!]X]S6'\.
M_!MGX0\.010KFXG19)I".22,X_#-=A0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %>4_%RUEOK[1[2YNC;Z7-+ME;/0X/\ ]:O5J\_^).DZ
M#JB6J:UJ+VJ@_*%/WJ .:3X2^%3&I77.,<?Z0M>G>&M*MM&T*VL;.?SH8EPK
M[MV?QKQ<>$_ 8&!XAE '^T?\*]B\(6MC9^&K2#3K@SVRH DA/44 ;M%%% !1
M110 4444 %%%% !1110 4444 >6?'G_D11_UT_PK6^#W_).=/_W?Z"LGX\_\
MB*/^NG^%:WP>_P"2<Z?_ +O]!0!WM%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '">*?B?
M8^%-6^P76G74A(&V1!\K$]AQ75:)JRZUI45\L$D D_@D'(KS'XQ:UIR7NBVK
MW"B:"\BDD7^ZN]3G\J[+7O'FD:%X;74EG67>N(57JQH L>,?&5CX1TI[B=PU
MPPQ%$#R37AFC:/K7Q3\3M>WSN+16R[MT5<_='X4W2],UOXJ^*&NKIF%JK99S
M]U5ST'OBO=H4TKP;HT=E:(JA%X4=6/J:B<XP5Y%QBY.R+EG::9X5T=+:W5(8
M8AT'5CZUS%[J=[K]U]GM580D]/ZFF(FH>)KW+$K"#^ %=GINE6^FPA(E^;'+
M=S7GMU,4[+2)UVAAUKK(IZ-X?@TY!(X#S$<MZ5MT45WTZ<:<>6)R3G*;O(9+
M)Y4+R8)V@G [UXC#XKE/Q@?6/[%OA;.GV4'8>N-N>G2O<:3 ]*T($1M\:OC&
MX X-.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #R*
M:J*@PH 'M3J*+ %%%% !1110 4444 -5%4DJH!/6G4446L V1=\;(3C<",UY
M9??"C3;N_GN'UIE:1RQ7S>E=]J_B+2M*8V]]>)!(Z\ GU[UX_?:%8W=]-<)X
MY\M9'+!,GC]: +.D>'K3PA\3-/@;4&NHYE/E;7SM;!Z^M>W5X]X+\,Z%;^)X
M+N;Q -3O5_U*D]\'U->PT %%%% !7,>,/&^F>$+!Y+J3=<E3Y4*\ECVKIZYG
MQ'X4T?4GN-6O+59KJ*V=4W\J,*>U &%\*_&NH^,]/O+K4%C79(0BHN,"L;Q)
M\0_$=[XMN/#_ (0MH9);0$SR3 $9&<CJ/2JWP)_Y FJX_P">KX_2L_X8<_%O
MQ:9/O[SU_P!XT =E\/OB%-XA@O[/5X5AU/3@3<!> 0/3\C7)W/Q*\9:W>ZC<
M^&;*W;2[ G>TB@EP#R1R*S_"^\?$KQUY6/\ 52Y_\>K0^"X7_A7FM%L9_?9_
M[YH [/0?B19ZIX E\13)L:W!66/_ &P/\37!_P#"S_'(TY?$[V%N- ,NTKM&
M\#(]_?TKEM'\T?!_Q'Y?W//'_H8KLY=G_#.@W=/+3^8H ]=T+6(->T6UU.WX
MCN(PX![9[5??_5M]#7"_!XN?AU8[\]3CZ8%:.N_$3PWH%\^GZC>F*X";BHC)
MX- 'G/PQ_P"2O>*_^NG_ +,U>XUX-\([V#4?BCXFO+9MT$QWHV,9!9J]YH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#S+PU_R6#7_ /KE'_Z":]-KR?2M3LM*^*OB*ZO;F*&%(8R2
MS ?PGI6%XO\ CJ9':P\+6[RRG*^<R$Y^B]: /7->\4Z1X;M&N-2O(XPHSLSE
MC^'6O#O%'QGUGQ'<'3?"EK+%&YV^8%+.?<8Z52T+X8>*O'=VNI^(KJ2*W8Y_
M>DEB/0#.17N7AGP+H7A6!4T^S7S0.9G +D_6@#R#PK\$]2UJY74_%=RX#G<8
MMV7;\:Z*^\/Z9X?^*GAVSTVTCAB$$F< 9;[O)KV*O,/%'_)8O#W_ %PD_P#9
M: /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/%F
MB>&]6\G^WG1=A^3=(%_G6[J5_#I>GS7MQGRH5W-@9->.>*_&/@'Q@(1J4UZO
MDG*^6K#^E %GQ)X0\ 0:'<S6MU&LZ+E-LRGGZ"NW^&US%<^"-/:*$1 1@$ <
M&O&XXOA7'(KF;4G .<'=S^E>[>$Y],N/#EG)I"%+'8/*!&#B@#;HHHH *KWU
M[%IUC-=SDB.)=S8%6*CG@BN86AF0/&PPRL,@T ?/GB'XI:OK?BO34TL7-CIA
MG"JQROG>_;BO5/B5XKE\)^%FN;;'VN8^7"3T!XK@/BS:P67BKPW;VT210I*N
MU$& .M:OQ[C=O#VE2#.Q+K+>W H Y:;5/'7A&RTGQ+?:R;NUOG&^V8'" _C7
M7_$?Q_>VVEZ3:Z$WEW6J$8D/5%/0UD?$V6-_A3H(5@?,*[,'KTKG/$\4EM?^
M"'G!51!$I)]>:8C=M]:\6?#[QCI^GZ]JO]HV=[@,S Y4G/ R36GX\\4:]JGC
MJU\'^'KO[&[#,DXSD'GT(]*S_C.1-XN\/11G,GG*<#TS3(O]'_:+_?'&_<5)
M[\-2&:7@?Q-KVC>.Y_"'B"]^VDC]S.<Y/7GDGTKV*O"+Y6N/VC+7R>=BD-CM
MPU>R:_K,/A_1;C4YT9XX "57J><4 >?_ !Y_Y$4?]=/\*UO@]_R3G3_]W^@K
MROXE_%72_%_AK^S[6UFCDW9R_3M[5ZI\'3GX=6'L,?H* .]HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HI&=44L[!5'4DX KS#QQ\7++11)8Z3BYONF\<JO\ C0!SWQT;0[&X
MTZYDM89+\RJT@VC+HI'!]L5QFA:/J7Q)UQ!''Y&FQ'HHPD:^@]\5CZSIOB#Q
M+=6>J:P\BQ7<ZPK)+D8RP' /;FO;M*2'PKH,6AZ45DD'WYD7[Q-8UJ\:4;LU
MI4I5'9&VLFF^#])33-*B7>HP2.Y]3573=&N]:N?M5ZS"/.>>]7-$\-/*XN[_
M ))Y"G^M=>B+&H50 !P *XX4IXB7/5T78Z95(45RT]^Y%;6L5I$(H4"J/2IZ
M**]%)15D<3;;NPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F_$/@;0_$]TESJ<
M,CR(NT%7QQ7FGB33/AEX:NS:7$=S)<#[R1N3CZD"O:KK?]CF\O[_ );;?KBO
M%? <7AZ75=6_X2;R#JOGMN^U8VX]MW?K0!N^ -.\!W^H)?Z$)5O;?D)*^",\
M=".:]2KQ/9I:?%^P7PQM"[3]H$/^KZ'TXKVR@ HHHH *@OH6N-/N84^_)$R+
M]2"*GHH \]^%O@[4_"5A>0ZF(PTTI9=C \?A6%K_ ( \4:5XRNO$'A"2 M>
M^;'*0 "<\\GWKU^B@#SCX??#Z[T--2O];D234]2!6;:<@ __ *S7*O\ #SQQ
MX>N=2LO#4ULVEWQ(/F$ HI],FO<:* //= ^&<&G?#R?P[<N'FN07E<?WN/ZB
MN'/PY^(#:.OA5[BU.AB7<9=PWE<CWSVKWJB@#,\/:-#X?T*TTR$Y6WC";O4@
M=:S=9\">'M;O'OK^P26X*X+''05TM-?_ %;?0T >%?":T@L?BGXGM;9-D,3;
M47T 9J]WKP[X8_\ )7O%?_73_P!F:O<: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 1@2I ."1UKQTV_BQOBD=%'B+%O\
M\?&/+.-OWMO7TXKV.O-Q_P EW;_KQ_\ 9* /1D!5%#') P3ZTZBN-\7_ !*T
M'PC PN+A9KK^&&([CGWQTH Z^66.&,R2NJ(.K,< 5Y7XV^->EZ&9+/2!]MO1
MQE?NJ?Y&O-M1\5>-/BEJ'V/2XI8+)FP%CRJ@?[3=*]$\$_!'3M&,=[K9%Y>
M[MA^XI]QWH \4TO1M?\ '_BF4,)%DGD#3LP("J3Z>F*^C?"'PK\/^%8DD%NM
MS> <RRC//L#TK)\*QQP_%S78XHUCC6&(!4& /E->H4 (    , 4M%% !7C?B
MGQ'I2_%W1I#=J%MXY$E/]UB5P/TKV2L6;PEH%Q<M<3:19O,QW%VA4DG\J -B
M.198DD0Y5U#*?4&G4U$6.-40!54  #L*=0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9X,$UEIUM!+OQNCC /:NJ^#W_).=/^G]!63\>?\ D11_UT_PK6^#W_).=/\
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M2O>*_P#KI_[,U>XT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)SI_^[_05D_'G_D11_UT_P *UO@]_P DYT__ '?Z"@#O:*** "BBB@ HHHH
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M&_MHM1-M]H<XA$H!.?;-:U>5?%RWO1=Z7>Z;I\US=029#1J6 &#U% 'J@
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M)^S/#'G YQR!]* &>%/'$>I0:WI=[H]OIFL6UNX80QA=V ?8>]9'PAL+;4/
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M'=NL)RQ! 7C->P-XS7/R0 _4U$\13ANRH4)RV1UM%<B?%ETPS%9J?^!&HO\
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MU76_"$FGZ3")99F 8$XXR#7<5RGC_3=;U'0/^)!<F&\A;>%_O^U 'D\C^/\
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MK^C7&F7#LD4XP67J.<T >6?&S7](U'P6(K+4;:>3?]V.0$]JZCX/?\DZT_\
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M.?#1-*C\(VXTF[DN8>K,[EB&[CDFNRJM96%KIT'DVD$<,><[44 59H ****
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M:]M?B[]MMK6,L0MN%)Z@_+7O\6@:;;C*P#CN37E33^%V^-WSS69B$(4$GCS
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M)SI_^[_05@?'R^M8_",=H\RB>1\HA/)Z5L?!>]MKGX?VD4,JN\7RNH/W3@4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR.15J@#SKPW\)[/P[KEOJ<>HW4SPDD(Y&#D8]*]%HHH **** "BBB@ HHHH
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M'M[U]-5RFH^$M$U'Q3#K\]P!>0@  .N./_U4 <#_ ,*M\>?]#D/U_P#B:/\
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M_;:K(>%Y YX]Z[!/AAX\>-7'C$?, >__ ,37H'B3PAHGB+6+"_OY]MQ8MNB
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MX;@9_"NU_P"%->)/^AJ?\S_A7H/B+PSX?O-9M=9U618YX2!&S' )'2NJ1U=
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MGVAF.>A->EZK)9#3YHK^9(H)5*,6..#6/X/T/0M$LYTT.5)(IGWN5(///^-
M'2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+PA>74EQ%$"\+2')4#M^M=1\0/%6MZ=<0:+H&G23WMW&Q$X^[$!QGKUYKB/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3;'XZS)X@B3[)*F^,RCY2QP16GI:V4'QWV>&PHLS!^]$/W.@S_6F![O1112
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .2\2_#GP[XJNENM0M?\ 2 ,&1,!B
M/>M;P]X:TOPQIXL]+MUACSDX'+'U-:]% !1110 4444 %%%% &+XA\+:9XGB
MMX]2B\Q;>3S(_8_Y%:T$"6UO'#&,(B[5'M4E% !1110 4444 %%%% '+>(_
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MXUT=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %07MN+NQGMFZ2QLA_$8J>B@#PSP-\)-7T7X@/JNHQ1BQ1Y#
M%AP2<GY>*V/B_P##C4_&%S976D1HTT8*R;F"\<8ZUZW10!Q-KX&4_#5?#4^$
MD,7)'028Z_G7GMEX=^(>AZ:?#]GI]E(@<^5>';D*3]:]XHH \S\0?#S4M=\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gvndnkt0ksj3000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvndnkt0ksj3000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ":!E # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*6H;6YCNX%FB.5;I4U<!Z(4V3_5M]#3J;)_JV^AH ^=M3_Y'^#_KXKZ"L/\
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M&54FO0*X'XG720:2 Q^\IQ54OC1-:W(SPKPLS1^(%V]<_P!:^I]*).E6Q/\
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M3_.OJK4?^0=<?]<S7RKXO_Y#$GU/\Z[,)NSBQG0]U^&/_('3_<KOJX'X8_\
M('3_ '*[ZN>K\;.BC\""BBBLS4*@O?\ CQG_ .N;?RJ>H+W_ (\9_P#KFW\J
M:W$]CY4\7?\ (:D_WF_G7L_PI_X\!_N5XQXN_P"0U)_O-_.O9_A3_P > _W*
M[Z_\(\W#_P 4]*J.XA%Q;20M]UQ@U+17GGIF1I>A6^F-NB10?45KT44VV]Q)
M):(*;)]PTZFR?<-(9\S_ !(_Y&.X_P!^N^^$'_(._P"!_P"-<#\2/^1CN/\
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MFB?\A2V_ZZ+_ #KT,-_#9YF+_B(^LM+_ .0=!_US7^57*IZ7_P @Z#_KFO\
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M[36E*+E)6,JTU&#N>.0'.KJ1_?'\Z^HO"W_(&M_^N8KYIT+0[_4+^-E@D W
M[L>]?3GA^V>UTN&-\Y" &NG%-62.3!IW;-:BBBN(] K:C_R#KC_KF:^5?%__
M "&)/J?YU]4:DP73;@DX_=FOE7Q7(LFK2%3GYC_.NS";LX<9T/=_AC_R!T_W
M*[ZO/_A@ZMI* $9"5Z!7/5^-G31^!!11169J%5[W_CPG_P"N;?RJQ5>^_P"/
M&?\ ZYM_*FMQ/8^5?%O_ "&I/]YOYU[/\*?^/ ?[E>+^+<?VS)@_Q-_.O:/A
M0P-B #SLKOK_ ,,\W#_Q3TNBBBO//3"BBB@ ILGW#3J9)@1G)P* /FCXD?\
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MDN.M=3VS7/Z5X5M=*D+PJ@SZ"M_M7'/EO[IVPYK>\+1114EA2, 5(/0\4M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>genzerafbudl000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B Q$# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&E
MI* (IIT@C+NP 'J:QKKQ1;0*PP2>Q%9/B^]=;U+16(5U[&L62UMOLZ!Y6W?6
M@""^N_[=U5>#@C'-.B\O0KE7V_>/.*GM;,1?/!\S#I4VH6275MF0D,!VH Z:
MS\46TT2G!K<@N(YT#(P.?>O*-."0O]G9SM]<UU/ABZE\Z5"25S@9- '9T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<&EU1HK>U+\'>/RK(T>64ILD^YFF:X\I557[M &=9MON?,*Y%=#X>9UO2,$
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M* %HI,T4 +1129H 6BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M .KTGQC#/A9BJ$^M=3;WD%RN8Y V?2O%)+3:VZ,;6]ZN:?KM_ILP!D.T>@H
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MGRJ< UFS7;RD2(?E P:TM'B^^Y[\T#-<4M(*6@04444 %%%% !1110 4444
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MF%1WQS5BEH 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKY $<J?:@"729(VMQM/-:(KF]-TBXL2"9V8>E=$F0@SUH ?129I: $-+110
M4444 )BEHHH 0U#/;K*O(YJ>B@#"DM7B)&.M.O=-^U:>%QR!6R45NH!I=HVX
MQQ0!X]J>F&VD97&!FJFFWTNE7BLIPA:O2M?T5;F!G4 -[5YQ?VC0NR%3QT-
MSUC2-3CU&T616R:TJ\D\+ZR^GWB0RL=GO7JMM.MQ"LBD$$9H$34E&:6@!.U4
M)]*@GN5F<'<*OL0!DG%1&XA_YZ"@""'3H83(4S\XP:B71X%MFA .UCDU>26-
MONL#4E &?)I4$L*QL#A1@52_X1NU/7=6Y10!CS:%;RJB\X6I8M$MHT"@'BM.
MB@#.DTBW=<$&HH- MHG+_,2?6M:EH IQZ=#%*)%SD4V#3TANI)@.7ZU>HS0
M=J*3-&: %HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1
MS8\IJDID@RA% '/607^U9C[54O?,N/$<$1/[HCD?E6K;V3I?R2$$9%1-8/\
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MZ /:86#0(1W44^J.E7(N+&-AV4#]*O"@ S2T44 %%%% !1110 4444 %%%%
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M*-S[5B>$](:^O6G=>%;/(K-;S-<U/:N6R?6O4]!TM-.LU 'S,O/%,#4BC6)
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MRYV#I7H5I>17<8>-A@CUH&6:***!!1110 4444 %%%% !1110 4444 %%%%
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MI:PI=>C6V,BD_+UJ"+Q!S&SYVN<"@#I**9&X= P[BGT %%%% !1110 4444
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MTS6-<>/+>,$",D^U ':]JK3WMO;C,CXQ7FUWXWGG)$(=:R)=4U*]R"[D'VH
M]&O_ !99VR_NI0S5Q^I>,KFZ<I$!@^E9EOH=[>,"Q;GU%=/IG@P(RF4 T#.1
M6#4-5FRV_&?6NLT7P@/E:<'/O7766BVUJO$8S6BJ*HX&*!%*RTV&T3"H./:K
M_2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJVX9KFM9U!;BTMI(7/S2#I]171P?ZB,G^Z/Y4 24444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %*ZOOLW)3-4EU]7?:L>:OWUO'+;R;AVK TJSB^T=* .EBE61%;I
MD=*>6 Y)XKE8+R[GO)8H6^6-L5/<SWT>0S#:*8'1Y!'!HW =37)6>N3M!-N;
MYE.!3DOM0F42!AMZT@.LH# \ UR\NMS"U9E/*\4ZPO;R5#*7&W&30!TI8+U-
M58[^.25H\C(-8CWUY>R?Z.P\L<&L>*XN(;Y]QY#<T =]VHR,=:R5U!_[.\W/
MS5G'69G)CC;YCQ0!TVY<9S57[?&20""16)'+J*[O,8;<5FPO<1&1R>] ':QR
M>8N<8IX8'H:Y=M8E6VC6,_O"<&G&]O;2=#,?E(S0!TVX>M ((X-<@NJ7MS<N
M(&X%7=/U&Y_M);68]: .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (
M;GFWD ]*Q=+C=9R2I'6MXC((--6%%Y44 <YI4,B75\2G5N/TJG<)/]N<N6"X
MZ&NN2"-&+*.3UIDME!,VYUR: .+M+>7;-^Z/)K:@@<6 &S!QTK;2TA085:?Y
M2 8 H Y-8Y([64&#.3UJI%!<<^66^;C:.U=J;>,H5V\'K38[*"([D7!I@<Q9
MO-IWRM$3DYR:H^3/<W,DHB( .:[:6UAF/SKFB.TAC!"K@&D!RLEW,NF^0(OF
MS4,-I*I6?8>.2*ZTZ?;[MQ2I!;1A"NW@T#.>%]-<DQ+!T[U4D618W7R^3751
M6<,#;HUP:&LX7.67F@1R'V.:.*.4(3SDBKES*]](BK'T7!Q73>1'LV8^6F16
M4$+91<'K0!S.D6DD=Y-O0BK,<+_\)%&^S"@=:Z 0(K%@.3UH$*>9OQ\U $M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>genzerafbudl000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &*!$P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W[-&:#4,C
MB-"Y/2@":HGN(H!F615^M<1K?C.YAF:VL;2620'&Y*P)=/\ %>NO\UW)"C=F
M% 'I,VOZ9#]Z\B_[ZJ%?$VE/R+R+_OJN B^&6H2C-S?H^>N14@^%TR_ZN[1?
MPH ]'CU2SG \JYC;/H:M!QMR#FO)V\$>(-.??:ZEP.<!:L6WB+Q!H<H2]MY[
MF,<9 H ]2SFEK(T76DU:#S!&8V'4&M>@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,TM)0
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M M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML%WL' 60C]:!'M8&!124M !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$BG(W"O0*6@"&"".WC$<:A5'0"N5^(1/_"-3@=?6NPKD/B%_R+D] %/X=?\
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MI&"#5*TT6RL23;PJASG(K2HH 0# I:** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M17R]XCUNZOM6D=KAW5'RF37M'P=U.[N["-9I689[F@1Z]RN !3J** "BDI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BDI:
M"BBB@ I*#2,VU=WIUH 7-&:Y+7_'>G:,QB$J/-CA#7,-X]UNZ/F6VF;H^H(/
M6@#U0L :,UY?:_$N:VF$>IVBP>I)KT+3-5MM4M5FMW# C)QVH OT4W<,9I<T
M +129%&: %HI,T%L"@!:*I:CJ,6G6CSRD!5&>:S]#\26^N(&@*D'N* -VBDS
MBC.>E "T4E&10 M)FBLC7]7&D6,EP0#M7.#0!L45S/A3Q,OB"S28 #<.@-=-
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGIBM7325S5T[*YV2L'%/Z"HUP  *?M]ZP=KF+' TM(*6@D**** "DHR,XH-
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MM%G_ '15Q8PN  % Z 4 2=Z6DI: "BBB@ HHHH **** "BBB@ HHHH ****
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M@/GH!67X86QCN2\Y^8-QQ6O-[IKS+ET.X\/V2P:;%N0!L<G%7-1T];^!HR2
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MD5U3BE"]C.,M3ID^Z#3J0=*6N,U"BBB@ HHHH **** $I:** "BBB@ HHHH
M**** "BBB@ I*6B@ HHHH ,4444 %%%% !1110 4444 %%%% !1110 4444
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MS@G<AR/GKT&UA^SVZQ^E $]-QS3J* &XYS2[0*6B@!*0@FG44 ,VD-FG4M%
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ I*6DH :PR*X'Q]X?OM:1H[>0*I7'(K
MOVSVKB?&$^NQD_V6[+QV7- ' 6/@KQ/8#]S>J%]-I_QJ\= \6Y_X_A_WR?\
M&D6^\>'_ )>)/^^#_C4<NI>/8\GSI3CT0_XT :.GZ)XH2^A:6\!0'YAM/^->
MIV*R+;*LK9?O7B6C>,?%,FL1VUY<.JE\$,N,U[98LSVRO(<L>IH M9I:0"EH
M **** "BBB@ HHI*  UQ_P 03_Q3DXKL#7'^/QN\/3A!EJ:0T5?AX,6LF/[M
M=KDG@FO%?#WBNXT5O+,,A#\9%>G:5XAM;VS626548]F-)Z"NC>#>]!)'/45F
M2:SIZ1DBXC)'^U7%:GX^EMKYX8$=D7H10',CT<L.M9.I:Y::<C&21=V.%SS7
MF]U\1[YQY<44JL>AQ5"UCN=:NC-?98 Y -4K7U&FC3UO6[C6681PR>6>.E<]
MY$H.TH03VQ747ER]E9%;2V=<=\5QLVM7;W!Y8.#QQ7=1C=:%/$\NAWG@R%H[
ME0\3 XZD5Z0",+7E7AN[UJZ"L'8 CKBNF:?6(5^>1F^@KBQ%TS.56^IUY=<G
M)XI$D5^58&N!O-=U&WB^<OSQTJ'2?$TT3;9-S9.:Y55,'B%>QZ/CWI<<YKGX
M?$4+@;P0?<UIQ:I;R])%'XU:DF:QFF71D'DTA8YXJJ^H0#JX_.JUQK-M$F=X
M)],TW-%<Z-0L .N*I3WT-ODNX_.L"YUN>X.RW1^>]01:/>WS;[J3*'L14\S9
MFY]A=:\1VYC94&[Z&N(DN//NMW0$]Z[BY\(Q.O[H!35$^"G)^^OY5RSIR;.2
MK3G*5Q-*TI+P*QD4FM>7PW"(2Q7) XJ?1=".G$%B#CTKH O%;0IV1T0INUCR
MG5+"XCE(BA?'TINF)?6MVC)$X&>>*]2DM4<Y9<TU;.)#]T4O8:W,_JSYKW(M
M.FDDMU,H.X]:OC%,"A!P.*2241IO/05O!-:'7%60\Y% )Z5C2^)[&.0QM(H8
M<'FG#Q%8"/?YZ'VS6WLY6#G1L$9&?2HI)XT7YV"^YKDK[QJ,F.TA=VZ96LQ8
M]?UM^9FBB/9A3C3[A<U?$U]I<UG)&[)*Y' 4UY/%8K=ZJ8HUVQE@ #78:SX4
MN;/#QJ9)",Y4=ZP8=+U:"?SDAD#YSG;792:C'1F4TVST?P]X4L[&-)"@+X!S
M75(H4!0, =*Y/PI=:I,%6]#\'&2*[#'-<E63;-8*R H">@I#&N>@J0#UI"*R
M'H)M IU '-+2 3 HH-+3L 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1R
M.(T+'H* 'MGL:@ENX(/];(J_4UC+XML7OWLPP\Q3@C-9OBC0=1UA=UG="%2O
M3% '2_VI8GI=1?G0VJZ?@YNHNGK7EG_"O_$7;5 /^ TO_"O/$!X;5%/_  &@
M"GXRO[/_ (22R.G2(S[_ )MASSS7J_A^2671XGFSO/7-<+H7PN2QO%N[R6.:
M4-N!Q7I5O$L,011@"@"2EI*6@ HHHH 0^](6Q0?>N>\2^)+?0;8N_P SXRJ@
M\F@#HL\4@.>U>0CQ_KE\/.M;*Y$748%:WA[XBM=WJ6=_"\$K' \P]: /2#TY
MKA?'5W+!9R* 2F.U=J'6:,.IR#WKE?'2I'H4TC+N(JZ;7-J#V/)?[2RV"#6C
M;P37,>Z*4*#1X=\+RZW<R-]U0<\BN[@\!30*%CND4>F*ZZGLK&7)(X9M.ND^
M9IP0.M9\]Z()"I!)'>O3CX'N6&&NT(/M6%JWP[F1?,BE5F)["HA[,F49'(65
M_%+=IO0X]Z[.#5;.&%5BT^25_5:E\/\ P_C \R]"M@]"*[>TT+3[, 0P!32G
M*FMAQ@SS35M9OMI BDAB]&%<<S%[DR$\DYS7O6H:#::C&8YHPP/K61_P@>DG
MI;H*NG7C% Z;.)T+6M1M]L=NS.!V6NHC\831$)=:?.2?XC70:;X9L-,?=# %
M;U%7I].MKD8EC#5E4J1DRE!I'F_B'Q#!<1Y1"O/W2:S-!OH+S4$C*8R>IKN=
M7\&Z=<Q,8K=5D/>N?TWP%=1EI$G6-@QQD4*%)Q(]FKG5)HEE/&-NW=W-5+O0
M'@B)MY IJB^E:[8_ZN[+@>@JO-J6N0J5>*9_H*Q=&,G9!*.FACW^HW-O,(VF
MZ'!K=T*R34U621@V:\ZU<:BUVSS!P6;(!%=3X9U6[TVR0F"1R/2F\&HJ]S&,
M9<VIZ=:Z;!;* B 5=P%7IFN''B^\/ LIJ:WBW4<X6RGQ0J5MCL25CMI)D12S
MD(H[FJ?]M:<K[3=19],UQ=_KFIW]HT7V.;GVK@VM=0>_.(W!W=,5K"BFM27-
MH]]AN([E-T3 KZBI!P>E>::9JFKZ?:"%;:;\!5S_ (276LX^RSG\*S=.S'S'
M;W.HVMK_ *Z9$^IJ"+6=/F;"7$9/UKRWQ(^J:C#N>WE3G.2*S]!TC5+N3=$[
M)M.,XK:-&/+JQ<Y[)/JEG;C+W,?TS6!J?B^T6)HXXC,?]@U0M_!=S<X:]N5D
M![$5NV7A+3+3!\A2P[UG:$2KW1Y'J4%Y>7YDCMY(Q*W&176Z#X)GEB62Z<%3
MU4BN_?1[1RF8A\G2KR1B-=J]*J5;2R(4=3&L?#>G6(!2$;NYK85%1<**=M&>
ME*%P<U@VV:#"@Z$=:9]F3.<"I\"DP<]:%)@,"!!\O IPIQ&:,5+NP%HHHI@%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H+#\J8CO?[1L_\ GX3\Z/[1L_\ GX3\ZX%? FL#_F+#\J/^$$UG/_(6'Y4
M=]_:-G_S\)^=']HV?_/PGYUP7_""ZQG_ )"P_*@^!-9_Z"P_*@#O?[2L_P#G
MX3\Z3^T;/_GY3\ZX,> ]8Q_R%AGZ50UCPCK&GZ=-<#5,E%SP* /2_P"T;3/_
M !\)^=+_ &E9_P#/PGYUXSX6TG6]:(+:F1D9Y%=0/ NL'_F*C\J .^_M&S_Y
M^$_.C^T;3_GX3\ZX+_A!-8_Z"P_*E_X0;6/^@L/RH [K^T;3/-RGYU+'=0RG
M$<BM]*\]_P"$&UC/_(4_2M_0/#]_IDX>XO?-4=L4 =32T@I: "BBB@ HHHH
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M\-:<EPD*[Y6"+ZFO)_A]XBO1J%SI]U(SB%M@)_"G_$#Q#>3:DVD6,K*V1RM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $-5;^U-Y;-#NVAN]6Z2@#S&Y^$EO<7\ET+W:S'/W?_K5FZ_X%_LBQ:9M
M6.%]O_K5Z\2%!8]J\-^,7B@QS/I\,F RYR#0!V_@WPVMM"MRM_YV\9QCI71Z
MYX=L]<MS%/&I)[D5YM\)/%'VB%K:63<0 !DU[!@[LTP/-9/A6ZR%8=29(F/*
M@<?RKH?#_@>ST*3S?EEE(P6QS76=J!2 0#   Z4ZBB@ HHHH *CEC612C+E3
MUJ2DQ0!P^M_#JSU*X:X@98)6.2RCFLN+X72/(/M.I-+&/X6'_P!:O3,4M &-
MHWAZST:$)!&H8#!8#K2:UX>LM;M6BN(U;/<BMFDQVH \QG^%SQ%C#JC1PGJH
M' 'Y51T&+2M!\3-9,T<TRC_6'J:[_P 4ZHFE:/<.SX.S(KY?N/$TK^)C?!SR
MPYS[T ?7<)5X49?ND<5)7+^"=>CUK2$96!** :Z?- "T444 )1BEHH ;CG-8
M/B'PU%KZXDDV\8Z5T%(1QQ0!EZ+H\>C6,=LC;M@QFF:WH%IKEJT4Z*2W&XBM
M<9V\T"@#S&3X5.DA^SZFT<;?PJ/_ *U;N@> K319%F<K/,/XR.:[&C% #44!
M0 , 4^BB@ HHI!0 =ZY'7/%UKIUY%:R%3YC;2":Z+5+U+"R>=B!MKY:\9>)9
M;WQ&TBN0(9<C!H ]YU'P1IWB)/M<6R&1OXP*RD^%TY?;+JC/$/X".,?E5CX8
M^*$U71XX9''F^A/->B >] &%H7A:RT.-1#&F\#&X"K.LZ%::U;M%<1J<C&2*
MU:*!GF4WPK99/]&U%HHR?N*./Y5MZ%X L](F6=V6:5?XB.:[+%&*!"(H1 H&
M *=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %(3S2TG?- &9KEQ+!ILQA3<Y0XQ7RUXML=:O-2DN+JVDV@D9
M-?6SQI(,.H(]Z\Z^(MG FF2E(54^HH \=\$V6N:;JD$L5I)Y3."2/2OIW3IG
MGLT>1=K8Z5SW@ZRM6TB!C"A8)UQ75HH5<!<>U #Z*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&>.-*NM4L)(K
M:,NQZ8KLZ8P'I0!B^%[&6QTR**52KA,$&MRD7I3J "BBB@ HHHH **** "BB
MB@ HHHH **** &2H)8V0]",5S2^#;)-8;4 !YI]JZBD[T -1=B*H[#%.%+10
M 4444 %%%% !1110 4444 %%%% !1110 E+110 U@<<54GTRUNBK3P(Y'(W#
MI5VB@"&&W2!-L:A5]!4HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>genzerafbudl000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0<!YX# 2(  A$! Q$!_\0
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MJ:C<7T,=FXRLS'Y356T\6^'[^UENK75;:6"(9D=6X4>]'6P=+E/_ (6K8_\
M0!UW_P  S2/\6-/C1G?0M<55&23:' %7K+Q9H&I7HL[/5;>:Y/2-&YJWK/\
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MKO\ X!FC_A:MC_T ==_\ S7344 <S_PM6Q_Z .N_^ 9H_P"%JV/_ $ ==_\
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M:A'Q@TEKMK0:/K1N%7>T?V4[@OKBNLKB;3_DL6H_]@N+_P!"H$:'_"U;'_H
MZ[_X!FC_ (6K8_\ 0!UW_P  S734C'"$^@H8['-?\+5L?^@#KO\ X!FC_A:M
MC_T ==_\ S53P]XHO]1\3ZGIMU&@AMY"(F5<<#U]Z30O%%_JGC"_TZ2.-;.!
M?D.WYBV<=::5[>:N)Z)OL7/^%JV/_0!UW_P#-'_"U;'_ * .N_\ @&:KZQKF
ML76LMI'A]85N(E#2S7"[D /3I2V.M:W!:7T.K01_:[925FC7$<G&>!UJ4]+C
MMK8G_P"%JV/_ $ ==_\  ,T?\+5L?^@#KO\ X!FM'PYJ,VK>'[*^G"B6:,,P
M4<9K5JI)Q=F):JYS/_"U;'_H Z[_ . 9J&Y^,.DV40EN='UJ&,L%#/:D#)Z"
MNLKB/BG_ ,BI;_\ 82M?_1@I :/_  M6Q_Z .N_^ 9H_X6K8_P#0!UW_ , S
M735B>+-4NM'\.7E]9A#/%&63>,C-)NRN-*[L5/\ A:MC_P! '7?_  #-'_"U
M;'_H Z[_ . 9J!/%%T? [:RT(%R!]S'&:DT77K^]\&?VI=+&+K8S$*,+QG%.
M7NWOT$M4GW'_ /"U;'_H Z[_ . 9H_X6K8_] '7?_ ,UDW_BC6F\+Z1=V/V9
M+V^9%)E0E!GVJ2UUGQ/I6MV=IK[V4\5XXCC-K&5VMUYS3Y7S<OR^X&TE<TO^
M%JV/_0!UW_P#-'_"U;'_ * .N_\ @&:R=8\97^GWNIQ((1':K&REE_O'G-=%
MI/BK1M8E%M9ZE;SW07+1H>1QS26JNOZTN#T=F4_^%JV/_0!UW_P#-1W'Q>TN
MTMWN+C1M:BAC&7=[0@*/>NJKE?B5_P DXU[_ *]3_,4 /3XL:?(BNFA:XRL,
M@BT/(I?^%JV/_0!UW_P#-;.C_P#(#T__ *]H_P#T$5S7B/5_$*^(K/2=#DLX
MVFC=V:Y0L./I2ZI#MI<N?\+5L?\ H Z[_P" 9H_X6K8_] '7?_ ,U5TG6->M
M-=&DZ]]FGDDB,JRVJ%54#CG-=&NKZ>UI-=+=QF" D2R9X4CKFGTN+K8QO^%J
MV/\ T ==_P# ,T?\+5L?^@#KO_@&:BUOQ-/9ZE81631207 8EB,]%R,5/HWB
MBWET"VOM5N8;=Y<]> ><4)75_P"NJ_0'H-_X6K8_] '7?_ ,T?\ "U;'_H Z
M[_X!FMRUU&SO86FMKA)8TX9E/ IUI>VU]&TEK,DJJQ4E3T(ZB@#FY?C!I,,\
M4$NCZTDLQ(C1K4@MCTJ;_A:MC_T ==_\ S6?XJ_Y'[PC_P!=9?\ T&NVH YG
M_A:MC_T ==_\ S1_PM6Q_P"@#KO_ (!FNFHH&<S_ ,+5L?\ H Z[_P" 9H_X
M6K8_] '7?_ ,UTU% ',_\+5L?^@#KO\ X!FC_A:MC_T ==_\ S7344 <S_PM
M6Q_Z .N_^ 9J&Y^,.DV40EN='UF&,L$#/:D D]!765P_Q5./"EL3VU*U_P#1
M@H TO^%JV/\ T ==_P# ,T?\+5L?^@#KO_@&:HW>M^(=7U6XM/#@MH8[5BDL
MMTA92WMBB;Q-JUIX7O;JZM5BOK4$$LOR/CN!Z4+57"VMB]_PM6Q_Z .N_P#@
M&:/^%JV/_0!UW_P#-6-'\7:+JS0VT.I6\MZR M"C<@XYJ74_%>@Z-<K;ZCJE
MO;3-]U)&P30]!+4I?\+5L?\ H Z[_P" 9H_X6K8_] '7?_ ,UJW&NZ7:V$=]
M/?0QVL@RDK'@BF:5XCT?7&==+U""Z*<L(SG% :6N9O\ PM6Q_P"@#KO_ (!F
MC_A:MC_T ==_\ S5V;Q;H%OJ7]G3:K;)>#_EB6^:I[_7])TNQ6]OK^&"V8@"
M5S@&B^EQVUL9L/Q6TN2^M;672]6MC<RB&-Y[8JNX].:[VO)O%NL:?K4'AZXT
MV[BN81JT(WQG(KUFAIK<5T]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9+!U*G(Q,W'ZUU4,*6\"0QC"(-JC/:M)-2;D0DUH25Q'Q3_Y%2W_ .PE:_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU- 8E^ZG^SCTKK-%T^TTWXLWT-G;QPQG2XR51<9.[K4QLX<_<;TERGH%%%%
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M[#O1<:_I%I(T=QJ-M$ZG!5Y "*Y[7F5O&.A,IRI+D$>FVL!=&L;Z_P#%,]U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]0J/_P!"KM5974,K!E/0@Y!KBK7_ )+%?_\ 8+C_ /0J&V%D=M1112&%%%%
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MS--U[PAI?B*XAGO?M"RP@A6@F,9P?7'6N=E\8>+;.R34+[PY:1V)VEGCNMS
M'IQCWKNK6X2ZMHYT^ZZY%-J^KZ"32T74PK'P1HNGVUY!!'-LNP1-NE))R,=:
MQO&&B6F@_"K7;.R,OE"V8CS9"Y'([FN\KE?B5_R3C7O^O4_S%%V%C=T?_D!Z
M?_U[1_\ H(JR88C*)3$AD P'VC(_&JVC_P#(#T__ *]H_P#T$5=I#(;JVBO+
M:2WF7='(-K"N>TWP'HVE7_VR WCR Y"2W#.@^BGBMC6=0.EZ7/>+&)#$A;:3
MC-2:9>'4-,M[LH$,T8?:#TS0M^9 ]K,R]=\'Z5X@=)+L3QNG1K>8Q$_4CK1I
MG@W1])G@FMHY?-@1D5WD+$@]<GO6-=>*_$LVN7=AH^A6MU';*"SR7.P\^U;/
MASQ#+JYGMKVV%KJ%L0LT*G*@GG@]Z(;7CZA+SZ:%E?#>G+!>PA'V7K%YOGZD
MC''I6A:6L5E:16T((CC4*H)SP*FHH XGQ5_R/WA'_KK+_P"@UVU<3XJ_Y'[P
MC_UUE_\ 0:[:@"KJ&GVVIV4EI=)OBD&#ZCZ'L:Y_3/A[H6E7J74(NY70Y5;B
MX:15^@/%5]8\4:[#XA&E:-H]O>-Y9=FEG\O&#5S0/$MY>W\NF:Q8I9:@B[_+
MC?>I4GCYO6B&OO1"6UF:]SH]G=7]M>RHWG6^?+PV ,C'2HH] L(VO65'S>G,
MWS=>,<>E7)[ZTM6"W%U!$3T$D@7/YT]KF!(?.:>-8O[Y<!?SHTL'4S/^$9TW
M['9VGEOY5FP:$;^01TSZU9BT>T@U634D5OM,D8C8EN,#GI4\%]:7.?L]U!+C
MKY<@;'Y4B:C92S>3'>6[RYQL652V?IFG=W%I8LUQ'Q4_Y%6U_P"PE:_^C!7;
MUQ'Q4_Y%6U_["5K_ .C!2&=O5&UTBTL[V:[A5A+,,.2V1ZU>IKN(T+MT R:5
MTM0WT.>U?P1H^MW_ -MNA<I,1@F&8QAA[XZU*GA#2$TR+3UBD^SQ.LBC><Y!
MR.?K6&?&'B*^,MSHNA6]UIT;%?-DGV.2IPWRUM6_B&>^T>"]M;55D=U5X[AO
M*V\X.,]:J*:6F@2WU- Z+9G5/[1*-]H\LQYW<;3[5'!X>TZ"PN;)8B8+AV>1
M6.<D]:L2:KI\+E);^UC<<%6F4$?K3GU*QCC61[VV5&Z,TJ@'\<TNE@6]S%TC
MP/HVBWC75L+EY">//G,@7Z ]/PK6LM(M-/NKJYMU827+!I"6R"0,5;BECGC#
MQ2)(AZ,C BGT]161QGQ Z^'O^PM#7IE>9_$#KX>_["T->F4@"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_)/\:Y3X@^)M5O?#L$5QX1U:R07UNXDF"[20X(7@]3TH&>N45QW_  F.N?\
M0AZ[^2?XT?\ "8ZY_P!"'KOY)_C0 :EX>AU+7)[G2O$$]C>JJ^=#;,OS =-V
M>U4AK6KW$&I:1JD5N+B*-MK6[%LJ%.=WO6+K$5[JU\;Q?!OBBRG8 .UJZ(6Q
MZ\U<T6ZO]$BD5/ WB*Y>7AY;@HS-]3FIM>/*QMZW7D=1X/NK4>"K%FD01Q0
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M[3@\YKF['2?$6KV\6LIHEB;AY@3?OJ.TD!O[O2I@TXI_?][7IT"5TW_71/\
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MW?\ X$I7>44 <'_PF/B[_H0[O_P)2C_A,?%W_0AW?_@2E=Y10!P?_"8^+O\
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M4 <'_P )CXN_Z$.[_P# E*/^$Q\7?]"'=_\ @2E=Y10!P?\ PF/B[_H0[O\
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M]"'=_P#@2E=C?=8/^N@JW0!P?_"8^+O^A#N__ E*/^$Q\7?]"'=_^!*5WE%
M'!_\)CXN_P"A#N__  )2C_A,?%W_ $(=W_X$I7>44 <'_P )CXN_Z$.[_P#
ME*/^$Q\7?]"'=_\ @2E=Y10!P?\ PF/B[_H0[O\ \"4H_P"$Q\7?]"'=_P#@
M2E=Y10!P?_"8^+O^A#N__ E*/^$Q\7?]"'=_^!*5WE% '!_\)CXN_P"A#N__
M  )2C_A,?%W_ $(=W_X$I7>44 <'_P )CXN_Z$.[_P# E*/^$Q\7?]"'=_\
M@2E=Y10!P?\ PF/B[_H0[O\ \"4H_P"$Q\7?]"'=_P#@2E=Y10!P?_"8^+O^
MA#N__ E*/^$Q\7?]"'=_^!*5WE% '!_\)CXN_P"A#N__  )2C_A,?%W_ $(=
MW_X$I7>44 <'_P )CXN_Z$.[_P# E*/^$Q\7?]"'=_\ @2E=Y10!P?\ PF/B
M[_H0[O\ \"4IC^-?%:,BMX$NP7.%_P!)3FN_JG>?\?-I_P!=/Z4 <?\ \)CX
MN_Z$.[_\"4H_X3'Q=_T(=W_X$I7>44 <'_PF/B[_ *$.[_\  E*/^$Q\7?\
M0AW?_@2E=Y10!P?_  F/B[_H0[O_ ,"4H_X3'Q=_T(=W_P"!*5WE% '!_P#"
M8^+O^A#N_P#P)2C_ (3'Q=_T(=W_ .!*5WE% '!_\)CXN_Z$.[_\"4H_X3'Q
M=_T(=W_X$I7>44 <'_PF/B[_ *$.[_\  E*/^$Q\7?\ 0AW?_@2E=Y10!P?_
M  F/B[_H0[O_ ,"4H_X3'Q=_T(=W_P"!*5WE% '!_P#"8^+O^A#N_P#P)2C_
M (3'Q=_T(=W_ .!*5WE% '!_\)CXN_Z$.[_\"4H_X3'Q=_T(=W_X$I7>44 <
M'_PF/B[_ *$.[_\  E*/^$Q\7?\ 0AW?_@2E=Y10!P?_  F/B[_H0[O_ ,"4
MH_X3'Q=_T(=W_P"!*5WE% '!_P#"8^+O^A#N_P#P)2C_ (3'Q=_T(=W_ .!*
M5WE% ' R>-?%D2;G\"78'_7RE._X3'Q=_P!"'=_^!*5V.H_\>A_WA_.K2_='
MTH X3_A,?%W_ $(=W_X$I1_PF/B[_H0[O_P)2N\HH X/_A,?%W_0AW?_ ($I
M1_PF/B[_ *$.[_\  E*[RB@#@_\ A,?%W_0AW?\ X$I1_P )CXN_Z$.[_P#
ME*[RB@#@_P#A,?%W_0AW?_@2E'_"8^+O^A#N_P#P)2N\HH X/_A,?%W_ $(=
MW_X$I1_PF/B[_H0[O_P)2N\HH X/_A,?%W_0AW?_ ($I1_PF/B[_ *$.[_\
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MH **** .#^)O^J\._P#87AI/B)XLU/PDEO<Z9:V]Q),VQQ.Q  QGC%+\3?\
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MO5@_U4R_S^\[C_A='BW_ *!&F?\ ?QJ/^%T>+?\ H$:9_P!_&KAZ*/KU8/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI)_R%(/\
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M %]R_P!*!'J=<'\6/^19T[_L+VG_ *'7>5P?Q8_Y%G3O^PO:?^AT =Y1110
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M+L $&/&XG:,YQS6A9>9J<?B+4I,&%H]L)QSC80?UKIK#P'X=TV]%Y:V 28#
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M )$^V_["=I_Z,%=[7!?%W_D3[;_L)VG_ *,% '>T444 %%%% !1110 4444
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MZM6ZJ0_\A&X_W5JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !523_D*0?]<VJW523_D*0?\ 7-J +=%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5+[K!_UT%6Z
MJ7W6#_KH*MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=W+KFEO'$EI&4Y8 ')Z'UKY=8JO&I4G5MR13Y7HWTUWUN;2K3Y;W:?\ P?\
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MA>&NS7_D(/\ [@KC/B;_ *KP[_V%X:[-?^0@_P#N"D,LT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4A_Y"-Q_NK5N
MJD/_ "$;C_=6K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %5)/\ D*0?]<VJW523_D*0?]<VH MT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4ONL'_705;JI?
M=8/^N@JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !5.\_P"/FT_ZZ?TJY5.\_P"/FT_ZZ?TH N4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>#>'?^3H=7_ZYR_^@K7O->#>
M'?\ DZ'5_P#KG+_Z"M 'O-%%% !6#XN\,0^+=%&FS74UJ%F2=98<;E93D=:W
MJ* . _X5UJO_ $/>N_FG^%'_  KK5?\ H>]=_-/\*[^BLO84OY5]R'=G ?\
M"NM5_P"A[UW\T_PH_P"%=:K_ -#WKOYI_A7?T4>PI?RK[D%V<=X>\!'1/$#:
MS<Z[?ZG=&#R ;K;PN<]JT?$GA*Q\1QH\C-;7D1S#=Q >9$?49KH*Y_5O''AC
M0[S[)JFM6MK< !O+D;!P:OEBK): KF/:?#B,7T-QK&N7^LI#S'%>;2JG\*VY
MO"]M-XHM-=\Z19K:%X5C &TAL?X5!I_Q \)ZM>):6&O6=Q</]V-&))JSK/B_
MP_X>ECBU?5K:S>09196QD5=VK,25[I%C7M#M?$.DS:?=C"2*0' Y0^H]ZI6?
MAN>RTBVT^+6KW$#<2\;F7& I]A5>T^(W@Z_NX[6U\0V4L\K;417.6/ITKJ <
MC(I6LO7] ;OI_6HB JBJ26(&,GO6%JNE213-J.G@"4\S1=I?4G_: Z5O45AB
M<-2Q-)TJJNF73J.F[HY&+6K5E/V@M:MV2<;2?>G_ -L:=_S^P_\ ?8KH;G3;
M*\</<VL4K 8!=<FLJQ7PQJ-U-;6<=E-/!_K$1!E.<<U\E/@V#DW"H[>AV*O!
MJ_*S)D.IZTABTZ%H$##S'F&W*Y_A]:ZG^S;;^RFT]8U2!HS&54< $<U; "J%
M P , 5BZSXO\/^'94BU?5K:SDD&565L$BOH<ORO#X"FX4^N]^IA4K2GLK)'
MWGPP.DR%;/5]172Y#\]I"H(8^A'I5V'PUHD%Y'<)<B/8@40G  ('7ZUT=K\2
M/!M[<QVUMXALI9I&VHBN<L?RIFK>)O!.CWA@U34-/M[@@.5EZD'OTKCS#(WB
M)<U.HX7*A6@_C6OD<;9^ O#]AIM]9P:BRF\D#R2C&X8.<5H^%O",&C75ZNG/
M/.UZX=II5 4 #!VD5O:9XH\"ZS>I9Z=J&G7-R_W8X^2?TKK(XTAC6.-0J#H
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MY?+(2"8X_-6,G_= Q5[7/$?PYU^*)+N\NH_*&%:V22)L?4"O3OL5I_SZP_\
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M_@2?\*/K%+^9!_9&/_Y\R^YGN-%>'?\ "\->_P"A;M/_  )/^%'_  O#7O\
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MD_Y"D'_7-J +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 5+[K!_UT%6ZJ7W6#_KH*MT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 53O/\ CYM/^NG]*N53O/\
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M7B7=KIVV9/NEI&;'X$UROBO1+#7?BMH]CJ$/FVYLIFVABO((QTIT])I+K?\
M)B>L9-]$S4^(%EH0\+SM;0VB7:@F VRJ&W]ON\UO:;=:A:>&=+*64EU,T*"0
M;\%?E')S7!>(/!]GX'UJT\0:;;,]BA"SPLY8(.I:O4;+5;*\T^"[CN(A#*H*
MDN .G2B/P-KO_7WDR^))]OZ^XNH244L-I(R1Z4M ((R.0:*0SBOB%XKMM%TJ
M6P!9KRYC(4*<%0?XLUY+X3\47/AK5_M2#S(YL+.IZN,^O;FMWXJ65W!XB2::
M:2>*1,H2F @S]W-<& 20!U->OAZ4/96WN>]A:$/86WON?5-M.MS;13H1B10W
M!SC(KSG7H[67XOZ0MXD+Q?89^)@"N<CUKJ/ VG7>E^%+2VO,>=RW#;N#R.:X
M[Q9HMAKWQ7TBRU&$RP&RF8J&(Y!&.E>5:U9):[_DSQ9I14TGI9F[XTM/#J>%
M+]EBLHY!$QC:!5#@^Q'-<7X!@MI?&MT-4C@D']FP%/M(#<9_VJ[RV^&/A.UN
M8YXM-/F1MN4F5B,_0FN3;POI/B#XKZG;:C;>9%#8PE%#E<<D=J5/2;MU3_0B
M6M-^7^:+WQ%M-*2PM'TR*WCOQ,GE&U4 XW#.=OM7I%KN^RQ;_O;1FO)+C0K7
MX<>+H=2B@9])N2%;>Q;R#T'YDUZY!-'<0I+$ZO&PR&4Y!HC_  ]._P!VVGZD
MR^.SZ+[SGOB#_P D^UW_ *]'KD?V?_\ DF2?]?<O]*Z[X@_\D^UW_KT>N1_9
M_P#^29)_U]R_TI#/4ZX/XL?\BSIW_87M/_0Z[RN#^+'_ "+.G?\ 87M/_0Z
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M<^>QFTC4W,F[)[*..M=#X?U#[3+XCL;@I%J4RAUM@,,P"<X%1%Z-K6R?Z?\
M#C>]N[.NM?B5I5U?I;_9+Z.*1PD=T\6(G)Z8;O5F7Q!8V&OWS7&H7&R"U$KQ
M-CRU&>H]ZX:+7-+U#PGH?A^T*2ZM;R1B:S7[\..I(]J9XCL[E];U)5B:8PZ<
MADA'5QGI3M9V^5^^VOR!:[_=^AJZIX_DU+6=*@L$O[%'E8-YR;!*.V/6M/XL
MDGP79D]3J5I_Z,%<_JOBKP_K-_X=M=-GAN+F$[9%CY,)"@8/\JZ#XL?\B59_
M]A*T_P#1@HBK1?J_R0KWDO3]6=_1112&%%%% !1110 4444 %<A\4O\ DF'B
M'_KT/\Q77UR'Q2_Y)AXA_P"O0_S% '0:)_R -._Z]8O_ $$5?JAHG_( T[_K
MUB_]!%7Z "BBB@ HHHH **** .#\7?\ )1?!G_7:;_T"N\K@_%W_ "47P9_U
MVF_] KO* "BBB@ HHHH **** "N"^+O_ "*%I_V%+3_T8*[VN"^+O_(H6G_8
M4M/_ $8* .]HHHH **** "BBB@ HHHH X/XF_P"J\._]A>&L;XR?\>EC_P!=
M3_*MGXF_ZKP[_P!A>&L;XR?\>EC_ -=3_*N?%_P9'L9!_P C*EZ_HSR&BBBO
M!/UD**** "BBB@ HHHH **** "BBB@ JSX<D$7CBTD;[J6DS''L*K59\.1B7
MQQ:1M]U[293^(KKP7\=7/!XE_P"1;/Y?FBSK&I_VQ?\ VD+MC5=L?J1[U5MY
MWM+R&ZC 9X6W*#T-6M8TS^Q]0^S!MT;+NC]0/>JMM ]W>0VL;!7F;:K'H*^Z
MCR<BY=K?@?&T_9?5_P"Z>EZ7J,>J6"748(#<$'U'6KM4]+TZ/2[!+6(DA>22
M>YZU<KPI\O,^78\%VOH%%%%0(**** "BBB@ HHHH *YW0M5U'3_C4EO967VB
M&\MHHKJ3!_<IDG=^==%47@7_ )*MK/\ V#(O_0Z!,Z";Q3XA3XF1Z"FC;M&9
M 3?;6X.,]>G6D\;^*O$6@ZYI%IH^B_;K:Z8"XEVL?*&X#M[<UW-%,1P_B?Q3
MXATKQEI6EZ=HWVK3[K'GW.UCY>3CMQ3=8\5>(K/XBV.AVNC>=I$X7SKW:WR9
M!SST[5W5!&1CUH ^)X/$VM^'/$NHMHU_/;-+=N'6(X\S#G -?4'PV\4>(/$U
MA=R:_I/]GO"RK%\I'F CD\T[0_A7X8T.^N[Q+3[5+<OO;[3A]ISGY?2NU "@
M # ' % "T444 %%%% !1110 4444 %%%% !1110 4444 %5)/^0I!_US:K=5
M)/\ D*0?]<VH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!4ONL'_ %T%6ZJ7W6#_ *Z"K= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4[S_CYM/^NG]*N53O
M/^/FT_ZZ?TH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>#>'?^3H=7_ZYR_\ H*U[S7@WAW_DZ'5_^N<O_H*T >\T444 %4=6
MT;3M=L39:I9Q7=L6#&*49&1T-7J* .2_X5AX(_Z%JP_[X_\ KT?\*P\$?]"U
M8?\ ?'_UZZVB@#DO^%8>"/\ H6K#_OC_ .O1_P *P\$?]"U8?]\?_7KK:* ,
M/1_!WAWP_=-<Z3I%M9SLNUGB7!(]*T(]*L8M1DU".UC6\E0(\P'S,HZ"KE9V
ML:]I6@6ZW&K7T-I"QP'E. :+I:CLWH:-4WTJPEU*/47M8VO(D*),1\RJ>HK,
MTGQOX9UVZ%KI>LVMW.?X(VR:DUKQ?X>\.RQQ:OJUM9R2#*K*V"10]+"6MTC5
MNK2"^M9+:ZB66"5=KHW1AZ50C\-:+%91V::= MO$Q=(PO"D]35'3?'OA76+M
M;73M<M+F=ND<;$DUT=%K!>^@BJ$4*HPH& *6BB@#GO&/AO\ X2?13:"0I*AW
MQ^A;W]J\Q\ >#$U'7;DZG$S06;8'&4D8'!&:]OJ*"WAME98(EC5F+$*,9)ZF
MMX5Y0@X(Z:>*G3IN"ZDB*J(J*,*HP .PJH^E6$FI1ZB]K&UY$A1)B/F53U%7
M**P\SF"J<>E6,.HR:A':QK>2H$>8#YF4=!5RB@"KJ&FV6K6C6E_;)<6[$%HW
M&0<4^TM+>PM8[:UB6*",81%' %3T4 <U\0?^2?:[_P!>CUR/[/\ _P DR3_K
M[E_I77?$'_DGVN_]>CUR/[/_ /R3)/\ K[E_I0!ZG7!_%C_D6=._["]I_P"A
MUWE<'\6/^19T[_L+VG_H= '>4444 %%%% '!^ ?^1F\<?]A?_P!D%=Y7!^ ?
M^1F\<?\ 87_]D%=Y0!Q/C+4=?CUG2]-T2_ALWNG96DEA\P<#/2H-(U3Q'I7B
M:/1]=OX-0-Q&\D<L4(C";1T([U6\>V5Y?^*=!@L=0>PF:5L3(H8CY?0UK:+X
M-N=/U%M3U769M5NE0K$\D838".1Q1#2-W_>_6P3[+R,6VG\;:_K.KKIVOV=G
M;6ESY21R6@<XQGK6[X)UK4]0CO+35Y$EN[:9D,J*%# <9Q7%V>B>(K[4_$]Q
MHOB&:R9+H[;=8U*NVT8R3TKI_AK]F33;B-YB^IB9OM>\88OW./3/>G!:?)>O
MJ$]V_,[JJ&N?\B_J7_7K+_Z":OU0US_D7]2_Z]9?_032 Y_X6_\ ),/#W_7H
MO\S77UR'PM_Y)AX>_P"O1?YFNOH X?Q[XPO="LGCTFV,MRA4RR$<1*2,'GKF
MNPL97GL899/ON@)^N*YCXE*O_"%WC;1N)3)Q_M"NDTS_ )!EM_US7^5./P/U
M_1#G]EKS_0MUY\"1\9-4(_Z \?\ Z'7H->? $_&35 !G_B3Q_P#H=9U/@?H.
M'Q(S?AW?RVL&K"YNG>,RR>7YC%B#N/<U9^&CW+ZGK4UU/)(S2@X9B0HQV':L
M*+3]1C\/0/:P2I(U]-YGR')7=Q79^&;)[?7=93RV56V;25P#\M;/1M^5ON_X
M%B'K%KSO^*_X)%J_Q!FM-0G@T[2?M\-L2MQ*+A4\L^F#UXK%\3>+=0N=1\.S
M:9I\L\3W"L524#<VTY2N=U+2="TC7]73Q#H5W=W-U,9+5X%D=7&,?,5X'-;V
MI)'HMEX8O1I<MM:QW0D:&!6E*C;W'6HIZN+?E]]GH.5[R2\_^''#Q+JNG>--
M4^RZ7/?R?9HF> 2X$?&3UXKI_P#A.[5?"46MO;LK2L$6WW<[B< 9^M4-%1Y?
M%VN7(@D6.6SC*,R$9X/'UKG9--OCX(CFCM79K>Z61HRI!VA\D@?2A?#%2TTC
MKV[CMJVM==N^ESJ+#QS?3W4ECJ6A2Z?>-"TL,3RAO, ]Q[UR7A_X@ZIIDD\%
MUHD\SW5^\<1,P^]_=K9MM3_X37Q1;WNFVES':VT)61[F%HFW9S@!NHKG=,D=
M_%5G8FTNA)%J[RLS0,$VD$9W8Q54TW*STO\ EW);]V_;\^QW5UXWN['3(7N=
M&:+4IV98K)IE!8#ONZ=*33?'-S?VUV'T=HK^WY^RB96+#&2<CBL;XEZ/!-?Z
M;J>H6$EYIMNQ,Z1;BX&,<!>357PO=:%IB7^K:1X>N;>U3Y4D=)/,D)''R'G&
M:A.Z;?G\NWZ#:LTEY?/O]QT1^(EJUA:M%:.]],P5K0'YDSZFJ&H?$N[LO.F7
M0'DLX/\ 73&=5V$=>#R:YN#2=9TO4/\ A-BCO]N/S683/E*W<#KD8KG-9GL-
M;T76&OM.U*ZUQB_V9C:R(JIGY>G!IK>[^:[>0TDW:^G1_J=]XD\2:H?%?A]K
M'3I9K>3YQME #Y7)'X5K:MX]N+2]>VT[2/MY@'^DD3JGE<9[]:YVXN#IQ\*7
M<]M=&) 5?RX68J=@'(K'U?3-#TWQ-J,_B/1;NZ%Z0]H]NDCYXZ-MZ<^M-KEM
M'_%^>WW:DIW7-Y+_ (?[SO\ 4?$R:GX,^U6O[N6Z'E;0W*,W;-<_!IMQXCU*
MW\/W=W.EG;6J2S".0J[,>#\PYJ*RT[[5'HFGP:4UA:$K=[%+,!M/0D]*U-:N
MW\&>+O[9FM9IM.NHEA8P1F1U(.2=HYI6CS>]U_-+_AP]YI*.Z_*_^1>T_0[O
MP8;M["2:ZTT(&C@ED+N#_$=QK0C\9V3^%TUO:0C-L$>>=V< ?G570O%EQXIU
M"9+32Y$TD)CS[A6CD)[_ "$5R,.D7+^-)O#FT#2Q()T*G.TK\V".W-%I2:B^
MJT_7\-?D.\4N9=-_Z]?S+4'BC6KKXA61.CSI"]JV4\X85<_>Q[5I:M\2;G3Y
MKB2'0WGL+8D2W/GJNW'7Y3R:;K%U_9?Q'M7:"X*S6C1QO%$64,6XR1TKSOQ%
M]CU'3=<BU'3]0N]>5W$#_9W"*N?EP1P:%)6CV_X/Z#4=;/R_(],/Q"N;G56L
M-+T.6]D6*.5BLH& XSWIVL>/KRPNY(;/0WNU@&9V,ZIY?&>_7\*ROAQ;SIK%
MZ\EO+'FSA4%T(Y ]ZY[Q&]E<ZYK=KX@LK^\N5!%B([=]BC;_ 'EX/..M$_=L
MO*_Y:"B^9-O^O,Z'Q9XI^U>&]"UJU611//&XA1\$Y)^7-;>C^-)M0O9-/U32
M9=.E\L/&&D#>8#TZ5YX(;N'X<^'&^PSE[6XB>2+RVR ,YXQ73V>I'Q;XFCN;
M.SN(H+.-3(TT+1DD<$#(YHFDE)+:[^2M<.S_ *WM^6I-9>-X]-L+>#3-)N;F
M:YN9DCA>?+%E//)[5O:#XR.IQZ@-1T]M.N+'_6Q.X;MGJ*XGPY9W*:IHK/;2
MJ%OKDDF,C ).*W)-,N;S7O$D20N/-7Y200&^3UIU':]M6[_@QI)OTM^+L2Q?
M$B9[R-FT8KIDSA8KS[0I# ]]O6G:=(DWQHU&1#E6T>(@^OS5P.C:=X;MA8Z5
M)X8NI=<AD5)BRRB('NP?H:[O28_)^,=]'L";=&A&T'('S4VERZ?\.1=\W]:'
M:SZ;IMQ+ON+*TED/>2)6/ZBGQ164$9@BCMXTZ&-%4#\JXSQ?K%QI6NV_V6%Y
M9I!A0 <#CDFJ%Q#%'I]E?17+S3W,R&61N"3N]*F'O)>;M^-BIOEOY*_X7/0I
MK>Q:%8)X;<Q#[L;JNW\ :CBM],MGW10VD3@=455->?ZY<76H:W?!K83PV3GD
MN5\M1SN&.I'I5F_T[3=1AT^"V1S=78 :;<04!'WL4+5)KJ-JS:?0[@Z7ILDG
MG-8VC/UWF%2?SQ3X[>Q,[2QPVYEQ@NJKN_.J.HPSV7AYHK+F6- !D]?6N,T+
M5;./7;2#3X[F%I89&G$L;*&8=\FA;M+H)Z*[_JQWR6FFQ7)D2WM$G)Y944-^
M?6I3':F4Y2'S&&#D#)%<!#%=6FNR7^HZ? ]O/< 17"W!+#/3Y15O4K2_M-:3
M5?+1XHVWES)@E?0#O235EZ?TAM.[.OCTS38Y-\5C:*^<[EB4'^5<=\7/^1/M
M?^PG:?\ HP5K>&=7LY2UL9I'NG8DLZX!!/0'OBLGXN_\B?;?]A.T_P#1@JFA
M=6:DNOW$/CJ/2Y)XDLVMFD(; .X'UHT_7KB[\;7>FB:.2TBMED4+@_,3CK7.
MZ[X=TSQ#\2X+?4X#-&MFQ WE>=WM4GA70]/T#XB:A::="8H?LBMMW$\[O>BG
MJHW[/\PJ:7MY'41:S'#J^H+<ZG$T-O&K&'R\&//<GOFH;#QYX>U5GCL[[?(#
MC#(1D_C7 >)U<ZIXDP&9!'!N"CG&ZKNKW&CS:_X?%@T3R"!N8B"!TSG'?ZU,
M=8Q\[+[TM1S5KVZ7?W&O8_$6RL]2U2VUR\$?DW7EPA8CPN.Y%=W;7$5W;1W$
M#;HI%#*WJ#7F.GV-L^G^-)7A5G,[\D9_AKM/!I)\+V0)^[& /IBJ6L==[+\4
M*6CTVNSGM:U;Q#?:]=V6DZI;:9':1J[&XA#^;D=!FM[P;J]YJ^AI-?K^_7AG
M P'YZ@5R$]OI>N^)M2A\2SHOV9%:W25_+"GGD'(S6]X$U-YH;BUEG5XXVQ;,
MV%,B]R![4J>L?57_ "_SV"I\7SM^?^6Y4\6>-+_3]6L;+2[<F%KM(+BX8<*2
M?NX/MWJ[\3R3\+-?)ZFS/\Q4'Q%51!HY"@$ZC%G ZU/\3O\ DE>O_P#7F?YB
MG'^'\V.>ZMV.BT3_ ) &G?\ 7K%_Z"*OU0T3_D :=_UZQ?\ H(J_2$<O<ZOJ
M&C:^(]0D633[EL0NJ8\LGHI]?K3M7U>^FU>VTS1W029#W$I7<$0]_P ZO^);
M:*XT&[,J!C'&74^A ZUA^$;79X5EF3+7$F?G/7Z5'-9._P!E7]>PVKM>>A<G
M\>^'K'4%TVYO_P#2P &Q&Q7/UZ5;UKQ?HOA]8FU&[\OS1N3:A8D?A7C^FZ8T
M^AW3WOC">S073[K,VZ&3[_&,_,:Z#5]-AENM/^P^()K._@MW\MKF!527O@EN
M!Z5<KK^O)L2W/2]&US3]>M/M6G3^;%G!.""/P-:-><_#74KF2:]L[RPMXKH/
MNFN+:;S$E;'7(X'X5Z-5226VPD]TS@_%W_)1?!G_ %VF_P#0*V?%^N3Z38QQ
MV147D[A4+#(4$X)_"L;Q=_R47P9_UVF_] J+XD6+7-SITLDCQVJL$E=1G@L.
M/I[UF]7%=VE^)2=DWV3(EU7Q;X?^T3ZE?VFL6R0,X:W18]K#MUJ&PU_Q58WV
MEWFJW4-QIVIRA4A2$*T((SDGOZ5A>)](TO2&D7PP1(KV[&98)3*#^IYK6O-5
MM=2TOPKI]M(LEP951T0Y:/Y.X[?C5P=]5J[V^77_ (<EJUUTLW?SMH:6LZSX
MDU/7[FP\/W<-I'91K+*\D0D\P$9P/2ND\):U+KFA0W5PFRXY$B^^:Y/3[ZVT
M+Q7K<-]*L6^UCV-(=H<X/ )ZUL_#M6?P_P#:BK*L[%E##'<T0^'RLG\_ZO\
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M"GKJ?_@<_P#C6UX9\ Z'X3OI[S3$N?/GC$;M-.9,J#GO73T4 %%%% !1110
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MH;?7O MI?RWUOJ6EQW4HP\JRC+?6M'_A#/#/_0"L/^_"T?\ "&>&?^@%8?\
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MK;PQH3?&&^LSI-F;9=+C<1>4-H;=UQZT =G_ ,)OX7_Z#UA_W^%'_";^%_\
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M * 5A_WX6A:.Z!ZJPW_A-_"__0>L/^_PH_X3?PO_ -!ZP_[_  IW_"&>&?\
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M9)O!KW#NOBBV2(R+(L(E7:F#G KI_P#A#/#/_0"L/^_"T?\ "&>&?^@%8?\
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M&7A.>)HI=;T]XW&&4S#!%,M?%G@^RA$-MK.G11CHJS#%6/\ A#/#/_0"L/\
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MZ^Y?Z5UWQ!_Y)]KO_7H]<C^S_P#\DR3_ *^Y?Z4 >IUP?Q8_Y%G3O^PO:?\
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M^2VZA_V"(_\ T.N\K@[3_DMNH?\ 8(C_ /0Z .\HHHH **** "BBB@ HHH)
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M110!P?B[_DHO@S_KM-_Z!7>5P?B[_DHO@S_KM-_Z!7<R2QPH7E=40=68X H
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MWYZ?UZD+1V_K?3\">BBBH*"BBB@ HHHH *X.S_Y+;J?_ &"(O_0Z[RN#L_\
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M=APY4Y(%9LVK:QJWB32(+S1;G3O)B92MP!F7!'*X[5,-5%?X?NT'/12?K_P
ML-8\1:9?^);C2+.UEMH+LO,9V(. O\.*]0T74?[5T>UO2H5I8PS*.Q(KD;#1
M]1CT[Q5&]I(K74S- "/]8"O:NC\*VL]GX?MH+F)HY54!E;J.*M?#9]E^0I;W
M7=GF6H:AHNJZ]?2ZWHUQJ^WY(XXHO,\C&1N]J[WPD;.U\*%]/GF>!(V98Y@
MT>,G&*PWCU+P?JUZ;/P]=ZK#>#A[4#*$\G<3VYK0\.6E_8QM:7.G7 &H1NSN
M,!8.,;3[G-9T[^SMY?C_ %?7_,<OCOYO[OZZ'"-=^']4FOKK6=%N]1N)9"4N
MH8=_V88Z9[>M=9XN6!/@GK"VUQ)/"+'Y3)U XX-5XQJWAF.^T6V\-7E]%=,=
MEU;JNQ1C'S9Y-2^*],ETOX+Z]#.?WC6K.1_=R1Q50^"WDOOZZ?J3+XK^;^[I
M_P ,=SHG_( T[_KUB_\ 015^J&B?\@#3O^O6+_T$5?H&%%%% !1110 4444
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M$#C+$=<5R/Q=_P"10M/^PI:?^C!66DK3^)= 1="FM1&[@SL%PW'7BM/XN?\
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MYXQ6SXLM]0U);72[:"0VMR^RZF7^!,?IS5>\K-;_ -:_\ 6FJ>W]:>?DSG=
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M:*O?\*=T?_H+:S_X%FC_ (4[H_\ T%M9_P# LT!<HT5>_P"%.Z/_ -!;6?\
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MK/\ X%FC_A3NC_\ 06UG_P "S0%RC4OPK_Y#WB__ *^X_P#T"K/_  IW1_\
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M_7W+_2IO&OQ'\':AX*UBTM/$-E-<36S)'&K'+'T'%0_L_P#_ "3)/^ON7^E
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M ( #_&C^P?B'_P!#?8_^  _QKO** .#_ +!^(?\ T-]C_P"  _QH_L'XA_\
M0WV/_@ /\:[RB@#@_P"P?B'_ -#?8_\ @ /\:/[!^(?_ $-]C_X #_&N\HH
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MC1_8/Q#_ .AOL?\ P '^-=Y10!P?]@_$/_H;['_P '^-']@_$/\ Z&^Q_P#
M ?XUWE% '!_V#\0_^AOL?_  ?XT?V#\0_P#H;['_ , !_C7>44 >+>(](\9Q
M^-/#$=SXDM);J227[/*MI@1G;SD=ZZW^P?B'_P!#?8_^  _QH\7?\E%\&?\
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M"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %2^ZP?]=!5NJE]U@_ZZ"K= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %4[S_ (^;3_KI_2KE4[S_ (^;3_KI_2@"
MY4%[S87'_7-OY5/12:NK#3L[GSU\*[>>/XNZR[PR*I#X9E(!Y%?0M,6&)&++
M$BL>I"@&GU5_=C'LK$M7G*7<IZK:&]TNYME^])&P'UQ7S)X>U76OA/XJNXKG
M2)KE)2WRH.2>@.:^IZC>W@D;<\,;'U90:F*<9\RZJQ3:E#E?J?*/C2^\1Z]K
M]EXAU#3)8+7<!$-N[ SGG%>M?$O?=_"*$Q([LUL.%4YZ#M7JAMX64*T,9 Z
MJ*4Q1LFQHU*_W2.*4HITO9+O<%)^T]H^UCS/X&Q21>!(5DC9&WMPPP>M<'\:
MM)O=.\::?KL-I)-"KB1M@SR&&!^E?1*1I&NU$51Z*,4CQ1RC$D:/_O+FKJ2<
MJBJ+1K_*Q--<L7%]?^'.2^'_ (R?QAI#7$NG2V31MMVR'[WO74WEPMI:2W#
MD1KDXJ1(HXQB-%0?[(Q3B 1@C(]Z*CYK\N@07+HSXU\8ZWJ/B3Q=-?7UI=2P
M))M$05@, XXKTC0OC1:>'],AT^P\&W<<48Q][D_4XYKWW[';?\^T/_? I/L=
MK_S[0_\ ? I0]R*@MAS]Z7,RGX?U8Z[H5IJ1MV@^T1A_+;JN>U:=(JJBA54
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M(:O2J* /-?\ A1/@7_GQN?\ P(:C_A1/@7_GQN?_  (:O2J* /-?^%$^!?\
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MS0ZX)P">/RK9MM,L;,RFVM(8C+_K"B ;OK1;:98V<<L=M:0Q)+_K%1  WUH
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MQSYN]<9QGI^5&A>---\06&H7EHDPCL<^9O7!. 3Q^5;-MIEC9F4VUI#$9?\
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MS ZX)P">/RK9MM,L;,RFVM(8C+_K-B ;OK1;:78V<4L5M:0Q1R_ZQ40 -]:
M,32O&^F:QX?O-9MTF%M:9\P,OS<#/%,\+^/-+\67%Q!8).K01B1O,7'&<5O0
MZ586UK);0V<,<$GWXU0!6^HI+/2=/T]V:SLH(&<88QH!D4 8^@^---\0/J"V
MB3 V.?-WKC.,]/RHT+QKIOB#3]0O;1)A'8Y\P.N"< GC\JV;;3+&S,IMK2&(
MR_ZS8@&[ZT6VEV-G%+%;6D,4<O\ K%1  WUH Q-*\;Z9K'A^\UFW286UIGS
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M.15V'2K"VM9+:&SAC@D^_&J *WU%26ME:V,'D6L$<,6<[$7 S0!A:%XTTWQ
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M_P" R4?\(7XK_P"A^O\ _P !DH [RBN#_P"$+\5_]#]?_P#@,E'_  A?BO\
MZ'Z__P# 9* .\HK@_P#A"_%?_0_7_P#X#)1_PA?BO_H?K_\ \!DH [RBN#_X
M0OQ7_P!#]?\ _@,E'_"%^*_^A^O_ /P&2@#O**X/_A"_%?\ T/U__P" R4?\
M(7XK_P"A^O\ _P !DH [RBN#_P"$+\5_]#]?_P#@,E'_  A?BO\ Z'Z__P#
M9* .\HK@_P#A"_%?_0_7_P#X#)1_PA?BO_H?K_\ \!DH [RBN#_X0OQ7_P!#
M]?\ _@,E'_"%^*_^A^O_ /P&2@#O**X/_A"_%?\ T/U__P" R4?\(7XK_P"A
M^O\ _P !DH [RBN#_P"$+\5_]#]?_P#@,E'_  A?BO\ Z'Z__P# 9* .\HK@
M_P#A"_%?_0_7_P#X#)1_PA?BO_H?K_\ \!DH [RBN#_X0OQ7_P!#]?\ _@,E
M'_"%^*_^A^O_ /P&2@#O**X/_A"_%?\ T/U__P" R4?\(7XK_P"A^O\ _P !
MDH [RN#L_P#DMNI_]@B+_P!#H_X0OQ7_ -#]?_\ @,E<E;>%_$+?%2^LU\87
M:W2Z=&[7?D)N92W"XZ8% 'M-%<'_ ,(7XK_Z'Z__ / 9*/\ A"_%?_0_7_\
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M!WE%<'_PA?BO_H?K_P#\!DH_X0OQ7_T/U_\ ^ R4 =Y17!_\(7XK_P"A^O\
M_P !DH_X0OQ7_P!#]?\ _@,E '>5R'Q2_P"28>(?^O0_S%4O^$+\5_\ 0_7_
M /X#)7-^/_"OB.S\!:S<W7C.\O(([<L]N\" 2#(X)% 'J.B?\@#3O^O6+_T$
M5?KSC2O!WBB32+)T\=WT:-;H506Z84;1Q5O_ (0OQ7_T/U__ . R4 =Y17!_
M\(7XK_Z'Z_\ _ 9*/^$+\5_]#]?_ /@,E '>45P?_"%^*_\ H?K_ /\  9*/
M^$+\5_\ 0_7_ /X#)0!WE%<'_P (7XK_ .A^O_\ P&2C_A"_%?\ T/U__P"
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M(UU'=6\>J>$]4TR&>01K/<,FW<>G0UW:L'4,IRIY!IV=KDW%HHHI#"N#L_\
MDMNI_P#8(B_]#KO*X.S_ .2VZG_V"(O_ $.@#O**** "BBB@ HHHH **** "
MN"^+O_(GVW_83M/_ $8*[VN"^+O_ ")]M_V$[3_T8* .]HHHH **** "BBB@
M HHHH *Y#XI?\DP\0_\ 7H?YBNOKD/BE_P DP\0_]>A_F* .@T3_ ) &G?\
M7K%_Z"*OU0T3_D :=_UZQ?\ H(J_0 4444 %%%% !1110!P?B[_DHO@S_KM-
M_P"@5WE<'XN_Y*+X,_Z[3?\ H%=Y0 4444 %%%% !1110 5P7Q=_Y%"T_P"P
MI:?^C!7>UP7Q=_Y%"T_["EI_Z,% '>T444 %%%% !1110 4444 <'\3?]5X=
M_P"PO#79K_R$'_W!7&?$W_5>'?\ L+PUV:_\A!_]P4 6:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J0_\A&X_W5JW
M52'_ )"-Q_NK5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "JDG_(4@_ZYM5NJDG_ "%(/^N;4 6Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J7W6#_KH*MU4O
MNL'_ %T%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *IWG_'S:?]=/Z5<JG>?\?-I_UT_I0!<HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ/_'H?]X?SJTOW
M1]*JZC_QZ'_>'\ZM+]T?2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K@_BQ_R+.G?]A>T_\ 0Z[RN#^+'_(LZ=_V%[3_
M -#H [RBBB@ HHHH X/P#_R,WCC_ +"__L@KO*X/P#_R,WCC_L+_ /L@KO*
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ME_R3#Q#_ ->A_F*Z^N0^*7_),/$/_7H?YB@#H-$_Y &G?]>L7_H(J_5#1/\
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MBBB@ HHHH **** "BBB@ HHHH **** "JDG_ "%(/^N;5;JI)_R%(/\ KFU
M%NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *E]U@_ZZ"K=5+[K!_UT%6Z "BBB@ HHHH **** "BBB@ HHHH ****
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M@A)VRS@QA@/=ABM*MHR2CU5S.+T;ET=CW:BOG:Q^(7C7PCXJM=-\3WD%\L[
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M *X/XL?\BSIW_87M/_0Z[RN#^+'_ "+.G?\ 87M/_0Z .\HHHH **** .#\
M_P#(S>./^PO_ .R"N[)"C). *X3P#_R,WCC_ +"__L@KNI$$D;(W0C!I.]M
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M!--T/3FTO2X[5Q &0G_4IM!_^O3M<_Y%_4O^O67_ -!-7*U]!1O;4Y_X6_\
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M;=P3[ ]:):VY>MOQ''1OFZ7_  )]#\=6>M:A]B:QO;&<KN5;N/9N'M755YO
MFHZ?XILY?%+0W-RZ^7!/:ILC7)^Z0>^:ZW5=?>PODLH+":YE< YC(POUH;7*
MF2KW:-NBN4T_QDU[);[],N(8II&CWN1A2O7-7-0\2FTGGBM[">Z^SH6E,9&%
MP,XYH>FXUKL;]%<9#K[:_;)>6ZRV\;VAD,9;E6]#BET7Q7$]I(!OF2V&Z:;/
M [$?6BV]_4=MO6QV5<%\7?\ D4+3_L*6G_HP5JIXP;^T[&TETFZB6\9A'*Q&
MT8&<UE?%S_D4+3_L*6G_ *,%.SM<1WM%%8NL^+= \/2+'J^J06C-]T2$\U+:
M6X69CZO\08](NY8)-!U>98QDRQ093\Z?;?$32[GPY_;?D7,<!8*B.F'<DXX'
MUJOXH\1P:CI5I:Z/<+<-J+[8I(SP0.OZ5'XG\-3P^';)=)M?.>T='^SJN2^&
MR<>]"ND^;NE?\W;R&[-KE]?\OQ-;0_&EGK4K1/9W=A*HR$NTV%AZBJUO\0M-
MN-;731:W:[I3"MPR?NBPZC-<I<ZOJ6O>+-/^U:'=Z3\H4I<;=[#/4$=JFU'P
MQJFA%K^ZU"T;1[2X:[2%4(E)/!&>E.]O>>VO]?Y(G5^ZM_Z_IG>'Q#:G71I$
M:223X#,4&50$9&:UZ\DT;Q*/#MU/)+I-YJ%U-M-Q<1,-L49/R9SST->JVMS'
M=VT<\1RCC(IVT_K^O\POJ<3\3?\ 5>'?^PO#3?B+XKU3PFEM<:7;V\TDS;'$
MY( &,\8IWQ-_U7AW_L+PUC?&3_CTL?\ KJ?Y5A7FX4W)'HY5AJ>*QE.C4V;_
M $.7_P"%S>+_ /H&:9_WTU'_  N;Q?\ ] S3/^^FKB:*\OZ]6/O?]5<O[/[S
MMO\ A<WB_P#Z!FF?]]-1_P +F\7_ /0,TS_OIJXFBCZ]6#_57+^S^\[;_A<W
MB_\ Z!FF?]]-1_PN;Q?_ - S3/\ OIJXFBCZ]6#_ %5R_L_O.V_X7-XO_P"@
M9IG_ 'TU'_"YO%__ $#-,_[Z:N)HH^O5@_U5R_L_O.V_X7-XO_Z!FF?]]-1_
MPN;Q?_T#-,_[Z:N)HH^O5@_U5R_L_O.V_P"%S>+_ /H&:9_WTU'_  N;Q?\
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MLO\ G\M_^_J_XURO_"JO!W_0)'_?U_\ &C_A57@[_H$C_OZ_^- '5?VC9?\
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M /?U?\:/[1LO^?RW_P"_J_XURO\ PJKP=_T"1_W]?_&C_A57@[_H$C_OZ_\
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M?]]M_C1_9W]X/]<G_P ^?Q_X!X!YL?\ ST7\Z/-C_P">B_G7O_\ PJ+P1_T
MXO\ OMO\:/\ A47@C_H!Q?\ ?;?XT?V=_>#_ %R?_/G\?^ > >;'_P ]%_.C
MS8_^>B_G7O\ _P *B\$?] .+_OMO\:/^%1>"/^@'%_WVW^-']G?W@_UR?_/G
M\?\ @'@'FQ_\]%_.CS8_^>B_G7O_ /PJ+P1_T XO^^V_QH_X5%X(_P"@'%_W
MVW^-']G?W@_UR?\ SY_'_@'@'FQ_\]%_.CS8_P#GHOYU[_\ \*B\$?\ 0#B_
M[[;_ !H_X5%X(_Z <7_?;?XT?V=_>#_7)_\ /G\?^ > >;'_ ,]%_.CS8_\
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MP1%_Z'7>5P=G_P EMU/_ +!$7_H= '>4444 %%%% !1110 4444 %<%\7?\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2^ZP?\
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MVN"^+O\ R)]M_P!A.T_]&"@#O:*** "BBB@ HHHH **** "N0^*7_),/$/\
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MPH^NT>X?ZLYE_)^*_P SZ=HKYB_X3/QK_P!#1=?]^U_PH_X3/QK_ -#1=?\
M?M?\*/KM'N'^K.9?R?BO\SZ=HKYB_P"$S\:_]#1=?]^U_P */^$S\:_]#1=?
M]^U_PH^NT>X?ZLYE_)^*_P SZ=HKYB_X3/QK_P!#1=?]^U_PH_X3/QK_ -#1
M=?\ ?M?\*/KM'N'^K.9?R?BO\SZ=HKYB_P"$S\:_]#1=?]^U_P */^$S\:_]
M#1=?]^U_PH^NT>X?ZLYE_)^*_P SZ=HKYB_X3/QK_P!#1=?]^U_PH_X3/QK_
M -#1=?\ ?M?\*/KM'N'^K.9?R?BO\SZ=HKYB_P"$S\:_]#1=?]^U_P */^$S
M\:_]#1=?]^U_PH^NT>X?ZLYE_)^*_P SZ2A_Y"-Q_NK5NOE\>+_&2R-(/$]S
MN;J?+6G_ /"9^-?^AHNO^_:_X4?7:/</]6<R_D_%?YGT[17S%_PF?C7_ *&B
MZ_[]K_A1_P )GXU_Z&BZ_P"_:_X4?7:/</\ 5G,OY/Q7^9].T5\Q?\)GXU_Z
M&BZ_[]K_ (4?\)GXU_Z&BZ_[]K_A1]=H]P_U9S+^3\5_F?3M%?,7_"9^-?\
MH:+K_OVO^%07GCOQM:VDDX\37+;!G!1>?TIK&46[)D5.',QIP<Y0T2ONO\ST
MSX[^*)-&\+1:9"D@EU%MJS1OM,>W!KPBWTW6I8%>36;N-B,E?.8X_6NC^)NL
MW7B7QI8V$FH">TBMHI$V$,%<H"W3OFFJ,*!Z#%=U.">K/ G)K8ZGX$Z[JR^+
M+_0+B]>XM%C:4^82S;A@=3VKZ%KY$\-W]SX;^)>GSVM[Y"7<H6=C@#83R"3V
MKZY1TD17C961AD,IR"*SDK.Q2=T.HHHI#"BBB@ HHHH **** "BBB@ HHHH
M*J2?\A2#_KFU6ZJ2?\A2#_KFU %NBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *E]U@_P"N@JW52^ZP?]=!5N@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J=Y_Q
M\VG_ %T_I5RJ=Y_Q\VG_ %T_I0!<HHHH **** "BBB@ HHHH **** "BBB@
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M_>W^M&-DAG<K"3_&F<AA[&JCTMMRK[[(AWL[[\S^Z[.UJAKG_(OZE_UZR_\
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MDTS1K"=K66[B,DLZ'#KMZX^M<SJO@<:1HVG:Q%?ZG=VD2H]U:RW!<."!C /
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MO_$2XO(/#Q%E>36DKL%\V$X8<BL.\T37/"]G!K$'B74=1PR![>[<;-K=3QW
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7!_%C_D6=._["]I_P"AUWE<'\6/^19T[_L+VG_H= '>4444 %%%% 'D.AZS
MKVF>,/&<>D^'FU.)M4R\@F";3L''-=%_PEGC3_H1Y/\ P+6CP#_R,WCC_L+_
M /L@KO* //YO$GBVY39/X!\U?[KW",/UJ.#7?$]L2;?X>)$3U,<T:_R%>B44
M ></JWB*1R\GPWA=V.2S2QDG]*LQ^*/&$2!(_ C(HZ*MT@ KOJ* .#_X2SQI
M_P!"/)_X%K535?%/C&31[Y)/!4D<;6\@9_M2G:-IR:]'JAKG_(OZE_UZR_\
MH)H \O\  'B3Q5:^ M%@L_"+W=LEL!'.+E5WCGG':NC_ .$L\:?]"/)_X%K5
MWX6_\DP\/?\ 7HO\S77T ><2:OXCE<O)\-X78]6:6,G^530>(_%ELFR#P!Y2
M^D=PBC]*]!HH X/_ (2SQI_T(\G_ (%K7)6_B'Q0/BI>W2^%'-XVG(C6OVA<
MJN[ALU[37!VG_);=0_[!$?\ Z'0 ?\)9XT_Z$>3_ ,"UH_X2SQI_T(\G_@6M
M=?<:OIEI*8KG4;2&0=5DF53^1-36U[:WJ%[6YAG4=3%(& _*@#BO^$L\:?\
M0CR?^!:TV3Q1XPE0I)X$9U/4-=(0:[6ZU&QLB!=WEO 3T\V4+G\S4L4\,\0E
MBE22,]&1@1^= '"MXG\8-'Y;> V*8QM-RF/RJ-O$'BIH/(;X?*8?^>9G3;^6
M*[Y+B&6,R1S1N@)!96! Q0D\,D7FQRHT?]]6!'YT <!!KWBFU)-O\/5ASU\N
M>-?Y"I!XF\7B0R#P&1(1@M]I3/YUV4>LZ7+-Y,>I6CRDXV+.I/Y9J6ZOK2R4
M-=W4,"DX!ED"@_G0'D<0OB;Q>LC2+X#(=NK"Y3)ID_B#Q5= "X^'RS8Z>9.C
M8_,5W%KJ=A>L5M+VVG8=1%*K8_(U:HL!Y]#XC\66R;(/ 'E)_=2X11^E/3Q/
MXPB!$?@-DR<G;<H,FNWN;RULX_,NKF&!,XW2N%'ZU#!K&EW4HBM]1M)9#T6.
M=6)_ &C<-C@M7UOQEJNG26C^"'"N1DFZ4]#FK<7B?QE%"L8\#2848_X^UKOZ
MJW6I6-D0+N]MX"W02RJN?S- '%)XG\81EBG@-E+'+%;E!D^](GB/Q;'(TB>
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ME^Z/I0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5P?Q8_Y%G3O^PO:?\ H==Y7!_%C_D6=._["]I_Z'0!WE%%% !1110!
MP?@'_D9O''_87_\ 9!7>5P?@'_D9O''_ &%__9!7>4 %%%% !1110 50US_D
M7]2_Z]9?_035^J&N?\B_J7_7K+_Z": .?^%O_),/#W_7HO\ ,UU]<A\+?^28
M>'O^O1?YFNOH **** "N#M/^2VZA_P!@B/\ ]#KO*X.T_P"2VZA_V"(__0Z
M.>O(/!\WQ$U;_A)UL#B"+R_M1^O2M/P,EA;^(]9_L%5&D @KY7^K^[_#5^'P
MG%?^--6N=4TJ.6VE@C6*66,$$\YQ1X4TJ]\,ZQ=:+'IKG2'):"Y4#"C'(8]^
M313TBE_=_3K_ %N.I9MOS7]+^MBII.A6'C'6]8N]<A6^BM[@Q0PS#*HN,\5T
MND: /#]C=6\,SM;,2T<9Z1CT'M7-RR:]X-U^^>QT*[UBQOI#-BTV@QGH 2QK
M>\/S^(M0LKFXUB!+=9"?)MBF)$';<>AJ9:TGR_R_C_PX*ZG[W?\  X#P_P"-
M/[-\.7UC_8>JW'^D3_OH8<IRQ[U;@U&XB^&6G1V\DD#7,ZHQ'!"L^"/R-=3X
M6TN^LO"5W:W-L\<[SS,J-U(+'%9T'A6_N_ -O9M&;>^@E\Y5D']UBV./6M)M
M<TN;57C?S6MR==.73?\ X _6/A_H6F:!->:?9Q6^HVT9D6Z1<.S#U-8/B.ZT
M_4M.\*2>(#"]NTZBX,Y^4_+SFM6ZUWQ5KE@=%;PM?VDDP\N6]EV^5@]2 #FK
M.K>$I''AJR-F+RWM)E^T$KE<!<$G/:DD^9=K_H_N&FDO.SN9&GQ>'8/&^FCP
M>+=86)^UBRY7&.-WXUZ5,=1_M*W$"P&R*GSBQ.\'MBFV&B:7IC%['3[:V9A\
MQBC"D_E45WK0M-<L]--K*_VE&?S@1M3'8T[Z*/J)+5R\OR1R7Q26P>STU=3$
M1M#=Q^9YOW<9[US]_:^#HM8T1_""60OA=#?]BY.,?Q>V:[+QSHT^LKIT4=G]
MJB2Z1I5P" H/.:R]:\*_V!K=GKWAW2%DE!"7%O#&!E!S\O8'/>IIZ6;TU?\
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M2L2,P@8/./RK'D^$&E_V>85U76"57*H;P[-W;CZTM5)R?3^G_E]XU9Q4>_\
MPW_!^XH>(RDGQ*TV\B<X6$MN7NNZF^(&&J?$31+P;C!'*H3/0-@TW2?#NNC4
MS#=6$X2VL7MX[A^DC=01WJ[IGAO5;>WTCSK:5I8M0,DA/\*8Z_2J@DN6VRU^
M^_XBNW>_56^Y?U8W?'$AN+6RTE7"M>OCK_=P:S[RVDU:]D2 E8=+ QMZ/QG^
ME6-9L-3NO%"W8L998;.,& C&"S#!_*DL?AU;_9B]WJ&H+<2Y,ODW!53^%=V
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M44 %%%% '!_$W_5>'?\ L+PUV:_\A!_]P5QGQ-_U7AW_ +"\-=FO_(0?_<%
M%FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *D/_(1N/]U:MU4A_P"0C<?[JU;H **** "BBB@ HHHH **** "BBDR/
M6@!:*3(]12T %%%% !1110 4444 %%%% !1110 54D_Y"D'_ %S:K=5)/^0I
M!_US:@"W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% %2^ZP?]=!5NJE]U@_ZZ"K= !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %4[S_CYM/\ KI_2KE4[S_CYM/\
MKI_2@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQKT+P9';1>&XA8WLMQ;X/E^<NUD'H1VJ8OFAS?,):2Y3?DN[:)]DEQ$C>C.
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MVU_\ A1_9_C_ /Z&VU_\ A76T5YO^LF9?\_/P7^17L8=CDO[/\?_ /0VVO\
MX!"C^S_'_P#T-MK_ . 0KK:*/]9,R_Y^?@O\@]C#L<E_9_C_ /Z&VU_\ A1_
M9_C_ /Z&VU_\ A76T4?ZR9E_S\_!?Y![&'8Y+^S_ !__ -#;:_\ @$*/[/\
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MXG?]!_0?_ -_\: .\HK@_P"SOB=_T']!_P# -_\ &C^SOB=_T']!_P# -_\
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M)'OCI7">([+QXOC3PPEWJ^D/=M)+]F=+9@J';SN'?BNM_L[XG?\ 0?T'_P
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MZFUO^?J^YA]878Z*BN=_X5-I7_08US_P.:C_ (5-I7_08US_ ,#FH_U-K?\
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MB@ HHHH **** "BBB@ K@_BQ_P BSIW_ &%[3_T.N\K@_BQ_R+.G?]A>T_\
M0Z .\HHHH **** .#\ _\C-XX_["_P#[(*[RN#\ _P#(S>./^PO_ .R"N\H
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M+#./7%)%/%."8I4D"G!VL#@T 2444R6:*%=TLB1J3C+-@9H ?112$@#).!0
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M+_Z#FA_^ ;?XT8^)?_0<T/\ \ V_QH_U@RW_ )^K[G_D'LI]CTBBO-\?$O\
MZ#FA_P#@&W^-&/B7_P!!S0__  #;_&C_ %@RW_GZON?^0>RGV/2*J2?\A2#_
M *YM7!8^)?\ T'-#_P# -O\ &HS!\26G68ZYH>Y00/\ 1&_QH_U@RW_GZON?
M^0>RGV/3**\WQ\2_^@YH?_@&W^-&/B7_ -!S0_\ P#;_ !H_U@RW_GZON?\
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M !\VG_73^E7*IWG_ !\VG_73^E %RBBB@ HHHH **** "BBB@ HHHH ****
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MI <_\+?^28>'O^O1?YFNOKD/A;_R3#P]_P!>B_S-=?0!#+=VT#;9;B*-O1W
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MM8;'3Y8VE\N"4OYN.>?2A)MVC_77\M0NK7EM_2_X!ZC%<P3Y\F>.3'78X/\
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M@K9?^!"_XT?V_H__ $%;+_P(7_&CV-3^5_<%T:-%9W]OZ/\ ]!6R_P# A?\
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M +-^)W_0P:#_ . 3_P"-']F_$[_H8-!_\ G_ ,: .\K@[/\ Y+;J?_8(B_\
M0Z/[-^)W_0P:#_X!/_C7)6UCX\/Q4OXTUG2!J0TZ,O*;5O+,>[@ >N: .GE\
M*W-SK%[J<;S)<Q@& '[HYYQ]15W5_MNKZ;I\HLIED65=Z%>1ANM0?V;\3O\
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M  K?P9_T+EA_W[H_X5OX,_Z%RP_[]UU-% '+?\*W\&?]"Y8?]^Z/^%;^#/\
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M5+[K!_UT%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *IWG_ !\VG_73^E7*IWG_ !\VG_73^E %RBBB@ HHHH ****
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M\]!6L.1FO'O$6HZA>27,/GG?'JR10MQ\@Q73Z5-K.B>(H;+4=3EU"&Z4!3(
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MXN_\BA:?]A2T_P#1@KO:X+XN_P#(H6G_ &%+3_T8* .]HHHH **** "BBB@
MHHHH X/XF_ZKP[_V%X:[-?\ D(/_ +@KC/B;_JO#O_87AKLU_P"0@_\ N"@"
MS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113!-$9C")$
M,JC<4W<@>N* 'T444 %%%% %2'_D(W'^ZM6ZJ0_\A&X_W5JW0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !523_D*0?]<V
MJW523_D*0?\ 7-J +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5+[K!_UT%6ZJ7W6#_KH*MT %%%% !1110 4444
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M]5X=_P"PO#67\7KS4;*ULGT[4;BR=I,,T#8+#'0UJ?$W_5>'?^PO#6-\9/\
MCTL?^NI_E6&(DXTFUN>GDU&G7QU.G45XM[?)GEG]O>)_^AHU3_OY1_;WB?\
MZ&C5/^_E5**\?ZU6_F/TC^PLN_Y](M_V]XG_ .AHU3_OY1_;WB?_ *&C5/\
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M% 6,3^R-:_Z&_6?^_@_PH_LC6O\ H;]9_P"_@_PK;HH"QB?V1K7_ $-^L_\
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M]=!5NJE]U@_ZZ"K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %4[S_CYM/^NG]*N53O/^/FT_ZZ?TH N4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U'_CT/\
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M=W!>&;<V,8!([5?^+G_(GVG_ &%+3_T8*;5DB>MO([ZH9KJWMSB:XBC)Z;W
M_G4U8FM^$=#\12+)JMBMPR?=)8C'Y&H=^A2L<1?Q:[#XROM4A\/PZO:21H(R
M9%PN.IYKH)?&%I:>%_M/DQVDY(B\@$ 1NW ]NM5)=,\5>';A[7PU86=YI;@!
M8[FY\ORO4CCFKMKX$TZ^TIH=>LXYY)6#R1[B54CT(H2O'E6WW/?_ "OKW$W[
MW,]_PV_X8YCP3;F/Q3?K<7J27=RC-(1(#AO;FJ[Z-J^FWZO=Z8D5E:7CW3ZA
MO&YE/&,=:W]"^&^GZ+XLEU"WT^&*V /E;9"2#VXK>\2Z5?ZS+9VD>P:>9/\
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M;'_ST3_OH5] _P#"I? __0 @_P"^F_QH_P"%2^!_^@!!_P!]-_C1_9W]X/\
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ML?\ ST3_ +Z%'FQ_\]$_[Z%?0/\ PJ7P/_T (/\ OIO\:/\ A4O@?_H 0?\
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M]M_C0%SF/MMK_P _,/\ W\%'VVU_Y^8?^_@KI_\ A5'@K_H!P_\ ?;?XT?\
M"J/!7_0#A_[[;_&@+G,?;;7_ )^8?^_@H^VVO_/S#_W\%=/_ ,*H\%?] .'_
M +[;_&C_ (51X*_Z </_ 'VW^- 7.8^VVO\ S\P_]_!1]MM?^?F'_OX*Z?\
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M5+[K!_UT%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *IWG_ !\VG_73^E7*IWG_ !\VG_73^E %RBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *FH_\>A_WA_.
MK2_='TJKJ/\ QZ'_ 'A_.K2_='TH 6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *X/XL?\ (LZ=_P!A>T_]#KO*X/XL?\BS
MIW_87M/_ $.@#O**** "BBB@#R'0_"]QKOC#QG-#K^HZ<(]4VE+5P WR#D^]
M=%_PKJ]_Z'37O^_J_P"%'@'_ )&;QQ_V%_\ V05WE '!_P#"NKW_ *'37O\
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M&KATTY)#<B0>8P+?=/M7M-<':?\ );=0_P"P1'_Z'0 ?\*ZO?^ATU[_OZO\
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MN9?$6IZ@IU2)?*NG!4<]?K7K*_\ (0?_ '!7&?$W_5>'?^PO#79K_P A!_\
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M%I%=@B*6.<29X[XZ5?T.ZGTZ^U#2>9?)RULK-RW&2,_6O-]$5(?%5M_PB?\
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MH^NT>X?ZL9E_(OO7^9]/T5\P?\)AXT_Z&N]_[X7_  H_X3#QI_T-=[_WPO\
MA1]=H]P_U8S+^1?>O\SZ?HKY@_X3#QI_T-=[_P!\+_A1_P )AXT_Z&N]_P"^
M%_PH^NT>X?ZL9E_(OO7^9]/T5\P?\)AXT_Z&N]_[X7_"C_A,/&G_ $-=[_WP
MO^%'UVCW#_5C,OY%]Z_S/I^BOF#_ (3#QI_T-=[_ -\+_A71^![OQ=XL.I^?
MXSO[<6<BH"D:'<",Y.:SK9EAJ--U)O1>3]#EQ>38S"14ZT;)NVZ/?*C,\(.#
M*@(_VA7C\FLWWAG42=0\7ZKJ$17:(DMU9L^H"\D>]:NG>(_#>JVMS<[9U>!=
M\PN(S'(>>NTFO/Q.?TZ<5.E3E)/K:WYG*L,EI4=F^AZ8LT3'"R(3Z!A3Z\;_
M .%@>&_+>33[?5XI!E5N(K)V"GZ]*3P_!XCU^W:XC\=ZE&C'*#R4R15T\\I*
MFZF(@X6[K_(F6'3UINY[+17F?_"+^*/^A^U3_OS'1_PB_BC_ *'[5/\ OS'4
M?ZSY;_._N?\ D9^QGV/08?\ D(W'^ZM6Z\Q'A/Q*LC./'FI[FZGR8Z=_PB_B
MC_H?M4_[\QT?ZSY;_._N?^0>QGV/3**\S_X1?Q1_T/VJ?]^8Z/\ A%_%'_0_
M:I_WYCH_UGRW^=_<_P#(/8S['IE%>9_\(OXH_P"A^U3_ +\QT?\ "+^*/^A^
MU3_OS'1_K/EO\[^Y_P"0>QGV/3**\S_X1?Q1_P!#]JG_ 'YCH_X1?Q1_T/VJ
M?]^8Z/\ 6?+?YW]S_P @]C/L>F45YG_PB_BC_H?M4_[\QT?\(OXH_P"A^U3_
M +\QT?ZSY;_._N?^0>QGV/3**\S_ .$7\4?]#]JG_?F.C_A%_%'_ $/VJ?\
M?F.C_6?+?YW]S_R#V,^QZ917F?\ PB_BC_H?M4_[\QT?\(OXH_Z'[5/^_,='
M^L^6_P [^Y_Y![&?8],HKS/_ (1?Q1_T/VJ?]^8Z/^$7\4?]#]JG_?F.C_6?
M+?YW]S_R#V,^QZ917F?_  B_BC_H?M4_[\QT?\(OXH_Z'[5/^_,='^L^6_SO
M[G_D'L9]CTRBO,_^$7\4?]#]JG_?F.C_ (1?Q1_T/VJ?]^8Z/]9\M_G?W/\
MR#V,^QZ917F?_"+^*/\ H?M4_P"_,='_  B_BC_H?M4_[\QT?ZSY;_._N?\
MD'L9]CTRBO,_^$7\4?\ 0_:I_P!^8Z/^$7\4?]#]JG_?F.C_ %GRW^=_<_\
M(/8S['IE5)/^0I!_US:O/O\ A%_%'_0_:I_WYCII\)^)3(LA\>:GN48!\F.C
M_6?+?YW]S_R#V,^QZ=17F?\ PB_BC_H?M4_[\QT?\(OXH_Z'[5/^_,='^L^6
M_P [^Y_Y![&?8],HKS/_ (1?Q1_T/VJ?]^8Z/^$7\4?]#]JG_?F.C_6?+?YW
M]S_R#V,^QZ917F?_  B_BC_H?M4_[\QT?\(OXH_Z'[5/^_,='^L^6_SO[G_D
M'L9]CTRBO,_^$7\4?]#]JG_?F.C_ (1?Q1_T/VJ?]^8Z/]9\M_G?W/\ R#V,
M^QZ917F?_"+^*/\ H?M4_P"_,=(?#'B@*3_PGVJ<#_GC'1_K-EO\[^Y_Y![&
M?8]-HKC?AAJ=_JW@U+C4KM[JY6XEC,K@98*V!TKLJ]Y--71D%%%%, HK'U;Q
M/I6B:C8V6H7'D27I81,W"<#)R3TK4@N(;J%9K>5)8FY5T8,#]"* )**** "B
MBB@ HHHH **** *E]U@_ZZ"K=5+[K!_UT%6Z "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *IWG_'S:?]=/Z5<JG>?\?-I_
MUT_I0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMK@[3_DMNH?]@B/_ -#KO*X.T_Y+;J'_ &"(_P#T.@#O**** "BBB@ HHHH
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M\?FL#YBCJ1BFE9V73_._^8KO?^MK&!K?@>\U2]>99(=ILG@ 8]6)XS[5D?\
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M ]?FJ;ZI%):-GI&GZG8ZM:BZT^ZBN8"2!)&V0:9J>LZ;HT(FU*]AM8SP&E;
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M1T:;1XIGDB=?WK+)\[#W:O%K5J,J\<2G*VETEHDM_P#AM#XJ<)>T<TKIN_\
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M]?SHLP'44WS(_P"^OYT>9'_?7\Z+,!U%-\R/^^OYT>9'_?7\Z+,!U%-\R/\
MOK^='F1_WU_.BS =37^XWTH\R/\ OK^=->1-C?.O3UHLP.&\)Z=J^J_""YM-
M#O/LFH/>S^7-NQM_>'/-;=]X<\83?#.UTBWUG9KZ,IDO/,/S $YY^E/^$/\
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M+]T?2JNH_P#'H?\ >'\ZM+]T?2@!:*** "BBB@ HHHH **** "BBB@ HHHH
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MI_!]AJVC27&EW-LHT^-B;:8$?=[+CZ=ZH?VM\3_^A8T/_P &#?X4?VM\3_\
MH6-#_P#!@W^%-.WW6^X'K]]SO:H:Y_R+^I?]>LO_ *":Y'^UOB?_ -"QH?\
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M(Q5S^UOB?_T+&A_^#!O\*0SO:*X+^UOB?_T+&A_^#!O\*/[6^)__ $+&A_\
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M*C\*_P!R_P#_  ,?_&N[HI\D>PFVSA/^%1^%?[E__P"!C_XT?\*C\*_W+_\
M\#'_ ,:[NBE[.'85SSR/X4>&&O9HRM_M4 C_ $Q_\:L?\*C\*_W+_P#\#'_Q
MKL(?^0C<?[JU;H]G#L.YPG_"H_"O]R__ / Q_P#&C_A4?A7^Y?\ _@8_^-=W
M11[.'85SA/\ A4?A7^Y?_P#@8_\ C1_PJ/PK_<O_ /P,?_&N[HH]G#L%SA/^
M%1^%?[E__P"!C_XT?\*C\*_W+_\ \#'_ ,:[NBCV<.P7.$_X5'X5_N7_ /X&
M/_C1_P *C\*_W+__ ,#'_P :[NBCV<.P7.$_X5'X5_N7_P#X&/\ XT?\*C\*
M_P!R_P#_  ,?_&N[HH]G#L%SA/\ A4?A7^Y?_P#@8_\ C1_PJ/PK_<O_ /P,
M?_&N[HH]G#L%SA/^%1^%?[E__P"!C_XT?\*C\*_W+_\ \#'_ ,:[NBCV<.P7
M.$_X5'X5_N7_ /X&/_C1_P *C\*_W+__ ,#'_P :[NBCV<.P7.$_X5'X5_N7
M_P#X&/\ XT?\*C\*_P!R_P#_  ,?_&N[HH]G#L%SA/\ A4?A7^Y?_P#@8_\
MC1_PJ/PK_<O_ /P,?_&N[HH]G#L%SA/^%1^%?[E__P"!C_XT?\*C\*_W+_\
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M4 %%%% !7!_%C_D6=._["]I_Z'7>5P?Q8_Y%G3O^PO:?^AT =Y1110 4444
M<'X!_P"1F\<?]A?_ -D%=Y7!^ ?^1F\<?]A?_P!D%=Y0 4444 %%%% !5#7/
M^1?U+_KUE_\ 035^J&N?\B_J7_7K+_Z": .?^%O_ "3#P]_UZ+_,UU]<A\+?
M^28>'O\ KT7^9KKZ "BBB@ K@[3_ )+;J'_8(C_]#KO*X.T_Y+;J'_8(C_\
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M3?\ H%=Y7!^+O^2B^#/^NTW_ *!7>4 %%%% !1110 4444 %<%\7?^10M/\
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M$]OFP*G\&ZO>7GVJSU&99+B!AAMV=P/-.*YMNUPEI]]ON.LHHHI %<%\7?\
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MB!F,R#(-2375O;@&:>*,'IO<#/YUX';:5XBUZ&?5AHFCS2BX91J,]^4D4*V
M,=*Z+Q7I&LZ@=.FFLM.UA8(&\^TDNR/?*A>3@54KK<2U>FQZY%-%,FZ*1)%]
M48$4^O.OA=J.FRVES:V8NX)-^YK.>(HL''W5)Y(]S7HM5)68D[G!^+O^2B^#
M/^NTW_H%=+XBUU- TW[4T?FR,X2./.-S$X _.N:\7?\ )1?!G_7:;_T"K7Q
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M$W_5>'?^PO#6-\9/^/2Q_P"NI_E6&(FX4G*.YZ>48>GB,;3I55>+>OW' ?\
M"Q/'?_0<B_\  9:/^%B>._\ H.1?^ RU@45Y'URMW/T+_5O+?^??XO\ S-__
M (6)X[_Z#D7_ (#+1_PL3QW_ -!R+_P&6L"BCZY6[A_JWEO_ #[_ !?^9O\
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MG>GZ=XV@\?WEUJUZDGA]Y#]DA$@)7TXQQ5K5=.\;R_$JPO+"]1/#*!?M$!D
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MVE2Z?<>)+-(Y""2DHSP<U>@\=^#[>!(5\16)5%"C,HK2_P"$5\/_ /0%L/\
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M%-!X%>6X:+QHL$=PY>6..<!7SV/M7HG_  BOA_\ Z MA_P" Z_X4?\(KX?\
M^@+8?^ Z_P"%:QKU(NZ9/*K6.7.N>!/M.GSIXBLD-E]Q5E&#QCFHM?U?P3KL
MT-Q_PE=O:7$((2:"8!L'J*ZW_A%?#_\ T!;#_P !U_PH_P"$5\/_ /0%L/\
MP'7_  I*K--.^P[+8XJPNO EC9WUO_PE5O,UZ#YLLDPW$D8S]:2VN_!$$%C$
M_B^*<6<OF1&28$],8^E=M_PBOA__ * MA_X#K_A1_P (KX?_ .@+8?\ @.O^
M%-UZCZARHY.+5O L6A2Z2/$UJ899#(6\T9R3FFW&J>!+FXAF?Q-:YAA>$ 2C
MD,,&NN_X17P__P! 6P_\!U_PH_X17P__ - 6P_\  =?\*7M9WO<+*UCSRS@\
M"6;6ZKXS5[:!@PMFG&PD>U=HGC[P?&@1/$&GA0, "4<5?_X17P__ - 6P_\
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M7;:^L/$.FI&J,LJF7[Q/0UV/_"*^'_\ H"V'_@.O^%'_  BOA_\ Z MA_P"
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ML?VG8_\ /U%_WU1_:=C_ ,_47_?5?4__  BOA_\ Z MA_P" Z_X4?\(KX?\
M^@+8?^ Z_P"%']G0[A_KCB/^?:_$^6/[3L?^?J+_ +ZH_M.Q_P"?J+_OJOJ?
M_A%?#_\ T!;#_P !U_PH_P"$5\/_ /0%L/\ P'7_  H_LZ'</]<<1_S[7XGR
MQ_:=C_S]1?\ ?5']IV/_ #]1?]]5]3_\(KX?_P"@+8?^ Z_X4?\ "*^'_P#H
M"V'_ (#K_A1_9T.X?ZXXC_GVOQ/EC^T['_GZB_[ZH_M.Q_Y^HO\ OJOJ?_A%
M?#__ $!;#_P'7_"C_A%?#_\ T!;#_P !U_PH_LZ'</\ 7'$?\^U^)\L?VG8_
M\_47_?5']IV/_/U%_P!]5]3_ /"*^'_^@+8?^ Z_X4?\(KX?_P"@+8?^ Z_X
M4?V=#N'^N.(_Y]K\3Y8_M.Q_Y^HO^^J/[3L?^?J+_OJOJ?\ X17P_P#] 6P_
M\!U_PH_X17P__P! 6P_\!U_PH_LZ'</]<<1_S[7XGRQ_:=C_ ,_47_?5']IV
M/_/U%_WU7U/_ ,(KX?\ ^@+8?^ Z_P"%'_"*^'_^@+8?^ Z_X4?V=#N'^N.(
M_P"?:_$^6/[3L?\ GZB_[ZH_M.Q_Y^HO^^J^G8O"^@G4)U.C6. HP/(7_"K7
M_"*^'_\ H"V'_@.O^%']G0[A_KCB/^?:_$^6/[3L?^?J+_OJC^T['_GZB_[Z
MKZG_ .$5\/\ _0%L/_ =?\*/^$5\/_\ 0%L/_ =?\*/[.AW#_7'$?\^U^)\L
M?VG8_P#/U%_WU1_:=C_S]1?]]5]3_P#"*^'_ /H"V'_@.O\ A1_PBOA__H"V
M'_@.O^%']G0[A_KCB/\ GVOQ/EC^T['_ )^HO^^J+34[%/$NBS-=1".*YW.V
M[A1@\FOJ?_A%?#__ $!;#_P'7_"C_A%?#_\ T!;#_P !U_PJZ6"C3FI)['+C
M>)ZV+P\J$H)*7J>(>(M1T'5K=&BUBU$\62@\S@URL+P2RHDUS'!$W620X&/\
M:^F?^$6T#_H"V'_@.O\ A4$'@W0(+BZF_LZ"3[0P9DD0,JX&/E&.*]FCBG3@
MXOY'AT<5*G!Q1Y59>(?#MC90VL>L6Q2)=H)?FI_^$LT#_H+6O_?=>J_\(KX?
M_P"@+8?^ Z_X4?\ "*^'_P#H"V'_ (#K_A7&VV[LYKGE7_"6:!_T%K7_ +[H
M_P"$LT#_ *"UK_WW7JO_  BOA_\ Z MA_P" Z_X4?\(KX?\ ^@+8?^ Z_P"%
M 7/*O^$LT#_H+6O_ 'W1_P )9H'_ $%K7_ONO5?^$5\/_P#0%L/_  '7_"C_
M (17P_\ ] 6P_P# =?\ "@+GE7_"6:!_T%K7_ONC_A+- _Z"UK_WW7JO_"*^
M'_\ H"V'_@.O^%'_  BOA_\ Z MA_P" Z_X4!<\J_P"$LT#_ *"UK_WW1_PE
MF@?]!:U_[[KU7_A%?#__ $!;#_P'7_"C_A%?#_\ T!;#_P !U_PH"YY5_P )
M9H'_ $%K7_ONC_A+- _Z"UK_ -]UZK_PBOA__H"V'_@.O^%'_"*^'_\ H"V'
M_@.O^% 7/*O^$LT#_H+6O_?='_"6:!_T%K7_ +[KU7_A%?#_ /T!;#_P'7_"
MC_A%?#__ $!;#_P'7_"@+GE7_"6:!_T%K7_ONC_A+- _Z"UK_P!]UZK_ ,(K
MX?\ ^@+8?^ Z_P"%59/"^@_VE"O]C6."C9'D+_A0%SS3_A+- _Z"UK_WW1_P
MEF@?]!:U_P"^Z]5_X17P_P#] 6P_\!U_PH_X17P__P! 6P_\!U_PH"YY5_PE
MF@?]!:U_[[H_X2S0/^@M:_\ ?=>J_P#"*^'_ /H"V'_@.O\ A1_PBOA__H"V
M'_@.O^% 7/*O^$LT#_H+6O\ WW1_PEF@?]!:U_[[KU7_ (17P_\ ] 6P_P#
M=?\ "C_A%?#_ /T!;#_P'7_"@+GE7_"6:!_T%K7_ +[H_P"$LT#_ *"UK_WW
M7JO_  BOA_\ Z MA_P" Z_X4?\(KX?\ ^@+8?^ Z_P"% 7/*O^$LT#_H+6O_
M 'W1_P )9H'_ $%K7_ONO5?^$5\/_P#0%L/_  '7_"C_ (17P_\ ] 6P_P#
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MC&]O4^]6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J=Y_P ?-I_UT_I5RJ=Y_P ?-I_UT_I0!<HHHH **** "BBB@ HHHH ****
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M#_[@H LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!4A_Y"-Q_NK5NJD/\ R$;C_=6K= !1110 4444 %%%% !1110
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MN"_L/2O^@=:_]^EH_L/2O^@=:_\ ?I: L=[_ ,+"\(?]##8?]_:/^%A>$/\
MH8;#_O[7!?V'I7_0.M?^_2T?V'I7_0.M?^_2T!8[W_A87A#_ *&&P_[^T?\
M"PO"'_0PV'_?VN"_L/2O^@=:_P#?I:/[#TK_ *!UK_WZ6@+'>_\ "PO"'_0P
MV'_?VC_A87A#_H8;#_O[7!?V'I7_ $#K7_OTM']AZ5_T#K7_ +]+0%CO?^%A
M>$/^AAL/^_M'_"PO"'_0PV'_ ']K@O[#TK_H'6O_ 'Z6C^P]*_Z!UK_WZ6@+
M'>_\+"\(?]##8?\ ?VC_ (6%X0_Z&&P_[^UP7]AZ5_T#K7_OTM']AZ5_T#K7
M_OTM 6.]_P"%A>$/^AAL/^_M'_"PO"'_ $,-A_W]K@O[#TK_ *!UK_WZ6C^P
M]*_Z!UK_ -^EH"QWO_"PO"'_ $,-A_W]H_X6%X0_Z&&P_P"_M<%_8>E?] ZU
M_P"_2U5\ Z+I=QKWBA)M/M9%CNHP@:($*-G:N',<<L#AW7DKVMIZNQ4(<SL>
MC_\ "PO"'_0PV'_?VI(/'7A:ZG2"#7;*25SA563DFN(\33>']%AQ#I-@TV[:
MJ^0IW-_=''6L;1[S1HM;LQJ/A2;2IYF'DRS;-KMCL *\B'$+G2=3V+\M5?[M
M/PN=#PT8*]25CURY\2Z+9P-/<:G;Q1+U9GP!6+)X_P#"9U&%QX@L=H1@3YM<
M/>>+K?69;O3;/P==ZE#$<2/"R ?K3_#4FE:C)<Q/X>MK<VC!)+6:%&E7(SDD
M<<4EG]2--RJ4;-=.9;?B_O&\/"3M"7W_ .9W_P#PL+PA_P!##8?]_:/^%A>$
M/^AAL/\ O[5&/P_H$T:R1Z58LC#((@7G]*=_PC>A_P#0(LO^_"_X5Q/C&FG9
MTG]__ (^K/N7/^%A>$/^AAL/^_M'_"PO"'_0PV'_ ']JG_PC>A_] BR_[\+_
M (4?\(WH?_0(LO\ OPO^%'^N5+_GT_O_ . 'U=]RY_PL+PA_T,-A_P!_:/\
MA87A#_H8;#_O[5/_ (1O0_\ H$67_?A?\*/^$;T/_H$67_?A?\*/]<J7_/I_
M?_P ^KON7/\ A87A#_H8;#_O[1_PL+PA_P!##8?]_:I_\(WH?_0(LO\ OPO^
M%'_"-Z'_ - BR_[\+_A1_KE2_P"?3^__ ( ?5WW+G_"PO"'_ $,-A_W]H_X6
M%X0_Z&&P_P"_M4_^$;T/_H$67_?A?\*/^$;T/_H$67_?A?\ "C_7*E_SZ?W_
M / #ZN^Y<_X6%X0_Z&&P_P"_M'_"PO"'_0PV'_?VJ?\ PC>A_P#0(LO^_"_X
M4?\ "-Z'_P! BR_[\+_A1_KE2_Y]/[_^ 'U=]RY_PL+PA_T,-A_W]H_X6%X0
M_P"AAL/^_M4_^$;T/_H$67_?A?\ "C_A&]#_ .@19?\ ?A?\*/\ 7*E_SZ?W
M_P# #ZN^Y<_X6%X0_P"AAL/^_M'_  L+PA_T,-A_W]JG_P (WH?_ $"++_OP
MO^%'_"-Z'_T"++_OPO\ A1_KE2_Y]/[_ /@!]7?<N?\ "PO"'_0PV'_?VC_A
M87A#_H8;#_O[5/\ X1O0_P#H$67_ 'X7_"C_ (1O0_\ H$67_?A?\*/]<J7_
M #Z?W_\  #ZN^Y<_X6%X0_Z&&P_[^T?\+"\(?]##8?\ ?VJ?_"-Z'_T"++_O
MPO\ A1_PC>A_] BR_P"_"_X4?ZY4O^?3^_\ X ?5WW+G_"PO"'_0PV'_ ']H
M_P"%A>$/^AAL/^_M4_\ A&]#_P"@19?]^%_PH_X1O0_^@19?]^%_PH_URI?\
M^G]__ #ZN^Y<_P"%A>$/^AAL/^_M:FDZ]I6NQR2:7?P7:1$!S$V=I/K7/_\
M"-Z'_P! BR_[\+_A63\-X8+7Q3XSMX(XXHUO8]L:  #Y.PKU,ISZ&8U72C!Q
MLK[F=2DX*]SO+[K!_P!=!5NJ5ZZEH%# D2#C-7-ZAMI8;O3/->^9"T4F]=VW
M<-WIGFC>N[;N&[TSS0 M%8UIXLT*^UFXTBVU*&34+?/FP G<F.N:V<Y&10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53O/^/FT_ZZ?T
MJY5.\_X^;3_KI_2@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %34?^/0_P"\/YU:7[H^E5=1_P"/0_[P_G5I?NCZ
M4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<'\6/^19T[_L+VG_H==Y7!_%C_ )%G3O\ L+VG_H= '>4444 %%%% '!^
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M"X] *J.F^]E^GXBGK>W<ZNJ&N?\ (OZE_P!>LO\ Z":OU0US_D7]2_Z]9?\
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M5JT03[+;6\L<A+<Y;&,"G#2HGZ_D/[$EY,Y#4=3O)/'=VMKI"ZK<0*T:02,
MH7UR>,UT_@>:SDCNME@;"\\QC-;[]P!SV[5%K&D:]IFM/JWAJUM;N68$2PW,
MOEKD]\CG-7O"VBWMD9[_ %18TOK@G?'&VY5&<X!J:5U%)]G^8JFLM._Z$MUX
MSTBTDD5Y),1G#D1G [58M_$^FW"3L)&7R" X92.HR*RKCPY>R:5=VX2+S)9
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M_OZO^-227J*H_P!M:7_T$;7_ +^K_C1_;6E_]!&U_P"_J_XT 7J*H_VUI?\
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MHTZ*S/\ A(]$_P"@M9?]_P!?\:/^$CT3_H+67_?]?\:/85?Y7]P71IT5F?\
M"1Z)_P!!:R_[_K_C1_PD>B?]!:R_[_K_ (T>PJ_RO[@NC3HK,_X2/1/^@M9?
M]_U_QH_X2/1/^@M9?]_U_P :/85?Y7]P71IT5F?\)'HG_06LO^_Z_P"-'_"1
MZ)_T%K+_ +_K_C1["K_*_N"Z-.BLS_A(]$_Z"UE_W_7_ !H_X2/1/^@M9?\
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MN:P+Q/LZ(D'E &)AU^;OZ5U81 Q8*H8]2!S3J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J=Y_Q\VG_ %T_I5RJ=Y_Q\VG_ %T_I0!<
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"IJ/_ !Z'_>'\ZM+]T?2JNH_\>A_WA_.K2_='TH 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X/XL?\BSIW_87M/\
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M '^'^%'_  KBY_Z''7O^_P /\*[RB@#@_P#A7%S_ -#CKW_?X?X4?\*XN?\
MH<=>_P"_P_PKO** .#_X5Q<_]#CKW_?X?X4?\*XN?^AQU[_O\/\ "N\HH \_
ME^&,DX7S?%VNOM.X9F'!_*I/^%<7/_0XZ]_W^'^%=Y10!YCJOABQT,(=4^(6
MKV@<X7S;@#/Z4W2_#FG:V[+IGQ$U:[9?O"*Y!Q^E/^(TIA\2:&XT9]6(D?\
MT50N6^7_ &N*HZ=>I)X[TWS_  W/X<402GRV*@3>_P OI[T4_>M?S_"XYZ;&
M_P#\*XN?^AQU[_O\/\*/^%<7/_0XZ]_W^'^%<YK_ ,3+I=9O8;#7]-TZ.R<Q
MO;W5LTCS$<_*1TK7N_&NK7VF:+_8[PI<W\HA:62/<@.W.<>E$?>2:ZB>DK,N
M?\*XN?\ H<=>_P"_P_PJ"[\"_8(?.NO'&MPQY"[GG &3T[5-HOB+7+#4]3T_
MQ'<VMS);0K)'+;Q>6IW=L&N7\1WOB[5_#:ZE<-;'2Y;F/9:+#B50&QDMG'O4
MS=E=?U<J*N[,Z>/X>32QK)'XSUUD89!$PY_2F7'@![2W>>X\;:Y'$@RSM.,
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M_P *XN?^AQU[_O\ #_"N\HH X/\ X5Q<_P#0XZ]_W^'^%'_"N+G_ *''7O\
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MP?\ ]"[8?]^JZ:B@#F?^%=^#_P#H7;#_ +]4?\*[\'_]"[8?]^JZ:B@#F?\
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MOZE_UZR_^@F@#G_A;_R3#P]_UZ+_ #-=?7(?"W_DF'A[_KT7^9KKZ "BBB@
MK@[3_DMNH?\ 8(C_ /0Z[RN#M/\ DMNH?]@B/_T.@#O**** "BBJ%UK6EV,O
ME7>HVL$F,[9)54_K0!?HJK9ZE8Z@";*\@N O4Q2!L?E4JW$+RM$DJ-(GWD#<
MC\* ):*B6ZMWF:%)HVE7[R!AD?A4M '#^,[+7/[;TK4]'TU;XVKL7C,H3J,=
MZ@M+'7_$FOVU[K>DKIL-K&R!!*'+D]\CI7?TC,%4LQ 4#))[4+1:]!O7\CS"
MYT3Q#H>JZD-,T2VU*"^D,JSR; 83C Z]?6M>XT#5IYO#TTB1L]M<"6XV *$&
MWT%=5!K>E7,_D0:C:RS?W$E4G\JMRW$,!42RHA<X7<V,GVIQ=K>7_#">K9R-
MSX<N[OQ3J-S)&!:SP(BOGN!7,7FG>-FT5/#T>DH\$<ZL+WS0-RAL_=KTNZUG
M3+*4176H6T,AZ+)*%)_.K0GB,/G"1#'C._/&/K4<JY;="N9WOU_X%CS34=!U
MZRUVQOK72%U)!:F)TDE 6-B>N#P:S_!7@K7K7Q+)=ZO9)#;+<FYA"L"%8GT'
MM7KD4T<\2RPR+)&PRK*<@T^M+M2YNNOXW_S(LG'E]/P./LO#3/XNU:\OK.%[
M6XA1(V=0W(SGZ5'X:T;4_#>MW-A!:H=%D):)PP!CXZ>^379LRJI9B !U)J'[
M;:^0)_M$7E,<!]XP3Z9J8Z62[6&];^90TK5Y=0O]1MY+7REM9O*5MV=XQUK6
MJKBRT_S)6:.'SGRS,V-S55;Q+H:.4?5[%6!P09UR/UH![W-2BFQR)+&'C=71
MAD,IR#3J "BBB@ HHHH *X.S_P"2VZG_ -@B+_T.N\K@[/\ Y+;J?_8(B_\
M0Z .\HHHH **** "BBB@ HHHH *X+XN_\B?;?]A.T_\ 1@KO:X+XN_\ (GVW
M_83M/_1@H [VBBB@ HHHH **** "BBB@ KD/BE_R3#Q#_P!>A_F*Z^N0^*7_
M "3#Q#_UZ'^8H Z#1/\ D :=_P!>L7_H(J_5#1/^0!IW_7K%_P"@BK] !111
M0 4444 %%%% '!^+O^2B^#/^NTW_ *!7>5P?B[_DHO@S_KM-_P"@5WE !111
M0 4444 %%%% !7!?%W_D4+3_ +"EI_Z,%=[7!?%W_D4+3_L*6G_HP4 =[111
M0 4444 %%%% !1110!P?Q-_U7AW_ +"\-=FO_(0?_<%<9\3?]5X=_P"PO#75
M76HV6G7I>]NX;=&4!6E<*"?QH TJ*R?^$HT'_H,V'_@0O^-'_"4:#_T&;#_P
M(7_&@#6HK)_X2C0?^@S8?^!"_P"-'_"4:#_T&;#_ ,"%_P : -:BLG_A*-!_
MZ#-A_P"!"_XT?\)1H/\ T&;#_P "%_QH UJ*R?\ A*-!_P"@S8?^!"_XT?\
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M0!K45D_\)1H/_09L/_ A?\:/^$HT'_H,V'_@0O\ C0!K45D_\)1H/_09L/\
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MS8?^!"_XT :U%9/_  E&@_\ 09L/_ A?\:/^$HT'_H,V'_@0O^- %N^ZP?\
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M^\2W?Q%CTSQ'KKR6ODR925E"E\#;SZT[-:BNCZ+HHHI#"BBB@ HHHH ****
M"J=Y_P ?-I_UT_I5RJ=Y_P ?-I_UT_I0!<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ/_'H?]X?SJTOW1]*JZC_
M ,>A_P!X?SJTOW1]* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "N#^+'_ "+.G?\ 87M/_0Z[RN#^+'_(LZ=_V%[3_P!#
MH [RBBB@ HHHH X/P#_R,WCC_L+_ /L@KO*X/P#_ ,C-XX_["_\ [(*[R@ H
MHHH **** "J&N?\ (OZE_P!>LO\ Z":OU0US_D7]2_Z]9?\ T$T <_\ "W_D
MF'A[_KT7^9KKZY#X6_\ ),/#W_7HO\S77T %%%% !7!VG_);=0_[!$?_ *'7
M>5P=I_R6W4/^P1'_ .AT =Y1110 5Y/K/_"*?\+)N?\ A)_L/E?9%\O[5TSG
MM7K%<5_PC2WOCVZO;_3(Y[-K54225 PW9[9I*_/?R8[^ZS%\*_V5%XRU*7PT
M(QI(@0L8/]5D YQ[YK4\.SHEOK'B*213]H),9SW (Q^E9+:+K/A6YO\ 3="T
MEY]-NL-&\8&8V8Y;)[CT%:&H>%;R\\-6'AN&.6"W<^9/.K8V8.2,CG)YIZN/
MN]DM?-Z_=;[@=E+7:]].R7Z[^IFZ6]U87%IXIN!(!J3 .A_@W?\ ZJUM1\3>
M(KGQ3)H^A0V;!8%F$LX..3CM56[^#^C?8&2VO]8,B+F%7OF90W;BG^"])UBT
M\2S3:A92Q0QVJP)*Y'[S:>M5&S=NB)DVM>K&>*/&6N:/<K LFF66R,,\EZ2%
MD;'(3'O5>^\6W.O> [&YCE$4UW.D<C0GC!?!Q[$5!K6FZM;^*]2=O#=SK,%S
M"JPRDJT<1P<X5OZ4NA^$-6D^'RV-Q:FTOH)1,B..NUBVT >O2HA9PO+R?XZH
MJ2:=H[[?AHSI3\.]&MX[9]/@6TO(7#-<Q##R8[$^]5/$+F\\3V%D7#?V>%NG
M7U!XJM!XC\;ZBMM9Q>&[C3IPP\Z\N0KQD=\*#D5I^'=&OVUF_P!0U>'$\B^0
M&Q@,H.00*)*3V\VO6PE9+7R1D>%?"VF>)=.N-3UFW2]N7FDC1IANV!6(&*Z2
M+3CX>\+W$!D-TD4;%1-SQ@\5S%I<^)O!LUUI=MX=NM6M7=I(;BW*JJECGG<<
MG%=#:1>(;SPK<C6/*:\FC;9%''M*\'@T3:<6X:*W]?,(IJ24]SC&^(%];66D
M6>G'2=.:>U\S%UE4ZXPN*Z-O%VKVW@:]U>ZLT%W;ABH4'9(!C!7V-<W)H^L6
M?A_3[2_\,-JT/V7RVBMT19XCG^^?Z5471-4TKX=ZT9X[NTB:-A#;7LGF.@R,
M<],53:O)>?ZA'=&U=>*/%%K;03:Q;V8T^\C.#"#O7Y<\Y^M8.HR:H?AQHYT\
MP"-KE"WF9SN\SBM.<>(_%%AI^FOH-S:V\40W7,A4K(-O&,<BK5SH&L0?#BQM
M8].EFO+>X1S;KC<0'S_*B-E=O^:/W?U<2;;2\G]_]6+GB3[9J4FF:1>O$+I4
M%S*L7W3M/./:JO@SP7X<U33K^:]TBUFF-W(/,=,G%:>C6&IZEK-WK&HZ;-:2
M>4T4$4I!(4\]O>L?1=9\3>'([ZR7P3J=UON7D2:.1 I!Z<$TE973W?\ F)I^
M[;9?Y$NE^)1X3T+4HKJ4R):.3&SGH"V /H*AT/XD7MQK$5G>:AH]RMPK&,63
M$LI[;LU9D\$ZC>>#[E;CRSJ5PYE*,F1C=N"D>O:F:(FKSZC %\%Q:5';QMYD
MLL$9,K#IM(Z9IQO?W]7I?[M7]]_,<]FX];V^_3]"]<^.=1T:6ZL=6M4^W,^V
MS$0^63T_6NOT2;4+C3(IM2CCCN'&XH@Z>Q]Z\]U#PCJGBV^GUW4()[.[LVS8
M0,WXC..#S74^'/$5_=78TG4]*GM;J&%6:5R-K]N *4%[NN_Z?Y]PEI+3;^OP
M['54444#"N#L_P#DMNI_]@B+_P!#KO*X.S_Y+;J?_8(B_P#0Z .\HHHH ***
M* "BBB@ HHHH *X+XN_\B?;?]A.T_P#1@KO:X+XN_P#(GVW_ &$[3_T8* .]
MHHHH **** "BBB@ HHHH *Y#XI?\DP\0_P#7H?YBNOKD/BE_R3#Q#_UZ'^8H
M Z#1/^0!IW_7K%_Z"*OU0T3_ ) &G?\ 7K%_Z"*OT %%%% !1110 4444 <'
MXN_Y*+X,_P"NTW_H%=Y7!^+O^2B^#/\ KM-_Z!7>4 %%%% !1110 4444 %<
M%\7?^10M/^PI:?\ HP5WM<%\7?\ D4+3_L*6G_HP4 =[1110 4444 %%%% !
M1110!P?Q-_U7AW_L+PUA?&NWAN;*P6:-7 E) 8>U;OQ-_P!5X=_["\-8WQD_
MX]+'_KJ?Y5ABFU1DT>MD48SS&E&2NK_HSQ;^R['_ )]8_P J/[+L?^?6/\JM
MT5X?M)]V?J?U/#_\^U]R*G]EV/\ SZQ_E1_9=C_SZQ_E5NBCVD^[#ZGA_P#G
MVON14_LNQ_Y]8_RH_LNQ_P"?6/\ *K=%'M)]V'U/#_\ /M?<BI_9=C_SZQ_E
M1_9=C_SZQ_E5NBCVD^[#ZGA_^?:^Y%3^R['_ )]8_P J/[+L?^?6/\JMT4>T
MGW8?4\/_ ,^U]R*G]EV/_/K'^5']EV/_ #ZQ_E5NBCVD^[#ZGA_^?:^Y%3^R
M['_GUC_*C^R['_GUC_*K=%'M)]V'U/#_ //M?<BI_9=C_P ^L?Y4?V78_P#/
MK'^56Z*/:3[L/J>'_P"?:^Y%3^R['_GUC_*HKC3+);:4BVC!"$@X]JT*BN?^
M/6;_ '&_E3C4G=:F=7"8?D?[M;=D=-I&D:%#X%LKZXTZT>X:W!#2+]]JY]8X
MMRN;>-D#;O)8?)],>E:+O=?\(=H<93_0_(4EL?Q\X%4:^XP=-1IW[GYC@*$9
M0<I=3M=)T/PYJFGI=)HULH/!!3N.M7?^$2\/_P#0(M?^^*RO!$<X%S*P;[,V
M!&<\9[XKKZ\[$04*CBCS:L%";BC%_P"$2\/_ /0(M?\ OBC_ (1+P_\ ] BU
M_P"^*VJ*Q(,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - B
MU_[XH_X1+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ
M* ,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XH_X1
M+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7_A$O
M#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XH_X1+P__ - B
MU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7_A$O#_\ T"+7
M_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XH_X1+P__ - BU_[XK:HH
M Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7_A$O#_\ T"+7_OBC_A$O
M#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XH_X1+P__ - BU_[XK:HH Q?^$2\/
M_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7
M_OBMJB@#%_X1+P__ - BU_[XH_X1+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^
M^*/^$2\/_P#0(M?^^*VJ* ,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#
M%_X1+P__ - BU_[XH_X1+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/
M_P#0(M?^^*VJ* ,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__
M - BU_[XH_X1+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^
M^*VJ* ,7_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[X
MH_X1+P__ - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7
M_A$O#_\ T"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XH_X1+P__
M - BU_[XK:HH Q?^$2\/_P#0(M?^^*/^$2\/_P#0(M?^^*VJ* ,7_A$O#_\
MT"+7_OBC_A$O#_\ T"+7_OBMJB@#%_X1+P__ - BU_[XKR#XBZ9;V?B];33[
M5(D:%"(XQC)YKWFO&?B#*D'Q'MY96"HL2$D]N#36XGL36D*06L<:($ 49 ]:
MQ-6V:?KVFZGY)\J&9))64=<,#^?%= I#*&!R",BL/Q3-&--\@L/-=@57N0*Z
M9I<ISQ>I]=Z)JT.NZ)9ZI;JRPW48D17Z@'UJ_7+_  X!'PZT$$$$6B\&NHKF
M-PHHHH **** "BBB@ JG>?\ 'S:?]=/Z5<JG>?\ 'S:?]=/Z4 7**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:C_Q
MZ'_>'\ZM+]T?2JNH_P#'H?\ >'\ZM+]T?2@!:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K@_BQ_P BSIW_ &%[3_T.N\K@
M_BQ_R+.G?]A>T_\ 0Z .\HHHH **** .#\ _\C-XX_["_P#[(*[RN#\ _P#(
MS>./^PO_ .R"N\H AFNK>VQY\\46>GF.%S^=$-W;7.?(N(I<==CAL?E7GOQ!
MM=)O/$VA0:SY1LVD;>)7VK]WUS571[71]+\=6]OX7,:V,D,AN%MFWIN XR<F
MB'O+[_PO_D$_=_#\3TA]2L8G*27MLC#JK2J"/UJ>*:*=-\4B2+_>1@17D6FZ
M-X,U'Q#XAD\0K9-<+>83SYMIQM'N*Z+X:JD*:E;V19M.2Y?R<] ,]!ZBG%76
MO:X2T>G>QWU4-<_Y%_4O^O67_P!!-7ZH:Y_R+^I?]>LO_H)I <_\+?\ DF'A
M[_KT7^9KKZY#X6_\DP\/?]>B_P S77T 037EK;L%FN88V/0/( ?UJ965U#*P
M93T(.:X'Q?X<T.-[C5]<M[K4V90L,:1%O*([C;6QX"-Q_P (M;)=3+)*N>C9
M(&> ?PHAJF^J"6ECIZX.T_Y+;J'_ &"(_P#T.N\K@[3_ )+;J'_8(C_]#H [
MRBBB@ HZ=:*ANO\ CUD_W:F4N6+8TKNQ$=4T\-M-];!@<8,RY_G4TEU;Q1^9
M)/$D9Z,S@#\Z\!TB7P4+.\.J>'-1NK\7,W^D1VLCK]XXY!QQ6GK4\,OPSTZ6
M_>:\MVG3=&%RVW?TP.>E7;\TO+43TOY7]=#VB*_LYWV0W<$C>B2 G]*G9E12
MS,%4=23P*\Z\%1^"Y=6+:'X=O;&Y53^\GMGC&/J36WXVOW%M:Z1!DRZC)Y!*
M]4!&<TI)I*V[".K?D=2LD;)O5U*_W@>*2.:*5=T<J.H[JP(KA-!F?3M/U#P_
M<NS36\9D#-_%N]*QO %V-.\-7\<DK_O=_E#TZ]/QI-JS?1)/^ON#7\;'J<<\
M4Q812H^TX;:P.#2^9'YGE[UW]=N>?RKSKX4P/#%JIE9C*]SN<MUSBM70U;5/
M&5_J98-'$OV=0#P&4U;C:7*^PF]&_/\ ,[.FK(CYV.K8ZX.<5G:_J(TS2)KC
M&6QA5[G/%<YH'FZ'J2VUT[-]M4RAFZ#':MZ>&<Z3G?T\[;_<3.?+8[:J6I6%
MGJUI+878#QR+AT#8.*S+;Q%+/'K#&!!]@D*+@GY\#/-<KHNM:SJ'C9KAK2V6
M%K=?,_>GY4SU'O6E/ 5)*3>G*K_JA2JJ*NN]CT:&%+>!(8QA$4*H]A4E<._C
M'67CEU"VTNV?28I#&TK2$29!P<+]:[*UN$N[:.=/NN,UE6PU2BKS_/\ ,<9Q
M;LA\LT4*[I94C'J[ 4D4\,XS%+'(/]A@:XCQ@L0UJW;5K6YN])\HYAAC+_/G
M@X%7- L-'L[E[S1[LPPM&"UCQ\ON1G(-;/"15%5&W=^6GI?O\A.;Y^5'5275
MO"VV6>)&]&< TK3Q)'YCRHJ?WBP _.N(T30+/Q/;SZGJZ?:IFE>./>?N;3@8
MQ6];>&X&TC^S-2/VR '*B3_ZU35H4:;Y7)W6^GY:Z_@$9N6JV-3^T++_ )_+
M?_OZO^-$=M;-=F]C :1T";P<@BN!MO!V@/XNFM&TZ,P*C$)DX_G7H%I:06-N
MEO;1B.)!A5':EB:-&E;DDVWKJDOU80E)MIK8GHHHKD- K@[/_DMNI_\ 8(B_
M]#KO*X.S_P"2VZG_ -@B+_T.@#O**S?[<L0)RTA00#+EABH1XEL/LD%RPG1)
MFVH&CP>N.E"UM;K;\=@>G]=C8HK(U/Q)8Z5.D,PFD=C@^2F_;]?2J=UXTTVS
M&Z6&\V8SO$!*X^M 6.CHJO'>0R68NLE8BN[+C'%9VG^)K#4;R2VB$Z.F?FDC
MVJV.X/>G9WL%]+FS16,OB?3WU3[ /-W]/,V?NR?3=ZT]O$5BNJIIW[TS.<!@
MGRY^M):@]#6K@OB[_P B?;?]A.T_]&"NTM;Z&\W&$E@IP3CC-<7\7?\ D3[;
M_L)VG_HP4 =UYL?F>7O7?C.W//Y4"6,R&,.I<#)7/->:^(?$EMX=^),$]U!>
M3(UHPVVL)D/WO05)X1UZ#Q!\0=0NK:&[AC^R*-MS$8V^]Z&G#WTFNS?W!/W=
M_(]&$L;.45U+#JH/(I]<%<^*+71]9UN8Z?&LEO%&3(I):0DX (J&V\;>(8KZ
MWL]:T>TMC>*6@:"5G&T?WO0TEJE;K;\1M6O?^K'H*2)(6".K%3@X.<4ZO(+#
M7_$&E:AXDFTK3+:ZMH+LO.T\K(5 49V@=:]1T?4!JND6U[M"F:,.5'8D=*:5
MX\R\OQ0GH[,EDU&QB<I)>6Z,.JM*H/\ .I89X;A=T,L<B^J,"/TK@?'/A;PK
M%93:A=:1!-?2X56+-DGIV/O6[X+\-Q>&?#45I%]\KN9B?Q%*.L6WT"6C5NIO
M27UI"^R6Z@C<_P +2 &N6^*+!OA=X@92"#:'!'U%</KD&D2:MJBZS927VH2R
M'['<PJ72 8XW,.%YYYK?\4130_ _5XYIUF9;'&Y6! Z<9HCK&X2TE8[K1/\
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MG\?^ ?/?G1?\]4_[Z%'G1?\ /5/^^A7T)_PJCP-_T+MK_P"/?XT?\*H\#?\
M0NVO_CW^-']G+^8/]<I?\^?Q_P" ?/?G1?\ /5/^^A1YT7_/5/\ OH5]"?\
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MJ#_OX*ZK_A57@C_H7[;\V_QH_P"%5>"/^A?MOS;_ !KEDW)W9SMW.5^W6?\
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ML_\ GZ@_[^"C[=9_\_4'_?P5U7_"JO!'_0OVWYM_C1_PJKP1_P!"_;?FW^-
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J2?\A2#_KFU6ZJ2?\
M(4@_ZYM0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"I?=8/^N@JW52^ZP?\ 705;H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG>?\?-I_UT_I5RJ=Y_Q\VG
M_73^E %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *FH_\>A_WA_.K2_='TJKJ/_'H?]X?SJTOW1]* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N#^+'_(LZ=_
MV%[3_P!#KO*X/XL?\BSIW_87M/\ T.@#O**** "BBB@#@_ /_(S>./\ L+_^
MR"N\K@_ /_(S>./^PO\ ^R"N\H **** "BBB@ JAKG_(OZE_UZR_^@FK]4-<
M_P"1?U+_ *]9?_030!S_ ,+?^28>'O\ KT7^9KKZY#X6_P#),/#W_7HO\S77
MT %%%% !7!VG_);=0_[!$?\ Z'7>5P=I_P EMU#_ +!$?_H= '>4444 8/C(
MD>%=0PQ7]RW(.".*\TG\*>&+?P&=5AOI5U);82*PO68A_P#=SS]*]-\7P-<>
M%[Z)(VD9HF&U1DGBO/;GX:Z7#X3L-7T[2UCU.T03M%S^_;'W6_\ K5*TN]M5
MKV+WY5OOIT9IWUY?:O:Z%HC3M$EV-LS#@LH4$?2MC3? Z>'M7@N=&N)HX"I^
MT12R&3>>QY/%9&J75S+9Z3XGM-/FQ8DK/;F,A^ %^5>IK2T_QU>Z]JMO;:/H
MUP+?!^T27T30E3_L^M:+XM-[N_\ 7:QC]G7:W_#_ #O^AF^(/$]GX<^(]O+J
M$EP(&M'&V*-GYW>@I_A3Q%:^(?B!?3V,DYMQ:*-LJ,G.[T-:DMI*_P 3(9S
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MPS:/0?E1M'H/RH_M%_RA_J;'_G]^'_!/<_\ A='@K_G^G_\  =J/^%T>"O\
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M@]QZ\4^2[,WB6Q,<K>4\3G /!I*:;21+DCHJ*P;[Q(UO<R0VFG37OE<2M$P
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M9E%:?_"(^,_^A3OO^^E_QH_X1'QG_P!"G??]]+_C1]4K?RA_K!EO_/U?<_\
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M_0@:M_W^CH_X2GQ-_P!"!JW_ '^CH_U?S+_GT_O7^8>UAW.OHKD/^$I\3?\
M0@:M_P!_HZ/^$I\3?]"!JW_?Z.C_ %?S+_GT_O7^8>UAW.OHKD/^$I\3?]"!
MJW_?Z.C_ (2GQ-_T(&K?]_HZ/]7\R_Y]/[U_F'M8=SKZ*Y#_ (2GQ-_T(&K?
M]_HZ/^$I\3?]"!JW_?Z.C_5_,O\ GT_O7^8>UAW.OHKD/^$I\3?]"!JW_?Z.
MC_A*?$W_ $(&K?\ ?Z.C_5_,O^?3^]?YA[6'<Z^BN0_X2GQ-_P!"!JW_ '^C
MH_X2GQ-_T(&K?]_HZ/\ 5_,O^?3^]?YA[6'<Z^BN0_X2GQ-_T(&K?]_HZ/\
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M4-<_Y%_4O^O67_T$T <_\+?^28>'O^O1?YFNOKD/A;_R3#P]_P!>B_S-=?0
M4444 %<':?\ );=0_P"P1'_Z'7>5P=I_R6W4/^P1'_Z'0!!XZT*#7O%&AVMW
M%,]N9&WF-BN/E]1TK(&C6GPZ\4M=I!<7%E<QL8V):0PG& ._4UZS@$YP*"JM
MU /U%$?=2MY_B-N^YQO@NQ:YLM3U"X5@^I2^:5<8*Y&,4S3[:ZO-3EM)@WE6
MK;HLCCTKM0 !@#%&!G.*B<%)J_:WX6):OKYW/,XK/2[19;:^LKE[[S20BLVU
M@3QR.*Z..V,6NZ>J0M&@A?CKC\:ZG:N<[1^5+@9SBE&G;^O(CV:6QR,6HQ:!
MJ-^E]')^_E+QE$+;AC':LJYO8KW4G_M2WECMF0- D2$%CZDCVKT(JIZ@'\*-
MJ_W1^52Z3:LV4XOH>=:7:RGPY(8H7Q%,S"-@>1NJ[<ZM#JVJ6*6L,OR(5=FC
M(VFNXP,8P*-JCHH_*G[/5:Z:/[O^&)Y-+(\YN;+3;/4;X:I;7+2RR%HO+9L,
M/?%1WEHU]J^E64=K)!;VA6ZP22#D8QFO2BJGJ ?PHP,YP/RHA2Y5;^MBTK2;
M..^'T3Q>%IT>-D/VF? 88_B-.\$1R1SZIO1ES*,9&,UUX  P !0 !T %;N5Y
MN7=6_%?Y!;2WG?\ /_,\Z\0V<L_C=W6)SML)"C;>-V>*R]-M+QTT6XNHW,XU
M$JQV=%VUZS@9S@9HVCT'Y5,/=2*;N_Z[6,CQ(K-X=N%5225' %9NDZBFB^"8
M;FX23*@@*$))8DXXKJNM)M&,8&/3%*S]ZW6WX7_S%_+?I?\ &W^1YG-X<OM3
MT]_$C KJ6\7$,>.54?P?G74:5XOM+BPL6NQ+%<W$GV?88S_K ,D?3WKI<#&,
M<51O=+AOIK61SC[-+YB@#J<52:6BV#?5[_U;[A^HW0M-/EGP3A>,#)R>E<3I
MOA7Q(\$UQ_;@MFNLF2,P!N.G7Z5Z!@8QCBEKIHXJ5&#C!+7ND_S(E#FM?H>3
M74&H:((["\:2Z6"Z699%CX\M>O _E6S8:D-;\:&YM8Y?LOV=5#/&5^;/O7?E
M5/4 _A0%4=% ^@KJGF*G'6'O6:O?OY6(]C9Z/0\OMR]WX3OK&&*4W,%R\C(R
M$ @OV/>M(ZBGB;5+"/3HI1]GC(ED>,KL/MGK7?;5'11S[4!57HH'T%3+,(MM
M\FNK6O??IJ+V/GY?(YZ'2?$":CYTFO![;=GR?( X],UBV?\ R6W4_P#L$1?^
MAUWE<'9_\EMU/_L$1?\ H=<-2K*I:]ODDOR-5%)MD'C>PCU'Q5HEM*N0S/CZ
M[>*R1J,C>*M*LKELW=G#(KY[]Q^E>@W^@17^M6.I-.Z/:,2J ##9&.:H7O@F
MQO/%EOX@\UX[B%&1D51A\^M9PTY5Z_FVBY:W]/T.*_L2#Q&?$6K7]S-]JLIF
M%L4E*B,;<\@'GFI)+BY\06NAZ/>7+K;2N$F96VF5=O0&NAU#X>?:M2N+BTUR
M\L;:Z??=6D**4F)ZYSSTK0U7P39W^E6EI;3R6,UF=UO<PJ"\;8QD9XI1T2NM
M--/EO^H/5O7777]/T.+MM"@\/^-=0@M)W,/V=2J,Y9EX/<\U)-?&+X5V,K3N
M&:\C7=N.3F2NBT;X?#3=2GU"^UN[U.YF01N]PB@D 8'2J+?"M71;9O$-Z=/2
M42QV9C78A!SQWZT*_+RO^M6_R?\ F--*7-Z?DE^9F:M=I:>)A-+<- HTR3,@
M7<1SZ5R]JMWI7B;P_?Q:;+!#=W8_TI[LM]H&"?N'[OK7JFH^![74;IIY+N56
M-LUN,*.,_P 7UK&C^%KF?3Y+SQ-?W8L)/,@62- %P, <5<&E-/\ JVIG;W+>
M7XV*<&@P>(_'^IC4)9V@BAA=(TE90#^%:'Q8C6+P7:1KG:NIV@&3_P!-!72Z
M=X=BT[6;K4EN'=[B-(V0@8&WO7.?%W_D3[;_ +"=I_Z,%+:*BNQ3UDVSO:**
M*0!1110 4444 %%%% !7(?%+_DF'B'_KT/\ ,5U]<A\4O^28>(?^O0_S% '0
M:)_R -._Z]8O_015^J&B?\@#3O\ KUB_]!%7Z "BBB@ HHHH **** .#\7?\
ME%\&?]=IO_0*[RN#\7?\E%\&?]=IO_0*[R@ HHHH **** "BBB@ K@OB[_R*
M%I_V%+3_ -&"N]K@OB[_ ,BA:?\ 84M/_1@H [VBBB@ HHHH **** "BBB@#
M@_B;_JO#O_87AKLU_P"0@_\ N"N,^)O^J\._]A>&NS7_ )"#_P"X* +-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5
M(?\ D(W'^ZM6ZJ0_\A&X_P!U:MT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 54D_Y"D'_ %S:K=5)/^0I!_US:@"W1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M2^ZP?]=!5NJE]U@_ZZ"K= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %4[S_CYM/\ KI_2KE4[S_CYM/\ KI_2@"Y1110
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M &$[3_T8*I%IM*G@;3SY4)D<1O<#S-K#[WYTSXA7TFH_#K3[J5-KOJ=KD?\
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MRA)"N[Y?;WHE[KM_6URDKO[OSL=C>ZI#92F-U9F"%\+Z"I;*_BO;=9DRH8X
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M;_DW^%'_  MGP/\ ]#!;_DW^% 69VE%<7_PMGP/_ -#!;_DW^%'_  MGP/\
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M\*/^%K>"?^@]!_WRW^% '945QO\ PM;P3_T'H/\ OEO\*/\ A:W@G_H/0?\
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M_?+?X4 =E17&_P#"UO!/_0>@_P"^6_PH_P"%K>"?^@]!_P!\M_A0!V55)/\
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M:*X[_A:G@K_H.P_]\M_A1_PM3P5_T'8?^^6_PHN@.QHKCO\ A:G@K_H.P_\
M?+?X4?\ "U/!7_0=A_[Y;_"BZ [&BN._X6IX*_Z#L/\ WRW^%'_"U/!7_0=A
M_P"^6_PHN@.QHKCO^%J>"O\ H.P_]\M_A1_PM3P5_P!!V'_OEO\ "BZ [&BN
M._X6IX*_Z#L/_?+?X4?\+4\%?]!V'_OEO\*+H#L:*X[_ (6IX*_Z#L/_ 'RW
M^%'_  M3P5_T'8?^^6_PHN@.QHKCO^%J>"O^@[#_ -\M_A1_PM3P5_T'8?\
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M=A_X!K76Z)_R -._Z]8O_015^@#@_P#A%_''_0[#_P  UH_X1?QQ_P!#L/\
MP#6N\HH X/\ X1?QQ_T.P_\  -:/^$7\<?\ 0[#_ , UKO** .#_ .$7\<?]
M#L/_  #6C_A%_''_ $.P_P# -:[RB@#Q;Q'H'BN+QIX8AN/%(FN)9)1!-]F
M\H[>>.^:ZW_A%_''_0[#_P  UH\7?\E%\&?]=IO_ $"N\H X$>$_&H<N/&:!
MCU;[$N:7_A%/&Q;<?&:;O7[$M=[10!P \)>-  !XRC !R/\ 0EJM-X#\67$D
MCR^+XW9U*G=9*>#7I%% 'G5EX(\7Z?9I:VWC!$A08"BS7I3Y?!OC&:,QOXQC
M*_\ 7DO%>A44/7<#S/\ X5WXG$\$X\6QB2 DQL+)003UK ^(^@^*[3PW;R7_
M (I%W"=0MU$?V8+ABXPV?8U[77!?%W_D4+3_ +"EI_Z,% "_\(OXX_Z'8?\
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MH\F+_GFG_?(I]%%V')'L,\F+_GFG_?(H\F+_ )YI_P!\BGT478<D>PSR8O\
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M4?8K3_GUA_[]BIZ* (/L5I_SZP_]^Q1]BM/^?6'_ +]BIZ* (/L5I_SZP_\
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MCGEW"Q5_LVQ_Y\K;_OTO^%']FV/_ #Y6W_?I?\*M44<\NX6*O]FV/_/E;?\
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M<2,_EXP5!.1GWKK***IVV6R#NWU"N#L_^2VZG_V"(O\ T.N\K@[/_DMNI_\
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MKC*L&'L<T +7(?%+_DF'B'_KT/\ ,5UC2QJ<-(H/H37)_%(Y^%_B$C_GT/\
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M:]NHH"YXC_;&L?\ 0HZS_P!^A_C1_;&L?]"CK/\ WZ'^->W44!<\1_MC6/\
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MTM+BXGM[>..6Y8/,ZC!<@8R:LT4 %%%% !1110 4444 %%%% !1110 4444
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MQPS6K.%_N@D<4X?!;R7W]?F3+X[^;^[I\CO=$_Y &G?]>L7_ *"*OU0T3_D
M:=_UZQ?^@BK] PHHHH **** "BBB@#@_%W_)1?!G_7:;_P! KH/$V@2>(;);
M/[8]O!N#2!.K 'IGM7/^+O\ DHO@S_KM-_Z!5WQ_XDO?#^DJ;"RN+B>5@I,,
M98HI."PQW'6IE;J5%-O0P[/1+3PWXXM[30))BKQ$SQO*9 !GGD]#[5Z--<P6
MX_>RHGL6 ->>^"=?TB.?[+%8ZR]_.=TUW=V13S&]2>E;VJZ7'?\ B>)KBV,L
M2HI!(. :J;<8I;[D+E;;7D="E]:RN$2XC9CT 8<T^2Y@B.))HT/HS 5Y]I6B
MBUMK&:.S=)DNICG:<@9XI_B"2TMM0U'^T[2:Z,D+?9_*0OL&WG..G-$_==OZ
MVN4E=_=^=CKKS6D@DV0JLP\HR@JW! J6PU6*\MTD<K&S'[NZN(\#VTEQX0%Q
MY4B[+8Q1(RX.*JVUAJ6GI<^>LDK72;+>9AS$V<X/H .]-KE;3[!;\[?\$]*6
M\MFD"+<1%ST7>,FN)^+O_(H6G_84M/\ T8*QHI]-E\4: EII]Q%,DD@DD>(@
M$XY.:V/BY_R)]I_V%+3_ -&"AK2XNMCOJ**YWQ#X>U/694>Q\2W^E*O5;9%(
M;\ZEL:.<\;^$?#D=K/J=S%<M=R850MRZY/3H#5C1/A[IR^$8+#56N)L#>[>>
MRGU'.:9J&CWK:[H.GW5S<ZC#$[M-/*GWN.,XXKK];9XM#NA"C%S"RJ%&3R"*
M':%-M=?T_P"#^@:RDE_6O_ _,\X\->$+'_A++V^TEKA+6SS"J/.S!GZ@\FL>
MSDCA\60R?Z8NK+?L9F??Y?E<XZ_+UKTSP+IYL/"=B)8REQ)&&FW##%O>H?&!
MN;J.WTBTA<?;G\J6=5_U:XSG-4U*$DEJUI\_\N_D3[LDV]OT_K;S,OP]<C6/
M$$VM7]RD,2_N[:)I0OS#ACCOFN^!!&1S7B?B/1H;'6IK>[TNYNI"D0LY8HF9
M48?>)(Z5Z_I"3QZ7;I<G,H0;J%9QTZ?U]_<'=2UZ_P# _I'(?$W_ %7AW_L+
MPUV:_P#(0?\ W!7&?$W_ %7AW_L+PUV:_P#(0?\ W!2&6:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J0_\A&X_P!U
M:MU4A_Y"-Q_NK5N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "JDG_ "%(/^N;5;JI)_R%(/\ KFU %NBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *E]U@_ZZ"K=
M5+[K!_UT%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *IWG_ !\VG_73^E7*IWG_ !\VG_73^E %RBBB@ HHHH ****
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M #UT'_OEZ[RB@#@]GQ._YZZ#_P!\O1L^)W_/70?^^7KO** .#V?$[_GKH/\
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M=K#YL]J7U:K>UOZ0*<6KG.[/B=_SUT'_ +Y>C9\3O^>N@_\ ?+TSPMXGGM]
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M #UT'_OEZ[RB@#@]GQ._YZZ#_P!\O1L^)W_/70?^^7KO** .#V?$[_GKH/\
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M/^_E?-WV2W_YX1?]\"C[);_\\(O^^!1_:*_E#_4VI_S]7W?\$^D?^%C>#O\
MH8[#_OY1_P +&\'?]#'8?]_*^;OLEO\ \\(O^^!1]DM_^>$7_? H_M%?RA_J
M;4_Y^K[O^"?2/_"QO!W_ $,=A_W\H_X6-X._Z&.P_P"_E?-WV2W_ .>$7_?
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MO"\VDQ7+_N7F*L'8_0>E>1_K%4E1]I"B_O6WY_<?/_5X0UJ,]0.O:4JEC?P
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M *&.P_[^5!_PC^C?] FR_P"_"_X4?\(_HW_0)LO^_"_X4?ZY4_\ GT_O_P"
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M_ #ZN^Y/_P +&\'?]#'8?]_*/^%C>#O^ACL/^_E0?\(_HW_0)LO^_"_X4?\
M"/Z-_P! FR_[\+_A1_KE3_Y]/[_^ 'U=]R?_ (6-X._Z&.P_[^4?\+&\'?\
M0QV'_?RH/^$?T;_H$V7_ 'X7_"C_ (1_1O\ H$V7_?A?\*/]<J?_ #Z?W_\
M #ZN^Y/_ ,+&\'?]#'8?]_*/^%C>#O\ H8[#_OY4'_"/Z-_T";+_ +\+_A1_
MPC^C?] FR_[\+_A1_KE3_P"?3^__ ( ?5WW)_P#A8W@[_H8[#_OY1_PL;P=_
MT,=A_P!_*@_X1_1O^@39?]^%_P */^$?T;_H$V7_ 'X7_"C_ %RI_P#/I_?_
M , /J[[D_P#PL;P=_P!#'8?]_*/^%C>#O^ACL/\ OY4'_"/Z-_T";+_OPO\
MA1_PC^C?] FR_P"_"_X4?ZY4_P#GT_O_ . 'U=]R?_A8W@[_ *&.P_[^4?\
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M'8?]_*@_X1_1O^@39?\ ?A?\*/\ A']&_P"@39?]^%_PH_URI_\ /I_?_P
M/J[[D_\ PL;P=_T,=A_W\H_X6-X._P"ACL/^_E0?\(_HW_0)LO\ OPO^%'_"
M/Z-_T";+_OPO^%'^N5/_ )]/[_\ @!]7?<G_ .%C>#O^ACL/^_E'_"QO!W_0
MQV'_ '\J#_A']&_Z!-E_WX7_  H_X1_1O^@39?\ ?A?\*/\ 7*G_ ,^G]_\
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M_GT_O_X ?5WW)_\ A8W@[_H8[#_OY1_PL;P=_P!#'8?]_*@_X1_1O^@39?\
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MZY4_^?3^_P#X ?5WW)_^%C>#O^ACL/\ OY1_PL;P=_T,=A_W\J#_ (1_1O\
MH$V7_?A?\*/^$?T;_H$V7_?A?\*/]<J?_/I_?_P ^KON3_\ "QO!W_0QV'_?
MRC_A8W@[_H8[#_OY4'_"/Z-_T";+_OPO^%'_  C^C?\ 0)LO^_"_X4?ZY4_^
M?3^__@!]7?<G_P"%C>#O^ACL/^_E'_"QO!W_ $,=A_W\J#_A']&_Z!-E_P!^
M%_PH_P"$?T;_ *!-E_WX7_"C_7*G_P ^G]__   ^KON3_P#"QO!W_0QV'_?R
MC_A8W@[_ *&.P_[^5!_PC^C?] FR_P"_"_X4?\(_HW_0)LO^_"_X4?ZY4_\
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MV7_?A?\ "C_A']&_Z!-E_P!^%_PH_P!<J?\ SZ?W_P# #ZN^Y/\ \+&\'?\
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MO\*-WQ+_ .@#H?\ X&M_A1_JQF7\B^]?YA[:!UE%<GN^)?\ T =#_P# UO\
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M .@#H?\ X&M_A1N^)?\ T =#_P# UO\ "C_5C,OY%]Z_S#VT#K**Y/=\2_\
MH Z'_P"!K?X4;OB7_P! '0__  -;_"C_ %8S+^1?>O\ ,/;0.LHKD]WQ+_Z
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M7_T =#_\#6_PH_U8S+^1?>O\P]M ZRBN3W?$O_H Z'_X&M_A1N^)?_0!T/\
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MB7_T =#_ / UO\*/]6,R_D7WK_,/;0.LHKD]WQ+_ .@#H?\ X&M_A1N^)?\
MT =#_P# UO\ "C_5C,OY%]Z_S#VT#K**Y/=\2_\ H Z'_P"!K?X4;OB7_P!
M'0__  -;_"C_ %8S+^1?>O\ ,/;0.LHKD)9_B3#'O?0=$QG'%XW^%/W_ !+(
MS_8.A_\ @:W^%'^K&9?R+[U_F'MH'645R>[XE_\ 0!T/_P #6_PHW?$O_H Z
M'_X&M_A1_JQF7\B^]?YA[:!UE%<GN^)?_0!T/_P-;_"C=\2_^@#H?_@:W^%'
M^K&9?R+[U_F'MH'645R>[XE_] '0_P#P-;_"C=\2_P#H Z'_ .!K?X4?ZL9E
M_(OO7^8>V@=917)[OB7_ - '0_\ P-;_  HW?$O_ * .A_\ @:W^%'^K&9?R
M+[U_F'MH'645R>[XE_\ 0!T/_P #6_PHW?$O_H Z'_X&M_A1_JQF7\B^]?YA
M[:!UE%<GN^)?_0!T/_P-;_"C=\2_^@#H?_@:W^%'^K&9?R+[U_F'MH'645R>
M[XE_] '0_P#P-;_"C=\2_P#H Z'_ .!K?X4?ZL9E_(OO7^8>V@=917)[OB7_
M - '0_\ P-;_  HW?$O_ * .A_\ @:W^%'^K&9?R+[U_F'MH'65R/P[TJSUS
MP+K.FW\?F6MQJ=RDB9QD;Z=N^)?_ $ =#_\  UO\*VOASH.I^'_#L]OJZ0I=
MS7DMPRPON4!SGK7TO#>58K U*DJ\;72MJF8UJD9)6-K1_#NFZ%H@T?3X#'9
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MU/!G_0:C_P"^&_PH [&BN._X6IX,_P"@U'_WPW^%'_"U/!G_ $&H_P#OAO\
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M_P#?#?X4?\+4\&?]!J/_ +X;_"@#L:*X[_A:G@S_ *#4?_?#?X4?\+4\&?\
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M9_T&H_\ OAO\* .QHKCO^%J>#/\ H-1_]\-_A1_PM3P9_P!!J/\ [X;_  H
M[&BN._X6IX,_Z#4?_?#?X4?\+4\&?]!J/_OAO\* .QHKCO\ A:G@S_H-1_\
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M!J/_ +X;_"N3\?>-_#WB'2=.L-*U!;FY.J6S^6J-G ?D\B@#UVBBB@ HHHH
MX/P#_P C-XX_["__ +(*[RN#\ _\C-XX_P"PO_[(*[R@!LDB1(7D=44=68X
MJ*&]M;DD07,,I'41R!L?E7'>,C+J>MZ7H7G/':W+D3JO\8QG%3VW@.PT34H;
MS0E^P(J,)XHONRD]SFE'57>VOX?\$'O9;G3R:GI\3E)+ZV1QP5:501^M3Q3Q
M3IOAE21?[R,"/TKR'3=)\$W_ (A\0OXCCL&N!>80W$NTXVCW%=%\-42%-2@L
MBQTU;E_)_N@9_A]1515UKVN$M'IWL=_5#7/^1?U+_KUE_P#035^J&N?\B_J7
M_7K+_P"@FD!S_P +?^28>'O^O1?YFNOKD/A;_P DP\/?]>B_S-=?0!!/?6EL
MVV>Z@B;TDD"_SJ2*:*>,20R)(AZ,C @UX_XFDTJ?QY>/XDT"\O[)(D$'E6[.
M,]^E>D^%SI/]APC1K?[-: ?+"004^H/2B'O0Y@G[LN4VJX.T_P"2VZA_V"(_
M_0Z[RN#M/^2VZA_V"(__ $.@#MGM+:1MSV\3-ZE 34@1538% 7T XIU%.[8$
M*VELC;DMXE;U" &I2 1@C(I:*&V]P&-$IB:-0%# C@54TG34TJQ6UC.0I)SC
M'4U>HI 0RVEM.VZ:WBD(Z%T!_G3HK>"W&(88XP>R*!_*I** *TUO8AO.GAMP
MW]]U7/YFGR-;Q 3RF) HP)&P,?C7+_$8D>%Y,''SK_Z$*RM:C;7]>TG0)I6%
MB\!DFC'1RH!&:%=Z+O;\+@[+5_UK8[B*33[L/Y3VLP/W]A5L_6H$N=$MG(2?
M3XG!P<.BD5S\7@BRT&\>[T,?8;4PD2VT?W7/]XYYS7F^C?\ "%O<WZ:OX6O;
MZ[-XX\^.U=UQGU!HC9RLOZU!Z*[/<%LK%QYBVULV[G<(U.:>YM+-3)(88%[L
MV%'YTVPC@BL85MHC%#L&Q",;1CI7&?%5+:3PY"EWM^SM=1!]YP,;N<T/1I+J
M[#A[VYV$-_IK2%8+NT+N>0DBY)_"I_L\&6/DQY888[1S]:\CUO2/!5A_9T_A
ME;./4/M28-G)O8C/?D\5ZY:EVM8C+]\J-WUIVNKDWV\PE:W@0/*8HT3HSX %
M0IJFGR,$2^M68] )E)/ZUR_Q.6)O"$ZSX\HLN[<<#&17&:YHW@:ST6TN-!6S
MCU030[3:2;Y.HSQGIZTD[ZOO;SZ?YE<NR74]B^SP[BWDQY/4[1S2M%&R;&C0
MI_=*\5%8-*]C"T_^M*_-]:L54KIVN3%W5QD<,4(Q%&B#T50*<RJR[64$'L12
MT4KO<9"EI;1MN2WB5AW" 4^2*.88EC1P.S*#3Z*.9WN%AD<,4(Q%$B#_ &5
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MMO\ OTO^%6J* *O]F6'_ #XVW_?I?\*/[,L/^?&V_P"_2_X5:HH J_V98?\
M/C;?]^E_PH_LRP_Y\;;_ +]+_A5JB@"K_9EA_P ^-M_WZ7_"C^S+#_GQMO\
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MDK/H=QITD4%LQ\F<+A77H/QJO_PF_B;_ *)]JG_?^.C_ (3?Q-_T3[5/^_\
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MO^B?:I_W_CH [RBN#_X3?Q-_T3[5/^_\='_";^)O^B?:I_W_ (Z .\K@[/\
MY+;J?_8(B_\ 0Z/^$W\3?]$^U3_O_'7/0:KXKB\>77B(^!M1,4]FEL(?.3(*
MG.<T 7;S3=1N-;O;M-DMI!M8V_7?SSD>U:_B&]M[_3M,GMF4QF5 -O;YA4(\
M9>(E+$?#K4ANZXFCYI@\6:Z$5!\-K\*IR%\V+ HA[JBOY;?@*?O<S[W_ !*&
MKJD6NZL]W?M:N&:2!-V/- [>XK8CN7UFYTO3'51&D233(OW64C&/I56;Q3K=
MP^^;X:WTC8QN>2(FG)XOU^-PZ?#C4%8+M#"6,''I1'1)/H5*S;:Z_P# .VOG
MM+33G:Z""VC7D-TP.E<1IM[:>)-5:]2>*,PP2QVMLI^?!'.14DGC/Q',A23X
M=ZDZ'JK31D&H8O%&M0/OA^&E[&WJDD0-"WN%]+(BBN;1=,L=/296OH[I/.CS
M\P(K8UK1HX+F"XBEF%S(_P"Z13QO]ZS!XIUH2F4?#2^$A.2_F19S]:F;QIXC
M=E+?#S4B5.03-'Q2:N@;UT_KJ3>&=<G6ZAL6CB$,LCJ%0?,K#J3]:B^+O_(G
MVW_83M/_ $8*A3Q5KL4QE3X;Z@KGN)8JQ?&>J>*_%&BQ6$7@;48&2[AN-SS(
M00C;B/QJF]$3;5GKM<C86%W'\0[V\>!Q;O:*JR$<$[NE4?\ A-_$W_1/M4_[
M_P ='_";^)O^B?:I_P!_XZ2T=QO56+NC:?=P^-M9NI+=U@EAC"2$<,1G.*YG
M5/#>JW4NN30VKAOMD,\08?ZQ4Y('OQ6S_P )OXF_Z)]JG_?^.L[6]>U[7M.:
MQNO >N1Q,02UO>I&W'N*6J2Y=TDONM_D4FKZ]64O[:U#7O&-@9M)N;#9!@QW
M"X9CGJ/:M6VTC4%\#^(;5K243SS2F*/'+@D8Q6)H']H^'+AI[7P%X@GE88W7
M=^LI ]L]*Z3_ (3?Q-_T3[5/^_\ '3:7*TNI,6U)/M;\#J?#\,EOHMM%,A1U
M0 J>HXK"U33;G4/'VF326[M900R;F(^7=P1^-4_^$W\3?]$^U3_O_'1_PF_B
M;_HGVJ?]_P".FW>?,)*T>4[RN0^*7_),/$/_ %Z'^8JE_P )OXF_Z)]JG_?^
M.L7Q;KGBKQ)X3U+1HO FI0O>0F-9&F0A??%(9Z/HG_( T[_KUB_]!%7Z\[L/
M%_B>STZUM6\ :FQAB2,L)X^< "K'_";^)O\ HGVJ?]_XZ .MUJ)YM%O(HE+.
M\3!5'4G%9'AC3)H?#!M)HC#(^<JPP:R?^$W\3?\ 1/M4_P"_\='_  F_B;_H
MGVJ?]_XZEQ3O?JK#N]/+4XZWT0Z.9M-F\$+?WK3LZ7WV<&+#-GD]>!70^*--
M>.*U2^\,1ZE:B(J%LX<R1$],9Z5H?\)OXF_Z)]JG_?\ CH_X3?Q-_P!$^U3_
M +_QU3U6HEH[HK?#+3=5LEN//&H0Z>K;8(+\_.HQQCVKT6N#_P"$W\3?]$^U
M3_O_ !T?\)OXF_Z)]JG_ '_CIMW$E8/%W_)1?!G_ %VF_P#0*O>/M6UK3=)5
M-%TVXNYI6 <PKDJI.#CWQTKD-9U7Q7JGB;0]53P-J*)IKNS1F9"7W#'%=#_P
MF_B;_HGVJ?\ ?^.I:N5%V=R#P9JIMI5LQX8UF"20YEO+M!ESZL?6M[4=*%[X
MECEFM/-A5!AF7(!K(_X3?Q-_T3[5/^_\='_";^)O^B?:I_W_ (Z<_>W)5TFN
MXS3- DM;6R=; QS1W4K$A>0">*;KQ%K?ZCY^FRZ@9H6\LQKGROE[U+_PF_B;
M_HGVJ?\ ?^.LO4M9UK5)XYI_ &M*R?\ /*[10WUQUHE>3_KM8I.W]=G<N>!K
M">7P@)GMY(V%OY<4;#G::K0:+J>F17.^.21;M-BRL.8#G.2>PJ]#XQ\1V\*Q
M1?#S4U11@ 3Q\4YO&OB5U*M\/=3(/4&>.G)W;:[6!/KYW,F.2*;Q-H"QZ+-;
M-'(X:9D #''6M7XN?\B?:?\ 84M/_1@K+L=5UC3[IKF+X?ZT\A.1YEVC!?H#
MTJGXSU3Q7XHT6&PB\#:C T=W#<;GF0@A&W$?C3;T2%U_ ]/U?3#JUBUL+NXM
M=W_+2!MK"L[0?#+:"LN=6O[_ 'KC%U)NQ]*P_P#A-_$W_1/M4_[_ ,='_";^
M)O\ HGVJ?]_XZAK1KN#UM?H2^"](NX?"=Y9WEN\,DEQ.55QC@L<&N7$?B&32
MX/"?]CW2F&X5VO2G[EE#9.#UZ5T?_";^)O\ HGVJ?]_XZ/\ A-_$W_1/M4_[
M_P =4W>5WL[:>@W)W;6]V_O(-=M]1\->(;;6+#39[^ 6Y@:&V7+Y)SGZ5J^!
M=/O8+6ZO=0A:&>ZF:01L,,JDY /O5'_A-_$W_1/M4_[_ ,='_";^)O\ HGVJ
M?]_XZ$VM_P"NI+2LDOZL3ZCIM_K_ (AF,\,D5K9QY@)'$C$8-<GX9T6]C\16
M:)H=Q97$"N+B^=,++SGK].*Z7_A-_$W_ $3[5/\ O_'1_P )OXF_Z)]JG_?^
M.E'W6GV_,<O>33*WQ>9DTG163[PU.(C]:MSZ78+X>DODM8OMARPEV_,&^M8>
MOWGB7Q;<Z/:OX-OK&&WOXYY)I9490HZ\"NW3PAIB:@+P/=%P^_RS.2F?]WI0
MOBOZ?@P>L;&S:Y^QPYZ^6N?RJ:D    Z"EH>X(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "F2H7B91U(I],FB6:)HV+ ,,$J<&E
M)75AK<X>TTZ?P]J*3WEI8,CR,5DB0^9R?6NZ!RH/J*PK3PCIUI>BZ62[E<$D
M+-.77\C6]57T)ZW"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,/Q39VUSI+230I(\;#86'3FH]29E\-1A!PS*K#V/6K>L>'
MK/7%1;M[A57H(I2F?KBG66A6ECI[V4;3/"XP?-D+$?0FI:O%HJ]FGV,";2["
MPDTR2RMHXI'D4,Z+@D5V58>F^%-.TNZ^T0O=2.!@":8N!] :W*T;T(2L%%%%
M2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BCH,UB0>+M"N->?1(M0C
M;44!+0<Y&.M"U=D'2YMT5!>7EOI]G+=W4@C@B4L[GH *K:1K>G:]9_:],N5N
M(-Q7>O3(H6H&A5+5;6"\TV>.XB65 A;:PR,@<5=JCJFEP:O:&VN'F5"<DQ2%
M#^8I/8:=F8NG6+7?A,VD 0%DVJ&'RU6T&%]#U-;.[M+-)95"K);)C/UK2M?!
M^G6=K);PS7HC?KFX;(^E2Z=X>T[1'>Y22=VQRUQ,7Q],]*I.SN2TVK?UN;5%
M0M=0+;-<&0>4H)+>PJ#3-5LM8LUN["=9X&Z.O2D/S+M%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &;K,6FO:;]1MXIE7[JN,Y/M6-
M8V,FF>&KUTC6+>6>-$&  2,5K:SX?LM<1$NVG 4Y'E2E:73-!M-)A>*%[B1'
M&")Y2_\ .IM[LEW'>S1S=SI6GVVD0W5O;1+=%P?,5?FZ\UVR?ZM?H*PK7PAI
MMI?"[1[IG!)"/.63G_9Z5OUHWH2E9A1114C"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "JU_%:2V<@ODC>W ^8..,59JEJFEV^KV;6MR9
M1&W7RW*FD[VT&M]3G])TA&GOKBRMXK>VF7;&H7&<>M4]+LI?#FHPB]L[']YE
M5DMTP_)[FMJR\(:=8*RP3WVUAC#7#''TI^G^%-/TZ[%S')=2R $ 3S%P/P-4
MM&2[M,W****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH H:Q8F_L'A2&"5ST6<96N8\/P_V9/J=K)"D-T06VPC$9PO:NHU/2H-6
M@\F>2=%]89"A_,5!I/AZQT<2?9S-(9#EFGD+G\S274;V1S9TNP?09KYK6(WA
M^;S"OS!J[#3\G3K;/7RUS^59+>$-,;4/MI>ZW[]^P3G9G_=Z5O* JA0, # %
M4OAM_6Q+W%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!&^XWTKP!8S:_%'5]7B!\^&\CA&/[K 9KW]ON-]*\:TF
MT%[XT\7QYPRN74^XCXJ8-QK*2Z)E.SI-/9M?F=E\0K[/A^.SC&[[:XB(']TU
M1^$<*V7A.XA/"Q7<J\]L&L;2+]]?O[.R:3>MC99F.?\ EJ#6OX$4MX0U=5!)
M-Y-@#ZU5^2%22ZJ_RN[$.\G3B^CL_7J33^/-5O;VX3PYH:ZC:V_$DSS>7TZX
M]:T],\;0:EX<O-12';<V:$SVY/W6 )QG\*ROA7<VQ\*3P)\LD4\QD4\$?,:Y
MS2/WL_CJ:#_CV9C@CH?W9HJ+DYHI[*]_N_!W'#WK2\[6_KJ;%C\1M>UO25U'
M1O#:7,*IF4O/LVMZ#/6LOQEXRO=>^&MW=:?8X(+177[W:82,9QZ\\5TWPUC1
M/AW9;5 S""?>O/XP3\-_%F!TN9O_ $,4ZL4I2CVL_P 2Z6K4O.WYG?\ AZ[U
M.Z\ R'4K%;4BW.S$F_<-O6N/\ ^)M>M_"Z0:)H2ZA';[O.=YO+VG)/'KQ7H-
MB0WP_4@Y_P!%_P#9:R?A0BKX%C*J 6!S[\FJE\=1^2_-F4/X4/7]"_HGCVUU
M'0;S4+V$VLEB2MS$/FV,!DCWK.3QCXONX3=Z?X4AGLF^:.4W04LO8XK'\*6U
ME>7'B^VOY$BMI+MU=V. !@5</AKQ7X?2UO/#GB&35K53G['>NJ0B/' !49-1
M*WQ/2Z7IL7:S<5K9L[3PYK\?B#3_ +0()(9%)5XW4C!'!Z]:V:Y;P+XHG\4:
M,US=VL5M<I(R.D1)3@XX)KJ:J:LR5V"BBBI&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (1D8]:Y_3O"%AINM
M:AJD3RM-?',BL>!QCBNAHHZW#I8YW1_!FF:)<ZA/:A]]ZY>3/;/85=T+0+70
M+2:WMF=DEE:5MY[MUK5HH\OD#U=WZG&:E\.;&\OY;JUU&^T[S?\ 61VC[%;Z
MUK67A33K#09=)@5ECE0K))_&^01DGUYK=HI67+R] OKS=3+T30K;0M&BTNV=
MVAB38"YYQ69:^!],M=(U'30TKP7[L\NX\@L<G%=/13E[U[]03MMZG.:+X0@T
M73;BP2_O+B&8%<3/G8#Z5<T#P]:^'=)73K1Y&B7."YYK7HIMMW\P2LK'.6?@
MK2[0ZED-,NH2&25).1D^E8S?#*/++%XCUF&$GY84GPBCT ]*[RBD.Y0TC2+3
M1;%;6SC"(.IQRQ[D^]7Z**;;;NR4K!1112&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>genzerafbudl000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0U!&P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *3>O]X?G6'XPU6?1?"U]J%M_K
MH4RO&:\!TKQ%\2_$T<MYIV9(/,90RQ9'!Z=: /IG>G]Y?SHWI_>7\Z^=\?%K
M_GG)_P!^?_KT8^+7_/.3_OS_ /7H ^B-Z?WE_.C>G]Y?SKYWQ\6O^><G_?G_
M .O1CXM?\\Y/^_/_ ->@#Z(WI_>7\Z-Z?WE_.OG?'Q:_YYR?]^?_ *]&/BU_
MSSD_[\__ %Z /HC>G]Y?SHWI_>7\Z^=\?%K_ )YR?]^?_KT8^+7_ #SD_P"_
M/_UZ /HC>G]Y?SHWI_>7\Z^=\?%K_GG)_P!^?_KT8^+7_/.3_OS_ /7H ^B-
MZ?WE_.C>G]Y?SKYWQ\6O^><G_?G_ .O1CXM?\\Y/^_/_ ->@#Z(WI_>7\Z-Z
M?WE_.OG?'Q:_YYR?]^?_ *]&/BU_SSD_[\__ %Z /HC>G]Y?SHWI_>7\Z^=\
M?%K_ )YR?]^?_KT8^+7_ #SD_P"_/_UZ /HC>G]Y?SHWI_>7\Z^=\?%K_GG)
M_P!^?_KT8^+7_/.3_OS_ /7H ^B-Z?WE_.C>G]Y?SKYWQ\6O^><G_?G_ .O1
MCXM?\\Y/^_/_ ->@#Z(WI_>7\Z-Z?WE_.OG?'Q:_YYR?]^?_ *]&/BU_SSD_
M[\__ %Z /HC>G]Y?SHWI_>7\Z^=\?%K_ )YR?]^?_KT8^+7_ #SD_P"_/_UZ
M /HC>G]Y?SHWI_>7\Z^=\?%K_GG)_P!^?_KT8^+7_/.3_OS_ /7H ^B-Z?WE
M_.C>G]Y?SKYWQ\6O^><G_?G_ .O1CXM?\\Y/^_/_ ->@#Z(WI_>7\Z-Z?WE_
M.OG?'Q:_YYR?]^?_ *]&/BU_SSD_[\__ %Z /HC>G]Y?SHWI_>7\Z^=\?%K_
M )YR?]^?_KT8^+7_ #SD_P"_/_UZ /HC>G]Y?SHWI_>7\Z^=\?%K_GG)_P!^
M?_KT8^+7_/.3_OS_ /7H ^B-Z?WE_.C>G]Y?SKYWQ\6O^><G_?G_ .O1CXM?
M\\Y/^_/_ ->@#Z(WI_>7\Z-Z?WE_.OG?'Q:_YYR?]^?_ *]&/BU_SSD_[\__
M %Z /HC>G]Y?SHWI_>7\Z^=\?%K_ )YR?]^?_KT8^+7_ #SD_P"_/_UZ /HC
M>G]Y?SHWI_>7\Z^=\?%K_GG)_P!^?_KT8^+7_/.3_OS_ /7H ^B-Z?WE_.C>
MG]Y?SKYWQ\6O^><G_?G_ .O1CXM?\\Y/^_/_ ->@#Z(WI_>7\Z-Z?WE_.OG?
M'Q:_YYR?]^?_ *]&/BU_SSD_[\__ %Z /HC>G]Y?SHWI_>7\Z^=\?%K_ )YR
M?]^?_KT8^+7_ #SD_P"_/_UZ /HC>G]Y?SHWI_>7\Z^=\?%K_GG)_P!^?_KT
M8^+7_/.3_OS_ /7H ^B-Z?WE_.C>G]Y?SKYWQ\6O^><G_?G_ .O1CXM?\\Y/
M^_/_ ->@#Z(WI_>7\Z-Z?WE_.OG?'Q:_YYR?]^?_ *]&/BU_SSD_[\__ %Z
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M/_"%>&_^@1;_ )&C_A"O#?\ T"+?\C6]11];K_SO[V'*NQ@_\(5X;_Z!%O\
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M="RL9KDJ6$:[L#O7'^&_B-#XBUR33$L)(60$[V8$'%"UERK<'I'F>QW%%%%
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M0 4444 %<'\82!\/+O(S^\3^M=Y7!_&#/_"O;O R?,3^M %7X*G_ (M[9?\
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MI)$8*/?BN!\":[;>&-9N++5A&L09@6<#@U[?I.EP:/IZ65MN,2=-QR:Q-;\
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M.OF)_6N\K@_C ,_#R[YQ^\3^M065O@KC_A7EECK\V?SKT6O.?@K_ ,D]LO\
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MYQ?4NH[S@UT/&_"]POAOX@-#>_N41RI+5[3KVK6MCH,US),JJ8\J?6L#Q?\
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MD^L_^!?SKT:O.O@J1_PKRR&.?FY_&O1: "BBB@ HHHH **** "BBB@ HHHH
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MP7PFU:]U;PBDU],TLPE=2S')X-=[7CXK#RPU:5&3NXNQI%W5PHHHKG&%%%%
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MO&D@PZ*P]&&:Z<'B7A:\:R5^4F2YE8Q?!UO):^#]+@E7:Z0 ,OI6Y2 !1A0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5ROQ&S_P@^H8Z[1755ROQ&R? ^H8./E%=>!_WJGZK\R9?"SG_
M (+?\B8/^N\G\Z]*KS7X+?\ (F#_ *[R?SKTJNC./]_J^K%3^%!1117F%A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXI?\DYU?_KE7*? '_D2W_P"OF3^=4_'7BO6;WP9J5O<V'EQM'@ML/%7/V?\
MGP4__7Q)_.@#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KE/B-C_A!]0STVBNKKE/B-C_A!]0R,_**Z\!_O5/U7YDR
M^%F!\%O^1,'_ %WD_G7I5>:_!;_D3!_UWD_G7I5=&<?[_5]6*G\*"BBBO,+"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X/XP''P\N^,_O$_K7>5P?Q@S_ ,*]N\=?,3^M %7X*_\ )/;+_@7\Z]&K
MSKX*X_X5Y98Z_-G\Z]%H **** "BBB@ HHHH **** "N#^)/AV\U.TM]1TR/
M??6K+M _NYR:[R@@$8(S0!Y/KFL:GXPT;_A'+?3RIN$\JY;/W!Z^]=C<W]QX
M9TK2;2"T\\DI _.-HQC-=&L$*-N2*-6/<* :<R(^-R*V.F1F@#S+QI8:KI_C
M72_%-E:FX@MH'CE&<8W'_P"M6;KM[J'C^\T^SLK$QVZN?-G[I^%>OLBNNUU#
M+Z$9%-CMX8O]7#&G^ZH% #+* VUC! 3DQQJI/K@5-@>E+10!QWQ2 _X5SJ_'
M_+*N4^ /_(EO_P!?,G\ZZOXI?\DYU?\ ZY5RGP!_Y$M_^OF3^= 'KE%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_$;
M/_"#ZA@9^45U5<K\1L_\(/J&.NT5UX'_ 'JGZK\R9?"SG_@M_P B8/\ KO)_
M.O2J\U^"W_(F#_KO)_.O2JZ,X_W^KZL5/X4%%%%>86%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?Q@!/P]N\''[Q
M/ZUWE<%\8<?\*\N]QP/,3^M %;X*_P#)/;/_ (%_.O1J\Z^"K$_#RR'8;OYU
MZ+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''?%+_ ))SJ_\
MURKE/@#_ ,B6_P#U\R?SKJ_BE_R3G5_^N5<I\ ?^1+?_ *^9/YT >N4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<K\1
MAGP/J'./E%=57*?$?'_"#ZAGIM%=> _WJGZK\R9?"S ^"W_(F#_KO)_.O2J\
MU^"W_(F#_KO)_.O2JZ,X_P!_J^K%3^%!1117F%A1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!<JY3X _\ (EO_ -?,G\ZZOXI?\DYU?_KE7*? '_D2W_Z^9/YT >N4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<I\
M1B!X'U#(S\HKJZY7XC9_X0?4,#^$5UX#_>J?JOS)E\+.?^"W_(F#_KO)_.O2
MJ\U^"W_(F#_KO)_.O2JZ,X_W^KZL5/X4%%%%>86%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?Q@S_P *]N\=?,3^
MM=Y7!_& 9^'EWSC]XG]: *OP5_Y)]9_\"_G7HU>=?!4C_A7ED,=-W/XUZ+0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOAW18-+G\)WMXMNH1) PY'XUU^@^/=8U;5(+6Y\*7EG%(V#,[@A: .]HHHH
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MHH X[XI?\DYU?_KE7*? '_D2W_Z^9/YUU?Q2_P"2<ZO_ -<JY3X _P#(EO\
M]?,G\Z /7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N5^(V?^$'U#'7:*ZJN5^(W/@?4.<?**Z\#_O5/U7YDR^%G/\
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MXC^PLBP,I\@MR< ]Z^F?[$TK_H&VG_?E?\*\1\5V-M'\;]-MTMH5@9X\QA
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MW_H'_P#)F7RS[GE?_"[IO^A<G_[^"C_A=TW_ $+D_P#W\%>J?V3IW_/C;?\
M?H4?V3IW_/C;?]^A1]=RW_H'_P#)F'+/N>5_\+NF_P"A<G_[^"C_ (7=-_T+
MD_\ W\%>J?V3IW_/C;?]^A1_9.G?\^-M_P!^A1]=RW_H'_\ )F'+/N>5_P#"
M[IO^A<G_ ._@H_X7=-_T+D__ '\%>J?V3IW_ #XVW_?H4?V3IW_/C;?]^A1]
M=RW_ *!__)F'+/N>5_\ "[IO^A<G_P"_@H_X7=-_T+D__?P5ZI_9.G?\^-M_
MWZ%']DZ=_P ^-M_WZ%'UW+?^@?\ \F8<L^YY7_PNZ;_H7)_^_@H_X7=-_P!"
MY/\ ]_!7JG]DZ=_SXVW_ 'Z%']DZ=_SXVW_?H4?7<M_Z!_\ R9ARS[GE?_"[
MIO\ H7)_^_@H_P"%W3?]"Y/_ -_!7JG]DZ=_SXVW_?H4?V3IW_/C;?\ ?H4?
M7<M_Z!__ "9ARS[GE?\ PNZ;_H7)_P#OX*/^%W3?]"Y/_P!_!7JG]DZ=_P ^
M-M_WZ%']DZ=_SXVW_?H4?7<M_P"@?_R9ARS[GE?_  NZ;_H7)_\ OX*/^%W3
M?]"Y/_W\%>J?V3IW_/C;?]^A1_9.G?\ /C;?]^A1]=RW_H'_ /)F'+/N>5_\
M+NF_Z%R?_OX*/^%W3?\ 0N3_ /?P5ZI_9.G?\^-M_P!^A1_9.G?\^-M_WZ%'
MUW+?^@?_ ,F8<L^YY7_PNZ;_ *%R?_OX*/\ A=TW_0N3_P#?P5ZI_9.G?\^-
MM_WZ%']DZ=_SXVW_ 'Z%'UW+?^@?_P F8<L^YY7_ ,+NF_Z%R?\ [^"C_A=T
MW_0N3_\ ?P5ZI_9.G?\ /C;?]^A1_9.G?\^-M_WZ%'UW+?\ H'_\F8<L^YY7
M_P +NF_Z%R?_ +^"C_A=TW_0N3_]_!7JG]DZ=_SXVW_?H4?V3IW_ #XVW_?H
M4?7<M_Z!_P#R9ARS[GE?_"[IO^A<G_[^"C_A=TW_ $+D_P#W\%>J?V3IW_/C
M;?\ ?H4?V3IW_/C;?]^A1]=RW_H'_P#)F'+/N>5/\<)$0LWAV<*.I\P53N/C
MRDMO)'_84HW*1GS!Q7L!TC32,&PMB/\ KD*K7FB:6+*8C3K0'8<?N5_PJX8W
M*[J^&?\ X$Q.,^Y\Z^%?'ATGQ-=ZFNG/.UP^\(K8QQ7IVC?%Z75M9M=/.@S1
M>>^S>7'%<]\/K*VD^(.JQ26\+(LQ 4H,#@=*]H33+".17CLX%=3D,(P"*]#.
ML3@HU>65&[Y59W?;3[B::E;<M*=R@D8R.E+117R)N%%%% !1110 5P?Q@)'P
M]N\#/[Q/ZUWE<'\8,_\ "O;O'7S$_K0!5^"O_)/;/_@7\Z]&KSKX*X_X5Y98
MZ_-G\Z]%H **** "BBB@ KE_']K-=>%;E(I-@"DN<X^7'-=15'5K*WO].F@N
M?]2RG=]* . \!Z+X,F\):>KV]B]PL0$C2, S'WYKL+#1?#5M=++8VUDLZG*F
M-@2/UKR.YM?AIHU[)#_:,8G1L. S?+7:>#=-\*W=ZM_H=ZL[)@G#'^M 'HM%
M%% !1110 4444 %%%% ''?%+_DG.K_\ 7*N4^ /_ ");_P#7S)_.NK^*7_).
M=7_ZY5RGP!_Y$M_^OF3^= 'KE%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\(V]J8EACS.,?=*G-='K$X\0>._#=KI<>1I4X>>11C VXH ];HI!D  G)I:
M"BBB@ HHHH **** ..^*7_).=7_ZY5RGP!_Y$M_^OF3^==7\4O\ DG.K_P#7
M*N4^ /\ R);_ /7S)_.@#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR?SH ]<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M);_]?,G\Z /7**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X/XP$CX>W>!G]XG]:[RN#^,&?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M <=\4O\ DG.K_P#7*N4^ /\ R);_ /7S)_.NK^*7_).=7_ZY5RGP!_Y$M_\
MKYD_G0!ZY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT;Q-8A)KE]D$SJ!YA]A5?P[\2+;1]#M=-U73[BWNK>/8^X!0Q]A55]4G\?\
MC70KFRL)[>TTRY\UY9%X<$$<&@#UQ8T3[J*OT&*=0.!BB@ HHHH **** "BB
MB@#COBE_R3G5_P#KE7*? '_D2W_Z^9/YUU?Q2_Y)SJ__ %RKE/@#_P B6_\
MU\R?SH ]<HHHH **** "BBB@ HHHH YGXA_\D^US_KU;^E>=^$6E\"V.E3,Q
M&DW]NI<GIYK<"O4/%NFRZOX3U/3X"!+<0%%)]:SX_"R77@6ST>[ ,T%N%5AV
M<#@_G0!CZ+>75E?^([JRLVO)1*NR)3@MQ5K_ (2[Q/\ ]"A<?]_!5'P[X%U"
MVT+4-.U"\)>X*D2Q.5;CWZTK?#$$8&J7V,?\_+?XT :WBS3#KGA&ZGNXV@D6
MV:0QYY4A2<5F_#YI?^%.Z28@6D-K@#UZUU5QI;+X7GTR-V9S;-$K.<DDC%8W
MAGP[>Z9\.=/T5I%%U!"%+#IF@#B-+O=7\-Z=YFI>&)DLHYG>6=G&$4GK7KFF
MW<5]IMO<P?ZJ1 RX]#7!:G9^)]4TJ3P]<^25GRDLPC^78>F#Z\5M^;J.AG3=
M+M=CQ1Q(CC;D_6@#K:XCXI';X.NSMW8C/'K7;USGC31I]<T&:SMR [J0,T <
M8=8N[SP?;Z?:^'VDDEMQ&'7 *Y&,U#-/XCT"T\+Z!9W#17#6C"9,9.0W6O3-
M(L%LM)M('1/,BB520O<"L?6=!N;_ ,7Z5J<;H(;:)U<$<DDT <]<7?B9KFVT
M&#5?]-#9FNMG0'IQ[5+#XAU/P]J]YI>JWOVV2"S-R)=NW/M5WQ1I6HVFKVNL
M:4H9U;-PA&2R@<8JE%X>OM7O-0UK562'SK-K;!&W:,=30!FS7GBVY\.)XFM=
M:VVUSAX[7R^54]L_A56Y\3^)+N;0K&TOS%-?S&.27;G;Q4%Z=5TWP5%I%MJ-
ME+9P%(XY%&>,]S6YI/A>^DN] OFV@6LQ>0$=1CM0!#XB\3WNE:C'H$^OK:78
MC$K73)G(/;%'A/QM=W-S>:<]]_:<J!C',HV\ =<5J^*="NXO$:Z_9V\-P[1B
M%XY(P_RCV-3Z/I.KLES=SPV,+/DP+' $91CHV.M '/Z#XDU&ZU6))O$*R2M(
M0;+9@CVS4GB3Q)JJ:Z;1M7&C1^6"N]-V\TO]AZWK,L<%Q!;VTT+$M-%%LW9]
M"*NZI8ZQ!=FV>U@NH&@$:N8@S*WKDT &M>+IM#\'PS2WPDNG**)\?>!."V*Q
M-'\:7-KXEL+27Q&FJQWC8*JFWRN*U)O!5^?"KQEHY+OSDE0.-P"CJ,59T>PU
MJ^U6VFELK"WM(3^\!M@LA'L: *(U#Q#XL-[>:5J?V6QA+1^7LSN93@UI?#!9
MDL]46X.Z87(WGU.*I#1M<T":\T_3 AM+G<ZMLSM=CDY-=!X&T.]T2PNEOW5Y
MYI Y*].E %'Q'J>L7VNQ:/H]R;-LXDGQG'X5G0ZYK>BW6JZ1J5_]JN+>T\^.
MYVXR3T&*T_%&FZG:ZS:ZOI05MC$S(5R6],52@\.:IJNH:IK%X41[NS%ND97!
M4COB@"SX'G\0ZJZZCJ%^3:A2OD%?OD]&S4?Q-&;&WR.,]3]:Z/POIDVDZ1';
M3$%U !(K-\>:'>ZSIJBQ91,G3<,B@!/$FB6.H^"7\Z% R6H96 Q@X'-</I^L
MZE9^'+1/-^2&>.)21GY<UT=YI_B[5]*326FMHH6C$<S;,$KCL?6I]1\%2_V1
MIUC:LH%NT9<G^+!YH Y[5?&US=^)-0L8]?728[)@!N3=YO%6=.^(-Q<>&D59
M_.O9IGABF QDCIQ5BZ\/ZGHOB2^O+:UMKJ"^8%0\(<I@=\U<E\)ZG=>&E^TB
MS34H9&EA,$811GID"@#F?%%CXB@M=-N-6U+[5!)=1';LQM.X8%=QJ/B7Q!:7
M\L%KX9FN84.%F60 -7-7FC^*-?MK&&Y:)([::,N"F-Q4YR*V]4^'XU'4[B\_
MM"[C,K9VK.P _#- %JWN=3\56%]INJZ/)IL,D6W>[@[LGIQ7$^+[=-._LO3V
MTYK6"&XBVWA;AL$<?C72_P#" 366F7WV34;HWDD6V(R3LR@_3-9$^G^)M>L[
M/2;V.,?9Y49YFC^\%/.#0!ZE#(LL*NC;E(X/K4E0VMNEI;)!'G8@P,GFIJ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K@OC#M_X5Y=[NGF)_6N]K@_C <?#R[XS^\3^M %;X*D
MGX>60[#=_.O1:\Z^"H_XMY9'/7=_.O1: "BBB@ HHHH *P?%_P!J7P_<2VDY
MAFC4NI!QG Z5O5YYXQ^(GA[3KAM*O-L^X?.H)X'>@#-\*>(O#7B#2(1KEO#)
MJ4"A9WD7JWL>]=SI.I:&C+:::8DR<!$(KC_#&A?#[Q39M)IEM'(4P)%5C\IK
MJ].\$:!I5XEW9V7ES(<AMQH Z&BBB@ HHHH **** "BBB@#COBE_R3G5_P#K
ME7*? '_D2W_Z^9/YUU?Q2_Y)SJ__ %RKE/@#_P B6_\ U\R?SH ]<HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *C,$1F\TH#(!C=WJ2B@ HI"P!P2!^-
M+GC- !12 @]"#2T %,FB2>%XI5#(XPP/<4^DW#U'YT <Q_P@VFB?(9OL^[=]
MGV_)D=*Z9$6-%11A0, 4ZB@ HHHH **:74'!8#\:4,#T(/XT +13?,3^^OYT
MNY2,@C'UH 6BFAT)P'4_C3J "BBD!!Z$&@!:*3(SC(H) ZD"@!:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *X/XP9_P"%>W>WKYB?UKO*X/XP
M GX>W>#C]XG]: *OP5_Y)]9_\"_G7HU>=?!4C_A7ED,<_-S^->BT %%%% !1
M110!'.YCA=UZ@<5Y5\,+*WU:[UF\OH(IY%O)(P9$#8&?>O5I4\R)D]17C=CX
M$\:Z->WS:=)"L,]PTH'G@=30!H:):1Z9\5KF&T'EPS.S.B<+D =J]7KQ)/ 7
MCJ/66U19HA.Q)_UX[UUGAS2/&=OJL4FJS1FV#?,!-NX^E 'H-%%% !1110 4
M444 %%%% ''?%+_DG.K_ /7*N4^ /_(EO_U\R?SKJ_BE_P DYU?_ *Y5RGP!
M_P"1+?\ Z^9/YT >N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MC7Q5U'4[3QCHB6$[ %6+(I/(W5UWBO7\>"PEG+_I=Y'Y4+ _Q@#-9?BFR>\^
M)^BY@+1BVF!;:<9[5SVA6>H:CK-IHUQ$X_L>Y:Y9V! =6R ,]Z -[X>^(7T_
MP;<7.KSF25+AD +<L?09K;TSXA07M_':W.EW=AY@RCW& #7GFI:1=W?A">.-
M)81'K!D<QJ<A >2*O?V1I.H7]C&FMZS<3LA,0>'Y5&>Y[4 =WJ?CRWL=6;3[
M?3KF]D0 R&#!" ]S7)>&/$%OJ&D7$^HO<8_M%E0+(05.> :L:+J=KX8\3:I!
MJ<<QD,2#S1&3O'IFN9TB-[CP]+)%:RHDFL,Z[HR#@GK0!ZCJOBR+15MHH=/N
MKUI4W 0\D#WJ-/'5FVB7NHO:S1M9IOEMV(W@5Q^JWLUSK,-E<-<6,44; 3P*
M=QKGM/#/I7C&-&O)@;50LD\9#OSZ4 >BQ_$FU=X"VEW:02D 3-C:":[%)TGM
M//B.5925(KSS6K/;X#TU(8&R-K$;3G.!79Z"&'ABT# @^3R"/K0!YG:V>G:]
MXSUJ/6-3N8%B"[%CN60?I4VD:C<V7B+5-'T^]^U:5%9>:DQ8N0_<;C5GP[X?
MBU+QMKTEW"RIM7:2O!KL[C0M.TK1;TV-G''(T1!*+RU 'GFBV'AG4UGGU77;
MF*X#8*B\91^5;VL16VA>!KF;0KJ>YA=.)FE+X_$U-X,\,Z5=:=-+>Z5"TC,#
METY/%:'BJY3PWHB);:7%+I:@^?$JDX'L!UH XW3]#T9X[>]\/^(I&U,X:6.:
MZ:1<]QMSZUZ.=5GT^QM!=0//<. ',0P,DUYQKL/AR32?M>AP2V=\Z[HUMX<?
M/COZ5W&CZD+'PQI1U5)7NGB4.0A8[B>] '0W;D64C+P=M>0^ _$.I:/K,]MJ
M\_F6-S<NENY_OECQDUZ[>_-8R8!Y7BO.].\-MJW@JX41XO8+N:6V+#&&SP:
M+V@WMQ+X]NH7E8Q#?A237/>.]9U6ZUFYETV1@FCL/,1<_/FJ'@>^U&+5M2DU
M&"5;JVBEC+;3AFV]CWK0\/>$=2UG29M6EN)8I=0&Z6,G'3IUH ]1TB\2^TJV
MG1@VZ-=V/7 S5ZO/_AC+=V5A<:-?+(9X97?<P."I/'->@4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSKJ_BE_R3G5_^N5<I\ ?^1+?_KYD_G0!ZY1110 4444 %%%% !1110 4444
M%%%% !1110 5'/,EM;R3R'"1J6;Z"I*K:C;B[TVYMRVT21LN?3(H XBX^(CN
MDUW8VCR6,+A7<H<G/<>M:VH^+TBTNSN;)/->[8I&I'\0&:X91XCT;2+C1;;2
MQ+8H-J7GF <?2G:3HMU?^%]!B&IM87<5Y(ROMR230!W.E:WJ\LDCZC:QQ6Z1
MERRYSQ4<'CJQGNP@CF$).!(T9 _.L*VFU;2?$C:-JNK/J4%Q#U8 8S]*GO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M72@#<HKGM6\3#2[C3(C"&^W2*@.>F1FL5O'.I7-W>V^F:2ERUK*4;+D<#J:
M.[HKF[+Q-+?Z+)=06JM>1XWP9Z&MVTEDGMDDEC\MR.5STH GIID175"P#-T!
M/)H?=Y;;?O8XKS&_NM=B^*FA0W,C):2A\)G@T >FR2QQ+ND=44=V.*;%<P3_
M .IF23_=;-<IXQTO5]7NM/@M)6ALEES<L#]Y,=#7.Z&D^C_$Q-+L;I[BR:U9
MW3^$-0!ZE3!+&9#&'4N.2N>145[Y_P!E?[.,RX^6O,O"5SK/_"TM9MM3F=@M
MO&54G.,DT >JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<%\82!\/+O(S^\3^M=[7!_& D?#V[P
M,_O$_K0!6^"HQ\/+(^N[^=>BUYS\%?\ DGUG_P "_G7HU !1110 4444 %%%
M% !1110 54U+3+75K-K6\CWQ-U%6Z* .0L/AKX=TZ^BNXH[EY(FW*)9RZY^A
MK9U?PYIVMBV%XCD6T@DC"/MP1TK6HH Y7Q%\/- \474%QJ<4[2PJ40QRE< U
MEQ?![PI#(KHE]N7IFZ:N^HH C@A2W@CACSLC4*N3DX%2444 <=\4O^2<ZO\
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M#A_#=I,/B;J]Q)%B)M/@",1WJSX7M9H?$]Z[QE49F(..*[18(DD,BQJ'(P6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P
M?Q@S_P *]N\'!\Q/ZUWE<'\80#\/+O)Q^\3^M %;X*X_X5Y98'/S9_.O1:\Y
M^"H_XM[9?\"_G7HU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<=\4O^2<ZO\ ]<JY3X _\B6__7S)_.NK^*7_ "3G5_\ KE7*? '_ )$M_P#K
MYD_G0!ZY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7!?&';_PKR[W=/,3^M=[7!_& X^'EWQG
M]XG]: *WP5)/P\LAG@;OYUZ+7G7P5 _X5Y9'/7=Q^->BT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!QWQ2_Y)SJ__ %RKE/@#_P B6_\ U\R?
MSKJ_BE_R3G5_^N5<I\ ?^1+?_KYD_G0!ZY1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_&#/
M_"O;O'7S$_K7>5P?Q@&?AY=\X_>)_6@"K\%?^2?6?_ OYUZ-7G7P5(_X5Y9#
M'3=S^->BT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWQ2_Y)
MSJ__ %RKE/@#_P B6_\ U\R?SKJ_BE_R3G5_^N5<I\ ?^1+?_KYD_G0!ZY11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7!?&''_"O+O=T\Q/ZUWM<'\82!\/+O(S^\3^M %7X*
M@CX>61QP=W\Z]&KSGX*G_BWME_P+^=>C4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!QWQ2_Y)SJ__ %RKE/@#_P B6_\ U\R?SKJ_BE_R3G5_
M^N5<I\ ?^1+?_KYD_G0!ZY1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/.T@RJPC)ZUB2?%"U@C$MQHVI0PXRTDD>%4>I-4OB@]Q'>:<]I&LEP!\J,<
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MB@#E[KPB)?$::I!,D*DCSHPOWU':D\)^&[SP])>))=B6">9I54+C;GM74T4
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MHH **** "BBB@ HHHH 9-&)H7C/1ABLG0_#T&BQ7D:$,MS(7;\:V:* .'O\
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M589!ZBN&;X=I]L;R[K;8O(97@YY)/-=U10!#:6L-E:QVT";(HQM5?05-110
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M".U '<T5Q_@SQ1<ZQ<WVF7\)BO;!@LN3R2:["@ HHHH **** "BBB@ HHHH
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MJQ^T)=K=R9+@[C'@=R>E>KUS^@>$;'0F:56-Q<M]Z>0?,:Z"@ HHHH ****
M"BBB@ HHHH S=<U.WTG2IKN[B,EO&N7&.,5YIXYA2Y72M6L[V,0^<C+"S9]\
M 5ZK?64&HV,MG<H'AE7:ZD<$5REM\.=/AO5FFNI;B%&W1V\BC8A[8H ZC3+A
MKO3+>X9-C2)DKC&*MTU$6- B !1T IU !1110 4444 %%%% !2,=J,<9P,X]
M:6B@#B=3NK#7OM=G#-]BNX1\^6VD_7%4_A1*RZ)<6I"MLN9?WJ#@_-_.M?6?
M EGJVHM?)=2VLSG,AB ^?ZUMZ/HUIHEB+6TC"IDL<#&2>IH T**** "BBB@
MHHHH **** "L+6]:T_3YTM[Y HE&%E;& 3T&?6MVLCQ!X>L_$5E]FNN,,&5P
M,D$4 >=O#+IGQ0TGRKI;J*Y#L,G<4^F>E>M#D"N9T/P59:-<I<O/)=W$?W))
M@,K]*Z>@ HHHH **** "BBB@ HHHH K:A<I9V$UQ)&9%1<E .37G/C.*TUO2
M&U/3[](O(&XPA\!B/X<#O7IKHLB%'4,IZ@UQ9^&UA]O:X6\F6%GWM;A1L)H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5P7QA('P\N\C(\Q/ZUWM
M<'\8"1\/;O S^\3^M %7X*D_\*]LAV^;^=>C5YU\%0/^%>61SS\W'XUZ+0 4
M444 %%%% !1110 4444 %-DC25"DB*ZGJ&&13J* ,^VT33;2;SH;*!9,Y#"-
M<CZ<5<EMX9]OFPQR;3E=Z@X-244 13VT%S$8IXDDC/\ "Z@BJUGH^GV'-M:0
MQM_>$8!_/%7J* "BBB@#E/B0<> =5.,_NJY#X"?\B=+_ -?4O\ZZ_P")&?\
MA =5QU\JN0^ G_(G2_\ 7U+_ #H ]:HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"@@E'_  G7A[_H()7F_P#PH6+C_B82>_[UJ/\ A0L7'_$PD]_WK4 >D?\
M"=>'O^@@E'_"=>'O^@@E>;_\*%B_Z"$G7_GJU'_"A8N?^)A)UX_>M0!Z1_PG
M7A[_ *""4?\ "=>'O^@@E>;_ /"A8N<:A)[?O6H_X4+%_P!!"3I_SU:@#TC_
M (3KP]_T$$H_X3KP]_T$$KS?_A0L7'_$PDZ<_O6H'P%BXSJ$GO\ O6H ](_X
M3KP]_P!!!*/^$Z\/?]!!*\W_ .%"Q8_Y"$G7_GJU'_"A8N?^)A)UX_>M0!Z1
M_P )UX>_Z""4?\)UX>_Z""5XC<_"D0>+K?2A?2&.5]I_>MQ73?\ "A8L?\A"
M3K_SU:@#TC_A.O#W_002C_A.O#W_ $$$KS?_ (4+%@_\3"3KQ^]:@_ 6+G_B
M82>W[UJ /2/^$Z\/?]!!*/\ A.O#W_002O-_^%"Q9_Y"$G3_ )ZM1_PH6+/_
M "$).G_/5J /2/\ A.O#W_002C_A.O#W_002O-Q\!8N,ZA)[_O6H_P"%"Q<?
M\3"3K_SU:@#TC_A.O#W_ $$$H_X3KP]_T$$KS?\ X4+%C_D(2=?^>K4?\*%B
MY_XF$GM^]:@#TC_A.O#W_002C_A.O#W_ $$$KS?_ (4+%S_Q,).G'[UJQ_$G
MP;31M,^U)J$F=P7_ %K=Z /8/^$Z\/?]!!*/^$Z\/?\ 002O*-$^"::CI%M=
MOJ$F9%R?WK5?_P"%"Q<?\3"3KS^]:@#TC_A.O#W_ $$$H_X3KP]_T$$KS?\
MX4+%_P!!"3K_ ,]6H/P%BYQJ$GM^]:@#TC_A.O#W_002C_A.O#W_ $$$KS?_
M (4+%S_Q,).G'[UJ/^%"Q9_Y"$G3_GJU 'I'_"=>'O\ H()1_P )UX>_Z""5
MYO\ \*%BX_XF$GO^]:C_ (4+%Q_Q,).O/[UJ /2/^$Z\/?\ 002C_A.O#W_0
M02O-_P#A0L6/^0A)U_YZM1_PH6+G_B82>W[UJ /2/^$Z\/?]!!*/^$Z\/?\
M002O-_\ A0L7/_$PD]OWK5S'A[X4#5M4NK9]0DQ"S*/WC=C0![?_ ,)UX>_Z
M""4?\)UX>_Z""5YO_P *%BX_XF$G3G]ZU'_"A8N/^)A)[_O6H ](_P"$Z\/?
M]!!*/^$Z\/?]!!*\W_X4+%_T$).O_/5J/^%"Q<_\3"3KQ^]:@#TC_A.O#W_0
M02C_ (3KP]_T$$KS?_A0L7.-0D]OWK4?\*%B_P"@A)T_YZM0!Z1_PG7A[_H(
M)1_PG7A[_H()7F__  H6+C_B82=.?WK4?\*%BX_XF$GO^]:@#TC_ (3KP]_T
M$$H_X3KP]_T$$KS?_A0L6/\ D(2=?^>K4?\ "A8N?^)A)UX_>M0!Z1_PG7A[
M_H()1_PG7A[_ *""5XEXC^$XT?5],LX[Z0_:V(_UK=JZ-/@/$T:M_:$G*@_Z
MUJ /2O\ A.O#W_002C_A.O#W_002O-_^%"Q9'_$PDZ?\]6H'P%BXSJ$GO^]:
M@#TC_A.O#W_002C_ (3KP]_T$$KS?_A0L7'_ !,).O\ SU:C_A0L6/\ D(2=
M?^>K4 >D?\)UX>_Z""4?\)UX>_Z""5YN?@+%SC4)/;]ZU'_"A8N?^)A)TX_>
MM0!Z1_PG7A[_ *""4?\ "=>'O^@@E>;_ /"A8L_\A"3I_P ]6H_X4+%Q_P 3
M"3W_ 'K4 >D?\)UX>_Z""4?\)UX>_P"@@E>;_P#"A8N/^)A)UY_>M574O@='
M9Z9=7(U"3,4;./WK=AF@#U+_ (3KP]_T$$H_X3KP]_T$$KQGP?\ "$>(O#=K
MJ3W\@,Z;A^]:M[_A0L7/_$PDZ<?O6H ](_X3KP]_T$$H_P"$Z\/?]!!*\W_X
M4+%_T$).G_/5J/\ A0L7&=0D]_WK4 >D?\)UX>_Z""4?\)UX>_Z""5YO_P *
M%BX_XF$G7G]ZU'_"A8L?\A"3K_SU:@#TC_A.O#W_ $$$H_X3KP]_T$$KS?\
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M2O#D]IXXU?6)'/E72H$'TKJZ "BBB@ HHHH **** "BBB@ KSKXR?\BMI_\
MV%+;_P!#%>BURGC[P]/XDT6UM+<D-%>13G'HK F@#J8_]6OT%.I%&$4>@I:
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M16;<=,M2?7RQ6I10!4L]+L=/W?8[2*#=U\M<9JQ-#'/$T4J*\;#!5AD&GT4
M,BBC@B6*) D:C"JHX I]%% !1110 4444 %%%% %&ZT?3;V4R75E!,Y&"SH"
M:B3P[HT;JZ:9;*RG((C'%:=% $,]I;W)4S0I(5Z;AG%2@   # '2EHH ****
M "BBB@ HHHH *:Z)(A1U#*>H-.HH R/^$6T'S?-_LFT\S.=WE#-:AAC,/DE%
M\O&W;CC'I3Z* ,R'PYHUO<?:(=,MHYO[ZQ@&M/H,444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1103@9/04 %%5$U2PDN/LZ7D+39QL#C/Y5;H **J7&IV-K*L5Q=PQ2-]U7
M< FK8((R.AH **** "BBB@ HHJ%+NWDG>!)D:5/O(&Y'UH FHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*I]JFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>genzerafbudl000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )K!68# 2(  A$! Q$!_\0
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M>(?^@_/^0H\SQ#_T'Y_R%6J*/J=#^4/K5;^8J^9XA_Z#\_Y"C?XA_P"@_/\
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M_P"NO]*Z2N;UK_D-Z?\ ]=1_*L<1\'S1K1^(Z2BBBMC(**** "BBB@ HHHH
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MTOT_I4S^%E0^)%7PV,:'#]36M63X:_Y </U-:U31_AQ]!U/C84445H0%%%%
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MSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6_TVP@-G(R97DCZUE4J3J.E);LTA3C3E4CTL<7JOA/4M(A$LZJRG^X<XKJ/
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M4 %%%% !1110 4444 %8/BK_ )!IK>K!\5?\@XUE7_ALTH_Q$;-M_P >D/\
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M0_4UK5-'^''T'5^-A1116A 4444 %%%% !1110 4444 %%%% !1110 4444
M%,F_U+_2GTR;_4O]*'L"W,+PT<SZE_UV'\JZ"N>\,_Z_4O\ KL/Y5T-8X?\
MAK^NIK6^-A1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S
MEH/^*M<Y_P"61KHZYNT_Y&Y_^N1KI*QH;/U9K6W7H%%%%;&0444Y!EU'J: -
M_P />%Y]:;S6(2W7EB>,CVKISX.\.LC1QWF9P,8\WO5J&1M-\",\ PX0D$=J
M\R^T2K<-.CE9"<EAUS7GQ=7$3E:5DM#NM3HTXN2NWJ6=6TYM+OY+5G5BAQQ5
M&NI\-:*WB*\DN+V9F*D%V(^]73X\'1S"S:&(S9VYV]ZUEB?9OD:<FM[&2HJI
M>:T7F>7T5U_BSPY'IT\,]H 8).6'3'-= - T1-+M[JYB2)5P6('WN*'C(*"G
MW!86;GR?,\PJ]I>F3:K=K;PLJL3C+5Z(VD>'M9TV9M-AC5HQRP7VJCX*.EPO
MY,L:B]#$ XYZ\5+QEX2<4[H;PK3C>2LSB=4TN;2;K[/,RLWJM4:],\7SZ"(W
M22-/MG8[>:K>'=$TN\\/^?=0H& R9,<TH8S]USS1=7"I5>2#//**['7$T&[,
M-II2JLV\*S*N#6W'HOA_P_:Q_P!JA)&8=66K>+BHIN+N^G4R^K/FY4UIU/,Z
M[SP%;PS6-\98D<@\%E!QQ6A=Z'H6LZ5)<Z4B1[ 2"J]<57\!Q&&UU&)ARK8/
MY5C7Q"JT)6T:-(4'"I%WNFS@KQ52\E5/NAS_ #J"K-\%^V2[1@;S_.JU=\/A
M1SUOXDO4****HS"J6K_\@B[_ .N1J[5+5_\ D$7?_7(U,_A94/B1[-\,_P#D
MF^A?]>P_F:*/AG_R3?0O^O8?S-%?*'T9Y!J?_)2_%/\ U\#^535#J?\ R4OQ
M3_U\#^535]%@?X$3P\7_ !F%%%%=9S!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7-:;_ ,C#=\'_ %A_E72US6F_\C#=\G_6'^58U?BCZFM+:7H=+111
M6QD%%%;OA.TAO-86*= R8S@U,Y<L7)] 2N[&%17K.H2^%=*F$%U:('Z<1YK&
M\4>&[%[(:E9?NU(^X!@8KCACHR:O%I/J=DL%)-I23:Z'G]%/2&6092)V'LI-
M#0RI]^)U^JD5W71QV8RBN@\-^'EUJ5EF:2-0"00M9^K:<VG7TD*K(47HS+6:
MJP<^3J6J<G#VG38SZ*ZO5+C1I?#<44%NR70V[G\LC/XURR1O(?D1F^@S13J<
MZ;:L$H<J3ON-HJ1H)D&7B=1[J135C=_N(S8]!FM+HBS&T5(+>9AE89"/932+
M$YE";&W$],<T706&45UEQX2CBT%;]9)C*0?DVURIC<-M*,&],<UG3JQJ7Y>A
M<Z4H)-]1M%2&WF49:&0#U*FHZTN18**** "N;UO_ )#>G_\ 74?RKI*YO6O^
M0UI__77^E8XCX/FC6C\1TE%%%;&04444 %%%*H+, .I.* $HKT/0O"UE96 U
M#5&!R,[&P1BKJ7OA"^E^RQ0(LAZ'R\?UKCEC%S-1BW;L=,<,W%2DTK]SR^BN
MH\7^'TT>:.>#)AE.%XKJM,L]%M- CN[ZTC8$#+;<FJEBX*FJB5[@L+)U/9L\
MMHKU2&Q\.^([::.PB$; <L$P17*^'M*B'B.2UN8UD12< \]Z(8M24KIIH)X9
MQ2DG='*T5ZO?3^%+&Z-K/:(LN<<1YK \9>';:WMHK^R 59/X,8&,5%/&J32<
M6KERP;5[23:Z'#T445VG&%%%% !6#XIQ_9QS6]6#XJ_Y!IK*O_#9I1_B(V;;
M_CTA_P"N:_RJ6HK;_CT@_P"N:_RJ6M%L9O<****8!1110 445);PM<7"0H,L
M[8% $=%>E6F@:/X=TY;O5OWC,,LI7./I4.HKX:U?397L0(9(U+#"8S7']<BW
M[L6UW.M81\J<FE<\[HKU'1K#1[;0%N[VUC< #+;<FI+>U\-^(8IH+&$(X7E@
MF"*F6.2;]UV74(X1M)N25SRJBKFIV1L+^6 G(5B ?:J==L9*2NCFG%PDXL**
M**9(4444 %4M5_Y!\GT-7:I:K_R#I?H:F?PLJ'Q(K>&\?V'#@=S6M61X:_Y
M</U-:]31_AQ]!U?C84445H0%%%% !115W284N-5MXG&59\&ANRN!2HKUN\C\
M-Z/;1?;;.,94<A,YK/U30M(UK2?MVG+Y(494*N-U<*Q\7JXM+N=GU*6RDK]C
MS2BO0?!NFV$EG/)>6Z2>6S EAGI6I!+X5U&[^Q06RB8\?ZNJGC%&3BHMV)AA
MN:/,Y)'E5%;GBC1AH^JM%$=T1 ()]ZPZZ:<U4BI+J85*;IRY6%%%%60%%%%
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M@"N;UHXUJP_ZZ_TKI*YO6O\ D-:?_P!=?Z5CB/@^:-:/Q'2=Z***V,@HHHH
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MPSW[5G^!]51)9[.XD40L,+N/'6N>5*4E.2Z/;N:1J1@J:>OF<A?W,EU>RRR
MAF8D@]JJUK^)+%++5I?+D5UD8N-K XK(KV*33@G'8\ZM%QJ-/<****LS"BBB
M@ JEJO\ R#Y?H:NU2U7_ )!TOT-3/X65#XD5O#7_ " X?J:UJR?#1)T.'ZFM
M:IH_PX^@ZOQL****T("BBB@ K1T+_D-VG^_6=5_176/6+5V.%#\DTI?"P1ZO
MJ]OHD]O%_:TBJ,#&YL5@:QX@TO3M&?3]*=6RN%*G.*J>.KF&:V@$<J.=H^ZP
M-<'7EX7"JI!2DW:^W0]+$8ATY+E2O;<]*\",LFFS^?\ <8L6-:MEIV@QW$EW
MIP$MQ'U"MT-<_P"#9X8]!N5DE16(; 9@*R?#VJ?8?$9!<"%V^;GBE4HRG4J<
MKM;\14ZJA1BY*^IG^)=0GO\ 5I'FC:,CY0K>U8U==XXLH!?B^@EC99 !M5@<
M5R-=^&E%TERJQS8I-57=W"BBBMSG"BBB@ J.;_4O]*DIDW^I?Z4/8%N8/AG_
M (^-2_Z[#^5=#7/>&3^_U+@?ZX?RKH:QP_\ #7]=36M\;"BBBMC(**** "G1
MN8Y%<=0<TVK%C)''=QM,,IGD8H8'?Z;XHTS5;);/5%"!1C<QZU2\0>%(?L1O
M](F#0#K&I)S[UH_\(WX?U6-)Q=B'*C*A@*-:U2RT70VL+.;S9. "3D8KQU)*
M:]C=.^W0]6"<HVJ-./<9X<S_ ,(9<AA@A#Q^-<"I8:FI4D'S1T^M>B>$FMKC
M0'@N+B./S 0<N >M.B\,:!87!O#>B0K\VTN#_6M(UXTJL^;J9>S=6A%1&>)Q
MN\*QM(1O"<9KS*NJ\7^((]4E2"V)$,1XXQFN5KIP<)1A>6EV8XJ46U%.]E8*
M***ZSE"BBB@ HHHH YRS/_%6N/\ ID:Z.N<M/^1N?_KD:Z.L:&S]6:U=UZ!1
M116QD%%%% !1110 445TUKX&U>\MUFB\G:PR,O43J0@KR=BHPE-VBKG,T5T5
M]X+U:PA\R5$91_<;-<Z1@D'J#@T0J0J:Q=QSISA\2L%%% !)P!DU9 45(\$T
M:AGB=0>A92*CHN 4444 %%%% !1110 4444 %4M7_P"01=_]<C5VJ6K_ /((
MN_\ KD:F?PL<?B1[-\,_^2;Z%_U[#^9HH^&?_)-]"_Z]A_,T5\H?2'D&I_\
M)2_%/_7P/Y5-4.I_\E+\4_\ 7P/Y5-7T6!_@1/"Q?\9A11176<X4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBMX;Q_8<.#GDUK5D^&O^0%#]36M4T?X<?0=7XV%%%%:$!1110 4444 %%%%
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M ,DWT+_KV'\S11\,_P#DF^A?]>P_F:*^4/HSR#4_^2E^*?\ KX'\JFJ'4_\
MDI?BG_KX'\JFKZ+ _P ")X>+_C,****ZSF"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF]:_Y#6G_P#77^E8XCX/FC6C\1TE%%%;&04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6#XJXTX]ZWJP?%/_(.-95_X;-*/\1&S;?\ 'I#_ -<U
M_E4M16W_ !Z0_P#7-?Y5+6BV,WN%%%%, HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *I:K_R#Y?H:NU2U7_D'2_0U,_A8X_$BMX:_P"0%#]36M63X:P=
M#AP,<FM:IH_PX^A57XV%%%%:$!1110 4444 %%%% !1110 4444 %%%% !11
M10 4R;_4O]*?4<W^I?Z4/8%N87AG_CXU+_KL/Y5T-<_X:QY^I<?\MA_*N@K'
M#_PU_74UK?&PHHHK8R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YNT_P"1N?\ ZY&NDKG+3_D;G_ZY&NCK&AL_5FM;=>@4458LK26^NDMX02[=
M*V;L9%>BO1[?PEH>F6D?]LW">8_0[B/PK.UKPYI(M1=:9<(T8=5(!)ZFN2.,
MIRE9)^O0ZOJE2UW:_;J<317I\7A;PY;V$<U]\A8?>+XJM?>$='N["2XTF16V
M G(;/2I^O4[[,%@YM)W6IYS12E&5MK*58'&#6WJ/AJ?3])BOS,KK(0-H'(KJ
ME4C&UWN81IRD[)&'16AHMFE]JD5O)]UCS7H<_AGPK9*@NV$3$#[SUE6Q,:34
M6FV^Q=*A*JFT]CRRBN\USP?9BQ-[IDBF(=LYS1X7\-Z7>Z8US?H?ESD[L8J?
MKE/D<^Q3PLU)1[G!T5Z</#/A>]W0V,JM/CH')K@=:TU]*U26U(^5#PW8U5+%
M0JRY4FGYA4PTX1YKW1GT5N:5X;FU73YKN.=$$8)VD<G%8JQNT@3!W$XQ6RG&
M3<4]48N$E'F>PVBO1+'PGHUAI\<VM3*&DY!+$=:SO$GA_2X-,:^TN1712 0#
MGK7.L93<N57]>ANL+-QYKKTZG&45W7A3PYI=_IAN;]2<9R=V,5I'P]X3N28+
M6=///0;S2GC(1DXV>@H8:4X\UTCS.BMSQ'X?DT.X4,P:-S\I K#KIA.-2/-'
M8RJ4Y4Y<L@JEJ_\ R"+O_KD:NU2U?_D$7?\ UR-$_A9,/B1[-\,_^2;Z%_U[
M#^9HH^&?_)-]"_Z]A_,T5\H?2'D&I_\ )2_%/_7P/Y5-4.I_\E+\4_\ 7P/Y
M5-7T6!_@1/#Q?\9A11176<P4444 %%%% !1110 4444 %%%% !1110 4444
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MT#^S[6;S9  %.<\4_P &PK=^')(IFVJX.XYZ<UY>68]23]37H_AHX\&W&#_
M?YBBOAU2H-7NVUJ31K>TK125DC3L/#VG:'-+J,%R\S!3D#!_E7(M]G\3^)7^
MT2F&)FQD\8_.K?@[5C'JTUE*Q,4F[.3WK+\8Z<^GZRTB*5BE/RD44H2C6<9O
M5K1E3DI4FX*UGJCT+2= L=.L)K>WNO,CD!!;<.,UR&N^&=.TBT:\MKXRR)R%
MW TWPQK%G::+=0W-T$D96"ACS7+0&-[U5GD+1$\Y-.E1JJK)N3T\MQ3K4W0^
M%>GZGH=EJNE>)=,2RO&"R*N,L,8[=ZP]?\+W>F61DL;EIK(?>&[/TX%:3>!+
M:_6.>PO%B0J,@ ]:OZA-!X>\/-:2W*RR@  >M8JI&$E[%[O8UC&4XVJ+3N4_
M#'_(H7/^ZW\ZX-97AU3?&Q5A(.1]:]$\'VXN_#TT*G;YF[GTYJ"+P!';7OVJ
MYO$>,'<5VUK&O3I5I\[W,72E4H14.['^)5%WX5CGE +JI(+=:\SKMO&FMV\T
M<5C8R QQG#8[UQ-=&"BU3;>EV9XMJ\8]D%4M7_Y!%W_UR-7:I:O_ ,@B[_ZY
M&NJ?PLY8_$CV;X9_\DWT+_KV'\S11\,_^2;Z%_U[#^9HKY0^D/(-3_Y*7XI_
MZ^!_*IJAU/\ Y*7XI_Z^!_*IJ^BP/\")X6+_ (S"BBBNLYPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KF]-S_P )#==/]8?Y5TE<WIO_ ",-WQC]X?QX
MK&K\4?4UI?#+T.DHHHK8R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KF]:_Y#>G_P#77^E=)7-ZU_R&]/\ ^NH_E6.(^#YHUH_$
M=)1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^*O^0::
MWJP?%/.G&LJ_\-FE'^(C9MO^/2'_ *YK_*I:BMO^/2'_ *YK_*I:U6QF]PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6J_P#(/E^AJ[5+5?\
MD'R_0U,_A94/B16\-?\ ("A^IK6K)\-?\@*'ZFM:IH_PX^@ZOQL****T("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IDW^I?Z4^HYO]2_TH>P+<P_#)
M)GU+I_KA_*N@KG_#0/GZD<?\MA_*N@K'#_PU_74UK?&PHHHK8R"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH YRT_P"1N?\ ZY&NCKF[3_D;G_ZY
M&NDK&AL_5FM;=>@4445L9%F/4+R%=L=S*B^@8BF2W=Q/CS9Y'QTW-FH:*7*K
MWL/F=K$TEW<2H$DGD91T!;BB&ZN+?_4S/'G^ZV*AHHLMA78YY'E<O(Q9CU)-
M-HHI@.CD>)P\;%6'0@T^:YGN#F:5WQ_>.:BHHLMPNPJ9+NXCC,:3R*AZJ&XJ
M&BAI/<$[#TEDC?>CLK>H/-.FN9[C'G3/)CIN.:BHHLMPNPHHHH M)J-[&NU+
MJ51Z!C44MS/.<RRN_P#O'-144N57O8=W:Q8AO;JW7;#<2(OHK8IYU.^88:[F
M(/JYJI10XQ?0%)H4DL<DY-)113$%4M7_ .01=_\ 7(U=JEJ__((N_P#KD:F?
MPL<?B1[-\,_^2;Z%_P!>P_F:*/AG_P DWT+_ *]A_,T5\H?2'CTF@^(]8^(?
MB;[%);B6.X'G%ER"<=JO_P#"$>-?^>MK_P!^Z[?P-_R4?QM_U]+_ "%>CUO#
M$U8+EB]#*5"G)WDCP'_A"?&O_/6U_P"_='_"$^-?^>MK_P!^Z]^HJOKE;^8G
MZM1_E/ ?^$)\:_\ /6U_[]T?\(3XU_YZVO\ W[KWZBCZY6_F#ZM1_E/ ?^$)
M\:_\];7_ +]T?\(3XU_YZVO_ '[KWZBCZY6_F#ZM1_E/ ?\ A"?&O_/6U_[]
MT?\ "$^-?^>MK_W[KWZBCZY6_F#ZM1_E/ ?^$)\:_P#/6U_[]T?\(3XU_P">
MMK_W[KWZBCZY6_F#ZM1_E/ ?^$)\:_\ /6U_[]T?\(3XU_YZVO\ W[KWZBCZ
MY6_F#ZM1_E/ ?^$)\:_\];7_ +]T?\(3XU_YZVO_ '[KWZBCZY6_F#ZM1_E/
M ?\ A"?&O_/6U_[]T?\ "$^-?^>MK_W[KWZBCZY6_F#ZM1_E/ ?^$)\:_P#/
M6U_[]T?\(3XU_P">MK_W[KWZBCZY6_F#ZM1_E/ ?^$)\:_\ /6U_[]T?\(3X
MU_YZVO\ W[KWZBCZY6_F#ZM1_E/ ?^$)\:_\];7_ +]T?\(3XU_YZVO_ '[K
MWZBCZY6_F#ZM1_E/ ?\ A"?&O_/6U_[]T?\ "$^-?^>MK_W[KWZBCZY6_F#Z
MM1_E/ ?^$)\:_P#/6U_[]T?\(3XU_P">MK_W[KWZBCZY6_F#ZM1_E/ ?^$)\
M:_\ /6U_[]T?\(3XU_YZVO\ W[KWZBCZY6_F#ZM1_E/ ?^$)\:_\];7_ +]T
M?\(3XU_YZVO_ '[KWZBCZY6_F#ZM2_E/ ?\ A"?&O_/6U_[]T?\ "$^-?^>M
MK_W[KWZBCZY6_F#ZM1_E/ ?^$)\:_P#/6U_[]T?\(3XU_P">MK_W[KWZBCZY
M6_F#ZM1_E/ ?^$)\:_\ /6U_[]T?\(3XU_YZVO\ W[KWZBCZY6_F#ZM1_E/
M?^$)\:_\];7_ +]T?\(3XU_YZVO_ '[KWZBCZY6_F#ZM1_E/ ?\ A"?&O_/6
MU_[]US6F^%_$DOB&Z@@>'[0LA#DKQG%?4=>;>',#XA:ECC]\>/7@4GBJKWD-
M8>DMD<5_PA/C7_GK:_\ ?NC_ (0GQK_SUM?^_=>_44_KE;^87U:E_*> _P#"
M$^-?^>MK_P!^Z/\ A"?&O_/6U_[]U[]11]<K?S!]6H_RG@/_  A/C7_GK:_]
M^Z/^$)\:_P#/6U_[]U[]11]<K?S!]6H_RG@/_"$^-?\ GK:_]^Z/^$)\:_\
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M;^8/JU+^4\ _X0GQK_SUM?\ OW1_PA/C7_GK:_\ ?NO?Z*/K=;^8/JU+^4\
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M ?\ "$^-?^>MK_W[H_X0GQK_ ,];7_OW7O\ 11];K?S!]6I?RG@/_"$^-?\
MGK:_]^ZIZOX,\7V^GR//+:F,*2<)7T56)XK_ .1?N?\ =/\ (T?6ZST<@6&I
M+[)X+X9\)^*KS0H)K*2W$+$XW)DUK?\ "$^-?^>MK_W[KU'X:C'@BS!&.6_G
M774EBJR5E(;P])N[1X!_PA/C7_GK:_\ ?NC_ (0GQK_SUM?^_=>_T4_K=;^8
M7U:E_*> ?\(3XU_YZVO_ '[H_P"$)\:_\];7_OW7O]%'UNM_,'U:E_*> ?\
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M@ HHHH **** "BBB@ HHHH *\V\:?\CIH/S8_P!*'X\5Z37FWC0$^--!Z?\
M'T.OTH ])HHHH **** "BBB@ HHHH ***HRZSI<#E)=1M4<=5:90?YT 7J*C
M@N(;F(2P2I+&>C(P(-24 %%%% !1110 4444 %<%\4_^1>;G'3G\:[VN"^*9
MQX>;IVZ_6@#LM+_Y!%E_UP3_ -!%6ZJ:7_R"++_K@G_H(JW0 4444 %%%% !
M1110 4454N-3L+-]ES>V\+>DD@4_K0!;HJ"VOK2]4M:W,,Z@X)C<-C\JGH *
M*** "BBB@ HHHH *Q/%?_(OW/^Z?Y&MNL3Q7_P B_<_[I_D: ,SX:G/@BS.<
M\M_.NNKDOAKSX(L^G5NGUKK: "BBB@ HHHH **** "BBH+F]M;-0US<Q0@]#
M(X7^= $]%5+;5-/O'V6U[;S.!G;'(&/Z5;H **** "BBB@ HHHH *@O?^/*;
M_=-3U!>_\>4W^Z: .$^&I_T_Q%\P/^EC\/E%>A5Y[\- 1J'B+IS=CI_NBO0J
M "BBB@ HHHH **** "BB@D 9/ % !14$-[:W$C1PW,4CK]Y4<$BIZ "BBB@
MHHHH **** "BBB@#S?23_P 79E&?^75N*](KSC20?^%LRGC_ (]6KT>@ HHH
MH **** "BBB@ HHIKNL:%W8*H&22< 4 .HJM;ZA9WA(MKJ&8CKY;AL?E5F@
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M!I:* $P/04M%% ";5_NC\J6BB@ Z=*3 SG%+10 4444 %%%% !1110 4444
M%>:^'./B%J?;,YX]>!7I5>:^&_\ DH6J8_Y[G.?H* /2J*** "BBB@ HHHH
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M "BBB@ KS7PWS\0M3[_OSSZ<"O2J\U\.?\E"U///[X].W H ]*HHHH ****
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M.?QKO:X+XI_\B\W('3K]: .RTO\ Y!%E_P!<$_\ 015NJFE_\@BR_P"N"?\
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MU.+R;R_8220@Y"'TS7:T5,/<5O*WR*G[S_'U84444 %%%% !1110 5B>,?\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !4%[_P >4W^Z:GJ"]_X\IO\
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M5T5RG_"R/"7_ $&(*/\ A9'A+_H,04 =717*?\+(\)?]!B"C_A9'A+_H,04
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M;$&?K2#XC^$S_P QB#B@#JJ*Y7_A8_A/&?[8@H_X6/X3QG^V(,4 =517*_\
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M^8Q!S[TO_"QO"F<?VQ!F@#J:*Y4?$?PF?^8Q!Q1_PL?PGC/]L04 =517*_\
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M/_O@5T%% '/CP9HH)_T2/G_8%'_"&:*%(^R1\]]@KH** .>_X0S1=N/LD?\
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M?_? KH** .?/@S12 /LD?'^P*#X,T4L#]DCX[;!7044 <_\ \(9HN[/V2/\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !4%[_P >4W^Z:GJ"]_X\IO\
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M *4/PXKTFO-O&F/^$TT'.?\ CZ&,?2@#TFBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N"^*8SX=88STX_&N]K@OBIC_A&WZ[N,8^M '9:
M7_R"++_K@G_H(JW532_^019?]<$_]!%6Z "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Q/%?\ R+]S_NG^1K;K$\5_\B_<_P"Z?Y&@#,^&O_(D
M6>!CEN/QKKJY'X:X_P"$(L\9QENOUKKJ "BBB@ HHHH **** "BBB@ HHHH
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M:N%%%%(84444 %%%% !7!?%/_D76R<=.?QKO:X+XJ$_\(VZ\<X_G0!V6E_\
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MY&@#-^&O_(D6>#GEN?QKK:Y+X:\>"+/D=6Z?6NMH **** "BBB@ HHHH 0G
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M\U\.?\E"U/M^^/ [\"O2J\U\-_\ )0M4QQ^_/7OP* /2J*** "BBB@ HHHH
M**** "BBB@#R?XB:;<Z7XHL_$T,9:",+')M'09&:A\6^.K#QAH<F@:$DL]Y=
MKL"O&5 /UKUN2*.9=LL:NOHRY%11V%G$X>.T@1AT98P"*F,5R\DM8IW*YFI<
MZWM_PQF^%M,DTG0;:VE_U@0;AZ'%;5%%:2DY.[,XQY58****DH**** "BBB@
M HHHH *\V\: GQIH/&?]*'\J])KS;QJ/^*TT'@G_ $H=/I0!Z31110 4444
M%%%% !1110!SWC719->\+7UE",S21$(/>N&\-_$?3= T9M)U;SHKRU'E(JQ%
M@<#UKUJJS:=9.Q9K.W9CU)B4G^5**:NNC&VFE?IL>>^ ]+N-1U^_\3W"%([L
MAH@?:O2Z:D:1(%C144= HP*=5-JRBMEH2KW;>["BBBD,**** "BBB@ K@_BG
MQX<9L @8_G7>5P7Q4Y\.L,$].!]: .RTO_D$67_7!/\ T$5;JII?_((LO^N"
M?^@BK= !1110 4444 %%%% %:_MA=V4L!_C4BO(O"WB.#X=WEWHFNK+%&'::
M-D0MG<2>U>S5!+96D[;IK6&1O5XP32C>,FUUW&[./*^FIY;IROX[\=V^MP(X
MT^S1H@[+@G.".#]*]84;5 ]!BF100P+MABCC![(H'\JDJM%%0CLB=7)RD%%%
M%(84444 %%%% !6)XK_Y%^Y_W3_(UMUB>*_^1>N?]T_R- &9\-1CP19@C'+?
MSKKJY'X:<>"+/@CENOUKKJ "BBB@ HHHH **** $9=R,I[C%>07%T? 'C^[U
M"^C<:?J+@^8BEB /85[!44UM!<8\^".7'3>@/\Z2NI<R]!Z.+B]CR77=9A^(
M^IV6GZ*)'MX)5F=W0KTZ]:]9M;=;6UC@4Y5!@416EM;G,-O%&?5$ _E4U4K*
M/*O4EW<KL****0PHHHH **** "H+W_CRF_W34]07O_'E-_NF@#A/AI_R$/$7
MR@?Z6/Q^45Z%7GOPT ^W^(N"/]+'7_=%>A4 %%%% !1110 4444 %>5>/;*Y
MT+Q78^*XHB]O;QF*3 R1N(_PKU6F211S)LEC1U_NLN12U4E*.Z'I9Q>S/*?$
MGCO3_%ND?V%HGG2W-XOE-NB*[:[_ ,+:0=%T"VM'_P!8J#?]:TDL+.)@T=I
MC#H5C -6*I6BFEUW)=VU?9!1112&%%%% !1110 4444 >;Z3N_X6S+S\OV5J
M](KS?2R/^%NR8S_QZ-7I% !1110 4444 %%%% !1110 4444 >5>/K*YT/Q5
M8>*HHB]O;H8Y<#D;B/\ "H_$?CS3_%FD?V%HOG2W-XOE-NB*[?QKU:2*.9-D
ML:NI_A9<BHDL+.)PT=I C#H5C -)17*H2U2?](;D^;G6^QF>%=(.BZ!:VC_Z
MQ4&_ZUMT45<I.3NR8KE5@HHHJ1A1110 4444 %%%% !6)XQ_Y$[5_P#KV?\
ME6W6)XQ_Y$[5_P#KV?\ E0!G?#/_ ))OH7_7L/YFBCX9_P#)-]"_Z]A_,T4
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M0 4444 %%%% !1110 4444 %%%% !1110 5P7Q4P/#;G)#<8Q]:[VN"^*?\
MR+S<XZ<_C0!V6E_\@BR_ZX)_Z"*MU4TO_D$67_7!/_015N@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "L3Q7_ ,B]<_[I_D:VZQ/%?_(OW/\
MNG^1H S/AI_R)%GR3RW7ZUUU<C\-3GP19G.>6_G774 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5!>_\ 'E-_NFIZ@O?^/*;_ '30!P?PT/\
MQ,/$?)_X^QU_W17H=>>_#4_Z?XB^8'_2Q^'RBO0J "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /-])/\ Q=J48_Y=6YKTBO.-+./BW(H.
M1]E8UZ/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6)XQ_P"1.U?_ *]G_E6W6)XQ_P"1.U?_ *]G_E0!G?#/_DF^A?\
M7L/YFBCX9_\ )-]"_P"O8?S-% &)X&_Y*/XV_P"OI?Y"O1Z\X\#?\E'\;?\
M7TO\A7H] !2,P12S$ #J32USGC/4S8:%+'&<33J4CQZUG5GR0<C;#T95JL:<
M>IA6"?\ "2>,I+S)-O9EHB.Q/45W,MY:VV%FN8HSZ.X%8?@O2_[.T1'9<2W
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M \WTG;_PMJ7KN^RM7I%><:5Q\6I05Y^RL<UZ/0 4444 %%%% !1110 4444
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M<]NGUKO:X+XJ''AMR#AAC'YT =EI?_((LO\ K@G_ *"*MU4TO_D$67_7!/\
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M>0F/I0!Q)^)ZC_F7M1.?I0?B>N<?\(]J)/X5VWV"UQCR$X]J/L%KG/D)GZ4
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M^,[2W'C/0AY8 -T!@#KQ0!H_\+.3!_XD&H<'':D/Q/4-M/A_4?TKMO[/M/\
MGW3\J#I]H3DP)^5 '$_\+/&<?\([J/Z4?\+/''_%.ZCS]*[?[#:_\\$_*C[!
M:\?N$XZ<4 </_P +0'_0NZC^E+_PL\?]"[J/'TKM_L%K_P \$_*C[!:\_N$Y
M]J .(_X6>/\ H7=1_2C_ (6>/^A=U']*[?[#:_\ /!/RH^PVO_/!/RH X?\
MX6>/^A=U'GZ4?\+/'_0NZC^E=Q]@M>/W"<>U'V"U_P">"?E0!Q'_  L\<_\
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M5.W[\]>_ KTJO-?#?_)0M4QS^_/7Z"@#TJBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\W\:[AXST$] ;H?RKTBO-?&W/C3
M0 <\78Q^5 'I5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%<%\4QGPZW!/3^==[7!?%3_D76Z]NGUH [+2_P#D$67_ %P3_P!!%6ZJ:7_R
M"++_ *X)_P"@BK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M8GBO_D7[G_=/\C6W6)XK_P"1?N?]T_R- &9\-<?\(19X!'+<'ZUUU<C\-<?\
M(19XSC+=?K774 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>
M<V4P_P!DU/4%Y_QY38_NF@#@_AIC^T?$8P01=C/_ 'R*]#KSSX:8_M'Q'@G/
MVL9S_NBO0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M.-*P/BU*"#N^RMS7H]>;Z60?B[)@D_Z(W6O2* "BBB@ HHHH **** "BBB@
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MQ]!0!Z51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<^I%3=N:A%7;*LN5R>R/H:.ZMY3B.>)SZ*X-2U\P/IGB7X6^)+$2ZG]IAF=
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M=J__ %[/_*MNL3QC_P B=J__ %[/_*@#.^&?_)-]"_Z]A_,T4?#/_DF^A?\
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ME,##:<H.E;X6453BHM>=PKQO)\VW2Q;N]?DU;7+)-,N)8X@%WHO ]Z]/4$*
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M_P"1?N?]T_R- &;\-?\ D2+/@#ENGUKK:Y'X:_\ (D6>!CEN/QKKJ "BBB@
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M#%@*YZXKSY6B\EM7: _V)IOSP(RX\T=]PKT/QEI^O>*M;@T@64T.E*1))/\
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M110 4444 %%%% !1110 4444 %>:^-0/^$TT MG_ (^QC\J]*KS;QMN;QGH
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M'>K:5\1GUVQ>(64KEY%+<]L<5ZG11'W9J:W!ZP<'LQ!G:,]<<TM%% !1110
M4444 %(V=IV]>U+10]0/*+7X<ZQ/\2'U[4GA:S5F\M0^2 <=J]64;5"CL,4M
M%-.T%!;('K-S>["BBBD!YMI/_)6I>O\ QZM7I->;Z3_R5J7G_EU;BO2* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/&
M/_(G:O\ ]>S_ ,JVZQ/&/_(G:O\ ]>S_ ,J ,[X9_P#)-]"_Z]A_,T4?#/\
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M#OP* /2J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<$_]!%6ZJ:7_ ,@BR_ZX)_Z"*MT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5B>*_^1>N?]T_R-;=8GBO_D7KG_=/\C0!F?#3CP19\$<MU^M=
M=7(_#3GP19\D\MU^M==0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !4%[_ ,>4W^Z:GJ"\Q]CFSTVF@#@_AH,:AXCX(S=CK_NBO0Z\\^&A_P")
MEXD&20+L8S_NBO0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOB$;O^)<.!G[A_PH ](HKS?_ (37Q#G']G#D9^X?\*!XU\0G;_Q+A\W^P?\
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MT5YM_P )OXA_Z!H_[]G_  H_X3?Q#_T#1_W[/^% 'I-%>;?\)OXA_P"@:/\
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M$.0/[.'(S]P_X4#QMXA.W_B7#DX^X?\ "@#TBBO-_P#A-O$.,_V<.N/]6?\
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M(5(']FCG_IF?\* /2:*\V_X3;Q#YFS^SAG_KF?\ "@>-_$+$C^S1Q_TS/^%
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M (4#QKXA.W_B7#YO]@_X4 >D45YO_P )MXAP#_9PY./]6?\ "C_A-O$(#?\
M$N'!Q_JS_A0!Z117F_\ PFOB')']G#@9^X?\*/\ A-?$.0/[.'(S]P_X4 >D
M45YN/&WB$[?^)</F_P!@_P"%)_PFWB'&?[-'7'^K/^% 'I-8GC'_ )$[5_\
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M2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_P!T?E2T4 )M7^Z/RHVK_='Y4M%
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>genzerafbudl000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 genzerafbudl000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '8!X(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOTKCZ* .P_MJP_Y[?I1_;5A_SV_2N/HH [#^VK#_ )[?I1_;5A_SV_2N/HH
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MI1_;5A_SV_2N/HH [#^VK#_GM^E']M6'_/;]*X^B@#L/[:L/^>WZ4?VU8?\
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M#^VK#_GM^E']M6'_ #V_2N/HH [#^VK#_GM^E']M6'_/;]*X^B@#L/[:L/\
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M;]*X^B@#L/[:L/\ GM^E']M6'_/;]*X^B@#L/[:L/^>WZ4?VU8?\]OTKCZ*
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MOTKCZ* .P_MJP_Y[?I1_;5A_SV_2N/HH [#^VK#_ )[?I1_;5A_SV_2N/HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN(F;:'7/UJ6BUA--;A1112$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M%.(!&X=#3:XVK:&Z84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3:='_K%^HH [U?NCZ44+]T?2B@#B]4_Y"EQ_OFJE6]4_Y"EQ_OFJE !1110
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MX@TF"$[U)OIC>M,!YIH9..:7:<=*8IJRK*J=:3 BVD=J:WJ*E:4GL*C+>HI
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M93B5 P]:VK/6;6[P-X1SV-#@T$\/.)HT4=LT5!@%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 44FX#J:6G8 I"<#-+3E0,#GIBJA&\K$R=D9LQ+,<]J:(L#>1]*O):A
MI!D\$U/J$:!%5!C:*]#;0YKF3L+'FGK#4BH:G5!W-)@;%C9:;#HYO+V(E5&6
M(R36?-K'AMXP+>"?>2.L3=*W+:.UD\/.EU+Y<!4[GST%8-V^@6]LHL;Q+B3(
M 4')KDO>;N;)>Z:FGS>']1NC;PPR^8!D[D(%4]1U#P] UQ:Q0RFZ3Y0 AQGZ
MU-H"1?;MRKAL5B2H/[>OV(&1(,?E3Y7S\MQ)^[<VGM=(TG38[K5%=O, ("J2
M>?I63JDNG8@FT_=Y<IQM(P16VNIZ9J,"6>I*J,O"NW3\*SM9T2*P\N>(AX7Z
M'O0FU+4>C6AFJPIX:H,$<CI3UR:Z3(GSQ12HA/:GE,<4"%45!,/WF:L \XJ*
M526S20R&E%/\NE"4Q ,BIT.1[U'MIV*F44U9E)V):*53N7GJ*2N.<>5F\970
M4445!04444 %%%% !36.U2?2D\V/=MW#=Z5%>3BWMV<]>U5%.Y<8MR2.>U&?
M=*1G)K/&",FB>3?*S>IJ,-S7?T/=A&T;#B!V-6(,+R>PJJ>N:>KGI3130KDL
MQ)IM//6FT#0I'%1D<U*.>*:RXYIH0B'FI14(ZU,O-)C%IK#C%2E0H'K3<9-(
M+C H5?<TT_,"*D)J/O0(A YQ4Z\+2;-TOUIQ&#B@8M)WI">:"<B@ ,ASCM6U
MH?,C&L0(<BNBT6':K2$=>!6=5^Z<^*:5-FO1117$>(%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z/_6+]13:='_K%^HH
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MJ8#-4O-"]ZDBNE[FG8;1:VD54OKI;:(LQJ6:_A2,LS8 %<=J6I-?W)P?W8/
MI,VH4'4D37&I2RL0K$"JZW<T9R)&_.H!TIK'BL7J>W"C&$;%QIH[H_O,ACWJ
M673;>V@65Y0S-T6L9IB&P*G$C28W$G%+E)Y7>R+\=X8T\M  GTILA609'6JV
M<"HV?'>BQHXI:D@C._);%:0U2Y%N(%<[![U1A"&/>Q^E+G)XHL0ES/44[G;+
M$DT >U/ XIR_*^1VIHZ(H9MJ:( <\AAT(IZ[<%V'/:F><0>.*8V:NGZW-;,$
MF^9/>NH@GCN8A)$P*FN!\S=UJ_IFH/93  Y0GD5G.%]4<=?#*2O'<[.BFHZR
M1JZ]&&:=7.>6U9V"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SG
MBV:VATUD>,%V^[@8.:N7WB2PL)O*D<E\\A><5C>+7M+[2([F.==PY49Y-<M>
MI%P:6YZ>!H35:+DM&<LNJ:C&J.)VVH, 9KL+/Q5;?V0)+H@R="OK7%:?;3:G
M=):(0,]2:=JFF-I&H&&0$K@$'UKS*5:M&+ENCZ7$X3"U:D::T9KZ5=:=>>()
M))H0B/@(O;->A1HD<86-0%'0 5Y':HUW?0QVXPY8=*];@0I BL<D#FNW S<D
MVT>+G=)4I)1E<DHHHKT#P3B_$OB2ZM;S[+;$(%^\2.M:WA?5)M1LF,X^93C.
M.M4?&&E6K64EZ2$F49_WJT?#ES9-IT4=N5#8Y'>N*/,JSN]#V:BI2P:<(Z]S
M;HHHKM/&"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HIZ1E^E2>1[TK@045(T16HZ8!1110 4444 %%%% !1110 445'),L8YIJ+
M;LA-V)*1@2A*]A5%KPEO;/:K;S>7;X4\L*Z(4'>[,Y5%T,B>5O,)R?SJQ97+
MLX3J*A\HS284<FIXD^RN5 R?6MYP35B%)HT&<*.34/VD@D#H>M5F+.<FD/ I
M4Z:B$YW-2)OE#5#<2Y-);2?N,&H9#EJU,P!-/S48J04F,Z*UCAO= >T>XCB+
MC&6(K+F\/V6GVGFB\@=D';&365<V4=R!O&<55&DVZL#CI7/[-\UT:*2M9G2Z
M!*@O-Q8*N.I.*R6=&UR^.X%/,'(^E-*)Y/ED<$5%!;QVZD(,9ZU?)[_,3?W;
M'0OHVG7J*Z7D:# R&(SFJ'B'5+9+>UTFT?SF3AVSG QZUBW&GPW#[B.:DM;"
M&W.549]:ETFWJRE-)$Z1G I=FTU:C "D$9STII7UK0@6/\J>2!P*C' I!ECQ
M3$&<OQ3B*8H*DYY-))(5I#L2C:.M.RK=ZI,Y/1J0,R\YIA9EW S2U56;(YJ=
M7R*+")HOO'Z4VG1'DGVIIZUS5S:D%%%%<YJ%%/CB>5L**M?V<^.32;0%*J>H
M7/D0,%^\:TY+5XUSUKG;]Q)<\]!U'TK:C%2D;X>"E+4AANA:KYD@+.W09Z52
MO=2FN<@GY?2F7$GF3D]AP*@9<BNOE5[GK1I1O<KDFD!IS"F4S8E0\X-2PH&8
MD]!58&KD8VV_NQIHED9.312[:4*2:"@4<TYL8IKY%,!S0*UQ.]2+TIF*4-BA
MC+#<H#3!PI--#\=:5CP!2$)3F"MC9QCK3=P7DTF]2>.*!@0<@BBG$$KD4T4"
M&,>:04,.:2@9;MXS(PSTKK+=!' J@8XKG-+3S954\8-=.!@ >E<U9]#S,;/5
M1%HH ).!5A;5B,FN<\\KT58^S\]:1H,4K@044I!!Q24P"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_P#6+]10!WJ_='TH
MH7[H^E% '%ZI_P A2X_WS52K>J?\A2X_WS52@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBEP?2@!**** "BBB@ HHHH **** "BBE52QP*
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M/"^B2Z;"TLYP[_PCL*[(3J^TY6M#R:U'#>P]I%^\='11176>2%%%% !1110
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M]8OU%-IT?^L7ZB@#O5^Z/I10OW1]** .+U3_ )"EQ_OFJE6]4_Y"EQ_OFJE
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M,3RU)R:4(A.-U*5++Q0D7S#G)["@#0T>U,VH(",JIR:[,_RK,T;33:V1E?\
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MW;#X'2H !4T?RL#6;*+^,KS5NR4[<9JHA#+5JSD"R%2:$(T52E-&[BFELFF
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M5&#CFB5-2=S-PY3JO#+NDZQORL@PU1ZQ<_:]<:*,8CMODP.F>M4[/49K'=)
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MY)2<G=GFSFYRNQ20:B;&:4@CI3#GO00.'%!IO-.[4P&FDIQIM #3333C2&F
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MSW-;5]2L[OQ=;SP7"/%&@#N.@Y-2:GJ%I>ZW;S6\ZR1QC#,.@K!M989+GRP
M">]:0@2,D*H&:/8*-@=1LNZ[?VFH75O]EG67RUPVWMQ6[X>N0VF.)1GR<E2>
MU<NL*+RJ@$U)<:W<6VG26%M;#,HP9=W2LY0M#E0U*\KGFNN7/]J^*[NZ=CY;
MR>O:KGEPK&HM8@/5B.M:MQH"$B5!\_4CUH6UV+M(Q752@E%%3J7([(\ &MN
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M248]Q7-W8,T93>RCV.*I/:EU"AV7'=214/>YM&@WJCT'1M,3[,TS%1..%#=
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M8HY!Y>F%B>@IO0\TN<]J8AR<\&GFHU.#3R:8Q*;2FDS0 VD-*:2F 4AI:2@
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MS18!<TE%%,!**** $I:2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&P1G2QL35/YHYQG.#6W)&,5G3QC>*$,'.5XJO'$4E)]:LX &:9WJD E%%%,
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MPNL<QWQD<8[5.X^3VD;G1RS':Q/S8&<>M<O;ZG/;SDJ<QLYS&/K5B[UIV+K
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M!QTI;.PM[&/9!&%%6J*GDC>YI[6?+R7T"BBBJ,PHHHH **** "BBB@ HHHH
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MC[2)IYE4>M=7&NR-5]!7-7L>9CN6Z[CJ***YSSPHHHH **** "BBB@ HHHH
M*2EHH 2EHHH **** "BBB@ HHHH **** "G1_P"L7ZBFTZ/_ %B_44 =ZOW1
M]**%^Z/I10!Q>J?\A2X_WS52K>J?\A2X_P!\U4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4'%)10!'-;)-R.#
M5"73I#]*TZ*WC7DB'33*EC9"TW/_ !G]*MT4H P2> *SE)U)78TE%"M*(8&=
MNO:LP,[L2>YI]Q,9Y,#[HZ4BC%=U./+&QSR=V2(H/M4OE@=ZC4&G'@4Q#F<
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M;U[[=/JTRRJY ;"C%=WX<CN(]'A6XSN X!K@A:K5=UL>[5Y\-A4HSW-8 *
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M<"BBDDD4Y-Z,****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ593W"BBBI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-21QDFI2P]*;N-(9-N"C"]:8232"EH$)WIV_CI3:.M,"*0Y/2H,\U-*I S4
M'-- .SBC?1CBFXQ3 =N-.!--44\ DT /1L5G>(;SR-.(S\S<5HJG-<;XHOO-
MO?(4_*E1)G3A8<]1&+).^/O&LZ>3)QW-2RR<&F6\!D?)K(]IZNR)[*(Y!Q6X
M8PL:_P!ZJ]I;\C]:MRD%L#M3-HQL18IAR*267:*JM*SGDXH*98[YJ12<50&X
M]S3P)!T:D(O9!H YJ!&.WGK4@>F-,E=3MX-9TSL<BKSOO4=L57\L$TA[D$,C
M*<,,BIVZ\=ZD6 8W#J.U3Q0K.-O1ATJ=B&K:DVF0^;*!Z<U:-I+?WS)$,@'&
M:N:)I[D29^7MFN@MK2*T3;&.>[>M1*=CDJXA0>A6L=(@LU!(#R>M:%%%8MMG
MGSJ2F[L****1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5")L.0U35G7!*R$@]Z: T>M%9\%WM.UNE7U8,,@Y%(!:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "GK&S\@<"F4R1W"$*>M:4XJ4K,F3:6@
MVZE"IY><UGJWS4^3<3S45>@DDK(P3U)F52W Q4@C79QUJ-/G&.].^>/J*B1H
MAXB-/*[NN*B\REW\5#1:8[8 >M2!N,#BH=U.!J;%7'T9I :6E8=Q<TUSQ2BA
ME^7-%AW*Y/-&::<;J,CM3Y1\PNZ@&FTX4U$'(<*>I/:F@5)$N6SZ46(<B= !
M3Z0=*6N23NP"BBBI **** "BBB@ HHHH **** "BBB@ HHHH *9)&DJX=01[
MT^B@:;6Q5&GP Y"UCZKIWE-YB#Y3714V1%D0JPR#6D:C3-Z6(E&5V<0<@TX-
MQ6O?:.5R\0R/Y5E;"IPXQ79&2DM#UZ=2,U="ASBD+GUI=H[&@I3-!GF'-2$?
M(">]1%3G-/((5>: 88YK8TO3ED7S)!Q6.#S73:5(KVN!U7BLZK:CH<N*FXPN
MB\JA0% P!2T45Q'C-W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_]8OU% '>K
M]T?2BA?NCZ44 <7JG_(4N/\ ?-5*MZI_R%+C_?-5* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* '(=K U#<(Y)8<YJ2E#$5K3J.#(E#F,QE;/(IGX5K$(WWES]*9);HZ_N^&K
MIC73,G3:*<6<X(XJ5X !N4XIACFC/3/X5+O\R(\885=[BV*^]EIPD-,/6E J
MK$C]V: :;2T 2@\4ZHU-/!I +3\!1DTU>6%$K<T@(IWW=.*K#K4C\FD"U2 4
M4UJF5.,TUA1<!BU,E14C7$4*YDD H8U%O1$MS,MO;23.<!5->9W<_P!JNI)6
M_B:N@UW5S=_Z/#D1CJ?6N?,0(Z5DW<]C!X=PCS,JO$"0!6G:P*JC/%5ECPWK
M5Q' I'=%69:W87:O IM1B1#WQ0944=<TC2Y"PW-08AZ4ADP"W<U'YC'O0 YH
M\4#CBA-S&I'3'7K0(8*?4=+0(>30K8-,YHYI@7$*NG/44U6,<@=>QJ*-L'FI
MPB%<EN:16Z.ZTZ2.6P1T W$?-5FL+PS(Q5D/W:W:Y9*S/%Q$>6;"BBBI,0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** '(N]U4?Q'%;'_".S_P!]?SK)@_X^(_\
M?'\Z[ECQ0!S)T&8?QK^=1MHTJ_Q#\ZZ&0FJTAH Q#I<@_B'YTPZ>X_B%:KU7
M>F(SC:,.XIA@([BK;U7>@" J1W%1EL4]ZKO18!QF JA.VYC4KU7>F!7<\U+;
MWK1-@_=[BHGJN] '21RK*NY33ZYZVNWA8<\5N07"3KD'GN*D9+1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 57\G?*Q(XS5BB@!  HP!2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<RY7^=5!P<&KYY&
M*B,()KII54E9F4X7=T0J"3Q4\:\4JQ@4^BI6OH@C#JPHHHKF-0HHHH ****
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>onct-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9407922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:onct="http://www.oncternal.com/20201231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncternal.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.oncternal.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100080 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
        <link:definition>100090 - Disclosure - Commitments, Contingencies and Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements">
        <link:definition>100100 - Disclosure - License, Collaboration and Research Subaward Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100110 - Disclosure - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger" id="Role_DisclosureMerger">
        <link:definition>100120 - Disclosure - Merger</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit" id="Role_DisclosureStockholdersEquityDeficit">
        <link:definition>100130 - Disclosure - Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" id="Role_DisclosureCOVID19PandemicAndCARESAct">
        <link:definition>100140 - Disclosure - COVID-19 Pandemic and CARES Act</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100160 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100190 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables" id="Role_DisclosureMergerTables">
        <link:definition>100200 - Disclosure - Merger - (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" id="Role_DisclosureStockholdersEquityDeficitTables">
        <link:definition>100210 - Disclosure - Stockholders&apos; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100220 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100230 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
        <link:definition>100240 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
        <link:definition>100250 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" id="Role_DisclosureMergerAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Merger - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" id="Role_DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails">
        <link:definition>100300 - Disclosure - Merger - Summary of Purchase Price Paid in Merger (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails" id="Role_DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails">
        <link:definition>100310 - Disclosure - Merger - Summary of Allocation of Purchase Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails" id="Role_DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails">
        <link:definition>100320 - Disclosure - Stockholders&apos; Equity (Deficit) - Amended and Restated Articles of Incorporation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails" id="Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails">
        <link:definition>100330 - Disclosure - Stockholders&apos; Equity (Deficit) - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" id="Role_DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
        <link:definition>100340 - Disclosure - Stockholders&apos; Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" id="Role_DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
        <link:definition>100350 - Disclosure - Stockholders&apos; Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails" id="Role_DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails">
        <link:definition>100360 - Disclosure - Stockholders&apos; Equity - Restricted Common Stock and Unvested Share Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails" id="Role_DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails">
        <link:definition>100370 - Disclosure - Stockholders&apos; Equity (Deficit) - Summary of Unvested Shares (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails" id="Role_DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails">
        <link:definition>100380 - Disclosure - Stockholders&apos; Equity (Deficit) - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" id="Role_DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
        <link:definition>100390 - Disclosure - Stockholders&apos; Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails">
        <link:definition>100400 - Disclosure - Stockholders&apos; Equity (Deficit) - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" id="Role_DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
        <link:definition>100410 - Disclosure - Stockholders&apos; Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails">
        <link:definition>100420 - Disclosure - Stockholders&apos; Equity (Deficit) - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails">
        <link:definition>100430 - Disclosure - Stockholders&apos; Equity (Deficit) - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100440 - Disclosure - Stockholders&apos; Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" id="Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
        <link:definition>100450 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="Role_DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" name="NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" name="ProceedsFromStockOptionsExercisedAndWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_FairValueOfWarrantsIssuedToPlacementAgent" name="FairValueOfWarrantsIssuedToPlacementAgent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ConversionOfConvertiblePreferredStockToCommonStock" name="ConversionOfConvertiblePreferredStockToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" name="ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_GTxIncMember" name="GTxIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" name="AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ExerciseOfCashlessWarrantShares" name="ExerciseOfCashlessWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" name="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" name="IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_MergerDisclosureTextBlock" name="MergerDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_MergerAbstract" name="MergerAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_COVID19PandemicAndCARESActDisclosureTextBlock" name="COVID19PandemicAndCARESActDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_COVID19PandemicAndCARESActAbstract" name="COVID19PandemicAndCARESActAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" name="ReverseStockSplitAndExchangeRatioPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PreferredStockWarrantLiabilityPolicyTextBlock" name="PreferredStockWarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" name="ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_StockExchangeRatio" name="StockExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" name="OwnershipPercentageOfStockholdersUponClosingOfMerger" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" name="DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_MergerAgreementMember" name="MergerAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OncternalTherapeuticsIncAndGTxIncMember" name="OncternalTherapeuticsIncAndGTxIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AccruedClinicalTrials" name="AccruedClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockSubjectToRepurchaseMember" name="CommonStockSubjectToRepurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AccruedUnvestedShareLiability" name="AccruedUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AnnualBaseRent" name="AnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OfficeSpaceMember" name="OfficeSpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ChiefFinancialOfficerSonMember" name="ChiefFinancialOfficerSonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" name="ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" name="LicenseMaintenanceFeeToBePaidAndPaymentMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CollaborativeArrangementPotentialMilestonePayments" name="CollaborativeArrangementPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_GeorgetownUniversityMember" name="GeorgetownUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ReagentsMember" name="ReagentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementMember" name="ResearchAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_RegentsLicenseAgreementMember" name="RegentsLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfTennesseeResearchFoundationMember" name="UniversityOfTennesseeResearchFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" name="CaliforniaInstituteForRegenerativeMedicineAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfCaliforniaSanDiegoMember" name="UniversityOfCaliforniaSanDiegoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NumberOfDaysInWrittenNoticeOfTermination" name="NumberOfDaysInWrittenNoticeOfTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" name="NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" name="NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" name="MinimumPeriodOfWrittenNoticeToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" name="CollaborativeArrangementPotentialRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_UpfrontLicenseFeesPaid" name="UpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" name="SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdvanceLicensedAssets" name="AdvanceLicensedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementTerm" name="ResearchAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmount" name="ResearchAgreementResearchFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmountPayable" name="ResearchAgreementResearchFundingAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ResearchAndDevelopmentGrants" name="ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" name="DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_SubawardPaymentsReceived" name="SubawardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_RelatedQualifyingSubawardCosts" name="RelatedQualifyingSubawardCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_AmountAgreedToBeProvidedInContingencyFunds" name="AmountAgreedToBeProvidedInContingencyFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" name="ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" name="PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" name="PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" name="PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockSharesOutstandingPriorToStockSplit" name="CommonStockSharesOutstandingPriorToStockSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_AssetAcquisitionPurchasePrice" name="AssetAcquisitionPurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_AssetAcquisitionsLineItems" name="AssetAcquisitionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AssetAcquisitionsTable" name="AssetAcquisitionsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PrivateOncternalMember" name="PrivateOncternalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" name="CombinedPurchasePriceOfShareAndWarrantPerUnit" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_PurchaseAgreementMember" name="PurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PlacementAgentMember" name="PlacementAgentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_JulyPurchaseAgreementMember" name="JulyPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AugustUnderwritingAgreementMember" name="AugustUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NovemberUnderwritingAgreementMember" name="NovemberUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_DecemberUnderwritingAgreementMember" name="DecemberUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockWarrantsExpirationDate" name="CommonStockWarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ExerciseOfWarrants" name="ExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ExerciseOfWarrantsIssued" name="ExerciseOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantExercisedPricePerShare" name="WarrantExercisedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantIssuedPricePerShare" name="WarrantIssuedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" name="ClassOfWarrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" name="LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" name="SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandThirteenPlanMember" name="TwoThousandThirteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_GTxStockOptionPlansMember" name="GTxStockOptionPlansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockWarrantsReservedForFutureIssuance" name="CommonStockWarrantsReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" name="CommonStockOptionsIssuedAndOutstandingForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_IncomeTaxReconciliationPermanentItems" name="IncomeTaxReconciliationPermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" name="IncomeTaxReconciliationInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" name="ValuationAllowanceDeferredTaxAssetChangeNetAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OperatingLossCarryforwardsNonExpirePortion" name="OperatingLossCarryforwardsNonExpirePortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PeriodForCumulativeChangeInOwnership" name="PeriodForCumulativeChangeInOwnership" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>onct-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9407922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="onct-20201231.xsd#TemplateLink" roleURI="http://www.oncternal.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenue" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NoncashLeaseExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20201231.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedClinicalTrials" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedUnvestedShareLiability" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionPurchasePrice" xlink:type="locator" xlink:label="onct_AssetAcquisitionPurchasePrice" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="onct_AssetAcquisitionPurchasePrice" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="onct_AssetAcquisitionPurchasePrice" xlink:to="us-gaap_NoncashMergerRelatedCosts" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>onct-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9407922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="onct-20201231.xsd#TemplateLink" roleURI="http://www.oncternal.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ConversionOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:type="locator" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxIncMember" xlink:type="locator" xlink:label="onct_GTxIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="onct_GTxIncMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NoncashLeaseExpense" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_FairValueOfWarrantsIssuedToPlacementAgent" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_ConversionOfConvertiblePreferredStockToCommonStock" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" order="11910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:type="locator" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" />
    <link:loc xlink:href="onct-20201231.xsd#onct_StockExchangeRatio" xlink:type="locator" xlink:label="onct_StockExchangeRatio" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OncternalTherapeuticsIncAndGTxIncMember" xlink:type="locator" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAgreementMember" xlink:type="locator" xlink:label="onct_MergerAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_MergerAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="onct_OncternalTherapeuticsIncAndGTxIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_StockExchangeRatio" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_AccruedClinicalTrials" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10970.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20201231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="13530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="13590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="13740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onct_PaycheckProtectionProgramMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" xlink:type="locator" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ContingentValueRightsAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionPurchasePrice" xlink:type="locator" xlink:label="onct_AssetAcquisitionPurchasePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSharesOutstandingPriorToStockSplit" xlink:type="locator" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxIncMember" xlink:type="locator" xlink:label="onct_GTxIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsTable" xlink:type="locator" xlink:label="onct_AssetAcquisitionsTable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsLineItems" xlink:type="locator" xlink:label="onct_AssetAcquisitionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_AssetAcquisitionsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_AssetAcquisitionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_GTxIncMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_CommonStockSharesOutstandingPriorToStockSplit" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_SharePrice" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_NoncashMergerRelatedCosts" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_AssetAcquisitionPurchasePrice" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="12890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandThirteenPlanMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_GTxStockOptionPlansMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="onct-20201231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" xlink:type="locator" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10580.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>onct-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9407922+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, net of current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000 and none at December 31, 2020 and 2019, respectively; issued and outstanding shares &#8211; none</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares &#8211; 60,000 at December 31, 2020 and 2019, respectively; issued and outstanding shares &#8211; 48,802 and 15,387 at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NoncashLeaseExpense" xlink:to="onct_NoncashLeaseExpense_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options and common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:type="locator" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent" />
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants issued to placement agent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:to="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ConversionOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ConversionOfConvertiblePreferredStockToCommonStock" xlink:to="onct_ConversionOfConvertiblePreferredStockToCommonStock_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of preferred stock warrants liability to additional paid-in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" xlink:to="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxIncMember" xlink:type="locator" xlink:label="onct_GTxIncMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GTx Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GTxIncMember" xlink:to="onct_GTxIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTx Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G Tx Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on forgiveness of payroll protection program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock warrants liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired in connection with the Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired From Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition related costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from payroll protection loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised And Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock and common stock warrants, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Payment of 2019 bonus awards with stock options in lieu of cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued to placement agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Issued To Placement Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on forgiveness of payroll protection program loan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrants liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Preferred Stock Warrants Liability To Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net liabilities assumed in Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital vesting related to unvested share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares conversion of convertible securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value conversion of convertible securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital reclassification of convertible preferred stock warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfCashlessWarrantShares" xlink:to="onct_ExerciseOfCashlessWarrantShares_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital stock issued issuance costs shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of bonus awards with stock option in lieu of cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Cashless Warrant Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting related to repurchase liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to former stockholders of GTx upon Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to former stockholders of GTx upon Merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock upon merger (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon Merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of convertible preferred stock warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Reclassification Of Convertible Preferred Stock Warrant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of 2019 bonus awards with stock option in lieu ofcash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Bonus Awards With Stock Option In Lieu Of Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and common stock warrants, issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, Contingencies and Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration and Research Subaward Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerDisclosureTextBlock" xlink:type="locator" xlink:label="onct_MergerDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_MergerDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MergerDisclosureTextBlock" xlink:to="onct_MergerDisclosureTextBlock_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAbstract" xlink:type="locator" xlink:label="onct_MergerAbstract" />
    <link:label xml:lang="en-US" xlink:label="onct_MergerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MergerAbstract" xlink:to="onct_MergerAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_MergerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merger [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MergerDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MergerDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merger Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:type="locator" xlink:label="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split and exchange ration policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:to="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split and Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split And Exchange Ratio Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PatentCostsPolicyTextBlock" xlink:to="onct_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PreferredStockWarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="onct_PreferredStockWarrantLiabilityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrant liability policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="onct_PreferredStockWarrantLiabilityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrant Liability Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of purchase price computation of merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" xlink:to="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Purchase Price Paid in Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Purchase Price Computation Of Merger Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Allocation of Purchase Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant activity table text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfWarrantActivityTableTextBlock" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Warrant Activity And Changes In Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Unvested Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Share Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Components of Net Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_StockExchangeRatio" xlink:type="locator" xlink:label="onct_StockExchangeRatio" />
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchange ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_StockExchangeRatio" xlink:to="onct_StockExchangeRatio_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:type="locator" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" />
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ownership percentage of stockholders upon closing of merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:to="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of business basis of presentation and summary of significant accounting policies table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAgreementMember" xlink:type="locator" xlink:label="onct_MergerAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_MergerAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to Merger Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MergerAgreementMember" xlink:to="onct_MergerAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_MergerAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MergerAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_OncternalTherapeuticsIncAndGTxIncMember" xlink:type="locator" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember" />
    <link:label xml:lang="en-US" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Oncternal Therapeutics Inc and GTx Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OncternalTherapeuticsIncAndGTxIncMember" xlink:to="onct_OncternalTherapeuticsIncAndGTxIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined organization&apos;s</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Oncternal Therapeutics Inc And G Tx Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and preferred stock exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage of stockholders upon closing of merger</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage Of Stockholders Upon Closing Of Merger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials" xlink:to="onct_AccruedClinicalTrials_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual balance in accrued liabilities and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares subject to repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsMember" xlink:to="onct_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Options</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockSubjectToRepurchaseMember" xlink:to="onct_CommonStockSubjectToRepurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Subject To Repurchase [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedResearchAndDevelopmentExpenses" xlink:to="onct_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedUnvestedShareLiability" xlink:to="onct_AccruedUnvestedShareLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested share liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Unvested Share Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualBaseRent" xlink:to="onct_AnnualBaseRent_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OfficeSpaceMember" xlink:to="onct_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief financial officer, son.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ChiefFinancialOfficerSonMember" xlink:to="onct_ChiefFinancialOfficerSonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ChiefFinancialOfficerSonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Financial Officer Son [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceutical United States of America Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceutical (USA) Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceutical United States Of America Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General Insurance Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissions" xlink:to="us-gaap_InsuranceCommissions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Commissions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee to be paid and payment made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExclusiveLicenseAgreementMember" xlink:to="onct_ExclusiveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Georgetown University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GeorgetownUniversityMember" xlink:to="onct_GeorgetownUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Georgetown University</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Georgetown University [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Cancer Center.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MDAndersonCancerCenterMember" xlink:to="onct_MDAndersonCancerCenterMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Cancer Center</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reagents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReagentsMember" xlink:to="onct_ReagentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents of the University of California</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reagents [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementMember" xlink:to="onct_ResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RegentsLicenseAgreementMember" xlink:to="onct_RegentsLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regents License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseAgreementMember" xlink:to="onct_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Tennessee Research Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfTennesseeResearchFoundationMember" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Tennessee Research Foundation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Tennessee Research Foundation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Regenerative Medicine Award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The California Institute for Regenerative Medicine ("CIRM") Award</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine Award [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California San Diego.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfCaliforniaSanDiegoMember" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of California San Diego School of Medicine</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of California San Diego [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee to be paid and payment made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee To Be Paid And Payment Made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Milestone Payments</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days in written notice of termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice in fails to pay amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice for default in payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum period of written notice to terminate agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice of termination, period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days In Written Notice Of Termination</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice, to pay failure amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice To Pay Failure Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice for default in payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice For Default In Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum period in days of written notice to terminate license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Period Of Written Notice To Terminate Agreement</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential regulatory milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Regulatory Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Aggregate Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UpfrontLicenseFeesPaid" xlink:to="onct_UpfrontLicenseFeesPaid_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Worldwide sales milestones based on achievement of tiered revenue levels.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance licensed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdvanceLicensedAssets" xlink:to="onct_AdvanceLicensedAssets_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualLicenseMaintenanceFees" xlink:to="onct_AnnualLicenseMaintenanceFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Worldwide sales milestones based on achievement of tiered revenue levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Based On Achievement Of Tiered Revenue Levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance licensed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Licensed Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patent costs as general and administrative expense</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTerm" xlink:to="onct_ResearchAgreementTerm_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmount" xlink:to="onct_ResearchAgreementResearchFundingAmount_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmountPayable" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate research agreement budget</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research amount payable quarterly</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount Payable</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAndDevelopmentGrants" xlink:to="onct_ResearchAndDevelopmentGrants_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones to be received under research subaward agreements throughout award project period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subaward payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SubawardPaymentsReceived" xlink:to="onct_SubawardPaymentsReceived_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related qualifying subaward costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RelatedQualifyingSubawardCosts" xlink:to="onct_RelatedQualifyingSubawardCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants awarded to researchers</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones to be received under research subaward agreements throughout award project period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subaward payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subaward Payments Received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related qualifying subaward costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Qualifying Subaward Costs</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount agreed to be provided in contingency funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount agreed to be provided in contingency funds</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Agreed To Be Provided In Contingency Funds</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unsecured Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebtMember" xlink:to="us-gaap_UnsecuredDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnsecuredDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Paycheck Protection Program member,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PaycheckProtectionProgramMember" xlink:to="onct_PaycheckProtectionProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paycheck Protection Program</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PaycheckProtectionProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Paycheck Protection Program [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate, stated percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan forgiveness (other income)</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Value Rights Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ContingentValueRightsAgreementMember" xlink:to="onct_ContingentValueRightsAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CVR Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" xlink:type="locator" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value right entitled per each share of common stock held.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" xlink:to="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company&apos;s SARD and SARM technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which percentage of net proceeds payment would be payable under the CVR.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period from closing during which the grant, sale or transfer of rights to the Company&apos;s SARD or SARM technology could trigger a payment under the CVR Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value right per common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Entitled Per Each Share Of Common Stock Held</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net proceeds entitled to be received per CVR</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period from closing during which the grant, sale or transfer of rights to the Company&apos;s SARD or SARM technology could trigger a payment under the CVR Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSharesOutstandingPriorToStockSplit" xlink:type="locator" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares outstanding prior to stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockSharesOutstandingPriorToStockSplit" xlink:to="onct_CommonStockSharesOutstandingPriorToStockSplit_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionPurchasePrice" xlink:type="locator" xlink:label="onct_AssetAcquisitionPurchasePrice" />
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition purchase price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AssetAcquisitionPurchasePrice" xlink:to="onct_AssetAcquisitionPurchasePrice_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsLineItems" xlink:type="locator" xlink:label="onct_AssetAcquisitionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_AssetAcquisitionsLineItems_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsTable" xlink:type="locator" xlink:label="onct_AssetAcquisitionsTable" />
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AssetAcquisitionsTable" xlink:to="onct_AssetAcquisitionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisitions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisitions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of the combined organization owned by the Company&#8217;s pre-Merger stockholders</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding Prior To Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiplied by the fair value per share of GTx common stock (1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of consideration issued to effect the Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Value Of Assets Acquired1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Merger Related Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net liabilities assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AssetAcquisitionPurchasePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Oncternal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrivateOncternalMember" xlink:to="onct_PrivateOncternalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Oncternal</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Oncternal [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock converted into common stock shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined purchase price of share and warrant per unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PurchaseAgreementMember" xlink:to="onct_PurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PlacementAgentMember" xlink:to="onct_PlacementAgentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">July purchase agreement member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_JulyPurchaseAgreementMember" xlink:to="onct_JulyPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">July Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AugustUnderwritingAgreementMember" xlink:to="onct_AugustUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">November underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NovemberUnderwritingAgreementMember" xlink:to="onct_NovemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">November Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">December underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DecemberUnderwritingAgreementMember" xlink:to="onct_DecemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">December Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined purchase price of share and warrant per unit</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Combined Purchase Price Of Share And Warrant Per Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants excercisable and expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsExpirationDate" xlink:to="onct_CommonStockWarrantsExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Expiration Date</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfWarrants" xlink:to="onct_ExerciseOfWarrants_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfWarrantsIssued" xlink:type="locator" xlink:label="onct_ExerciseOfWarrantsIssued" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfWarrantsIssued" xlink:to="onct_ExerciseOfWarrantsIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Number of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Number of Warrant</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantExercisedPricePerShare" xlink:to="onct_WarrantExercisedPricePerShare_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_WarrantIssuedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant issued price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantIssuedPricePerShare" xlink:to="onct_WarrantIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant weighted-average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" xlink:type="locator" xlink:label="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" />
    <link:label xml:lang="en-US" xlink:label="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liability for unvested cash settled share based payment transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" xlink:to="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested share liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Unvested Cash Settled Share Based Payment Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, vested shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares unvested, ending balance</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandThirteenPlanMember" xlink:to="onct_TwoThousandThirteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Plan [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gtx stock option plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GTxStockOptionPlansMember" xlink:to="onct_GTxStockOptionPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTx Stock Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G Tx Stock Option Plans [Member]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares of common stock a participant may receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock shares provided for issuance of stock awards to its employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_EquityIncentivePlanMember" xlink:to="onct_EquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options vested and expected to vest, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" xlink:to="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding and fully vested</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price of options outstanding and fully vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding and fully vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price of options outstanding and fully vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options outstanding and fully vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing market price per common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost related to nonvested awards not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining weighted-average period</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsReservedForFutureIssuance" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Aggregate Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock available for future issuance</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation permanent items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxReconciliationPermanentItems" xlink:to="onct_IncomeTaxReconciliationPermanentItems_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation in process research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" xlink:to="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationPermanentItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets Net</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" xlink:type="locator" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation Allowance Deferred Tax Asset Change Net Amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" xlink:to="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_IncomeTaxesLineItems_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, fully offset by valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change Net Amount</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards non expire portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsNonExpirePortion" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OperatingLossCarryforwardsExpirationYear" xlink:to="onct_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards non expire portion</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Non Expire Portion</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year</link:label>
    <link:loc xlink:href="onct-20201231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative change in ownership percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CumulativeChangeInOwnershipPercentage" xlink:to="onct_CumulativeChangeInOwnershipPercentage_lbl" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period for cumulative change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PeriodForCumulativeChangeInOwnership" xlink:to="onct_PeriodForCumulativeChangeInOwnership_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative changes in ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CumulativeChangeInOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Change In Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for cumulative change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PeriodForCumulativeChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period For Cumulative Change In Ownership</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Expense</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>onct-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-11T22:11:01.9417954+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 5a4c0b100d0e4f6f90e6d2640d0f2212 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncternal.com/20201231/role/TemplateLink" xlink:href="onct-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="onct-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ConversionOfConvertiblePreferredStockToCommonStock" xlink:type="locator" xlink:label="onct_ConversionOfConvertiblePreferredStockToCommonStock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_FairValueOfWarrantsIssuedToPlacementAgent" xlink:type="locator" xlink:label="onct_FairValueOfWarrantsIssuedToPlacementAgent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" xlink:type="locator" xlink:label="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" xlink:type="locator" xlink:label="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxIncMember" xlink:type="locator" xlink:label="onct_GTxIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="onct_GTxIncMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NoncashLeaseExpense" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="onct_ProceedsFromStockOptionsExercisedAndWarrantExercises" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_FairValueOfWarrantsIssuedToPlacementAgent" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_ConversionOfConvertiblePreferredStockToCommonStock" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="onct-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="onct-20201231.xsd#Role_StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails" xlink:href="onct-20201231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:href="onct-20201231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:href="onct-20201231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt" xlink:href="onct-20201231.xsd#Role_DisclosureDebt" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger" xlink:href="onct-20201231.xsd#Role_DisclosureMerger" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger">
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerDisclosureTextBlock" xlink:type="locator" xlink:label="onct_MergerDisclosureTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAbstract" xlink:type="locator" xlink:label="onct_MergerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="onct_MergerDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" xlink:href="onct-20201231.xsd#Role_DisclosureCOVID19PandemicAndCARESAct" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct">
    <link:loc xlink:href="onct-20201231.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="onct-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PreferredStockWarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="onct_PreferredStockWarrantLiabilityPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="onct-20201231.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" xlink:type="locator" xlink:label="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PatentCostsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PreferredStockWarrantLiabilityPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables" xlink:href="onct-20201231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables" xlink:href="onct-20201231.xsd#Role_DisclosureMergerTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAbstract" xlink:type="locator" xlink:label="onct_MergerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:type="locator" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" />
    <link:loc xlink:href="onct-20201231.xsd#onct_StockExchangeRatio" xlink:type="locator" xlink:label="onct_StockExchangeRatio" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OncternalTherapeuticsIncAndGTxIncMember" xlink:type="locator" xlink:label="onct_OncternalTherapeuticsIncAndGTxIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAgreementMember" xlink:type="locator" xlink:label="onct_MergerAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_MergerAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="onct_OncternalTherapeuticsIncAndGTxIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_StockExchangeRatio" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="onct_AccruedClinicalTrials" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20201231.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20201231.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AccruedUnvestedShareLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedClinicalTrials" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedUnvestedShareLiability" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissions" xlink:type="locator" xlink:label="us-gaap_InsuranceCommissions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralInsuranceExpense" xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ChiefFinancialOfficerSonMember" xlink:type="locator" xlink:label="onct_ChiefFinancialOfficerSonMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="onct_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_ChiefFinancialOfficerSonMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_InsuranceCommissions" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20201231.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="13580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="13730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PaycheckProtectionProgramMember" xlink:type="locator" xlink:label="onct_PaycheckProtectionProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:type="locator" xlink:label="us-gaap_UnsecuredDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_UnsecuredDebtMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="onct_PaycheckProtectionProgramMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" xlink:type="locator" xlink:label="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" xlink:type="locator" xlink:label="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" xlink:type="locator" xlink:label="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" xlink:type="locator" xlink:label="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ContingentValueRightsAgreementMember" xlink:type="locator" xlink:label="onct_ContingentValueRightsAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ContingentValueRightsAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionPurchasePrice" xlink:type="locator" xlink:label="onct_AssetAcquisitionPurchasePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_NoncashMergerRelatedCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockSharesOutstandingPriorToStockSplit" xlink:type="locator" xlink:label="onct_CommonStockSharesOutstandingPriorToStockSplit" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsLineItems" xlink:type="locator" xlink:label="onct_AssetAcquisitionsLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxIncMember" xlink:type="locator" xlink:label="onct_GTxIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionsTable" xlink:type="locator" xlink:label="onct_AssetAcquisitionsTable" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAbstract" xlink:type="locator" xlink:label="onct_MergerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="onct_AssetAcquisitionsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_GTxIncMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsTable" xlink:to="onct_AssetAcquisitionsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_CommonStockSharesOutstandingPriorToStockSplit" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_SharePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="us-gaap_NoncashMergerRelatedCosts" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_AssetAcquisitionsLineItems" xlink:to="onct_AssetAcquisitionPurchasePrice" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails" xlink:href="onct-20201231.xsd#Role_DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_AssetAcquisitionPurchasePrice" xlink:type="locator" xlink:label="onct_AssetAcquisitionPurchasePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" />
    <link:loc xlink:href="onct-20201231.xsd#onct_MergerAbstract" xlink:type="locator" xlink:label="onct_MergerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_MergerAbstract" xlink:to="onct_AssetAcquisitionPurchasePrice" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" />
    <link:loc xlink:href="onct-20201231.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:loc xlink:href="onct-20201231.xsd#onct_WarrantIssuedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ExerciseOfWarrantsIssued" xlink:type="locator" xlink:label="onct_ExerciseOfWarrantsIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ExerciseOfWarrantsIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ExerciseOfWarrants" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantIssuedPricePerShare" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantExercisedPricePerShare" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails">
    <link:loc xlink:href="onct-20201231.xsd#onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" xlink:type="locator" xlink:label="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_li0l2" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:loc xlink:href="onct-20201231.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandThirteenPlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_GTxStockOptionPlansMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20201231.xsd#Role_DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20201231.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxReconciliationPermanentItems" xlink:type="locator" xlink:label="onct_IncomeTaxReconciliationPermanentItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxReconciliationPermanentItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxReconciliationInProcessResearchAndDevelopment" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator" xlink:label="onct_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="onct_DeferredTaxLiabilitiesRightOfUseAsset" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="onct-20201231.xsd#onct_PeriodForCumulativeChangeInOwnership" xlink:type="locator" xlink:label="onct_PeriodForCumulativeChangeInOwnership" />
    <link:loc xlink:href="onct-20201231.xsd#onct_CumulativeChangeInOwnershipPercentage" xlink:type="locator" xlink:label="onct_CumulativeChangeInOwnershipPercentage" />
    <link:loc xlink:href="onct-20201231.xsd#onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" xlink:type="locator" xlink:label="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="onct-20201231.xsd#onct_OperatingLossCarryforwardsNonExpirePortion" xlink:type="locator" xlink:label="onct_OperatingLossCarryforwardsNonExpirePortion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="onct-20201231.xsd#onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" xlink:type="locator" xlink:label="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesLineItems" xlink:type="locator" xlink:label="onct_IncomeTaxesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="onct-20201231.xsd#onct_IncomeTaxesTable" xlink:type="locator" xlink:label="onct_IncomeTaxesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="onct_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesTable" xlink:to="onct_IncomeTaxesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsNonExpirePortion" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_OperatingLossCarryforwardsExpirationYear" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_CumulativeChangeInOwnershipPercentage" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="onct_PeriodForCumulativeChangeInOwnership" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="onct-20201231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>onct-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:onct="http://www.oncternal.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onct-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001260990_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20210303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-03-03</instant>
        </period>
    </context>
    <context id="C_0001260990_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001260990_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_deiLegalEntityAxis_onctGTxIncMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">onct:GTxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">onct:OncternalTherapeuticsIncAndGTxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-22</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:ChiefFinancialOfficerSonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">onct:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_srtConsolidatedEntitiesAxis_onctGTxIncMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:GTxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_onctsegment">
        <measure>onct:segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_onctCVR">
        <measure>onct:CVR</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_0001260990_20200101_20201231" id="F_000001">0001260990</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_0001260990_20200101_20201231" id="F_000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001260990_20200101_20201231" id="F_000006">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001260990_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231"
      id="F_000293">P3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <onct:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20190101_20191231"
      id="F_000437">P4M24D</onct:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20201231"
      decimals="-6"
      id="F_000300"
      unitRef="U_iso4217USD">0</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:ResearchAgreementTerm
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231"
      id="F_000319">P5Y</onct:ResearchAgreementTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000434">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <onct:PeriodForCumulativeChangeInOwnership contextRef="C_0001260990_20200101_20201231" id="F_000517">P3Y</onct:PeriodForCumulativeChangeInOwnership>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000520"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20201231"
      id="F_000057"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20191231"
      id="F_000058"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20201231"
      id="F_000059"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20191231"
      id="F_000060"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20180101_20181231" id="F_000405">P3Y9M</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20190101_20191231" id="F_000406">P2Y9M</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20200101_20201231" id="F_000407">P4Y4M24D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231"
      id="F_000423">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231"
      id="F_000424">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20200101_20201231"
      id="F_000425">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20200101_20201231" id="F_000455">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20190101_20191231" id="F_000456">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001260990_20200101_20201231" id="F_000002">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001260990_20200101_20201231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001260990_20200101_20201231" id="F_000003">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001260990_20200101_20201231" id="F_000005">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001260990_20200101_20201231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001260990_20200101_20201231" id="F_000018">000-50549</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001260990_20200101_20201231" id="F_000000">Oncternal Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001260990_20200101_20201231" id="F_000030">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001260990_20200101_20201231" id="F_000019">62-1715807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001260990_20200101_20201231" id="F_000020">12230 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001260990_20200101_20201231" id="F_000021">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001260990_20200101_20201231" id="F_000022">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001260990_20200101_20201231" id="F_000023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001260990_20200101_20201231" id="F_000024">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001260990_20200101_20201231" id="F_000025">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001260990_20200101_20201231" id="F_000026">434-1113</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001260990_20200101_20201231" id="F_000028">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001260990_20200101_20201231" id="F_000007">ONCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001260990_20200101_20201231" id="F_000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001260990_20200101_20201231" id="F_000010">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001260990_20200101_20201231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001260990_20200101_20201231" id="F_000014">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001260990_20200101_20201231" id="F_000027">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="C_0001260990_20200101_20201231" id="F_000012">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001260990_20200101_20201231" id="F_000013">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityFilerCategory contextRef="C_0001260990_20200101_20201231" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001260990_20200101_20201231" id="F_000031">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001260990_20200101_20201231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001260990_20200630"
      decimals="-5"
      id="F_000017"
      unitRef="U_iso4217USD">27200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001260990_20210303"
      decimals="INF"
      id="F_000016"
      unitRef="U_xbrlishares">49281327</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000210">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant&#x2019;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#x2019;s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#x2019;s fiscal year ended December&#160;31, 2020.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">116737000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">20051000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">1266000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">736000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">118003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">20787000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">190000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">766000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">767000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">118809000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">21744000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">1143000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">871000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">2731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">1633000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">3640000</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">99000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">5858000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">7341000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">91000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000071"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000072"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000073"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000074"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000075"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000076"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000079"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000080"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000083"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000084"
      unitRef="U_xbrlishares">15387000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">15387000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">15000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">195699000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">79869000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">-82797000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">-65572000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">14312000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">118809000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">21744000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">3375000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">2425000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">12544000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">10159000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">18088000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">8373000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">7286000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">20917000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">35533000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">-17542000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000097"
      unitRef="U_iso4217USD">-33108000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">1268000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">301000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">16000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">188000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">317000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-1080000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">-34188000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000106"
      unitRef="U_iso4217USD_xbrlishares">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20190101_20191231"
      decimals="2"
      id="F_000107"
      unitRef="U_iso4217USD_xbrlishares">-3.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20200101_20201231"
      decimals="0"
      id="F_000108"
      unitRef="U_xbrlishares">20305</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20190101_20191231"
      decimals="0"
      id="F_000109"
      unitRef="U_xbrlishares">10329</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">-17225000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-34188000</us-gaap:ProfitLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">18088000</us-gaap:ResearchAndDevelopmentInProcess>
    <onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">301000</onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">1556000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">507000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">1268000</us-gaap:FairValueAdjustmentOfWarrants>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">150000</onct:NoncashLeaseExpense>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">92000</onct:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">44000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">272000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-4762000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">739000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-1255000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <onct:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-150000</onct:IncreaseDecreaseInOperatingLeaseLiability>
    <onct:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-92000</onct:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-2007000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">3640000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-17495000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-16746000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">18292000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">2155000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">16137000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">301000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <onct:ProceedsFromStockOptionsExercisedAndWarrantExercises
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">4000</onct:ProceedsFromStockOptionsExercisedAndWarrantExercises>
    <onct:ProceedsFromStockOptionsExercisedAndWarrantExercises
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">15000</onct:ProceedsFromStockOptionsExercisedAndWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">113876000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">114181000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">15000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">96686000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-594000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">20051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20181231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">20645000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">116737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">20051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockIssued1
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">415000</us-gaap:StockIssued1>
    <onct:FairValueOfWarrantsIssuedToPlacementAgent
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">5325000</onct:FairValueOfWarrantsIssuedToPlacementAgent>
    <onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">301000</onct:NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan>
    <onct:ConversionOfConvertiblePreferredStockToCommonStock
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">46588000</onct:ConversionOfConvertiblePreferredStockToCommonStock>
    <us-gaap:StockIssued1
      contextRef="C_0001260990_deiLegalEntityAxis_onctGTxIncMember_20190101_20191231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">29049000</us-gaap:StockIssued1>
    <onct:ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">1942000</onct:ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">5177000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="INF"
      id="F_000153"
      unitRef="U_xbrlishares">8148000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">46588000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">3762</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">1748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-31384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20181231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-29631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000160"
      unitRef="U_xbrlishares">19</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">1000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">1000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">30000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">30000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000167"
      unitRef="U_xbrlishares">3458</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">29047000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">29049000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <onct:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="INF"
      id="F_000171"
      unitRef="U_xbrlishares">8148</onct:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <onct:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_0001260990_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-46588000</onct:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000173"
      unitRef="U_xbrlishares">8148</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">8000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">46580000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">46588000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
    <onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">1942000</onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant>
    <onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">1942000</onct:AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-34188000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">-34188000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000183"
      unitRef="U_xbrlishares">15387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">79869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-65572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">14312000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:ExerciseOfCashlessWarrantShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000191"
      unitRef="U_xbrlishares">36</onct:ExerciseOfCashlessWarrantShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">13000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">13000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">11103000</us-gaap:PaymentsOfStockIssuanceCosts>
    <onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000194"
      unitRef="U_xbrlishares">33374</onct:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">34000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">113842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">113876000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">1556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">1556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">-17225000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000204"
      unitRef="U_xbrlishares">48802</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">195699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">-82797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000211">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Description&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Business,&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Basis&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Presentation&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.4pt;"&gt; &lt;/span&gt;Summary&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;Significant&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;Accounting&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Policies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Oncternal Therapeutics, Inc. (the &#x201c;Company,&#x201d; &#x201c;Oncternal,&#x201d; or the &#x201c;combined company&#x201d;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#x2019;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merger&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, the Company, then operating as GTx, Inc. (&#x201c;GTx&#x201d;), completed its Agreement and Plan of Merger and Reorganization, as amended (the &#x201c;Merger Agreement&#x201d;), with privately-held Oncternal Therapeutics, Inc. (&#x201c;Private Oncternal&#x201d;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;ONCT.&#x201d;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Except as otherwise indicated, references herein to &#x201c;Oncternal,&#x201d; &#x201c;the Company,&#x201d; and the &#x201c;combined company,&#x201d; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#x201c;Private Oncternal&#x201d; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.073386 shares of Company common stock (the &#x201c;Exchange Ratio&#x201d;), after taking into account the Reverse Stock Split, as defined below. Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately 77.5% of the outstanding common stock of the combined company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#x2019;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#x2019;s senior management holds all key positions in the senior management of the combined company. &lt;span style="color:#000000;"&gt;As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the Merger are those of Private Oncternal. &#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split and Exchange Ratio&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, in connection with, and prior to the completion of, the Merger, GTx effected a one-for-seven reverse stock split of its then outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company&#x2019;s issued and outstanding common stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All issued and outstanding Private Oncternal common stock, preferred stock, options and warrants prior to the effective date of the Merger have been retroactively adjusted to reflect the Exchange Ratio for all periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company had $116.7 million in cash and cash equivalents. The Company believes it has sufficient cash to&lt;span style="color:#000000;"&gt; fund its projected operating requirements for at least twelve months from the date of issuance&lt;/span&gt;. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $82.8 million as of December&#160;31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;prepared&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;accordance&lt;/span&gt;&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; GAAP.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;accompanying&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;notes&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and assumptions &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;that &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;impact &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;reported &lt;span style="letter-spacing:0.15pt;"&gt;amounts of &lt;/span&gt;assets, &lt;span style="letter-spacing:0.15pt;"&gt;liabilities, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;revenues and expenses and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;disclosure &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;contingent &lt;/span&gt;assets &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;liabilities. &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Significant &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;consist &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of those &lt;/span&gt;used to determine &lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;fair &lt;span style="letter-spacing:0.15pt;"&gt;value of the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s &lt;/span&gt;preferred &lt;span style="letter-spacing:0.1pt;"&gt;stock, &lt;/span&gt;preferred &lt;span style="letter-spacing:0.1pt;"&gt;stock&lt;/span&gt; warrant &lt;span style="letter-spacing:0.15pt;"&gt;liability&lt;/span&gt; and stock-based awards&lt;span style="letter-spacing:0.15pt;"&gt;, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;those &lt;/span&gt;used to determine grant &lt;span style="letter-spacing:0.1pt;"&gt;revenue and &lt;/span&gt;accruals for research &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development &lt;/span&gt;costs. &lt;span style="letter-spacing:0.15pt;"&gt;Although &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these &lt;/span&gt;estimates are based &lt;span style="letter-spacing:0.15pt;"&gt;on the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;knowledge&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;current&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;events&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;actions&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;undertake&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;future,&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;actual&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;ultimately&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;materially&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;assumptions.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;


&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of December 31, 2020, the Company&#x2019;s clinical trial accrual balance of $1.0 million is included in accrued liabilities and other liabilities. The Company&#x2019;s related 2020 clinical trial expenses are included in research and development expense of $12.5 million.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Merger, Private Oncternal had outstanding freestanding warrants to purchase shares of its Series B-2 convertible preferred stock (the &#x201c;Series B-2 warrants&#x201d;). Private Oncternal adjusted the carrying value of such Series B-2 warrants to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as a change in fair value of warrant liability in the consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase the Company&#x2019;s common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#x2019; equity.&lt;/p&gt;


&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently generates revenue from the California Institute for Regenerative Medicine pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2020 and 2019, the Company had deferred grant revenue of &lt;span style="color:#000000;"&gt;$1.6 &lt;/span&gt;million and $3.6 million, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 25,000 shares and 56,000 shares from the weighted-average number of common shares outstanding for the years ended December&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;31, 20&lt;span style="color:#000000;"&gt;20&lt;/span&gt; and 201&lt;span style="color:#000000;"&gt;9&lt;/span&gt;, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes: Simplifying the Accounting for Income Taxe&lt;/span&gt;s, which is intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company adopted this standard effective October 1, 2020, the adoption had no impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued &lt;span style="color:#000000;"&gt;ASU &lt;/span&gt;2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement: Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement, &lt;/span&gt;which modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard effective January 1, 2020, &lt;span style="color:#000000;"&gt;the adoption had no impact on the consolidated financial statements&lt;/span&gt;.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="C_0001260990_20200101_20201231" id="F_000222">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merger&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, the Company, then operating as GTx, Inc. (&#x201c;GTx&#x201d;), completed its Agreement and Plan of Merger and Reorganization, as amended (the &#x201c;Merger Agreement&#x201d;), with privately-held Oncternal Therapeutics, Inc. (&#x201c;Private Oncternal&#x201d;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;ONCT.&#x201d;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Except as otherwise indicated, references herein to &#x201c;Oncternal,&#x201d; &#x201c;the Company,&#x201d; and the &#x201c;combined company,&#x201d; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#x201c;Private Oncternal&#x201d; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.073386 shares of Company common stock (the &#x201c;Exchange Ratio&#x201d;), after taking into account the Reverse Stock Split, as defined below. Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately 77.5% of the outstanding common stock of the combined company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#x2019;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#x2019;s senior management holds all key positions in the senior management of the combined company. &lt;span style="color:#000000;"&gt;As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the Merger are those of Private Oncternal. &#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <onct:StockExchangeRatio
      contextRef="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607"
      decimals="6"
      id="F_000252"
      unitRef="U_xbrlipure">0.073386</onct:StockExchangeRatio>
    <onct:OwnershipPercentageOfStockholdersUponClosingOfMerger
      contextRef="C_0001260990_srtOwnershipAxis_onctOncternalTherapeuticsIncAndGTxIncMember_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607"
      decimals="3"
      id="F_000253"
      unitRef="U_xbrlipure">0.775</onct:OwnershipPercentageOfStockholdersUponClosingOfMerger>
    <onct:ReverseStockSplitAndExchangeRatioPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000223">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split and Exchange Ratio&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, in connection with, and prior to the completion of, the Merger, GTx effected a one-for-seven reverse stock split of its then outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company&#x2019;s issued and outstanding common stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All issued and outstanding Private Oncternal common stock, preferred stock, options and warrants prior to the effective date of the Merger have been retroactively adjusted to reflect the Exchange Ratio for all periods presented.&lt;/p&gt;</onct:ReverseStockSplitAndExchangeRatioPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctMergerAgreementMember_20190607_20190607"
      decimals="0"
      id="F_000254"
      unitRef="U_xbrlipure">7</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000224">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <onct:LiquidityAndGoingConcernPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000225">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the Company had $116.7 million in cash and cash equivalents. The Company believes it has sufficient cash to&lt;span style="color:#000000;"&gt; fund its projected operating requirements for at least twelve months from the date of issuance&lt;/span&gt;. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $82.8 million as of December&#160;31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&lt;/p&gt;</onct:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000256"
      unitRef="U_iso4217USD">116700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000255"
      unitRef="U_iso4217USD">-82800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates contextRef="C_0001260990_20200101_20201231" id="F_000226">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;are&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;prepared&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;accordance&lt;/span&gt;&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; GAAP.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.35pt;"&gt; &lt;/span&gt;preparation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;consolidated&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;financial&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;statements&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;accompanying&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;notes&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;requires&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;make&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and assumptions &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;that &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;impact &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;reported &lt;span style="letter-spacing:0.15pt;"&gt;amounts of &lt;/span&gt;assets, &lt;span style="letter-spacing:0.15pt;"&gt;liabilities, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;revenues and expenses and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;disclosure &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;contingent &lt;/span&gt;assets &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;liabilities. &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Significant &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;consist &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of those &lt;/span&gt;used to determine &lt;span style="letter-spacing:0.15pt;"&gt;the &lt;/span&gt;fair &lt;span style="letter-spacing:0.15pt;"&gt;value of the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s &lt;/span&gt;preferred &lt;span style="letter-spacing:0.1pt;"&gt;stock, &lt;/span&gt;preferred &lt;span style="letter-spacing:0.1pt;"&gt;stock&lt;/span&gt; warrant &lt;span style="letter-spacing:0.15pt;"&gt;liability&lt;/span&gt; and stock-based awards&lt;span style="letter-spacing:0.15pt;"&gt;, &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;those &lt;/span&gt;used to determine grant &lt;span style="letter-spacing:0.1pt;"&gt;revenue and &lt;/span&gt;accruals for research &lt;span style="letter-spacing:0.1pt;"&gt;and &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development &lt;/span&gt;costs. &lt;span style="letter-spacing:0.15pt;"&gt;Although &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these &lt;/span&gt;estimates are based &lt;span style="letter-spacing:0.15pt;"&gt;on the &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;Company&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;knowledge&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;of&lt;/span&gt;&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;current&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;events&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;actions&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;it&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;undertake&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;future,&lt;span style="letter-spacing:-0.6pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;actual&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;results&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;may&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;ultimately&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;materially&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;differ&lt;span style="letter-spacing:-0.65pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;these&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;estimates &lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000227">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <onct:ConcentrationRiskCreditRiskPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000228">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;</onct:ConcentrationRiskCreditRiskPolicyTextBlock>
    <onct:PatentCostsPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000229">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</onct:PatentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001260990_20200101_20201231" id="F_000230">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of December 31, 2020, the Company&#x2019;s clinical trial accrual balance of $1.0 million is included in accrued liabilities and other liabilities. The Company&#x2019;s related 2020 clinical trial expenses are included in research and development expense of $12.5 million.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000257"
      unitRef="U_iso4217USD">1000000.0</onct:AccruedClinicalTrials>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000258"
      unitRef="U_iso4217USD">12500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <onct:PreferredStockWarrantLiabilityPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Merger, Private Oncternal had outstanding freestanding warrants to purchase shares of its Series B-2 convertible preferred stock (the &#x201c;Series B-2 warrants&#x201d;). Private Oncternal adjusted the carrying value of such Series B-2 warrants to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as a change in fair value of warrant liability in the consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase the Company&#x2019;s common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#x2019; equity.&lt;/p&gt;

</onct:PreferredStockWarrantLiabilityPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001260990_20200101_20201231" id="F_000232">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000233">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently generates revenue from the California Institute for Regenerative Medicine pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2020 and 2019, the Company had deferred grant revenue of &lt;span style="color:#000000;"&gt;$1.6 &lt;/span&gt;million and $3.6 million, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000259"
      unitRef="U_iso4217USD">1600000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20191231"
      decimals="-5"
      id="F_000260"
      unitRef="U_iso4217USD">3600000</us-gaap:DeferredRevenue>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001260990_20200101_20201231" id="F_000234">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000235">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000236">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000261"
      unitRef="U_onctsegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000237">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 25,000 shares and 56,000 shares from the weighted-average number of common shares outstanding for the years ended December&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;31, 20&lt;span style="color:#000000;"&gt;20&lt;/span&gt; and 201&lt;span style="color:#000000;"&gt;9&lt;/span&gt;, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000262"
      unitRef="U_xbrlishares">25000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20190101_20191231"
      decimals="INF"
      id="F_000263"
      unitRef="U_xbrlishares">56000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000239">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,834&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20201231"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">5032</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20190101_20191231"
      decimals="INF"
      id="F_000265"
      unitRef="U_xbrlishares">841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000266"
      unitRef="U_xbrlishares">2226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000267"
      unitRef="U_xbrlishares">1958</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20201231"
      decimals="INF"
      id="F_000268"
      unitRef="U_xbrlishares">15</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20190101_20191231"
      decimals="INF"
      id="F_000269"
      unitRef="U_xbrlishares">35</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000270"
      unitRef="U_xbrlishares">7273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20190101_20191231"
      decimals="INF"
      id="F_000271"
      unitRef="U_xbrlishares">2834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000238">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes: Simplifying the Accounting for Income Taxe&lt;/span&gt;s, which is intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company adopted this standard effective October 1, 2020, the adoption had no impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued &lt;span style="color:#000000;"&gt;ASU &lt;/span&gt;2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement: Disclosure Framework &#x2013; Changes to the Disclosure Requirements for Fair Value Measurement, &lt;/span&gt;which modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard effective January 1, 2020, &lt;span style="color:#000000;"&gt;the adoption had no impact on the consolidated financial statements&lt;/span&gt;.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000212">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Details&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested share liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000240">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;582&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested share liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,731&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">412000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">582000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">980000</onct:AccruedClinicalTrials>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">624000</onct:AccruedClinicalTrials>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">77000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">424000</us-gaap:AccruedProfessionalFeesCurrent>
    <onct:AccruedUnvestedShareLiability
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">10000</onct:AccruedUnvestedShareLiability>
    <onct:AccruedUnvestedShareLiability
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">24000</onct:AccruedUnvestedShareLiability>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">1528000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">825000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">35000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">252000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">2731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000213">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments, Contingencies and Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense was $0.2 million and $0.1 million for the years ended December&#160;31, 2020 and 2019, respectively. On May 22, 2019, the Company entered into an office sublease agreement for 4,677 square feet in San Diego, California (&#x201c;San Diego Lease&#x201d;) which expires on March 31, 2021. Base rent is approximately $166,000 annually and the monthly rent expense is being recognized on a straight-line basis over the lease term. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and a lease liability of $40,000 that matures in March 2021, as of December&#160;31, 2020, in the accompanying consolidated balance sheet. The weighted average remaining lease term was 0.25 years.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Related Party Transactions&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#x2019;s Chief Financial Officer, acted as the Company&#x2019;s agent at Newfront Insurance. During the years ended December 31, 2020 and 2019, the Company paid total related policy premiums of $1.4 million and $1.2 million, respectively, for which Mr. Vincent&#x2019;s son received a commission of approximately $0.1 million in each respective period. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#x201c;SPH USA&#x201d;) entered into a Materials Supply and Services Agreement (&#x201c;SPH USA Services Agreement&#x201d;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2020, the Company recorded amounts receivable from SPH USA related to statements of work totaling $0.3 million (see Note 4).&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter (see Note 7).&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000286"
      unitRef="U_iso4217USD">200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-5"
      id="F_000287"
      unitRef="U_iso4217USD">100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:NetRentableArea
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522"
      decimals="0"
      id="F_000288"
      unitRef="U_utrsqft">4677</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522"
      id="F_000289">2021-03-31</us-gaap:LeaseExpirationDate1>
    <onct:AnnualBaseRent
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522_20190522"
      decimals="0"
      id="F_000290"
      unitRef="U_iso4217USD">166000</onct:AnnualBaseRent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231"
      decimals="3"
      id="F_000291"
      unitRef="U_xbrlipure">0.100</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20201231"
      decimals="0"
      id="F_000292"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseLiability>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000294"
      unitRef="U_iso4217USD">1400000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-5"
      id="F_000295"
      unitRef="U_iso4217USD">1200000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:InsuranceCommissions
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctChiefFinancialOfficerSonMember_20200101_20201231"
      decimals="-5"
      id="F_000296"
      unitRef="U_iso4217USD">100000</us-gaap:InsuranceCommissions>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231"
      decimals="-5"
      id="F_000297"
      unitRef="U_iso4217USD">300000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000214">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;License, Collaboration and Research Subaward Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Georgetown University (&#x201c;Georgetown&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, the Company entered into an Exclusive License Agreement (the &#x201c;Georgetown License Agreement&#x201d;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2020, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#x2019; written notice.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&lt;span style="font-weight:bold;font-style:italic;"&gt;The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;)&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2014, the Company entered into a collaboration agreement (as amended, the &#x201c;Collaboration&#x201d;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020, the &lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;293,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The amount recorded as research and development expense for the year ended December 31, 2020 was $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and the amount was insignificant for the year ended December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agreements with the Regents of the University of California (the &#x201c;Regents&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, and as amended and restated in August 2018 in connection with the spin-off transactions described below, the Company entered into a license agreement (as amended, the &#x201c;Regents License Agreement&#x201d;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement was amended on March 25, 2019 and May 15, 2019, to update the patents covered under the agreement.&#160;&#160;The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: &lt;span style="letter-spacing:0.15pt;"&gt;(i) $25,000 in &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;license&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;maintenance&lt;/span&gt;&lt;span style="letter-spacing:-0.3pt;"&gt; &lt;/span&gt;fees&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;research&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;and&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;development&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;expense for each of the&lt;/span&gt; years ended December 31, 2020 and 2019, and (ii)&lt;span style="letter-spacing:-0.6pt;"&gt; approximately&lt;/span&gt; $0.2 million&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;patent&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.1pt;"&gt;costs&lt;/span&gt; as general &lt;span style="letter-spacing:0.1pt;"&gt;and administrative &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;expense &lt;/span&gt;for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company believes it has met its obligations under the Regents License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#x201c;Research Agreement&#x201d;) with the Regents for further research on a ROR1 therapeutic development program. Under this &lt;span style="-sec-ix-hidden:F_000319"&gt;five-year&lt;/span&gt; agreement, the Regents will have an aggregate budget of $3.6 million, with $125,000 payable quarterly. The Company recorded $0.5 million in research and development expense under this agreement&#160;for each of the years ended December 31, 2020 and 2019. Such costs are includable as part of the Company&#x2019;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. &lt;span style="color:#000000;"&gt;The Company may terminate the agreement at any time upon at least 60 days&#x2019; written notice.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;University of Tennessee Research Foundation (&#x201c;UTRF&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2015, the Company and UTRF entered into a license agreement (the &#x201c;SARD License Agreement&#x201d;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#x201c;SARD&#x201d;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $0.2 million and $0.4 million for each of the years ended December 31, 2020 and 2019, respectively. &lt;span style="color:#000000;"&gt;As of December 31, 2020, the Company believes it has met its obligations under the SARD License Agreement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, the Company believes it has met its obligations under each of the UTRF agreements.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) Award&lt;span style="font-size:6pt;font-weight:normal;font-style:normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2017,&lt;span style="color:#000000;"&gt; and as amended and restated in December 2020,&lt;/span&gt; CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance the Company&#x2019;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.0 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $1.4 million and $6.2 million in the years ended December 31, 2020 and 2019, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2020 and 2019, the Company&#x2019;s grant revenue was $3.4 million and $2.4 million, respectively. Related qualifying subaward costs for the years ended December 31, 2020 and 2019 were $5.2 million and $5.4 million, respectively. As of December 31, 2020, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, CIRM awarded a $5.8 million grant to the researchers at the University of California San Diego School of Medicine (&#x201c;UC San Diego&#x201d;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinical Trial and Supply Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#x201c;Pharmacyclics&#x201d;) to supply ibrutinib for the Company&#x2019;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;SPH USA, a Related Party&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Development Agreement (&#x201c;LDA&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018,&lt;span style="color:#000000;"&gt; and as amended in August 2020, &lt;/span&gt;the Company entered into the LDA with SPH USA for: (i) the territory of the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (&#x201c;Greater China&#x201d;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#x2019;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) &lt;span style="letter-spacing:0.15pt;"&gt;either&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;party&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;event&lt;/span&gt; &lt;span style="letter-spacing:0.15pt;"&gt;the&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;other&lt;/span&gt;&lt;span style="letter-spacing:-0.5pt;"&gt; &lt;/span&gt;party&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;declares&lt;span style="letter-spacing:-0.25pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;insolvency&lt;/span&gt;&lt;span style="letter-spacing:0.05pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;or&lt;/span&gt;&lt;span style="letter-spacing:-0.45pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:0.15pt;"&gt;bankruptcy.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <onct:LicenseMaintenanceFeeToBePaidAndPaymentMade
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231"
      decimals="0"
      id="F_000298"
      unitRef="U_iso4217USD">10000</onct:LicenseMaintenanceFeeToBePaidAndPaymentMade>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231"
      decimals="INF"
      id="F_000299"
      unitRef="U_iso4217USD">200000</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231"
      id="F_000301">P90D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231"
      id="F_000302">P30D</onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount>
    <onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231"
      id="F_000303">P60D</onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment>
    <onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20200101_20201231"
      id="F_000304">P60D</onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231"
      decimals="-5"
      id="F_000305"
      unitRef="U_iso4217USD">1000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">293000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200101_20201231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">122000000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:UpfrontLicenseFeesPaid
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000308"
      unitRef="U_iso4217USD">500000</onct:UpfrontLicenseFeesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="INF"
      id="F_000309"
      unitRef="U_xbrlishares">107108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:AnnualLicenseMaintenanceFees
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231"
      decimals="0"
      id="F_000310"
      unitRef="U_iso4217USD">25000</onct:AnnualLicenseMaintenanceFees>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000311"
      unitRef="U_iso4217USD">10000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531"
      decimals="INF"
      id="F_000312"
      unitRef="U_iso4217USD">12500000</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000313"
      unitRef="U_iso4217USD">75000000.0</onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels>
    <onct:AdvanceLicensedAssets
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000314"
      unitRef="U_iso4217USD">1000000.0</onct:AdvanceLicensedAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231"
      decimals="0"
      id="F_000315"
      unitRef="U_iso4217USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231"
      decimals="0"
      id="F_000316"
      unitRef="U_iso4217USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20190101_20191231"
      decimals="-5"
      id="F_000318"
      unitRef="U_iso4217USD">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20201231"
      decimals="-5"
      id="F_000317"
      unitRef="U_iso4217USD">200000</us-gaap:GeneralAndAdministrativeExpense>
    <onct:ResearchAgreementResearchFundingAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000320"
      unitRef="U_iso4217USD">3600000</onct:ResearchAgreementResearchFundingAmount>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231"
      decimals="0"
      id="F_000321"
      unitRef="U_iso4217USD">125000</onct:ResearchAgreementResearchFundingAmountPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000322"
      unitRef="U_iso4217USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000323"
      unitRef="U_iso4217USD">500000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20200101_20201231"
      id="F_000324">P60D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000325"
      unitRef="U_iso4217USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000326"
      unitRef="U_iso4217USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000327"
      unitRef="U_iso4217USD">18300000</onct:ResearchAndDevelopmentGrants>
    <onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000328"
      unitRef="U_iso4217USD">14000000.0</onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000329"
      unitRef="U_iso4217USD">1400000</onct:SubawardPaymentsReceived>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231"
      decimals="-5"
      id="F_000330"
      unitRef="U_iso4217USD">6200000</onct:SubawardPaymentsReceived>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000331"
      unitRef="U_iso4217USD">3400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231"
      decimals="-5"
      id="F_000332"
      unitRef="U_iso4217USD">2400000</us-gaap:Revenues>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20201231"
      decimals="-5"
      id="F_000333"
      unitRef="U_iso4217USD">5200000</onct:RelatedQualifyingSubawardCosts>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20190101_20191231"
      decimals="-5"
      id="F_000334"
      unitRef="U_iso4217USD">5400000</onct:RelatedQualifyingSubawardCosts>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="-5"
      id="F_000335"
      unitRef="U_iso4217USD">5800000</onct:ResearchAndDevelopmentGrants>
    <onct:AmountAgreedToBeProvidedInContingencyFunds
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="INF"
      id="F_000336"
      unitRef="U_iso4217USD">1000000.0</onct:AmountAgreedToBeProvidedInContingencyFunds>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-6"
      id="F_000337"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-6"
      id="F_000338"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000215">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Debt&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Paycheck Protection Program Loan Payable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company received a $0.3 million unsecured loan, bearing interest at 1%, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;), a program implemented by the U.S. Small Business Administration (the &#x201c;SBA&#x201d;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) (the &#x201c;PPP Loan&#x201d;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. &lt;span style="color:#000000;"&gt;The loan forgiveness was recorded as other income of $&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;"&gt;301&lt;/span&gt;&lt;span style="color:#000000;"&gt;k in the statement of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531"
      decimals="-5"
      id="F_000339"
      unitRef="U_iso4217USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531"
      decimals="INF"
      id="F_000340"
      unitRef="U_xbrlipure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200101_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">301000</us-gaap:OtherNonoperatingIncome>
    <onct:MergerDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000216">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#000000;"&gt;Merger&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Merger, which closed on June 7, 2019, was accounted for as a reverse asset acquisition, as substantially all of the fair value of the assets acquired were concentrated in a group of similar non-financial assets, and the acquired assets did not have outputs or employees. Because the assets had not yet received regulatory approval, the fair value attributable to these assets of $18.1 million was recorded as in-process research and development expenses in the Company&#x2019;s consolidated statement of operations in the year ended December 31, 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Merger Agreement on June 7, 2019, the Company, a representative of holders of the contingent value rights (&#x201c;CVRs&#x201d;), and Computershare, Inc. as rights agent entered into a Contingent Value Rights Agreement (the &#x201c;CVR Agreement&#x201d;). Pursuant to the CVR Agreement, the Company&#x2019;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#x2019;s common stock held immediately prior to the Merger. CVR holders are entitled to receive 75% of the aggregate amount of any net proceeds received by the Company during the 15-year period after the closing of the Merger from the grant, sale or transfer of rights to the Company&#x2019;s SARD or SARM technology that occurs during the 10-year period after the closing (or in the 11th year if based on a term sheet approved during the initial 10-year period) and, if applicable, to receive royalties on the sale of any SARD or SARM products by the Company during the 15-year period after the closing. Effective in March 2020, the Company terminated the SARM license agreement with UTRF and no longer has any rights to the SARM technology. The CVR Agreement will continue in effect until the payment of all amounts payable thereunder. As of the years ended December 31, 2020 and 2019, no milestones had been accrued as there were no potential milestones yet considered probable. The total purchase price paid in the Merger has been allocated to the net assets acquired and liabilities assumed based on their fair values as of the completion of the Merger. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of shares of the combined organization owned&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; by the Company&#x2019;s pre-Merger stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,458,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="width:55%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Multiplied by the fair value per share of GTx common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; stock (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of consideration issued to effect the Merger&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%; border-top:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.45pt;"&gt;
&lt;td style="width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="width:55%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Based on the last reported sale price of the Company&#x2019;s common stock on the Nasdaq Capital Market on June 7, 2019, the closing date of the Merger, and gives effect to the Reverse Stock Split.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allocation of the purchase price is as follows:&lt;/p&gt;
&lt;p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:78.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash acquired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:16.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,292&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="width:78.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net liabilities assumed&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:16.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,177&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.45pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IPR&amp;amp;D (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,088&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,203&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:17.14%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Represents the research and development projects of GTx which were in-process, but not yet completed, and which the Company plans to advance, consisting primarily of GTx&#x2019;s preclinical SARD technology. Current &lt;/span&gt;accounting standards require that the fair value of IPR&amp;amp;D projects acquired in an asset acquisition with no &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"/&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</onct:MergerDisclosureTextBlock>
    <onct:ContingentValueRightsEntitledPerEachShareOfCommonStockHeld
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607"
      decimals="INF"
      id="F_000342"
      unitRef="U_onctCVR">1</onct:ContingentValueRightsEntitledPerEachShareOfCommonStockHeld>
    <onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607"
      decimals="2"
      id="F_000343"
      unitRef="U_xbrlipure">0.75</onct:PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights>
    <onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607"
      id="F_000344">P15Y</onct:PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR>
    <onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement
      contextRef="C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607_20190607"
      id="F_000345">P10Y</onct:PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement>
    <onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000241">
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of shares of the combined organization owned&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; by the Company&#x2019;s pre-Merger stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,458,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="width:55%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Multiplied by the fair value per share of GTx common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; stock (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.40&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of consideration issued to effect the Merger&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%; border-top:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%; border-top:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.45pt;"&gt;
&lt;td style="width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Transaction costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,154&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="width:55%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.12%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;Based on the last reported sale price of the Company&#x2019;s common stock on the Nasdaq Capital Market on June 7, 2019, the closing date of the Merger, and gives effect to the Reverse Stock Split.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock>
    <onct:CommonStockSharesOutstandingPriorToStockSplit
      contextRef="C_0001260990_20190607"
      decimals="INF"
      id="F_000346"
      unitRef="U_xbrlishares">3458170</onct:CommonStockSharesOutstandingPriorToStockSplit>
    <us-gaap:SharePrice
      contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctGTxIncMember_20190607"
      decimals="2"
      id="F_000347"
      unitRef="U_iso4217USD_xbrlishares">8.40</us-gaap:SharePrice>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">29049000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">2154000</us-gaap:NoncashMergerRelatedCosts>
    <onct:AssetAcquisitionPurchasePrice
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">31203000</onct:AssetAcquisitionPurchasePrice>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000242">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The allocation of the purchase price is as follows:&lt;/p&gt;
&lt;p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:78.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash acquired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:16.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,292&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.5pt;"&gt;
&lt;td style="width:78.6%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net liabilities assumed&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:16.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,177&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.45pt;"&gt;
&lt;td style="background-color:#CFF0FC;width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;IPR&amp;amp;D (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,088&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:11.15pt;"&gt;
&lt;td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchase price&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,203&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="width:17.14%; border-bottom:solid 1pt #000000;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom"&gt;
&lt;p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Represents the research and development projects of GTx which were in-process, but not yet completed, and which the Company plans to advance, consisting primarily of GTx&#x2019;s preclinical SARD technology. Current &lt;/span&gt;accounting standards require that the fair value of IPR&amp;amp;D projects acquired in an asset acquisition with no &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;

&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"/&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">18292000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_0001260990_20190607"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">-5177000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">18088000</us-gaap:ResearchAndDevelopmentInProcess>
    <onct:AssetAcquisitionPurchasePrice
      contextRef="C_0001260990_20190607_20190607"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">31203000</onct:AssetAcquisitionPurchasePrice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000217">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Amended and Restated Articles of Incorporation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, the Company&#x2019;s certificate of incorporation was amended and restated to authorize 60,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock, each with a par value of $0.001 per share. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&lt;span style="font-weight:bold;font-style:italic;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Merger, all of the then outstanding shares of Private Oncternal&#x2019;s convertible preferred stock were converted into 8,148,268 shares of the Company&#x2019;s common stock. As of December 31, 2018, Private Oncternal&#x2019;s convertible preferred stock was classified as temporary equity on the accompanying consolidated &lt;span style="color:#000000;"&gt;statements of convertible preferred stock and stockholders&#x2019; equity (deficit) &lt;/span&gt;in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of Private Oncternal&#x2019;s control, including liquidation, sale or transfer of control of Private Oncternal. Private Oncternal did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because the occurrence of any such change of control event was not deemed probable.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Securities Purchase Agreements &lt;span style="color:#000000;"&gt;and &lt;/span&gt;Underwritten Offering&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#x2019;s board of directors) for the concurrent sale of: (i) 1,943,636 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. In addition, the Company&lt;span style="color:#000000;"&gt; issued &lt;/span&gt;warrants to purchase 116,618 &lt;span style="color:#000000;"&gt;shares of &lt;/span&gt;common &lt;span style="color:#000000;"&gt;stock at &lt;/span&gt;an exercise price of $3.2156&lt;span style="color:#000000;"&gt; per share &lt;/span&gt;to the placement agent, H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d; or the &#x201c;placement agent&#x201d;) as part of its compensation, which warrants were immediately exercisable and expire on May 21, 2025.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;July Purchase Agreement&#x201d;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 1,290,933 shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.3825. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $2.32 per share and expire on January 21, 2026. In addition, the Company issued warrants to purchase 154,912 shares of common stock at an exercise price of $2.9781 per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on July 21, 2025. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#x2019;s largest stockholder, Daniel L. Kisner, a member of the Company&#x2019;s board of directors, and Hazel M. Aker, the Company&#x2019;s then General Counsel.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;August Underwriting Agreement&#x201d;) with Wainwright for the sale of 2,428,886 shares of the Company&#x2019;s common stock at a price to the public of $2.10 per share, resulting in net proceeds of $4.4 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 145,733 shares of common stock at an exercise price of $2.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on August 27, 2025. An investor participating in the transaction included Michael G. Carter, a member of the Company&#x2019;s board of directors.&lt;/p&gt;


&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;November Underwriting Agreement&#x201d;) with Wainwright for the sale of 7,258,065 shares of the Company&#x2019;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on November 17, 2025. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;December Underwriting Agreement&#x201d;) with Wainwright for the sale of 19,161,667 shares of the Company&#x2019;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on December 9, 2025. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, &lt;span style="color:#000000;"&gt;other than pursuant to a new at-the-market offering facility with the placement &lt;/span&gt;agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The&lt;span style="color:#000000;"&gt; Company does not currently have an active at-the-market facility. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Warrants&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000405"&gt;3.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000406"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,265,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000407"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, all warrants met the criteria for classification in stockholders&#x2019; equity.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted &lt;span style="color:#000000;"&gt;Common Stock and Unvested Share Liability&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Merger, the&lt;span style="color:#000000;"&gt; Company issued restricted common stock subject to vesting and repurchase by the Company. For employee and non-employee awards, the issuance date fair value is recognized over the requisite service period of the award (usually the vesting period) on a straight-line basis. In addition, the Company has outstanding unvested shares related to the early exercise of stock options. The Company has the right, but not the obligation, to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The consideration received in exchange for unvested shares is recorded as an unvested share liability on the accompanying consolidated balance sheets and is reclassified into common stock and additional paid-in capital as the shares vest. At &lt;/span&gt;December&#160;31, 2020 and &lt;span style="color:#000000;"&gt;2019, the unvested share liability was $&lt;/span&gt;10,000 and $&lt;span style="color:#000000;"&gt;24,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s unvested shares is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#x2019;s 2015 Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#x201c;2019 Plan&#x201d;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b)&#160; up to 275,579 shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#x201c;2013 Plan&#x201d;) as of&#160;&#160;June 7, 2019, that are subsequently cancelled will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, &lt;span style="color:#000000;"&gt;2020, 937,837&lt;/span&gt; shares remain available for future issuance under the 2019 Plan (see Note 10).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000423"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000424"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;965,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000425"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020 under the 2013 Plan, there were: (i) &lt;span style="color:#000000;"&gt;111,145&lt;/span&gt; outstanding and fully vested options with a weighted average exercise price of $&lt;span style="color:#000000;"&gt;63.58&lt;/span&gt; per share, and (ii) &lt;span style="color:#000000;"&gt;145,652&lt;/span&gt; cancelled options that were added back to the 2019 Plan as of December&#160;31, 2020. As of December&#160;31, 2020, the former GTx stock option plans had an aggregate of &lt;span style="color:#000000;"&gt;118,024&lt;/span&gt; outstanding and fully vested and exercisable options with a weighted average exercise price of $&lt;span style="color:#000000;"&gt;75.16&lt;/span&gt; and a weighted average remaining contractual term of 0.4 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a &lt;span style="-sec-ix-hidden:F_000434"&gt;four-year&lt;/span&gt; period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan allowed for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2019 Plan and 2015 Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,662,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(173,753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information about the Company&#x2019;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value per share of option grants for the years ended December 31, &lt;span style="color:#000000;"&gt;2020 and &lt;/span&gt;2019 was $&lt;span style="color:#000000;"&gt;2.53&lt;/span&gt; and $&lt;span style="color:#000000;"&gt;3.69&lt;/span&gt; per share, respectively.&#160;&#160;The aggregate intrinsic value used in the above table of options at December&#160;31, 2020 is based on the Company&#x2019;s closing market price per common share on December&#160;31, 2020 of $4.90. The intrinsic value is calculated as the difference between the fair value of the Company&#x2019;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, &lt;span style="color:#000000;"&gt;2020 and &lt;/span&gt;2019 was not material. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000456"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility. &lt;span style="font-style:normal;"&gt;Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term. &lt;span style="font-style:normal;"&gt;The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate. &lt;span style="font-style:normal;"&gt;The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield. &lt;span style="font-style:normal;"&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2020, the total compensation cost related to nonvested awards not yet recognized was $3.4 million and the weighted-average period over which it is expected to be recognized was 2.5 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under equity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; plans&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20190607"
      decimals="INF"
      id="F_000355"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20190607"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20190607"
      decimals="INF"
      id="F_000357"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607"
      decimals="INF"
      id="F_000358"
      unitRef="U_xbrlishares">8148268</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="INF"
      id="F_000359"
      unitRef="U_xbrlishares">1943636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="-5"
      id="F_000360"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000361"
      unitRef="U_xbrlishares">971818</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000362"
      unitRef="U_iso4217USD_xbrlishares">2.5725</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000363"
      unitRef="U_xbrlishares">116618</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000364"
      unitRef="U_iso4217USD_xbrlishares">3.2156</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      id="F_000365">2025-05-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="INF"
      id="F_000366"
      unitRef="U_xbrlishares">2581867</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="-5"
      id="F_000367"
      unitRef="U_iso4217USD">5700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000368"
      unitRef="U_xbrlishares">1290933</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000369"
      unitRef="U_iso4217USD_xbrlishares">2.3825</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="2"
      id="F_000370"
      unitRef="U_iso4217USD_xbrlishares">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:CommonStockWarrantsExpirationDate
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000371">2026-01-21</onct:CommonStockWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000372"
      unitRef="U_xbrlishares">154912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000373"
      unitRef="U_iso4217USD_xbrlishares">2.9781</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000374">2025-07-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="INF"
      id="F_000375"
      unitRef="U_xbrlishares">2428886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="2"
      id="F_000378"
      unitRef="U_iso4217USD_xbrlishares">2.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="-5"
      id="F_000376"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="INF"
      id="F_000377"
      unitRef="U_xbrlishares">145733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="3"
      id="F_000379"
      unitRef="U_iso4217USD_xbrlishares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      id="F_000380">2025-08-27</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">7258065</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="2"
      id="F_000384"
      unitRef="U_iso4217USD_xbrlishares">3.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="-5"
      id="F_000382"
      unitRef="U_iso4217USD">20400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlishares">435484</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="3"
      id="F_000385"
      unitRef="U_iso4217USD_xbrlishares">3.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      id="F_000386">2025-11-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="INF"
      id="F_000387"
      unitRef="U_xbrlishares">19161667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="2"
      id="F_000390"
      unitRef="U_iso4217USD_xbrlishares">4.50</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000388"
      unitRef="U_iso4217USD">79000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="INF"
      id="F_000389"
      unitRef="U_xbrlishares">1149700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="3"
      id="F_000391"
      unitRef="U_iso4217USD_xbrlishares">5.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      id="F_000392">2025-12-09</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <onct:ScheduleOfWarrantActivityTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000243">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,620&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000405"&gt;3.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841,424&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.97&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000406"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,265,198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,781&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.22&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Outstanding - December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000407"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</onct:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20181231"
      decimals="INF"
      id="F_000393"
      unitRef="U_xbrlishares">841620</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20181231"
      decimals="INF"
      id="F_000399"
      unitRef="U_iso4217USD_xbrlishares">37.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ExerciseOfWarrants
      contextRef="C_0001260990_20190101_20191231"
      decimals="INF"
      id="F_000394"
      unitRef="U_xbrlishares">-196</onct:ExerciseOfWarrants>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_0001260990_20190101_20191231"
      decimals="INF"
      id="F_000400"
      unitRef="U_iso4217USD_xbrlishares">6.13</onct:WarrantExercisedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000395"
      unitRef="U_xbrlishares">841424</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000401"
      unitRef="U_iso4217USD_xbrlishares">37.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ExerciseOfWarrantsIssued
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000396"
      unitRef="U_xbrlishares">4265198</onct:ExerciseOfWarrantsIssued>
    <onct:WarrantIssuedPricePerShare
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000402"
      unitRef="U_iso4217USD_xbrlishares">3.47</onct:WarrantIssuedPricePerShare>
    <onct:ExerciseOfWarrants
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000397"
      unitRef="U_xbrlishares">-74781</onct:ExerciseOfWarrants>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000403"
      unitRef="U_iso4217USD_xbrlishares">3.22</onct:WarrantExercisedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000398"
      unitRef="U_xbrlishares">5031841</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000404"
      unitRef="U_iso4217USD_xbrlishares">9.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
      contextRef="C_0001260990_20201231"
      decimals="0"
      id="F_000408"
      unitRef="U_iso4217USD">10000</onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions>
    <onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions
      contextRef="C_0001260990_20191231"
      decimals="0"
      id="F_000409"
      unitRef="U_iso4217USD">24000</onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000244">

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s unvested shares is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000410"
      unitRef="U_xbrlishares">35000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000411"
      unitRef="U_xbrlishares">20000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000412"
      unitRef="U_xbrlishares">15000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000413"
      unitRef="U_xbrlishares">1678571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000414"
      unitRef="U_xbrlishares">275579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607"
      decimals="2"
      id="F_000415"
      unitRef="U_xbrlipure">0.05</onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20201231"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlishares">937837</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000245">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000423"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000424"&gt;8.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;965,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.61&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000425"&gt;8.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000417"
      unitRef="U_xbrlishares">2107625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000420"
      unitRef="U_iso4217USD_xbrlishares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">2509000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000418"
      unitRef="U_xbrlishares">2107625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000421"
      unitRef="U_iso4217USD_xbrlishares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">2509000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000419"
      unitRef="U_xbrlishares">965129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000422"
      unitRef="U_iso4217USD_xbrlishares">3.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">1525000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231"
      decimals="INF"
      id="F_000429"
      unitRef="U_xbrlishares">111145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20201231"
      decimals="2"
      id="F_000431"
      unitRef="U_iso4217USD_xbrlishares">63.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20200101_20201231"
      decimals="INF"
      id="F_000432"
      unitRef="U_xbrlishares">145652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">118024</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20201231"
      decimals="2"
      id="F_000436"
      unitRef="U_iso4217USD_xbrlishares">75.16</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731"
      decimals="INF"
      id="F_000430"
      unitRef="U_xbrlishares">631120</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000433">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000246">

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2019 Plan and 2015 Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,662,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(173,753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">1662253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_20191231"
      decimals="2"
      id="F_000443"
      unitRef="U_iso4217USD_xbrlishares">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlishares">624260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000444"
      unitRef="U_iso4217USD_xbrlishares">3.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">173753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000445"
      unitRef="U_iso4217USD_xbrlishares">2.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_20200101_20201231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">5135</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000446"
      unitRef="U_iso4217USD_xbrlishares">0.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">2107625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_20201231"
      decimals="2"
      id="F_000447"
      unitRef="U_iso4217USD_xbrlishares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20200101_20201231"
      decimals="2"
      id="F_000448"
      unitRef="U_iso4217USD_xbrlishares">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20190101_20191231"
      decimals="2"
      id="F_000449"
      unitRef="U_iso4217USD_xbrlishares">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20201231"
      decimals="2"
      id="F_000450"
      unitRef="U_iso4217USD_xbrlishares">4.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000247">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000455"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000456"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="3"
      id="F_000451"
      unitRef="U_xbrlipure">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20190101_20191231"
      decimals="3"
      id="F_000452"
      unitRef="U_xbrlipure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="3"
      id="F_000453"
      unitRef="U_xbrlipure">0.916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20190101_20191231"
      decimals="3"
      id="F_000454"
      unitRef="U_xbrlipure">0.776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000248">

&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;237&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;507&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000457"
      unitRef="U_iso4217USD">544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000458"
      unitRef="U_iso4217USD">237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000459"
      unitRef="U_iso4217USD">1012000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000460"
      unitRef="U_iso4217USD">270000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">1556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">507000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001260990_20200101_20201231" id="F_000464">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000249">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,032&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,958&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under equity&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; plans&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;938&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,196&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000465"
      unitRef="U_xbrlishares">5032000</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000466"
      unitRef="U_xbrlishares">841000</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000467"
      unitRef="U_xbrlishares">2226000</onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance>
    <onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000468"
      unitRef="U_xbrlishares">1958000</onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000469"
      unitRef="U_xbrlishares">938000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20191231"
      decimals="-3"
      id="F_000470"
      unitRef="U_xbrlishares">495000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000471"
      unitRef="U_xbrlishares">8196000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000472"
      unitRef="U_xbrlishares">3294000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <onct:COVID19PandemicAndCARESActDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000218">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="color:#FF0000;"/&gt;COVID-19 Pandemic and CARES Act&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#x201c;COVID-19&#x201d;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#x201c;stay-at-home&#x201d; orders, and restricting business functions outside of one&#x2019;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#x2019;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#x2019;s results of operations and financial position at December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#x2019;s income tax provision for the 12 months ended December&#160;31, 2020.&lt;/p&gt;

</onct:COVID19PandemicAndCARESActDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000219">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,688&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the Company&#x2019;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December&#160;31, 2020 and 2019.&#160;&#160;As a result of the Merger in 2019, the Company recorded deferred tax assets of $13.1 million which are fully offset by a valuation allowance. The $13.1 million net deferred tax assets do not include federal and state net operating loss carryforwards and federal research and development credit carryforwards that are estimated to expire under Internal Revenue Code Sections 382 and 383 as a result of the Merger.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $69.1 million and $47.7&#160;million, respectively. Of the federal net operating losses at December&#160;31, 2020, $43.4 million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in 2033 and 2029, respectively, unless previously utilized. At December&#160;31, 2020, the Company also had federal and state research and development credit carryforwards of approximately $1.3 million and $0.9 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034 unless previously utilized. The state research and development credits do not expire. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a &lt;span style="-sec-ix-hidden:F_000517"&gt;three-year&lt;/span&gt; period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#x2019;s formation due to the complexity and cost associated with such a study and the &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December&#160;31, 2020 and 2019, there were no unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#x2019;s 2013 through 2020 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000250">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate and federal statutory tax rate is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,617&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(65&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,354&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;265&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,074&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">-3617000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">-7179000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">-1113000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">-968000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">-65000</onct:IncomeTaxReconciliationPermanentItems>
    <onct:IncomeTaxReconciliationPermanentItems
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">873000</onct:IncomeTaxReconciliationPermanentItems>
    <onct:IncomeTaxReconciliationInProcessResearchAndDevelopment
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">3354000</onct:IncomeTaxReconciliationInProcessResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">505000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">464000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">226000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">265000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20200101_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">5074000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20190101_20191231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">4119000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000251">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,987&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,688&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;393&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,551&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,599&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(32,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of use asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">17852000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">18108000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">1952000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">1446000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">367000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">214000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">11987000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">7688000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">393000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">143000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">32551000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">27599000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">32540000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">27546000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">11000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">53000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">11000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <onct:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">53000</onct:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">11000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">53000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000506"
      unitRef="U_iso4217USD">13100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <onct:ValuationAllowanceDeferredTaxAssetChangeNetAmount
      contextRef="C_0001260990_20200101_20201231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">13100000</onct:ValuationAllowanceDeferredTaxAssetChangeNetAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000508"
      unitRef="U_iso4217USD">69100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000509"
      unitRef="U_iso4217USD">47700000</us-gaap:OperatingLossCarryforwards>
    <onct:OperatingLossCarryforwardsNonExpirePortion
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000510"
      unitRef="U_iso4217USD">43400000</onct:OperatingLossCarryforwardsNonExpirePortion>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000511">2033</onct:OperatingLossCarryforwardsExpirationYear>
    <onct:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_000512">2029</onct:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000513"
      unitRef="U_iso4217USD">1300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000514"
      unitRef="U_iso4217USD">900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
      contextRef="C_0001260990_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000515">2034</onct:DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear>
    <onct:CumulativeChangeInOwnershipPercentage
      contextRef="C_0001260990_20200101_20201231"
      decimals="2"
      id="F_000516"
      unitRef="U_xbrlipure">0.50</onct:CumulativeChangeInOwnershipPercentage>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000518"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001260990_20191231"
      decimals="INF"
      id="F_000519"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001260990_20200101_20201231" id="F_000220">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Subsequent Event&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Inducement Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;In February 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Equity Incentive Award Plan (Inducement Plan) and initially reserved 700,000 shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#x201c;inducement exception&#x201d; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#x2019;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20210228"
      decimals="INF"
      id="F_000521"
      unitRef="U_xbrlishares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953755320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oncternal Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001260990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text"> 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,281,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1715807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12230 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-1113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the Registrant&#8217;s 2021 Annual Meeting of Stockholders, which will be filed subsequent to the date hereof, are incorporated by reference into Part III of this Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrant&#8217;s fiscal year ended December&#160;31, 2020.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954276472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 116,737<span></span>
</td>
<td class="nump">$ 20,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid and other</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">118,003<span></span>
</td>
<td class="nump">20,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">118,809<span></span>
</td>
<td class="nump">21,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="nump">2,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease, current</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,858<span></span>
</td>
<td class="nump">7,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease, net of current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000 and none at December 31, 2020 and 2019, respectively; issued and outstanding shares &#8211; none</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares &#8211; 60,000 at December 31, 2020 and 2019, respectively; issued and outstanding shares &#8211; 48,802 and 15,387 at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">195,699<span></span>
</td>
<td class="nump">79,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(82,797)<span></span>
</td>
<td class="num">(65,572)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">112,951<span></span>
</td>
<td class="nump">14,312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 118,809<span></span>
</td>
<td class="nump">$ 21,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243960987640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">48,802,000<span></span>
</td>
<td class="nump">15,387,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,802,000<span></span>
</td>
<td class="nump">15,387,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243958036216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 3,375<span></span>
</td>
<td class="nump">$ 2,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">12,544<span></span>
</td>
<td class="nump">10,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,373<span></span>
</td>
<td class="nump">7,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,917<span></span>
</td>
<td class="nump">35,533<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(17,542)<span></span>
</td>
<td class="num">(33,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">317<span></span>
</td>
<td class="num">(1,080)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,225)<span></span>
</td>
<td class="num">$ (34,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (3.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">20,305<span></span>
</td>
<td class="nump">10,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243957034248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (17,225)<span></span>
</td>
<td class="num">$ (34,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan', window );">Gain on forgiveness of payroll protection program loan</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="num">(529)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">272<span></span>
</td>
<td class="num">(4,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">739<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="num">(2,007)<span></span>
</td>
<td class="nump">3,640<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,495)<span></span>
</td>
<td class="num">(16,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in connection with the Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisition related costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,155)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from payroll protection loan</a></td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ProceedsFromStockOptionsExercisedAndWarrantExercises', window );">Proceeds from exercise of stock options and common stock warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="nump">113,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">114,181<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) increase in cash and cash equivalents</a></td>
<td class="nump">96,686<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">20,051<span></span>
</td>
<td class="nump">20,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">116,737<span></span>
</td>
<td class="nump">20,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of 2019 bonus awards with stock options in lieu of cash</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_FairValueOfWarrantsIssuedToPlacementAgent', window );">Fair value of warrants issued to placement agent</a></td>
<td class="nump">5,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan', window );">Gain on forgiveness of payroll protection program loan</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ConversionOfConvertiblePreferredStockToCommonStock', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital', window );">Reclassification of preferred stock warrants liability to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Net liabilities assumed in Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=onct_GTxIncMember', window );">GTx Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of 2019 bonus awards with stock options in lieu of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ConversionOfConvertiblePreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ConversionOfConvertiblePreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_FairValueOfWarrantsIssuedToPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued to placement agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_FairValueOfWarrantsIssuedToPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ProceedsFromStockOptionsExercisedAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options and common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ProceedsFromStockOptionsExercisedAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of preferred stock warrants liability to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=onct_GTxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=onct_GTxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954096120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible preferred stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="num">$ (29,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1,748<span></span>
</td>
<td class="num">$ (31,384)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash', window );">Exercise of warrants for cash</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to repurchase liability</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to former stockholders of GTx upon Merger</a></td>
<td class="nump">29,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">29,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to former stockholders of GTx upon Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Conversion of convertible preferred stock into common stock upon Merger</a></td>
<td class="nump">46,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">46,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46,588)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock upon Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant', window );">Reclassification of convertible preferred stock warrant liability</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 14,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">79,869<span></span>
</td>
<td class="num">(65,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="nump">5,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfCashlessWarrantShares', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to repurchase liability</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="nump">113,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">113,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash', window );">Issuance of 2019 bonus awards with stock option in lieu ofcash</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,225)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 112,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 195,699<span></span>
</td>
<td class="num">$ (82,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">48,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification of convertible preferred stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital stock issued issuance costs shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital vesting related to unvested share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfCashlessWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfCashlessWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of bonus awards with stock option in lieu of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961086104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock and common stock warrants, issuance cost</a></td>
<td class="nump">$ 11,103<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951949272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Business,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">Basis</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.5pt;"> </span>Presentation<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.4pt;"> </span>Summary<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.45pt;"> </span>Significant<span style="letter-spacing:-0.5pt;"> </span>Accounting<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">Policies</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;Oncternal,&#8221; or the &#8220;combined company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221; &#8220;the Company,&#8221; and the &#8220;combined company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.073386 shares of Company common stock (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split, as defined below. Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately 77.5% of the outstanding common stock of the combined company. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#8217;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#8217;s senior management holds all key positions in the senior management of the combined company. <span style="color:#000000;">As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the Merger are those of Private Oncternal. &#160;</span></p>


<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split and Exchange Ratio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, in connection with, and prior to the completion of, the Merger, GTx effected a one-for-seven reverse stock split of its then outstanding common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company&#8217;s issued and outstanding common stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All issued and outstanding Private Oncternal common stock, preferred stock, options and warrants prior to the effective date of the Merger have been retroactively adjusted to reflect the Exchange Ratio for all periods presented.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had $116.7 million in cash and cash equivalents. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $82.8 million as of December&#160;31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>preferred <span style="letter-spacing:0.1pt;">stock, </span>preferred <span style="letter-spacing:0.1pt;">stock</span> warrant <span style="letter-spacing:0.15pt;">liability</span> and stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p>


<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2020, the Company&#8217;s clinical trial accrual balance of $1.0 million is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $12.5 million.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, Private Oncternal had outstanding freestanding warrants to purchase shares of its Series B-2 convertible preferred stock (the &#8220;Series B-2 warrants&#8221;). Private Oncternal adjusted the carrying value of such Series B-2 warrants to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as a change in fair value of warrant liability in the consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase the Company&#8217;s common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#8217; equity.</p>


<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2020 and 2019, the Company had deferred grant revenue of <span style="color:#000000;">$1.6 </span>million and $3.6 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p>

<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 25,000 shares and 56,000 shares from the weighted-average number of common shares outstanding for the years ended December<span style="color:#000000;">&#160;</span>31, 20<span style="color:#000000;">20</span> and 201<span style="color:#000000;">9</span>, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,834</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes: Simplifying the Accounting for Income Taxe</span>s, which is intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company adopted this standard effective October 1, 2020, the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued <span style="color:#000000;">ASU </span>2018-13, <span style="font-style:italic;">Fair Value Measurement: Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement, </span>which modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard effective January 1, 2020, <span style="color:#000000;">the adoption had no impact on the consolidated financial statements</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961025928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953316616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingencies and Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $0.2 million and $0.1 million for the years ended December&#160;31, 2020 and 2019, respectively. On May 22, 2019, the Company entered into an office sublease agreement for 4,677 square feet in San Diego, California (&#8220;San Diego Lease&#8221;) which expires on March 31, 2021. Base rent is approximately $166,000 annually and the monthly rent expense is being recognized on a straight-line basis over the lease term. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and a lease liability of $40,000 that matures in March 2021, as of December&#160;31, 2020, in the accompanying consolidated balance sheet. The weighted average remaining lease term was 0.25 years.</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company engaged Newfront Insurance as its primary insurance broker. The son of Richard Vincent, the Company&#8217;s Chief Financial Officer, acted as the Company&#8217;s agent at Newfront Insurance. During the years ended December 31, 2020 and 2019, the Company paid total related policy premiums of $1.4 million and $1.2 million, respectively, for which Mr. Vincent&#8217;s son received a commission of approximately $0.1 million in each respective period. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;) entered into a Materials Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;), pursuant to which the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of the License and Development Agreement between the Company and SPH USA effective as of November 2018. During the year ended December&#160;31, 2020, the Company recorded amounts receivable from SPH USA related to statements of work totaling $0.3 million (see Note 4).</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offering, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter (see Note 7).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953391288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration and Research Subaward Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration and Research Subaward Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of December 31, 2020, the Company had not triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;<span style="font-weight:bold;font-style:italic;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020, the </p>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The amount recorded as research and development expense for the year ended December 31, 2020 was $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the amount was insignificant for the year ended December 31, 2019.</span><span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018 in connection with the spin-off transactions described below, the Company entered into a license agreement (as amended, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement was amended on March 25, 2019 and May 15, 2019, to update the patents covered under the agreement.&#160;&#160;The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain&#160;annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded: <span style="letter-spacing:0.15pt;">(i) $25,000 in </span><span style="letter-spacing:0.1pt;">license</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">maintenance</span><span style="letter-spacing:-0.3pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.45pt;"> </span>research<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">development</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">expense for each of the</span> years ended December 31, 2020 and 2019, and (ii)<span style="letter-spacing:-0.6pt;"> approximately</span> $0.2 million<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">costs</span> as general <span style="letter-spacing:0.1pt;">and administrative </span><span style="letter-spacing:0.15pt;">expense </span>for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, the Company believes it has met its obligations under the Regents License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000319">five-year</span> agreement, the Regents will have an aggregate budget of $3.6 million, with $125,000 payable quarterly. The Company recorded $0.5 million in research and development expense under this agreement&#160;for each of the years ended December 31, 2020 and 2019. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. <span style="color:#000000;">The Company may terminate the agreement at any time upon at least 60 days&#8217; written notice.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2015, the Company and UTRF entered into a license agreement (the &#8220;SARD License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#8220;SARD&#8221;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $0.2 million and $0.4 million for each of the years ended December 31, 2020 and 2019, respectively. <span style="color:#000000;">As of December 31, 2020, the Company believes it has met its obligations under the SARD License Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company believes it has met its obligations under each of the UTRF agreements.</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Award<span style="font-size:6pt;font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017,<span style="color:#000000;"> and as amended and restated in December 2020,</span> CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.0 million in development milestones under research subaward agreements throughout the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received subaward payments of $1.4 million and $6.2 million in the years ended December 31, 2020 and 2019, respectively, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the years ended December 31, 2020 and 2019, the Company&#8217;s grant revenue was $3.4 million and $2.4 million, respectively. Related qualifying subaward costs for the years ended December 31, 2020 and 2019 were $5.2 million and $5.4 million, respectively. As of December 31, 2020, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $5.8 million grant to the researchers at the University of California San Diego School of Medicine (&#8220;UC San Diego&#8221;) to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for the years ended December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018,<span style="color:#000000;"> and as amended in August 2020, </span>the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) <span style="letter-spacing:0.15pt;">either</span><span style="letter-spacing:-0.5pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>in<span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">event</span> <span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">other</span><span style="letter-spacing:-0.5pt;"> </span>party<span style="letter-spacing:0.1pt;"> </span>declares<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">insolvency</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.15pt;">or</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">bankruptcy.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953699784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Debt</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Paycheck Protection Program Loan Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company received a $0.3 million unsecured loan, bearing interest at 1%, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;), a program implemented by the U.S. Small Business Administration (the &#8220;SBA&#8221;) under the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) (the &#8220;PPP Loan&#8221;). In December 2020, the underlying principal and interest were fully forgiven by the SBA and the Company has no further obligations thereunder. <span style="color:#000000;">The loan forgiveness was recorded as other income of $</span></p>

<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">301</span><span style="color:#000000;">k in the statement of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953273128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MergerDisclosureTextBlock', window );">Merger</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Merger</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger, which closed on June 7, 2019, was accounted for as a reverse asset acquisition, as substantially all of the fair value of the assets acquired were concentrated in a group of similar non-financial assets, and the acquired assets did not have outputs or employees. Because the assets had not yet received regulatory approval, the fair value attributable to these assets of $18.1 million was recorded as in-process research and development expenses in the Company&#8217;s consolidated statement of operations in the year ended December 31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Merger Agreement on June 7, 2019, the Company, a representative of holders of the contingent value rights (&#8220;CVRs&#8221;), and Computershare, Inc. as rights agent entered into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;). Pursuant to the CVR Agreement, the Company&#8217;s stockholders of record as of immediately prior to the Merger received one CVR for each share of the Company&#8217;s common stock held immediately prior to the Merger. CVR holders are entitled to receive 75% of the aggregate amount of any net proceeds received by the Company during the 15-year period after the closing of the Merger from the grant, sale or transfer of rights to the Company&#8217;s SARD or SARM technology that occurs during the 10-year period after the closing (or in the 11th year if based on a term sheet approved during the initial 10-year period) and, if applicable, to receive royalties on the sale of any SARD or SARM products by the Company during the 15-year period after the closing. Effective in March 2020, the Company terminated the SARM license agreement with UTRF and no longer has any rights to the SARM technology. The CVR Agreement will continue in effect until the payment of all amounts payable thereunder. As of the years ended December 31, 2020 and 2019, no milestones had been accrued as there were no potential milestones yet considered probable. The total purchase price paid in the Merger has been allocated to the net assets acquired and liabilities assumed based on their fair values as of the completion of the Merger. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td style="background-color:#CFF0FC;width:55%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of shares of the combined organization owned</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; by the Company&#8217;s pre-Merger stockholders</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,458,170</p></td>
<td style="background-color:#CFF0FC;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td style="width:55%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiplied by the fair value per share of GTx common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock (1)</p></td>
<td style="width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.40</p></td>
<td style="width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="background-color:#CFF0FC;width:55%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of consideration issued to effect the Merger</p></td>
<td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:12%; border-top:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,049</p></td>
<td style="background-color:#CFF0FC;width:1.12%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.45pt;">
<td style="width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs</p></td>
<td style="width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,154</p></td>
<td style="width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="background-color:#CFF0FC;width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,203</p></td>
<td style="background-color:#CFF0FC;width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="width:55%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.12%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Based on the last reported sale price of the Company&#8217;s common stock on the Nasdaq Capital Market on June 7, 2019, the closing date of the Merger, and gives effect to the Reverse Stock Split.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price is as follows:</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td style="background-color:#CFF0FC;width:78.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash acquired</p></td>
<td style="background-color:#CFF0FC;width:1.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:16.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,292</p></td>
<td colspan="2" style="background-color:#CFF0FC;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td style="width:78.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net liabilities assumed</p></td>
<td style="width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:16.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,177</p></td>
<td colspan="2" style="width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.45pt;">
<td style="background-color:#CFF0FC;width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D (2)</p></td>
<td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,088</p></td>
<td colspan="2" style="background-color:#CFF0FC;width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,203</p></td>
<td colspan="2" style="width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td colspan="2" style="width:17.14%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Represents the research and development projects of GTx which were in-process, but not yet completed, and which the Company plans to advance, consisting primarily of GTx&#8217;s preclinical SARD technology. Current </span>accounting standards require that the fair value of IPR&amp;D projects acquired in an asset acquisition with no </p></td></tr></table></div>

<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top"/>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MergerDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MergerDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243986285816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amended and Restated Articles of Incorporation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company&#8217;s certificate of incorporation was amended and restated to authorize 60,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock, each with a par value of $0.001 per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;<span style="font-weight:bold;font-style:italic;">Convertible Preferred Stock</span></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger, all of the then outstanding shares of Private Oncternal&#8217;s convertible preferred stock were converted into 8,148,268 shares of the Company&#8217;s common stock. As of December 31, 2018, Private Oncternal&#8217;s convertible preferred stock was classified as temporary equity on the accompanying consolidated <span style="color:#000000;">statements of convertible preferred stock and stockholders&#8217; equity (deficit) </span>in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of Private Oncternal&#8217;s control, including liquidation, sale or transfer of control of Private Oncternal. Private Oncternal did not adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because the occurrence of any such change of control event was not deemed probable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase Agreements <span style="color:#000000;">and </span>Underwritten Offering</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors) for the concurrent sale of: (i) 1,943,636 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. In addition, the Company<span style="color:#000000;"> issued </span>warrants to purchase 116,618 <span style="color:#000000;">shares of </span>common <span style="color:#000000;">stock at </span>an exercise price of $3.2156<span style="color:#000000;"> per share </span>to the placement agent, H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on May 21, 2025.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 1,290,933 shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.3825. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $2.32 per share and expire on January 21, 2026. In addition, the Company issued warrants to purchase 154,912 shares of common stock at an exercise price of $2.9781 per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on July 21, 2025. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#8217;s largest stockholder, Daniel L. Kisner, a member of the Company&#8217;s board of directors, and Hazel M. Aker, the Company&#8217;s then General Counsel.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;August Underwriting Agreement&#8221;) with Wainwright for the sale of 2,428,886 shares of the Company&#8217;s common stock at a price to the public of $2.10 per share, resulting in net proceeds of $4.4 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 145,733 shares of common stock at an exercise price of $2.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on August 27, 2025. An investor participating in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</p>


<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of 7,258,065 shares of the Company&#8217;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on November 17, 2025. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of 19,161,667 shares of the Company&#8217;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on December 9, 2025. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">other than pursuant to a new at-the-market offering facility with the placement </span>agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The<span style="color:#000000;"> Company does not currently have an active at-the-market facility. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,620</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">3.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000406">2.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">4.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, all warrants met the criteria for classification in stockholders&#8217; equity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted <span style="color:#000000;">Common Stock and Unvested Share Liability</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, the<span style="color:#000000;"> Company issued restricted common stock subject to vesting and repurchase by the Company. For employee and non-employee awards, the issuance date fair value is recognized over the requisite service period of the award (usually the vesting period) on a straight-line basis. In addition, the Company has outstanding unvested shares related to the early exercise of stock options. The Company has the right, but not the obligation, to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. The consideration received in exchange for unvested shares is recorded as an unvested share liability on the accompanying consolidated balance sheets and is reclassified into common stock and additional paid-in capital as the shares vest. At </span>December&#160;31, 2020 and <span style="color:#000000;">2019, the unvested share liability was $</span>10,000 and $<span style="color:#000000;">24,000</span>, respectively.</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested shares is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger&#160;&#160;closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b)&#160; up to 275,579 shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;) as of&#160;&#160;June 7, 2019, that are subsequently cancelled will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At December&#160;31, <span style="color:#000000;">2020, 937,837</span> shares remain available for future issuance under the 2019 Plan (see Note 10).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000423">8.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,509</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000424">8.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.61</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000425">8.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020 under the 2013 Plan, there were: (i) <span style="color:#000000;">111,145</span> outstanding and fully vested options with a weighted average exercise price of $<span style="color:#000000;">63.58</span> per share, and (ii) <span style="color:#000000;">145,652</span> cancelled options that were added back to the 2019 Plan as of December&#160;31, 2020. As of December&#160;31, 2020, the former GTx stock option plans had an aggregate of <span style="color:#000000;">118,024</span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;">75.16</span> and a weighted average remaining contractual term of 0.4 years.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a <span style="-sec-ix-hidden:F_000434">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2015 Plan allowed for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019.</p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,662,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(173,753</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,135</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about the Company&#8217;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the years ended December 31, <span style="color:#000000;">2020 and </span>2019 was $<span style="color:#000000;">2.53</span> and $<span style="color:#000000;">3.69</span> per share, respectively.&#160;&#160;The aggregate intrinsic value used in the above table of options at December&#160;31, 2020 is based on the Company&#8217;s closing market price per common share on December&#160;31, 2020 of $4.90. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, <span style="color:#000000;">2020 and </span>2019 was not material. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">6.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p>

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the total compensation cost related to nonvested awards not yet recognized was $3.4 million and the weighted-average period over which it is expected to be recognized was 2.5 years.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961000616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19 Pandemic and CARES Act<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActAbstract', window );"><strong>C O V I D19 Pandemic And C A R E S Act [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock', window );">COVID-19 Pandemic and CARES Act</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#FF0000;"/>COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., the Company expects that COVID-19 precautions may directly or indirectly impact the timeline for some of its clinical trials. For example, some of its clinical trial sites, including those located in areas severely impacted by the pandemic, have placed new patient enrollment into clinical trials on hold or, for patients travelling from out-of-state, have implemented a 14-day self-quarantine before appointments. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy in China has been delayed. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at December&#160;31, 2020. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property (QIP), and authorized the PPP (see Note 5).&#160; The CARES Act had no material impact on the Company&#8217;s income tax provision for the 12 months ended December&#160;31, 2020.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953338200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(968</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,446</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,688</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,599</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,540</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the Company&#8217;s history of operating losses, the Company is unable to conclude that it is more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December&#160;31, 2020 and 2019.&#160;&#160;As a result of the Merger in 2019, the Company recorded deferred tax assets of $13.1 million which are fully offset by a valuation allowance. The $13.1 million net deferred tax assets do not include federal and state net operating loss carryforwards and federal research and development credit carryforwards that are estimated to expire under Internal Revenue Code Sections 382 and 383 as a result of the Merger.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company had federal and state net operating loss (NOL) carryforwards of approximately $69.1 million and $47.7&#160;million, respectively. Of the federal net operating losses at December&#160;31, 2020, $43.4 million do not expire, and the remaining federal and state net operating loss carryforwards will begin expiring in 2033 and 2029, respectively, unless previously utilized. At December&#160;31, 2020, the Company also had federal and state research and development credit carryforwards of approximately $1.3 million and $0.9 million, respectively. The federal research and development credit carryforwards will begin expiring in 2034 unless previously utilized. The state research and development credits do not expire. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#8217;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a <span style="-sec-ix-hidden:F_000517">three-year</span> period. The Company has not completed a Section 382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#8217;s formation due to the complexity and cost associated with such a study and the </p>

<p style="margin-bottom:0pt;margin-top:10pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fact that there may be additional such ownership changes in the future. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company&#8217;s effective tax rate.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized. At December&#160;31, 2020 and 2019, there were no unrecognized tax benefits recorded in the consolidated financial statements. The Company does not expect any material changes to unrecognized tax benefits within the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to taxation in the United States federal and state jurisdictions. The Company&#8217;s 2013 through 2020 federal income tax and state income tax returns are subject to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company is not currently under examination by any tax authority.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its consolidated statements of operations since inception.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951773448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Inducement Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>In February 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Equity Incentive Award Plan (Inducement Plan) and initially reserved 700,000 shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961222472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Merger</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the combined company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221; &#8220;the Company,&#8221; and the &#8220;combined company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, each outstanding share of Private Oncternal common stock outstanding immediately prior to the closing of the Merger was converted into approximately 0.073386 shares of Company common stock (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split, as defined below. Immediately prior to the closing of the Merger, all shares of Private Oncternal preferred stock then outstanding were exchanged into shares of common stock of Private Oncternal. In addition, all outstanding options exercisable for common stock of Private Oncternal and warrants exercisable for convertible preferred stock of Private Oncternal became options and warrants exercisable for the same number of shares of common stock of the Company multiplied by the Exchange Ratio. Immediately following the Merger, stockholders of Private Oncternal owned approximately 77.5% of the outstanding common stock of the combined company. </p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). Under this method of accounting, Private Oncternal was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the facts that, immediately following the Merger: (i)&#160;Private Oncternal&#8217;s stockholders owned a substantial majority of the voting rights in the combined company, (ii)&#160;Private Oncternal designated a majority of the members of the initial board of directors of the combined company, and (iii)&#160;Private Oncternal&#8217;s senior management holds all key positions in the senior management of the combined company. <span style="color:#000000;">As a result, as of the closing date of the Merger, the net assets of the Company were recorded at their acquisition-date relative fair values in the consolidated financial statements of the Company and the reported operating results prior to the Merger are those of Private Oncternal. &#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock', window );">Reverse Stock Split and Exchange Ratio</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reverse Stock Split and Exchange Ratio</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, in connection with, and prior to the completion of, the Merger, GTx effected a one-for-seven reverse stock split of its then outstanding common stock (the &#8220;Reverse Stock Split&#8221;). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All of the Company&#8217;s issued and outstanding common stock have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. All issued and outstanding Private Oncternal common stock, preferred stock, options and warrants prior to the effective date of the Merger have been retroactively adjusted to reflect the Exchange Ratio for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the Company had $116.7 million in cash and cash equivalents. The Company believes it has sufficient cash to<span style="color:#000000;"> fund its projected operating requirements for at least twelve months from the date of issuance</span>. However, the Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $82.8 million as of December&#160;31, 2020. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.35pt;"> </span>prepared<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">accordance</span><span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> GAAP.</span><span style="letter-spacing:-0.6pt;"> </span>The<span style="letter-spacing:-0.35pt;"> </span>preparation<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">consolidated</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">financial</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">statements</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">accompanying</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">notes</span><span style="letter-spacing:-0.45pt;"> </span>requires<span style="letter-spacing:-0.5pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>make<span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and assumptions </span><span style="letter-spacing:0.15pt;">that </span><span style="letter-spacing:0.1pt;">impact </span><span style="letter-spacing:0.15pt;">the </span>reported <span style="letter-spacing:0.15pt;">amounts of </span>assets, <span style="letter-spacing:0.15pt;">liabilities, </span><span style="letter-spacing:0.1pt;">revenues and expenses and </span><span style="letter-spacing:0.15pt;">the </span><span style="letter-spacing:0.1pt;">disclosure </span><span style="letter-spacing:0.15pt;">of </span><span style="letter-spacing:0.2pt;">contingent </span>assets <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">liabilities. </span><span style="letter-spacing:0.1pt;">Significant </span>estimates <span style="letter-spacing:0.1pt;">consist </span><span style="letter-spacing:0.15pt;">of those </span>used to determine <span style="letter-spacing:0.15pt;">the </span>fair <span style="letter-spacing:0.15pt;">value of the </span><span style="letter-spacing:0.1pt;">Company&#8217;s </span>preferred <span style="letter-spacing:0.1pt;">stock, </span>preferred <span style="letter-spacing:0.1pt;">stock</span> warrant <span style="letter-spacing:0.15pt;">liability</span> and stock-based awards<span style="letter-spacing:0.15pt;">, </span><span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">those </span>used to determine grant <span style="letter-spacing:0.1pt;">revenue and </span>accruals for research <span style="letter-spacing:0.1pt;">and </span><span style="letter-spacing:0.15pt;">development </span>costs. <span style="letter-spacing:0.15pt;">Although </span><span style="letter-spacing:0.1pt;">these </span>estimates are based <span style="letter-spacing:0.15pt;">on the </span><span style="letter-spacing:0.1pt;">Company&#8217;s</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">knowledge</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.15pt;">of</span><span style="letter-spacing:-0.65pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.15pt;">events</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">actions</span><span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">undertake</span><span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.15pt;">the</span><span style="letter-spacing:-0.3pt;"> </span>future,<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:0.1pt;">actual</span><span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">ultimately</span><span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.65pt;"> </span>from<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">these</span><span style="letter-spacing:-0.3pt;"> </span>estimates <span style="letter-spacing:0.1pt;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of December 31, 2020, the Company&#8217;s clinical trial accrual balance of $1.0 million is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $12.5 million.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PreferredStockWarrantLiabilityPolicyTextBlock', window );">Preferred Stock Warrant Liability</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Merger, Private Oncternal had outstanding freestanding warrants to purchase shares of its Series B-2 convertible preferred stock (the &#8220;Series B-2 warrants&#8221;). Private Oncternal adjusted the carrying value of such Series B-2 warrants to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as a change in fair value of warrant liability in the consolidated statements of operations. Upon the completion of the Merger, the Series B-2 warrants were amended such that they were converted into warrants to purchase the Company&#8217;s common stock. As amended, warrant liability accounting is no longer required and the fair value of the warrant liability has been reclassified into stockholders&#8217; equity.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no financial assets or liabilities measured at fair value on a recurring basis. No transfers between levels have occurred during the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At December 31, 2020 and 2019, the Company had deferred grant revenue of <span style="color:#000000;">$1.6 </span>million and $3.6 million, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black- Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have </p>

<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 25,000 shares and 56,000 shares from the weighted-average number of common shares outstanding for the years ended December<span style="color:#000000;">&#160;</span>31, 20<span style="color:#000000;">20</span> and 201<span style="color:#000000;">9</span>, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,834</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company is currently evaluating the impact of the pending adoption of this new standard on its consolidated financial statements.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes: Simplifying the Accounting for Income Taxe</span>s, which is intended to simplify the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new standard also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for annual periods beginning after December 15, 2020 and interim periods within, with early adoption permitted. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The Company adopted this standard effective October 1, 2020, the adoption had no impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued <span style="color:#000000;">ASU </span>2018-13, <span style="font-style:italic;">Fair Value Measurement: Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement, </span>which modifies the disclosure requirements for fair value measurements. The amendments relate to disclosures regarding unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty and are to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, and early adoption is permitted. The Company adopted this standard effective January 1, 2020, <span style="color:#000000;">the adoption had no impact on the consolidated financial statements</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PreferredStockWarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrant liability policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PreferredStockWarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split and exchange ration policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953726968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,273</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,834</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951784232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">582</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested share liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,731</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953273128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock', window );">Summary of Purchase Price Paid in Merger</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following summarizes the purchase price paid in the Merger (in thousands, except share and per share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td style="background-color:#CFF0FC;width:55%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of shares of the combined organization owned</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; by the Company&#8217;s pre-Merger stockholders</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,458,170</p></td>
<td style="background-color:#CFF0FC;width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td style="width:55%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Multiplied by the fair value per share of GTx common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock (1)</p></td>
<td style="width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="width:12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.40</p></td>
<td style="width:1.12%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="background-color:#CFF0FC;width:55%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of consideration issued to effect the Merger</p></td>
<td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%; border-top:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:12%; border-top:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,049</p></td>
<td style="background-color:#CFF0FC;width:1.12%; border-top:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.45pt;">
<td style="width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transaction costs</p></td>
<td style="width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,154</p></td>
<td style="width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="background-color:#CFF0FC;width:55%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.74%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,203</p></td>
<td style="background-color:#CFF0FC;width:1.12%; border-bottom:solid 1pt #CFF0FC;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="width:55%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:12%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.12%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/>Based on the last reported sale price of the Company&#8217;s common stock on the Nasdaq Capital Market on June 7, 2019, the closing date of the Merger, and gives effect to the Reverse Stock Split.</p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Allocation of Purchase Price</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The allocation of the purchase price is as follows:</p>
<p style="line-height:13pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr style="height:11.5pt;">
<td style="background-color:#CFF0FC;width:78.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash acquired</p></td>
<td style="background-color:#CFF0FC;width:1.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;width:16.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,292</p></td>
<td colspan="2" style="background-color:#CFF0FC;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td style="width:78.6%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net liabilities assumed</p></td>
<td style="width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:16.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.19%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,177</p></td>
<td colspan="2" style="width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr style="height:11.45pt;">
<td style="background-color:#CFF0FC;width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPR&amp;D (2)</p></td>
<td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,088</p></td>
<td colspan="2" style="background-color:#CFF0FC;width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:11.15pt;">
<td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase price</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:2.04%;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="width:16.64%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,203</p></td>
<td colspan="2" style="width:1.92%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9.5pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="width:78.6%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="text-align:center;line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td colspan="2" style="width:17.14%; border-bottom:solid 1pt #000000;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
<td style="width:1.42%; border-bottom:solid 1pt transparent;" valign="bottom">
<p style="line-height:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:0.5pt;">&#160;</p></td>
</tr>
</table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Represents the research and development projects of GTx which were in-process, but not yet completed, and which the Company plans to advance, consisting primarily of GTx&#8217;s preclinical SARD technology. Current </span>accounting standards require that the fair value of IPR&amp;D projects acquired in an asset acquisition with no </p></td></tr></table></div>

<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top"/>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alternative future use be allocated a portion of the consideration transferred and charged to expense on the acquisition date. The acquired assets did not have outputs or employees</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of purchase price computation of merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954587656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ScheduleOfWarrantActivityTableTextBlock', window );">Summary Of Warrant Activity And Changes In Warrants Outstanding</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2018</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,620</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000405">3.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841,424</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.97</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000406">2.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,265,198</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.47</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,781</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.22</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Outstanding - December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">4.40</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Summary of Unvested Shares</a></td>
<td class="text">

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s unvested shares is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000423">8.3</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,509</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000424">8.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">965,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.61</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000425">8.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,662,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(173,753</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,135</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text">

<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.92%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,032</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,958</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; plans</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">938</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,196</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.16%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000455">6.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000456">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.16%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954232872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate and federal statutory tax rate is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,617</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(968</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,354</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">265</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,074</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Significant Components of Net Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,446</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized research and development costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,987</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,688</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,551</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,599</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(32,540</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use asset</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953910616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (82,797)<span></span>
</td>
<td class="num">$ (65,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,737<span></span>
</td>
<td class="nump">20,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrual balance in accrued liabilities and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,544<span></span>
</td>
<td class="nump">10,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
<td class="nump">$ 3,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Weighted-average shares subject to repurchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_MergerAgreementMember', window );">Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split of common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_MergerAgreementMember', window );">Merger Agreement | Combined organization's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_StockExchangeRatio', window );">Common stock and preferred stock exchange ratio</a></td>
<td class="nump">0.073386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OwnershipPercentageOfStockholdersUponClosingOfMerger', window );">Ownership percentage of stockholders upon closing of merger</a></td>
<td class="nump">77.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business basis of presentation and summary of significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OwnershipPercentageOfStockholdersUponClosingOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ownership percentage of stockholders upon closing of merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OwnershipPercentageOfStockholdersUponClosingOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_StockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_StockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=onct_OncternalTherapeuticsIncAndGTxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=onct_OncternalTherapeuticsIncAndGTxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961468600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">7,273<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,032<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember', window );">Common Stock Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243952212152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrual balance in accrued liabilities and other liabilities</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedUnvestedShareLiability', window );">Unvested share liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,042<span></span>
</td>
<td class="nump">$ 2,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedUnvestedShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedUnvestedShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954112408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 22, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember', window );">Shanghai Pharmaceutical (USA) Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember', window );">Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceCommissions', window );">Insurance commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">San Diego, California | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="nump">4,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onct_ChiefFinancialOfficerSonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243873670664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,373,000<span></span>
</td>
<td class="nump">7,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,375,000<span></span>
</td>
<td class="nump">2,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember', window );">MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Aggregate cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_ReagentsMember', window );">Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_UpfrontLicenseFeesPaid', window );">Upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels', window );">Worldwide sales milestones based on achievement of tiered revenue levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember', window );">University of California San Diego School of Medicine | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod', window );">Development milestones to be received under research subaward agreements throughout award project period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SubawardPaymentsReceived', window );">Subaward payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_RelatedQualifyingSubawardCosts', window );">Related qualifying subaward costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade', window );">Annual license maintenance fee to be paid and payment made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount', window );">Days after receipt of notice, to pay failure amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment', window );">Days after receipt of notice for default in payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement', window );">Minimum period in days of written notice to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Agreement | MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember', window );">Research Agreement | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementTerm', window );">Research agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmount', window );">Aggregate research agreement budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember', window );">Regents License Agreement | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember', window );">License Agreement | University of Tennessee Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AmountAgreedToBeProvidedInContingencyFunds', window );">Amount agreed to be provided in contingency funds</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Exclusive License Agreement | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdvanceLicensedAssets', window );">Advance licensed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdvanceLicensedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance licensed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdvanceLicensedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AmountAgreedToBeProvidedInContingencyFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount agreed to be provided in contingency funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AmountAgreedToBeProvidedInContingencyFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones to be received under research subaward agreements throughout award project period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee to be paid and payment made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LicenseMaintenanceFeeToBePaidAndPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period of written notice to terminate agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice for default in payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice in fails to pay amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysInWrittenNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days in written notice of termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysInWrittenNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RelatedQualifyingSubawardCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related qualifying subaward costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RelatedQualifyingSubawardCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Worldwide sales milestones based on achievement of tiered revenue levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SubawardPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subaward payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SubawardPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_UpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_UpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_ReagentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_ReagentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243957425192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Loan forgiveness (other income)</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Loan forgiveness (other income)</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=onct_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=onct_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961344040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>CVR</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development | $</a></td>
<td class="nump">$ 18,088<span></span>
</td>
<td class="nump">$ 18,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember', window );">CVR Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld', window );">Contingent value right per common stock | CVR</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights', window );">Percentage of net proceeds entitled to be received per CVR</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR', window );">Period from closing during which payment of percentage of net proceeds would be payable under the CVR</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement', window );">Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value right entitled per each share of common stock held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from closing during which percentage of net proceeds payment would be payable under the CVR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954250968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Summary of Purchase Price Paid in Merger (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AssetAcquisitionsLineItems', window );"><strong>Asset Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockSharesOutstandingPriorToStockSplit', window );">Number of shares of the combined organization owned by the Company&#8217;s pre-Merger stockholders | shares</a></td>
<td class="nump">3,458,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of consideration issued to effect the Merger</a></td>
<td class="nump">$ 29,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Transaction costs</a></td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AssetAcquisitionPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 31,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=onct_GTxIncMember', window );">GTx Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AssetAcquisitionsLineItems', window );"><strong>Asset Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Multiplied by the fair value per share of GTx common stock (1) | $ / shares</a></td>
<td class="nump">$ 8.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AssetAcquisitionPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AssetAcquisitionPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AssetAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AssetAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockSharesOutstandingPriorToStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares outstanding prior to stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockSharesOutstandingPriorToStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=onct_GTxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=onct_GTxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243957338232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger - Summary of Allocation of Purchase Price (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">$ 18,292<span></span>
</td>
<td class="nump">$ 18,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net liabilities assumed</a></td>
<td class="num">(5,177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">18,088<span></span>
</td>
<td class="nump">$ 18,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AssetAcquisitionPurchasePrice', window );">Purchase price</a></td>
<td class="nump">$ 31,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AssetAcquisitionPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AssetAcquisitionPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243954025288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Amended and Restated Articles of Incorporation (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961026184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Convertible Preferred Stock (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 07, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember', window );">Private Oncternal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock converted into common stock shares</a></td>
<td class="nump">8,148,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243873159000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">5,031,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,031,841<span></span>
</td>
<td class="nump">841,424<span></span>
</td>
<td class="nump">841,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsExpirationDate', window );">Common stock warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants excercisable and expiration date</a></td>
<td class="text">Dec.  09,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">1,149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="nump">19,161,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined purchase price of share and warrant per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CombinedPurchasePriceOfShareAndWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onct_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onct_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243962486856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">841,424<span></span>
</td>
<td class="nump">841,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfWarrantsIssued', window );">Number of Shares Underlying Warrants Issued</a></td>
<td class="nump">4,265,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfWarrants', window );">Number of Shares Underlying Warrants Exercised</a></td>
<td class="num">(74,781)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">5,031,841<span></span>
</td>
<td class="nump">841,424<span></span>
</td>
<td class="nump">841,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 37.97<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantIssuedPricePerShare', window );">Issued</a></td>
<td class="nump">3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantExercisedPricePerShare', window );">Exercised</a></td>
<td class="nump">3.22<span></span>
</td>
<td class="nump">6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
<td class="nump">$ 37.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant weighted-average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ClassOfWarrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issued price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961025336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Common Stock and Unvested Share Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions', window );">Unvested share liability</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for unvested cash settled share based payment transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951971864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary of Unvested Shares (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares unvested, beginning balance</a></td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares, vested shares</a></td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of shares unvested, ending balance</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243949109496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Equity Incentive Plans (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,196,000<span></span>
</td>
<td class="nump">3,294,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">1,678,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of shares of common stock a participant may receive</a></td>
<td class="nump">275,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance', window );">Percentage of annual increase in shares reserved for issuance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">937,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember', window );">2013 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options outstanding and fully vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price of options outstanding and fully vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan | Private Oncternal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember', window );">GTx Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber', window );">Number of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember', window );">2019 and 2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.53<span></span>
</td>
<td class="nump">$ 3.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Closing market price per common share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243873119272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Shares</a></td>
<td class="nump">2,107,625<span></span>
</td>
<td class="nump">1,662,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember', window );">Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Shares</a></td>
<td class="nump">2,107,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Number of Shares</a></td>
<td class="nump">2,107,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Number of Shares</a></td>
<td class="nump">965,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">2,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951616792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance | shares</a></td>
<td class="nump">1,662,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted | shares</a></td>
<td class="nump">624,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="num">(173,753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="num">(5,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance | shares</a></td>
<td class="nump">2,107,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">3.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="nump">2.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">0.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243953084424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.60%<span></span>
</td>
<td class="nump">77.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951702216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243961025336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation cost related to nonvested awards not yet recognized</a></td>
<td class="nump">$ 3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243986497528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsReservedForFutureIssuance', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,032,000<span></span>
</td>
<td class="nump">841,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance', window );">Common stock options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
<td class="nump">1,958,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">8,196,000<span></span>
</td>
<td class="nump">3,294,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember', window );">Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,000<span></span>
</td>
<td class="nump">495,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock options issued and outstanding for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243962508584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes</a></td>
<td class="num">$ (3,617)<span></span>
</td>
<td class="num">$ (7,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(1,113)<span></span>
</td>
<td class="num">(968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxReconciliationInProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit carryforwards</a></td>
<td class="num">(505)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">$ 5,074<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxReconciliationInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxReconciliationInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243957390680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,852<span></span>
</td>
<td class="nump">$ 18,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">1,952<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">11,987<span></span>
</td>
<td class="nump">7,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">32,551<span></span>
</td>
<td class="nump">27,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(32,540)<span></span>
</td>
<td class="num">(27,546)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243873135864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, fully offset by valuation allowance</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount', window );">Net deferred tax assets</a></td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 1,952,000<span></span>
</td>
<td class="nump">$ 1,446,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CumulativeChangeInOwnershipPercentage', window );">Cumulative changes in ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PeriodForCumulativeChangeInOwnership', window );">Period for cumulative change in ownership</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">69,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsNonExpirePortion', window );">Operating loss carryforwards non expire portion</a></td>
<td class="nump">$ 43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear', window );">Research and development credit carryforward expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative change in ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_OperatingLossCarryforwardsNonExpirePortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards non expire portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_OperatingLossCarryforwardsNonExpirePortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PeriodForCumulativeChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for cumulative change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PeriodForCumulativeChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance Deferred Tax Asset Change Net Amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140243951911160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Details) - shares<br></strong></div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">8,196,000<span></span>
</td>
<td class="nump">3,294,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=K1_A-/.9ND VB$7^&@(\W$"P.,30(.YTU[MZ_O.&%S;0L<8[)!SS<%>YTS
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MTWAYT(@L&C\S@0N#V]KM=JQ_U^OG2K4AV-6I8&4I%\*=Q?O:[?T^SZE:2+@
MMYCF<UF/-=Y1<UHW)V)E65,V13M@7;''019R"O3S /7S +51 TO42US@*B,
M"QDT>PM\^ 8@#R:FT3I$BMM(:N=Z7,U1&OEPN7@\+JAN%HXMKG4+& ?)V.C&
M\#0?^DG0FXWR]?M\_;/R?26'@F]Q3?CK<W)?'Z*&1VH2&"2>YYGE!+V<X%>5
M?QUH!0FB,$G, L)>0/@[ZG$5:O7PXPB9M42]ELBIY?J)U!GE1&U"[7(%;*=6
M#P>2I"##?&N:E9&F! :3^>8T&4F->ZGQ"Z4>5]14P%C7E)HU);VFY&Q->US7
M6.WGKLHENH1)X5P6(XUIKS%U:OQ*N*#5@^Q-#AN98/)RU]395G8)H*#XGA82
M)R:UJ3[CO(E<I\E(+_0&3GI.Q1\X;]H5(JN:'6!P&' I735XI#[<=T!49G]]
M?@+-3AI^)/4#J8W@\S2I*/6"=+*5=F;':QY-<K9$BBUY'_4'\#?G?6H%= )&
MPQ6$EOT,#D"#;J(=\-]VP*UT:S,@NQ.9RRBW4Z.&-,7C+;A+3$=7,ATU<R3;
M;!WH!MUX>W'RY3E#MX8Z#N>*AQ;Y PVA&X>_;^S64,?GW,%/.  4N@GZBS2?
M7"TZ<1T5'Y +W<S]1+("<TYE/XG%&3ET8'%OU=  W#30=JX35N.,!C)#-YK;
M5GVN3IVY*K8\BO,V,Z-0G<*A%T]UNHW&,@=80S>M_R&RB(R;CT4Z=^=^ *<;
MS<UIN[&X@=+0C6E+6YH:Q:9Z-Q_X$$TW18/9]%P =8#':1*ET[1ULWD4AK%E
MZJ"!]<C-^C.:86,)D,Y@&/I)?'P\Z,Y&%DN+\H'6R$WK_]<Z=T%'1XJI8-U$
M.\WI'+=TU^CH5.J&^(O[ZTND$S:$?F@1-@ 6G0"L?'1!. ?$T&V;]FVDH]*/
M+"H&3B(W)U_01B.=@]"?CFB@SU+?HGG@)')STM90O@&5W KEA_39(&-<&*7K
M"(10+IYH.F=#+45_>B2TQ++A!PU 16Z@_ER:IZB/=$;ZOA_;UM< 2>2&Y+%*
MM:N!>U8U'& YDW,.]E1L1\M.O<@K*&FDN74OT2D9:!O\":-Q,@-*D1NE/T-\
M9#C2AF$TU7G":BQTP"IR8]7%?&2 &HP1FI3PYK3=^+W8 #__//B-@8<\DUA?
M/Y="B-)P^BK08#<]XUZ;8J5AE$ZI;[";)RA.+>ST!W;Z;G:>IKZE" ;N)8DT
MUJAOLYPH7QR]SE<_[WS$]0.5R"O(1OIY;V,9H#[\8G*X$6S7ON&_9T*PLKW<
M$BR/X\I ?K]A3#S?J!\-^M^M5O\!4$L#!!0    ( #"+:U+1J_N35 (  -\$
M   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?53;;MLP#/T5P2BP%BCJ
M2])U*!P#3=-A>R@:-.OV,.Q!L>E8J"ZI1,?MWX^2'2\%EKY8I$0>'AZ)SCMC
MGUT#@.Q52>UF48.XO8YC5S:@N+LP6]!T4ANK.))K-[';6N!52%(RSI+D<ZRX
MT%&1A[VE+7+3HA0:EI:Y5BENW^8@33>+TFB_\2@V#?J-N,BW? ,KP*?MTI(7
MCRB54*"=,)I9J&?137H]G_KX$/!30.<.;.8[61OS[)WOU2Q*/"&04*)'X+3L
MX!:D]$!$XV7 C,:2/O'0WJ-_#;U3+VONX-;(7Z+"9A9]B5@%-6\E/IKN&PS]
M7'J\TD@7OJP;8I.(E:U#HX9D8J"$[E?^.NAPD)"E1Q*R(2$+O/M"@>6"(R]R
M:SIF?32A>2.T&K*)G-#^4E9HZ510'A:W1E<D,52,+&>DJ#B2LT):2'MTS-3^
M: <6Q5H"6Y)J8&V(,>4SXWJP&B,KL.X3NWMI!;ZQTP74HA1XQDZ7W!)4 RA*
M+L_8"1.:_6A,ZRC9Y3%2'YY-7 Z<YSWG[ CG-&/WAO <NR/RU7N F 085<CV
M*LRS#Q$74%ZP27K.LB1+GE8+=GIR]@'L9!1W$F G1V!'%=E#_4ZDO4:_;]8.
M+;W,/Q]4FX[5IJ':].A5*D7OW(W74AYN=-Q:3O=YSH1S+=<ET+G#_ZG?E[D*
M9?Q0[XHT39-)'N\.V<4'CTZ!W831<@3::NS?W[@[3N]-_VC_A?>C?\_M1FC'
M)-24FEQ<74;,]N/4.VBVX0FO#=) !+.A/Q!8'T#GM3&X=WR!\9]6_ 502P,$
M%     @ ,(MK4OR;JW8W&@  ;DT  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6S-7$MSVTB2ONM75'AG-^P(DA8EO]K]B)!E>\:S[;9"LJ</&WLH D6R
M6B# 1@&2Y5^_7V;6"R0HN7<O>[%% JC*S,K\\@G^=-NTUVYM3*>^;JK:_?QH
MW77;UT^?NF)M-MK-FJVI<679M!O=X6.[>NJVK=$E/[2IGIX<'[]XNM&V?O3+
M3_S=1?O+3TW?5;8V%ZUR_6:CV[LWIFIN?WXT?Q2^N+2K=4=?//WEIZU>F2O3
M?=E>M/CT-*Y2VHVIG6UJU9KESX_.YJ_?/*/[^89_67/KLK\5<;)HFFOZ\*'\
M^=$Q$60J4W2T@L9_-^;<5!4M!#+^]&L^BEO2@_G?8?7WS#MX66AGSIOJ=UMV
MZY\?O7JD2K/4?=5=-K?_,)Z?Y[1>T52._U6W_M[C1ZKH7==L_,.@8&-K^5]_
M]7+XG@=._ ,G3+=LQ%2^U9W^Y:>VN54MW8W5Z ]FE9\&<;:F0[GJ6ERU>*[[
MY:UQ16NW+*%FJ=[T#C<X-U%OM+..OKIHC3-UIT6(=:FNY/SHVI5=U79I"UUW
MZJPHFK[N;+U2%TUE"VO<3T\[D$@;/2T\.6^$G),#Y,Q/U,>F[M9.O:M+4PX7
M> K>(H,G@<$W)_>N^-84,W4ZGZB3XY/C>]8[C0([Y?5.#ZSWJ5WIVGX3<9PW
MM0.OI7PZ@W &TOJT5.]MK>O"ZDI=X4L#=>Z<^J^SA>M:*.1_WT/0LTC0,R;H
MV?^7$[R?G/GL:)>B0 >1XM=5!ZA6G^JB,VT->7U>FU9O3=_9 LQ\J'&,C[NU
M4?_Q;Z].3HY_/&\V6UW?3?CC_,?P=7P^7FA:E3U6-)L%=BI5(<_[NYY,% &<
M::L[=5TWMY"34W___%4VGJA;?+1UT;3;IL4QEOB@/IN:2#:&/ER9+4YW85HU
M_^&'ERSEUNP^\=94^E:W_ !0\Y1O@VP(5OB&*XV;K%DU$W6N*PN2:JMG) KE
M^:7;M2H@=9Q9-74=D%,M;+-=:V!4P>*"\#QW8 H8@K4A91)":6X PUO20I)Z
MW> CK@%$FM4=W0&)T^DLO= ZX'P7[H:.%*9U *ANK7!XLE-?;^ Z-J;D3[4Q
MY8!>DN_\Y8\NDJRV=FM(:4B>55]BM\*VFZ[_UF_T8@+FUO@#%@:J-TW=%%5#
MV@#]M(NF)")U!X;KTJFN49>?+N?J\:4I(/ZFG79W;4.*I*YA=LY,*WMMU*<6
MPJE5N$G-<=@D^,__>3)_01NZC:XJ; 9/T5=$U]HN+)L!R0#"A728='8AMF/#
M>??Y:KK4&PN%@2G729N7N N[D%2W;=-!"=S^"5:N"8=!^VAU?G8Y_:P>%VMX
MO-86S._*D-_S5'^>%G!=[HG"HF5?='0<)2&/$9%TNET98 M)9*8^&GQJ84WJ
MGSW$\9+@;_[#A!D*ED,?8'Q;'#HSFVN\>NSM!=\D$R&MJ@PK,W8Z6[6& 8VE
M>5%IMF2_,WUU:9H,+">T@<;]P/6!)?LGXG)I/]:T;6MOP&5U-UV;JGP (/R2
M%_),NCFLR73]O;7?ON'<_,97_2*8N5:WZZ;"5D  4.GZA;.E]5"9R2YNE)9(
M5)=L[A]U6ZS5"Q'\3'T!VV)3N^Q.,CI@1_BS%,89'&HH^1XW7C)[WX/@]@8:
M*H?Y_<SL'49@9D8:H0J8S\H?>HT3),.[[QC$O,:H7EO(I#44++J_0N+D 1H^
M>0CS:A#4?GZ<Z_T8] LT-1L@C4*L55RKA8'*DDF7)$9\3:;[FW:E_A.8O+4=
MML/97@/T^GBFX/T:?[J[S0(17'!%OYU_G@4O].XKV3'QW!#,WEI'0$.@"669
M4'AK6@-\=0I7@1G$WT&7YB_D @J72/+WN+MX'V_XT$$2^UIM&]=-O8XNR)=/
MXBYX<J,>L#G9BM&:X31X>ISP7S#M"=W<,,4>A7SDD$QJ!L")4L1]I+J1S81L
MW['.1=^ZGB(B3S.QZ88WY?9K-+0:"0^<<<U:X];DY#GRVK70@:[ES]@-^5"6
M1B*1U;8BE[;:V9X"DJ*I;TPKL05NUENXAJ]V(VL<SXY?GIZ^>B'$,/7!W@<T
MY,8/)64S4Y>$V G1]+(C*>IK)I3WDE"1*;J$'VNASE>\WM6VLAUC/7(C5KT%
M97XS]>$O,8@5X),3[?N2W/+9M@0;O+%XLTRBM] %9;Y&Y""ZTX+#@QC9 !1#
M^\O2>N<%<O+5&_;V#AN8MK!.+Q Y4-CTX+IL/(@"$31T8X_SF5KZO,OAZ&H+
M4Q <!G+N79S$Z^CNNN=0%0L>%DCN(3;(<2T.EDZ3XT0U5)7AZ2X!Z<UMB)_"
M>?+"0/N2P&"4%7$"0S5^^7+V_-\#.;G\Q\C=13N)NS@\TU($(+/QNHO;2";L
MA5JOPAKA/$"Z^+.WCL^=@G*ZORTI^!6WB[ ,Z 2O15<H["_#DD075!OY'H"%
M$@:FZDMMZ1[._YCS,P[Q=(JQSLXNDL<-D0+"1$36ZZ:D1](&DQ'!W;*U 8U*
MLJF%X6TSFIBA%JL2P\N8D;8&N8D0W2--<88#54MK$>+AOB@S<(6,D8)=R55\
M/D&QKN/X<S( L#$->*T>VR?[Q$<O/-0/406."#J*A4'N1O_1M#[ZIF5O&J:]
MI;I+%/:>P\.N8]N"1X?4ET,UO;?TAE.Y"/G(7)B"1:-;/HX2TJ0HWQW2/'&1
MV/I^EDU-.(AT!UD<1]+$OV.LN39WY'FMF+7G;O^!@YI_)GKM8+F,QN%&#[:<
M..P@+OU=D_Z3%;A=#& X!=NP!9(98[]M<V.9\J(MDERJM$$Y</E&5[W)3B?4
M2\CZHB*Z5!K9V30$&J*JI'@Q71'>W-"7A.RC)1N 1A] ]A&7Q5L-46T_?0(;
M8*'V%45" SGHH3_+XXK)0,(4DICE$L^SVC6UF<(DIP[DU!&$!-(<$P7R+5O8
MCF\[Z,)'.$O00FBXU?Y0HFQU#U&UG' G;^ 929OP\=<-Y%3^T3NF/VE8>&)D
M=V@B><[!L48#L,[UM!(H.<C=6D.7%H8%U+6-E'$)? ,=$#L<)95Y!37'#I>1
M'G1 >VQ3DM)P28R*%43> 3KN#]\FNPYZ,NZ%!\HAIT_FL6^!?Y'572=\'Y,7
MR2MQ()B7+3]_EV'Z:DWN6D:ME=1U/*FS!K'\P9R-GLU21?Z.CP8,M*&<%3=F
MW4U^W66B,Y5EUR45-2(/<H#6ZSS2?Y#?F?K5 MA*<@I<,VA((2"X @2J]VVS
M(8F8K02'N1#6[(SAG#SOWGW1,8HAD(2@!L S3E/*M@<<6U<T4%O9+"_3T6=0
M2R4?"2],K*2YKB^I6L>WA"^[%IOM5)S6;*HDER&$PEK@Q!+*.EWYY:ARB3AQ
M"R[$^1XPX)C-T4,;28L)?/L:01Q ;::N>@1)SBW[2@Y,PBI*(;I.@V;FJ5DB
MKZ8HU=/&+H_$N*5R$:30;[F#L[9&JANJ,ERZ7#)JUN1B=&G^[+D<AC"_WY*_
M&"6Y0#H+T;40:-\:=I18YJTII'P;6@6[AUJJO\WG+V8OU<96E8\,"^VD3,-_
M8'O 127:DXL?"1#H)B_8\5&X?KFD*GC=R8,@>-E[TX$L_A#WD'LZ#M_$#MG(
M._"OP49W:RKH_49:)DO22B[S>F@A6..X]8MXPG>NX[C:C5=H'\2 +!*FF'5V
M2"N^8Z5:@F9^CGB$9_&JA^BCWW@<Y<JFQ4T>\/0FXDYE]<("VAE5DA)@ ?,5
M6N/\!Q8'C MA3R\Y.8@CJ0;;RM:9#;HAQ 3L0WBD4()C3O:<!]CV3D#<5ECW
M3H5R":WA"15&=RS]K,(]_6I-:]-YU:.;4'>B,N6*J:#5HC1%9%R40JH>D+KK
MJ4A?=2&ADL5W!#U3YT&5^8]W294'FLPRX0"=L&R-R!LK5@R4L >H>"?'RWD2
M-NQ;%JP(K#514Z'#%:'&+<4U2#[@QEQ,7O:-Z?R0G46OQ!<L^4U=4I:B;[2M
M&%&*M2FN)0G*? ?H0'P= ,M?F0F^UUWR%>=P[K#:2^NNLU:>K0D_A%56T8B3
MV!J8_T=PT$%N!$E#U4K;2/(M^[2T3U"\E'-Q\^6[H(8JJQU75X&=E#UPZ+TT
MI<]8<:5O!T9)O-BNCVF&^5KXZMS^4^Q!1GP+A85D=7#Q8(PT&UK1.">!O^N+
M]5#Z.2#:^'CC52"7% N$P!9/,N<+76DN\)6]"3%58B8D3,%"O1#(QV5\$E%2
MBA:CC*(BST652#@%7_<A]H>> #H.O;)N#6)7T'ON93DHW@JY(>O9EEW?T"#$
M/>;VD%T-A7':7M)2$40X3/CEI?%Q2!6B$L1TFI0.A#EL(/]R[B4/+P$^1 UE
M)U3.9$<K3X#"B@K/$JH.LCH7JAN"$"4B*>M846], -8<9/D1&&$O43"%1+P:
M0ID ?U1D(@W@)T!Y3QF&): J"*AL3>F8,]PNH97?9I#X+H?RLZ)H 69N>'N.
MH!'Y,^PN6#"1Q% &VX55;OG6<MUMR7^U/B% E HD:;P,VD-[^]X@NY&#! HQ
MNC7C\O.1%R,:<OR>RBM0&0F1V"SW%IOLW.B_]!LYUQ26-<*WTKXK>"1_NNJA
M22$V#-U=O:2<WF6\3A1B+CYF\B8MAP;Y5424'/A[LZ\- CTW\4QRJ9R<Y52*
M2A0.0"B^6[@T>&RK;2EF;MMRBBB^$R<$AZ;9<J#(K)-\-^=O4+TUO, ^2E$J
MU(9"\ W(:GIW^#PI3&BYO,6BB_?E>#E)DHO7\Y9G?L/PF 9W"=W4%O+E&U:B
M"WV7(C[OM:-D68<&I;A!CX(Z2S>V)->O0Y\BPLQ&WR$D6E)C)$:,0 ;*O/8-
MQM<W BT;1-E<$RUO^*RIB6-:G@WCHV<PX00UI5^#.&\0&GHP5SR^Q U!3M5L
MF4DD%*.HT@3[-SL16W[( F-.;B2@(,D9'_.68TC0U*O&UY(>MNK?*5@Q% 'J
M.!P@24<1"X<C- [=AX9+N?MF.-#'R;AX9,ZT-]#E@7'PR5!HI*2QD+6K)/*C
MFV\:>HP'!>Q-Q"Q1WL#U,++]HR]7R2V9F!208BQ,/.-0!8Z4^+/)CB)Z8RD'
MPL2D6LV'$8O+7(Z 3Y58--3M$ ]4Y9XB[N)RI.[[$K7]<1.&M* 24>.PT-_F
ML^.4S,50LO0E_]UCS%3RD +&S8,;)O)V*4G926L&>Q[4P>!VF>:3V?- -%5U
M0OU):EV_2\E)_1ISCXO]XNA8 X'2V[SPM01FI#Y:*&1AF1"K9Y5""IRN#(/\
MF^G)O0VLO%"9/1(V2(7*D:99+(%1]08/,)K$=(PCC)$E/>LVQX%4ER:UY>9M
M4E8"IDF8O[B+)XF#0FI!QP9QEB9\L*$-$E?,0RGMIQ8X!$^W@%Q/7I8DCA7(
MAV7Q5!J9J2_;)K8[1GO88A1C N$Z;AC#8;')^-#:^!+_3E=Y]/3'D_Y4&I7V
M@VPR&>$VZTUQ_(]LH:8"J*]TE#%U'XJ-OME?C'R[+YH6%=P%8"ZV>[.>DB>4
M<R<*G]_3TO_BI3_B-/M08/D\[)U1C,^0(>ULEY$TR9(!/FV).LEFERVXIWED
M=C,;7I\-*],]B:(U3;)E%0KV69K=]!]-&SJ26:$" 1#48D6QF:PKW9A<4G!3
M5IPGR03N3D(."+J>IB]XEL/+01ZTJ6E/ZDO)H.4\M# 4$_IZ<O1]&S\"@-UO
M&<P7)KDADKZI*(_P/&#_&,U1(7#)] TL@";(8#QMF*GS3=N%Z6[I?'VZ3E&@
M+>Q6<_9[YEB+)[D >$92[O:AY2:=L!#LUH'BX.;8G?F :J\&-;*UY[GG01X6
MDN1;B=W(F^_&L<!#EY_K*!P!<WJ<-ISL=F^C!@ZUC0LJ4SBA-F=]C<_D1>Y"
MM,?=!_@JBCDD--P"Z%7O)T['5=/Y#JY[K7[E0NO\M?JTH!"%:RI^#4\Y4@ N
M=K.>.'&?G"N)T*B4SFN<O%8?^,&)]Z,=C64230\L($? (S6)!J_ATHFE&DG+
M4:]\"EN>OE9?ZF:/\"S_)\3#H>"4NLJ(C83#!@CK-+/&P)3U(DED9 P=5W>\
MOV9G*-/#66WM<^ZRLA+F*(I2<$H $FL:/@#>J56R.((:Q=)9M%%)5F4/2[CJ
MMK[ME'=E:7:D=Q%:81-M-^69KIIJ%2;5/K.*UUCY9Y_<9A FW8-4.41Y1/HM
M(82+QL\%?]_G:0H?PY>BNAR=[C>]+GVQ]1(^>57;V.R*U4R1-91'BAX=A]'R
M3 I(XQPVM%=2/P'I2^.?(JE^I R9!H^WV>B83C&=ZQ<T^5VF=$P]ILGQWZ#X
MZMF39*P-TC9OJ;'QSJE[R, X4L3AU (D4D+YG@2&,V/Q4IP;]%S:"W@?@O3+
MG'\V\$BZY22#)/DMZZWQ<^$@HE7%P(G+ TO6_)#A^"RQ%L65="6415+:Z451
MQO DE*VXJ-O4I<WJW:*^^S).7<&-Z41Q1^ZBMQ-($1< V*ETYCQ6LS0;(R7*
M@ &.6S>43/F.E!^")E#.D^$&6+WBB$TZF5RBB/XQT9T(T=QB)Q]-_2#BU(/'
M:#5G_]F#1:64DTM8"LUJ:C\^\F#>\6 :?SA.?=]3=!-YCD8U<@B[=<C8*1D:
M@W4^%^5^-I5\DTN.E%*$Z.=C L3Y9DBPA3&M:7DXHCN$S+EH.'G7&\<S@@DA
M)1>^9:>2$[VTK>N"&%R$;1TGS+)J"JL]B9A)K :6,RPEQ&#7>^+ALC* *=E7
MD"4%%)5ZS&'ED\%: ^ 9V?DO,?K08FDBPG9>.[:^5IMQ,&0VUG;4BL-_$::8
MR%FW7Q5@;=Y[YX$3W2B6L)((1TH"+R25GK[A4/ \JTCZ"_NERF@HT?NZD=Q%
MT@[%ND81D*BJD"!)YT%P[5UP<F\J#1+458&<AA!=WC@)L>>F*4VU7Q+C-5VD
MDAO(3(4?9VPUF1QU(_B0BK4I^RKX"\%R&?&*1:I 6"AZR6J/>R<^A1NE?CFY
M\XD +'42:%IORN__A/R#$IY<.$RA>)*PBG6IK=;D(!O">PN".T":-Y$(72YA
M2L;.Q@\>[+#CQYQ)\ W21^E."G DF \3@F%'V@,*OTAH/2)[D+LTOO41IG0\
ML]I;;WX+QS=D<CR$\5E_'7;L4S-MR5$OW]7Q79E7&4D<99YT)Z9U7B@I1J(!
MQV C6/90!!I:*21L]BW+GH-&>H0L&<O++'YJ5+,O3TXY+W\-&WGY(,[>0.SD
MN\B3;EK,[;S!+<++B#(8L(PO#(0X\Q =4I+ =G&% _N*M9I:RJ_TA$26U%OE
MX:\HN#OXW4$N,B H./0B#G[Q6)OHF%^)J,B*3&FSIOXN&>V%=%Z9AO@C4QCA
M;3VI\X([-@>"KH-J3\.D8V2$6;BO7<S'<Y".[6'?]?"TMS0^@'_HI3Y&&62/
M%)>%U >!YC<*^S]0I> ZI=;#<>9)/CT[G&=(0P/21[Z1(DUM5K[_25ZMIEI(
M*M%[G9?#H9X#*?M7*[ %EGDYJ!"]!=K>Y0<\R69]DN7X-)5.84*?I]M*UP)6
MU(8U*^XH2$PG=70.X0J&IBSR^K#,^8QVX/:E'4LW0FH3),G.>>ST@K$*S8.1
M <DVZ=A3*,?Y[D#JLN.&9E2H7,*57:G,-+YKO[NI\ET7\B)4E]!\"F(WLAIN
M[POC8T.$'_RC ;OP.%-7ACL?2'-"#O\ICEDY$[HBQ%8I,;X$HS%@%L.OI9<(
MOTOJN6CZSM/B9-!01HZ0IIG!H(7\A()O-R1EXXI?8M"_8$$N9YD-@96F8*:F
M)#>&#:_DX4(^@P#=:/J6&G*05I%>_"9A.N?]<O"A0_.]H=\]D#I&FL63\04Z
M0+D4Q_Y !OG 9E>(H^\^(+/'4?[:X+D+>M^1WY*BM\,+5AF:&"&Z_.M35L3>
M=_+2"3<T0QP4;_?"NN4?7S#E5-/@P2I_P264I7V_(F]R>!@6E).B/QWE,(ZF
MN_+QGM)6/:.!H[)%:@W%!D58]G]%4ZQT9>$.PDI?=Q_I:7_U'G1O-[_XZ#I$
MP\GSR?'Q<;B-.'C^(O\FYFK_)]F2BZ/..Y$88W1$YS^HBP=D2LB^&Q\4NBIH
M+B$$*?28*4>49Y+RO@8)O')-!G/8=1IVG+"P4[U3/>81_VS\/(U:>3Y_%&J:
MWE'I_LGKHSSW.*+<XXCRCJ/?QQHG^=)'.('3DZ-7S^9'YX.7F:1N>'0R.3EY
M<32?_/#\U?"&T3,]FC\_.GU^]')R\O(4C[XZ?79TR6X!\OT@X^WY[SNT3=W0
M!(X@'ESF6;^"_F8=U?=G5V_"8/S9U1>^,CU^,<$Y+OB=@OG)C_2G9!'GW#5R
M 6@^<7'VDR^A/[[J%UVSA9T_>WD\/3E^X@=]N,O'*3%]_H<I5Z#-+WT>YR\@
M[G=<:(VI^*?;FD<4$=*FI5_-GT^?'3]YG;-):GB>-20_9(-[/.R8;Z+OV2<X
M&V<WVTIR[ITJ?5Z-6XY."LKO)D"'*#)L*40H=B=9I2GD=TQ!1MY3M3LLI#D5
M%KVO20_FFD+'ZPK!),\ \%!;=J8Y6SLL<<L@C!%+BCY*RH("OTW#T]G2N7)I
MZ)X34Y>Z>Y*EA%*WC!(/7K:D78D^7I(J)EZP" 6Z*H9NH00803-NL$PY99(/
MS,57(R-G951!Y+UP8AS*;*.[W#GM@#? -(K(<F?U^-W%U9,!/A&.>*HU=8MG
M X'?VHI>W<Q>!Y%7\QP-"@AH+A#K2>0G>6F$F?ES+G&<YAK";TG83:R"DZ[9
M4+')EYVI=[KE5TI\\< R&QO;\7OH:5-6XXP<T7^^?H"@8W%/C!L\YB[J%DJX
M43=#[XU)D"I(Z'"E]]02(7[$ %$P#7!D-.W]JD:JY^],Z?@)<K\TCR&26(,(
M^'OJ0YM;Q1Z,W_+S0Z</OR@28?:,%GP(9S,O&(I3^T@[_V$Z/YD,"@"OU95H
MXUW@:@?GLIL'>#Y_-;[+>/_[M7J;>M'O8Q>;\63^HSKG7#-F<-F]E[LO*8RO
M[[N;0?14CZN;>$#?^9;@V*\F/<U^ XM_18-^Z8NGC.I.?@XK?AM_3.Q,?D,K
MW2Z_1/91MRL:H:[,$H\>SUX^?R1OF88/<#C\BUJ+INN:#?])(X>FI1MP?=D@
MN/$?:(/X$VN__ ]02P,$%     @ ,(MK4N0.<-B1 @  6@4  !@   !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6RE5,%NVS ,O>LK!&.'#0AB6W::M$@").F&
M#5BQH$6WP["#;-.Q4%G*)*5I_GZ4G'@9T.:RBR12Y.,C)7*ZU^;)-@".OK12
MV5G4.+>]B6-;-M!R.]1;4'A3:]-RAZ+9Q'9K@%?!J94Q2Y*KN.5"1?-IT*W-
M?*IW3@H%:T/MKFVY.2Q!ZOTL2J.3XEYL&N<5\7RZY1MX />X71N4XAZE$BTH
M*[2B!NI9M$AOEKFW#P;?!>SMV9GZ3 JMG[SPI9I%B2<$$DKG$3ANS[ "*3T0
MTOA]Q(SZD-[Q_'Q"_Q1RQUP*;F&EY0]1N68632):0<UWTMWK_6<XYC/R>*66
M-JQTW]EF643+G76Z/3HC@U:H;N<OQSJ<.4R2-QS8T8$%WEV@P/*6.SZ?&KVG
MQELCFC^$5(,WDA/*/\J#,W@KT,_-EUQR50)]"#_@%AP7TDYCA]#>("Z/,,L.
MAKT!DS)ZIY5K+/VH*JC^!8B14T^,G8@MV47$6RB'-$L'E"4LN8"7]8EF 2][
M V_-#[R08.E"5711EF;'I:4_%X5U!K_&KPLA\CY$'D+D_UO+RS!L2%Y%ZEA#
M1:7@A9#""<RFU-@?UE%=4]< K;7$-A-J0]\+A1J]LUQ5]L,-P7I"6X#Q-26^
MIKBDU^0>+'!3-A3-\#<_8Y=NL><<>4?RE.$ZFC"R0HJBY)(Z([!JY'J2D"N6
MDZ^P064-8,EX3'+4/*IGL XYVH8;Z)D>2(KQ<K+2+4X3RWU#DG0P8A,R82/R
M#:D;DHT(&_F0V2#)_<X&XRQ][5WBL__>@MF$KO:UV"G7??U>VP^.1=<O?\V[
MJ7/'S48H2R74Z)H,QZ.(FJZ3.\'I;>B>0COLQ7!L</B!\09X7VOM3H(/T(_3
M^1]02P,$%     @ ,(MK4I22NS1P!@  & \  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&ULO5?;<MLV$'WO5V!4MQ//*-3%\J6)[1G;BNNT<>*QD_2A
MTP>(7$H8DP +@)*5K^]9@*(EWSKI0U]L 5SLY>SN6>!P8>RMFQ%Y<5<6VAUU
M9MY7;WH]E\ZHE"XQ%6E\R8TMI<?23GNNLB2S<*@L>L-^?Z]72J4[QX=A[\H>
M'YK:%TK3E16N+DMIEZ=4F,519]!9;5RKZ<SS1N_XL))3NB'_I;JR6/5:+9DJ
M23MEM+"4'W5.!F].1RP?!+XJ6KBUWX(CF1ASRXOWV5&GSPY10:EG#1+_YG1&
M1<&*X,;?C<Y.:Y(/KO]>:3\/L2.6B71T9HH_5.9G1YV#CL@HEW7AK\WB@IIX
M=EE?:@H7_HI%E-V%<%H[;\KF,#PHE8[_Y5V#P]J!@_XS!X;-@6'P.QH*7HZE
ME\>'UBR$96EHXQ\AU' :SBG-2;GQ%E\5SOGC,U.6R@-E[[KBS&BO])1TJL@)
MJ3-Q387TE(DK:?U2?+92.QG@=(<]#_.LI)<VIDZCJ>$SI@9#<0D#,R?>Z8RR
M304]^-TZ/UPY?SI\4>.8TD3L#+IBV!_V7]"WTX*Q$_3M_#L8X@31;^(Q5BXM
MC*LMB3]/)LY;(/'7"U9'K=51L#KZ/U+PLJF=Y(?_;$U\(%0_!+07= =2P&(A
MG=CJ)T-49E&$)H,*; S:#="&\#,22Y+6">+$"Z2-R@G9-G7AV+ _^*6+/G<5
MA4XMEHGXI,6E7(KAL-M\9E6(H))Z"66>+-0I[0TT")/G*B70RZ0(GLJI)>)
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M- W ^]*8+GXA </OUE[^&U!+ P04    "  PBVM2E_H"6"8#  "N!@  &0
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MX5A=6P-O)D]]D]Y;M6R\7&HH-/S9]5KAQ+?)8IJ@C[1F2N 00[VQ>0 ,AU]
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M6<ZQL6@36@<"Z@?21<Q*:DHQTU^A.J*:VKG'2D'18@>.2)K78=(UY,XVII7
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M?&OP-B1>Z=O@LUAY/=7="NE'FR]B^%:AN$3%F*D@8S^*"I@XV22B"%D+SR3
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MZ2:A_P6A@)2:0K&->&%#2)!QO9C<9+(V@BQ#8VBH5^BR&@K-5' GG6R>\/H
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M%\#O<P-9E_N !X2W3[[_?U!+ P04    "  PBVM23\@QLBT#  "2!@  &0
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M9T<JV9*Z2@XBWE V8.-1GR5Q$A_ &^^2' >\\>$D_[Y,K3/0P3\',"<[S$G
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M.3VA-=1XZ!U<];\X+[L]_'4I8+4FR$&H$^QF9*'IM'%,:<<V( I]U)(<Y?V
MUGKL"9/5$N?LM<#S)ZXRZK=BL<[?+G#UMTMNNHC[,LY08I%QR>XO[VZ8HZQ4
M6NK59L"N&V- -^+2D5'<]Q56-*X!S08%2'<G 1%R5FNS?R2OI>J\"@L"7A[X
MHX20::O=9W1>P.GV>H=SLB)XY8 >L(?M:G"VEE"X'.^!+TW)P0E-N&Y\-0TC
M5$EO"*<Y>$O%P[T.4OF+XOND!5<\$&TSV:WN6O%EVX%>S-L^?HL$!"HNJ8!K
M/#B%;DW;&]N)TW7H1ZEVZ&YA6.)S@HPWP'ZAM=M.?(#=!\KB)U!+ P04
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MM2X0>=#EPZ#KCT>TZ@["!GQ+>3CHAB/?ZN^[G/\W_7BHH.OA-UJ! &.7!\[
M';2EYZ!)S\%!Z8F!?<A6H"GD983W95X[UD[FF25@*--<9,_VK.$'S8I:@RYS
M"!--:#:7"::89D>8CV8I"XUNT,<O4Z[QE3![ M0/G._;X,X1>NVX10:7_:#%
M@T'CP>!0#]HRQ[[F]B;8BFB75:81^VZ><KPK<&"DG:XF;:90&=SG]W8+7CBJ
M81?;3\0]&U[GGXW+,PBECYW)8J%@(0Q@N3(JQEMSQKZ+I #GA7-/G=(/.Z7%
MX5W?"Y&E :;QP/60M&X?/WDW\,:-P&KC+-AR%DT?!@ ;;SICHB8?6]X-?=Q.
M#/*[ 6^+_;")_?!_Q;ZN\/MBV8[X)H>TU2/S3;=!9;V@:FSW$QG8+2:]]1^.
M@G*TP[5M<E5.>SMI6NF'I7?(NSSHV[CXH?.)K@2L?$-.Y=%69;<?.E<$D22V
M'H?];H@"5!.Y&X3;Y1)CAH2F%<\-PW86_YH2+7$-F[B&!\>5*'5RB2U99&.!
MK:*POB<>9WHO7=\ IPB>3"WB;!L12D1L0V=RD<7_X#HVQ$PD"8.R91)X7T>:
M+3&24P!J6'.IB!ZV= (F!W(3NUFZT.>8)!C'DA$M9?9OHG;9/NTXURF=2\&]
MPV9 J-G2IE0$*VP)<M*"#@\&="=RC.PGR%!=8O>(")O(6!M2OP),#L_G#@^]
MDGK!D 2]L"50HR90HU9?8D12]%Q)/C)3K2JO?2Q,H;!.X15-J;,O3 =!EWQ3
MV]#S$CJNH-^XQE[QZ0Y\W8;9:YY3L[&[+JO"%MN&P[IXMZIR/D3/CH/1KIQ8
MB3BA,FCM;@PNJT654SE22SOC_L@9C -GU*4VJ=_EXT%+>,9->,9OIWI=%&U%
MT"VHOK=Y3GCMN/ALC H\%F;Y!$^55OYYT.55<0T&;RX48A]%K,HK:N_CHEW-
M-Z34NBZ+HJJ*8DM?H3?<NTP$TAHMD_B4J0MTCI63+M541I"095%C&<G,R;H5
M64<GV2GMB[(O7X."G<)]"%UC_7@R5X"9B25848^!1 0JI<X[QW>'^+?I0E8R
M09(FF G.N%P*P]T=YI<F8(@P0]?;;(CP#HH <_(YAB1J6MMWFZ]]0>]M/2=3
M4 O[:-98$8O,E"_+9K9YF$_*Y^AF>_FJ_R+4 IL1EL <1?&8V"^I\J%<#HS,
M[>-T*@T^=>WG$@22@#;@^EQ*4P](0?/OBHM_ 5!+ P04    "  PBVM2F(<Q
M20L$  !Q"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R55DUOXS80
MO?-7$.ZB<  U^K;DK&W 27;1''8;Q.D61=$#+8UL8B72):DXZ:_OD+)5)[6]
MVXM$D3-OWLP\DIILI?JJUP"&/C>UT-/!VIC-E>_K8@T-TY=R P)7*JD:9O!3
MK7R]4<!*Y]34?A0$([]A7 QF$S=WKV83V9J:"[A75+=-P]3+-=1R.QV$@_W$
M U^MC9WP9Y,-6\$"S*^;>X5??H]2\@:$YE)0!=5T, ^OKE-K[PR^<-CJ@S&U
MF2RE_&H_[LKI(+"$H(;"6 2&KR>X@;JV0$CCKQWFH ]I'0_'>_2/+G?,9<DT
MW,CZ-UZ:]720#V@)%6MK\R"W/\,N'T>PD+5V3[KM;+/Q@!:M-K+9.2.#AHON
MS9YW=3APR(,3#M'.(7*\NT".Y2TS;#91<DN5M48T.W"I.F\DQX5MRL(H7.7H
M9V9WHI -T$?V#)H.']FR!GTQ\0U"6P._V,%<=S#1"9@PHI^D,&M-/X@2RM<
M/G+JB45[8M?16<1;*"YI''HT"J+@#%[<)QH[O/B;B=);KHM:ZE8!_6.^U$:A
M-/X\$R+I0R0N1'(BQ*(3-I45?8!"BH+7G#GMX<R'J@*G0$?A@1F@3)3T(Y2@
M6$T7AIG62/3>+Q]KPOGX<]PE;\.:-= ;V6R8>/GQASP*L_>:0D_%8"RUIU+M
MJ.B>2K_,-66:5K+&/8PRX0)Q9:O12U]<D=^!J5WC*;8-FB4HVSIB6X>/<$SV
M:?*N"\;*C;PCP]@;A1FYL,/,"[,Q#FTEX)6A1P6>3IC,GN$2!%3<D&'HA6&,
M/L/Q*,?7/> ^%2 ,Y08:38:C%&?S+"9WXJ>-D@5HC372R+=8NYQ+>,)S:8.G
MC"&N/M%[$GMQFI"'$V:T4%!R?#&E7O!0W#)58J0TL*&&R2C!UR]8=>58DR@:
MD0AIW*R96-FTZ!.KVZX]S):3B0)(Z@590A+,9DSNE7SB[LQ#]+<%VW/L1V=D
MF_:R3;]7M@N^$KSB!<,\K6JD+::V*Y^Q [=0@<+LG43G6H/1QT3ZC6@'(8I7
M(8Y)U3:^W(>U<F0N+&6X=\\H\H0*;_^+=$5L9GC'H<ZY6%$\%_2;WKXC8>;E
M:60'N1<&^?_41NB-T3GTDF1$YD6A6B0 SWBK:FQI/,I(%";DAFVX837_&Q=/
M*13KI0WB(6">D<P;Y?FAU.)Q3,(D)H\2@8Y5C<21EZ8AB3(O'8_)ER-"'%J3
M)+!2ME;(^ +CD31^73L\8)9XRA@.6$!WD=L&MAJZ2+@Q0PN1VKUYA,Z!^RO3
MS\>[_;VZ]P^NP0;4REWVV$W9"M/=B/UL_S\Q[Z[1?\V[GY%/3*VXT+2&"EV#
MRPQ%K;H+OOLP<N,NU:4T>$6[X1K_B4!9 UROI#3[#QN@_\N:_0-02P,$%
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M0E?H)DV9T20%NN--FAH[;]=4$U:H=^@-8AS]GHM:@6VU<#0X9: Y2>O ;>.
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M[&FM^,'F=-6,0SVCDN''2SC@Q[9?82-V8 8-S "%>4>E A7Q @Z,%F3)<B:
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M/["L @  /@<  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULM55-3]M
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M:#J5&Q;FYP/*)ICU7$I\#&R[ZG]G\7]02P,$%     @ ,(MK4G;^(X$9 @
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M5QVBA3X_";/R+WA4;:T)\/-,))$2EAY$05S]]Y[40-0$I)YV :0$T$L!UB&
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M3;G^1<<JUC)06'!!LPHL%61)7OZ3UVHC&@#L]0!P!< M@.WW )P*X'P4X%8
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M9@?C;O%^+=[_GRK!OU+C68XMT]Q2?1W753&KSK#>BIG4]B:#]I[U]0#1S>(
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M4P'R_992<1ZH!>KN??X/4$L#!!0    ( #"+:U) (S A$@(  (<$   9
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M? 'FMUJ[4^"'<?CWY'\ 4$L#!!0    ( #"+:U(QAJAC?0(  /<%   9
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M+.!);%$;S&%=$87:F1E"F3Y+0F.I., PZ\,NNK#QB;"C&.ZE,)6&.Y%C_B=
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M86R$0%;'==6-%D5YO'0OM!99>;D$FH*T!N;]0@B]O[$G5LVAZ?0?4$L#!!0
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MN8.,X'DC=[6N)9![I6I:IF!0FC*N#$KE5(*:N!HIFHW<M*$S/]()SM"Y@_6
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MPV@ ZY^U([87_(NJ/1.:<-BA5W"58:RJ;:_:@9&'ID-YD ;[G>:QPI84E#7
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MV_<X(15;=K,>S$&TLWK[A]F>YS<%^[>KZ"]02P,$%     @ ,(MK4I>*NQS
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M.>2S[G_K]!-02P$"% ,4    "  PBVM2!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #"+:U+0UM*F
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( #"+:U*97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,(MK4A3.XAPB!P  NAL
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M965T-2YX;6Q02P$"% ,4    "  PBVM2*)P I;H%  ##&@  &
M    @(&3(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M,(MK4M&K^Y-4 @  WP0  !@              ("!@R@  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #"+:U+\FZMV-QH  &Y-   8
M          " @0TK  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  PBVM2Y YPV)$"  !:!0  &               @(%Z10  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,(MK4I22NS1P!@  & \
M !D              ("!04@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  PBVM2$RI&$3H-  ##)@  &0              @('H3@
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #"+:U*7^@)8
M)@,  *X&   9              " @5E<  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ ,(MK4FCR9*?C!@  21   !D
M ("!ME\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  P
MBVM2P$1K<]<0  #/-0  &0              @('09@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #"+:U+X/*;&!@<  )$/   9
M          " @=YW  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#
M%     @ ,(MK4A*OQX\1"   JA4  !D              ("!&W\  'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  PBVM2E2J81?H!  !Y
M!   &0              @(%CAP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+ 0(4 Q0    ( #"+:U+-H/;COQD  (E2   9              " @92)
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ,(MK4D_(
M,;(M P  D@8  !D              ("!BJ,  'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6Q02P$"% ,4    "  PBVM2JF:I.YP"  !3!0  &0
M    @('NI@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M #"+:U(!&+BE!@0  *P(   9              " @<&I  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ ,(MK4J#AL6H4!@  NA   !D
M             ("!_JT  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  PBVM2F(<Q20L$  !Q"0  &0              @(%)M   >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #"+:U(.2[DD2@0
M +8-   9              " @8NX  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ ,(MK4@T: VI1 P  \@H  !D              ("!
M#+T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  PBVM2
M1BT;@=@"  !*"   &0              @(&4P   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( #"+:U*&50M\M0,  '@,   9
M      " @:/#  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ ,(MK4JEK:!A*"   '"L  !D              ("!C\<  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  PBVM2W>(_L*P"   ^!P
M&0              @($0T   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( #"+:U+<0D#F1@,  /$(   9              " @?/2  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ,(MK4D[O XW^
M @  6@<  !D              ("!<-8  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  PBVM2">$<*G<"   9!@  &0
M@(&EV0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #"+
M:U)KN$"Q<0(  -H&   9              " @5/<  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ ,(MK4G;^(X$9 @  9 0  !D
M         ("!^]X  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    "  PBVM25%;9O9@'  !F+P  &0              @(%+X0  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #"+:U+[OKWIA0,  ,D+
M   9              " @1KI  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ ,(MK4D C,"$2 @  AP0  !D              ("!UNP
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  PBVM2,8:H
M8WT"  #W!0  &0              @($?[P  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( #"+:U*+HF!.%@4  $ 5   9
M  " @=/Q  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M,(MK4F9RQ4W[ P  ^ \  !D              ("!(/<  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  PBVM2QJ,X1RX#  !8"@  &0
M            @(%2^P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( #"+:U*4B#:PQ (  #T'   9              " @;?^  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ,(MK4E(ID%+J @
MTP@  !D              ("!L@$! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  PBVM25/^8QFD"  !+!0  &0              @('3
M! $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #"+:U)"
MQ A8V (  '@(   9              " @7,' 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ ,(MK4BN58D=% P  ,PD  !D
M     ("!@@H! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M  !J#0  #0              @ $,& $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( #"+:U*7BKL<P    !,"   +              "  94: 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( #"+:U+R[7RM&00  /\@   /              "
M 7X; 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  PBVM2CF$X^KT!  !Z
M'0  &@              @ '$'P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  PBVM2G"O3#[T!  !W'0  $P              @ &Y
L(0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y (8/  "G(P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>118</ContextCount>
  <ElementCount>351</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Commitments, Contingencies and Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - License, Collaboration and Research Subaward Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - COVID-19 Pandemic and CARES Act</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct</Role>
      <ShortName>COVID-19 Pandemic and CARES Act</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Merger - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables</Role>
      <ShortName>Merger - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Merger - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails</Role>
      <ShortName>Merger - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Merger - Summary of Purchase Price Paid in Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails</Role>
      <ShortName>Merger - Summary of Purchase Price Paid in Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Merger - Summary of Allocation of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails</Role>
      <ShortName>Merger - Summary of Allocation of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity (Deficit) - Amended and Restated Articles of Incorporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Amended and Restated Articles of Incorporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stockholders' Equity (Deficit) - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stockholders' Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stockholders' Equity - Restricted Common Stock and Unvested Share Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Common Stock and Unvested Share Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity (Deficit) - Summary of Unvested Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary of Unvested Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity (Deficit) - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stockholders' Equity (Deficit) - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="onct-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Subsequent Event - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="onct-10k_20201231.htm">onct-10k_20201231.htm</File>
    <File>onct-20201231.xsd</File>
    <File>onct-20201231_cal.xml</File>
    <File>onct-20201231_def.xml</File>
    <File>onct-20201231_lab.xml</File>
    <File>onct-20201231_pre.xml</File>
    <File>onct-ex1014_496.htm</File>
    <File>onct-ex1037_578.htm</File>
    <File>onct-ex231_826.htm</File>
    <File>onct-ex311_7.htm</File>
    <File>onct-ex312_15.htm</File>
    <File>onct-ex321_8.htm</File>
    <File>onct-ex322_16.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>genzerafbudl000001.jpg</File>
    <File>genzerafbudl000002.jpg</File>
    <File>genzerafbudl000003.jpg</File>
    <File>genzerafbudl000004.jpg</File>
    <File>genzerafbudl000005.jpg</File>
    <File>genzerafbudl000006.jpg</File>
    <File>genzerafbudl000007.jpg</File>
    <File>genzerafbudl000008.jpg</File>
    <File>genzerafbudl000009.jpg</File>
    <File>genzerafbudl000010.jpg</File>
    <File>genzerafbudl000011.jpg</File>
    <File>genzerafbudl000012.jpg</File>
    <File>genzerafbudl000013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "onct-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 118,
   "dts": {
    "calculationLink": {
     "local": [
      "onct-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "onct-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "onct-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "onct-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "onct-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "onct-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 443,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 12,
    "http://www.oncternal.com/20201231": 7,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 23
   },
   "keyCustom": 78,
   "keyStandard": 273,
   "memberCustom": 33,
   "memberStandard": 14,
   "nsprefix": "onct",
   "nsuri": "http://www.oncternal.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Commitments, Contingencies and Related Party Transactions",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions",
     "shortName": "Commitments, Contingencies and Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - License, Collaboration and Research Subaward Agreements",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements",
     "shortName": "License, Collaboration and Research Subaward Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Debt",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:MergerDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Merger",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger",
     "shortName": "Merger",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:MergerDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Stockholders' Equity (Deficit)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit",
     "shortName": "Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - COVID-19 Pandemic and CARES Act",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct",
     "shortName": "COVID-19 Pandemic and CARES Act",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Income Taxes",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Subsequent Events",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherPrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Merger - (Tables)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables",
     "shortName": "Merger - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stockholders' Equity (Deficit) (Tables)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables",
     "shortName": "Stockholders' Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_onctsegment",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
     "shortName": "License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherNonoperatingIncome",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_us-gaapDebtInstrumentAxis_onctPaycheckProtectionProgramMember_us-gaapLongtermDebtTypeAxis_us-gaapUnsecuredDebtMember_20200531",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607_20190607",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Merger - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
     "shortName": "Merger - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_us-gaapTypeOfArrangementAxis_onctContingentValueRightsAgreementMember_20190607",
      "decimals": "INF",
      "lang": null,
      "name": "onct:ContingentValueRightsEntitledPerEachShareOfCommonStockHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_onctCVR",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockSharesOutstandingPriorToStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Merger - Summary of Purchase Price Paid in Merger (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails",
     "shortName": "Merger - Summary of Purchase Price Paid in Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfPurchasePriceComputationOfMergerTableTextBlock",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockSharesOutstandingPriorToStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607_20190607",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAcquiredFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Merger - Summary of Allocation of Purchase Price (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails",
     "shortName": "Merger - Summary of Allocation of Purchase Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "onct:MergerDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607_20190607",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAcquiredFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity (Deficit) - Amended and Restated Articles of Incorporation (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails",
     "shortName": "Stockholders' Equity (Deficit) - Amended and Restated Articles of Incorporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20190607",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stockholders' Equity (Deficit) - Convertible Preferred Stock (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity (Deficit) - Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_20190607",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stockholders' Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
     "shortName": "Stockholders' Equity (Deficit) - Securities Purchase Agreements and Underwritten Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531",
      "decimals": "4",
      "lang": null,
      "name": "onct:CombinedPurchasePriceOfShareAndWarrantPerUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Stockholders' Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity (Deficit) - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "onct:ExerciseOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stockholders' Equity - Restricted Common Stock and Unvested Share Liability (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails",
     "shortName": "Stockholders' Equity - Restricted Common Stock and Unvested Share Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "onct:LiabilityForUnvestedCashSettledShareBasedPaymentTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stockholders' Equity (Deficit) - Summary of Unvested Shares (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails",
     "shortName": "Stockholders' Equity (Deficit) - Summary of Unvested Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stockholders' Equity (Deficit) - Equity Incentive Plans (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity (Deficit) - Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails",
     "shortName": "Stockholders' Equity (Deficit) - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity (Deficit) - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails",
     "shortName": "Stockholders' Equity (Deficit) - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stockholders' Equity (Deficit) - Share-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity (Deficit) - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity (Deficit) - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20210228",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Subsequent Event - Additional Information (Details)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "shortName": "Subsequent Event - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Balance Sheet Details",
     "role": "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10k_20201231.htm",
      "contextRef": "C_0001260990_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "verboseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "onct_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Accrual balance in accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedUnvestedShareLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for unvested share liability.",
        "label": "Accrued Unvested Share Liability",
        "terseLabel": "Unvested share liability"
       }
      }
     },
     "localname": "AccruedUnvestedShareLiability",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash",
        "terseLabel": "Exercise of warrants for cash"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital reclassification of convertible preferred stock warrant.",
        "label": "Adjustments To Additional Paid In Capital Reclassification Of Convertible Preferred Stock Warrant",
        "terseLabel": "Reclassification of convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertiblePreferredStockWarrant",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital stock issued issuance costs shares",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Shares",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsShares",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital vesting related to unvested share liability.",
        "label": "Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability",
        "terseLabel": "Vesting related to repurchase liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdvanceLicensedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance licensed assets.",
        "label": "Advance Licensed Assets",
        "terseLabel": "Advance licensed assets"
       }
      }
     },
     "localname": "AdvanceLicensedAssets",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AmountAgreedToBeProvidedInContingencyFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to be provided in contingency funds.",
        "label": "Amount Agreed To Be Provided In Contingency Funds",
        "terseLabel": "Amount agreed to be provided in contingency funds"
       }
      }
     },
     "localname": "AmountAgreedToBeProvidedInContingencyFunds",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AssetAcquisitionPurchasePrice": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition purchase price.",
        "label": "Asset Acquisition Purchase Price",
        "terseLabel": "Purchase price",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "AssetAcquisitionPurchasePrice",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AssetAcquisitionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions.",
        "label": "Asset Acquisitions [Line Items]",
        "terseLabel": "Asset Acquisitions [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionsLineItems",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_AssetAcquisitionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions.",
        "label": "Asset Acquisitions [Table]",
        "terseLabel": "Asset Acquisitions [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionsTable",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_AugustUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August underwriting agreement.",
        "label": "August Underwriting Agreement [Member]",
        "terseLabel": "August Underwriting Agreement"
       }
      }
     },
     "localname": "AugustUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_COVID19PandemicAndCARESActAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act [Abstract]"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActAbstract",
     "nsuri": "http://www.oncternal.com/20201231",
     "xbrltype": "stringItemType"
    },
    "onct_COVID19PandemicAndCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActDisclosureTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_CaliforniaInstituteForRegenerativeMedicineAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Institute for Regenerative Medicine Award.",
        "label": "California Institute For Regenerative Medicine Award [Member]",
        "terseLabel": "The California Institute for Regenerative Medicine (\"CIRM\") Award"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAwardMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ChiefFinancialOfficerSonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chief financial officer, son.",
        "label": "Chief Financial Officer Son [Member]",
        "terseLabel": "Agent"
       }
      }
     },
     "localname": "ChiefFinancialOfficerSonMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ClassOfWarrantWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant weighted-average remaining contractual term.",
        "label": "Class Of Warrant Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_CollaborativeArrangementPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential milestone payments.",
        "label": "Collaborative Arrangement Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialMilestonePayments",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential regulatory milestone payments.",
        "label": "Collaborative Arrangement Potential Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialRegulatoryMilestonePayments",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CombinedPurchasePriceOfShareAndWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined purchase price of share and warrant per unit.",
        "label": "Combined Purchase Price Of Share And Warrant Per Unit",
        "terseLabel": "Combined purchase price of share and warrant per unit"
       }
      }
     },
     "localname": "CombinedPurchasePriceOfShareAndWarrantPerUnit",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding for future issuance.",
        "label": "Common Stock Options Issued And Outstanding For Future Issuance",
        "terseLabel": "Common stock options issued and outstanding"
       }
      }
     },
     "localname": "CommonStockOptionsIssuedAndOutstandingForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_CommonStockSharesOutstandingPriorToStockSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares outstanding prior to stock split.",
        "label": "Common Stock Shares Outstanding Prior To Stock Split",
        "terseLabel": "Number of shares of the combined organization owned by the Company\u2019s pre-Merger stockholders"
       }
      }
     },
     "localname": "CommonStockSharesOutstandingPriorToStockSplit",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_CommonStockSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock subject to repurchase.",
        "label": "Common Stock Subject To Repurchase [Member]",
        "terseLabel": "Common Stock Subject to Repurchase"
       }
      }
     },
     "localname": "CommonStockSubjectToRepurchaseMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants expiration date.",
        "label": "Common Stock Warrants Expiration Date",
        "terseLabel": "Common stock warrants expiration date"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDate",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "onct_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants reserved for future issuance.",
        "label": "Common Stock Warrants Reserved For Future Issuance",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsReservedForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk credit risk policy.",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ContingentValueRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Value Rights Agreement.",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "CVR Agreement"
       }
      }
     },
     "localname": "ContingentValueRightsAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ContingentValueRightsEntitledPerEachShareOfCommonStockHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value right entitled per each share of common stock held.",
        "label": "Contingent Value Rights Entitled Per Each Share Of Common Stock Held",
        "terseLabel": "Contingent value right per common stock"
       }
      }
     },
     "localname": "ContingentValueRightsEntitledPerEachShareOfCommonStockHeld",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "onct_ConversionOfConvertiblePreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock to common stock.",
        "label": "Conversion Of Convertible Preferred Stock To Common Stock",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockToCommonStock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CumulativeChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative change in ownership percentage.",
        "label": "Cumulative Change In Ownership Percentage",
        "terseLabel": "Cumulative changes in ownership percentage"
       }
      }
     },
     "localname": "CumulativeChangeInOwnershipPercentage",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_DecemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December underwriting agreement.",
        "label": "December Underwriting Agreement [Member]",
        "terseLabel": "December Underwriting Agreement"
       }
      }
     },
     "localname": "DecemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research expiration year.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year",
        "terseLabel": "Research and development credit carryforward expiration year"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "onct_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies line items.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of business basis of presentation and summary of significant accounting policies table.",
        "label": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones to be received under research subaward agreements throughout award project period.",
        "label": "Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period",
        "terseLabel": "Development milestones to be received under research subaward agreements throughout award project period"
       }
      }
     },
     "localname": "DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "Equity incentive plan"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license agreement.",
        "label": "Exclusive License Agreement [Member]",
        "terseLabel": "Exclusive License Agreement"
       }
      }
     },
     "localname": "ExclusiveLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExerciseOfCashlessWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants",
        "label": "Exercise Of Cashless Warrant Shares",
        "verboseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfCashlessWarrantShares",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrants",
        "terseLabel": "Number of Shares Underlying Warrants Exercised"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ExerciseOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants issued.",
        "label": "Exercise Of Warrants Issued",
        "terseLabel": "Number of Shares Underlying Warrants Issued"
       }
      }
     },
     "localname": "ExerciseOfWarrantsIssued",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_FairValueOfWarrantsIssuedToPlacementAgent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants issued to placement agent.",
        "label": "Fair Value Of Warrants Issued To Placement Agent",
        "terseLabel": "Fair value of warrants issued to placement agent"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedToPlacementAgent",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_GTxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GTx Inc.",
        "label": "G Tx Inc [Member]",
        "terseLabel": "GTx Inc."
       }
      }
     },
     "localname": "GTxIncMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_GTxStockOptionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gtx stock option plans.",
        "label": "G Tx Stock Option Plans [Member]",
        "terseLabel": "GTx Stock Option Plans"
       }
      }
     },
     "localname": "GTxStockOptionPlansMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_GeorgetownUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Georgetown University.",
        "label": "Georgetown University [Member]",
        "terseLabel": "Georgetown University"
       }
      }
     },
     "localname": "GeorgetownUniversityMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_IncomeTaxReconciliationInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation in process research and development.",
        "label": "Income Tax Reconciliation In Process Research And Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "IncomeTaxReconciliationInProcessResearchAndDevelopment",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liability.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of bonus awards with stock option in lieu of cash.",
        "label": "Issuance Of Bonus Awards With Stock Option In Lieu Of Cash",
        "terseLabel": "Issuance of 2019 bonus awards with stock option in lieu ofcash"
       }
      }
     },
     "localname": "IssuanceOfBonusAwardsWithStockOptionInLieuOfCash",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_JulyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July purchase agreement member",
        "label": "July Purchase Agreement [Member]",
        "terseLabel": "July Purchase Agreement"
       }
      }
     },
     "localname": "JulyPurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LiabilityForUnvestedCashSettledShareBasedPaymentTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for unvested cash settled share based payment transactions.",
        "label": "Liability For Unvested Cash Settled Share Based Payment Transactions",
        "terseLabel": "Unvested share liability"
       }
      }
     },
     "localname": "LiabilityForUnvestedCashSettledShareBasedPaymentTransactions",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityRestrictedCommonStockAndUnvestedShareLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LicenseMaintenanceFeeToBePaidAndPaymentMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee to be paid and payment made.",
        "label": "License Maintenance Fee To Be Paid And Payment Made",
        "terseLabel": "Annual license maintenance fee to be paid and payment made"
       }
      }
     },
     "localname": "LicenseMaintenanceFeeToBePaidAndPaymentMade",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_MDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Cancer Center.",
        "label": "M D Anderson Cancer Center [Member]",
        "terseLabel": "MD Anderson Cancer Center"
       }
      }
     },
     "localname": "MDAndersonCancerCenterMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_MergerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger.",
        "label": "Merger [Abstract]"
       }
      }
     },
     "localname": "MergerAbstract",
     "nsuri": "http://www.oncternal.com/20201231",
     "xbrltype": "stringItemType"
    },
    "onct_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Merger Agreement.",
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_MergerDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger disclosure.",
        "label": "Merger Disclosure [Text Block]",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "MergerDisclosureTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMerger"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period of written notice to terminate agreement.",
        "label": "Minimum Period Of Written Notice To Terminate Agreement",
        "terseLabel": "Minimum period in days of written notice to terminate license agreement"
       }
      }
     },
     "localname": "MinimumPeriodOfWrittenNoticeToTerminateAgreement",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash or part non-cash gain loss of forgiveness of payroll protection loan.",
        "label": "Non Cash Or Part Noncash Gain Loss Of Forgiveness Of Payroll Protection Loan",
        "negatedLabel": "Gain on forgiveness of payroll protection program loan",
        "terseLabel": "Gain on forgiveness of payroll protection program loan"
       }
      }
     },
     "localname": "NonCashOrPartNoncashGainLossOfForgivenessOfPayrollProtectionLoan",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_NovemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November underwriting agreement.",
        "label": "November Underwriting Agreement [Member]",
        "terseLabel": "November Underwriting Agreement"
       }
      }
     },
     "localname": "NovemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice for default in payment.",
        "label": "Number Of Days After Receipt Of Notice For Default In Payment",
        "terseLabel": "Days after receipt of notice for default in payment"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice in fails to pay amount.",
        "label": "Number Of Days After Receipt Of Notice To Pay Failure Amount",
        "terseLabel": "Days after receipt of notice, to pay failure amount"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysInWrittenNoticeOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days in written notice of termination.",
        "label": "Number Of Days In Written Notice Of Termination",
        "terseLabel": "Written notice of termination, period"
       }
      }
     },
     "localname": "NumberOfDaysInWrittenNoticeOfTermination",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_OncternalTherapeuticsIncAndGTxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncternal Therapeutics Inc and GTx Inc.",
        "label": "Oncternal Therapeutics Inc And G Tx Inc [Member]",
        "terseLabel": "Combined organization's"
       }
      }
     },
     "localname": "OncternalTherapeuticsIncAndGTxIncMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "onct_OperatingLossCarryforwardsNonExpirePortion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards non expire portion.",
        "label": "Operating Loss Carryforwards Non Expire Portion",
        "terseLabel": "Operating loss carryforwards non expire portion"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNonExpirePortion",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_OwnershipPercentageOfStockholdersUponClosingOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ownership percentage of stockholders upon closing of merger.",
        "label": "Ownership Percentage Of Stockholders Upon Closing Of Merger",
        "terseLabel": "Ownership percentage of stockholders upon closing of merger"
       }
      }
     },
     "localname": "OwnershipPercentageOfStockholdersUponClosingOfMerger",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs policy.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program member,",
        "label": "Paycheck Protection Program [Member]",
        "terseLabel": "Paycheck Protection Program"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net proceeds available to the stockholders eligible for contingent value rights during the 15-year period after closing from the grant, sale or transfer of rights to the Company's SARD and SARM technology.",
        "label": "Percentage Of Net Proceeds Entitled To Receive During Period Specified After Closing From Grant Sale Or Transfer Of Rights",
        "terseLabel": "Percentage of net proceeds entitled to be received per CVR"
       }
      }
     },
     "localname": "PercentageOfNetProceedsEntitledToReceiveDuringPeriodSpecifiedAfterClosingFromGrantSaleOrTransferOfRights",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_PeriodForCumulativeChangeInOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for cumulative change in ownership.",
        "label": "Period For Cumulative Change In Ownership",
        "terseLabel": "Period for cumulative change in ownership"
       }
      }
     },
     "localname": "PeriodForCumulativeChangeInOwnership",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement.",
        "label": "Period Which Grant Sale Or Transfer Of Rights To Company Sard Or Sarm Technology Could Trigger Payment Under Cvr Agreement",
        "terseLabel": "Period from closing during which the grant, sale or transfer of rights to the Company's SARD or SARM technology could trigger a payment under the CVR Agreement"
       }
      }
     },
     "localname": "PeriodWhichGrantSaleOrTransferOfRightsToCompanySardOrSarmTechnologyCouldTriggerPaymentUnderCvrAgreement",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from closing during which percentage of net proceeds payment would be payable under the CVR.",
        "label": "Period Which Payment Of Percentage Of Net Proceeds Would Be Payable Under C V R",
        "terseLabel": "Period from closing during which payment of percentage of net proceeds would be payable under the CVR"
       }
      }
     },
     "localname": "PeriodWhichPaymentOfPercentageOfNetProceedsWouldBePayableUnderCVR",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_PlacementAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent member.",
        "label": "Placement Agent [Member]",
        "terseLabel": "Placement Agent"
       }
      }
     },
     "localname": "PlacementAgentMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PreferredStockWarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrant liability policy.",
        "label": "Preferred Stock Warrant Liability Policy [Text Block]",
        "terseLabel": "Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "PreferredStockWarrantLiabilityPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_PrivateOncternalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Oncternal.",
        "label": "Private Oncternal [Member]",
        "terseLabel": "Private Oncternal"
       }
      }
     },
     "localname": "PrivateOncternalMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ProceedsFromStockOptionsExercisedAndWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from exercise of stock options and common stock warrants.",
        "label": "Proceeds From Stock Options Exercised And Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock options and common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantExercises",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement member.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ReagentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reagents.",
        "label": "Reagents [Member]",
        "terseLabel": "Regents of the University of California"
       }
      }
     },
     "localname": "ReagentsMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of preferred stock warrants liability to additional paid-in capital.",
        "label": "Reclassification Of Preferred Stock Warrants Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of preferred stock warrants liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfPreferredStockWarrantsLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_RegentsLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents license agreement.",
        "label": "Regents License Agreement [Member]",
        "terseLabel": "Regents License Agreement"
       }
      }
     },
     "localname": "RegentsLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_RelatedQualifyingSubawardCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related qualifying subaward costs.",
        "label": "Related Qualifying Subaward Costs",
        "terseLabel": "Related qualifying subaward costs"
       }
      }
     },
     "localname": "RelatedQualifyingSubawardCosts",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement.",
        "label": "Research Agreement [Member]",
        "terseLabel": "Research Agreement"
       }
      }
     },
     "localname": "ResearchAgreementMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAgreementResearchFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount.",
        "label": "Research Agreement Research Funding Amount",
        "terseLabel": "Aggregate research agreement budget"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmount",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementResearchFundingAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount payable.",
        "label": "Research Agreement Research Funding Amount Payable",
        "terseLabel": "Research amount payable quarterly"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmountPayable",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement term.",
        "label": "Research Agreement Term",
        "terseLabel": "Research agreement term"
       }
      }
     },
     "localname": "ResearchAgreementTerm",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_ResearchAndDevelopmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "Research And Development Grants",
        "terseLabel": "Grants awarded to researchers"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrants",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ReverseStockSplitAndExchangeRatioPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split and exchange ration policy.",
        "label": "Reverse Stock Split And Exchange Ratio Policy [Text Block]",
        "terseLabel": "Reverse Stock Split and Exchange Ratio"
       }
      }
     },
     "localname": "ReverseStockSplitAndExchangeRatioPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide sales milestones based on achievement of tiered revenue levels.",
        "label": "Sales Milestones Based On Achievement Of Tiered Revenue Levels",
        "terseLabel": "Worldwide sales milestones based on achievement of tiered revenue levels"
       }
      }
     },
     "localname": "SalesMilestonesBasedOnAchievementOfTieredRevenueLevels",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ScheduleOfPurchasePriceComputationOfMergerTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of purchase price computation of merger.",
        "label": "Schedule Of Purchase Price Computation Of Merger Table [Text Block]",
        "terseLabel": "Summary of Purchase Price Paid in Merger"
       }
      }
     },
     "localname": "ScheduleOfPurchasePriceComputationOfMergerTableTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant activity table text block.",
        "label": "Schedule Of Warrant Activity Table [Text Block]",
        "terseLabel": "Summary Of Warrant Activity And Changes In Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shanghai Pharmaceutical United States of America Inc.",
        "label": "Shanghai Pharmaceutical United States Of America Inc [Member]",
        "terseLabel": "Shanghai Pharmaceutical (USA) Inc."
       }
      }
     },
     "localname": "ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number",
        "terseLabel": "Number of options outstanding and fully vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of options outstanding and fully vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding and exercisable weighted average remaining contractual term1.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average remaining contractual term of options outstanding and fully vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.",
        "label": "Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of annual increase in shares reserved for issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_StockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exchange ratio.",
        "label": "Stock Exchange Ratio",
        "terseLabel": "Common stock and preferred stock exchange ratio"
       }
      }
     },
     "localname": "StockExchangeRatio",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "onct_SubawardPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subaward payments received.",
        "label": "Subaward Payments Received",
        "terseLabel": "Subaward payments received"
       }
      }
     },
     "localname": "SubawardPaymentsReceived",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock upon merger (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value conversion of convertible securities.",
        "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon Merger"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen plan.",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 plan"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2019 and 2015 plan"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 incentive award plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandThirteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand thirteen plan.",
        "label": "Two Thousand Thirteen Plan [Member]",
        "terseLabel": "2013 plan"
       }
      }
     },
     "localname": "TwoThousandThirteenPlanMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UniversityOfCaliforniaSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California San Diego.",
        "label": "University Of California San Diego [Member]",
        "terseLabel": "University of California San Diego School of Medicine"
       }
      }
     },
     "localname": "UniversityOfCaliforniaSanDiegoMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UniversityOfTennesseeResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Tennessee Research Foundation.",
        "label": "University Of Tennessee Research Foundation [Member]",
        "terseLabel": "University of Tennessee Research Foundation"
       }
      }
     },
     "localname": "UniversityOfTennesseeResearchFoundationMember",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UpfrontLicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees paid.",
        "label": "Upfront License Fees Paid",
        "terseLabel": "Upfront license fees paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeesPaid",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ValuationAllowanceDeferredTaxAssetChangeNetAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance Deferred Tax Asset Change Net Amount.",
        "label": "Valuation Allowance Deferred Tax Asset Change Net Amount",
        "terseLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeNetAmount",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_WarrantExercisedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercised price per share.",
        "label": "Warrant Exercised Price Per Share",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "WarrantExercisedPricePerShare",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_WarrantIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant issued price per share.",
        "label": "Warrant Issued Price Per Share",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "WarrantIssuedPricePerShare",
     "nsuri": "http://www.oncternal.com/20201231",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r266",
      "r267",
      "r271",
      "r272",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r266",
      "r267",
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r181",
      "r183",
      "r184",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r181",
      "r183",
      "r184",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r139",
      "r140",
      "r179",
      "r180",
      "r341",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r179",
      "r180",
      "r341",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r142",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r21",
      "r79",
      "r294",
      "r296",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable Related Parties",
        "terseLabel": "Amounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r218"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r185",
      "r187",
      "r221",
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r167",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r187",
      "r212",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r122",
      "r131",
      "r136",
      "r144",
      "r266",
      "r271",
      "r277",
      "r321",
      "r332"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r42",
      "r77",
      "r144",
      "r266",
      "r271",
      "r277"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r188",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r258",
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net",
        "terseLabel": "Net liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r72",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r82",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired From Acquisition",
        "terseLabel": "Cash acquired in connection with the Merger",
        "verboseLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r28",
      "r66"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r67",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r61",
      "r66",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r278"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r75",
      "r77",
      "r96",
      "r97",
      "r98",
      "r100",
      "r102",
      "r106",
      "r107",
      "r108",
      "r144",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Common stock warrants excercisable and expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r177",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "periodEndLabel": "Weighted-Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price",
        "terseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "periodEndLabel": "Options outstanding, Number of Warrant",
        "periodStartLabel": "Options outstanding, Number of Warrant",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r261",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration and Research Subaward Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r158",
      "r326",
      "r336"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 3)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingencies and Related Party Transactions"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock available for future issuance",
        "verboseLabel": "Number of common stock shares provided for issuance of stock awards to its employees"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; authorized shares \u2013 60,000 at December 31, 2020 and 2019, respectively; issued and outstanding shares \u2013 48,802 and 15,387 at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r18",
      "r19",
      "r168",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Convertible preferred stock converted into common stock shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r322",
      "r324",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r81",
      "r168",
      "r172",
      "r173",
      "r174",
      "r285",
      "r286",
      "r287",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r15",
      "r16",
      "r237",
      "r323",
      "r330"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r242",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credit carryforwards",
        "verboseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfSignificantComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Aggregate Disclosures [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Compensation cost related to nonvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option Grants",
        "verboseLabel": "Common Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r105",
      "r145",
      "r167",
      "r175",
      "r215",
      "r216",
      "r217",
      "r246",
      "r247",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Aggregate Cost",
        "terseLabel": "Aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r64",
      "r162"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of preferred stock warrants liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r72",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r150",
      "r151",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r147",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "Patent costs as general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralInsuranceExpense": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).",
        "label": "General Insurance Expense",
        "terseLabel": "Insurance premium"
       }
      }
     },
     "localname": "GeneralInsuranceExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r235",
      "r241",
      "r248",
      "r250",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Expense",
        "terseLabel": "Interest and penalties"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r93",
      "r94",
      "r121",
      "r229",
      "r249",
      "r251",
      "r339"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r72",
      "r225",
      "r226",
      "r235",
      "r236",
      "r240",
      "r245",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Income Tax Reconciliation Other Adjustments",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Income Tax Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Income Tax Reconciliation Tax Credits Research",
        "negatedLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfEffectiveTaxRateAndFederalStatutoryTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceCommissions": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned.",
        "label": "Insurance Commissions",
        "terseLabel": "Insurance commissions"
       }
      }
     },
     "localname": "InsuranceCommissions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r53",
      "r120"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease And Rental Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee Operating Lease Discount Rate",
        "terseLabel": "Lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r77",
      "r144",
      "r277",
      "r325",
      "r334"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r77",
      "r144",
      "r267",
      "r271",
      "r272",
      "r277"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r62",
      "r65"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r49",
      "r65",
      "r77",
      "r86",
      "r88",
      "r89",
      "r90",
      "r91",
      "r93",
      "r94",
      "r99",
      "r122",
      "r130",
      "r132",
      "r135",
      "r137",
      "r144",
      "r277",
      "r327",
      "r338"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails": {
       "order": 10020.0,
       "parentTag": "onct_AssetAcquisitionPurchasePrice",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.",
        "label": "Noncash Merger Related Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "NoncashMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails": {
       "order": 10010.0,
       "parentTag": "onct_AssetAcquisitionPurchasePrice",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Value Of Assets Acquired1",
        "terseLabel": "Fair value of consideration issued to effect the Merger"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1",
        "terseLabel": "Net liabilities assumed in Merger"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r122",
      "r130",
      "r132",
      "r135",
      "r137"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Lease, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease, net of current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r33"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income",
        "verboseLabel": "Loan forgiveness (other income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r146"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense Current",
        "terseLabel": "Prepaid and other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Common stock and common stock warrants, issuance cost"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r56",
      "r260"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses Gross",
        "negatedLabel": "Acquisition related costs paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r188",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitAmendedAndRestatedArticlesOfIncorporationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, authorized shares \u2013 5,000 and none at December 31, 2020 and 2019, respectively; issued and outstanding shares \u2013 none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock and common stock warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds From Issuance Of Long Term Debt",
        "terseLabel": "Proceeds from payroll protection loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r60",
      "r77",
      "r86",
      "r93",
      "r94",
      "r122",
      "r130",
      "r132",
      "r135",
      "r137",
      "r144",
      "r265",
      "r269",
      "r270",
      "r273",
      "r274",
      "r277",
      "r328"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r182",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r182",
      "r293",
      "r296",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r223",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r72",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research And Development In Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfAllocationOfPurchasePriceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r175",
      "r218",
      "r333",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r145",
      "r215",
      "r216",
      "r217",
      "r246",
      "r247",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r48",
      "r77",
      "r118",
      "r119",
      "r129",
      "r133",
      "r134",
      "r138",
      "r139",
      "r141",
      "r144",
      "r277",
      "r328"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r256",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions By Acquisition [Text Block]",
        "terseLabel": "Summary of Allocation of Purchase Price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Capitalization Equity [Line Items]",
        "terseLabel": "Schedule Of Capitalization Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule Of Capitalization Equity [Table]",
        "terseLabel": "Schedule Of Capitalization Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Summary of Significant Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Reconciliation of Effective Tax Rate and Federal Statutory Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r187",
      "r211",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r187",
      "r211",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule Of Nonvested Share Activity Table [Text Block]",
        "terseLabel": "Summary of Unvested Shares"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r188",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r194",
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r38",
      "r75",
      "r106",
      "r107",
      "r163",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitConvertiblePreferredStockDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r72",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Maximum number of shares of common stock a participant may receive"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options exercisable, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of options, cancelled",
        "terseLabel": "Number of options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r196",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of options, ending balance",
        "periodStartLabel": "Number of options, beginning balance",
        "terseLabel": "Options outstanding, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "terseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]",
        "terseLabel": "Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Number of options outstanding and fully vested",
        "verboseLabel": "Options vested and expected to vest, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price of options outstanding and fully vested",
        "verboseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r186",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r72",
      "r188",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Multiplied by the fair value per share of GTx common stock (1)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerSummaryOfPurchasePricePaidInMergerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r206",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares",
        "periodEndLabel": "Number of shares unvested, ending balance",
        "periodStartLabel": "Number of shares unvested, beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares Roll Forward"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Remaining weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "negatedLabel": "Number of shares, vested shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfUnvestedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Closing market price per common share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r75",
      "r77",
      "r96",
      "r97",
      "r98",
      "r100",
      "r102",
      "r106",
      "r107",
      "r108",
      "r144",
      "r167",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r105",
      "r145",
      "r167",
      "r175",
      "r215",
      "r216",
      "r217",
      "r246",
      "r247",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r105",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitTables",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "positiveLabel": "Payment of 2019 bonus awards with stock options in lieu of cash"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r19",
      "r20",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Issuance of common stock to former stockholders of GTx upon Merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r40",
      "r167",
      "r168",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon Merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r167",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r167",
      "r175",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of options, exercised",
        "terseLabel": "Exercise of stock options for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r41",
      "r167",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period Value Acquisitions",
        "terseLabel": "Issuance of common stock to former stockholders of GTx upon Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r167",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r77",
      "r143",
      "r144",
      "r277"
     ],
     "calculation": {
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r175",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split of common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureStockholdersEquityDeficitSecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureMergerAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r224",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Deferred tax assets, fully offset by valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation",
        "terseLabel": "Weighted-average shares subject to repurchase"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20201231/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-03.7(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r361": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r362": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r363": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r364": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r365": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r366": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r367": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r368": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r369": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001564590-21-012588-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-012588-xbrl.zip
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M8I=]T&%Z#>#6<Y0:?''1 @,\E"\SC6" "!L,F%;?KUV"[GO:6UIM\RR+@AZ
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M#$+,:*-;%;TN\:)M5OXY,Z=A3=@;Z6Z1-QZ:N49X?HQBR(Z<O^QOC:"7\/V
M%0\##*]?K/.7V&.?$MG#9^!$<5F4'+LQ_Y1H'FZ$D4ZCY\V+3L+AK&3@P\]@
M#CT+N(V5^$W1<8P##6Z7K%IM;FIOSJ])J1Z0PP!TH#,ITMQ*;6P\JO1E$#0<
MK-9G5?+LU53#XMM(6[OXGGXOCI7D1*1H-E$4 L\6R>K!Q,J(,:ZGI8KL]_4P
M6(5K7-6Q3L@N!7H1)/3Z#SIB#96"VOO4E\*HG\Y8<PSGC#L[*5675WM/$L0-
M::=V> 'D-M% >U*:KEQ$J7F(!<_[>%?]UU;+_8G+Q/ Y%K5E9S !?IZXGTO^
MHQ/X#KE3'7^X-]UFWK(^*DP$;LVGNW0OV],!-J^FS?RR^4RS)WKDPB\?;BKR
M$Z:W>/IKW8?K%KA<KNP(H 2'05P*@P&4V0CK-B#H*Z9!G0Z-=RV1A/UMBZLH
MHK9[F"D69(\.EJKS%2)XN71EGED4MK +E"4@X^E2L S7E3BL9][-?Q;:+E^E
MQH$B0M\#T@$F!P[(274_Z=;%24HS;UU3Q4%^4EPRB2<SXO UKH^F;(!YMNW%
MX>. A;BHA?X38\V"@IW2?&,;^B#3UKU(T]/RHZPXW.'-@ZIWG\SGZML7N6NG
M6@JA]@CY6"$))_&*E1:,U^\NE^AE&/=\V@XJGS_,*+G$D^J_X([N+@JT'; A
M0Q]W%FIQU6+EQ,9</0Y=+0OV<.'9FA>0W1"?.#A*UUESO069'=?%-%C=-"Z9
M)6.QK1V%EB!DYHU^-1@]T6B?_)KS+/))V7VUN8I<3;&2PMWPTDAB(^30.VQ"
MU@I,4CHC)>4;]I2ILOHY(&%=;_2#9C!CG7#ZK&[L\W&=N"-M.I6*5Y0("IZ[
MO)O#7AR/=U*3G2,U_>[/=2C>7\!*L>CF4!*SF7T7J*OH9B[WZ;EVN"P3(M'1
MBTL;'>XIN@&\QK'6"%O[]4-Z&G41UHZ ..C0:S#6R]2)KXHI:[@&[-VYMY\V
M#Z$)>WMQ>E)QQU]";K^E)AR/[*+;*MJ<!Z7RS$[<JTUTL:%^/';M1H+0FQ8N
MM$!+3@_9!3,-PB[FSLXD:=F;-U%:5(2R@E\Y-/8Z\+@D35OQ$RT0+R!-*"&K
M.B=K?%**WM&7#J35M+1%C!M=U>6GY@=]30B29SR#RGS>IU,7N&,Y\R3>SGRF
M==$-,OC\$W5!R34U#X[@=4U5_0&:7LYQY\-; UWEJ%J4XI621"LVAVLFB-7"
MV,44_/SB59\<O3KON5!XYXRO4)!6UU7U6C0F[2(\+;<RF/&,CY46E$_!?J.\
M!C:' >*W/)4_9'ML/S3B"D]<U_$H"WX^:!S_+'&Z5#Z=+(AW713'Q)4V'C7$
M)<>L3P@>1W_4 !RWA8+ ).,U\ISNW+5A\OO([+(!1G;MY W^7?T.L;3+4G5]
M$',_;V(Z]A9V;[MN2>!,;2PB>_8<C**_RN_049TZZ+UFQWH[;!,&#"=<VZZ^
M&TDR]?9)F&R;G1F-HZVNL:<0D[FH(58PGD=<\W6+O%R98.J%AU+(P_HC_AN/
M1TH$.DRK5W(W-8B'$)#)C.I2=0MJ=B*B\H6S*1+O%CWLE*:WP1$,&[A8\KHW
MQ#F].:GAMB[WJ0UW\TA7-&5+OX5Z?L"_;^B"+TWG2[JYLCA734QH1L3HLC-=
MR,BJ3)KYF&Q>&?981+?YV\FY:O1.;3F\%9L358>>FZLCPKB0 N\]F;Q'Y?>;
MOG1D+2^=D0"0770FN4!9>JH@R4'0DSP^4L6R7(:=X4!S-]1 VEBWNT6;76N9
M8RE'!UD&-,/VV5^9N:I(E_15F#]Z97YN,1B=2QODP@3I5/B?.'LO?8D2C2"K
MHY@G>^[%>VFD".T89LGQL;I9.SD%D<PQQ#?_^E!5AO_6G#:6=BW$P N].!T&
MM,J.0*OHH*\8(=H#< ^%!CZ?^G#S<A\?H=== @:$=,]?ML*  QP]B(,(#GC!
MKAP&V(I<(FLRP_U:Y=\5DEJX0Q&2_A &Y'^ .@SGO33/=X8!.MXK!6K6#:9'
M>3QB%7X]AH65Y1[OF_@Y"LD!P1'CY)-@F=+=TMP,.<>D,5O!LC&7^551@L3>
M$DS9%E5(P?[P4I...&=\,]H+5QOU@TM"J8%JWNCA@D#K,N0<&R8C*]X+15=C
M/TB@</.\OGG'2Z)*W_Z[WDZX"OP>9AX"RKT.(AA-*69EV&86,1\7T'7YJ!<<
M#A-N1&_FOMGQ\\%\5224/761,ZG)UWK!K^Z6C]YD-__VX*CBP_@7]/:-S0@J
MI+KYAT.'^GCGA-)% \\L2LM>3FJ1;1)W> J!22!T_O8ENXM#VQ^?%I67W8P"
M> U0G=?'O.XYN+AS,4IA^N84R&&\)#\V[C187M<]4PA)6.OGCK\5#KY%$&,H
M?0T[:"IF6.* XM; <[]]Q6KS);Q,<\?[R<9\RTACE0]VN8-1:RO?#TW).2G2
MZR)3/NEQ-R(B2D"'$KY^6-Q7+69Q+VJ,>MQ62M+ INPPAYFQOAN*?;/+<B"U
MIH3BJ2CW]9F=T?7^W)6SYO"C2<\;'6&8I0G<*5]DYN/%MM4/LC?I'BKBC#&?
MFEC>WMN,2>Q\C38^Y84)-\R;)4AYZSAMG+I'4@#O%#9X.&WP@)Q[K[Y%J_^X
MR4JP@ZP +YZ5.;AG77G5-2TJT]GH'*09FZMSJQ./<0%A]:5BW;#].W+A!NG^
M)8[/Q=1EA,@WL4B%1-"!P4%.; R3Z/#8FMXXC4K2^\N^/9+S4Q78N*LW$M>+
M1UMH#_3NT>5=Z[(X*=8=.&2]N>K$'8FH]?C&$J\*]VR1Z[F&5<#VIH,(;H^3
M,7T$FAJ"%U72RRDOOK/O_;.?RSJ4%-PZ5G?X!0:DVA*,7'##UR0$O.X# V2!
MYEV1BX"QUY<.7&$Z4W1PPB>EJ]"OZ"^'=;[<SF7NT'2#Z9.B"4OM\4<:8YZ'
M+JF.E9YUQJ8[9^8HE2;;;4_\*] B#A,P%?$*%#%770V2&4M3]B@?W=/7)-L_
M\4_/6X%2]#8.7\<8(=QO%DS](G!]Q7D]>OYVI=-@8O2:L4?*L\FW=\HNM//%
M[.;*'9A9YET;WY9*& 1PC/H#8U98*Z61&I4/QBP.&_LW)QVS'#.%Q%H((HUF
MY<";L3I,I7:FZ8B=FMX3STNX,.6DAO/N5%-05@QTT&LG=.QNW6.+3I[==*QO
M/U8KJJZ(VF#I38@]M?Q(?;SD=7=E?R7,.4S1@J5?SA3'OPV/>T:2UZS.)E4J
MZV2Z48ZZOV51]S6%KI$(_<RYAGZVL[GDR%W+G$/-**?"\-AKU\KG(0:07=H/
MM4PC^3HK-]RRK=^7#NR3(:R*$O.CODPS-*F,A:;>S8@H>L1NQ L#!-4JXWS2
M)D]<,:UD@K22]Q&E QJ\>)D/>U(U!P[EZ 7)\[3E[A'RL#-)4/0[ 5*S&AN0
M2VY6()9=SJO,\_$=]O2TC4MZ1'W-^C=G::]-\?>+)AX8:!B5-_.NKO!EZ0P*
M$[^9,CW:5<0<RE-32+^C09ZMJKSK\,JU]K6=*5LT+Z7)%J(W%A;O\NJ9AF<Q
MMN\-?<-Q,UMY.\J[$>?7].+=[1-NZ$@$O]XR(,7OY[JNX<XXQ?^>4.B2\=C[
M+I[<;E#VDR#]1PA(/*K#L:QO.-URQ1_6D)24]NH2=,68B*+56M^3@FCT74BE
MZCB/:]1%;S!#OJ#RC"EL-Q G8.$>0T6V1-:3P1Q*:F4L-%71$HO:H\%I9HS?
M7'*F7DCP*8T&Z'!,9,&\Q_R[F@E2C\DO?KL_L $ERQ;.=<\\[DI&:<F3>*&C
M.V5J@#7X:&12JY9DBI@:Y7*WV\U_Z8(@:\R4WW>BS,Y%CJ;X#O?UTR"V_HI3
MECP6:G$;P:)-7@JC"'C\2Q&<CTE@WX4J;]CU_E7]@Q@FGX"P#=Z+]=AA0:'T
M%2BM'YINU-U4I14JXB>*.W/!M]:.^'V#WI'GU$N6!KR5A!NLR)$5<[/])AV1
M"YIAGK;;<9-W1C?PH1MG,V=**%8;^B"XF_W,1ZZF(*(=CSY42>I3P*[/P:9Z
M"2:IO#ZBO,9<N[Y\V<:]>IOB]/DX<U%S'?5JG9X+A<5J\U$MJ1HMQA@R@.U+
MCA6F8OKH*0^57G3_LS#V^G;9\FTOA,WU+D F:86;)"\1[/BX0E]XPE*Z=/$C
M#' *=HW4ZK4_#T1?5B\L*B\P-T9(_ CZ2(;%L64V%.]OW[.9JW/=0(MSO1]=
M!M116("ZQ;>I-58V:E00UK:+V740,*HE8U$%'IN@1\*J/SPX'\WKPYGB>)_'
MSO^D!JU)$U?_0J"@/*IH[V& <\M.]/XE-ZE<X'VB_'1S-PV1ZA!)V>#TX9H;
M*K4[D.W7E/W@TACF"HR .WQ/$(@$C6H EWBS?S[L_('2BRKQ\YE*GI'D)62L
M4CC$RJF/;/JI+%'2%F1%ZG8V=)+'G.?^I._NF[VF]*+N%8$M RBDY22RT?&8
M@@QNQ->_(N_XXK[I8 "QY@]GG-!IE_0?ZK8=WHA]QUQ%_[RM Y<>2?><JF%L
M8$U#XXGZ(.7D[2@8$("5X-ALHQ4'"I;B%O:8^N22.6')N-.<PHC5%3*5ME.;
M_\QHCNG\4V9U^5,_":G;,:&2C$MO<TVS9WD&=$Y,1YX_K/;/>?CN$-@7O;D>
M1U3HH][O6U4#J4T:=Y3Y\B[-+CY7H(G?,S)5%Q+C*E\O?XO-689^_M1.89>B
M,,5,R>0]S4(1-9_VA$^-6(N(3L'95+S1;$<'X9"NZO[[''K52^W##NQ]?\!=
MF*2_)&,CH7H@;SO/2@TU])ZC>-PI09=S^GT2K(+AE:8D!VQBR_+C//]]K0&N
M<U*9I:'% <LD,=(DCDVX:7(LWU1K=B".(&UCI51!MI-N#&7;WHX&^OL<Y,WF
MW(38NY<,&:A)C93NH=J"<\TOI*O\YM5*_/DT9&Z_?N'K1@$QJH^,HQ@H>6YZ
MB&"5H7#->*^#J-FFA6A5BX*RM"_Q+?6 @REKFHN(2PWZ)ME^KU,"!LG/BT&\
M/^+]00)6!]PY"GV< Q[I!'>9!^6U_%#][F8I_[7[2?,TM*(-!B1$+YHG[!@D
MFZ8Z1Y-6?7VEE,5[5TQ($DT6V#C0]9!3T']\&,GT=&T3MWUF87]@)XN=G/("
M);4GD]C]0YQD$'VS8$-%N7",)G:F&2&ADQW\4.RZRTS)2-Q&U).8&RBG6E2^
M(QR6WL)KGD'K&"I(@3 )Y40P:HPC*RQT(Y?MTN<\+Z@:N?VQC?CS=C^D))=0
M?.BB@\@^>Y2$=TS,A?ZVS.;94M*@H%1*:6"B)+&QFVEXVJM,,@NJ ]H2JEWN
M$*N\&AAPU!@VW@7Z4+#QZ,YVC!'1/"@0>'QBV*#AQ) QH9\]61-F<<Y/YA(+
MKD\<.-"5=VNJ)V*VO+O1Q].&[Q/>8O;\D]#KH\"NM755K8<L/*SM#VU9!6>0
MSH:G+V@=-:88\:2H.DSZ7&S;,Q <-Z:[O9CT3%PU$I/7\+1']4?EC"@N]QD0
M]8Q'5O4$.=K,!>T:;:B?LH>,GHTH9TBEW9!K +VUW')B8/LL=]'25\3FOV2A
M@E;ERZ+7@L3_ELA!O8?62TB\?K@LV@)RN7&\FLGY?OO6*NV<P,A'_=B1L KY
M@'Y<S0&Z5*=*KA[?:JZ[(Z4ZC2,J1*TWBVYBK^H13+:,Y=/&6_911;0,]B)S
M_G1]09"< &YM@/O>(_5@_NY<<B2H)+D(M!;OM!=-?)<)*@E?I>M>T.?E8QNU
M-.#6%M"E-:ASA/3W_K:K<& &ID ]%!2ROR@TW[R&/87,"W58)NC77RL-G,EE
M;V9H&;]=84H,\"GO/X(F>?&\L,<N<MXZDD&X-X9:<5ZA&G<?6I<J-E>1.KQI
M;SS6M'7C/5LH E40HX=5\ZVP$UD!<S[U[64U.1]OHD>V=M,A9\-<4Q7(CORD
M8WK/ESK)9U@9G0_GA[VXZ?HOV%+-K%<([[5Q=9Z@;K2]I #+YIK.9! VECF6
M:2)KZR1\:'6F4; )&X!H597OY!7FBN<H9@AJ QUFK78A6VB'&3GNAL_L\J=K
M+IX+W&AM?(BE@&],W#(" <Q-Y1-K0_(Z4J2H[S*WR^ ]#0"L&]9[%O6: Z))
M=*F+5S7/7KT*H6T4N'G^!++)ZLZ6-&KV7MN,79ZF$PUKQ5J15[GEM$O<-,\T
M4ABO=*"N)&7@N6]P-)7"\V6^5GR$Q,=).BMU-^TA$/9K6\Q3%OD7Q)A-SU;'
MU%S3RO)/P^1 862AK!&C;6@U)EUS^K=/.J2J";^6EI6PM5$Q68]:5KOY=_4>
MUO"/J(\\CUBXZW2OM0#N%.$ZD],CV7Y>K=O)I6&AO97H:=/L9+D,"K0M7(G@
M@>)7#-Z=#)T;5IRBLF>4:9GO+^%D-I*._#+"3YOI:*&P'5X?JAMSYHG?@S M
MA54E_*ES./*V5RH[D4\#J.&T%]41DCRZ2D(1)\=A.)'Q?F8G.TAJ76_1WI.G
M3G<;MSN#P*CLLM^7S*;)[L/OKM<U"]SOP=U= \6S4ZL%R/SA!@A#9$$S#%JK
M>_K/9$<<FVX#]O@E2H@+NYO2DB9)7@B?;]L+91Q=N2YDUOQX_7 OFLR:-P4)
M.63P.!5N]M#(X<8/J:UMZ4.H@CP-/A# X[ 4*?C$GQ[AVF3 T4'JL>!Y-'T"
MLG+Q5O_"61P<$'!&2J.'WIYLR<57 ESX$O9':O"5$'IM).!_->QAP.EU'?C6
M>0H_-'TUOL] P(_:-W5[?!/@"A#4FRDB+WV.]2+(";0E!3>@_HL9O[N,2[H:
M0BO5<&32)ADZ?0)"00LU=CO<]*)@2%J[]L/U 7J;L,?62C&H+ K,/+)/^8Q$
MM-K%C ]4"-C(?_XR8R<G 9 7RH65X7]00K@:VV^+/KC!ZI14$UHN<I!W__M$
M@2C1]X&'N6XC#-CC, ,=#@[+_^5ZLX*/8I*!/@$I8\GWU!F^TU&OG,+["/!U
M1<Y@DH R81=MB<!WVU.M1 GP,99]B-EXS F?D%"[F)A+4VPZNORK.8!^^-G:
MK.BT7(1F8Y]M@O:XEB'?U3@1EDN^NU4EWY<+JQ):A?>;27V<8&T+GS9"^#A'
MY#]/AGPY@D\E(5\*V16O8]./DJ*)S02?DI7TG*U,G]U0M\('M[:!88#^I]/H
MXE\)U[.FZ.%"A\( :!7//B="R'< B,OY=9S]"&O\*GVB-\("C/W%V] 2T?BN
M.F-1F)OLHG.%+Y $# QT'7H@P1.L\UUJX?U!:HH0/5+1@,C"1W/0X3YH7V<^
MN_#[VJ\3GW(;QZ<_PA]@ !#>8:7!OZC(\'&^#O%6@$N*G8Z?,+, 9I2E1Q"[
MO5Q#N?#D-ZOE.S,][&"R MJ[MPH##G?BN[WX06\-]]A:8( >VCY7\\BS'TSX
M=_?Q?RD,]SABKI8.$E(J$;![M:'.^N!_$][;A4F:PL5\7/ZX8NF#3?_5XL2P
ME>)RDQNR/'#SBVL7(POP8Y?U^7(VQ$B/(,?!]ISF8TRH@@SGA]_?PJ"XH35@
MGQ(LP(#\"*B<@8C!EYT&J(2+R/IB76@OFBE<XTB@+9P8F^'JU\K][HQG@0V*
M<^?.J2QRDD:+BNDZAU]%ALIZ1]H-*.$3YG<U85SVLQF,N6E&&MDO5Z9'H3=A
M0&+W./0R>#?Y' 0/L@_X=<'3== :%RZ"D<-KQ_?..JLHBB^#9^#>+#ESW?8T
M## (W@"CP7?LJ@4,\(3_?+@PJ SGQ,[I*%P7&85BPP'[X8!PC:Y 6W; EU@1
MT\?;\.$;R$N E(*M_P3\OP08O)L=K?GZ@L,A:US">*Z<A87'3SI46"O(9F2L
MVJRR#FXGE>SCKVP&DIK:%TDVVPKE1ED52/##7;_8V?%@G"[:Y#GINY:RM"OZ
M[%)(:+F/8("1LSCTM8#5^3'<7.4YS8U<?"#M.5LDA'HQO4F*0^?P#C^^_H3Z
MDX:0\0_+%?2#C.MM&=EGK]S"#J,<_Q%?\AK.%D@[TF@87'@!@@'BJ667Y_ -
MW_>C,JJC_843*6;_Q/L3[U_ JP<=\(V#IPNA7&6STNYLJ>L[7>9S[]PJ%E"I
M?351WGERS3I4S=2=DG-:G9T'GP[V(!$U5863B5L."\4KG3C<2LY0=![+IHPJ
M(]@3:UE7KYO5$(,!8G!C7H=T85Y-SF#>Q=]] TKP%'1 9'6^(](<?*+^'MS[
MN&[[,PP@V39)P/J3^!MB6=X%'?F([TP?YJ[ZVZ'J:5;J&9P!X<,Z"<#:<"?[
M-MS); !/OX1R@NMS?* ^F' +B'8RXO8G]9^AVI*P-IS8>SR95B+Y]/ Q]2LV
MB[;;017'&8<BKY7-=&)&7JN97 S?56WKOG[<Y6BOA(8" ]"+L,\P>"Y/0/-2
M%XRM(BOWIH]GP(%.)7\2_S&1PV+F8^X%CTNR1TV4)376T[W= *-2CVRJ[U9]
MU1@]DC<,\-5&NT0EA5Y@[R;_2?P'Q.Q;(IB)1;7>JP[/C?!??KX79.T)&>L3
M)6MY4TT >L-%4&7QH%[CWJ<'NE7QKFW?-\P[\@=F?K#4)G^2_V^1S?-VFE_5
M4O2/=;%@S+0:NNC7B,Z#? TS9\_C P$9"69\!++XM?$5\T56>(S5VG 51D?7
MYH9=ZGI@NJ?.@4Z)K.!^0[&F)]*<,2W3T^?*$@1K,2\E\%7@(2J#UW>W/5[P
M4//1=X],W4:G3_KX0XCH ,:L6TA8%=DN@WH-M6MJ[HQ 9;'"X/V1P@!1L_:Z
MG:_V4&J]$P@,H$'=AU9(P&TV^AQ3V8\_+%_PS:[GXZ[5/88XSU-B!%/%X6-@
MKS&:M$GZ6Q7(\W"'A$CH#W-6!1(JQS6O(%#?59M9(-.(3?=QT*W#F##/R&!.
M)"U0N$%_WNC!>S8<E*)2TU8\NKR2Y)]HAJ^LF=S/2M-/,X2#/]8XQV/10!D,
MH:,NN\&MG%2B*:\Z.SQXT?-1_QKBO!=W6-BIAM.+H[/>E+C/6][^3.8/=KJ6
M(,3ETYBY_KPR+,;66=</>@P3DE24AP)I.W68G QV.J.YOU+6E-:54BU%CXF.
M8R<",1H$.*%F*_)<"<HZ$94"/;.3XAK[J,S:^+1\%HW8ZS*9JT\:%/KSG'!'
M"CASTD^L%\&IBOPU_HN.%5$2^!JO?/&5I1']Z=,0?C,97C_%_8^^3<+DCO%%
M4/0]&)!>#@-B'ZL=::J.3HD[6%#Z.W]DYUU+4>NRDTCA+8DV'II/95TVY ?7
MN\W%GV%,>,I!\;_[3K#D<3_=+GM=6:K/Y2A9>&@__8*NE@$^(5TM"W6S4C]4
M!AF=L'-;"@\,/ )!+_-C16:%=A4O42U%:. 'PP\5X435<@]+H>"D_4U)CT#W
M51AP?=L?O,)A<\IZHOQ#Y1 ]MF'=9L.#\(2$8_-O#A(?/D;KLPDWD,3R:%^\
MT1_@@Z(&G&MVQ^_$G:1#?7A H?"M!/JAHI0Y(5Q&T0(7FM-X=.2/<28+-]?:
MPX!7QTTB!\3E%Y$7]#]4SGP59@_+CX3?]13^84[('U7DADD/Y \I,MY(:L9\
M6?%$T5T5;BH^!;>!ZX-_J&2H;8%T@XU6JL__F,JO5$ER.@#%F\:'Q^//Y_<,
M=Y)_J*P1"+P>GA\]8]WYHV)?8!(?<?VQE99Q@?G'Q#;CV/BC8HL@_9&5-O9'
MQ19N_K>O-?#+/[@5#6=,>@K_[5OQWZZ@R!KWY9\[$X&/7[_NI2=535>]:?1$
M5<I[Z-IBI7%?E9HB&J_4Q_(G5'1&0R8IW:+")9!6^[_V9-A_O&B]WO+D,L@1
M/Q8A 4+]Z1.N+<  C6EQ0P;GUU!)TJM$^]#AB]\=ME4[(#P^&P$J=G_Z?+7Y
MWSU9]$?*&I0$!K2)]8/7D\$KF'JI/Y^TAWUU!Z@YV3  ,UQQ3J+GG>&>DI7(
M^@?#,R #2EK,DIM)P/LXO17N*[QDEMDUA\IB+E_:OH,?Q@3O9CULF5'WMDR3
M0L6XLD41C;RE^997M9I9M.PCGWR"2';E6LG'-^I0!.<]R-D39F9QQ7U*] 6P
MZ^$:O#XO3]>DHUX5X2,_H(%R0(W:=C9","M")#7;(5=N# F==\']LF]#YL/+
MVU,CEG02(<0A.Y*;'F2:,IBP-S08_&&_K4=HG4_ED\:&S@?/?7$Q;Z@\]^1<
M[\'^S2=3%@NUFK$#+RN\J%9UWSL;/RP]2;=X?/2,.ZS^F0G/,[7-%6P]XZF*
M*$&Q5$,35XNX9)3M3X^J\-J8BL2@PPI2LSHB.[':X'H;T[S<E+DI(L$ZUL 6
M;_K%C/''SF,+1Y'\DL79:SIL?<P6<UII]ZJ?'3/=?M[6)AS.XI.=&MD@MSEF
MD3(ET1NP/;F_@!36HQPW%=YNRK_!34%5/AA'3,*G84U@$[+$A'#Z/'>5!!IK
MD62P2A)8T_'%[MY'3A0G1+8602/$F,R./=SH">DO%3MZGU$,>30-!%B4L[/B
M&_)3IK3'Q!^G]+PH3(S:8@DG[P!TO3][\;40- KG8KC>K?0HL67@F5OBYIV]
M_Q[A>$&C-#E_1><KI'*(.7_XC#>"+VXB[:NC%P*?H">^+-YJ <.#]EV-6*O4
MDZ"ML;YY\T>+26RM9!9"? 1E><6Z[OR]E&6GMV/C9,+=RCK:+KIL>:R0(U6$
MLMCOZS+F#J*O'!CBC4HDRB2M.ZKHZUCN4YJ\P29UPW5UTR@.J# :;FS*+B:4
M*OBD/L1<,IJ&0YH9(1C60N<MY7J@V=L_HL>-:WK&.X!WLR38V5L^/?N](=_"
M;M!02U>NR9&P6C3*J]Y)*<;V,A[F")5J+U3IBS4/<8V=[GS/,=^NB$3RSNRH
M4&Y#YOB1L'B%\%@)/H'4IVHN&HN-I><@'W=YBPHB*9N;*D%$.#4VWKRKVIY4
M,. ]MI\M>!$>U!R8#YGKF]T 8ZY%*_D>Z[<'!+#YHG_>/U7C3\LD/XI-&:=6
M\&M'??O.:(GF:Y$(O\VK#P/@86];#7:X\[?!_ILM]1Z^GQ_^[M6;F'C73PJ&
M-:)X?1+XQ 5PE^O-;U,M_U.%0>P9GZHW/XDL [;1T 72+J8-5G!VAT]LP02/
MXJ.6LY%L[VO=4A#W9(/B'1@PA[5+$98CG27:R(/A+-QIWMDT:[']>2O1<*/U
MT(P!WYN7CZ*V!+),_O*OI1#_DT6#$AZ#:&;?O.QI]J*^>LN #_S;+)"'/NM9
MZ1G)J52CR-Z]:1@P\CSO JVQ6T^AM3,I(K1&->!?T293]HDY/*9 DX$!>8'P
MLY++-GSHZHG-4)\4> ]7ST:1%.9?<*N+O"449@:WB5WEHI7!*XCE_IO0[^L9
M)]ABQ;M8Q0[FKD0MY,GM5;IHUE1HAYFI-.CHB@4+^<K)$4GI)445=5%)$-^T
M$+5"=;+YX7>Z N^^=M[JXPQ%N:OFB)296Q%RZRF^1@P%:&A+G83TNAXO1@J"
M-[:L5K5 CB)GB$1Z9[_DN+9-[YG*<K#-URA[]7+[CO&WB]ZDIA1:+UF\;,O7
M5?1-QL(#*WOL3*F5R8!.W@7E[M)R[2)?@I&.6=_XS]$:B4;FU"/'>)72:CMJ
MMUK(T<3TNI;BG=(5%_3'JU5FR'/X^P,EF%\V)4$(4NPQU2UJ>X?9WWA;T8$:
MUH,@*&F?W-Q#:W*+VPOV*95C(7J[6[>>R3+)RB-I^$OC;#S#Y&L4)YX 8^=J
MU@Y8<7XE8+6(N_4X'(._-PT^AG"37 9[3 TBC#VMUD(OHCA>M!KCFU)H_G@/
M-4QDF=*&2E8X\Z^O%K8A,6]N^"U&?7BF]$P4;=I'IW+[U0;ESDS-@')34\E-
M&7OBXG+IEV78#W'1YK7=3%8,J0KKE75K\?L2AKE46*G9M$7C7FQ#NT4_'R]!
M6"[(RBB$JGH/CO<VY^XV?5Q(0NH16FTO45U\HNQ8R;O&5!CECG52\F"0,L29
M)ZJ5VFF\BB@CLF%8Q9VW?$0,#)'P6$"E\Q,O(_/D='M6);[ Q\^4NJ.>0Q*7
M*1QN@Z%X5$YLY+06A, HMMG-H7>P2\3R[.4;9M(/U*X^_A#.Q78Y';T@?_KL
MFW_M;4/5L&UT"S[/G83K<).#,0K_Z=I_RGY\"P>=***2*A6O.TMN-QZ/:[+I
M2$I%L9ZX#<K:^%M*2#)74?5Y$CJ_5AG<T&G>8Z#VGWC,HIA^K)CKRJ7<7Y(M
M#U(,:N^^%R(I@)4^.+2V8]8F:Y$\G!8=^%%9@B#J\?\N*_*[7+*'+MTW*R+W
M5ZR(/],0;_U?>]'R'Y7*.K^ZJ[3A\?C5]<7B=T;%X\KK@E>P)%1/0NR^RPTR
M@E_%[W%,S4-?[L$ KHP?C$O%)%(CSQ3I(,FQ(MMI%W' Z;MR"]Z>O9Q9PKO\
M_ANJIFHOPAI<8\YNU5BY9LTZO7C_-&]12"RO\EQ2$774_)A=@I3YZZUA2P5#
M(V.;2PD[UYY +B''C@TGZZ]W)1J0R'2U*":6\IQ'] @CHA7"4":<E+5UO08D
MOV(LYPN=H;^55 FM9. ,8W%^IU5;LI/O9[&91^W-9ED4S^ ?.A[$[E'8],+Y
MG7I-Z8E/4@-*9X@4Y<M8Y0+RCUXRA]0V!G9N61/38U]U%:C8OC93!2,AY[F=
M#7V:QC&<7CL:BYG2'&,^<G%3#?ZP\%3UK&I@B=7$E;FX&H0GJ+ 32LZL_SY?
MR3TG>+BP&N1DES7F',75$;5<ZJ;(5CU,=^P56.-VD#5%M"N\?7-MK#G1#K.F
M<S@84ES"L7G;:#KUR9HP^Q!$@ X2DCL?I(+1A>RFH\)OR;><D'&D8CGE:Y=-
M:Z_)'[X4OQ,II2N0^7B?)563?I1NR2@X'7_=-'67?-H'7#+1J2=/ZCAU\Z+B
M4!!]WI*KJBKVUKB,A_?P9$<"4FAC3"@8#Q[_F$UZQ+6C,!$5W>UM(VI ;*$[
MS#["&K-4+)$R-,HT9W=7UHB6P>BQ?>*\\"2[./[]X6=X2/6U/YJ9GY5".)SJ
M?D'^E@%W<R^/$6KYJ;M==FO]"QWFK\'MYH78VV\.I^,@4>GFD='/P@]34#!X
MVHH>=81*E2U+%8:)+^MC5<D/;N?6$ND9-#DP3GQQQ.5SBFW-/?82*E9:RW;*
M=69MT-A[N#>AZ$9-W\_ST+=9,4W>MBUW2BJQ(\4]T)336PK%\T503']ME>?P
M+6Z355SMA\]]ASR?60I $;-'!2:="/G=X@)GWPGHLI)X>)^KU\0KTS\I]VGO
M?,A]P%P5$JQL\"SK3E/V5+,78\H6/H(7ZGR39=,NDLYK)?.3I"*Y=*3.J,<-
M;4'"1G'FG\JC\BQ3RZV1VA?'D0+B2E12N6@7&-JXGCK" -Q('&<GM."-!4%/
M K=-'&RBL=5C&I32Q-1Q,9;#^4O9D!Y+T3P[K<'<0\-KJ\PT#6V9.@*BZU1V
MBWN2:.EB6L?1D*'+ QX[?-SZD.9/A  RP+J"(INRD'/1;E<L("3;K(AVXHAY
M1_6.&>'(>(J#57C2?5&0^'N;39U@PD^[<GIE<NG>IIO/@K@-JMZ2"ZU[#0M*
M@//63#,,/H[9H[,3 O.I[,N&@RR0Z<V(#U)N=<[.?A,@,X+KNOI-F[C/C!X[
M'\<_U771>3)^'Z?;O*)42@392HGA+M=MMB"P7Q%VH]7-:@IM-W7;<M-AT!32
M&JF0&29ABTZS;UJ-;P;$F4*<Z7K2A!Q%>CY$;5Y%QK0@:2Y*O,'SJ2=#OS5Z
MV=C<FH E<59TYF2.(5[;N3@,6)&LS&5MZK+)+ZW*K*GF&--E%R-3?B1PTW$W
MKG&$7+#+QH:Z)["?S_'SEH+9?.>:?IZWXR(5W(@]^>DJ\$?;J*!8S5"R>%[O
M19<4B7DY<*H,J:L$,VH^X&Q,BC0'VT/5+*RVXMMC>W-^J+]+*,;UU\_]A9_%
MNU.6P;'L6'%1<ABZ>I%1>8.-/G5L>E(DG%3W/'TO:>7NG\W_[<W]?F;G:V+!
MAK?7![VJ!KG-N0VI=VJ$Q$^U2RE:V2DSAOA7&2E9?$5[54WE,F=^J$0BP"E2
M\\'QS&VD=E5'/2WP,7ELS'W>L%Y;Q5R6\-2QE3%W#0V;5_YL)V%K9IO.)P$/
MLCI:#U;ZU4:NSO'.%[]_[?E_N*C@ FUS(?I:S[1P-DQ6D#*^\UD8&T7L=K,.
MGX J3GJ1KQXME/KM(9Z?_?1W%RS37B=1'6^_$G\H^:"99?-.@@8?*%%1%KWQ
M3W_1U-P9O\I/0,]_N%+YEKP(!,^V5H)Q6=QUKH(&%QB@EP0/&E!L"*;<-4JC
M%4&310\VTN@KT,'E3/[GY#T7YQTPP#TZ&M>@F__5P/)33D\"GM$M\/*4X?E"
MWY% _.EQ)/24JXS3+>2YF(3BSS]P>@0M0ST684"M/%G?%CQ&\"00^5TK3CNI
M<NWWRJJ7O_""C"I@0+P+>#M,2M#--PKEGVW$^7<:V19A\<_8_9TAJL& 7Y%^
M@>BAF/W;@@FP@PQM_&7C-YQ$]K=9+_=,?E487_*$QM_"[**8+[Z=E/XKLW"+
M'0P0AOM5T[1!)L<WV-$9P843,*"GNNZX+?D7\.5@Z[_=S/E?:_:MM_&= !F>
M=P<?4Y1:CZ6O465T/?M5NY;.W,.S@L^2B\5OW[!_%9H>9,Y?I!>LDA#/+NP+
M;1K %GGR&GJ:"FT<$%EN!YTOY6-]@,SN=U2L9.0U86_(<T#=$^$H)K_2^Z0$
MJU[?=<,7*>3L.=V#MTT^QWL(UQ ]>#NZ3H)L;XNL<$/I%_;@7R#,+O'M.LIM
M6PKC+]^F@7L^B!QW@4:CC2].X>>.^[#O3T3Q7\%^Z2#[0+F'9;:#X@^.)^47
M6@E]<IQ^0X10  SXI:4I^'\7[%_1GC$,>&(:O[^(?;DO=40;!9]J)?A4<R7^
M$>7^;?VU5_W?D>6'$9G^0LQ%IU^.M%X,-A+YM:7AOXS[>TF)EQ_\]$NN[MCX
M6%KK'>D1OGK_:'\%%0_)4-W;2?X,&/^IH!I;-H@A^2,>:?:CF9D#SO&W,]YW
M1G!S3'U"N\J"FZN%6YHB== "K$BXN^.>O6CN1WS:PT>0PE#Q@G;##2)NYX"9
M6J4H\"K0M7!5[RX,(+!/'1@S208+@!@+YG>YZLUJ>2IV W#OSV_,\7P%18QJ
M@\\.E1)I#VD&I4I7QW+3,O':3&D/)<<4$[-KLI>9>1KYX_WRH5U6;O1!][%0
ML2D.5UU9FV+I-&KWM$GHJXO6J2BT@D8/D^SU]-]+.CT X[MK8\4^OHPR=W\_
MR=<9)6+C 0-T]O69FOF#0K _H>96I#VLXFLE.B">RW6_+R^@,KS-DL.B_ZH0
M-=*%5&RY3&>N^94E32=C$?O-+P@S^:GV][D#<V@/A61;YFJ369)?''OS;D@#
M[_D\O^:N0!FIUM9!7PN?;D*T=A1KS5L:6C(ODX8^2)")6HX*KU+XA8Y-II;=
MY&QZYKM/&C;HD'7$5EN_Y"B<X:<>C1RNH#YX[\),=A_[]=2=H:DY3,95SSZ$
MAV]+8](+N58GU_U3R&B,I*L239+\7_K^-OV"*@?-K?6K5=[%O@C@N?K?=;+7
MOO[N@M%I1IC6=LY1\AF^LD%F\[_BPQ#\>G=8.WV&I,F@;]A@=4K/KWB^>76W
M^,SPQ)8EOC&H:HXNP$$(U*S)[5BK^"&D6?)D,$Z-(D63&0;<P-,[+(4!=4Q0
M I&F_%-ZGOC#=M9+0!-'JS<939[;/Y./08 \^.*NO-WP./0B_RHA]UV3%F6=
M<W2/-\M1HS"@OG%$R*)NN_U;QK"0JT?7ZGRO;E;/ =\-W<,G3K^[!7J+MF+]
MZEEIS:NDJ^_;//! V>6IX4X>O[^0K_"7'I9EHV_@,"#]6U.I7WO5))>@J(]_
M=!2ZY2CR*_:_P+ <:5?XK6_7<?!T^+=,Y!/SN-+IXT5P??D:_1'^.9I@5>S?
MD5>J('V4;W%B _QKN^ 3K>CEW.]%V:3Y!PR_R/H3,#[X.^W9#"IO,!QAN3@)
M@'YMF/R=]IB"DH(?*Q:XR?PC#KN.BG]I8GY6SGQ&\JCJ!MQ6_YN5JE'F)VB3
M;49!/V!!MR>8F4= ^D(6Z_J99HS&MC<,6+#O@P'K6R++RBH!^*32&0IZ[<L#
MXJG,MP65HW>QI77H4[H 9ORH9$X]E"3_AWW6M^!_HED0^V2B.20^ZS!PR$E\
MAK,0)\W F5*["(&D,,[G[[Q*E*._XY4T_;N\*L\#?HL+9R-$,/F9]UOG89PE
M>HAPIF](DB;E-R1H3:Z8X(2??/G_T>O'#[]V(K7/J8)7\G2''FEYFFS]K!I*
M$]HTI=4K4V(Y@Z#WJK"+)>5VW)H(G>DD.TY\.E?_2=/<T(5VAHP%8U$46]72
MC!<:<9Y,B9$=9J/WDSUJ+PQK6[2'Z >$]3E&Q17I&+="HVXNF>2&F2)4&(U&
MM]:$;Q*HXX0^%?"F/*\-%XZF+A^2%0W$*$P7#+B'%+;=16$NN:]H._[TB;*^
MEX ?^&Q(L_>3=H@63>, =660H=G6PNQ;<E0F6Q-+E2]/!V;+@M@34S^WJ2J;
MO>=TU$"@]9,L?^WB<-Z0-MVX,*ADH(C;'(J$8Q/TR@?JL98P5R\K8<7M9I)6
M&>%",AYX'A;G&A1. RDH*^'0'N]BDO;]$,56)B1B,!1CF5)1'GTCH,UD\V50
MQ4'F)A?3J]@7*EQCY3)D96+Q.A\.;PC@>$"6@F8UN" Q+,1:9!"-JN@U*O0\
M\8)3O1 O-A]=I^BGN%U6U&9J<0\_[;F>/8\[4P_LOF6>F_55%%P59/)!]\::
MN3.'TI#])]^XYCFY,I6L/M^):R*R9^S],C00/QFUNT$OHSPPW>=WAN$'P*N
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M,\*C/3V=,1E.-F.WA%8]C)'$M=IK.X?'KVB'W=DM%TP4M 0L3Z6FYE>[[&$
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MO.C5F=+*+D:^4%#<XY@AKL1WTS?:!GW#E0[=-5CZEHYRE4:$".]> 5"Z6W1
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M9#$I)#]BPZ###ZXA73II: /9Z/V\-DE].5.->#G!MDSV4I1[DWU]2.<:<+&
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M;2L^1QUFX]X;64NW] C1>$.[-0&34@'DA6E!FMN'5<D1C*>4U$N&3:2BGZX
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M#N9@ G4H3L/.,^!B0)(87,;+J+@\UD5]54,:P\:YGA=Z(GW >H8"EPV<0$W
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M2[$5=$O7?\)VZ7'9+BU,4BOM"O $+E8,B#NHC'M)P\^T0UN7'5> @[O:P?C
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M@]R!AM.?E@K-E 51P*(OV3#,+3L$@__CL_0_-T._F9)_?X(*[_'-?IV@]%<
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M'=O0-KRIR&FIQ\9+W<5S'H;#P\/^5DQ-!3'WE*>3/O0BE(P&\1_WL=&3["0
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MN<Z-/A< 14]PS#HOS5RUJIQ&-M?0ZK&K#+,:3>.D=K,^D];UQ/)L>#:#6#O
M^SRSIKZ!B,I!+NSB#.JRVDI_QAIGY( Z(:22!.=T7VU+R%YDJ\979D<G $GW
M.';HF"31J>9P4I=49P-Q@EXDBO<?HP3>U>ZY>+;7-_5='U8S,S+0EIL=]V:I
M4BQ$\'+<B4R)@"JU%6VU[D)#XL[W)^=EQ$5 QL^()JQ%%_M'-YA$-&XS*QJ;
M/LD$VQCC,'0)^'$R#^#(*BMI&$MP;4%P-1!,J3EG>.\:0 %K^K&JG'<D? 8O
MOUF]C]L\!:_P>V?JGRD*932@P/&$<JX!PK#4WX+1G<,ISMYL<%X#H@\V& ?
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M'?FXB\NS0A"8734"57]T#< $KMA&P/*E:@HDI$B['G5:5]"(OOY?/I"$_\9
M8A<=7(*5?*S"1FT6@QH%[[-U; *]A6^P+%ZUWAQ<EM\]L3E>NCBHVBI)<C=2
M1[,F?#YJJ"6AB+MPD;039\))ICSSK:NJ]U5=:9(**W-(]B5LLKZ?N33)D'-L
M+6]>M!!X%:K=8D]JB<[3WR!J:H-DP=<V&8@>+GT';!;.0,^[!%=M+!^R"GE=
M7)B20R[^( TB7^B.U.8$3'+>/_5*6%EH.[H3;KE/C<+@OE)>P5_^>>]NHJD-
M""W+CXV2,7F<AU,?:&7V=G=BHP\38UVZB?TAWZ@;>KCXPO&@,@S'0@9=R[XW
MII]V+]]=/9E4R6(TURIB/JD%<^(!'N_FF9T4;*MXH+&@.'CIJ82<E17G<K.H
MM?^2@P^R(U^]76-P&&=OU#3U!XP[/K%B#\! &[_%:\#[F!Y R&/MFB#!, IH
MR2;!QY78K L2U9=K;)><1A%;7A:WW#,Q'GCK3K<[:&*24-5&=)/;FA?JU+CQ
M&C@D'15=/299S"X/OZ])9=HQ0<LO(^23P)NM(- [A:NZW!T3"J8F=3_,_MIN
MU^;LPA6>BK5FSR>F-Y<>U\4KR;O!H#'R2)^@ZV.7,>;8$IC1HH0ZA3TAK(@;
M]+BQR&2GC]!H%3>+;*S-";]1,C[+@J#+BF3**R\]),FK;?%H)3X#W'J@%CS-
M)+ZUQT[^E(2(RF5@Q,M@O7OBL7>)2<9,#H>H7MJ!R)U=_E$C*@B(?VFX^' 4
MV45T69:;T1W3TB2>K-G<&[6T_AWT'BWW W8&ZR]=>:'T%1FP15>0H%X I9\'
MJ3O4$ 4/IJ4P$1J)WU9$-6P4GZ(Y9<7"_D4E)66D3]^MP.MI=: XUX+>TZ>X
MY^KEF[S=O9I]132XR=V'2A+61G]H&U^#GWX<RKQ8\&%6DI&0;LN(A " ]'1I
MR'_]DEE!0_H2.8AQ_7"RM<:W,T*1'#$K'NG>UZ^$636*83LA>7JG7EGLLTS?
M.]>0F]MF.%]4EJM.3O?C.DN]F-T* \ZW#[Y-_W9H:GVW0KH_QB+^QICM:CKP
MW[9F_XL#:@<2I\Y4NU+H3K*%.9$8-B@$=G2W]$)UD#7AN:NJT@'^EN"FK.VJ
M\[,\E?&"")TNYXDTU0_&B=^H+O+&O-]]NI3*UQ^;DG:\\/D<@]K=<Z)8M2HS
MWR!&P;4SUV<<JSY!T4.I,=H$[(_<Z9$9EM77IFGEQHQ&>?^0_)D7;Z][>$;&
MU;)#1YZ>LMYF:7W*$_/R LE(H[L2]+Q:;I)$JYO00L5'-9527I*H#]N%# 0Z
M+"ET0D=Z-Q,DHW+'KE)Z9=_IKKBLAC:]+WZ^]JX/ZVFM'2&/T.LSOPO,%T.:
MCK.U[\][*E;ZQ=TLC^YZ/%Y&#:/GF@F*T-1[U-0X.($+V>$=:"N7HW:[0^K$
MF^NX5%L:Z8"\73\H'=AOPVCYZ-6K'4%A!J_CB**9]=ZWD3M<MN*,-F@!*:BD
MOIM Q*Q/U%59$T*BZ^3HP>_(?7M',,>A-1XKE"W40_4\++#$BE)>DE$MA89!
M7:3)S6-U .84/&'<$/1EO[U1 [ON4V>_CIJ'XD/@NET/<OW=8Y0[L6'A$/<=
MP; B7DFZ#]WVIE;IKI7\FQ55KD80%]V-K%=8NN7/"O/"03V%3D&&R]- <4HF
M@"05M6&E5X%ARPSC@8U1637&ZFWI1<">#D\P^VE&F-2]H L<4R\)I:$CNN^+
M-+=(%% %)?1*!#^FY'Q,'AE00C#/'PM)!A0UIR/N-[?K_NE&72+:*9ML5_+2
M:P!E4-/Y!FB6^B+DL 0))KS$YO+C/ETWTS:J[EXAPNC<#,AQ&.%_974-KV&N
MZ8S$4GCFQC2*8>/*"I><Q#Q)O%GO#J4]5>9JN0;@TX11W.AJ=O %\-KCLDO^
MPN+W8.;6\/+T>;/=!VQ)#N?J 6$W3*OZ&F G?(BETRM!2#^_2#""!U3@G(JS
MGXEQY[A2G]D+__3^#=[=$M%B)G?_R1Z;%: NEU%P"OC*$\:)5YC;K*AJ3!P9
M^@U:7S-$/"!A:$IMTT2S;-M!/G:[4'_SO5O1A#ZJM":7L<.H>:_!H,S+P*O"
M6I*"DIQ+FAP--NY8A>WXU9W%(JY^G5#:AM -*L'DH;)ZWJ]W4E"%*MY+T(IA
M +\4R/!/-7C9O=J3P@O)BO#G-8UI8?<6454G@*Z/1DRU>AOQKJ;G#ZOEFTM%
MQW$M?W/\O%G+ 3'FH[M0\?SF<IG88+>NE@&S7/H$8MSDCF1CE'Z'/QE\1+KR
M::T07G1?<VBR^X1[:>\.<^ZZ"[V%$E.EGV_U(](]U:41M4M)3D6Z;1RF.O9^
M%%@970[Q0VWL39D=J['-\'969NOM.Y7LG49H.>B$)W<CF2UF^M6TM@I;U>>Y
MGN%$/1*T!^%#A$KN:%0E<K'8.-I'7B4JQAA[AU#[Y'L!\$C/:WOF$[WHGJO-
M1W>MF/+V@=L_KWW,;</>Z$HXMX(GFI)BV!ES5#V,_ H50:(08U/EO+_NQ'AF
M0P,0*-3T'5!SIV^/-F0QKLY65H8$C2'ZSX#/'^W*R)$Z:>-*IIC%O64!H6>0
M9,:-?GE[4$8"\+L7"1H ,P50,=O:U:4%NG%R:PF9^>7R5&AC"ZRL0)ECT8U
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MI]P"J"Y9?8??P1K[F?U>[IK@/7C,E^R^')#=\0A3]Y?V_Z^][PQK<MO6#8J
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M=GE'.<Y( &NX+R&"_%GH[<,=O0^%M 8#CXN+S(\6,LV[1"S#F9I]!P>9$)
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M]P#7*/'P*?&P[0!6  "/$.]O&^!?-KQK^ 2$UXEN$-\DP56 WP)<P\/'OT:
M3TA(0("[ZH.[#B"@)*1B>RQ[_;:&&=$])VI!_[BO-]B?5;30: [M<CPQ_Q!
M?).6CIZ!D9.+F^?^ R%A$5$Q<0FYY_(*BDK*+[1>:^OHZND;6%A:O;6VL;5S
M=G%U<P=[> 9^# H."0T+CT_XE)B4_#DE-3LG-R^_H+"HN+*J&EZ#J*VK;VUK
M[^CLZN[I'1X9'1M'_?R%GIM?6%Q:7EE=6]_;/S@\.CXY/3O_0R\\ #[>OV[_
MMWI1XO2Z1D" 3T#TAUYXU]S_J$!)0,CV^#J5K :1F=/M>X+^-ZB?Q7VM:"%F
M?Z*Y2V/^8>@F+8?0'.?>'ZK]3;/_,\4"_A]I]C\5^[M>:  I/AYN\O I 4#
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MG,QME/1/;AYT6DX"?D;(_"KG'7!OSWC,B94&N*B-HRKEB6682.K4>KQIRH:
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MR@!+KP:C8@I5!O*#$G>GOY2;M%(>FU1X-/GF1CJM&= F5>@;R-O?N"<V^B#
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MT._[P6Y"NLQ8 '$T;F2>L32<<9\._>EHD,A"WFEF]_-&YB';1G,\)(KUMWV
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MV<\W6 .\E9W8K]8*+*V!T79EL R(Y,P^9TG#.1.CK8]S9S)"$_!FY.=$H?2
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MF6SQOS$>NI6FW7CJAP5(U,FX?S\<\_5,('G6PU"?E#,_DK=V[E8 ,K,OF'J
M[TSP\1. U%J*%%6XMLL)__BH<R+Q]9MS%(E/R;I$<-Q5"M /OG!],&ON2=>K
M(YFT>3[KE^71PT "<+!\Y!NA(!)?C^QSX94KG]::+@^CLO:R,V[&DRO/S.4'
M%*<O70?.;QW-]  [ZW:8P3FZR%V9,D=@(-Q+*1?!5O"9O[M3D3OC4[@T'2YA
MBF7)Q ),<..]>@^&(LH'-QO$*%?)[XH@[I7>P"]\^0@M?F>L^;<6_82]C;&
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ML7[378-< @9V;5NGJVE0\GC6J#!4W8YL3H &_8,:9I_WNOMR?3O0N="&<UJ
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MKOEWL3_]J1-DMI\8\'>I67]3=H?GOTK70J>H#G/MR%.J'6=2_^-/L/-B92R
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MFU?B^" W +GEE:%0R<N\6FQ[(^]&J3*1\$KE=EB;3W5^Z>M^<9@'P3PS.M!
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MCXK%.XF/"LK9RV>+31E,X>L>3?H;-;,<0T[6#PPV4RJ?7U7F>)O>.^AG 8*
MSE/2DPQ7)[^%\_KU/TP$I38-'6$$7NXW]R7GO51A8WV8\%C@@*RE.F<>(M@I
M0+-UJ&A[O2>Q2.>ZH&#36,?=N=R+D:?=%[7&#J<@K.*G<<8RKRB35#W_1VTZ
M*:Z]UXF2H1]+ D< L<>3NN_U48[&GAWI^<WP7/?7Q:G:-?%Y[VAV_7FEC4;]
M,GCE&<^9YT*%01A--?[B24;#*G/H)^9"(J;715[!^D@FGX\Z+*PCK])Z$@]F
M*"NB?2.COM7JLJCV9_,-.*?TRZK>Z1456X;'A?LIIRO%]L/O-HP6LM;7QNU9
MY-C[D!64J$H*CR,'U=6T)TH7G"CL&&+ZX-EE4W)7<QQ1;)3*-R7B5>60*EBE
ML'#PUB .\%"WZ5&.:F'9>$-PA#!CP2&GV9":<TM0$?IOSBAME4(7_ID:"=);
MV,<,GAB?CE\Q=F!:OVV>?];O7GU1RN\WL?FRB[FI$,.BQ97]V'\# 6]T 14A
M-A#VW-*CD,/0?@HU61<-5$$G8S.E-P>K=$.:A=GH@PV]%BH\Y_S"-9IGP;\4
MU&*VO/2E:%5)$I/IKS"&J#4F/47>C7-Z4^,ID9GG^8'QL^"-M0W-38;9M'P>
M80R:IF>)Q\JYOIQBY,C86G?XOKNX,/.5.X:%I"XNA/1)Y"/N;@RK<;[%1K:=
MO>K#QXR]OIXS(!?ZI#[F '5=7@@+GKDR8BYGM2B6Z-O1I+^_Y,O[89=-FD7D
M1ZGPFNF-XVN5WN;GQOV9OC"W096W;Y=0>)(]9)>7.*&$1Q"TX&[Y?6N,1P8.
M\!@:W'Y^:./CTT115JLA]BS7\5U2K']I-M(3_=[T*GC<%G9T/7A1NNEPSC9(
M_!W%PXD#EF ^(A9L<D:C[7V(0//[LB2GS_;I0&JO[&>)%HNJ]R?-])Z7<B98
M,WF(%[G-,6S-(43X2VU/*FP;HC/X+=]5N"1\_"(M!O7M2#>:I=*_73NZY[B8
M?E60<[1C7UH>M)GJ<;@N0QG*92JB3ZW)TL@SO[?G!($-['*6FLBHSBW;@;+X
MQJ]6BV0N;/$:!MM%<;89/22TI3]S&1V77X#8@\[Y1*>D:EP.N7+ZWOA054RB
MRDU#%[[%&RB\" BM:F%F?21K.[C*S?0>W4>!F%6:.\(V7F[<@<!(<0#HFH6\
M2T-!.20J4VX[<8I#)#"<[%VBO!QK^+'A/80O//098NRU.L-\J#3X^OM=J'9U
M[3'&SO,_'*:R(]CO*=GG#[23RK;@YRT)5,.(ZN8MD?DB3X+HR%*DZU\G*[0=
M[JOVGT?R9B&)PO>.;-7YI<2+-@,;JJ'3Y/WYC53)/T$X )57[)YA?>7^3LS[
M0421K<E*FNM1ET&=\(ZGSI"._W5X7[E6()_G?6TM+/5/>99J5U]PL0VM1X.K
M$MV%<>9YBM>WO2Y"*7C<V^7$WN\-L9\/B.5*)<36VPDQ-@;RAVZZ9S,!Y)\R
M&E7=/<[TL>QN,!JOUJ87;LV:+T:>JG=:)AK:TM?,'YT/(U!;!DEZ[_JL;(32
MH(A)2QT91T43O!5^NV.PI)2D6T^0/YK1?SNNX=J&'O;./C3UTS-$&2VMD\\!
M;765[2-&E>V6NH(]FOI4--!ID+_/%ZRS=7[.S%P8OBLL<*N[<%*><?);3L&'
MI&DWZN'Q.(--B=T0SI\,9E6QDJ^2C,Z0*9ZSKF_]2\>JI@9J-_:G=SJ/NZEV
M"C*!)BV9(6#?T:66/]VYT#[P\FT<8/?ZDLQ__DV.[W_L)_MC,T*)' YPAS'N
M5 <R^#\Z9JG-@0/$Y[$>]Y7,_.&X^T3B]C]PMOVZM%JVB#!NU(XEIN[!V(;K
M_T.'H683#A"7H7:^@>%9^2M][]+*?[<"+]$P\/*Z._A\30 ;5+TG_&_^NT&B
MIE]BU2&/:GI('N6F7M#G+ERDG^B>PN2HHYD KRWZ1$:(I8:7XKG=;.-9X:_5
M[.M;VCA SIXQ>@3-"_O\]80*ENS_P].:X+<[]_!$U+T$STE/H5A;+/7<D.*7
M?'3I[A,/EUF6?8HAJ<>(OOY&</$,G=1;QYK]^@&[(237NS(_10:I:/AX E.;
MYTT62\71UPW7UXZ=F+PLY)HN[A9##!#3 ,;>A"_.=F?F92EOH18(/[%H4SF7
M,E#J>8_<3Q<3!Y["?4A]DX"#:"2_\)R$?#J"-L0"X'"G DM]-1M)^-VG>M%
M#P3WI"4_M5#@2*\L0\':L"PI8M7^!HB^97KYY(H$78^R]N3=! N3P1T_N;R^
MPIEHCLC'SN)RF]*;R=FA:U^'^:M0U:73CZ=5.E>-7G&?4)N,+(H&E^\N55<C
M2=]7]DRI4_?KG;M!/S%%1^I\/<80-&Y@[-@N%94HF5\5](73E.8K4?45;<P3
MJSV21YAJ@!&$^4[J>N;.HQ5"F3PE&ZDO<@MV8Q7X[<;>8SY5EWHH=0[[;^
M4PR>:&P;#N ?N>[H-L7;1>X*HBJ[2N#>759*O=^9ZRY<_=%#4XWHO/TI_0N7
M/K_W*!$RU>^YM3D3I:VE!Y5WY8JWGIF/Y-C<?'#(8E;+F[UP#"V\$)FZX*XZ
MCM&X&MVIK0B@Z#,$\(00 FX0Z#4,1*&!"Y,:_*8Z-96)3Y+U#2]'GC/!>-OF
MN>LTMYK//VA!N+?+$K[-^CV0>!YB?^PO[U9//F![/8CNG&)#UVP?'G%EV9/X
M#?M$X%,NP"4B4XB;!XQ2BM'7E;FZ-MP^/UT!$0Y]TW508#=[=_]%G->K,6%2
MF=GYMRM6FT_VANL.;\0L<O:]R WI";$!QH"676H"+NUC0C/\K:]^[G'B(.?(
M90PE<S&0H=F/9A >V]P8D-KQ64#8:ET!W&#.TSE)6XR[M"5:;%UHQ^#>UXN9
M6%K.'F[XL?3,0F_I99$$0(PZF2^H\-%YA^Z]YG%_V(\WY2K;7=K0PH];6>3!
M;3+7D,_AIY4]]^<3%14)&<.WM,&_[4?8:L&KHFZ9<?#6T%8")AL'6$[CPOCW
M8G@W*+\JV<<J[$[YJVE"R1>[T%$2GIB0'>"_-@B@*G  MOY,',#,5^U?6P3^
M"-65VH85')(27L0!& PW4_FI$C<S1J]-?A4AF-!5P0%(#+\#CVXF8=% E+;:
MI:DVT0BTLU6H*+O._-=@]*7&[ H#\$ 9\'3[)1&AY]+<)9--D=H1DY_6-9RY
M;+0 RH<;!D2+Y>^NW=ZD?(7$YN  WQOV_BBA?L*K=G8<AL5$2NA)3,]7X0 L
MJ%O/TW<-09/!QDJKO0VTXO86PZ4;V(?[5U.+I^UH:FN)A;O.6U>ZJPX_+M'U
M^0A,0(!K<-:+DWL7U(7H<_S #.A@>?4&N%_]Z]N73XB!>_B?0C3'6NZA7O@S
MG-/M+0MP-D7F_@A0TB"RVVWIP"-KF2\XP%R%EG"CI/HG.PY#V6O5J5C]N-UT
MP.% V!Q%TZ-\+T+YBL9FM[J@"8[(.Q;! \Z\>?@Z(0NLY]?PW1' BN8.H#,P
M!+8)D%=.M?]TH.7XQ'$ @OS5'H#7R@6:?U28VYW8G5G]/N?%#E727? =XZLA
M2TZ7O#P&I_3M/&/H]R2Z[Z!_E,O]58[5'"^/;#WPWL1GF<VO$RS0[67P LA+
M$1M$"9X+PRNY97[L'2\'&=[9S1@O',#27YA-]\"0,]B:KL-G[P^Y\(945]?B
MFSM6Q)5 ,Y37Z;%-=S%*,+!Y'M;&#]( ;45A9+D_ KY/]%)^]"70W 3>DN)?
MV"/+4+TZ:_A5MY>B[#FYE&6B>(=/]I\5!B*-6W*]%W> 2B/"! 5=0AJ25<[L
MUJSJF@Z?&K#!V,-U*R^!3BSED-MCKD:O7>A#CG7^.8(&B_P'=C@ *6!4<<K)
M8Q,0,4YID904&$MJNW%R7AC69.94L&D0:5=S>C/U9SQ;LGC78]Z6NJH:%4^K
MFG<WQ3 3)1E&31A@[Z?/Z7XP((HK_AM^5-Y.I*5MB(XAYKP1PVL!5#=FSH[U
MNV*1F\G#V!U2K-%H0,M%5"YV6MPD63YIY&6W"=KJ)?!*>E["]/D+03B3]AZ9
M70UL/[2MU,XEK]Z<?OAF5W'7DQ?*/4K;$&?#4D?G0?#WDK==-:?J9HP1%,8K
MK_+<OK&5VS64MTF;+^W0BM:6BJ:PS]%^"".<OG[$+:Q*QD\M_/I9P(^M>KVG
MQ, 0U^S]KWY,CWF=G'L,;:TJ.+A/Q1:3# Y.2#"Y/ *4?F)1<M@?AJ5Q7W>G
M71E3N,27EX3M1CJS !6@SJ #9\=.SI\OWCR,>R$&+=2&'S&SJZC*+E)Y&<OQ
MM $\[<_OK99NR'#M[U9:N'@Z.*KS=UKJ[_C5$M)?%*8SSL ^)"KW[HJ'(G7;
M:H> 7QDV+>RN$NUF.Y\S.8. +T8#Z&U33A_(^?JS37>M-*KB^?T)AXLQ#^JT
MS=-CI#GD?:*$['"QKVS1! X HBNKJP)3F4Z G9X4?79DL3?P3,Q@\KA2D:"H
MBTJ>JFL(BVIAM?.A']H5N"_SXS'=LV4=-%)/![+?,NR>(JVI:PYKXQ@1Q"HT
ME):68H#M#%JU+M]2=.4L*^R-V*\LKS'WV:'Z#Z1YY76^AEYI2'_Z#$G73[<D
M).KD[3BW]"415C^XR-:,,B4KQ^2EILXZX@ /%/SF[K%:=EYQDE^"$;26*A5W
M>3^H3WS(R,J)K'(=H<*\V3Q5&;9WF_ KK@ZF2U0\2.4CTAR.\=1TG:=WXHM^
M,,=A92 ?HZ3+[*M>$V4HZ7].HK@GTX ML&_A0+F()+D42,\,3.[2-2Z*$UI^
MW'?I$LXV\]YO>]$<NLNX\V0M1#E7V<J/<+P(0N^F1K'N8R0Q!2K4D'_J69TX
M2:$G(AFX9Q)22,)[<<U1 \XDL8;1*TBN-OSD>'$,0]\:((\(8*K:>]A8-WMZ
M:1F[J]8BP?*^#]S.2N:GR*/BZ^^5R$6PTYY *4U,F+[=)+?(3]@F*3-CUS\P
MQ+_C!T>_[1,9;Y]E:ART@EN$\W]\&B;@2)W*_(;T18QIQ8N-\X_^8>$RC+8-
MSQLL:46O(DQ;6$3-P90\+:DE?H^&GW>23$W>^%3\Z"R1^O*KP(0.]W2U&+1
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M+/]E7)L!GX[Z9$'FI:GVCN$'3=S2JNHC?KX+QN8[#FX[;X97/3:8[)6$AX9
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MU6"\J'F'1O@\CDBH[H>E^QAEH >L770(&GB--7T##=PP2UX<#0^Y Z@R_"1
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M6+XY!/WUDYQ2MTM7.X1/-"Z'N4Z"#^T@6,,0V&S:L,U(K5B.)CN?:#P"K<Y
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M<I#L(\MPE.TOH;D1B[2OX78"<\]GA?A"<[?SC9&):)U0J+V.&;;ZO!OF2C)
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M!_!S,)X?:H.\'9*^T@M3+;F#PVX.BFC)K<X_HY^4?;PN0G^OE\I_;9.DJ<U
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M>J,<A-<FB\/\K'.@0#MRU%HD.1\%T5 2TDM4="EY4=I,9=K(&@X)9]\2G <
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M [6-K?<0=.Q1!/\['ZU=?^S T41U-[E#4&HYH F?//1[+QM<>_)0!/I^%?@
M#YZ"(>#'^\*ON7;L-[0A"6A@GJO@$#2AF\JMEEYTXDC&">_B.(4I(HNPTF-
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M9_6VK$$E]_BHH::=ZSLL%GCQ\U:X5^VI%I#NY6"B$L7MSV0W'M3S,(E#P%K
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M3I4*8J_CM @ ^0T" '^8!^#\1HN" #ABY$\ S'@B"(#/CY+P)Q#T!$#''HP
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M4[.V/_ 2%/S2 -37=#<\5NB_JUJV*\]\45W#TZCBF998S-<=L1OW[H^7?M#
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M46^4D?N#^4RYND7MU37\QD5C7@%X0C5,&[9<,I1S- 2&" "CU3--HGP<$7O
M+XM$KZCPYUF%$VQ5SQ&X2ZKP:^.Z;^M<D0S?X_6].FZ>+(?Y6'-^1N$!F(/+
M@//NC>)0VL'@)U?YZ,E2<C.D6,N:!!8A'\C&BT*!+OENZPENS00 <I,B=6/2
M/JD@WZL>+04VCSAGPG1#_3-=2Y!LUQ+T<=P0]VORD5.7)T%I.=>[ZU!::+02
M65UND?TS2-%6,7[3]6$.>&OX=/=;98C]XVK% 2IR88/V]ULI.[)CO3EUN_'D
MT"=K=_&=Q9V+IN436U\0XNP7AC/?6TA.Y@W,.9T8NEY<?;/D,%TDR_,HSY>;
M+1^IGI$\2&+BS5T0;56D3.N^!S55'G<QN9PSE.#&HNLNXVT44%($29B-<#7N
MABPD!C?F=!\+B>0(MQY&LZHX> V+!G.S:C"^IV^J&Y=15'D+ASGNO;OHQ1UB
MTQ[6,=T5 :,;E!]G@@QKFQ28]:E'3N],Q>YN] @\<J(_&#EJZ7PPU#?2RU\[
MK7!1XWZP+8WN5_PE(DW'0XC\+07:8SIG^=F1SZ"0975FUVB1^N0;-KNG=C<D
M%_-W%M#7,_<2SSW/NCE!.EYL=*(&WHJY0/)^J'^@?5.QQ4!1W\2Y0'F,J2"M
M\HPE98X^>M# (]03;-Z<(^[*<GZWR>@3KMIS<?&K\T?+0V[;B[+MPBYRG$*1
MQ_K716UCSO-];'4Q+,FQ9) L>L% Z4?V\+DBTU?>.T?ID%TVTN*9%B_)LYVE
MQ>TB8\W>E@S5B^T<M]1,E]W<'<%)3";CX%B.E\G@"'0Y*E0OTS<_LCG,=LXN
MCO].N:D(LTU\G>[3'NOL8>1D%(_7W:>O2EC]7-='C@TI.X^5G>=]V.5RBSG$
M/KA V5!\':<6%]+8T(L_K?3!H(DTZCA<N%[8U)\J=5IWF DC6N2?7P6S(,7<
M<'5I\0*+-[ $YJ('9C5+=C5V%V^['@?-&I"'I=8DSWY$RST[R?B>?;?+KWH
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M*!%6OK+77"5)04^<K4EA%]#YKVNK/4[M'4E$.$IL(:;<W(%S6K.@'/&Q10+
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MA[L IX!U<,-&B&$ZR\0BGA-JBN<G^H34PX^CK)YD>9K8UGV\8R_'4;"79$H
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MN?!/[6 C$&(H2/PQ$,5' ,C".+$43UURB:,HX&;63 B N(!M%(+HS1)7E/8
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M3Z^+Y/]MPQ\-9>#7\Q1[]I9%?QS(IQT:^IFS3.)%_WL:1,;OR6H_][^ ^\O
MB:EN?"GL5LF?+P$E/PO*?_OQ;!7V0/= +8I1SFWF<CNB0</V7GV;0?-M2EKO
MSK?)$>^/PPX:Y1-.2MC7MU W? 7C=M3\K[DMW_7G(U)'_GZB41JL[RSP6^+X
MJ>M@<E+.:K$4<%N@-'[/Z^R!G(\_Z8MR?!GW<G-D\Q3QYIU>9>C1RH-/>OS?
M^A"Q&C8WTQ*M6A$3I9C$\R:$%_5(S9G*82K%7BU$I%"\9FSNH66&2/C739E+
M_ML!^%- %B)^G8X$@"=JOX?F\_9ZQ+J( 6RD@!A\3.\L<DSGXK.FC)JP\#79
MV,3*A]]] SAV!0/?HV8TVEJ$58?D="YQSK69XN+]B;HQB^:?$L3>QA%%E%=
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M[]@S:'D*;2XTJ$05>2KO0D9:^Q<ETEVS;'M#L1#UD+&O+1FJ5*B'-P97SF@
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M">[F4Z(:A0/80FI5Q7DK+D#AG..B@72E..'2- BX)!^.!9P;K)@X&][O+&8
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ME -+GU1>,O5ZC"Q"3[WMA]:%;QFB#R>P@&DU4+**[$<WA9^F\3B$^O.U"A9
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M[@/*_CK[15_JS44#'"-[6X[T$P0.KN5 _VF$N6L?RE1M@Q<S/ADMSPH6+VN
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M\O$2,OOOH7.> "<\G)?'> "KF41DW?A_^8[;6FAF# ]0 \"MDV?FD5[,<RQ
M#Z?H=&7\3&G*S'_UZR^VDM'<.)V7+@-S@7DKY4C<\#OS:@3SP2YFUWF :@UQ
M]C.&TM 'NCBGCN-'N&>HJ>*!][%M"A8@G3@90I=<'?7+][J K7PTVB(1A7L,
M65N&"D#SU*&+?4<]<^J@0BS@S&>4BB<5;L:"U+" <[C"<3S_ L5>6PCZ$.HJ
M:9&,VS-#M!'C5O,& [],)L6W?.*/]Q/5KN]A 0K &:57VT_1#5V!7(]YW3CR
M8R0/AQ0@,M_$GY0@L\J"+]S= '6#Q->_BD[?-R#:X!Y-1O'/++%H)2,&KXA<
MT] M!%#Y.&R]E4BD]/!G+P^1U8KX$3$>]3'ABQC,@_WJI10:VEUI19* ?16;
M5U9DYM"1T1?15)('TB8.&Q0L)=E;*+$D * ?_I$0X/&U%S>\N&[$TLU<'-H;
MY=&V=CY5SFKDNBM1Z$,%Q5 N^.#8(J\I%H!/QKR5(<Q_>!$,1%VSD+7UH9*$
M$A5K5D6R9H$EU,\!^\BT<*MT-PG:K:B-F]7Z>WI)LH9GWLBCN3I(,&]UNC $
M=.?FB6]A :=> &>>FAGN7AF$;@ETTW"J@+" /U^<1,ZT>X CH,@B'/+X>I4W
M.T]A9*.!J[G0PTOY3[58R_IF@V4O/.:3"A8?DN*OM:)09HX2P>0M/76$C[#D
MAKRK> 0@,]0#V&,!3RVVA'(3TE],ST@;Z&)$1=) (Y41Z5N#OJ6SX&,ZD@^E
MEC0W;WOF>H ?2(G5]\K<C'/<AS',@9O$I4!6[V)DN#0']NHHGEGIQ!MOA<OT
M;295^A]IF+- VIB60E'^V_/U5(O,KB4Y@U-;Y"&Y?>%5$=$O],7N!;3ZZKII
M'$D_>2P_WI4F.B'<(6W^LH^GN]W:CK6NBGI)3,T!Z*/#!W,?LINR"& %$ 4O
MO6F&@T)F" *(6'C5=)[LC;G6I4MRJ85/YC@-@)_O[VJV+03')H\.CRL[7P^R
MW*!WSTO)$LG2VT3?@G!CO.D6,80BS%M9Q?F'I.!$%,- T-/+#>I1PCG\Y1^1
M7)7#2YEY3A@JT0C<R@;9X58V)@2E/@HZ)A#I0I-;A.R)EJ*/#>UH!FF,DY/+
MITY] LZHF1ON7AL";MW%T:D:&-HU\%/@L&[-7ATD@5NBV,>X)6K"$<";#OG3
M'5F!6!T<UBPP:^D'^_LO0L\ \5%*@W8;Z^'08R'E6 DGB0!!X_6K) 4]*F<&
M<P\+(!%NK Z^G N.U58 +L/D#V-U,9[YY7ZX7F;]S]++4U/>#\V"(Q97CCY[
M&#F*WUKTO IM(=3 2>.P9HS/Z68=70VBP*E:S>;FUQ[UV[H5['&42\,W7D:S
M;8]TJL9$W=8G7>E7DVWC3*YYW\"Y(BA+B1>=AG*2[V%/T!=2?CNHZ!VM(U)K
M-Q33]]^79O9_O9.LO.VR7\,W_AESR!>'"BR8-"S  ,?HE]CS!\A.Y^L$_ MC
MC=^S&_Z]C86*LLV%7#G=#RG^@@,_GG_Q9,^6SUN^^N@*KVKK^*Y&O (0!C!3
M>;11D.3T/)M @0.@ 5TGX;FZ7R9 8W,\/>W:'?&M2);EZRO2U$LNYYW2<"/D
M"N&Q*?0+52^O\[W3NO^%L$<E%RD)HVOSE:5]17H;2!SF17R+HF34EWO_LRV]
M.7TS8=^J6H\)GBP5@UVCZ.8M=8]JQZ]WOESDS R;O4@GJY!B3%OO\]PQ$?K8
MEU%-N2S^R]O#486H7/-;D<Q>PO\(P604<S.J[?:7CX'K/$(A>JJRDFIO7T2P
M$5OC  GCW:14NQG#";(O9+-X>KOC30S @U+U"J#U#B6@6-,.?'B[7&X@5P;_
M+5G=2T^X*U=*@B#;;;;04CF9CU Z@,??YX;\U4 %=-:L8?TW$[0_-%U*O,F>
M7RO<0"IB%/S>0U>[L0#!$^MI2@1N0?TPU10[E'C=9R)1)IWQV3]C0H;OC71"
M?S(D@ Z9(W9/HBN=*?Z3N'S^U(G[E&?B\B7AI' CQ7\:EP_?^P\QL%($"_B(
MDQ3+N /_G^\XSW7\NX;W?UC$K?R9_OK?RNCT'[.X_Q_-XB)^<0@XY>%PVE9,
MQ#,3G+C-OV*XM\J/>6N&_R\2!O^#/?Y=8"D2YJL-'+5#Y^:LPB.F*M-O<_L/
M0MS/"8/59G9QO!->M>1X'$+P- 7H!W.E"1$>"P+5VXZ.Z=+[F1A.O(D+]*\?
M0E-1P:J#\Y.6K?,RS"A=%*[59S5M2)G+*QG$[$Z]-%AWE=H702LY"3-1^M/&
M\?Q\><_6#6ZMTYC9.S=P@_5S<039AIU^0A(DR]E/I6=R3BEA<D1=F45:B,%K
MBYQ;J#&!>8!_$YX"-F5-W3_'.4Q.6]1;L57X.,6V=W/;K*VUD:_UJKD!V] :
M2Y^N2G&)ONA+8AB34R!>:PYX5OFRA?C>>G 4V/S':(6ORP=:U=M0!DV]B[-D
M1L(3[*L/RXO]Q_%N?O\\? __6FV7Q5*51+K^R&K,]_!OK93?$W03@GR:J>!/
M95V$\V$U>U;]G6+P:J NYNV(<]C*[)A>V*,4LHP6%<'$6)($<,30GI*3:L76
M>D>N8XK'-\Z\IV*0S77529G\Y?#5?=%#QH$?KH&!/>,R7IE$S7?O9O$)5[]H
M?K2UVYJNIZ]D*N!B%$+_E68R.\Z(EBL';-5NV)!ET"F=.H1A3WR$&&!3)+&"
MRYR_&7^_/;R)XFM.!?1]U7WJ2O KF.Y(+HV-<&CQ^3 !<8;!IP7)%C]+1V$-
MKO;?]&0(:IN?V<K/Z(ZF1[N)PE,Z&"N+K;^ULU+,2*I[;D9P0$"84<0SI\K2
MK!;G '7>F[4EA;YWDP94:)X#JUX[6*S:6UU:Y<[-2\S3'6M>O"Y03+OBQC#$
MGX-RT[MMT 7)4&(E4^%C!5#$WUOA=E-4,M9'LHE%':H?VHOZ$^T@CYJ8/L/8
MOBRGI2&F^?NCIV)6#X?0P=Z-,5D]:*"-?0J?P!<*._\<TS2]$=1K^?1/-'9>
M+R-0=Z24^_$;^8.%#^#,I'JRED*<M^JWKL<,].2E5/7RSG_PYGKRTLW&0#^?
MUND8.+-A.1'G"4V:'Z4;-QNU"DPZ>MG7&?6DQMUOD<-4)^KH7-<#^-9"Z:MK
MOMLN&AMI]WT_0SKIAV+&"K?FT<V-/8KX,OMCD6!3F_IS902%:S"T0LZ$.9WL
M0H"=*3C],6F4ZIM"!WQF/G+Y?!'STIN0XZF*41^E^3'#FE&:3;3AK()#93L9
M2V=/V.#YB 3W0%_:=0T(VFE6#%XT<+.P2$G4_*'2T/=62)6;9G5>")3F_5YK
M4,Y[DY(@%L_O]R2)V\/O#2B_L5^]8<P_:EPA[XQJ.?<D_$#5IQCQ$\K8R)<S
MM,W:?W-H;#:&2+-[[#@:619WX+*(S(5QZR'90S/ 8J.0M)3A,?VV'9>129=%
M2^[, =B>HC*3SN38LIA89*^NL#*/5L/+A(-,2+&2DCO5+(E<T4<]/25N6=HF
MO2N"_BKN7Q$X(::40D&!8W JE.,#VL$A?<S\16MN<@SR/K]SH[%:,5-R>N]F
M/EHEV5 F5_=^!:FDFNZ/QAOXU[.DK"V""S)6K,VI690I@G0FKE[127UL8B!8
M:WG!%,7_N%_X_9Y$.42$44AYN$Y"\< I+N+.6#"AL/DFQR).H]@=5D X'#):
M^F591(U29<(%6NU(LO6*4[<EYB8K)'*/@W$JC9ZAWZ;AO:UUV'A)X??1=TO$
M2?@FSJU=%NNF!+KRQ+>UG2ES]&M_ELY!H)<R4J/ E:YZR!!R7;2D!Q,2'M$;
MG++_ 3$8BMAD #EM#;Q2)FE*O>-U]<?F:F!,2Z\TL_:4L^K*F'IOBO^VX@?]
MEYSXQVOY(J:*6\<+U<EYT;#&3/,.,\?4DL(#1<Z]:S#ZHC #@X1D1T=/JR$,
M/09OB:IV! MHA?3CA,7+-!@_?3F?I/HO(_1:?)89JG85"VJLGB;E;J=B\Z[H
M5YQ#J%5EZ\#'(\7U&[\_SD4V?4^J>$E<J6W VH5F_5FV^J,$R*K=#[E?K$?U
M(YAZJ-% '$)-9CO;I8#I=+AR1\Y*@,-3"IQ:@=3+X7NS[ZS>F/4X>^PPDSMF
MKDIL!@N@7<%<[EO_,2@,[WWU'O]2J1%?E](D/&>V77FM,I%49RS,/<#+7V'1
M!V;2SU2-$UEO7[%U=3Q^6@>E7-(<JFOST!R4R /:]P+&CS3BY;7[[#]3>SS8
MIS>+36D9)JB25^J!Q^O*E?>S#=I?2Z+AHP/':IJ'4_0Y."B"+RP&"BLR:LYR
M#WNV<P$"F]D%.\GX0)X&B"WZ8_QHBT.HXMY0P3(U741DEB4?CZ5QV;M=YS$6
M&.C"=/_;H4:Z>5CHN1X^BHVAC:1OT^0#DSTI"GDI Z*)]_Y5Z&*N_ST%N2^H
MZ%DETWH5G:[D5LNPMB.&+B9DH*E_M(*LG:*Q#N4M4&:6*BA\A,E/UGT=MXRZ
MS8D[>SC=9%KPMZ0,8.<=C&<Q DT G-,ZM@S984H\1$1#NS)^YN](?TBN<<1I
MJK"YKH/#WA/[NM_R_L"K<*H;4,<0@\^,3%FUAWX&#J#;3\[DH-&[2E0[I6A>
M*R9HUR!.Y/!J_BUUP]GZNBGH6DS^@N'.\O$JNBO9+#\><;H3\F>K'TXP+U#L
M06__=IYHN.!Q]5\-0GYP"0L0@.8<1)V<GF$!0DLQW(M6*)U)21P(&#\6@!=R
MDC;E+ 3I4OD#[V/#[XC%OJ.A@\2'/882T+I!Y"+ZV!R*(H4VA?Q2?Z\"^)UY
M!?/JM\,_Q/=#=O^#,0QU:0AP<541I]$;GV1V.UT=UG-R$@G:X3_8Q>QA3'N$
M09U39^?Q;&T/W$(0GEZ'*E"= 0_*;W8,7 [;DV+"@XA]JE-4M;6)VP)[#ADB
M-6.&A%9'!S^^-G[*'CSQB:"+I?R6Z35Q.VN[GU&*0EU:.E6=O#IC"5&R+IVQ
M>69TXYV1=$?C3Z1-M>8M@8^S@ %57*]L>Q1F/<*;7$ 1P10(JL4\UO3%ELQ.
MC,^Q 34"..T:1#6_[1S;,-I0H#BS[B0O^D0TVF#B,\UNSC74B6S908$% ,;0
MX!+MA7/,C(I 81Q&MZFS5W7N_YY9HJKC.2JL2#)%K_NG $YQ3A9#]7\^7=4"
M.DA:>G+\<F)$WN81\BBY:HKY"D[9O9MT<G8.#3K3$ ZMM&Y/'1S6+&+NKV4,
M[_IS=R"1_!CO&&8,7BFJ)^0#=)<!1]%;9(BFD#WO$WO*G WH#Z;_P/V?#>X?
M*43TJ*5OXG8].QD<!8CB2#*P%GDS0SNX/&GCV3TLX*$5,N7X>3MT<>4H\8"P
M,-&XCS-?K+D!<4AN!D413,W)G:T,_ .7/KIQ[4NQ^.^XN^-(Z\N"'XZK0##"
MQK.&QX3"0#3^KV![_UO :D!+T58IJ)3Z?=>:I+3Q40L0U-2AM.36MPL<62(P
MTD5\@^2TQ\FV;KS0EJ=Q897R62JR5,L??].=-66<,V24G,T@6?=$'MSF_2!1
M$#A8=CW0.^8_1W7_SE$=N$(N+3Y"W8''FBM47[?SD:]S*FM>,T'9%*WP:&11
MNAF+2?#H<DL</Y+4E$HDXPW/+N]C[FI2>)S1->4K<1^4LSIN9E>.&=9CB*36
M2L6C$$5!;5+CQ/69Y@"6M&"M!?V>1WDUV;;<+;L=)'5T&>_=9=AK($]67=[M
MY(E>$@T>H>I&BY*<L] <#.S(:+:=O>**E^#UDTH%I+-?IBB?X<:X]]>.^ZF$
MP*U2G,3BAUCM@4;GU913_!*FB[34L5MTQ)(EJ)KQFPB+^*.DT(A/N[=LN0,&
M)4F2)_7U5RIVFU:YMEU@7V6#/]=F89AREY,@+Q:Z!:DQS^N-.>"7!R2P ,.M
M!SH6)<.KJ_\#<:7_\7?>1%WU>^V]%87T:./+!S[][$)E"=P435;S*+5GGLX^
M(8RNH.@I](,^/D]FOBC&O-Q2]F'Y!9'8=YWB&\LAKJPYA1M1DZ*YX5*9E^3N
MMT@U\MJZ!B. ?E6\&5,W"SN(_ 6YV.;OXW_95$'%-C7+P4M%1=L=;"3E-!X\
MHI<WD"5+Q3C>M,B?M_N:7#78/DOXWK2X8(!/6$)K-S;L2UN1H$/7T1T8Q27G
M[=G1?0E&<EYIM["W()HAE@M$KL]_2O=+"=..%_JIYMXFJLT6=76(# XKYFB3
MOPO9_(8^!#%(LRI@ 42?#K_ WRJVT(/K*7W"\^X8#1:^K!YR-YREEZ+7@?LV
M*T>*1K6_5<58WEWL?1?K&+(WM-W/!W.!'/.C"#,;[<X?;)L&/W$8GL8";MFV
MTQ>HAVK[/2.WT2N)G@[0Q]=2C*>*&>Q.NC+&U5:^MQC3*6M(AGY0:TI=\9'(
MN_3S4R41D][-@P\3[$>,?>T,,K?%O^P9^]-I]7OU<G8]28#7HU*#G!JIZ5B$
M7*Q+HVT)[Q&U8#1B8<<9NH,91ZP5,BE4K0;!@I6'ZEGF3HL_^1">/KJZKAZ;
MQKVO$J[1""DR& \,4RPJ^6^,.HZ1-:B*)=\16:CACNQJU'%\NY..XC,)K'H9
MVK\K(ETPXR%6&R4JGNY-,8P4Y:/2"F7!ZUZ<S.)VUU]3VBP%)X1KB#"*3JF7
M7-(G$/2C\'EM2RZK?#X!4J4*]<#W?)&:.O"Y;T4SH6YR]DY*F& ).ZF7-1Z5
MR>]B\9DH5IN_A!WVDFCS7QB5J#2__ME$[((6_O 04"R I00<$2-8(\WZ\""Z
MTX/+TEW&P]C8G'<B3H%G@S*Y_(:MS0.]5I<QY#!S)90;0Q^KXYAHE38L\\HB
M[;F/XQ>..U14^T&O,B=TQL>;=!2U)5N";;Q["^!0*D5S3TBN4>FG)ANQ>+XZ
M*<?#&#\5)%/Y*XM2<-IH,6FYWG>GTJ^&.DZ5JB2Z]X>@Y)(2+MF,#[0XKH1=
M5(^.( >.,&CZEL[PLC90]]2ZD?B\-Z*C$?S*K-)AQO,SS#Q V)IC5!N?:.3K
MW9^Y]%:7P<QCS$;5?;"49X%KR,>&9OB2AZJEPVM2GGP+07Z^PAUBC\*?E 3+
MOI4=_:X7!=SB*X=Q*VJMP8Q+_)RBZ'ST.\)#8'8%J.R9S5!,*_.^<5D0Q[A3
MI)2TX6/W!*Y0A^'<!D$24P]?.7<!X&,G*\_D$4:1LZ?;5$/FKMX6SZKJ>$-]
M;Z7NW9&.:#D35%C5XIM3<0\+#2>C(EY8^4*\@7ZF<UY7O>$5*[I]^F65]4MX
M8,O>Z<4R2O;RW&93DY[EV8<\ZN*1C/<D_:D?FMS*2\U_1O%X)Q]_U1H\R3^8
MSQLV?T.@Z9R>G+%1X+Z($*IP2*YLB$-)BMIL@_4]U0OW(2.?K@QA"'@?,8]Y
MH5,2Y<;DK:1PY=YC\1)R<G+PFR)D0N5Q$G5TGMG^8!3-Q6K)#T\"2C,X&)@M
M%NT3*<&'O+[Y#L9INA/F^S]MB[<[!$$J"8[!N[V5I7O#XF9N5"#P$=N+?*=S
M7U=(O>@4N2,0?3-E^!^,2>73Y1_O;#(Z*]9UZU2W+[\_].D/H"O9[]2:<Q0:
M30<%P/WH%9A"& J^5R:',GIH%'*'GW:&A_$3H3PD16;&]*443!_B#2=H'0Y:
MG4Y5I1?VM.5SR4#G69_YO,I4</F$NFM!H^HIDZH,BXK7='#OT7$^]>VJ7:-N
M#!7YLIDJ?(_O'%'+=>]Q59[02BJ0)FLF89KU8,+UBA[>Q9Y-_%87VNUUAI"]
ME +IN &73<0,25^O\8\.F 6?(TFT>UD]DV/DFM3RA&4)!I'.Z[CBRDA59\8D
M55X9LS(&>MO$_3G<%1;1E9"!I(I]A:31+X_A]DXS[\I0X RD=TMAF^.@%0R6
M%<Y;\_&@4$K^R-A&M*GXR/07?\&B;"[3Y]GB8=;<[T[KOCW(0V7V-R5<H:P[
ME]IR9Q39/9]+*3!FB1DUZL?S@#1WXF1L*-\YRA,>J _\P%PN[=5MO#SN;#$)
M$>\QYA8&W>HI*G'CMI63&,K4,QC3P4UF@K!4Q.=S4.+TW/";8F[4G-FA%I%"
MC[(8^_DZ?MZSME-5<@-;VH@T/'*=B2.6X4@NV-AK#$*>\AE473YL^,5G\&Q\
M ?V87WP&F_Y)5J'S?WA32\5_$\ZW._^(26%.5HHV#L] 5RHX(-<Y7T.:(U2R
MQ5C-,ESA*]=BQ(^7@U&^N;M=U$M7=2QZ//(&![X&_LAJYH!SELQ!N=&(KF>.
M3R<=#[" 2#\/QKU46(E$)F,U]3VE._JZQ37/$E@Y?N('8C3F)VFW/",X_#?A
MO"Q3:_O[L5^"-%K))V1LP=0#K*7()_S[$F5[6IOQBQ7.P_+S=B&?D8,QYG#/
M;"Q@:'&)? 7W;V_$)6'T5>"=!RL,NWH[ROE26^OC=)$(T?)L_5I":?WBVX\I
MWU9=P=O+OW_^\D=;"E?''CW00,J[?V9.5.+Y1X*S7.7 ;39'1W9Y#0*UH&;&
MG%@J-"U3TX/>[^9B4[NFH3W/CK.G,&XGN1O]I0>LL "IDZR.C<YZ^06'I249
MZ/9-]N2D(PT$^F< YHC2XX_?WC5\OM^/!41[_.A7!UJ48@$)2.C4BQ"X+A;0
MY8S8+)#G7F,:3=SAKXKQ]UO7Q )V)OF/UE3V<Z 'FS3'^YSS'MYC:IA7/\-5
M_GG[#/E?W2R@WVNV+6XQ_PES%(8%+%89_AQ.B=BG@"@?1$TJR<K\ ?./7MK6
MU*[C]J;;1ZV9F9Y_PF3^HYO!H&$I.'#!T$6$BN)/F']VL^V(\+>A2]',2$-G
MZ)'DXXOK\M>P ,>,JK$\YTWE7DOHW. HYR)7)=[G'PR' U;OZ-(3P>E@$CL/
MR&7P]\PP#;V@FH5\\*&G-WMR*1+</3)AV:8_UA)\L-MD\\80J/O$P:RXSTU"
M:BWTP))C*D)+WM-TIW]YCY_"S--T[+PY54<QI*@-DE@_3@Z?-V >S+>7(M]1
M#:\7G!KKXCPW'ZTL^::6:JD"Z@/1O&A2,<2TOV+_K3S<[#G1+B$5^,D6)BK%
M^:D2XZ:JF7LI&??E!+M.J2(]>QOAI3[[A0E%^(19OIL[%C 3K&PRIJ-KV%V_
M91)NQQ3JDJM_(7"B=?^SD:I G#7!G?Q[<,>P00YH5=O%/([ZL&5JUU<EB4S5
MYTM*&B N:;*6$L92W#F8R1Z<-LG]"@N #J'!48+[X9F[5@9=LCW446R4KQ!J
M<OZ=F*G??_*&!",,M5K" G:I"G%*FP].:=OQ"%*>AUKG!=%Q2QQ!Y7'J&BP*
M<YX?U7.,2,$I=YKM6, Y&K39O@@PXKC6WJQ'>VKL$'A\X35BZ\9),OIC9LS;
M$D/4)<2<?$$6.G^#).5?-2CU6WOZ=,*:3OL8G*!\7Y<?37229_YTXVL64.ZC
MMTL]R46(TEWH(?$(=/K!R>G8Z;:-U0X,QVGD@JCBSW;U;.MN=(EMF.D*8;/<
MS=.=/=/T<#\&]/-"3XJLZ2]]!9YNG*DI8QM1QO>?B?H?GJB=$'\_#=TNXGA2
M_*R@^S6=Y(*51GMH<,F9AD7:G<-5"JJ1B6^I>[<G'?6?1%Y^=.W-?.+C_=MT
M:MI!['T3F">=.7J!8\A/">):PH8HN5ZA&V/[Q[7.TZ;Y<XISM)+V%4W^DJ*A
ML:PAI1LDS=^%AL9$)GH,L^,X.)!X:,T8!M,ZXB#H0E"M%Y##$QX]NRSI6D/;
M$^*G*I1]17K\&A]A>Y>AZ^;2%XHP#(],MA)25(98:;^KZ!M#';E,!.T/^X7J
M@!FY\#F8],0+)&-+B'*ITM>QKZ3;+U\*>E;1[=XIUA=G?#JGJJB%&;*E>O4I
M,)*D]VSL@/_<Q9^ZB_]!QY@18"EI-">ZM9^1H7-/Y,FCTF?"[TIJ6UCA]M 1
MQ%7$TO-NZ-9%+*#)B]>YM^V0)(?12?E-'ENA;1<Q:=%;P6_9^P8\0PX3<M=X
M[.^NK;]-E-I,N66'Z1 [$IMU.B:EH\#@ 7$T&8N4P/B2G=B6)Z+->87=\(<,
MTB%^]>O\NM5(^I7#AR;:&\KADA]V *#LF)$MN@ES!6D?Z40VP3'![702'X>E
MNWN9P")/#FAW[8EM\M7?3)5/=RY+PJRDT-!:<7*JNG/[M.$ . S3<6+8+D-P
M8GJLC!%1T^BK80MB0G7DFT$NE7ZL@,6^!9EWWDTE:#YK4+!- =!ROQ?^38=[
M.68PB"RTA.#: MS$P<"9HSPOY/3@N@DHWN^MR_UL*-19H:/.YPLE(+Y9?%<[
MQ&-R,F+)@&% 3;TO8JXO+U>%X+S3Q>(AL3-S87:V=\+RC[:_1A:6XQ;0_"3>
MRK.3>"O00\:S@RVG=V-F@M;U5P4YQ)_X$CW8CM7<_NY6!G!=\)+*_LTUX6^F
M"J><<GO_TBS4!/T4"TCR/O%>X/C#>^$O5] ,/QFI=V4<9;G/:6S.9O;Y5N8/
MI!9=7J(31]V,2>2V2-?(N8-[[B/?YBB[UJ8^3.T*F %1Y[$ '/>R:M@\O";,
MC#X'12:9_\SX27Z8SYH,N<LOR<48WVNS_XHT5_Q2<M5<?21-E(YEFHNG#/R3
MJKSEW,>V;X/I\!GE#W3SWB-=LQ[LE):P"T4IGBZ9:U6TR'/-#S&M?@UT'"/[
M$3=A# 5=U5SL!XF@8T_81;/D2J@F.K":5;,?#B0RIZ/4D9J<I13IBCJ"57=:
MZ#O5/S-GNAY\I+XU,[@V.F%$0FE@G$*>L:Q+9^A;PVI.]Y*:NN9Z-_HSS0O+
M(EL;T"\HJ)[[XT?%!XB),=2XB_\M^Q&SWUS?]S!TY%:3S'.!%>F(_%D)?1F%
MZCYWF5=F/X$F 6V11$-\3L^MI;*FSJQ(R)E)DIW"+44:XKJ" Z8BTCZ?<M5U
MOX!.9ZE/6^L69B__64XXIFL&Y Y);W=)Y9W/-5%LIQ8:RPY6-*8*_SO,$KD-
M4N#SX3!U5-_JJ,F@#L\$_QP,QP+,)_C#7G#O ,CQCBT8A6:"?@Y/*J!5<G25
M;,)YK,O&NBP3(E+^%F$G\E'N/C $\VKW[&9QD&$=Z*L.;WI*]JB,?6$S"_O"
ML 2SZPJ? TY@I3<<T99),=0:D^4[\JL*L9QO$I!:63R-$"FG$:Y/^6%""14<
MXB#Q^:,LL9PXBP^SCW09\*_1*56H*OGOOO_NM//WE'$V7=29'@W=A!C/U2-5
M,<*#]F^RR,1OGZ(Z<1=W;CN[7(,5FZI6NVL$ ,^EQ3@/6?T!S%C.<H5[<MNK
MT%?Z2Z!0W]5GOU+:+RAU^:>+.PP%_9Q:7I[HAKG):ZIHYA"OL-AG6F'>KF#%
MIE F-Q$R"'\-X]_8TQ?E+DO;AA@IE):M'!,=#D#_>NS)XFR55!P=4*'R3Q$^
M;8$?,P @L9DC[@^O^?/RDLTV+&O/W_EA?2\W_Z\AI$$L:7H;!-.F0L$IZ?'6
MZ:/S"I\S6KXY=5B!786%))F48H2W2_I$)XVQ (O_B[WWCFMJ:QJ%@ZBH-)4.
M BHJ2!6DMZ!($P'I'420*D2DUR@("%($! 2D]Q(B)83>JW0(H*%7Z23TDH0;
MSWW..>!['\][;OF^Y[[W^6/_?MD[:\^:F35[ULQ:LV8*?\WE=Y8T0S,8"2ST
M;!:)VKLPSDK.W)DY3<9S!PCPB3A&\#.,4C<8OG4E\0CP%(PN4)R6" N=1B%(
M<Y=%'^P< 4#P"Y_UBGX_I9.W$"XX6(S,>_^YJ%SE+7Q8B?"=<XF,[KG)A#'V
MF'\J9?UZ8B%+^09]SPM2T37%]C?(/K>3F%P)I0W>*C#50.%R'+@K^06A94;2
MXB8!!\W*RA(J5/ 3GX.-F!X*VA3BH&QSNTHEO2[XW@3(;@'CX:NH:6?8K[@&
MWZ>,JZG653QT7V^2O//9?(#[>=35QIL-MD\=$!Y:":4QGC5GT%2%L ]*_/T?
M!T"<YVF;32V!I!B/J</H\H!F>B=$TQ.)49YKA","_3]+CBVW5HS:4V2$%V2/
M425@.H+T,E+D<5HN2<Z54 XBS8$U 6;F1=#-2MB'B^UEX1MKDV$MN7\A?(+K
MDB8W+3<2YH['%5 IGO@(A&8.R=]>VB/6]5+1ZYLOHI[MNB*87] 17B<1<BTQ
M[43,P7(W/T1L6J&?,UATQ[^0P76'0[?\FG.P1=Q)%EJ>FJ_.ZK&?X1)U@KOX
M\\_535X9 C>%G($19BV19A:D@2QX8@4*QCJ7@Y^0ZT7^\TG)6JW(2'FF!K*K
M==>3UY1DER9RT>BBKV*@*8-WWWDYAU%M+I?,-@$Q-_X08HV^;8W(YQ'?I$O/
M$XC/;B\:3OQ3"1ET>J1HPYB8&'-I$75SX.PG;L8 !RV;OYH_;<=&%71UQ(_7
M;8=@I 8*"DH./?+T'5[:SLM92K4_81 GUYO"R)G.-*.A_I?7=?N95M-C5KJC
M\ZG(QEW(,-KZ)PDTW+)QRC$<6%(/6EIOQMTH*O>5JQJ('CDS5Q%F\H3,.<QZ
MP4GB-JA*\4HDTNUS+LE=;BF!J%\J;_XX.'1:N6)_!'6M?XL:5EH8SDGB(.=T
MN\U(BC5(8"=HY#%":3Z!"QU-O1%L5?F%P:TG0^FD^/.HH<!-2LJN\S%-<>+/
MDS:_?$,(#0]]@K)BG0L51@Y6UO11 A_Z]Z24>Q7H],'L-TQ\2_/T%^FCXQE[
M/D8H[*1_N](I\F;[>Z_F C\H4*OW!J\-\E0J"8 3;R6N9G@^<F)'XGX<]&O_
MZ:!?US\.^KG.ON?O8B*\\M)![PA  YQ5^2,19Y3I)/2MEI#YE+A<6MO^S0>E
MW?7>B5%A:*;65GM7NS&8H85\XL3A_5'V>NLO];LA6:R?):S@J?<]<$2P88EI
M<I)1FXBT1JBUZ OC*=@3 LPRQ2\$C_Z1U=>&H>>F VM&/;JHL=:W5]BH=VNT
M/^X#QR4'>Q?H9<;#)SW\!.= W->?M](NOI?*_@L-Z0%QH=&<M=UC4;85:HCF
M[;H4.I5V]DDCB?[$> KZY?B$'"A=KYDUTA5GL,EV!- J6]8U_H5!H7DK@^-S
M2/^FB,HE5R^(0$Y*Y(.R6NYPKGQT:]F#QO4K.U"]_J=QI-SC8OYC[-GM!=*_
M,MVI:J'+M?8"+B_^6&6KX-*^UP\[3"&#F)#.VF>;Z6I?4X&XU;[+QSP[,QPP
M8CSHV)%GO"K_2E'?678LL5PB;T@;=Y\<-YEL 3P"7)BH3]KBU@%/5 "G]/?N
MXOPZR ]W#94H"3K #7"4!98XFGEW+6Q/"T>"_[Q>-N*PP^HR@)<3* B&[@AP
M?RX >YB&HZKU!2X8?#X"U#HA^J2NP#$<X+/@WG*3(_PT? 3P TWV'-!P M?'
MG/@?$W']:W=)>JQ+<VC U@<9F<^OV(,!-,GI8'*KRRPLBRB^S_5GW(,&4HMW
M-(X 45XMB<BL36#57.V?@.6.8;.<DUIR5_AK#:.K^$1W0..0F!0MD_'#XN,H
MC?^>M#^93/\888['4*N(8R.,/DX7\S%N%&0& 7[1_2L1T#%>]AWO><GROVB7
M@[J2>(9;WTE&;8?V!\MO+!?_6<[;]_]G"2PTG30FMH(7&NE:.K\P:!A)"Z<X
MHY)=X/\7Z87_'9[Q+W&2:LB&OBO:-ZO=*_NA*3QL_8Z:34+I7MJ43>7;R="U
M)_T7<XW&/ESV:DO?2V"OGSP,--2->AA!:;;-F/=^J,HBS37R47'O%E8497U9
M@2*YO,0RYH*L/,A:=7!W:.@PR$9FH'.[(S[;ELNL/+:AF3[:?"???H;Q8BL+
M-GLU]-I=QJPW$LMWFR,%POQ75FZ^-"N/LAVY$EE1UG-)/X1_"77U"*">GOMZ
M2Z#O?D2.$ T<PTM:HW%0_-4DBM7O9O <H_3M'?Z#30ZAX2T.+Y['98,9Y; H
M*0\M 'LPR9-0)7V8K8<A^E8&I3MBQ[FTP$]+0#T\>"8.[E_L'%&$JU5C$<NK
M7?J>HJE8+3O48N.:%6DS"HRA;=4JT%89XAD?:.KB&KBK]["#^(KG*VZ;N,$T
M!"S04\@>"Q57X5PBT"2R&MGUHT0-)Z1O'0%>VY?K<1W@B+(:LT=Z/+@^/6^Q
M_'#W5#H)TZ?!XKHNM]#B@J4=&O>2BT;EEE??L%PD:!>^58!4@%C6L S,5 VM
M\:P63+J816D\%YZA35OJ:N8_\#HPN )QR(MLBC-3*P'=Y>!L('N,W>S5^CQK
M7N71I!>:XG:S4])M@BD__/ZHIR_5P**ZC2CKVY0BA).(TSF[#V?X .*EDA^S
M./EFE23 D[<N)R1MC[>^[*12Y*TCO)7SS;HTSN?+T(:=3BAM^&M=22&$^8#G
M77M.YF4%3>9  *+/LD&%5,84)*:7Q\;=QB<O'KXW7[9=[%5[5]$ZYN5@8FWF
M!&RRM%S[D&'E8VB0?2(L(7-O66K0278 8A=;H%DZE<9^?H?5UX LQN)L>*9K
M_Y=NB?>0@:N/50B?62U1"PY5$/EQF\A0R%TO8\D1LRY1$BI->JLH.PT?Q$24
M+VYI1X\;[$5JH:DS;&T@/2:V-K97\N;\1&XX#&77Y[K&23 U&B7I?TJ/S.>R
M\OM:5S/Z'7))66L3/O,Y,2"G/?=;<PYW8O_T7!K?Z594$/^JUH"F@E&_TC*E
MO] ,K<E0U=(10+$V?CKN85Q7DZ5MH@KGU3H#[$2&J9[^G@\IA>'@BD!.?G__
MDK:^:T/4!]_11!FVI4CP4"F#'E)2#C:HCY4=>02G&!/1Z7C31C?[Z<)F&*UK
MO%J <C^]6/7]+^=C=G<%M7 .OB5.S'JU4PR5(<8/$"R5@S'JI6Q*5?U\@17,
M5;YKG_H@\2LW!H=C%]B_+-')L[M?DBY[P-D*<"H -AI;([;8N%(0-^$VMS4-
M!^_Q$723>=GD5DQWW_N$*<F5U"GG,1X\+6 %7$YIJVTVOB!WM\GN.V>P:M!(
M.<#7MYLC=T! 3,FH06SDMGC;#3JM%HXV3XD9+.&#7A[.]14H4J7DD7ASD7E8
MM/!^A?:S2>UW<J@FM26*>HLK3256-UY+T4G"G/7VG2@FMK#@@N^@$QF;D2-&
M^D:M\WJC,J)@=R$2X,/I_.,K&SET_SY6^#]UK%#]=!]=\/4'?-FCZBY7W:=?
M,?^^HR /GF6QQRT-5OR1B?]O'5(\HQ&)N_\>/"R8Y_3'8<-77#^S_*\V%-0.
M\YFW>S4K?I^N_]XI1^5-G*0M<#EK*R_JCY_)Q!_^!H@?EP8"/(,7B"I@@IYQ
MA624]HD]CL>G_@Y))[<Q7*+J,3I'@' +O!Q]KL["!4@QSOU15>$5>-8<W8KU
M.P+LW#.<^WF?XP- 59=^.(A?A>QM-S2[T?*&L,I=<9S&&$-S'/G;1[X*B*E*
M7BPV=F:3DLN9*'.^BZK3"/, %9K@QI4P7VE+U:0$F[']IKZOU1V5;W4PEEPY
M8)=6_NH32#DVQ;K@]<)*QZ#TB73XVDL_60*O1/ VV?'(Q^TV3[Q5%F$RM7ZP
M93QO \5;&O6#559371?65RH2(6=*9@D+-Q.]?6#/0:M.' \JBQ+,?>Y%.2U8
MZN4ENXOQ=?W:2JB=[J*?,>A+[/X6;O:4S !=G^O-@FI"9B98[]A]7G*N],S9
M#"9 6/1.XTW>Q2R/T(/1V;E>)T-%U0%N&/6K=ZZ;[->$-PFZ9=30-+Y0)X\N
M-?F,0+6U3JE8<=]/PPXR5LIIF>O,RP>%@OA/'5B":@WDOE%8,G@+)NH%=?T8
M8\?;Y4C/'2"9D&<=P\='6Q#[$. &('$P/$.E!A6Y51F1'/Y]>)P:?<5%M$3T
M>:E_A]K+?KJ/ZP;!]NH&KHI: 0_[(II7D<LJ'T0V%9 O> TA@PAJK76)3A_A
M]\]B*P@>*^;I2&<> 2S;'=]9P,%Q[J9#.4_-(7-' !(ARHF<UB5),L3ZFM/Y
MSO=G*X)N$K+Z9-TJ=2(]-;^L,6"GVGNS1.8*13LK(T=*D$;<S6A!DE!"#K+)
M@25#MX5*<)1OE/5AHE.N*XUFA5 8B)_C1LRR$QUK,F&UM>7!63AW:85_Y<WR
MBVP7\T\GRCG$K5CF'G3NNX$+ZB;C[V#T,P0+IY;?:0@[^)_VN((89T(\1?!G
M?V$>EQ449<J5NS($5_75W8UQ-WIM=7-LH-'JK+?;N;J>*8-A!3&\_"!;@193
M=(-5\C%\K#&YRCUTTE]\RKZ/%_&OGW.-4,1*DFIY&*]T"3[>P:E?7@.T,* *
M:F716@'3C'CQ%OT@Y$'&T-'#_#%/R[TE">P@ (,@7G:=;WI;K95CR'\$@/"7
M97";=;*)"SA1E^<9@<*^5+YF";9X+^L^Y+''AZVZ^2SC_+7-Y#)=G>_!1&.&
MSFEY.E:\G/#=VZ=XZWA&^PV6Z;WB&V)H[%OPAG$>*48C==7&S9N!4*1+6VI(
MOWFGHN#34 L!@;_);9%ZB9SWKLH'0&(;45,%F@2/&V%T1*]HT7$+ DF7K)B8
M7EL,0J=+ D,)%1)5IC0=P?2N#L;E-K8\6CY+S^C88KN!E^YKA['C*D(Q$$58
M,'Z>(M_S)R9668G/UM.)>1Z]6;B1%.P0U-(GS@OTBU0=A GG/Y\O.W.9@W.%
ML^[U<(W-0*X(9*I,*O)!!-O55XTL+!F,^NM8WAOY,2H;PM7"UDQ,J/G$WJ80
M!R=18K_([![CEDH1U8S29PN=MWLH7P(8J4H_!8?Z)SV(B)A;/#A542QBR-"0
M9(%J;HG,X50+-(]X1";7^8U*7P'EH9(EF#3MX:$D>TX?RYB^'P\RLBE.C7>Q
MK4GI;V:\*S=0HF\*ROS6;'->Y#9M78'LKV)%(VW7SNN;5OU<JN6O3H?]F.ER
MCP!6NO@O@9B\A!491'/)I15RW5KKI7%UD,&U"AFR/K)DIBT"NZ \LC0+>S>N
M=/6\T0<$X42:1!EZK(2L, "EIK[2PV[LO*+^FZADKP@_'/66@/6K"QP4.FCG
MUU/[$5S:&OY#<H>Y^]\WJ+),O6QR].1<+/BZ3ONR+_?VPK2EMIR?!<U*W@:W
MWT&38]V9YSFDU=!P_RV/J6?9UCL[NZSIH$]' /:.O1AQ;> %I\6I%^CJV&<F
MO<%!U+D+3*&M"B=,@B7_P"/ 55(Q7/53O*\D8WRBN@\9^8ET:1Q5!3\_P#?+
M8<IX)K#\K?5%R(M/):;9Q_;T?\JSOWJR9L_OEHV.7FMPE5BR ;&7MJ;/D'J?
ML0CVC)5514(TU)1Q+>E%#'4_27K@?R=\%"ZC$:9>%(U>F2F3+5/6XT5H>1K=
M06$.:G<T]-))O2I!$7<K)1/8]!9>+Y;#9=2]M!HD[G$RS9T9P'ZMC"N7^WB\
M"E ,VGU3M0A6Y"6F6E;D'$G2*TA,XBB0@Q;":@> 5WA(33W-\#.H(O/!$CC*
MY&UDR*VA[UF1JEG&C,H),JYP>'NB+K9Z&GQ +Z!RN"^WLXMGXX+E('!]3B.U
M"@S1PIENA:UP5N*\KD\<^X]Y9)P5/W&D:1P!:J/4@B1A^ON^A\1X 4N2A_\S
M:&%X8$]P#1VUW_OQ4Q?(-0GG'Z*.PZG^V5Z3+6U9L_8C\'/1^O[6._"Q/CZ
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M YY6/D ;\.00VUOQ?%-\KE_=:&+7.)0.HG@@\'&%&BFK;5OC:E+"K*)W?6S
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M_K;&$; 76V!5 ?<S#6I9O15!JM<IG_<IAX^L9(61V]V)\?9Y@-E[25@X5,?
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M+W >$6R>=)5X,#+\K2O/4.3$+,U.%NP72Y-\'3P/6\"G;:2*;'S/R\L7HE]
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M->T4BV_BT92 $@7%@3N^7+'KA/ZO184XI>S!:=] \7"XL=3\,Z1F %>$4UR
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M(JP!;MT8@(QUXE=UIK-X\M2^Q $@$CJ_0><-!YXK?Q+C&"#5X[(#14FX '&
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M;!<0O]@[7!;-_($=TP]:+?9"?G7HP>NH^@,UX \R]6?\+(G*(35HDIV/7)@
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M@Z3^1.40 9)M0=@!!F1_0#X/.M+BT#>:J(;ICUL^Y%[FDMW8YBH39H/C!Q[
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M??QA?6[<"X5O*7NWWM=RT9\44HVZ-J23N2FDDK\%">J9=^I=0=CE#S8S=T^
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M#0277ZC*KAOETU<2";8@';Q-NR>!+VUO%?F'#/;Z2;*U\:Z>R"M0<LQ'V5C
MR$WN7SR43H7W_H.J:C]5//LU.O;7DFA_'QU[II+T9&VNXSP"Z<=Y!)I N\N0
MCY\N^9S6<P=/WSG^5$CK_\<R78/ZYOPZ#BMNXU\L>S^<,]-C94%\(F'G8,%<
M"2'$^/ #D9>/SRF9:$F/"%Z"X#<@+5Y\67E)2'E>((IX!#+SX)>SQP^FH)VK
MQPDQ<(H;+6 HI1@RR]H#6;Z'$]JOB8X/%%4^X63XBT8LX PUVA1?)[ ="WB3
MBGNS?>KRQYSE_N6,4!HG^"7B2-'GP3@ S/]G 2!>=Z=']_'[[D-I0&_++1[J
M,SRDJ297,U*F&N5*'/^=N=(8_UUHB%[]&BCMT-T,LSQO3AZ1IS6357]X/+?.
MZ;X]!&64$:?[IY[$1)QV0$/Y)#9AIS !6*AH@TZ3$W2*E'CY4L]P[]53]/R_
M!\%O@><YF2?'R6F'61(=RE-A1HJ^2K?_LCP >XK_\=C^+X" :O-OFER!YW[3
M&#F-39Y6O.P]S#OH',X._U^ ;8%=:]W=XA(X5Z%=VIIC+H3^JE<S3Q1)>,]C
M0CLI]S"3N>Z _:$U$;&;288BSS] Y-<\J9P/FRH@9,;](C(%-5%UBC%RV@^B
MOXYWYPOS916$I2RG!$K^E3[H7Y(^Z!<U6S-B#00/A#2TXZ9[D_1#3'.4NO-0
M4W&IS+79!@P/X=P,LRJTWFE;*K%0?_A>C5C I-R,8WNZ/12S=M>=XRB2.KB,
MS9V7D5;V-1$-:/ 9?KS;8IF(L!!371&,[9;JGK>BB>A71F#ZL_*@/*3&(A:@
MU%,:G:14U2B->/UQ-%27Y<L.97*6L\;6=J/&-3J_^T\K[!:5A<KYG\X'A]JZ
M9.:&58]RND]!'>IF')\,6TP_:O>L1L54Z4YJZ>DX9\S($J1]%0+.3&(!J_F6
M,DU3-RL1BK%BOB1QYUZ_N/+]TGW!=74K#.GR]--GY= AXH!*7X.#&$E'6-),
M+8M6*>)VOSG5DV9BQ]PS\O.>VV9KZG0"5@$Q_&6K+<ZI+3J+8;:?;\<^CVIK
M%(E.\PTO:E-T&W3;I)I8F\(OJ@Q5H1BV2[/E90FFKF\MHB0HRU@=PG ,)-0(
MV.75VUW,XWF?3R]#**B!^5 %?,-G)@;D#&G.+JWS5N%A#*W6*N\A+)0/T&[8
MVH*$9F4S)Z363?L%KR@WUM)."9OTS^@JM.G=TVNZLV5<)+:KVL1E+:)L^$Q/
M8,]9-Q/\V#FGQSFL!14XKMT\6QTB]*KQ>TWE143X],5+4F9()VFHY0LLX/'@
M;-,6]SLZ&N)/\Y=9WT>,=Q7J7M#F= \/GP43F24R]1?PB;Z8Y+8R,&.4_F@U
M0AE 4_">4Q#IUK!_^2I)GQ0=);E="RGE-QT]9%Q]B;Z9XQ1#U6"^_IBL%6='
M3K9QHA-]O*:D&76 M0B'+5\86R%S2+D4O9L\W)E7*9-J-J5B=_M\1MJ'?<$6
MY&L/R^=IVBNM<OVQ;N![U-IJ:\%<'*G6U.9[4P2U@QMY/?KC?NP4#._Q@BGW
M^+K:4]>H/(']Z]SH.V.EH.=;8QSV4HF,29M)*^K4#P=Y"_U=>Q.%JV5C^2^/
M&[0O"A$'V_53*N6VNV"2&7K+'&!A%#KC$OQ%UB]X#]N^$U_?!$>++*UI"07'
M)B-M4A-$OC):?.!<-!&N^<[QR 8&HM R0UDL"_"7(QX*Z+6IY?E8T[3>S-=;
MIFT"7KIM:=R?'KLU-4L_7B!P&0CJ"!C5ARZ&31[IR97W;4$@NT9+;\5&L^4R
MS*@++U>I4?/D@>W71>;&<I#WZCWI!WG7#@KM@[0S!&Q)[_:S4&:F:IF[1I4X
MY9D+O1QZ[Z)$028O<4-9M'8-*#7DKC3;MID772^4,'08'<X<^O"BQ$H];V1D
M/XZE/\9ZKI>#YQ72D1^<E1\,I%1]:(L*57RY](G32\P[N0=SRV#"@DQ[RIQ6
MM&."@Z8YXDJ'FU67=D2]4,B2SX;&7*=09&.,/,\S8\>9-->]#-.WN=U97ZGK
M;<Q4QENFGA777^7YO%(:&I-)-ST]N *IUMR?_F8W^F6WMNX(]&"W.]2!@58W
MET%G4&RBN_S;0S%M49#.VHY<&5$(#UL9ZUSH; LL0,@-Z+H]*=D@E!EDG3GL
M<)ZEI+KDY8AX%S)XSJ?+08P>07DT.-+G(,KNIIMEJ&&F%U(X[L4FX5:UB8(D
MO8IZWV^]!O_AH*8BA7_QIZ1'6Z?*1B_CU_Q\C?Q3#H'JL9^R#+#BU_Y=%TE8
M-#J"]#(6,)R,,:I"G;XS^./:@R?/0 @)89L'K'7$6$!!/V3Y^$CB].]_D)>)
M@A/T@^U47J8'_9B&J'^8EXF0\#<G-4-WBPJ_Q8[Z%R%Z%^3P_,NL3CBJ35\%
MS?6U8JJ2%K2,XM2>]:X]4PG>IE5Y7P5=[J;"=!XG.]7" MA!Q3\@2T.@COQ>
M V!IDJ-GYJX("'T(MF6'/#].J)H'B02..H*VUX +&LNI8\K5I-FS6,#2V&&X
MZB%7*\;#&)WU^U@54M?Z/$8\E$F/<_M.!";]K:/,GGX8&M5ZH%[%NA>QT;CJ
M##G8JYM7^T<PR.!  *KB%(GNLOV;F7_KIW(4;8P;L0BC;A4HFG;X&94(Q'@4
M5E+^VBWL1S7P8#=L*]=>99UETG\ C@5LKWNT9?_:3>TW5'13PLS$?HAE^A_G
M?-V04OY;QZP"WDZF\@]!IO7G907W\B\&+F%$<3+2!AHI.) PE.'PZJ.GS&%9
MQ3/[,>GP9,D978ZU$*'>#=J)RWW<T^9+0X(5'''.H_A66UKN28JN&D&UP^@;
M8_3/03UH7Z8BM/N,.NUA, ,?K=.&I[%7\E6)#OU'PW(]Z/LY9BOVL7S%/O7G
MA$/+G#!DW,>Y)V\.8Y!YA6=E!*EY/EN7\)\U$3&IXR@L%"8[=S&4==N\_H$5
M*\XJ?Z-PG-;Q_'':1M93OSC, YM\J$^,E7KB>WX.*_Y?;7^U_=7V7]M6>!T9
ME*$[BJRUY#U4>TM+<5.PA<>ET*7P*M*'70)Q;4I;B_VVK)SH%]XAF!NYSH-W
M.JVTU\4IGI'J- V6FZ'VXK(/6#K\GKW74!DF)EUJMK\HR?K4]GQ;'HBBBZ;?
MW;NQR_&<9N69JA?1;-W4V;M3;W,E"Y:C7-.KBAL=:,(I45X>YD?'Q:SP@)=*
M+TN<U>$FJ I<%/B_9 [Y6>2ZO739;J9R=0FE!B5<GAS76VK[$JCG,#);=*"9
MB)8HZ[,644J6R#N0[DJSA&F.09V&^31ERGIWH RZXTB]EG(>R1M?=%],Q7G-
ML3 'N'5NHKDQ$B G.%I9UD.^A86-:;WXSFH^NS=()Y$M)4&@^:8L=$KZK&:X
M696 #Q_P,M)/^7)^A![G(GEWG%E+[P9'"M(\^Z*YQIY4W".%Z"V['N*=:RGQ
MZD.U!5=Z5Z9:/=3XN@^H=[E1N\?^N'R>619)6]RKX-TU;HRW&5[W:9>M LG3
M-Q.X#@OYU>=B%VE&=DBO$^YF1T8.\'Q^+GK^?@%A,X:^9\XM!*Q7434P^N'V
MW32IFA3AD+*B&48;+.!\6;&^8K%\Y?+H=1,OR,4;.=8Y%\R,,_]#MQI"#BG)
M55A F#9H,OM#I=%(7W41V2 O?%QI]_-3&Q^>I8.!/GW=9F#,+<0MD]1[7B A
M.,--\#DBX<8<9SN5*BCU/4B:C 5CX93@/+V-CNL O!/>_2CJ:+&FPJS?WM!V
MW&GGZU*Z/I2WIHR\#Z.YV[,74/ACR>/=9#VCZRVOI+[,%VI/OM6K.=R"<WRO
MH01Z+PP&F7HRU!95JH-J$D?G:% 1NI[\4!M+BS2)"*Y4EG?RN^+2=O)R:?G5
MYU>GPP?RPHNM-9] IP@#91<#U2?ILU:%<\]PO.EYX2&L/" "LOW1K]ORC'BZ
MN;JOJ ;/D7>3!-QZJ_!P$O-X9ZT?D396XG%%&77H VYIS6X54:4BDP\KG2W_
M+,A;]\S3)+K6:7<\$<*^7>A[1^2N>8:&,<?$ANVD7>!@SV"9\E7PZG,?F2M'
M">(B!*H:<V:V=0W6TFC<*I9DY 4<C*R.K/G$:SA"LT+NR<;.77UIJ%G93?G=
M])J5?S9G67^)1YEB<MRG5O.IQ*O?(Q*.1-:A$XI+G<;E.3J1OHGY9IR^(Z3T
M0?[B(X)YG=9D"B*NC327/;P?!'E[NA-OZQ4$Y5L(^8?$SN9S1E%5@._M9RXH
M[E[;31<Y)\<FD,D.7?5ESV%?JPV3]J.H>'TCV)#L0=8>)=.KS3F&YW/1C\O[
MUI/D B7IY/O(F"7J&XXLBLN^*%2;+BE7S?%%ON239]_&87&WQ<:JS;U$ZN)&
ME%JP:S6>' 7\^SV*HC;0R%.+ (1W$U^NXV"^E=5.$NLBC3'W]I+/:TU>(I)K
MWQ<V>=U*B#EI.(U;.S>D;4E>PL/5U*4GIZ,2HS>WR..6%F34F09K.,NU8=([
M)H"^4L0M3^..P*2IVP#T6D O+Q&(?+P[>W5E+SM6,U1T:<-2D*;96M?9BJ /
M5,+'N->&U_$6A!KD,U7).-!+&$)YZJPAS[Y8R!D9P/04XY2^3LBQ]_M#QZ$N
M1VMCO#3["S7TWAROR^&.7ABNV-[2Y6\7@Q\\FSL8_J2C(V%L%;77&P"3\%49
MBV(.H=68C[!<RU'8-;P@5QX[DAC(6B I7G"I&[=[,H]W#_27S7/J*@>W>S@$
M#FV;+G3*/A;G6?!C)X/IDA9+V#;8R\69$X01%@@]+BNK&D>,7$L:-C8*;!M
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M@[&/K2+8[4>M:L._5_),-!KU/KP1)?/XLGM'8S8?Z:GB7QIAC1 RHX\=L5B
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M>,GPK9U"'?#!>="A]^NH/^-2<?S))D6_L0)-ZE2HW\ "WH6T'N9J+/^9S#N
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M(O&)Y@PF>LHDZ(?4%1JT;WKXJEDM=%]$O/?(:4D2P7 AB%81HQ,2F>,M9Q_
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MD.=\>6D!"_KY@1T133U2F5KZ 6/JU0Y28ZXFM6*'3<#GT/<=PG+,,497N(:
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M*< &KI[,2W!8<)JWOO/$.1_;/,[+6=AH7J1IZ[?DV-85]9T;O3;:55*6<*>
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M5!Q@O&Q(@\A=IE0"AC3*#"&BE8K91NZ%$$&/34IE0TO'-UA_-^&&(Z71-CB
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M0,P*YTEW[V6B,49.:+)EX#%EJ1R7X:!Z+08'V&[D/IQ2^5D+MM>H [ABI72
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M$&(%#8H$I#0J5@!?0;_FN@"_S95E@A5GHJJ:-N%R[V\%9C\6.-?L8*+BO"]
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MU/7UN8P7\+$17Z(J)ONER0,O0#NW>ZE];R\QPWB\)_E5R^A/_=V=+C9*R[Z
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MYKU[;C# =R5-7,E],IHM;.^,Q.GY=#:.#Y]WVKK)35ZQV>T"U&KI73;N6U*
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MAG+(TD%.L2K)=+&6K'ZOWDD3 4\(OZ,F& 19(;RB[G&X8T7T4#P. 6<X("\
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M:T/GL>G4_K+!K^*:9Z[1DST(#Y*."5C-V$F[P)BW;)/AK5+X/?[1S2G*!;S
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MB!7U_-:W%W Z^*6A.CD4?^M@CWO.&T6I=O4>:@6B' /@S,(#Z@Z5$,LY23B
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M_$$UM9E<A2O.5+V82S@@FA>?VU;5UHPA;?RG'!*-%PY%6@MDF! ['  1A$H
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MI6)$*LLH0Q.S\!?^=&X2BMJ0GT!J^8Q;QR)S^!G[)\MQ^YE>UO9;AT7Y1LC
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MNH?2&KF_\)U3QLG+=]=Z8*L?*P3MDJS&AX1!'"!D$JDY/YX'#?%YK8W6=T2
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MTB/N(B((?SZ79H=EOW1N'7X%3YX8%BLO"*.PA,0@Q%4T/H,^,<.CY:=1V^]
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M &W?CN;*]YO?=ORO)PF&]N;>J%$97?=-G*^3 Y\T#K6<G;JTQH805^G."U/
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M<-;A:E<PQYF->EUKAQ7-@V4:^9FC(1>J>R[=<N=+K;\EBSL,L3B?_%U!<HC
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M1N,"Y!1V:XSL<93LJ\Z:6Y4R[#\4:H:;IG_I20#(YD"_#WVWN&BNF3%C9<!
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M6JTX+3HEO2=]&5N@/EOI;S.21 U]YYZ)YJD"J1E:"N- QCL]'36JU(=;6]B
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MO^C'YO48Q(3J%OCLI64BN+](.,O4';?$D^1T?ILW,3BR-L4\C-4. Z%,J),
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MN?6P6_;[U\A7RN&C79S+PV?W0AY-+-Z9U9D5>0QX/CV+6-9-+;G/#XU6>9U
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MN6?NV-6FU\Y&RC=,EZ=EHC5DH@M;ABH\X2\L]L"<8%*(U<6Z>CBQM+(0M%$
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MCZ^1+K42PEYW3I\DKUFB*Q$%-LT"SDD:I\]0)@HQ]*T[COI1YR=CZ,B_0UF
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M$)*7?>Z]6SS_?>Z[[_[/V>^.-_;*^,;(('.M.;_^^[XY%YAQS!S@FJ*<@AP
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M:_J_IO]K^O^YT^?9)L^V^E]G2U$;$>:\ED:$@ PU?H72GJ>#EO3+,0#OIFR
M&YC _5S&%/[6=4-0:)CORI$81S$P"<Z(?O3JD'$L%'"H^$LJ*ZA]/2W\\77O
M*S%&+@Z*.SR$URH'-O0\^H4V]J!X78705A(Y$IVE'J8H)BLF5Q.(N^B/;8LX
M[#IC989N2T,%0Z"N>/85*[+FXY^!3$SAKPD.@<NG#,F-/*4CPKXGU,NTX73G
MO58H;L_YL5)G_TS5RTLI2V7O'QG7(9)+=,MFG<!PTJ'ZGD4(*G83DH=V7\,
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ML^O(O#H<,64ZY;ZB9^!ET)TJ9JP/JO_?^'QQ0Z#I,MAY=9K&3<?JE^#"^$M
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M^QPX>=M!Y8J6W>9*ZKOBMH8D"\Y:?712_.E3IX<Z)"#NJCXC<KH/NJ4U[A)
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M::\ZMN)DF$6_OHY^UI 6N@_^6R"AW$H?1]A(X7V-+@-;*WWER"O!;PFX'&6
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M6?WO%QMQ?@A$'5INTQ&)OP>U@X-1H96@P^_UFHN>J(BQ63C9L@EL#@,X ;X
M;Z;ZJ]A@0^%'@;>@D+YNSHQ&O2G.C%# ?] O74Z3+A/1LX?@S@H;]#Y8$3"
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M6X6];)(E_C$;(4E=E8I=EQ 1-^'$RM[&SHKX@Z4G=9.L5@V<=FZ->Y,*[!A
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MWB$C(B;==?RSJ"8!#WE[)1[-68O*\I%MENLS=G,A&-";VI!>BSX-^P.B$?3
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MXB?FN.X &!%5F7E6?X8@HMXX;F.-K[-FJM"/A^A.][%YXMOQMEC5G)R4B0F
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MH&V0CAG+A8A\D8I<G(R!S(./\?(=YCKG(2\:Z_CVY\"Q]@'VF7D RS_#M4#
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M67ZBRD:T3T(N5079JRPFA3OZ>*GI&G:R(6!S:%XTBTH0&R+P*B)ARUYEPD:
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MU! E0?+W+WW:[<YE6I9T\)20T4VM8]W1D8W8=VT(K\'5E]YYV:PHC<H)XX4
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MS8^\1.Z7V1 GM!>1*-I7_\T_RSQ)EJC>92P<HZIKOFH^2[W>\Y#NE3-L34!
M:,KQU8QY3@T$-* H&VR6VDGE^%J$B@P'M)QEV03I@G#V7AGRE:UT6J Z"D0K
MYUQ#=,^3LBQ.MC.2A5QU8:D) @M^*$BOVK1>DR4LMR@<VBYW]C63-GV.:--=
M7BH@NBW)S<5KE8 #J)VP V9/X8 )9;W+ :,#%5O=HR \S>NX[\L$]'Z>D0'E
M'S<]*OMCN\&,.<_^0'XF8N>^EJ?,N_=?U6SW.TUN3!V@W&]4RJ6H4?F:]*$I
MU_QB5/'][\5KME4DA@9^XT_.BKW2*OQQK8MY]*0?]R__Y&S_#"9BC?:S3S%_
MT^-+M"YB%# C N %9PY ^,63Q;V832)(^VQ'OOB<FVD0B^>3CN)J%6;;:HL#
MQ=QH&R7JO9TOV%;1OL_\IVPKY=JNKF:,7+TZUW!FF^+;=M23'^+?*J/L@=*+
MY9^Z[@]R\K)%6L*8N>A. L**DIC,)QU2UP4E&PHEW5:-, P5MA>MH:,W_<XR
ME$&5H6#!K45!U1"[U16L>6H%?YIYO(RXX(!,<[ML]'M!R.#W%(I)B1G(H,&*
M_B>#0KP9.0;WWO5LR7[VQ^=+4D4)5N7/V2>EW=5>E!*1RAB2BAX0]/>L"X09
M3]L[4+7 *D+F)3YD1*M<7XC-7&#BE_7^@"85W-&-GRY]O%Z/G82$U\H.4/*!
MD[Z>WDMF?-30TVB_R>,5IG'8%-<[AN7:Q%#V"W;>L\!V"\KIKE3\0#Q=-*?)
MT1]XKPAUIUTCY+"Z'4U%HA9WBD<B-V#-!Z"H-+)9-QD/&Q>G%XA;P]?7YP,
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MI=XHUF7W!.%G/P-8S;+E=QGS5LWM2%[9?H<M5APCSY32$Q.261U<E#B(")E
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M$+C1C)D[#-B!4=Y=,=Z15]W?2<(!'_O(&F.VC=S@ ,[QT;^OK0H'/)>.@P-
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M[728JY.R^>,EY*&T& X8>ZAZ>#0ZS4%WUU ^5 0]!AP&')_! 5&4L+2 >S@
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M+>$0/\OZ3_MA?.Y-JGBC@O+[4B'6'L -ISBK\4+,6LM6_V= **<_Q'.^7VX
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MW)J]5)S^)J@!2X_'CE!13R.AM='<BP$@5DE5JH)\)4&7IW="E12WPA]GNKW
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MM:$K+ &]!7'S==89%\9IW2KZ##BW_"7RYDR=OHZ3);/("ZK0II-(X'>"U&2
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MRIA]H7?TB(?_P<2:Y3R"Z;H=JQ2(<4N2"M]^UO74\(EH+&9X!\TZE/F]:)^
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MSK-CT*BN":(\$8.V;N.J+AN91NTR0+W7(K"?7-)J*7@(L^C_&:U'+#-_4*!
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M*_-DCZ,$I;)\?X#UQTP5/?@LCV<S_UU"9>6,M-RBI)C_GI2TE;+RT,;1[,.
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MIBD"C3=:BQ,P8,NVDC=\93^-KBR[]6@,Z>/Q:VN!OGJR-K'XY;,7H;_[&HE
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M=N5-ZZ:@/*EWM.^OSBJBJ72F_$81MTD!@KN!^.?##B*Z PJ-OTLIA5%V?BB
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M/-ES769/T\ON:R%P82MR82(CM+6MW;/XN^8N$^ 2P 9_U8SZVCS2%$4"AAG
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M&@F@L"6#6"9%>M+V\25(\YM\<GT>@V'YF#GF/,%?DE:!.](R*&[@"J9_NW\
MHGW48FJ\)7\G,K(3SS0] '0(*WLUAM8Z3:M(E_SE('%<FNY=Y\I>)SI2&H/%
MG+[UI!5<T/5(:A&T[KPZ3&,_"\2B60/S,ZSHNGS:)6[V@]WW+8;^JA?S _#9
MY%E0&"_<:#3RCR ":@GZ;(;N<UCQ=MQM:U)@%CKE_P/<"Y][ "))IHEGY\/[
M8O@[>[Z$4)6#QL]CKS"$)UI__V"XXVVOVYD?>!3R]><064C:*87G1QZ'#Y<L
MTBES5,,Q;KV$QV!4:WB"'%&/Y%7^U&W<AZS(*?.XQQA,*3*MYM\GLMRY28\T
M=Q!47*-F'T(V6RD>"6H&PN1N]\L?U3^MW$UJTWV&0-Z)FJ*9'U#3K3\*\Y#@
MGZ$_ !Y-*VAT9X_WK0W,=#-AE8;S!%[::5XJ\JPSX/]XS5>W4D3?B(]Z9@0^
M2BRT53>GO(G-56#-T0D7J?WWE*3Q+089G(ZANX'\[#[YI*=)K!3'FLM4Y585
MQO5LLK#:^FZC7*8">WR]1LW=LG$PJI&%0X;V]W$6:6QW1-\+*D\C5Y,H*OJF
M;%P[,8D4^(*>M%FGD>ZCA9B'W$ ,U+JBNV>"*J/XWQTYYE4&%R2MR1L-,M>X
MVZSZZA)3\_@4EK*+[5@*1Y4A/0!ZTNQ-9NOBAE>HSNUZL P0G<6-9AE/IX-7
M>4O7\1RICN*OK*]08X'D86-QCLR$2F?U'7;!3@ K8,7GQ_PVIY- ;4A*B.Q?
M54E"5-3Z)QE,!=\9J5J'A*="0XT;,_5B[L56VN[LOE-O#L6P=.O#TQ9!!AG$
M]NX_1L1@+W.6[(0U*S)I9T?]9H0ZR-64%="%P0>U7N.<,,"-=$@Q/5TK)2%5
MZEN>4X[6;B38WR/3[-^;8N&% +.K@FTF%?CCX1"V@#DW!O)G/K5%UW='@IB<
MYCP<JUB_'>K\'42_,A58^E(_ .>EB7"\_)+7@0'IZ&(H!GUD E$.'AA]*;2V
M&JQ0?VF]ABEB7BE7$_HG+$PQ($^9]O8P=T/WE3]J('9E!FMEO0MYAIE,(\OV
M"J@WN,(N77D?LF?/Z/T<E[7;!VO;KI]?A\NCF-M:U= C?@0YQ.X#_T"Y==^I
M,EYTTFK&)Z7$A&FIYTN+*U3&W$S)U8H;VN%1YW="-B.Y-B54&=:,T[%A0@3J
M)*?#E+4AYB&*316R4P(M5+78 KRKC_5]5SO\E::7?AUY2",&N=E;+\>>HK>3
MCD6$].2ZTCP!R611'Z%EMU0"'CT?E^8K_7!'@DMCKZWO29"H.X@JF-M!XC;)
M6S0U!C,F##"&ZI3UB[FW/ Q9TT,(^I\4K09]KU /#J7J=MO9P.2MHDZD)&;B
M6,!Z/B+1W5/<8+XGEB]&7B>UWV<FW@-:/%_@1*L\8MN!)W#C79=FX:;#Y N>
M0V1:$TX4]*B\R,_P?8M*A-C7F.::/BM^JHFN+E(P+N'XO3V/T_%@0A1S%+VN
MG7;6\%LLQ4E20L:F-JX.9F+?4!4)35LHX&Q**&BLHJ8Y# $ Q\2L-E#]L4Y5
M<7V2U#BFTO035#J[040TI7^-8A</2Y94W9RM4U\6T<]G&.:NL7; K^/?T2S3
MY\I<:23L2KK/8&9EQNE4+%\#L1)-Y(\?#?HX;O%W159@ID\J.-TAGN<F+.B%
MA/#ZX'ECX?M\EX%W@/^PE2DBL:?*5)5:2&F\9/7P =C7Q@\3X7LMO5OCC( <
M^BF6V5X+Y@M$TF5T;Y'OV:",G--%&&Q_32_GTE (;#-6#Y?0#OQN2T;FVE7,
M8#ST:::)BU^I'1Y3SGUHWV5 ?"O),5%>.RMPA#>,BHG.\*,SQXHE7,*2NP0J
MF<X>1"9*.KGO^?O-)&.3B4K4*BS%B]R\3_-W;.(M:-S/[ &@/^B_J<4<.5X!
M%\Y0.OTLW<HUBRU\;W*K H'I/N6@Y*=>U0X,OQWR?@",8D_*C-EG*.Z9%YZ\
MX]O<)#QD1?EPU"=%7^_L<F'#-3CB29N=;-" B'8N6?#V(.1,I5LJ;^CU\-C/
M&4%E"Z;H)^V^Y:[\W)B<K^E)FQ=$X'5I,.F8'ZM1IS0A!Q/<>8L(>2)@V;%R
M$N<,WI1B-I1!Y:PJ?B\6K'/+Y0JR7YVU:/^H^&G*NC(')SV6>I\RL_M;JETU
M/:^F*[C<S[YBE[__XN;5*RL4\9+\?@)#=48#P2B^VW[&;Z+E@;V4(RTE_<1&
MMF/RM']"BAX J QM:W.MSVBXP3K_#AY'OP#4PYBGQW/?(7?3^P72^7H;QH_7
MHZMI#<>>C_')M1US\L"A5:NX]N<3?3X^J20D*U-RKY3>T-[>!$[:EEB$KO=:
M(,G+"D.B,HE>NA>T=8YZE76):NXV6DCJCG:G^$BU<8B0$Q'ED]MUS+,<?.N!
M$3;;'%>(^W^CUE2R 21QO1Z 'M_ VGU;X@22(L>N-J_X28;3"A'XMR^^_N6*
M IA8H?TLNS+4DPBY=^-G-_Z**BGZ?,)\-00<><<=/9)_.-T_RHOL!QO/)".7
M1SOB_' A1J7<DM!=%;?7IC24VU*;+2)!^HF86!=_S*@F7G66?(R=:=.2$9WX
M4($F10D[:)6S2<5N)E\!4D9)C^;YR&MGI\,P<W"Q0/2-W:S2!NXD0$\DPPV8
M;(>M5PZ'$&+ BLR+JC)'6"S56,3'@4. >?G7655T9I7H"X7 58'SAE"I316I
MD,*\(,JY7I< T=^R7U&&W:$3C1V4<@QS QOBSA,UWP^(\_$J!%Q,\)+D/!9B
M1,L? )VI9R!TJGZ5DPB*":<(E1IJ9P/*T+9%G85EQ?Z9)@8M.9B7R."W.>A:
M^E?HT;8M%= N[TXY4PKB2F<?G(5]-4SU_1RM'[8QPGZ?;^L,PK3RG'\C*LA>
M4T-=6?G[S?9HJ,-J7:-'//PT05ILQQWJ\]-0F8'(LCZ+U\3S?8*J6U6NQ#5E
M1ZGMI/ZK\JW*Y;,-'1V2RDK7%JOL,$%Q7T4ID+UX)%32LT<()C1,[9@8Y5;.
MHAY\R#/S0@ECHF+?P'>V0+XF//==*EM^]Z26KE5VZ+D7YZ9V<B5HDHM9?QTO
M/(2CK]90J&F*!.>@XOUDW@E7_LN[<</Q1.O,F,\?SK@MK$FVR$F6\D4+-6+.
M)[R[B_/ J'^]'TQ6(+$H'_NHA);WR2+7,XD$8K 4Q(9.JE:[&O?B9O^SI=C7
MDRC\BN.F?9!\DZ64$XV?V=\"KZ=G8\/FV3.B?M_--Q049H>=]2I>J0+]X$H)
M[:+L*YM =C]H4LZ<4/):BR2SS#$_D:2\[:]?52UX^87O:J8/C@+T#!EOM/O>
MEZ;LJLR8U[Q>KU,GLGOJB=.N^8=FKZX(7(==DFP>J<2291?XU*[^.R6I-C=^
MX?L=L>&ZC,\J&"R2'+D*^^9YO&JTZ=9.1W85W"B>Y:Z]\U$?1I02Y!ICIE$A
MT.4"OU(2-'\?YS?W/Y1R^4T&>IM7,\#))&GL;/S#:9$>C(GGY:E=]!Y3!"7V
MV0:EWQ?F^CW:58DHFC8*/4S(5%ES-2B&;L SCG+Z@N9EGVF^G&T7%?<_LR\A
M@0\[MXT(-^9H3EA]>DD_J5RD11[T1!(-8$&)5\T YPJ5V&,?</._CM6K\^AT
MAJ2*)(Z2Y@8F3 W2:*CR]K%5>!/EVG<7ND"^55\F4($<7/OLC*9KF;6JQ_I@
MAYK&K]^?.1N71XOX"C)DH7GW3A>,+R%QNQC2@-J.STM_V+54RYNIM9MG)16.
MEHSSJ+C3GQ66UU3^6S5P\%@EC_&^?.LS69R#^9JPX1W&<1E4]V7#%+TE1XBB
MF:%;=_]$B7)>$D1BMQ7YWIFCQ0&4/^['CY>1&S&$KV'\9'!W(G516RS!4JS:
MPN2=' )C2QTPWR+)P9F(<P6'R0&2(''CR;#"HE9%T7EG@^>^V\4@X:.BV=8!
MI.?*VP6*<7IJ90A^#9L>).C<$)%ZF\U> ._T>15-6Q) Y-1C$:@RZDAK!RE<
MZ'^:;<],7L%Q=%;*"X*<X;<)I+_U3WWTLZ]QT]OH[^F05:FWLCP^KL782:/-
M&K_,VROE]-6?W*)+E@?!F94.9R;U&F($))V:*EY-0B8.QZT:4"R^9*$!W@TA
M9_LM@<0"";VA"S,M*R3=C-<D.Y\X=8,-QA<,NSSSGCD::2U\!&O7Q_E:!4F,
MKFV%#I<7/4\3BJXKA5..^$+Y7F(=?FC%[VI1@CZ/.'RE+=65HNI5=+-'[D,H
M0]T?#-UJF*!7U@6A;E>?@\3#X9"?D3=M;:#6&)$\*BV[V)?:1[+RV&I5RBCE
MK"@C[0RV,)?^HL67M$>,EAT&+:MW5FKJRO>C\4+MW0OS>9.MED+0,M6B850U
M2N5*"P]HM/ZA@'?PY,'SK:#=F$=]R@7MX]0(RK5GN,0#1HF&E+_!Y_Z!ZB?V
M7$D9U.?4 =H[6FTMMKB>_CB![)M;KOHF%#-N;;IO4V:6R=OE1Q>1@T3QD0U6
M=JXM)@?)CORZG *^-47K7!IVP.8.UZ14E),I&"FO,?[$L2<KQ;'M][YR&T(7
M]7H^V@P&3@UY*)=L*SDU]!6^8U@^9AZZBH5>8;][=,A>#&&5,* @-W\JM#UZ
M +B/LQ&8)<^KZNM'DXE8QCX$2<B^FO;C6)\K[P$Z%9"DHT'[RTS3YW>\T /[
MJ3 CXH'[Y+T:/4/CC&$<^T,9@?C=>N?C. 6,F[P@"=C:1::O+6G78G_=KU<!
MR5KR$T?TB$A'9T:]*.+1=0Z8>4.(Q-=Q!7\T 8.%@BSKE.!PO[?HIF &[UK;
M&=X$<Q'2OEOAZN:Z_DS:\498@5+\+Z$J5)]W'Y9%2+[F:W>.(@=GJ/>HBAX]
M?8[LT+E=M3E6<>CWQ-&>@/X=8QQ^92DL@#_UG@BSC)8\S4"MB;X-"S/_!7Z\
MC&10CF($ J27V)UGZ+LD]=3E-\Y@XFV)A*IW&2)$X&D]+R.["Q:\?\MDE/F+
M&8<#R&OPG)W=YFQ?:=+N!SG=X1@&QFJZ[^?CC^-*7_WOI,76/FH9C;?*>[OB
M-O)2\"FS%&V9'-=7=E/HC;%G.:$)_WG:0_V#8@FVE8///MWJ_MU.I\.BOM[T
M!7PQ4&4!$;B6'BVAYNG6F&#> 3D@5JA4%H;6ZC\ ;MJ]4=P DLP.&J"\G/(O
MG5W^'P"VXJ!8N&QY5]NW?R!#C=8+BU"H_QG/,W>)0WU1<JLE51^/8H;JL("Q
M?-YK"J?[<C;\A)\9)_,%F<2T.C:BS4_^F1;FO"$*F\R(H..MC=A"G_2JXBU;
MOR:\Z*4CW=U98%=+!:E75G=W)?) Z*Q?OHT$+.L!Z.J&\5 -UU:&YHYJT3T
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M\1YVGFLR6E?1S)S;V4'O1%,A Y=\F+A+\UL5ONPU(5TBS=U1- M%8P]^<Z3
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M7FC1L*8G?R:2@\]VG/JI_%SM99V:'O%V.59B_)76K=;J333+VR]O)UXB/T]
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MOI0=%YO-7]?H=KN?_Z"G]+A,_"\)@A471L3  7DJ-,MG@^HSQ&@38V,X_S,
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M4Z&>,YV0I*R"(%MS/=W@=AC@0QI^[,,A0(>(C,PU8S-X/4C%DQ37QK('C3_
MJ%!8NO1([*=N3#!<[P _,/S5:".@P=OX/E;WZG*$KR&AX^*%:OF^*99$M?>,
M1E6C,N+GXT_7NU[I"0?+T$$APSFCL"29GIX?%)W11G+?_)_H/:FW^DI=CX/A
M$V8CH_6ECM2=6T5XOJ[8ZP],;C16UHE>2CN[[DQB-,B*9E45>6T:XPW@B3#:
MJ\XQ,1 C\,-'D F#UFCX&^LF?;60;HV=Q)&'!H_FT4-WES@*NQZ_ZND6OBI
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MZ^.]X@_GU;BUD^]S01?\M3D]GBS^W^!;7("M8OZ(P^@PD>$$?)U'A90(N-K
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MA/!\X,CZ3DI"3:RIJ_CS%9$Q=:UFVP<>F!]UN5B0)U*+'!#TN2<U0P:/$G\
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M0I0'Y/('>2LMS.&PH3LO ^$[_%&/\2]-,;HQYNK* Z*/BDTV^-E =K@J9L&
MV4S2NNI1)6.R!DZW']4DO:KF!V,<ZHI1U[*"JP3=M@5NDB?'\]&=O^$:9DF-
MD(PME<U]5<'^5MEJI'%*!I72I,"W_5)LH#MD%'B@R:=ZN41#U]'(C:=H_NW[
MP&W!R?MNC58S?KB/]7!-X\ P!F"WZXIRHVW,;GM4:GI1DP11R9HN!"3:KZY%
MJ-.CR8>TWD4C"!_(K&<)=40I/2_\R0-^A!RHGXW.B:<X"HT)MW<7P8_ @EJ1
M0*]MW",V%TX9SDFO"BP*^]32Y0)-CO-<HR"I))$8?2+#R0\%F9PK&/F$4[[J
MX;5"P9C,T@O7F%T7*Z^%*RI]>MS^7EP2JY-AZE& BY E=8?ZF4^[UZA?EY;I
M==9<I^J6ML&"&B6.X>]BUQ.MVJ(%1$S1I+NUS$%D,SM$2!O%<,_&2;H5,"^=
M# U%5K'EGK,_<>OSKLZ*[OB8M-A-(WK6)IMG["F>NFJP\U%Q@ 1-HCLY%F;J
M$O T9$0EOHE&VZ#EQK;X]_ZIPBG_FJ9QX4%Y)+Y7M1;BWW;V_PCP1TUR/ZMY
MRX@?9*&H4*MU*=IU8M!O!@0)6/GNE/7R]D(!ORTV;ERE$)'>J]:0 7$RUI]#
M$1">B[(?)S*E":,S$[!>0/LBJ;]$2]F[MXGF>F?Y?)"V!_UY,7AK=HX^1514
MCQ_.*S_0;29F:S/?>,N9A4>&OBI7G/BU6:2&VKTZ_XGRGK?]?6[\3((.]>0<
M5/US17,>"%,+LR^$;O7Q;VJ6B%>EEA5*0>M+W\7%.VQ9H6NSSO-5VMO2D3KG
MI5[5MV;8$E4JRZ4W3:_YB*K5-/A,%P$N*_?#JU0#/*.)(*/DB]5;!"]*GS8F
M;1![A^P9[;IU&Z:GL(;S@"WO<;H>1B/'Z[3MG7JS/9<0#+N"-IUX;KE9Q2$H
MQV=#ZNP1/(KA@MD=#B$NWTV7PCUW^SF35)\R\7G<Z^,/%Q?0C \S]>)ZK_,0
M_.Y$!$9TL74 XNOZGA_LUO1MEY0&$$6]FW,(&J1%T32_: 3OF<RM?.B(WTK\
M"-V  (?JAAU)IJ=L/*];YCZEE<F_MN? .+@U#OJ7EU'OW'G5$M[U)N5AC_W[
M2!UR5*7HN( O#T@V;%93(FO>8U*Q6<&=>R3IXE.@B4U[",VC:</XJ8&>8YD'
M%U>1W7A&*'=_V@V:/$ S9R%67YM&YZ6UY>DP.MN6+]DELV=M71EEK@Q"PG1A
M?QN0M1!*(6@*+\/8I?LA'X4KNS-GDHVCY'0_/ -,L[)</AD_0%+(PKTN^&F[
MI7GW8'3?9D?2RDC )+GYJ >8S9>"')1%_N\7)^CDZ^C6?$S9)Y&:29W518"M
M.D-?%21)SJG>_VZ;&.+N(FHMHB S<W52\!L(1G>/,W8XS#.#XTZ*  ,IU@UA
M(7LVB''/XFK*X&1U=!N*JT "VQ*6#E&?.)E$#-V%[UZ$OTV57AGC+VBJTWYA
MN@!&^C>\$& 7)232 K:>IF"?2VET;M0KVF]:K@H'#D7WN>='JY]L+_?0G%7Z
M%6A*%K"Q\,6L1[X(Y_O9.AJ-0E:T'@J/.$AW'EJK-J1 #-=5R<+=P/E"%S@8
M?)_GQJ!2Q!)[!968-6?2RW"!IX9)'2F^"E2<  $=C:<VW>IRGXFO" RJNB^0
M:J UHB@D&ZYZ[V%X^7(C++^!(HK>U#RJW)? (DU3/0$@[[1A(/23>IVITW_I
M-\:O]TX[8-I<AK%N#Y&X9YC_H?,6.EEU^3? 1IK[BGCK1X-[F5A.X8]ZP9]U
MJH4[GH2?ZF=S^)B>X\7&%Q?FZ<>[W^>*Z',!W^H.6MCX#016.AX8R;ELQ!GP
MK-GE;/;_Q %#3IV%!$M%QL<"VU.+N<**X'K;+_J68</;2#L-<#M8]JD0(<\M
MY3Y^"]O8B,"IKR([<BXW7E"D3EF]*!SU[(N\SL/$"P,7_7V%6Y!G18(04$8
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M5ZX<FJP9+T/8KJYU;+3_G%1E$'7%:'.ZI0N\*U'R\<&<)OGJ?23;$>)2E(@
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MHLKJ2K)J4G+RLG\)(;MTZ1(#/0,[(R.[[#7N:[+_X?&[%\!"2[9(\YB"3 !
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MY&]>3Z_?%/32QI]=J<29&%HABKDT4@(8"?SCP4I/!#D': /$RV:=E@G7>,)
M15:'A5\K<Q6\9__RT='_V_IHP%5BYJ;>K^_,?1CX1_%DF$#GS57'![@/*8=
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M[,Z,KU/LGLR8KS.\!F1\4X50L]\:\=2:4'=VS&0-$J1 E_#K\.=2DHH-F#2
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M_#M]?FTKTUPR((EVJ6=7]B#!UUUJY= IHF!T/Q7(;JZ9]%.P=UK*SL[V%Y+
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MP('51:(#9:G %(6M0LPER]L@X*;U;LH)#L,5?QM8%D&BL9;$V>N'T^YPE[8
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MQ<((A(,[#K#W();,!T^0. 7G<F%]'90;$JCXA+LYI?XDX4-;AI:*(B'4ST
M]P?0P'!@C0ERKC$V,7>/<JQ3#8RN2BU=]/]N4;2FSVTBQ$439[=9%+@DH_7Y
MNG5VP!^,FJA7+#9XM'*84/1]X6L"W51ZK[XF\P-6)X3J[D%"RB>!@7O2/;-0
M)Y;B+Y"]*M,X0]Z"=S4XI-X<">2N0'4-D1;D/REO<0M5F1=]?RXM+DX'DL18
M?>L&A7W&@#LMIZ"\HX)"0.I5%1<3Z"3(T?JAW6A"9A*02_[$9"& A1J:T&%
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M@X=!ARWNK= UN^XN"K:-3_U$8%_._JQ];.AZZTU.:K'98[7*S6<+:(%2H3X
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MKL2X8[)\%P(7-$99NI(D'(@6Z!0[S]ZTQS9K*FR H1FAF4U1-BP%<KX_?F*
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M@-2Q!P]QWZB;2='\MD9?A\1M-+DZWM]<!$+66  ##I &&$R8G&,>80%UAO/
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M(KQ+-=F&!=11.5V\]43<5^ MS!P&TY3:E%>#>[(\B1N:ON[.S<T0UG:"MHP
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MZ\0]+HM+Q?J,8>F.6WMWK._PBC"%:5I']\O%%OH]#O&L07KCN+MNAM0WAHG
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M IGG,4:.F>RI]9&\!8NN"I"<;-U4@'08I;Q(/B$YV>Y!T<>G/ZYH/QO]8G_
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M_*9)S"U7 ERWZVD9'M$TFU$(=+?O['ULJ#*A;+L=ZG6Z\3E1\"-2P]HL%8+
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M[W93PK3X D-<V\Q VUX.. N\I05$\P--IV9H_6I"&B=D !20T7,29QMKM/8
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M%&AB!.@,LM/9-@ASH9!K;O !;.H3<%_"(:6?C!-;3_2/ /+# %U/ ;HN9*L
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MH&RI',(&0@!B36!9YVX]&?0CWY5U,:-WEOI-S2MX.!BO^DC/8\'07<N=AI)
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M5'1 /EU:U ,0^ZESM]C3H[1C,9E2Z0*5ZY[1#<DF!'H]?AE4\J@7=IFW*[?
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M>=K=C12Q6]LR7RFSC%^;$< %*EVU3N(Y $L-ROS*HB+G49%M^XGQ.E7X!=7
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MYL%I4 91]'1;A5A518U.J+RB\2 Z17+.$43"&+@^.=V0*\ 0S<"PJ 4Z\>4
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MFPY=O44G_N)LT220R"QEV& P/CB??>)KL3%YUB;_Q-?T)#^V-LX.VC!)Y^;
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MG)(6ZUVX>HST/@F;)V#I*G82T,'@_P%02P,$%     @ ,(MK4C2:=B%1?
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MUM7_:._H[.KNZ?TY.C8^@43]FIQ:7%K^O;*ZMKZQN7]P>'1\<GIV?O&'7!@
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MP:W9N6 VP'\19O!9RRV Z>3P^KC<Z6/6 9/,M3O]SYI WEM KU3C+2  2+W
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M>Y!@Z%FX)3=<, P5-(I,2U^T>?A R+AT'ID7>@K:ZS:Q7#[C.NJANZ">#O/
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M(Z\CBI(;7;)8"3K-[HQL%+7.US8?2^;RV:]YEH>"HT[F#DPB':98<!0T:6&
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M(#-I VU&VK;GUS3M]$3*XT[SL]A.X4RZ$?D\D?[/][*]!B3: YD1^]B19/F
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M8AXI__;8*CZ:?2D!8;%+H:QJ@?NIG!DI>^-S8[^-\BC_%4AG^YR3+<93=_O
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MZUM ]HJC%7*VH7DM]0RD6K]OGK2FU5S[LEA11VIC*BF+%@D^08CP5[\E)HV
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M1ED7J\#.&UQ03W<I"/7J&KCE.G1.9A&H,*"^K-!X-P&'A3G_2N)0L9]4A0]
MN)I4X?_643Z6=3*&FB;+/J4OT;BXK(%,RW@LO^Y2W$3>FKZ]5G,.:!@0C%57
M%\/O>^]'8XW7WD1,)@]WA\Q4:\;@HX&LP]3L*6G$DE_XSF":@P>-^>^9"E.9
MA] :=!WY%>SLUPD19*,+A9:QB_UY<[*H)5L\9=RVUBDN:'D6_/"0LAH'Y<Y7
MI&]H-#V$2[V(_Y+&;XS+?2OCX?RE\))5A/62++7U6]_5S)A;P$=@T9)OAVM^
M6;TPOI0<9WU72$90\:92N<.]6X!R_(R1_JP<)\-YS7=6H<CEOJWPJ=$N=BK1
MG0>$?1OIFO%VDQX<>-_6]3H,M69\\'R($D2[%O545VJ=,^T=I;#E7/'V#MM7
MN\3(YD2A+V8<7YQ'')>'?C;R!E-8U J@6_'5X51N;%^F5]R,Z-(4^XL+OGW$
MT52UV9B?DIA'1U+$1J=1"^EUDNF1UTN.M#D/^Q=Q-=FI'I0E8_5O U^Y$73Y
MEY#NH^P&%/M)K,,!7D+M_F((H!$PW%0W\9.8YZ8/-+9#-YD\5;NB3>*E<E:*
M[UC)3AE$J? \(\M-GK.8E4GN6;,X6JRD;.B&UD@JI39DU>>;",^UKUZVCF"\
MJL?+R(; -U:5W0_)XR:T/9B6XBF7:E_LBWI(M0VX9LJ,[< $<:<X$9^T[WE:
MIH+:)]@7_3S><[VX[&X1S*[+G;?X79ZPXYZL5X/4.$\F+K>7J.@4'M*H;E$]
M&6/Z"'(/UI]C'D8+4;Q!9%J-=(E0W%OS@KO<X'BCX9?A>9_*N7\M,KQ#2%Y0
M:5^OCI%<_SJD*_I_S60/6R'=4U?32%&3<YM\[*+3M5K';L]'H?@T2M_15V6]
MH"59NCBAKMRGXC_C7R4<!BM)>4R2Y7BXH1SAG"ILKU%/<I^N*Y$2U-05F90)
MBBBV^6:T@P\&U CNS+]' 01>:0R56:EXZNL+;BA<'W "2B>P9-A9^VY%#_,Q
M[,^D^D[.!W[VE.(8TZUHXN+>L71M<OY1KN!"4JY#PT?K#.RIWB6P-WW"S77S
M1FV>[7&SRB,M$U@HK#H--'-=P]KP9<>:BU]@JK1WNV/:*./=4WDEP"/#_N0.
M0VV!<W[3UTR#?+6Z9C&\:U7#OZ;KY%VQ%W> O&I[9,'%ZW$SLX;=S#.1#6A\
M:?, >TO/]/IG&8G)NIZA)Y,:QOUI1CDS8B43P<768MB-\P;?8U4J:ZICT-![
MS]M$EP^@")6;T8&6/O))8?R,>1%U99=JF&-4A A97-T8Y"7"$\W[M3+'Y=?S
MPGDY)F0\DYH&./TYVM1M,5H:^(C<&'?G=ZVG1:"_B[+X4&*BC"=-=Y&.9U.-
M00>+U>$CN1D! SJ.?28ZVC%#.S7:VC=' SX\<67M+LM O^F,-\JC"9_G'ABZ
M7Y\?@(OJU--/4]F+VT8,U&1IJ)8;G9;.W$7E<GL8:[^]TT_'T&)U$$\D=2N/
M.9FS>^/2'[5<C$^@/@;Q7FN/G+9"K1+;/UOR40O<$_V=>ESVZW?JX.N(GP+L
M[803FKK@9%<M-55/2^3.[,I!DC:/!#:ID$]LJ.!YN:21,VM#_&)*['PWZ<8X
MIVB)%][EH%00F"W_^=^KN?Q?JFG]<X*E-7.#>K5'[VQ*Y2U@7<5,$?4748/L
M1[GE?ZIR"/I3X<.?I0X=EV^4ZT$HIRW3WC\+&4#?Z(X<2P<SS"'.*#=3AZX^
M.8*V4F#D9\RW $:ZDKOQ/3J&V?YA(#S^VD $.!K< I[UJ_><EUS9GH+9<IO=
MQ_]IC?L=<106O'<JMT(0OOW>^@PRHI0_\6VLJFZ53(80MCQ.C38S][/HV"&B
M%SB$2,3BG86II5'1Y1!/(_"3 372WZ 'X+(*[NGG@B:$#L(3<P:D,"9Z <*4
M\JTA'!4_:^_*F4?2SB\<G<6@/\#J&H7(HBQOF59$/5T^2D^K_=/(N_LV6R9J
M+=F=D*D/%KHZ*S2>0A5R8@C!A'7FO ^'ZU=2R\2ZHR9JJ&V&Y:=&@=)P7WIL
M%6  S;XQ]G3O;+P2=!"LA[Q^/6H_BW\M+27+E(".?]U[A8%!^G[GB8L=TXN%
M^KC43##S+B=?MX*[6ZIPB$=^NTNE-K]21A$.9NHX&*^7ZW?,QG!/ZT=M<YT+
M-M\RF1>&']Q\A4-<\M)2_#OCLIA?T$T 7]5.V,0OV#\/G] //^N2<]!0E;!;
M>6<$R^A'.ZD'J"NECE!P*C['+17GB?;*6U>QH:E(23X+%X5<L+L#ZXP'>SW%
MI+3D4([/#-"\HQ+P;;?O-Z38<8L!2L</=H\;PJUJHZZ:%1D"X9,C:KR)LT^8
M\LM;G?G^*L+UKQ(&:8=I0&.<(V>=8@],,'D1F3N55P&DY#:I-%3L3: W/'[(
MICRZ2CM;[I(:%N+!Z9V3\*I)_WT41LV;KY*^#ZMRSD :*L$^Y4/X").H%Y\N
M4#IR@MNLI16#<]Z^#B^OU^J^D4SID'A"E?L6X=?-S3Q3JQB.E4Y8VF$7[YND
MP0PS5+8.-:D[[S=3)<4+OWU89:4 T+L8^^RM1:+UMCT-$XLK-@[+R#&W3$/D
MF."U9BHT5IGX*>6+ZM4[B3Z>KFI UU&4%J(V K^"6N?M@RFW4?AZ8094);J#
MD4.A&.HXWU[5#E4!K9;H]MZK-^1PV'4CV*PS %_(CILDZ(9.K=)<@;5$K[:R
MLA:16;< W/M4(7!(M49W[XMO U[:6K'U8R98S/VI[[$:+RJWNF:F0\8FU)!X
MYSKH5[*CQR\)T%\%XH9[/BY5V^9LQF/E=-IE8M:,>A@X.>0@Y&6<[V^8"&?0
M7K3V^>]79:9AD :"R>)6Z'4OTV=A8>^#3>.O?A90K#GY;K#EAN1K^^'H\2S^
M U.'@_,WX.>'OQ7"?$%7]G=XW",FL?H"V+%/F3@:84UR0@<?3:]"01GOO7\<
MJ$@1:U&3OJ?H.842M[?5/#E[!U<RN?/N;P$"S2Z:!?GY)^$7Q<<V$$[.8FN&
MX.'@-ZG>#F/^H_GV$@WF>GP+1N>.1WDT,<8=RD$!9>1+QE6LD[*>0 N0#[&'
M?1W4@.V4E*40ZI5T$9(XV=DT0QPW)88)XJ@RY<T=LI"4_9 J2$[&IK![OY6@
M6WIBR\LP(RGE0[R92??#3$RQ5L&IT:7F&IZ_U)*P.SWVN;L]ZXBB^A;0O-4J
MS6(O[)O<@>8QXORV%CMHED*H,&<8EZ7\IVK!8ZS_JA_\;TSN[17! W4'T?66
MX"G$B^;/QA?A9!F>4JTT^N";[46:MB0U-%8-<F8]P6$SD8)+12604E'$*,EO
M!N[.:8\V:OIK+$;V!=_KA%.8$P,'_PQ9YYSYW.E3DUO R"T@PVW^?LMORPF9
MK9P;^%$*5WIEU.LL*Y<U0?;A[I^)0E8I?R0FO6W^SIEU2YV/%FS"?(NH:K2H
M5'-NO%P**5.I=:\;&3&HST38%-C9O*W[\@ PZ*:Q3L=0M4\;.[4=P6<5E65O
M)^+GCK>>Y68(YH"CMW6?4Q8,CFA.&7UZ#^X?@Q=[L#ZCR > B-:!:B6%07=;
M3A.06S>@WE6OFU F5V0B9E @:FI_4@6;M/5UFMZ9_R#IEF6H9]PXBV,ST#<^
MD5OEKNJ(,AM#GO0G/'$?L-,1'*MB%IP8UI"SGMTZ$0;R^6 \OS[&B5/,3_LU
MGEMJ5Q\E7I!J(IO%W25O/RN<.A+.EEM'Z[1$F)9K+_,N?LZG"%,T'%,KX(-@
MVJ^M8JC9ZWU(#<+CM]P[#]SC.'G.@GA9D@_H8?S4PG)HKZJ(E31X;2A*</C2
M=7*0TQ4W:8DT47H+'ZRBXRZQ9:'\U]$C=LJ@DO>BF"7E^HTZ!3/V:ZJA'GZ?
MQMDW7DY,XJBDN6N[#=$V<G.5DY)8)1C'G446XMT"*J\S705B13 =<&=_">M)
M4'%PWODG.086YCWM#."DT'+<F;]I#LME'GN7J>U-Y9E5O%T#3+25&]*R7BK*
M7$@/G _9ZQE#31ZC2TT&'G+BM<]QC34J5PH%DSUP5@-ZEA0BF 5_@(-V-KC0
M4S[2F\>E9!?732.1O6!Y ^Q7A$%QNJ.K<!)">=ML63G2B*5')'8WU"'6+1:E
MW8 1E_Q)A)Q->_F4>GZT$OTU#71[#?YV6-*D\"QNQ8B,>R5=1'![9WGBB8<U
M3]1\+I@=GZW42SP#DI_+;H71P\3C(V2FA'+P2."=K+HLG)K,X8P9X$S]JB%W
M[R%GUCYK9+D_?UQ:=5Q_EH=627D#?3C2"Z5TSRZY1W]!@*V3Z+0&UZ]T&\U6
MF+<;;7;?R@:[ MJH]<[.>;A';65+J3KCFR/4843[""U/JSP_&"P1L+FBI4ML
MMWVWV9^&_+E;3!I9XEVF/+K[M#IST7]#C11C#<KYSDJ+PG_1)57<+%N*-DS#
M.#-O&2VBUG+)^4JR=G,=>\2$.7%;Y*3$!1-;@9*$6X__%UU,?\7_LI[$I@=7
MGPL1D%F%.SKSXT Y!R&26@' [)JH"^:VVJ[6UBB][^.!K\6&$ND"/,%*CIE#
M+O,Z/&6642-49OCK[)(G,*8$8F7V-MK-6#"W$U-]#5)W=A6A9OCPB!_<CB5+
M]UGSJV:#<I 4G_;OF:_UD @-<!BK6E$R?#R3J_&COAVOY0I170_-(=ID=B[8
MKM1N>&KS@1513#<-,K63*J!G(C"8Y((G?N4EHJE_4.^&="T,M#9Y"]B%W<"]
M]3H<G@W)GR47M%E3OA;@D16[>6JF_I>:,U_C[]52_T<&2VAYZ)P$=@<>H4EU
M,#I03X'?'X#11N_LPW;?+6!NXP+6OQQX]W\RZ BT9KS;]A(G'/Y2$;-?2AU9
M'QNJB_985*DE64S_3I_AICN/*ZE2-#L@E'@+^&IEH?8 YA6V.>SC84CZ/G<%
M:(P*U[H9+1[=]"M*H3]%'1;I#<PQQ'9*/T&6.^P*B8#$/BW$I'0&X.9+*.4;
M2J17O<[/,N7D"C0Z5G8NH2QA=[#L^WR>46Z2"^;LX_KK \G9(\VRP:B-Y*[9
MY_I J3X<;-JBCYBCAK>T&-4IS66#=4^7>=HX#P3K,_5*-[L[Q-6O&-]%Q#_8
M?XI3"P4I[9,.)A>"+%[&/T#*:^[7C)W?D&[7!-X?W89!=Y;-YF;67(X&=$%A
MAC:_YBAB>FDC?;[U]I8V9]8XC1<!#=Q_+56#R.POK(CE:Q#$K^</1A7FP:EK
M;YIK*Z@:4YOW&3%_[XA2G@QXB2L$OQLSCZ=T)/@AVD7I AZX!838V9QTI:%=
M?5[_EAO$8B]K2?JM('=!24<[@>\RPSSQH_,>;*Z+S[@[PH,3]FA.P<.Z6%V\
M9X9>,/$JVM=[CR?CQ"!;C).MK3SQS.#=RKGFK&2<#4>^>Z[:P:I<=R)32H\=
M:+J9>YR'$BZ/ #-SW8N7L*F ;K7JG;J]<K'S$$DU=\T9\M<-C5B8YB98M:7(
M$GP,XM*997Q1,[*2LL"48N0"\<F%)B'-?$(*T8&W@$^KTA*CH&I_];6BBVD/
M/6,=;AL=$)G=GIV]TF/8;L6OF,3-PS/[T65-((K5C^=!*977QZ,!86")!;W0
MT-P)U+O[U#]VX&HPHF]^+>:"-UFKSU](ZJ3(>8ZJIN&2YK&[L^*@5#>R1HC
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M@/S.&4C""4L.@/DRN?TM*E9_J%K]RBF9=?C)7=$GYN*$/C4A)^ZK;<\X<C
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M#7YB;F/4J+2<^@AM/H-W"4P/MWB<C^I[Y5OM-LTR*85JPTZS>;%*FWKK(M=
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MZY@T+[O"PG$#[M)V4:UL]\W<9@9B4P[7C=CJ(;:0OF7DP GXZCK][@9$OU9
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MBTM:256_?=MG?Z]&EQR(Y5O@A+W1F4 S @-AU(.DGS9, )S&)EXLN51@)5>
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MD>9[A3%;!X$NL%QDS4D*Z!?%+D<)VO!J33R:%/AN],HPD[J!:<=?5IN=X0W
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M2M?X N[.C-^M#.JYM&I\DG.2N=6=,> ^02OU^&ZO91+^/*QT;G2%II0"LJV
M?FDDA;!B=NVAVPRY1M3!=0]L%]2*8B/#A5[L!8+WBO<O_,<#P7^DCYM_[3SK
MW08@E4/CCE\%&E=,"I% _U#>KMT+G6"W(>-R+Q(!/X0S)/6'8N1P#.&>QPE-
M &.08(FDCON)*$C65N<_LCGU/TC?167O@4/T)J26?!39A,L$H P 9Q)8-VGU
MR-=AT"68/PGPSL-J87OEB8 J%%ES@9,";0R?-2!/JWGL)172/OVOM#(_HV^V
M)/AOL0'_*FGT82:8[<B3SLCJT*W3(@#N0*YQ&N(RD4V\T[M[WU'V!J]<M=@;
M/0IH1KXJ% (P; 7I8ND8#U@&9H,[[C\= /Z#?<CM1^QE^;>8H=+HEV9QCA(%
M5.^UI@,C!1(, U>E_5#<.>^G;WQ#V:?1+28]S4$.Y=(3 5#-Z9>[MR$\V0<Q
M)&*]=6"( BJ%2[N+$$[$X9:9+"(LCB_ GOM"\9QPY8B>R.\QC"R08B/6D)Z
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MVIR,6[&G#P;_KD(,F(#S%)![#!1WW]F:C,22MT1.DB#6M,#D#B>;A!*U1MB
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MB4E=3OWE'Z NXW=> D1^O038),/M+MR[OJO*;GKKN<C0]S0-GI5()=!ZX/7
M6U[ E#<\7*96OW8M\]P]^RT8R7ST,Y(%.OT6N=E" 06#W-J8O_SLC,F\'4FS
M\Y'O\,1,7C1U7%(Z"8#(99 /?)8R_ 8#]39,:49ALCP#E?3C=Y#&I'L44'P8
M8& @9.%]R\(P[Y^?^ML;GACHNNL7%(6[&%][=L53DP)B34[4=]?$9E7UF4H(
MNW!**E@W/)$)2JQ@VQ$8IR*MA9*WX(2DK]IOZ%U^_6*55<\RF7M.M[ ]]F -
M6Z#[,AL5./O1O\#JSV\0"?5(<U=_U[>X]CGGF+Y:G/>]:7 PR(-3SEEL ]Y
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M@I(;8^<)/;T=B3\_@_3\BP@,HKI'FW0+P)4:Y'F)0FBRJB>JUGX^BX'296D
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M\5S0;')87.I-QEVG6 1_3D+1?P%7^U_BJ;TD"[_-3>'9*TN?J@*I#,##DA=
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MK7$GX>S&-UVR8!Z;Y1(*P5"T<_!J2V/MNT=A_$D,JSVLJPTT+6LA,DZ4::"
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MFXKVP$Y =@J'6'Z"B3*XKGN$R$Z^/C&=EZ<T:Q3<$FG&H)^153%1MO;>XT$
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M1YPL+^II> 6<N1%SKQRA[6^?M57LF#=/L]I^T@N2I9#;0MAE48A/?VW](0]
M*3:D'(DZ1*7NM@EG:M.^A3"5XS@N@';)<G/)V7!/)W%UP@-N^22$KB([?RL(
MJR%7ZB.\&S%YP#A+1;WF AQLG(._2PS*DPMJUE;4F"KC$UJTEXTJLMO_X\RW
MZ?P_3C\![@=_2FTH>U"E33T+:G,74* R)T7"KFP&,*BV@K_2VWLB^9Y[]\&S
M! =QMZ"]S<X7@-GT"7-_Z9/8867A,OZG.B:W"U'*39GDX^RJ+ZVO#(CU28Y,
MO\,X(\W?Y4%\^MOM5L65&0W:T6F;6+FE;:E.XZ#*:O4'05Y^ U$N'U\E]79:
M"MY\Y-? YDBK:\SZE]5"_&N4NJJ3![15.B YY""QHZ^F!MCKP?,? ^[E=^79
MP E%^A,)^N[XJOC-CZ*\Q),8^WYFFET ),?F%T!6U@70"G^6UA)9;F?X.;LN
MS2]VH?N7&BC?]P7O;>T/X>%FE+<LV"%!^I2_\J6/'"PPVDU*%X!B/C;6QY.(
MD;8\_-<:MN?#Y;#X(P&%9=K6A#(X"-.]9=&:25ID%:$:&,.N7M[_X"<+_XZ8
M.9^OHVBHGTZF3>A72^Y72]QR-]=[87)WTKW4:J?QT$_:#'%W1LL<)4ZRXQ[F
MS3[.6ZK-.BJ$M@]]N0!@:M@+X'3260L3;EUDGE\1T55WONI$)'C;PA$TL;B
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M<-J"J8T^V]WQH( 2HE'*N L?1+T.TU_).F=VNR'.EB084&WD6#TG%#^5QSF
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M\NLGDQ!?M'7'4?W 2^>B:%\7>]3K.\ NAC'@Y;7PKD5%T2LPN]#I&PB@13D
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M*P!=)]3)(U0UYJ7XO7B/5.ZV?>[_S-:$WN9YE@OM%/-.5^:<+MX<&W6:>?G
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M$ENQ3-GIQ\_<6)5B_T*UZV.Y,?<7>"U-$9'2,L78AX>3 RV^@5-)2_QQ-.<
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M9$[V8@LC'.O?:1_4K01_"!T]B!*VR25+=V:"I A>L?*;5CRP/>$'T>8!)D>
MD7"-./U[:1?$5&J=G674[E:/]U %CBGG0R7BH>>_1[OJ/.%7HO0FE6X-W.ZE
M,4U%\ZYD6',)?"Z=)O,:1<[5@BXG<;E/G*O]OJ+Q0)06S[?HS -9TN!=VX:%
MTG_S_,'H%MPN^3)?WU$."OTK3]QR4.WS$NIMSK.Y$&(,L!Y%YJGJZLV:-2=/
M.WN4..QH9'@-)79=FFFS@W;&+8"0VXK=]EX<TP[XIKXX8=O7:01=#]?V#AJ^
MU(GQAO4FD:W88 ;0JSL!N_J7ZI.,7J(':KTU.;-Z0_F"T!^EJA]ZRB7E-&.Z
MZV4Z/;\-B D;7'7(EW5D62B(:>,B^*-*L'?!=3>':Y[2ZNVMT(Z4P;]!QH3(
M4%R2U)H^ASWFQ%U329 >[9X90Z/;C.CP#BS=ZT[I)%IF+7X*TQJ,7T"SV 9K
M)* "A^(1])_KMQP$VI-:8:N2&@N;$#]DK\_RC8HP-DT.U__FV88$#ZEE(!,E
M9$QX3)B# &4$*0M$;+OP?250Y<=#Y=>SQ]X[#LEEO& %TL#&U:[/;0*[<6#D
M0_,'IDUD%+"W8C64?X2B[.I1VWRC/C&W[NN @,],N/Q_< J+)R./Y0[:[@A0
M>:D94EKJ5M?4^JQ.L9K18XD7"O36Y OKW-J[U.1TD#$]IBYM6/.U0JBZ^IF.
M%U=7X:;-'R8QG]JD*7KI6I.X0ZE;_!L+OVK"T.Q@S%OR[6#.PFNNV:,VV!W<
M"7V#.GWU"*&99H0%[@@0O8/0,EP_5+[4D,Z;UY3K?6N"HD2HRPEB7ZI\Q>?3
MW9D:SL<#6/N;%A _UQ.X1QB*T"C?5?;$L&4F2S4@FIR'^[R945?%>Q=.5UP]
M50@\18Z:]V*"%^!^KF'6>6!R5Q_>*I '>O<5!<:@HD<%.B"&[CI)_0G+TN/<
M2FB<&8K0WB7C?G'OVLN6X<FGSYE<\-# LC=T.DQE,H!-3>;?J^JW#M3R;?8'
M8[S&^6S0A-4"-E_C>[9C%CKQ\_;O[WJ*I#XN1=/F9Y!$%/0PMEA%;FNNX]L5
MPYQD;^ON08/Y=]87WQH;LM3*%PHIWDZ:UM8)N&DYU%=#T*N''R0JH1T_8-:_
M][^IS?9HB!(PZ0L#JNI>NE\J&;+"!#]+FRZ1*H'=:6[[Z-X0/O*=6]BKT?[U
M7 XG1=H-=J?]42JZ<9(8?NLAY;'0]3.*TL-C7D"RN"8!58.W9CR?*.,L))F"
M^&,L"WOJ? ZWO#2SN[7WZ98/[)#Q-^$:_F1H""Y/KBM[.KGIN6YPU*\*_#9[
M'R 4B0D^F8SS-89H\3^<V<BY/:UP8'.O[+<HU93PK@]>5<A+MLM*ZIO%-*GR
M\D(51E3ME<YR"7%97@\7/='SMU3HXP@>F[Q!,"F&)]5=9Q83N"DXWP0I*G=3
M@,SD[RH2XCRFEI[_*F05F.M]+J'&PK(NO;7#X+;HN;B8@G=,L*J0D*P=X*I
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M"^S5%9]%^D>Q6:PTY*?RO![EV3B*>*>^7.XCY-P0U"^4C%#W;LC9=>GPPUL
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M4B*4U^'KS(/6KYCCIY08&]("1U/!DL1'YR;2;BIP2]KP:5+!N8CU,X_Q4WA
MG53Z6'>F0Z8#_C/\CQ\-ZL2B1$P@'>2[32(I".WH+WP6QEG7"EXT[;RI,$:?
M9S43E5SLT,?Y2Q7O2)[N<9&%KC83;\_*M&62+,W(/JP+__Q5)V!!?-Q/<GQC
M*K7E7)^_DS<HQI9&!IIIUEL,S>P4->4[<@RM)!:T3-:<+Q8Q]YT=1\5FF4#]
MEEHOD^-'%<R_4W8H+6#6HK< 5%P!&*K3)8Z]D7"_^O$N'?YOMDSD=S>#'*1
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M.%K,\ZMV7GCO(:&5Z=\U6X[6+;6C7B*OY)6 Y*L9WEP2O:D%;]ZPF$#=5UO
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M?/@!56M/6#0I'0K;SXE -H]:GB@=XF[NFXZLI/./*0WSO7^?2RY/#C P'%S
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MSLQYY\PWUWM=WQ_/'R%A[[7W7OM>]UI[K?V0I./C'74867(5(*WC5 'B9N9
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MP:U-I!A-UD]Z)?U+#+T<@^+-A\5IU[L8)&[S3R$CC".,/A))^8JK0S(DKP(
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M)/AQ7?S168;S<YA0DQJV]TV.HSDV&YJ3[V=Y%S[VFD?XOOW.=P'\8GP(.I-
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MKX16X:.)KVAQ:9,#JAP3Q^\.S4SB<8=*T!XR^Y5J)+@;SI@A@'V@EW2V>,U
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M<%D8D9=#3@:/-F88VQVD2[4#;1W<)Y7^40)[_T%QTOXR[YZ#RS 0)KC%A<Q
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MH<>+5PWG-KTI1^UX#M9Z?X?,EAPA#_,4V#O$/*UF=C.H<L-L[AM5F@-5I!=
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M,$"8020R#Z*(+9-H Q&!!)5!$8BT,@0(-"@R" $%F9) F$$!H145, &524Q
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M?%7_[QUP'CP#RE3_+:X&[8S_ U!+ P04    "  PBVM2]+D53K4)! "@\"\
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MQ&)_V%U@FY_!\/ ]=&PM[>M<P=VZK!<59']V/PD<IC:N8!%XD9^ @FYE/FG
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M8+:$IU2(&5Z"3NWPW1?R#*7W^,O'W(&FR3\[_692BS8KX]M5[4 C;RCAAWY
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MWX4M7_@T&+6^"LDZ(-)KJ;PS2*'<4#$P-A<%YFZT//!T#-:Z]R@HWLD7J3G
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M5K,6JR0@88#XQI@\\-PDIQ8<$Y$(/BQ'(LV]O/#E&$((($TQCR81O9*23@I
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MAQQ[PL :X3W'LR@45A>J@D5$+F;#65K]1#0,->52L75D!]P)/,,K$$+ RH;
M7'T8$@D0"#RAC"X!3D$!BVI5-(/2)*K.-M#T%=?9HH+RZ*)94'%+=;%)DC*2
M[2- AF($X"6.%#-!/($ *$F3%::@)YWG*J9Z5VICNJA8#L^ARQ7@/& 81)AJ
M0O2O^(OJYG7<[="FCYN[&+^L!(8ZO\Y86.B#JC EF2C. -@W61W2Q89 W0X
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MSS;YZ'J2GMZP\NMH"&$+2_T(,D0,$<9Z*&,4,?0P+#>KG9 2 B1(HV?$M6(
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M#4P--&272J%)8EJSY:TK[+\ S4!?R]]8!>#A6S_@'VD![8HP;[\IX,,"+_N
M[+YY_<JSX.3,!5SK6X5U/#+IO-S%=$&[]>:N!7?\?S@6[1-YE;HSBSKG/6"V
M//,<'<:*%+^_1/'U5>G_P77*L8Z;BE>9K'G%==C)2.K*B50-MQ=)!YF7*:T=
M<PI365UU92<U,=!N4\KW2A7LO4D5$@VTVDK5W%3^H+YRHE%U-<"X'*GR :N"
M7-21,<7^9DNPJX ?$_R@6H]DBPZ3/\@XVXP;7/&>N(IX[+V+7/DW]G4T/FSE
M]M5N7025<8,D!=?16>U35D]L@J::HF@'_23-?S,^0.6K@:EUE3S*U(NKQ:.:
MJ"O=IR6FZ9*%=;C(1Y-1=TPQPVKL?L0K;X3M5) $GDY<GWK*YY,NGA\OG-H:
M8S3K[%&1/PKWH%V4QC'>DQYUW]1N*:PFUZ,8+#L#GK$WQM[)JL%7*D645&<L
M,>\0.)4O12F-9 *#3O>/B MBJYOV!!\(L'0QD@3]> FB3A6\Q1ML6PY&2C[K
MUF5 M57E(<MT!=#5+S,^1]7G.?;CQ*8X6 Q2Q3:0ZQXAISIE&Q(P'4AG WF2
M=<?F,\END2(;$+V# :!\,+53HKJQZB6@ZZ*J2],TQ>E#\?V)TH#YR$!SACNO
M]\7E[O-=7!:*GQ?E=N5W,6'"T3W63>53+3%5J&"@X\F#3UE_0M';.ZDC+D#G
MN:*VYBL,@!:PF[(U7]F:;Q-:\^4],[WD6F,'EC)SNZF:ERPQ0+5>V\H;(3?0
M8.9F+0E$7FZJW:6G6FZ?.@ADN<ES1WC$Y$8O7Q+*3SMY.M(R710_I?]5ECR3
MIUV8ONE2?F1M;"RWD.9#T5#F5B!ZQ 3+[71.99'IQ_[UT\[!#)-<S^:7A1'^
M#^;PZB1+!>G)= D%T,W3D>)]E6K24Q#1*VA*<W2BZ90)BAI8E-LDT8N>E^&
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M<\LGP3OV<9U)_A=0#5VS]F*QGIC)9^@)A=,L\2FAB'JP$FD>T5<P<07 GI@
M4GEEJ@_\ #4$0&%K"&P&Y *,&O([X:3X0@B')Q0=Y[XD>WX$E")[],HO'Q&<
MA0'J#7!#D*<.ORO8PFJL[>K30O8URQZ3PP>I?>OB^0IWB%P95!27] >9UBXU
M X/'9@Z,CG'JU(3O>,FIC?@$A92O-(6Q-PY!0U%\SA;ZZPS#K<4'O>[R'B R
M@B5.0-8*@+<C!5(/BBPEX1$*#'1)%*=$6 14$2%%*4@C07HNFH"#"6ET 0SA
M V4BW(!L/R5]Z@V4E%! @U+9H@_M77]?OWI41C_G-ZR'\XB'40^KPY@UE^?Z
M,&C]]Q_X4F>F+6@>A=[RY^<(U/&K&E"?EI*0^?9ICM.BP !:H!7\Y]2F__-1
MT,R3CDM1'W -3W$*->'7&9</;>2U-C5/%BPY/6+.?K.Y^SG%!.=@T,;23@9X
M<XXW%Q7RP9_UH*F&JLA\@?*$,S$VCLA7,*;W4FN@4W!Z2)"MR\P,NYUH@[VR
MW&S-G,D2D^_A"P9-C8<H5I2>1X@#LE["P2PW:,Z89!U1[Z%E8*' \*^?=@YF
M4)T\BS-^Q5+&%8U.2QE7RKA2QA52QAVG'7=+<?1ZGIAXN)#".X '2Y)'"#9U
M2;'$^]5Z;>MIIUX*T##MTH#.4UP>#M-Y]S9T9;/,]%/.XJ<]W1E5R?/%<N#,
M/8NEY@#9(^U'$(>Y_UAFKK'O#31%5M %+(.0'"[H5%&^E(?#$Q2O)R;QZ8?T
M[<YR![*=.XVY&'KP-HTSO%09UUCLE2ICJ3*6*F,A5<:OJ?M2<P.=<QGT<C>F
M):-_4F35!UVR^GM!M&G,_A6VM9'L_J4IZ)D9_J*H *\7"/_FGHB Z0B J0
M#*>;NB\FEIZV5TJVOFY(6;+UDJV7;+W ;%T_<VA8MLU#CCP\P#A!FZ)(N I2
M5MP957[8GNQY]J1J^]& 69[[[VC 0\'>MXX./Z1>YB$IZ:W.;ZQ9;];A/3="
MJ2#4,+:T 4@A\\6-@*_QMC-RHP ?\?K]JM+M/7^ 8=O>G;1D.*G=(P+6-?JG
M>^LA*$A*<>OO2 8D:2EFG$ GW1O/00EK>2,X+[QYU<'Z%,;M>V F430O !6.
M(F#):>'A?6)GPK=^L'_]M+7_F1UZ-36+#P/^ 8,$7Z5786W7JBFC*PRFCQQ.
M5AED7STQ].$;0.DV_+\S%'*4#';^]9AUD[BD8,%PM3D!6W1 ^\N'I!+$90CT
M;BTZI9[GV M/>)4JE=(?A=$_T8CW,BD3<%AG\"2<X2&:N:;Y#P'A<.A[0&'Z
M2VN"6M"IB'Z(D>0+(+&[-"#F8N,"V#P>%&>'I[%CV[L!)5"*VY4B\7:+1HJX
M(QUKE^0NX%NH]L*+U=\\>_!#NOI6)&"./N8:8;Z@Q!4^!I*\DR,@16?"MBO-
M>IVYL .+HK9A()Q%<&O()H+[)C/D>ZU3JR39.!R#]P:80R&0E=J2#UR*AM2/
MCZ1=W:T'-9:[9">-?1;W?>09G#)HD%^HH?1L''BRC>'_<1X&+)'WO @8.' F
MT-_[."2N-:!MLD:]2BN/7\"(8%R$Y\*&L]O?J3;J/S\V(6/G59'BSZ%T5,2E
M.E\36)F.P?3&BF7S&RX=XN1X6X.9._%-FLEO(!N"$II\T<=X3L^?X"E6$,&$
M=FXA1>DA/71^ :9Y[J *RL0(S"E7]&58,9DV06H.-;S.&'  &S"(%,4(/.>&
MPP #?LF4P\L\F.JK#RI$@L[=B0^8 :L ' =LI>#MK]W?*SEAUN_;(_C[!O2&
M7X)H/*OB[<.A@5XAJD-U$HTF,"L 7(B:AM;02'L#*V%O&]6\:/SE P%8C-!6
M1%T#D19OOVSNVRK(&'Z6;@JF0T\E?/0![@A5/!1],H#SA*^!2+Z@\0> SRZJ
M+K"3R(L"1P7,HF<2@ RCC(4O/9L % *N*>$'8TB?13 :2%J*<I_.B($MR3YL
M#Z1!K+,0P8SXOSU?QTEGT0&I%Y<$ @HS<7 >'[.N H5-\ LJ27;D$T[A*K/G
M32AF%I#L*'5.<8Y>"X&I,DIFHXPI7TL IJGP8EQ'CW17V(DC3 :- :+:KD[C
MHB60"#1@4SD\^ W/ "5R1R($5BCL>?)_#C_87UK^/YA#K*(!G&Z:V,,=R4#)
M%40OT#.!7<2"S]&J"F64VH _F+!E66")D#Z'6-G<J6ZIC$,.RH]Y(4@+-]9R
M&68>C@B9FO7*7G-*+N(R*/M1W(T!$07E6'J6%66$I%*+&P?FC@ _[*KD2C F
M.&;&"3-:^C5,8DOF5VZIQMY^!4RAF)YJ3(-B[,-SOD1QEIQU7Y&IAH$F;24[
M9\5TP/8:2F@25 8"1'6&=)&X]?-H+B74B<^#F1<B'^XYG@?4[?D_,+45 .C
M%G'])L.VKV4]*)6:N]DB). MU+'K,ZIEX9 2Y(ZY0?+B5&-R.U)R'PD) [@9
M&8$X2;FBA".!22L!=(4CC33 ^](/PBH*J81+7F;8,V(#<GOA_MM#5 BB'DX5
M2A#_BMOAC 9!D/^"#*FP7J2,7_,#G)4;@FE+"=2 SD&\+N*[COR!JA*@I.TQ
MV!H)H\PZ$+,E\G5<D%ZK'@,V#$*5 Z;[,O@!<M BV6X$-@97 1,>C1W@PK!M
M4A<Q"] E;P%WC#Z(6@P>_1U['YRU+]L?*MJ85]34BYP?$[,A-;7*#P4[GK*%
M,>]$D42(.<=54%L27<:EW,4I%R]*$LUUQAS>D0/B-BDIEH@67V@CLZ\TD@0S
M@DHV31(84S2*')U="OM2=J@6R*03M&S@VN98=,)H*L>)\N9A9J<*=.< I@"4
M)DC3<$".',DP+5WC%:*,)@<Y>4T<XJ-#[O0-3TQ83(L6*<;*X@]X'_/SX13Z
MJ&9B#E2/ *)[UCF8DST&48L2=!8SB&>"$A0K$>Q]>!];^D 0H6W'><.65P5<
M[$E;P6BSDD@/GB6)M'".I*)D%2J5U_\A0L.'TQ2O1'+!$B%10RC8DBKLQ,>X
MOPK[!E8?=X'AMT'3A7\Z8V#W%:79_*YX\2$P*9LC>4^K.%ES_#_V64\Z#H5>
M.,B.L:"&3_90CX03(+*QX6_2G#I=/B!F?_F9*:\(L\(FVE:*F):,24W TP/9
M*]C":NS/*?L4>4AL5DXGP\97SN3M MM%^!9J:-X8Y6;DHN6-C*A@N[023W+!
M5E9+7;H]WDO_.L[IM)\^'9:@$ZW)7X_.%V2>IZ?K;;_'.>)L[(44)X>F1CI=
M7*6((Q'H/'UC3_6$Q=&GA5HMT17FD%?%J.=/Z,H"C9V!<+&RD@2+0DWBPRPH
MQR=C!&DF,1+48!01:@"J B-U32?4;$&W[Z,!G;B.$?Y]&;KHJJ1B3U0;B6Q=
MT,YP]23+J )5/$EOD@[^J\4Y\NB-J2:/85T<O%B,XP>3&DJ),"//*[(7,FFR
MA7&4FJSC7(#]H,,KEJO+53R:$\&?*81T>=*ASQ<=JL<P&T0SMS*#,ECPC/2-
M*4$,^1T5SDB8* )?%<8QI3FFRG(HWU^@( \\M =6L=Z9\JFJR@VU1SI[F?+S
MKGF]AC1O450CW1M4O ;:J*ZP(?SHP@)L=+R#1D*FMKD[)[_ZJ 7ZDRW00:J1
M2JJJ8D =8V&ATY3U(]=2(V;,0#$&RW<<EQ!39C< F8C)%/,"[$^E[F83=V'1
M5.>H@I-A:0U$XX$SL;R8MI%DR=G"+%_2.3+?<\C[GN8.,*$(,70@N0H%>@0Q
MS7UKB/<6.@[@^R'K )R.I!AXK&,-/8_NF<[ 3K70 0/D8B'YFDI-J8"#9 'Q
MOEVU173I_1#D.3$$ B_0SICF':3I&G@2&+.7XW'=*BQC13E."$V CZ,.):<R
M7DIN&[:(1X=L#MZ;7:PY))9&&URZ'E=Q*IS(X3V,XL +(70VJML@+P)*M=#D
M)Y0 )BD#<GMT\88O8+_+\1@^G=6.:A5V.53_^%X?-H4A%"D8XVD=PY03%6Q]
M;-_"O%T>P 8.AUR2E_50B0=S@GA\F:.+:W\!*K*^[XW88?OJC!0VQ5\ />Z
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M/3X/!F@"P12SM)./+W%> Y)3\NZ5V@;)0$I02C8S\ :6'_,@C?J?=9'+J56
M(V5V182YTS*+3$B2+YSV[U+)Q'E^6K=1?8I_[.;:,G=2GN.V7MG8UGQXQU'Y
MI2I7J'.!NZQ BR[ !ZVZ7Y)!)&8@QF@'OV;Z8R\:JSXRX);)$.@*GFK(K7!G
MY$DZGM"FI2YU]H/N4IG06WV>3V;4O9E1A^L4V.Y[!;:=[A8!,3PVR^F 1/3:
MM\)P1KH01C=>PG>=<@R5 9G!S,P?N2GU*;N(P0-"U:1=#T3LDR>YN%Q M(1J
M96,D^V!X*>UZ";=04[NY!>-5;KG ,3 W SX;5]EEL&72:"ZHQ,T)"#!C$(MK
M09^J!NU8IS'QC0:C[8=OJO6KQS=Y_M<G!Z]%1C3S+/_A;U$YR]8GJ7JJUF9&
MQ\;-8K=F@U;8B_^KMNC_=:O=7+?MSP)#&,2DX#-/E!>^))6,>%XY&;3\A3S4
MHI:%R-=\/2CGJ-L]6&@^?4W+VV_I[E0V;\GQ-I)"\_;K8ZS"[$!6_/KR=+W$
MSR[2,^N/-^9\U'^4-,+2+;YA[1<TIXXNO)9%2]J<)[/X]L8QUL^CK3^IV7M+
MVFLLOG[WIKL[RQYD?7YJWEU/H/XCI/G=]SNB-8ET[XZIU.FMX7H3.+C38^S%
M7!&W)HT^'A):;_,_)VDSK/;]GSNM^ZXWO?ZC<?0'^ML^T-YFPS7I^8Z)2E._
M[O0J+;R$$P7O_;XV[4P:<Z^"A^'Y;(>MLT$2L;1VG.>9OLV-(?MOG9>KC;C>
M%AW>E 9@<C+X75TYI?_D^ ]L3?J3S-$GJW0;->LGJ_3)*GVR2O^R5FD>]\O\
MKBW3!14LR^]=S<N&LWB=4MU[T/%0*O= VB7LAOM7,!L7C33.AS$:[EZG7K '
MEU9UW>;NW;WF?G-GU)T3[*)%GS_,!GXU6_XKV;,;N?D>AF2_J@>CX4G-(+IS
M=E3_T7!=>("[MN;CM1TT-UX;;-5[]R[>^]WH-CRI10 WWGVO/'\]3S2GO]RW
MXB9!^R?3^Q&;#T^F]Y/I_61Z;Z?IO:X>=W,&3@+ESM]QM_;3_NV\"CF@:M9<
MX7T'U?>^@EMAY^9ZT9J64I-V<@LZV( "[]O.7'_O[M@.N\7=:MJ47C9H-('N
M<&DYC"T!-OYV][:)TE&QDDS6M7'OV,1D=?NNV>;=^S/6OJAW;7?>F,&N;W?>
MG+\B!'O'RUA[_SCT>]^ZA(LLW[>;/5K7DW_72@M,U'L65F2YV[+B/V-MZ>8
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M#*8CVI*HGWU.)C%-2ON&N@)UO /I!DU=>Z<>3,FG4>PA@>7Q1<(=JHHJ+ !
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M_K&S%Y?VHB@Y84"4X(5;E:KWP7-OVY@)Z0ATQB2>D)54L*>A>B"J:'_Y=YD
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M 4;>IW72WW(>#P\VMX*F2:"E,!JU<S]Z'7]0,B*QM*&EK6[%DS_G8P;;'<>
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M">VO;'=6YD+647^$B>GZ%?4:P-TM TSN;4<AL.IT2'H%=23ZZ:#L<Y^O03(
MWK/?];O> Z"?E>D@&": VN8^ '2'@5U^$4T-B<Z(U<X8A#^E(8&XSL#AF_<
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M"Y%?/X@T3VC1/EJ=3D*;A^!NU(B0WD_O6Z>9B)3^\X"/_?RKASZ;3R'Y4JM
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M2;24(9L*'9C$P)IF"3ML\)08H'Q-IV2BS18M3)YQ/$1[J80_PWL354XF<3Q
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M&Y$+M,W-J)=UP\W.QZE$ZY'^XH:OPJZX&39OI[UWM *;=XU*ST>"%_L>:>\
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M\C(O/Y-^?\=$NFSJ>PM3WS]>H"(B%B:(8WOJ"VC82P[=B,%J;ZX+CIVH0U/
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M0P+/82X?3'%B&Y4C]D06B&)I:T-%7JIKLW",9.,>.!:C7U;RXM9QCU1\_\G
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M6@GK_G[>0D.4(%+@?@O0[\OS)3YG84&61\VR+,72IQEW>'4.YE7[:Y-323F
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M?DS&?#87R6IJL "3R:(CT=L,Z4U>TU&AXLG;.'E">=9^6+^1[NJ9?">;C+U
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MM)!&\R+A+H*@ 4#BDW$_G286;>$370!9^D>3T&MIVBHL-"&S?K->?Q\,[0O
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M#;;@F>:#+J+QSD9?MVKJW3E\X?B%Q/4F0?/W9R=9:-@C*'7^[%F)OGCS&[_
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MRXHK]-KX&_Z[V"CZB\6^HB,PG\WIWSGW%BG19+,7)LG0FI8+9/=9SS[T=AG
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M+(O&Q$T[<W+M2\L"91;5<2E@H,XL.N-Z5.B+3-(X 6-Y]'/)<8?N[$C6E0!
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M<]=%V1T;ET2$*_4&)7S5[AJRIUGLFC,9PL,!7\4E--;R=\M89+9DS6_4/@!
M1^.)T>M.'JAD;!MZ*%<SP[LK+5%4-FRX-M+%AQS&LW*AJ<4-TS.ND0&_T;B2
MZ=W@L;&N;3BC3M _- 7$S^J=PL0!?\60FES^7TWO?&VTD1( ])%EU"D)6"B4
M?Z_96>HQ,P73GE&XD[3DXP5# LE+(\V(T4L$!6[;V"U38M-8Q@WR#O+?[]@!
MCF6&W(N>01/;.TO-[PI+>JV>[IJX&CEE(X>D5UX?"37BX4N(T"?/U%%O^XY&
M5LHJ0>DY?-66>XU.2W6LW"5RH.;E%F/\2#?^F+..DLNZYL)8G6$DA(KI/"OG
M,3C5@B-B_5!_@&Q;N4B"^^XMBZN+M;)2^Q4_QZV2*$5(0L\I9_.[8P?OKEV$
MT8),Q=G'@S[H%C%IO-!.W+$9]MN&2(6:%+;A6 OJH4W+6I7O6.B2<SVL7;EQ
M]?JN4FZ=[RKZ:A^A^3Z0PD-*Q\[EXX>/OHYG,O1Q0@D5JKL*$<@P(9"99M80
M0,CFH:.*%JS^<O(F2Q.TD0P4-%X;K?5*<K2/'[7=[)1^NVOVLU/(M!-C >5'
M)D^TA$ /9+#<K9?@9IE\7E*,F\ <7210;#R%U_B ;\A#<(V!-$[6L' (S&5(
M40Y ?@&[H+#/4#UI$(:_S!Z47XR7,T4>.0@&6=]0/<&, A5J>5AH%#)[V0R/
M&.Z$8Z.HZ!06A<_<9]HD&=\5P@5\U'-]@M7<9:K,,=JUPAPIJ#K++8466WS/
M.4!JJ$W!<;*')J2<#\JI.?<V%D9K1CIV05HHFXD.!O,>R\_B/=*-R@I*TZ5!
MT"ANG=<;#'DTXGX=I$/2!A.HCK%CKPE\/>2J>!%.OCX+$I,K*=8C=&1).NOT
MF+23>[#.J]A>911<(:ZW>"*(7"N,P:5%!OB.EP/D4:@*'"S%9$9G5%,J[;%@
M*"1S$?Q2Y&'9_4?EFO-3K_0#F9CYB+\U[JGR:4+&$0$&U ,&DEDESF6H-:T(
MR2R'VNK!=<$>Y3?.]A?=_0+40:H&Y;B%VD0T[KOG><3QG%]V@[/>/S#9C3-S
MLT4M%1"KO#I7MR,0)B8%CXPXYG,XF1/V'[;2AT#?,I;N2RE#$RB <0U8>C+U
MT V%FI*[V NJ&N>5.\,$%>2B91$ :#"B>O@LIN&9 4<OF;5(>9E,T],5::'(
M-*7]Q#'\9BJ?Y/MU:*-,,EQ^>/3\ \_H+4[D*P8%QCK^9RJX7]KA4GCI?]8D
MV+GL77:K/_]A,](?\+^KVZV.Y-E&5@$SO5&-W4<U_,?,X(\S39%"4S/]P_.+
M8BT_SF:G=25=>0+G6-(T+><"C('4N9"#(>74(UU% ,:.1=1F&(1R0)=\9MN8
M6X!$6]C3\)#=4N\:KMKJ]=\+P%J?*HFE.<96'!+], E]7\6KA]KVP;@[+3:.
M0\U<#/%R5<>*J+Q7XS%2%RF_1F_CA]^-CP!_?/0=Y*+BFO5KNOA)P)CT.7>U
MTY8L6M$RV#:U&:R,*^U<F3 TY\,:F!%\[L0V>\"SCQ%-'2/,48XM_>-!M!/.
M]BAD%.LZ3)OY 91D308C(_,/HQ4Q B=[+I@"R &(5HIT-G185'L"ERJ =YAL
M8;2NR%-R#JUW%8B)CIKM9E88^Z+S"*%5C_7LS:K'PT0K4;^5<K2IU=&@V%6+
MG98%V1>Y1 /WE[D\9'@!P>)K0A3<P8J:2]6<7P=3(%=&E"E>R8^F!GZ_L,3'
M5+,?9@JR5-HUS$JEZ)E4H-Q()(!MX$'^Q8W<Q<"Q+3F9Z2_0[.E7K3% T6GD
M;G",+92XL6<;((&L'L!9V;"W5<\>?3/3.D>'?CMG1I1ZMVV5<Y6%:<$@GYK!
M3?CL,@<R<[XJU^1D5MI_;%&OBY9A.ZUS<<^^2*I\^NE28[I?%>:56%2FQP]Q
M//N5_D%R"9+@\=<9J<+'#\44?3_+"%?->.B-+ CVJ?*/\++N4%#<[JJVZ,0)
M9M>'8: HJ'[-C0(PHB</,:(OLR JZHKW :HXRG_(:4=2=G.EVX^S@VUH0KPX
M;S54;Z#-CJ3K\FY0%6;>+DGOX9RL?'SPEZ=96J<KDR6Q>+L=^=Q@8-]^( SL
M'E2YC;0T_ 2CN+)]^:<84#\+X=GLWB=-<.?*_G[5TJI(.!ED1QH6Z)/(ZJ>7
M QIRQ]L0@QW!\BDK#5W58U2 L7M)M%QSM+*54E:VFXYG/TN$HFS!MK&7U! )
M(%*JW!RZ>EO5EU5\M(*^?7V8]-^:@<]=2!2-<-&_FRL5+XHJED>Y?&F?M<W:
MQML81<#&C#0HS0(X7 )" 83<IQ)U+ 2+A54P.B*X+#A.*;NV/5:T=XC?A19L
MX)1C7=<D"6&STET<QE-M"%HP)?]+RHH]RV41NQZC*B$8N9[V0-M41@9-3Z<Z
M0C4XW?"R0R?&D&3:I.7(QBUMJ]5*3N9<2)/5RDG70L)2I.)V55Y59$_/,85(
M:=ZCK1Y_-+3T1#^"\X2E3U9MG5^V6@-P'IGM3M-3,D[7C_'C""/OJ[U",RF<
M7!3;0D@<]&A'L+X#_^ U60+/D2;W"9F(^FA2PA@2;VQIR;EQ\W*=55-R=V6*
M;YI81X<<%QTZ8S%&SSE>*5#2;-A(G\56K F;* +BVCF8'T.69[,X$M*+]'S"
M1+HL$MKJFOU+NJAHS4W/Y@!#^JU &\D-:PPYH33BG$&JBL#GR#4 >M!I0W+'
MIVJSMGX_"BF12@:1AN,G9;3GJ>\W$+YTWT/S)Y;FC$S*B%;7NP;9W@J;X>1'
MW43QP7U>FW:G'9G\B6T#+Y.[W[J=RCIJ1)?Q4CO/:;S3%',\-0NU"YCIL'\L
MLUG2.3ATKW['HH53@$Y A5Z9Y-.9J_^#TA_3\5X@FY RA]+=G>_39A;2'(%+
MZHWH,Q&NZ>!P;%"=+T=-Y1>:JS=UA6[%/$,E$853L6N*WE-"W^/X)"UX$H2&
MJJ +;IW9]E<H1F &@JOU#2KCU[/>DWNU5DE3L2H>(P$9LCACHNW0LE3)A:*
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M.5RPWR?T\1C)7BP$_#C);.DL!ENO"<,LX.WC=1Z7.4J-Z(D5^YR=?M,B5F1
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MI"PL-M?[YXYAUASU/*VK\\8 #W+*%2/#G^6(YJKG9!MV(D<!3FC;00*JQRC
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M-U69AR@!2C;CKT]-)IB!;YE2?.[TY0E0UG]E@O''WUAT6>&'=?W6.IKP9WP
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MX<\^(U&QO85W,4/&0J3S&HD2\@,BV]*2[@$7D7DRB20,V_J!&9UM77'C)7V
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M32F.A3N"[-86T:D58LU>I#@RE5]EU81V.XL2--3+_90YPMX8KVO0K@-K)H2
M0TE&BA"2N<F\A*0,IS(!Z'*'QI&@L12$N*CQYY4F_NKAQRA%^@"^C3\@C'EU
MIO4/#*;>Q*[6T+Y0DYL X3.-YKA6R>&NN:I.I-)B+,(J!4"<7I&ZLTX-E5:
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M8>L]JAF$6 Q;%5^ZJQS()\Q!XD5RBF!4],YY.@LUL+*@X7,M= F77JMB@V.
MOH1G7?(+U]/2KE)0#;:*.LVD%6,2>5ZC/-OZ :BZ\,O7T@T@H]$2JEJ7W8]F
M\?S[\[8Q+"0VOLPO:FGA+ HTPIB$9AC1KW/(%@$@*O3)1>;.Z#ZR:V12K-UQ
M_4II*] .S+8ZY#=[YX,[9G+'V$Z=+FWE-.J3P8;C>$77+Y"61I"[1E+WBWQ/
M]_6(_D_^[:WOV(*O#X/K!ULL5#^II.^UY/@U9ISC17?TRE ?BX*[]_*%]7?0
MG>&_Z"K<=?"Z+/=UX'473,+X;]C%Y+I=20W/&^\1V0VD(X]TJ6Y++^-1@A,
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MS#\4D\&_KHB]?1@^AZQ5OJ%-<T"<OUV\C<#_*PUQ$Q2>J'TY!<H)*FDTK?D
M9@Y^$\!X/25)GP%&T2(V 0O;-U9S>+ZGM:-K!E(NB'A6*LHYG;!-OO;$:=S'
MQZ#US'IL7>= $'(,JWZDJT:'4L9Z .<H)VW3*<6-_C' 6VIW80+O)["-?=VK
M.!W #0[>,9U)\H/1#.\A5-<%D 7A[OI?]N$4Q[EN] F8!*!\Z(Z&869K)QAF
MT;O/9_)7GLD>P<;8">VS4#0I@5=Z5)0@C@Z@EEJ+IE*. 2\-,M_&[^!*(?XI
M3R:V"M8"\/F-:]9UOA+ . K?>&(-TG-!N\XW^.+1W6"_!4_0C\X4UMYE=[E0
MM$F]7;PS+GR/(0O&FHPVX/6>H6.?\8G7'W_W?*A8P59#.E)G"B.43&6'L*L*
M;&I,<QAIT9BKJBN-"$(A::>:%./^@NA:RX<("MG7Y5(_H).#BSMU'W$@ HY;
M0QX_]V1S^B D)S85.A^K97I8C#;&6@O 6U8??BU"W[\,31+32;3W 8J9+L3X
MQ&.[-"'3CY+F1!1?1A?*&=@5H/T@23&DZ<D3(2QHAU4NP/QBZ/-53;YEF:\6
M__;M@7Z^H\__'_(_;$O"&G[QG__SSPR;?2/J\D_/GM-.@\2(WUV2,(@U:6__
M\!\<E';'__KW &4[BA:)9_CRAC,RB^)T..ZY#'O Q3*%LPS>$P-,\^HQPK3T
MV @B<IB2N$&!HV(V(5V%U6,6@7PV\N.SG\DS&7W<^XI^DH_^]>LWSV\,TG=Q
M<&W&HW(R!8%$7W'R<-6,Y\DS&VO-2-4 ,<4H17V[^%&1H]DHZ1[S2YIHQ"\F
M$45S8#SI0U4X"HF5[BZ'9:+5DJZDO-SGJUR,Y]=O?X!Z^/KYYXNW)M#RTC\H
MW]%2RN,GP9Q?5QSO.L TBEZ$K01X<+.O[LN^DC0N6"!-MTK8*EU,9"NE]0ET
M+'][812PYN$6[#KB@0T>'"+ R,WY5I'9;(XEXVGQ6T68?4#H!].3'.+S70N'
M?&IK@C.0@3M^%,![XTRF$LH(U$<_-+F51.QI\?4]%&M6T]6R)2<3>$>/Y$EG
M[-[ZK>Y3?F;!3Q>RP_6>5%>-T1W:<"<M\4<>J'F+A<%&PG0M/<*SUR]&JUOO
MF*2#K5QDUP(4_[2%DU4*6-U!]ODT[!U)#6CU[(7,92_HK+;=H:J;V\7?2%&>
M:=H70DR#<4>P2W?,[ZI6YDUC8DP_TVEGD3'/UQ$RMKR<T4?R1[5M[R"DNU%8
M[FGJ1JCI["HIKRZL8K5>=_48BZZ@#<>1U[@CPZ23FQXK$=^Y[22*]Y;=QTGC
M"R=A9^0=3:QO+Q9D8U5UC1&!]C$8MA4#PT<@K)]&-OU3HDO_*/GV?\("C?E<
M^L[_N_?2__M7K68O)_]XYZ[/+S_!1?];O=0(//]3;O^^18%/Z>PDBS>QO:.B
M,+[\?;K>2,4K>;VJ\-B\#B */,!KX!/4_(3VM:3;]6F/A/W'1V/.FF'./MEC
M/9O$V23.)O$B32+7UH^M)$2W:>("+&:;NMMQHK.P. X![;=_^XKK."<#2,<O
MC2 XRI!N<\ &KTY2_Q3CR71DM#536.H6.TX#TYV)IE#]D3\)5I+D6.2JXZCL
M3S#BLV6YM-,Q6Y;9LLR6Y2(MR\8=R%P@,XA4Z]:U)\FF<6M8MCZ=4>-&)D??
M;;;*_5IMS0Y)!#9F/&9=?L7R..OR69?/NOPB=7F 6#B 41ZUKY0JZ4'=')<R
MOLRE+-4LOLO7C@?;7O1#C"^_>R$_3$<A?_N*/Q(3-5DK:8YF+]@=M,#9H\[V
MX8IE?+8/LWV8[<-%VH=#!NKTK*YY]/@0VB_.4OLB*1-*ZKUVZG5VE':  .83
M_UG;4A;5D:FVM1J_5;KW84@Q:_XKEMY9\\^:?];\%ZGY'6C/\V8O29["82S&
MQP@"P]K6^:J#@AXH]3 ;&!D"7&<Z/81^+O[R_=Z5,6?Y'F@3BZQ 2ULMW8(%
MJ-JC?D$A0)@-PA4+]6P09H,P&X3+-PC];,PQ:ZVGEF=Z'8]BU:[%N+;3-']2
M0'8_KXNN81J=T^S<?YKR..OR69?/NOPB=;G ;OHRKA9ARX4V#;&ZU+HNZ>1M
M7O3G2)HPK^!S\.J\GP2W:%;:UREXL]*>E?:LM"]2:8?Q1*ZXWA0HL"KX4K9F
MH%#-MC >#:GT39[MRJIIN1K;5N<\;$&9FQ7V-0K=K+!GA3TK[(M4V'&"A#,C
M='7QF,N$$0WY#X&R7]SO*U;.GA7R3#=\Z];[DKMM3K=/G%1[>,LN"M1C9-QZ
M"L@K&C,7S"$%L(9-E"95/W[.O]#1<\.9DCD"'28_UCDM"\^1AR'NZ7'RY21^
MS!-&RV.8[I+GVF7J'< 4&-?GH?B3:^49P'MC"'O\%_VM<.+%/;J^,1<@ 1+8
ML= IL-(C '-L/@.E%P',&6\: Q:"P[S@[>(O#.R%R[NL+DYG#\N-"K$@MM!3
M)8NK<%$K)Z!_=)\  &# ?2O' R@,'X"U"DO@-MIT/-JIG W?G5:2/Y ;L!S:
M']KPCFE[@V[K."B1O@7:VLX #=$5^2/R/K[N%43MT>!#]\Z+ RV6/847^NC%
M3/850PWPC/'9>AKDT+,OCI>#:?72(VIP>V$,^I"7@ YD<(W"E;MVK_+P\Y%]
MZ3OGNT]04,S*")ROZEK: K?TV'4Z*]P?,[;)8ER7Q7X4FI\WR!"J6<<HV!\_
M EU/!YKT#@*A,7)";:<A[X,AYHD#+"V?;E0,1Y Q_0%[FCQ\?FE6Y(Q,--'^
M*P0C\ <CI!$Y)9@L5PG( 70'D1"P,M9[0'7Q(@.]K7B.NRYC'>(4&H8OW-\;
M __RK V@BBCH^X)R8_>')6K6>[?I"I=H0&#M97F!83CV,H"9HK?C;6482$,<
MZ<OL"?=(L7KT--PNOG+-,1?,ED/>2)M6^'K\18_PQ_<<:M9U%O-.T&KQ\]HC
M>MT_=?$$>(O]@GW.'-?XF[TX]!Q<JE&3QBJ.9+(CRW#BC6,0SB>JNHOTD.S0
MHVMZ3!\-=K>9LGZF5E0G]95=P>!T8]<2J>I=;1FX]_)#?)EL  PUHA8-9TC5
M8EX&";M=O![=8'D\B%(S-F/*;P>A8P[B?74?<5!M1GV$]3YC="D'**HUT+UP
M%DCK:K_BCAZI@9=1 ]%_RAS0KX#FU'LDH%%Q&R4#:V<UO$!2XS%"W;T!)[95
MX<2E@2]'S\]4 F.JGU_+(+B8OR#R/*MR!_S!25BZ"*91T)Z 8:97 &@C#]]F
MA:+"ILA<C 7'Y =CMF\9H3N]*VGQ>0.2%X7K[6J6^?0MGL=O,:2ED0EA:0\Z
M5,(G)H++7W,1](=J;9&$"&E1Z77 SX/W6;BRKHH"1B+@$--#8?8 =UTJ./!Z
M[Y<^<K_HWAAL4$0T]K;1QS0^KQP',ST<=/XJ(Z^SB5D[O[T",$;K<E1VH:58
MMX3P@AU/W+5W 73P8N5DE/I6,DGRWV]A%ODUR)H)"C>G$%>-J^_..AABW> "
M>W*A5::,<D]RDVSD8\R,-'*"1^YOAQ.$X,%:R1V\YGA% E(!-PRXL7PCOH_N
MRR1H#-TZ\W%(UW"M+%</FY0R(,_ZEN3*46'^\Z.@PCSN/?Y)U!&_X7/@G)*T
M&66,R&%6G!J&F7NQ*+O#BI, VX R;T>_AT+/WUSE5<@)F8^3&](?1WX.)BX"
MI&U<N\K6[R;!<0&0M\ ^+[+U/G=F\?1818J 3U@.PXMS?;OX1E#Z61=#ZZLC
MG#6,#+XX59UR4#KO^%JTFH2]9EXUX@TG4P&#U>,)W@MCI+=X01@+NA[LA^BU
M9^.^9)1 NV(W\!L%V. TB!AX!O+$4%U8?PXP-*+%^L?^ $N1!1QC#,IC^MLV
M+VP:22[[\N))D=VDV[$9$ML1+&$ I^S?RHP3K!N^$< FA0$"/$OF;S9')QT)
M]7A,>R[!U>ZKQL543^%6EHR3.PI:IG<7#/7<0Y:7O;SD&#L WR9R@*NCHJI.
MIEI\8N5RX<-?J&?B.6%H%P+,M29?#^QT"')O'0&T"=\@J0A#?66LF:Y!*(Z_
MJG@(7BK_=4HX98\"LV&$8<O$AJP$.MH4/!A@@2$_O8RQ3Y)I9DP<D#Z\O2<F
MT99V+X S1/>C!.9+R=*>S2%#HS^ (L2C!&<SZ13'=DWKT8; 88 4SQA8<I0L
M/I<K'HUP(>E[BE[H(!N$M-Y5H(0GPZP>M/YY,/!!G.4Q@6_*['_]C^>__^.?
M[YPD^$:1D0VBFY3X'2/1DD3C"O3!]+JO7GY'*MS3YA0G#Y"L ,\>$_O]L9PG
MT:'?"^<Y"5U^5(="6"4J[53373UHAG?#/HCU'8OJ[_D6 ^02=598!<5L VTU
MZE*(\A"";>")(QP$F^M&?)P5JZ !I%8CCWP62"M'G6'CUN3J"&(WIQ7:(5$K
M1;H-?T8EEVE4SEF:SQZT-+^Y]O@QS1[88!"4@-J&-)NZ8V>BE.0GD]&X!].H
MDEA,K):6\2)<T8$!(J%8.3$PG)#AXEKDOGL_+*)"$R/)XHT"5?4GBQWG'IM+
MZQ.8>VSF'INYQ^8B>VP4'\8"B\<A46[R)MO5SFFF54')) V*'@=6]:SYDWZ-
MOM\X#R==L5C.*GU6Z;-*OTB5GJ23DG:SH3K_1=."TIX!CYT[6"2ZYH Q$PR"
MC"/RQI5-Y\/*4<O H4)4$YM5_!6+Z:SB9Q4_J_BK4/&U6]==CL3B(!\8J 0M
M[TF^.E+%QUJR7N3WN]:!F]!W<PK[YJR_KU@&9_T]Z^]9?U^D_K9>6ROVB@XW
M7[M<(+N"U+ET!+[YODD[J42Y-SE*=6AE<_4!57$MNDL^O>E6/W'-E=S[4+\K
MW:[B>H>5U+DAB]NOXLX6+M<>*DZS:]-;&QXBNO=L'ZY8QF?[,-N'V3Y<I'T(
M'4 A>9-V=\2=VGE)'G[;*=$PMR?0@Z^JK-XH*=6;+V=-?<W2-FOJ65//FOHB
M-37K5NZKZM#/S7U-,GV\U$[,C0+,^#9-G1[4F1ONC4G)!=6U7DH_E?2Z1',T
M/,SB6\O,OQ<USZ'"IL[N]19YG?3P^IO.EN"*I7FV!+,EF"W!15H"&7]LDH96
M/P7>5O3QV0F_9O&95>^L>F?5>YFJUW<6<E*:QPAR\;2% B]5PDBZU]7Q**!7
MXE+/KO'5R]BLGV?]/.OGR]3/^ZQ@N#!I5DGIZB)$M7]T]$[:1[@=FR'S&'!G
MOQC/SO%T4W:TN<>N<2.8%S/@^C6+[JSV9[4_J_V+5/N6G0;8D*;')94MO>6,
M[YLB*64*EL9MB?=N(0A(2&Y'EZ@=F0Y%_:T:7BF=XQ95(//*-]UQ]N:O6#1G
MM3ZK]5FM7[9:7^^KJK&.Q8(>N12D2:^0/=A(@ 7"KZ1'44$Q BW')!8):WK
M.^9'R>L(0L;1C72\STGV:Q;=6>W/:G]6^Q>I]@NZHK2?N']TP(CNI+LE!L"?
M=?&G(T^S+IYU\:R++U(7>Q?<CVHB(\[4+F@+C\"C&=#ZQE"R4M3-IZCG3P60
M^?./ L@\]9)/5[6S);S TSQ;PMD2SI;P(BTA*'I RL"Q24/&L.J:8.?N (0Z
M1N2T#8BFZR(3:CQ L#81@=#*&"<\?OP<T5RQ+,YZ?-;CLQZ_2#W>N,*M!^C
MKMP<JYQU,N"C%0"::P1%5>X8>9L5_B;EJ1*F!(^(+X0@>1,(C1CE'A#"69O-
M^OR*97+6Y[,^G_7Y1>KS;+&E!P,U2-KO.<$E$]B49725'6ZZ&ZO^E9,9V@WH
ME\@E?R_,8@8I=G3-6H@101E."UD*YVBS[]K%IKHO%QNA]+W+JT*Q,=FV*(7*
M7ZIJLWB5O,]K$,6MM4R]_LNKUY[*.J6/RXX@LQ.60=@Q+I'+U_)RZP+=W+JN
MFN:&:RJ94;M,=<0J1TRZQ,HZ.INV*SZ>LVF;3=MLVB[3M)7&=0JKP@9M5/]*
MS*)TET;*>Q+,-[#ES@KZBH5L5M"S@IX5]$4JZ':?UYL;[AB-2)%3(.1"&E?9
M=R:GW)6-A" <$N04<@1M30K>V+1'J#:7PO,N'[#H9H2.,P.!5H%8J&1*JQIX
M^GG3>HS/*#R8@H]8+G8<?T0L:W'H\9>7KY<AVHBBH#C:D%FW9(%H<X04KNF_
M#.B:V2Q89BY*IL4OQ;_G,@PWA<D+RFVJ>C9NUWE 9^,V&[?9N%V^<8MT]XJN
M)EK;K;*Z%L)/Q:"3?\ PW.>-(QU/:IP>N9]-$].QJ^Y<71K=\!D:V31'-F%Q
MF+/1@U(W&.OCD*ATPN.YS9DCF('L!,/412^E'*#Z!>'>-HYS'N5N*B&ES J/
M< >3)7DR>;NF P5U6"=ZFJ8['JNZ-5ZRA$"W,/KJVR?VQ?WS^L.NE+CXV](C
M%RZ90:[NCDI)GG5-$,67W__WMU_=//OC@A9_XP[Y&KMOA-3JL;US1;YG7\A8
M95VYID-&YU8V?)I16[E>:;>7.HN*'R.^X8ABV]+5RHP*FG.E>N\Y>2 N7@>V
MVO \=NMQJG8>@$H.J>%$RH(PZ;:N"X F5<HCP-\F'"^\>71=R9O[9A9<*5M\
MQ2?D!Z%G?E71:E3(67S)<,$XU>$R<"??,]]^NW@SKCAX-_6-D_<=+(TFXF,:
MV*V<X9@&UI#T90A!TN,C_O>:5.T&?,-]]JI85RUT7&W,%X^\<%K^8RA6@Z.]
MQTOMF>EQ18^7_][%BU"SUH1_?CA2!&./D(4'V%<%[717\@4;YTICXLZ;IM,R
MB_9&@=E8&X&7\3K&7-X925'IMGDK4$J"<IJAJ7CIDV#T3,%F ($Z*7]D&]KA
M'!?DZ< L%#H>-5(R7-_;1:)+HL>8VE?P=E=%OC8)1-M8:E_4(&4'-R1:".!1
M0I1VI*C'N'1H*?4);A<O^,MR2[ZF]2MTC<RM*VGU4!&D-\!1W\+VNI]]"6BI
MQQSJD 1G+;/RZZKA_:-03)47G5\.7K==T>-<SOK+^"1[\NSB#,HW7<W^RG+
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MX.M:FHXY',G=/QB)D$PH:%*)WFQ79P<OYSW.@W!@+93@DZ*4M4'/C+2%7;G
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M9:5MT\/6NCX6TW%9;Z0Z*=WY(#D=JTWBJU:>G&)7MU(BP"$"K2NNQ[6--II
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M5!\@5[R_?@Y)#K_=EH.9QCD)E[#%VAV2QNWI49:NZJ8W#!K+%+:^Z7Q;)7G
MZEJ=>;D GH:?84FB+\(7CX#MH#]22P9Y7(;<;@U9R^LA(LC8G)S;TFH\E6_C
M7SEIJPC5U3T(&62:J<^H&)$HLDQ",$@?"1P8B>.JRPM-GMY'Z8]D@\A)S8K^
MA=?9,4LR0'R^EF<$7_[^E /XB146/Y\!/#_><XSHLQBUI,[NO2%\O!I?QN1'
MZ7!O(J]YXF"./,J9@19T/D6GM//(:%-<I^B@C@[+1%.W(98-NT1&><=L)%PX
M"CC'CV';D+T4(Z-M*Q'H&KH+0D"269Q"8O$WZ:B,;BMY=O8WZ=V=W&3R4:!6
M5,E9\WZJ*B+.6%K]94QP!?@$GHJ.JEK+,ZNJVWM4LRM('I+PBTJ;6W2Y#315
MW.,7Q]+3MULSBD6;$GO%%_9>FR8E2LGR:-K(\*"C7+E$ODQZ/I4YBB8&O 3T
MIGVC#_=P>-(UIROM>>H>B-EKJ4,<.UUX9I <4E>(4WP*/DH42C5NS5_.C-2=
M@JISU5\1HBD[UT>F<][HF0Q9Q6<149@]<-STB7PR$3VH5F.JBJ7_17#T>4T"
M "$9YX83,$6"^X;>TL<R(86A@4"%U"2ZXTG.K$U]3V3G^0!L6&WZ!&P?S%7\
MU1 >.Y$64#W'\>_41IWC;QN/]%0U+Q_1'O  <UR^]8HQR>+[])1E]4?JBHEX
M+,\46^+D?S_5TY",R%\$K,@P,1DW*!VT,[O$0 L2I4F"]*=.K[!<K/.[G,N6
M%-7K?#X"0\;38;(509*N_98JH9MQ.=+'7/X+9E.0,N(2.93%^1BA-S\/U1,P
MMFK,S2&OS:=;'U2M9!PSI/L.!>X)K239YYFZ>[+<?"*0+2Q^4 21D/D>UJBZ
MY'[FA706N*?'*BT1^#CSH223R'LJP;!ZLCF#K4B =5!R"&WC]Q Y+[E_TFV9
M&=,OC?5Y9DR?&=-GQO2+9$S/RI1;,F?B-,4"\LF4$<"LJ'UNF8+[:^)XQ)9+
M4T,4[OZO__&??QSL[3A[^JS4+TTP9Z4^*_59J5^D4O<DPCK_V$=6BWK6EAJ"
MZ9#H,%^H#3#C<>VLP*]8"&<%/BOP68%?I )7 &9I\!]+!/8JK4(?:7TV<1%E
M=9K(M\ZJ^XK%;U;=L^J>5?=%JNZDI@DZ,AFR3WJ1!":&AX-66;O>G^N2@I[F
M,L6LJZ]3WF9=/>OJ65=?I*[6O@)M'@T5:FG!0#W_L4CP7&I.,^G"9!_ZMS:.
M7G%SCD/S]G$J_EK+SOTN&1U3Z4H_X-#PFS(C'=<1HB%LG9F8:I@1@^KKSU''
ML,XU?!T "V-LI>A^C[W7<M@G/?I(3'V9%\GT S=.S^7J:] ZL\6>+?9LL2_2
M8D==<F<;*./VHJGN5!EGU4;+03OEG!^[8BF<-?BLP6<-?I$:?%4;6M&PR]^[
MX38[DC2HSOKX:F5JUL>S/I[U\47JXZC??VK(+X'H'$Z#S9KYBJ5KULRS9IXU
M\Z>CF==[M^D*&2MD (VBF-7S%8O8K)YG]3RKYXM4SX>\":SQBIJGNIE^Y5KF
M\$P8[%.(25J!C6,@@MI)+EJ.^CLZL#?[ZAY:6WXU]_Y<K0C.ZGM6W[/ZODCU
M;7";"E5!WZQ=Z12J E@M9Y+1<*T5'%>)I!F<KC@)?[2PL0((C[M]NB=W]EPY
M\-@?/@KPV.5U-%T*%MGWXXA<!J7L018-ME&(<="1C)\%<]K%(-D3ETNX/S-
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MMR^]4R0(XCK2EW?[1=W1'[-W<&CCU^0I)_YYJ88!('F0^4@H$\OKBT!D\*!
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MY4U-$DOB1X&V.O,L:R>:9&5 ()\:6*A:HUNL(1VI>S=UQZ0!.HZYB\GG+*(
MZGE9.:_N@?,OVRWO8:=!1!U)T=AO=N(R'<]OC6Q8ELG)&A-X'*OBWL"CKX/$
M"SNIAQ ]Z2"1_=%M.'E_B:16C>M\.>[EV4$[ L*O?DOQZ.2KM)!M^4]EAV,D
MW8SF?4]W55_X 7O=[SE8=MXMFM[$+'!3Y"ZT3JM(&IG#%U<H@^N)N#BWR>A]
MU18^;[GCA$C46!/:+C@/81&VNUOZ";BH8-719D.-YGBRD9U/*$9)5[G;+3D
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M[LG)XB.SJ^; 9]+MQ3Z7= W+^)YZOU@>3%6$"!\2?W.\;2#O"UB,QGTR?>'
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MQ)-RRD2M!^N<^NC ;@9^E<WBQIW(_!=KY)SHACD5*#Y],%#\Q?70.Z>TT8_
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M1[J((@7<2\WA3FD&Y,&QWZZ[<=A&:!.!DQUR$:BEC]PIUC#B7EDZ=3TJ]02
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MVJO%_S>"[\ &D!X=UV@#&^S"3)7ZAV-E4;5I2[D75!D<(8JK!M\32H+]AH<
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M%XOKJHE]$@>W[&9S.2^0*7=]EG?DNGQ1A9N&54/Y!)!-,>*XU4/<5LR<3;(
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MIFR'MO!(NJ[\L2F7[J?-K<R&^H*5S6RH9T,]&^JS--3>%+RY/735DIY^\<9
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M*>MKX;.&HW$-W6%7XXBMD1&.J=V+(:^MO 6A2MD([@[G9&0!Q/@HEM9#JJ/
MELV(<W+\!1FQL<ZT-&=36*^W#XH%&3+!8*KY<=6M(>?7<;+#CZ4".J:=S&85
MF3[1C8 -S0I[H%@\27:SIXNF_N32CDS9Q-R9#*(O8YZ'2ZI6T5 0U3IERUSS
MKTL@(=UDNK]8 .G5(%ZG V;38>GL^MEA=;O9VRFB\5)EMJU00I&5:L'I[C#
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M-A5]9&_&95T!@74N8NY2Q0K$]0 5$,B;K,)]N<QCTVD'3JKT#^J_34+"<#T
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M  !;\;"TY6*ER8D[4*1(B@G -!T8KYJ4] "P%"J,H4Q_4!WCORT$W0\6"@0
M+!5NULSM_0E9,7&:E!F',:=?S6&G\DNQ\><41:;!KSFCR@%.(]U>MSV]AM7
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M.])5T56P*-2*CNP-MZ+J^=2U>]/AW EHIHLTT_::WK81V[&O:!<MD$\>"O[
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MZ^ZN*QT?L-L!4]*!R8"0N*M$'"8;L?>@;"R9W(P_PU.[.A!1XM$VH&*HA:R
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M<7Z>R9?&R5AJ,F[*#4\>-N6J4![7^R"38I[=9WB]8LPQJ*(SZ*S$<?;;B+9
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M<K-?P>A *SSWH++>!CC;4J^-:-!W>#FR>!A6BT:MC+@JV9YZE.7Q_KHB9O;
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MTEO>5CN=JN.57%7=KE=R6\?/B/%L811I]W60!B_/^,@,LFTHE[<YUE)$'W:
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MO7F;$]?3X[WY<_X[)9#&2[U[\\UK\\KYMV0![/8-4^:P0/V?GDY$I#M2D'&
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MML3O9=E,H@_4TG7F2#;<CU@-E_CE<^?+F*2$!1Z^>'YBBB;_.ZY'T[V_XL]
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M8;41A"5;V,0I/>]KV#K"C3GM-@D,*UD_WOIFCL5D&SA%ER(XJ=D6==6.M1V
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MH<<*.3"',T5U4-)HR?F8?#EP!9"'L3!3,09C"#G=:W6XSGG4E&LQRO7U;E3
MYA@VG<D^,\/$Z_\R"W9<1P>QL.NM^M <G%7!+]@12:J%%$E2O/A-5A5F" E#
M/"\J":>RU#&!-DK/:P*0T,BDSYC;R/0@DY6QG"V[;^8OA4*[KJ"T+5_VDLI=
MX.HAF3J&+CVSL?-KA*- @XS@WSG'6"G7TG9"EG9#=!PZQJRO0UOLZN#%FMI-
MQN*@)SOPZ=Z=32FY/'(/S9O*Y4N$=NF7[3BM;'!,TD16RJU->.N;0XT0>,FU
M$/OR/A23#&VUW*W/R&Q!4,#O)= ]UR87N6)H.NW6U!*04AJ;B'@EZ6/=W86-
M*4DQ:J@9J@2Q.5;(E,M6I8:'%(!^@2!CNO5T^&G+_K8>4U^/05M7.2MNA^JH
M'A=O04[*;^QBMMLMR8A%W!=?+B_8>BLQ^;1O4O(#Q8+3T4HE EZ#7"VP_USQ
MH>8-#?!34G&M2<R4\RA"GRERU_!#1/3.YN.D47Y/L/OL-2A3<6T9K$C)PM-]
M^)C_IR"W&$,K40U1SM>MC:P/!DL6VQ<-;$3=)>0@!>R2Z!&'\5)X0I]2PN%I
MD A%OFKP^)]'5R['$P";PO0Z:ZS&#4_#&!L:L:%]%=UN\5M>1P?[2T.9.*FN
M#BP D^>" ^2J*\'YPZ "Z%ELP9RYC@!\8:PJKD*A ])(1K2+Y4"<?=&@<<5G
M3,80VL?<GC&O]-0I1(5GB:$WPRW":#7A%A$*;2FO1HN.XPEDSMD#PX+ORDN:
M:%P1W8#E6?1.2HE:[[CHS91?&VP4G"GGT 87;)V > @;+7+=?<![\B< =*(=
M:&7%9CPOD?&\N4D+HS\^]KUU3SC+*%K5W]$;4>Z8#2-/6X]!H)R% ^Q_:QS&
M;=6-72DN':2C/(B#V"&F'$6:2HQD56H$[E2[D$-FVZW:+0L?(R[4>&P((NT/
M4[0RV"M#ZR:,Q8!H<KXH*N%#^907B[UIL9!!RRW,&"/%3*# !?JF@E1!KEF+
MQ1"Y07BZ3S45_(/FF5?M?(BW;!GJ=>UZ[<8H$2<1H6*%7^W\ZD@,'4=S#33&
M?3>>.<MH$Z)M/\J4WPZX:2_#:(>$,Q+0*SS(S&FJXFHSE/B()E5R$PR#FH#-
MP(+)OL.V^R<-!?P9RD3#FGI3:_5$Q"6U:W'"TWV65!2/J&BZ'0)RMNPR3 <W
MB170$577?KMVY4T@8EQ(U1XO#%W(5Z:#5L,\F-%7Z+FG- >(O3->,9FSL[2B
MQ#<L.^91UN[BT"$S8;3!M>.Z;/A$EX-3,YC3JM+R<G7>I"3U4C$-D]44  I1
M2IZ@"6C@B_0/KEQU3W7KPQ%.289K%"*35#4:P\(;5!O@7B\)?1$)I'PMK=P&
M)??#N%WI)=?FDQD[1#<E+]@$Z(ZC:R34N&Y!H+;$FLX-[%CF_VF8YOP-UR'S
MG<B\] 2S= 1R00QQ&P>33%:,Y+&CQ'6Q;$ON>M&IE7LD(1N:^T*HN1P"T![B
M1J98Y!7T<C674[XX=X=J28T71\EHL(%%<1X["L]NTQ@+UUB4KD;J-$;6J6DZ
MGA4<7+],R[63RNMLCZZ#_9<J0*@E5%V^]8#KUW4+ZI@YR=,%IE3'#>KA*34%
MH,\D%@_+U-BI[N)2-P^%S_:SM9_7B$JW^EV/-5QKBA5M$]&,._*[Y\J \W(;
MG!>9=G CF,I*=YY'8+)R53[!M P5;JCRBN)9E)*TEC$GQE*>TBWO]&"AUU>W
MOO/DJO/0@9Z/9@2)MZR2(<@QS(0V-/\)TXT#;7YPL8']S%P/#2QLAH1'\ID_
M,MQ=KN,39KMU,;@9*Z=E8;L%DH4[B]7Y X6=>"UD+*V]N8/6Q:,29GM8;G@I
M6_I5N*MWLG7?;)F#O96>S"[67$BI@K5_P2".##D<92D7]MZE(Y7WWH<.4Z*<
MGLNW 7;AG7M*W8W?H:D4';9V9VD+R[Y6\6RC%M-O9!&OZ,1KQ>,=A=]Y6GVJ
MHG,+\(IS!<Y8%E[@Y)?K]/OF6[L/_7XJ4Q,5LL>_&P$5QFKWDNJVO5$T*\-N
MQ*O7]EJ(T=VVWG3E5*DCM*H9:045WA]QE<3_CL[B.?(!HF=_4JR-^"^4!V 2
MD@@F$743V3!,[Y0Z4-E':IJ+0%1XKM((3.ORY_]S0/\/5L^]+&+::AZ0P97H
M&U#-E$R$MHN311&&$66BHV7+!L=:2/ZES..*:]VBIO#WT8)2[_)!<M918U$H
MB-J^2*WA!U&'I0DE4O5($,*K!86VLAC&%.85=0['&,G1(U*X5&OJ]6E,ILYO
MQR-.1(F*%QG.:M:KO+0%GOJYE=E![)2!D4:JFS+7%4U.9<+U>F-[_0_D)<W6
M9EP;&8W>R+85%D=7%58+YW%%U6R9E$'-FW(TC2NR,]9\58;O.AJ19]D&V;99
M]00>'ATFTXLDVB<:2TL];9H>+"?TL=-UM/"=)N;JB#+^*%;K76LMN_E)+AO]
MC(U>B/R;8'DXP5K)(IR)F<@/8.AR!+W)'31W"OV:N<;P#S)H\Y$TBYF7F45X
M/>4F!&-?.8CLG,2.V+B6;FF+-V/N,1P65&5/#4K"S'S2?*#>:,.U&H *Z<99
MPZ<RU%V08ZZ?(JN^J2H&9Z/5RQ0,M(2BU_PI,_M"=\D9QXI:WYW<P,_"T4EZ
MI7F:+<%,C9'MX4^<&A^2X?%?/QS\$(W@%$#!8-S?_#Q'<UQ^EN?P-_9H@/J\
M4C_K?_P"RB*II\#B</'X#27]+PV9A'>#15K,S6/XPWQW0-;6:@_?C>R_*./Y
M#^LL65K_AC'/FZZ8:-FXJ8O-KUNF:E !>W)0MP7(= 7.?_Y4)]MS0-<$Q_^C
MM>G_^*+3O*9%['IAF8#OS=J;7_@;&$03JFG=<S=R7YM:!Y:YX>N1<^#V/_W%
M"7"NX:"=O3O>X:TA;R<K=!]_V\H&N;W)QR(CXD'P#?$]()HW^J)CJJJ\+"BE
M3(&BRD!RYCSCA@RG+,ZQUZ<U!N[_^S]/7JPP ?Q/B?^#,AW^"V(_2/\^<G"0
M_D'Z!^G?2^GOUMZO#M]< 3"HZB8Q!4I<T&B^3R$4_IIU>=TD MO^^#=)G#K.
M%(=[R:5 .Q\+PX/ WUJF#0(_"/P@\'LJ\&\!W\23<K!K38KK,6PDF&T1N &*
M4O&FQX0+<ZAK?%[,30<11H>P8;2I%#U0S\TCV/\,X;=-=?P:(*^@#+:8H8,R
M",H@*(.^*P.GX&D556@%@R((Y"UFJB"0@T . KF7 GED)ZA1\4%=-HCL2E&3
MJ8JS>CK">CS=;2O]TH.(,!RX0@.^FC%VY-C4,_*X*8-@1G+=>1P_)LCT+>;+
M(-.#3 \RO9<RG02YS*!%.,8XS1H+6.]@5DDAW\  ]A2V>#(V>!4=89H@N;>8
M^X+D#I([2.Y>2NXTSXLK&]O..2#- )8BF+FJL:EL>8Q)>0:IO,6<%:1RD,I!
M*O=2*F,7/PXPYE#U.NE+@)D.6"L9UXPR4 TPL *&\R0=46&]# 6%W_\+X>TB
MA$=H2LY0ZJX<+&U/:1;(;03[K@!U/+LE4$=0:#=?2F'HH-)N/*)=4VKWL*V=
M5&O?^P9YQW<;NE]/VLW4WLV?N<5>OK:"\'5RJ28Q ;:W2T2QWPM!N98>R+Y3
M8#KP9V>Y".O84)L2A!>I_(%?41I<KYTQ'[=03P77*^BH7MR=;^QZ>;-&P8MJ
M")"-X7GJ,ATV@E-/19UZ2C:"UP2!O,5,%01R$,A!(/=2(!-,O]0,"6@6(4I@
ME&N:SF4B0;YTID039 ))[I3^:28UX*@\JC7R6GPMPMIJS"Q(]2WFS"#5@U0/
M4KV?4GTT3=65&:V(P$(XZLI4_E1QILR K'%:"\)"$,=;S%)!' =Q',1Q+\4Q
M+=<,ET(;VXXQ-,%M)QAM@0UX@ @6[*MRI-(K!GI#%$L9)0$_-<&,WF;>"W([
MR.T@MWLIMP5/QDR:K=8/%&#,&9ZL556-1MV$7S<E)QWC/,Z656WF699J3@G,
M B,NE*?,$U8209QO,4L&<1[$>1#GO13G&I[[JLB:F>J"U0Z2=XNY)TC>('F#
MY.VEY%45RL2TFNJ(--5UF*E]5)$W+;)$IBK!D_?,CT%*[Q2G!2D=I'20TKV4
MTC'-'5H9->H@!XP;&ML6!/ 6,U$0P$$ !P'<2P',91EB\?(,I"'B<=& -:[7
MH-^*;1S$\!:S4A##00P',=Q+,:Q'^\&7\V*6C@9F7+B,CFMG!4V%L[JB]D4"
MZ:+1<P,SP9MG)V,IQU M"QQ=2U&-O"Z++ CR+6;&(,B#( ^"O)>"7$<N9%($
M=ITT,HOWDUK:R?8D?U&V!QF\G7P49'"0P4$&]U(&IWD-(D^-ZH:19T'HXF!I
MW8F2I3K@;(QH^"F=Q#RI>1*G>55'#<XTWT0T;S:*G';N@F/=^RSR-S;,/M!%
MAO.XJ@=>P(?'A*<Y?(YF?H^RN*H(V 3.*HL758-3DO2A73=]? SZI5BD/"8\
M+1+2B<ZL<5G"S)G1K4?T5<H^1]<RTB+WHXL&7!Q+/MC)&*-7=5HWN%Q+S0$.
M LE@ W$#CVNH]71UFOVHJ 3@!:@+;(.^5#RAKB9Y,?P5F#\W4[U!N8-;-<*Y
M4^QO\6OHV&+X.EP4@H))X''P8C4> V-&!=?D#YLJS56%;:RF.M\X>?KQ9M8A
MSUD'VV)?D,W:K$>,]GS>)1RZ<-F$F89 :9>5$#HN'=V&-6_!=>\1/OJS&@%[
M7&$]U!C(C#YKDI:*YZMSBQB0)IW3\$;+BT1<8 =L'RZP;X'PIVOXST3A-08*
MI!D=8)WF#?U9O%W"=;# >C1Q0":\1S%\988TA7<#*\S26F;;>]< YX'IV6/[
MT>NFQ!?."D2^KA>%#J#:71#]ATKE^"T$Z&/053@9.[FL:X_K2-LM53:AK$.L
MIRW+Y<[ON7?A=4HWXJ4:J=D0Y/?QX2 Z.C@Z&# \^8W\-2D57DSL=<FC)_]H
M<QE+HG@R05"H&@? +7"\,]'_<XIW&CCHQ?ZS@W]H8A9-C3*$:OW<NI$O817X
M4 8D4""^G/4-HHL/_QW]>7&Z'\$AQ"(@L#L>9 ^[%]+9H]+2/-&VV@^+N$P8
MUTH6,"!QCL!7_CVB==%!V/SLE]RG[K?3H];=-*3%*&L,+)=L1Y?T\ !6+: '
M]!&%BM]*SYD>%N@S@#M&$*-E+NHF<2!K.#B:*EJ ,8'_]=]&C]'R.XK'XSB%
MVQM=3M,*3PD!,UE:TT(7 M<)#UC:@]7*8,SP,X1/DZBQ*A&JAB83EA3>PY]B
MP4Q [A0JP.G,YBKAO\X4L$J)6BZOBBQ-1!W6\2>%Z&76UC%K!CX=@M:A-:8Y
M:.(K?)*@E!'J65/&$W[ZO""=1YAF"/B/X<:RF,%V/O$'X,\)O@5V9-^U2$%(
M(RO,YL)@.L%O^&C<TH.X7Q3SQ,ZQ2XMH08IUJ'(U3FN#[^"(SFA[U>)?*DH*
M^+'6XV_H2N&AXJ'-@6G 'DEAF6@VY2OE:33;F&FO_MW0UP?1$C_EW%WIT":9
M43=EC@^BSP#Q0<@04]/%3]0<7UR00"IQ1H\QK>"N6&,13;2N8KF@PS:E.4F"
M7.']!%<'I#U(2AI(FB8DED9Q-364[R+\?@1/L2R#5BS:%+7B-LZ%8HH"P?'6
M"5:*BLL<KB.+6J2D,T=O8,U,DG#J,YC=E19CSE5E(YEYUGDM;T.++Y)IJSNQ
M;\8A?952%,+BU>U'GF-" [H5SH$222U[2-00W@L*6N ;4:X2)F.3D'5/TDG>
M;UX+*C-?:NYO6WAT4"A4<.X4*F0>(LNZ2Y2/N0SBF*2E)L,E?C$"V9\7T:2)
M@0% Z3(1*O"(5&=5*;_3/)=D.RBEAJ:HD"2< =F(=/;"(5G)T5AUT^;@B$SC
M2B5Z;?3FE>OHA!*V$=?Y^2UQG;^>&/I>VF!MX.R[KN)"EX;$GHN<-V1R4T7U
M6L86^]5C4<W%S1#6;%.:UBFW)2C,Z7#OQF!-NG&8H%6^)=4Z*222FM  YB3[
M2*IQ6(;+AV8\NV\TH@<B07WG -1:,U(KX9W.-5 [ZPPT(*/C._9+&9,YF8"%
M@[)2@]S7T[)H)E.>/0C+H;W;^E'X-'[?=L62W]3M/)Z<# Z>/1L<'#YMG=(Z
M]XZ2ZV-00K!);/5"/38@ #/X!KIF->S3C["Y9SN(FCQ#74I!#<)<,!+<#Q:
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M$\F8$1A,G2/D9+TL<:2$BD#@@T+9PW;*Z'T)5,CMAPZI-^K\_3E6JT:3LEC
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M:30%.5PBW E<XHG*[>VZI.-E\IZ>[UT.1,AA)@C,@H0Q6A'HACBEDMO*78G
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MY.B<3N$'TIM##5U_!&'\$]]<3VP;)4!@:\Y26BP$[BVYL<ZJO,$@[LII#2A
M$>/YT^I&^ 9UKI(Y^8(Y^?;I$OF1YCT"ZYP ZP067D67^;]-+D.BS)!N.[0<
MJ-C,.=3G2%@GM.7R(0E_\E9!D?RM*D])@?@B@X+C52#@5(Y#(>,)Q]4P-#.S
M[]#Q'3M&&(VC]8:?#-5!+D7534PKLRE/+\[>T_QQF9E#8_D('9)W?6J'0_'F
M9=RX?2O/57<4 U<M<?74BFVFQ?)/CDS&R\C>N,I!FV0V9J2'N-NRDE$QQ2 /
M86%2XU@-J[?OD$$6/,F,,#+IB=UV8HR%4C'5<!'@(WZ H@F_7?Z/ULN$M"NW
MKI(*LA5[@$;^RJ'414W36]S7@D"QKY:MP2L3\+C^AJ_I7>+'9']Z0*=WPL*'
MS\VS!AR52W@,-3ES#G2*>)5XNA2OL!/=94X];.,"##%%E#+LC1ZD = $L<LQ
M.H[_@H@#6ZE1_@=*L!Q+QF,T9A:"D64TU27A>KTKUW]LWXUY!BNWKLA:9=[B
MFC:^ZD*/J9H;P$B<:S-88T^;@V]=%S@E=W&=I@>8334XI_%GM"%^&V5[1Y9C
M!IMM ,E-S\ZR>%B4SM-I5NV9;2&-+D;3HJ"%O4/?GL#RX C=S^Q<3\/3;S=Q
MI<<JIY^X,Q<IHD&NA%--J!?_/)? ,$[@.K; N3P-$.>%5+5.LOF#NLM)G*=_
M:S>#X&DI#&5R0IBHR>E794PA*@UN.)!X+4/!TM@3ZSF*(T<U=#2:*Q/7HP8[
M3'&BA)'%:S,PFT0=.;J4+VF,^=E/LCA2JM?KI'-E4[;31:=883RKO KM/W.N
MKI;Y!U4SC#&/ SZAC#Y'M[)>H*O;,.5<<6B4@0()F K"*XWUOFH7D/]X>+)_
M$,&Y9,+ [M+@UXB/FM/ 1$(+Q*$/E#6@U<B >4Q1ID4R,+-E='Z!3+3W(/!!
MQ_*^J$7^\!G^G4K<I7F9.^>/O".XY#=&+V'=,_, ^>B!O6-8CJMX+*>3G+8X
M ;+RG_O-S8]ZO;JTUZM[K)VO'J]Q4N+XJSGWI5..[\?#HR?.U3/N3%HACC^#
M:_JC@A^EZ>-^<W''+GN]WI,7O5[>S>R14PX")3PXMV-5HF%ON:77F^OWZD2F
MD-*<UWQ?#_>?NIK2*&4*A44&GE 4K71,^7H9-?6C?N_\JM>K>\Q],KX@?;Y_
M; AC3I^\RSQW*FBX^B,K*JD'<FH<3*E/KS??;^$O!4K1FT'$D((#787$AZP+
MP#HKEWJ],\\NY0;-:ZW2A)F4<J#X#RPONHHS#5X*DN3I_C/-L7>" .V[)Z][
M]VAH)"HE/0&448U5#$X-XG%CKHM&+8@+[9WT>W\,AI18*./M(NAPWF#(:\Q#
M(#@T.IJF\ ?\U!C\9/F^.PQOJN(KRB+* ,V&9@>,FVRUHP\+!1LN6IFI$@N@
MTK]C,Z#5'Y=&%;!29UF8P02KKOG*'IVSH3CUCX?/]H^,0,-U_'A\XOSFD<WB
MH^P[=&1?IKTO($Z)WC^Y_S,6<C3.\[%)J! >>L01[6YVIG>#O_9BH*M9"<OL
M]M<![C2.T9@UO#X>VL%:]?G1_G-S%=P'7WACG3$A)6?L'!?Q& ?HM;[50V2%
M[U:UP,]P?H];@0YO'F*7<R[&-[-@)J$2FZZ[,K.DJZH +L'5F*IHZY6Z]1=<
MB=CY'?X\AH0H>^^.PEAJ$P)7 [) TM3K-]#]"JOYO"-WYG'31!A81*.<6;0.
M2#FGI2GG08=HUBR4H3I>G:2@G B67-*D&S@_AN)?\VH]@(;1WR64I2=ZH+>_
M,FS>'SC<G@>^8@804?))P36/>M;W@+#0<0 M 4)3PV_"J<N?MZ1A9[.&32<V
M3NN_6=%LI!U\W;.QKL@48FCLR5']O%&HO3OQNJ9KIK='=$V"X3]:V_Z/+SK/
M:WJ?KM?U":([D.CB%_X6CSZ!BP]7<$^V$C=U<8_;ZC :;_-ZY!ZP29_^<LO>
MJ]VZ0=[QK2%Q)SMT$Z!=Z2*?D1*Z5E4 AW@[X^(@N,%>J--Y9LKX68=*^IHC
MO%)'+#4$- _PAC:O(,3[QX)!B <A'H1X_X6X<<&-Q 8'I!COP?_A $GPX2-P
M<6,6T5( FZ^4G>:Z"K!=>>K(^2#)MY,/@R0/DCQ(\OY+<FV.8RP$&TOV;#\2
M=:-T-:,4G88Z!K52&VQQFDHP;NJTE< 3.6_FM)?P .\@Y[>.2X.<#W(^R/G^
MRWG,VQ3<%T#5(S-8+F<AJ<3^_?^^>;EW^"*"CR9JAAUVNI.NBJJL6"!8AJWF
M3W,!,_%KQH,4WU8>#%(\2/$@Q?LOQ77S<+LU)S8=0&S$SXLJI6QTL+%W@+>"
M= [2.4CG+9+.)N+MR&7!R*&(^*O+BVC<4"NOAJ[ 2K'B2I4"KA,BWUO+:T%:
M!VD=I'7_I;5;URAA;%=>K];K!H&\G>P4!'(0R$$@]U\@"^PL(2SG>.P'+W[)
MTA'6?@LJ^!IX@UJ-ICFE&H.0WE86"T(Z".D@I/LOI&<X  #^_X#AR!BVD((8
M(^[6Z8:6P=;.<9&E19#/V\E=03X'^1SD<__ELZI01*;8=>XT*R-,>X.P[@P#
MQL!C%AJ,T0*S932:Q@1ECWL$J>TW5"-^89HH]['_;K"_D@;"%#08M<M$QQ90
MKB9!8,5X&15#FKM:J@GV 2,*H 9'#-IA.WD[:(>@'8)VZ+]VJ)3ZU"5WI4^_
M6WY3([X%QT U4<SFL&'56?\7Q/?6,5\0WT%\!_'=?_'M&O=5G"%6"1S2)V[7
M(<07Q*%)AXV@$(_+&'YN1@1 1% N%KU(N>+^]D8ZOBY(^JWCTR#I@Z0/DK[_
MDAY$G\4+0XQW.W@3Y?S,#!KU!I)6RZI6,TZ*PI<KQ+O*7+ Q\TO4!C(APDPE
MQEE<VOQO ^ )B-TJ_)T,4O1F^[2>353A\:8(RZ>!S.P 48$TV[_E7.X;Q_H@
MM_W\9/_9L3_59^]H__GA5QGKXW#V5DZ7>/9-IDNLV^7#':'TEV)HNKRH5]$K
MR9 S&)8-3R[&.X?3>#,TQV[PO=MW=;WE9B:-KP6CC-Z,\8TW/ (M1P%A7%.2
MD12T6;H4W"X8=P@/!-J#TZBFZ9P@(BWHX"K0H$$!=, MG?&#.O5( XY7WX0A
M;8L@JJ631X+K;.EU,X_:"W;J!^^ Z7C[^66K//_ ;UI[4A?-N;]2^$^^@0J!
MT2TPI$LQ#2G94E]2)^J@6^)<"5*Q35DU#)U@QK3HR6?[T9]T?>'N3G'TO&(%
MB??$B@"7OSO%P0#A)Q$KL\5M; VH]K +C:,6>[.:X*8B2&:-=W:L, $$O)ZH
M8:V-"OK%!+L/<IX)R@=!TY6X\$HFU7BFA)YR13+)F=X$GY*J+3XE>4(*[!##
M#2EIS)@[2<P ?Z+;B5)C"(>EAY7$.)>]121JEG!$"YTQO\:9BU+X+P/O5N5$
M?YXM-XZO8,'T&E4BL"L#E<)^O&6Q/!S':6:7HS%(.U;AO#_F[3NO'6C?FN!J
M\2N6_G"*"0BV)2+L A]0%9S"D6HYSW]5*V)^4RCB#@E=E/PR_CMR,8/PVLEE
M(/P-$?%@L#2/;;BU8]ZW$Z#Z-S6*FTKI1OB\@3,M<()<6GW2:GBD2E2'E.9L
M"_0.@]E,W6ERS<;S$B>6,0!NC42=T*G.P'.@@[?C9(V:HWB,HBGBZ=C(+^=J
M:'QK)+<4Y?A8U_O1JRM$6AGK]>AO=IL@ACOY"@)[6>SL3%US*58^RU?/W7_5
M5*OKPUL8N^)U&%=I-6!\&%G+T'V*J=AOB3T<*2G^2X9D8+KAW*&B'+&E8"\5
MWG:^5/Y3=HNM.V&4:4KPY!I,>LUB?MX?1:Y[6#C$N N2F7X)@AH=10^6N1L#
MN@9W$0=MPP:F*ZJ )SCSD'B<$: G2A'/5%4SFVN-!P]&1D'K5,FXJ459H/8B
MZ8L^:Y/AO9K"/>>3B*^ <XFI]-+M++:J@%.ED?>Y5;G[T6]J6>CI]O,BE4MN
M38HN5:4?OE9?:Y"-$0Y39;4'6P-6[9<AB.]XOK$O*TP\+++D"Z_#G46ZML7^
MI+&TT;F9S*EA3J[9Z-,;-]JSFW[IPK<LBC)+%EBDHX%<",'%#KQU35]Q/J8J
MSFH6""#(\P*_-)J"':3 =.(;#A<P!M-QQ'>?/X0*PP:EV'42P:O/WQ71%"2C
MRT]KQ+FKY*S)7:')=3@*VYJA^-NFGM*D8)X6P: U.&M:3>BI;$?%GU1.^.WX
M*VRZU5$ITCQZ!FX%AQ G-(A63LNU9G&:DG;\9D62CI?X$YPV_1>)0!5.,L<$
MCG"Y%]=[4]![9IH)9B8JECIPW(AF2<=E3@/$J*RQ:.H*:<3VFID?B4^C>;2,
MU5,I.]MNWM3VH?0(V.-LGA5+18/K0>FQN"O*3[1@G(# 0E^-&D*"*%"D*PV;
M/$,77C^A<I4PG%5:TH/@C;,"AP/N1Y<%XGDZ"QKBQ,$5O2R>$WH$#CY%Q]Q#
M'C$+!J64AYDYL>[L8Q>>OU5HX,889-0&SH: 98S2.=YYW!Z% \IF;AB#AWS0
M^EK3;?60\?WHKVF:*6TP^<>RL@A]&#AXL%S$!'O'>XI'- "-1M@"5WO>&ZH0
MB[=4HOW)*T0UEH#2'.%>"@9!E9^8\[7Y"'Y!3L8-:*N9'3GBKPZGRB/]8PP7
M#:[Y)"_9'TE1@";+BI',"L6S0!PH=$2560W\:;BD)5G0*&;6+![1I)>%INL*
M=E3[)(&=IZ P(AP;[/$#\W;F\'2-(+-P 9$;>;0,;G F\[RCPY.]!,ZQ4MEX
M[]]-C!.Y\+"&:HPN43PGY<W>)QV09QG9D=+:8I9))^9B,>:XG4'2R=&P01P)
M@G.M,8ID6)"GA238WQ\13&[)-SG.B=97:=+(,R)[!FP5>S.N>; W3ZE =G>7
MWKZ/>MJGF=^-EMB4F*$DTF8BAN$SK E&-#U:U?A8])KQ/LAVK'RPGB*P=5%)
M?AF9X2HM&['+R+.J#+/O8W#1DV).*,]#(0,J4PS:[H1,2#3R,I (*I%)H^2U
MI;*7L6=[==%E3IY>!T]Z\\T'781U)J NR)X<HA4[B84]](W0<4)_(K<>8C*J
M11OJR3O:%1R#)BTKM##VIB"/<A!M>C:9QN5LH7$"Y<ZFH'U)O9,P)H<>5A"=
MYA)*,#)/0L8Z1+ J*Y@S\7N&6[4 ]@N#:>MTZ^((S?&20V@@%^!@%9D(R-!N
M1&P@X3C2GZT FK4?@-!\8J!KICC+-4/.JL4#83.Y$ZA.!CI=*S:_8#D#;V 4
MAHTX$>:X^\+L>&NF8-7!:TW$P!6JL8U,XJM1.KJI.^/(*!K2I.6#:[5J\%1C
MZ[#E(Q<^)@G!?!RE]< =:45CJ,#G:3@J=!6/1CHX: <;X>?YY3)5$I<H]F;E
MVTUNK@^_I<U&?=XY*8]L((8:_LNS]%+/]A/;<>=FMS__+MFU>_/V;JYC<%W!
MFQ=XQW,^ ^$&?Q8>/;>7^[VYW%_D[O5GI[_3>-%SS@S<*D+PM-\NK([WH#7O
M)@]-NL,$+-T*93]O*JH.K;Q**?),6%23U8$:P(V?2]7"-?E0DN?.1$!QZU!Z
M=R=&3?CTA@2O7J@L[B^EPS\Z1IR.!Q3YI8P$*;^XUKI0QYS,._13S5C@U:P
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M.CX<1#A@E+Z.X_.BA2I5].,AL&8$^\G2(J>__0@2Z4C_9H!!Y+D:U2F\;SF
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MO()*38@F3E<MYPDDA<W=;_A)*4S+MO&A#*B(9T9C2YK@\/\0I7WPMT"90,;
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M*?&R^<&4*F:J9E@>C9J]4^75=Y+)D/3'I#S_RK=Q3\=\IS7E")]6_G1L8.%
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M>4:T.U*2,77Q[<<@]%RA<7G!L)H9J79IA3Z0C-^R\!XO_XSJN>\[%U(YEXV
M-#-+ZU/]I+>]R,:N3H+(A-HHLK'#K T"8VVT.($Q@3&!\=; >&9>VR9@O"3N
MD0?CUDE+GXY%!,:4EG%(%/E+W(HY->N)A=8CDS$-;@1QQ"/+Q]W;8H"#DCCT
ML:G>ZK2(;*I#IB495KNO25ED3,WTFTZ4=5_JZNMX/&#AS5 85C>9PMY2P*.^
M[$3I4[-NMNJ4WG$8S*=MXPQ";6TT/:'V\="24'M_J#W3K7D'J+TD,K(<M1N
MVLTS0NTUF4\R6,)?RUCQ+7IU_!Q9L#OPJ>,^K;?XPEK_/;^VYB0J/'*!A-L,
M&\>\+N)S'R3VP8W@3O:&,KW&+MXS9EBV'8PGEO\"[ =_B1@_67F-N"*Q.[-K
M7KR;]3=FE2^U4[6@49BL: *ZIC8(F?6]9@UA01\M[]EZ 5WU,URW _*JY0P"
MSUF;NF77?>/;\+Z^Y1D/(U"N$Q9'KLU-X\JW5Z>P]LL4Z')^<WU_\_7JHO]P
M>?'M_@'^\_OE]</]M_/^_7]_^_+UYJ_[=Y_. U\D=%J '\9]!/_!CD\<IW:>
M6WQD?/&"9WX\^_+IO>L;T2B(.2 H_S"]L%++6.VMIS2ETL-"+2LD$T!L,\]#
MK *UD_ZN4%#\7GC1CU8<!;\H' 0,\JP)9Q^3'WXQ%%;6ZZKA_DS<_(W.-CK=
MDWKI1@0EF.UUP#Y<#V!K"7][; PQ(_V+[*?>*J"X53K F\"R@1"==QH<4K?J
M)ZU7")5LVAL(C1YD^W_,"KEQ">_E&!?,9N@:&:V&N??CV[=P-/0@P>HM 2L+
M,+H2BJ!&&SJD4-/4 6H:K9->9_U*KVIC$9Z!$>Y45YV5DA+2=Z3O#I2N>'I
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M @@""'WHH*6($$ 0]U>7# 0099)-NH5N,+D\D8=@0;[]]"EV(>^DV+3E+WF
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MU1>$EL3]U24#H26Y4_K004L1(8 @[J\N&0@@RKA39[MRI\@).FQ6HHD+^Z:
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MWW-KZTRBPA-W?]><4K#ABRQ\72O,?8[87 Q!N?:&:F -TMPS9EBV#8:TY;\
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M5.I1ID W5$7M]$-F3QT/V%$@4AYE $,/9M!/*$F/ZG0HW1%7P\PXE90T%ER
M?@'4&V,-%"6*6>B'<+SMJ+G=S*<Z"G\G6#>?4^_D%['!)S?I.U!1K(!"R-+
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MS4&>SZT<>(9,4+(H_'7=;&_ "R^8$QA_@!+'C6\T2(S ^M[X#.J?Z^/?QD7
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M]TZIJ(.7[ ZP?:YJM]8$/COH[,GG6K& 8V8!E>BKZ+Z4CM=*ZI77\=IY_OX
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M_RQTPH9Q"=^ 0,"[5=,/9, A#5^+IL2*LH1=!KMR&?XI$<!9 ._FTO3"K0E
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M3!?TQYF$])KQ=O1./&#$,TSEWP'>^<S@/<'[@3DN,L@+/_@-:X]*"/96OPM
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MKZ8@>1Q8#DAQAK4]]'26,HC /DD""V.@G'"*_9."]5M@E#1M<U%4E,JX3S[
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MB^\^$JI<TE9A0_H,BG^=:TI...?2(:<^_+UQ"[@). MCX,DAM^) ,,U')YH
MDP'^@9_,Q90#Q38E[\_B4](!$)QO.=24.]-?EV$NUY$@;(F7<T.$*6:/V FS
M@,RNIU]>7W4RMR+!91QD#Z'A@>0)C!D#CF&Q<)*L$-)-I"=\0[(L(A"/E@,,
MSMB\X"<D:@,.(. UT6Z9>4OW!RC_#P]\':O+^VSG)TDD?;:39M<\> #QLR15
MT'5]B_YU-;X!^73O 39M,</@W ^C<).6V^N:9R?"USZ+TIW_95M>])=I#4?=
M4=NLV^U.N][A@V%],!ZTZ@/&A[U!N]L:#T>DB2^HI/E9-QMT1R+"7S^)1FFM
M"Y3]0K-^+NJBXQN<>1*H(\U 6-1'P%)^U-D83O2>N8]L'KXQ?B7BT &AD8?9
M%T"VN^VN->IVZZP'D.[8/;,^Z/1L ')OQ.W^L-L;M=^L6FAK;!WJ2!K1]5ZP
M>$OO>L]%UWN0F^J2D*P%>6KPOV/2FI$7A\0=1C@C 90:/XC2UNJ@HT1BR+F8
M?P'"6*HT2T8";3G?9Z^VUXGU2>_DYT=6?=)?LP-BP4#/JL%AZ?JDMX:9]@Q5
M_\*J3WK5)_UU><3K]TDOF2PM*Z(JJ5H>1)2O;?!3&T"?G-BM^J2__C5Z>8!7
M3=(K;G>:W*YJDEY*-?OUBJ51[3[>E)4;'H)=;4TH ",3 ]"76K[J$%*RCQ<1
M92VMJAJZ9O'TC_*AJ+69H#_M',F-)I)GFL+D1BW+F"ZWBT.^<G[S^A'*EQ[F
M*]VJL-57&2C6!RHKMGSFV9]3IBS?L'RT<MHEIIZVB6F_^=CM=*K^KF6CR/)R
M_ KFE92MI&PE95]"RN82K4HG95?T8OO_[;UY<]LXMO_]"I[W@'+?.[_DEB2+
MU)Y,I\JQG6YW)[:O[>Z>^<L%D9#%&XK4<+'C?O7/ 4AMEFQ+UD*(_$Y-I2V)
M"X #G.6# V#6RIHU'$VB78_4997]!J;Q\B267Y*D:84=N#UP/">,9-[6_9O/
M9\O%7)XV\M%UN=]R23$%UW!ZB&K685I+7/"99GRF3H8^4ZJXR64ZFE';*[*)
M9+77SP?.#VK$>&#[4?K[M$-EE.A>;7:W74H#35L':"%]90-!P')#5+#<N[7<
MS>H>6.[E>4>K"N.\%QU5ESR+ER"([<=R3919@:G>#2)\ 7A %AKAVE4S^&:$
M5TB_:G]GCS8B2OA<,S[7W$GW:_M<FZ(;C88^Q^X^YT ]:PH*I5&TL-0PTUD+
M F8:9AIF>CMFVMR"F5X:932J^J1N[(LE3CK/<(GE(;L@&?/[;,YL8K2G.VUF
M,WB/(C;:=R"I3LTH,>GK)EM;1G[$W=E=?"Q?;N0F7)[N'DA/EWOJR0VYDMU[
MY :!CR*:WN9';D7Y7ZOKB;D3K)?:C^M\5"!U2F=X(ZLP_;O<D^O<C_XMHLEN
M76K/HHMDH[]7HH$Y[=(8:Y?FP:=:93[]FI%@W=$>A+)5$_D)NSS:PG"T6Z/<
M,BW=XC"2^^0]V:7Q28L^MZ59O;GXD-/NZX><=I\><IJVR<5D?\B_TL(?)66_
M&FV">.R/]T"\$<' 7"VHF@JCY($V'^PXD$<Y'GPB'?ATW[+DD,?*:GOUM9\9
M[-,+XZ9&TNH[]ZTPZ(Z3K655IV,R,S&X3_?"^A)'<2#861C&W+/$RQO7S>4&
M3#:N4X_^_'CL\G CV\\MW]!-W33<\=0^OBR8;NQ>TMA.VMAJ6U'L(Y;M/F+-
M5^<CL8]8D;(DYW2T)HN7M=M'K%:MU):<R2_,$G_LJ*7):,EZ1RWMK(JN@H)]
MT4<0VNTQT\8>,ROO,8,=M;(>1IGJ,VRJ!857+(6'3;6T]+2SVE0K\;SS.[$]
M0Q<?N 3J4:C?9#=VU-(U5:10:2"ZRLE<SM0CS^.9^=L?W<!UU!F%X<P$;F,T
M0^5[5O0AT95J:NJO5%..)K^^^$$R]36:^5IU$G;93,Q&J5K;W#I3;-V1<\4
MNPF["3G!;N[8;C:W8S=?2XULUPV81MVZCRZ[6B'&GSHU-E190^H04GOZ\&3]
M%OC#@\EH"XR"*RD]Q) X*/ _5O0_6L_Y'VDZ\)E2?D>>/947O+,0WBR9YN86
M4T(%Y%P%P "B]Q=7##" ;S* [:T;P,6Q^)*["70:;1A W;J9+I/Q&\AYS9-8
M9J)W?L\=5RVDD0N QBM_J/5%P,1_8B=Z7'FASQZU1=)%DW_9T*5;--R1JH!]
M5%>^CXT\]T94LU,Q:XD+SN"L,SBWSG;*'SSF0[E46"V>?M.L3/K,2U+&Y_02
MM8NG=#I/E3$Z\V2&J',OY.]3&VZ_/(_3J6W./=S6%A?8K3-[;0(CK(\L8(1S
M("H8X6T9X=;<=MI9&^'7DBGJG0:,\%[T1ETR+%X"-]C_48/5?)"%?H@9>W'F
M199+)I-B0\XM>%=S&V=OTKM:!"S.SK\L.=O5+AD=?=(]]F7'SB*J%IAL?60!
MDUT$6<)D9V>RYS;1WJS)GL<;RYOL6LGLS&^#"Y.]WYML3^W F\%&J//[?#^[
M,:[Q)'OKXL^S$Z-SR:D( \<Z\NSCHZO3ZR,K.G%"R_5#&A*;V".7I:43]E$T
M*<JM;7G1;:,I:@;O\'+-JO%RW3*[Y4ZO5RW7>+=5K=5,PVQ9!^EFKZ.&372=
M[$/IGJQOW #VM4U?C>JSN[Y.\Z[DXF0[W_D1LG" R![0'B[2U-/=^+GM4U;0
MQ&]6NW*_H5&A-2E3N_+/0UFLY_2EE,GF&_MMI5UI+,\T]EBWJR+0CTF=U5@M
M&QTV&JUJ@94:KXP&[+A)E)::U5'/-$ES89/,[U"MC2MP1'_>"Y?),SL=C_D]
MTBN![_%[)XA#]N[ZZ*I\[/]9-M\SB\<AC77&62CN12#WAP^'3L C/WADMA,*
M'@KV[A\_M4VS^G'4LNJC\?%]26TA3\;;):-GTS/N7+_+738<-7SW4>U5_Y<?
MN#;[57 WZK.+X(Y[SM_)00!4N&\\L/KJN( *&XNN3\\=RHVV/;ES?1AW98)L
MY,AGD\&E)_>3ATG)"M*9OGR;U>>N*[P[:FGYO=R*N]<3Y#A0_=*+1%AB/<<C
MST4^BV3Z743)U5W9#B(,F3\4 4_6YW'E0R3;[<LJ5-B9W&K+4S_3_?*^/RK7
M%78G=]WWY(;W\MLXZON!$]'+9/V< :DX68M W*FG]OF]8!'_+CR6>#7J,NK6
MHD>"C>0^_:'K/ZC7AM0(W)8"'#5-B2ZVW%@J:)5[*/]+'>!1_E?VBU!>G,J+
M&NVQS*-RWQ^(5&9,*7)J!5EV:N"(S)YJH'']>[&7EDJN271L(1](?4T^P&A]
MI/+3TV1+J*Y"UXGDF =Y* #W'A/1Q='DX>I15+OTW 7I)LF^*0M K?I=%3SP
M!\R)Y&$%PHKE-!F]M.=8U((/#HEY(!\\>D X,I+R3GJS$ZCGT L'?B3<QPK[
MJ^^0E9LN%/4%*PZD9^8^/KF=6:[C.>1W4L&H4X3RV 19!Y7/^< ?I7!",E74
M':S IP:2]TBISU8[.69!_LJC23\F\=$(2]I@P.6(HB]D&63FJ#?^E/21Y+0,
MTA14H"2Y-*2FELTOF^9),2N,?'%Z*Z=6(0D\?V52^.EN0]V3!G5Z6H[J>]3)
MPE0!C$M#/Z7#=S2<2TG7';IDLFWFD3(;TDB@-F7""\@AD/V?'D?]]VF3DOC[
M9#2HUB55K_2^,.T+[K@/4)<K^SW2>U2T]'6.K. @402<&?6R3>T8"K=7_D_,
MY4)VV5A=08\5C ^'/A5 7DT-=$1N3#)2W<<988V[<B*T=+3+@J42D.6AQNPY
M02A5?+D?4P]DMA^F/\A6OKJX,J15*=_(N\A]43WEN$_:1?6?KJ !;@N7/PI2
M'#=3787ZGQQ74F7*]R7-'4X/<ME@\B=. WR0+A96JBZDPG'9%^,P.=&#.IB,
M.!*YTV4R=%9BG6BY<'3*<_(,6Y *HQJJMW/5Z0)YG C]X_E,/EWU&FY3;PBG
M2N<M;$$:Y;&;%'Y:<7K3!1A2NREMSY\[*"9IGU[LNB222'8CJEIRB(EZZ7@X
MC0S+@T.7OCZ8GI9VK.26*38U9])_2NGKQ%#(E=K>Z- 'FP:,ZP]5MU=-*071
M)R-.A2 E*H*(C._TP*->P=-7RS?+$>1X233LJ/:E9T@M0=(*[H0L #U$GHLR
M:8'1\2\CRY'8$3GD2*DI6T^=F(8S#<0HZ?-A;%G*K@6LQQU7%IS>?<\M\OF3
M]PX#_R[@@S"Y/GFYS&A/BYBZ%^&L%:*Z/-#(E?]5=XV,<-KZ]%BI8-Q2:O;D
M7S-VTYFQI*DEKJ1IY<_DSZM#6*K[YHQ-64HIJ(4=.E5/(Q]5^54AN>I*/]--
M+G^039KZ2JUTU*2M=3-]*TEFX$LM)<<U/95ZSUCY"]E??DAYWSNAZC[J#"9E
M$WSZFTR_K0+$(7^4"EU=;9&>(NU2HN[>(\4A.SMUA-08!^.A%?J)LB'[3;[/
MHWR$TCDD=A&-!AF]R)4FE"RB.W(!96>P>! \2FJ3GF)$=PU\VR$/(!V9:;O)
M1ZF.0XJ0RF/'">ER26-'4V,X$E8_L3_D]DJM,'X&U8>&,7WE)"\?"#*&=J+[
MR9RX]$K9Y /91$IGRL:B,E&%WOWOV>7[Q&]*/;R_4P5^>7G)WH7DV9R3_\$:
M[Q?*A6R"/:-@)P-ED:8B@4F+/B.NL84R3&H>+^J3 :/N8S^G5--1](2[++&'
MK!IGYJOC; 1BG@R='5&G+V732&O8#T95&O([4>Z2_OM>YCVJT0?ND@L7'K!#
MA7JFV<\,[%F1L*S D>82O\^49&_XCQV0HTY2+UZSA=%N&&7>J/6H7D:[W#$L
MDQ20U:[6J-*6:.63'!E+T@P]8-&N2M$9T2$M2K,&JUI)O#O 4\G89C2X1?@2
M9WI6733F4E0GY[&=)C#C7HPUR!79$GG^(/FK;F+0;N1+-J%.UD5AF<*O8*9-
MI+NR,/@;M:>RLN2>B"0 $*2OTK I5AAL_+,NA[MM;P+G_\-1<3@J3KO,&YQL
M@:/B]D!L_Y9'RK)3&9(]-08YKC4.R--$1^" O#T1%*RJ/H+ >5%[+U<<D)?]
M,,(!>?LB*2B\O9<K#LC3U-/& 7G; 5-?4B0[F105.!]OO^@@SOG9E9S^2S\1
MX8B?)>3V[H7U6T[HUTVC]<?UR<SRK=JSN06SLX+CKT]_#(47BL_"$STG.HI2
MQ7H]FNJ:F5E<;?;PR18VJLN5EU[KU31:VFQT@\V(TQ[Y7C\)P,;"QFH@)]C8
M_93;&VQL/3L;:W12&_O,-G$KV=A6R6AU8&-UZY'OU^<*.)3OK8TOQZ28H0II
MMGIOG 7638:Q?MMFP!/">23%%0..)'J3,]-8TIE1BO'(L[_*)5SC:^3F,;M"
M D;),&K:;/\"?; N$H AS)D&+EC'UU4,,(1O,H3-;1K"9>/VJ<-6FCB+3[MN
MM8'0'%/^;VW\2T%_>&I#D4@,,-N_7_8.>##G8H#;\2:WHS6SJ>0S/L=8]9U)
MS;>1D'OB:33U.5 &@QSS[%"K1>[XNHH!UNW%W<2?,6[M#1NWU\+HR>D>K<V1
M8HSMG!V(5MP0^LPK#P/?2K<[%&KKN&0#R/&VA?HQ)C@>0'O%%0,<#RF;MFF8
M&@H'8T0+,<!"H/<75PRP$&\)33O+A*9GWF7B+E^EWO*19Y],?.5U8M4E5T'5
M&OJ<> 5-@.7?FDC@ZIGH-=V:/-D]G)[RP ,;,\79CP\]FKWP:DH/,<!A><M,
M<7MN'^AGG!;ZXC@YH&&D)=>:,!X[(XTJ)HJUZT>8*(96+63'UU4,,&YO,F[&
M=HS;TA/&]>;FXFR,<7W2K3%7_-;&OY"GA:G%S_KQ)K@8P'S%%0-<C#< _[:Y
MI(>A]-Z1_7]QF!P:NYG@V32;X/BZ=2)=!SC,&WI_<<4 \_86\[;LQI\KF;>E
MPV=S@XN(,,!S-DV]@<. \B26XS[W[N0>8[+YTX.'N3P_DGN6R(HY:7$HD#8B
MTA4N+W>Z7L&5G!ZBFMU\=2UQP=.9\726W7XUT;-GWHGHB2 0-EUP%(8B"O\<
MJ=VCD=9=)\9?*I&O4:JV])E@6$J;3&MZ:!08X@+* H8X!Z*"(=Z6(5YVZ]!-
M&>)-9-372X:ASY[G,,3[L%[\)7YA^W'7%<RL%,<F7P;^O1-*%4&7;N0 MFV<
M %I<^>C*]5<_TW-&>(5TJMY\JLRVIV=V(\I<.UP9KVI_SO=X5F,6:N#I=Z0U
M#)INFA &#08-!@T&;47A) (8M?]+HMI%+'T8<6H=^M9V[C^-P,AY/!"!8ZW6
M&#-U_V]-#,9,?2;PRFS,+3BYMOK"CEUQT9OC5'*W?X=W'=>)'!'>R :[H=)\
M=GWK^VI31R*T^%#J@2 6"_N:;$QSN$@O3#=OO=*H9]K"US2DG9YC<;GDWA\,
M?;E_8RA/28OZ@AW3-]Q[5/J@]3%4!ZC9::-*4L"X:E9&PY#^9#U?XK^0O7,\
MNMV/0^[9X?L/4GY[WP&I G)@254HNTVJFGX^J%*_$:XKE0^IL?'G5*VISS/5
M_L#CR/^8*C92*BX?AN+#Z(^/+%%^K6J:-SI'R':D?==*\IDRCA;]*H)-6$<]
MNH%F0<3N9A*GF[3KN_:S!K&]C$'<J""H)%1MDD3S0 ,WM%:MU):<I]K!J-%#
M;"?"$H.N"%C-*&7N5>["6]2CV9>?=RFL5=%54+ O^@AB;%],'>R+47L3YBBV
M 9*!&PQ/@?79FX8)%!X4WI[*5>960>%IZ&EC(]'M()J3>2SY0;\<5BP(SSC+
M^UGK4:C)6UWEM.0,;M%G9_447N$79>LA!I@8F!C("28FC\(KO(G)W=Z91JW2
MTEL(YR)B_E $/*(F8*X?AILYE *[CNTE7(9RTCT!N-BF>_75O\VG"91S:9,7
M(_7WE;3?\;3R>R5I\LVK>XU6J=TPL1.9;KU+5]T+DX?>#Y,'D[>DR6MMR^2M
ML:&%T2X9U39,GFZ]JP!3N_H'X3@F4F?I !="#/!1-NRCM%_U4<9':,WX)TN>
M%?EV/Z74V6!DCL&?\\$/TX?>7UPQP/2]Q?1UMFGZU@G12_7ZYDY_PN#7+$+'
M-/D:0CBRK" 6-A,_AL(+L]M"$IZ(9LU>>&6DAQC@B;S!$^E4E_%$1M^=)JI/
M>B'!O9";#2FE2#Y&JARG]AYZ0W0^\4-JS1;F"73K7+H.?)@]]/[BB@%F[RUF
M;VY/O9V8O5?/IC0V=_(2!KYFP3>FQ]<0PC$?.A$U\]\4@ ?/3I7[882Y\>S'
MAQ[-7G@UI8<8X)^\Q3\Q7_5/SKS+P+=$.)X3(+?D9*(,MS8Y;I0Z[<T%YQC^
M.1_^,'[H_<45 XS?6XQ?;:O&;XWI\5:IV=Y< CM&OV81N@9; .<L;+^(^B(H
MR5,5=-HJ<XLBV;N1H@M2Q"'5>R(J'%*]+;>G_OJ:/:E.UYM8[]2TF6' D=+Z
MCG^837UD ;.9 U'!;&[+;#8V8#9?FY@WZC";^]%_"C!;K[D$;OR(NXL.4=2/
MDV%R CO)0DY+^BS8279##LOKV]&=BZW-W]?,4J-A8 Y#MVZDJPZ B82)A)Q@
M(G=K(E_?ONXU$[G&++_9*C4Z'9A(W;I14:?Y-1?+G]R-N1K7W'7]!^Y9 K,6
M.@A&5Q2.68N]$15F+9:3W[O579S7=[\;*]:CD5[=)A2H5S'#L1=][3VLJPYB
MT%5EP[KNC:A@7;=F75_?8&]%Z[HF3]C@KGJPKCNSKD@=V"=%C4F0G#4[)D'V
M0TZ8!-G")$BC^OK6?%/[#KTM96!Z73\F/'3K,KJ.=YA#F$/(">9PM^;P]2W[
M5C"'KR7\-S:7[P]SF+/Y_^+&YR?32?WN9+1]T(^MPD?!WJ#%%0/V'=)7-A@B
M6H@!!@*]O[AB@('05S:%'R+93+MB][:Y,\GEDYC?8W$HDC7<63$0I)[M _A$
MZMG>B JI9UM*/6M4QUNW^YX534/J*3RM!'?1^R,4BESG9>86J65;2=R&]2R"
M2H;UW!M1P7INS7K6-FP]]VBB%]9SRXG96/B][8W>IN:$L4I-!QGIRSA?S8^"
M-[0GLEPRWPWNTA;<I6?WC#_S+'\@9OTF73 #5K!IB1E@>8N@K6%Y\R-+6-[L
M+.^SV\ZO;'EWB"A@>35'%-M,8K#]N.L*9E:*8X3/1:333O0O>$@%%(ZN=']U
MBSHCO$)Z2/^EGQC?YAR]392Y=H[^\5/;-,S,!NIS/L>S&K-0 R];)0J#IH\L
M8-!@T&#08- V)IQ$ */V?TE4NU@-<!AQ:AWZUG;N/XV R'D\$(%CK=88,W7_
M;ST,QM(5,)]4H%YIU#.MPV<>4FSM>RSJ"W;L#X;<>U0#K/4Q9'TGC/S@4:XA
M\(<BX!$-!>;Z%(2'I>D;F!.RV),"9I$O69GEQC;]W><1<R+YZ\ /!'.=[\)]
ME%][5( H^5T^IBL\T7/46@4G"A>%_.S!<5VZC@6"QOG?PJZP(\NB\4<E<A]G
M"]/G(1L&_KUCTR,XZ\5TY_W\+O=R]\=G7T>/H,*<"$L,NB)(!%TS2DQ.M#'N
MV4QROTKR??+O$=U$I0MC5]5#%NB;".X$O<-35\\6,A"R]/3216^G^_]K=:0Y
M=S#5_!Z93_?<."91W(DS[VA &O*U/.:J4346SS0VQKRS>?#)J%7FYQH9]6U7
M5H.4H=5GI!B57&37ZE$Y6/>16F^!D"KLAAKM#8W1FDE$6[8ESD6TNZ;P%M,M
M9OMJ=#CI*.H),C+<5;TNC'@DU(VSXY%9/ @>J4,_\, .U:6CVZA+"A[(-O=D
M9[L7KC\<D.IA%KV6QMSLG6I(2NF(,*(J1;)D/A,_A@Y]1T:4NO,9M4O@T9.O
MZ&%>++LTE?):J-J%K-8VU:MJ[9H<18O'1&4EI6D\5?N9:\VCZ!G=\%03V<N)
M[]WYQ=?W3T1!#<:'I,=^*#G04'G#*)C;I?YB]-ZO]-KCZ?>]T./3F\<S(T=Q
MU/<#)WH\^N&$HU]/Z#?J,]:Q'#[!XS?5.$N,D6;GI3$B6^T-]9[;/WA[];Z6
M,CWR[*\^5>FW.'!"VU'%7+H%ZJU*:ZX%DFZ5-D-)#J*A'&$T?!\K["(92Z.N
M-=^A:"SPY[OHZ@UJ5&?4Z?.M>>Y[ITI97/J!?'16O:I>J]2?[U6IADW46DEU
M,MF>@1APQY-M^ :=FSHHI+.2Y\K+Z.]_SGBZTTUJ+-FDJCV5\?HW*?+M->BL
M3?MD5FNUIWZZ:H_G:V1F4J-E!N!<W<S.T[K-CK$2C0E7A-*1%/>.'X>D?^/(
M&;F>RZE_ZI?^,S9@-:N\ 5-@U%[=?XW^.%9OGQ'655K2K$:R49F?/U_3/!C/
MIMWMJ"W6MQG5ROP)=^P9:W$S92I6ZW<KZ[3&<\L_EFG5[!1=?4[1O33Z97LN
M-8K#64-387ON]5[&01C35S(D6#X*D/;5B^E*N0U!&@4\!0T+K*N\^]GVE='2
MPAX[X(^2$KC.P)&QBY-P#5E$"FN8%0]BE\MQP2P5[\D+_ =/!&'?&<K"*4ZA
M ,4+6N5'-W"=81R(&:72G.G[Q^-7C6+LB]%[+D5@47GXW6L'0CT;99IC55 V
M#SXUYH]^^F_F6Q9)BT9PU*<Z<O;/D!I\U._*H;#*SH]RW[&I9WU(*] Z^!3U
M R'*C]3H_SR4-WQB)!3'3SO]-&"1W9J&W] 5D:(LJ>25X,,HMA]E)Y$!+8GR
MH2]("@%)<:JQ4P'(9ZFRRB#8#\;7RG_DK_>2#@F/46M&#KUM[@DA"QU)<Q9U
MJ^1\#^7QQ0I-R8N24O\@=:&ZE>6'D2RH;SDJW)4MQL)8=KJT(B/W,!V]3U3%
M0N@NY2N"F=%L#A=1^$4P\\D WA&Y_5(VS;2&_6!4I2%UTG(W$/Q[F?>H1A^X
M^\ ?*68Z5#O RM[K>"FS&0\%T^C<VI87W?*:+8QVPRCS1JU7KEM&N]PQ++-L
M=*QVM=84-4NT5B#ARS7)%O>\G1Y"&9:C1X-\S$YID*0Z3\Y42$&0IE7==WZ@
MI-JP%T>QM$9G/2:DHO1DOR^E$9"K!H$B4>S!CUT[@:X#_YZ^[@7^0%TWCZU(
M(?6%'=, 50.(=*T?2#?$]R2BI2?8<:(@TD(L9'TGDU%* S2,A!S8J<E8<$,I
MT?,\,3ED#U39NX]I#>=;H,0<\J0]\NZ59Z,H&VD,*UJH/42OESA1JI9DFT0E
MU8KKV?%&Q<S6CM\\X=!W'KU*HCI9SQ&+5[+FTNY9(HBX%!O].O1#U<FDGO:6
M8ON3.U*"'\:A?!Q)*J;>08+FJ@LJQS5AGDF'"7TW3B3K*Z%-.N=P*,@,2FLA
MTW/ODEY!X9$EDIF)[O2<1B2LON>0M6127T<A]7OE-\Y4ARI!I:(KA'03%E8H
M;:BD!R95FW006WJ#U'/56$D;]*4X<3R%4$K'\(/\9_5 9H[O_>%-WD^>\>=$
MF*LN'3H[_S)S.);T%^0!60\^^5C">\/VW\8<D7M+2>=3K5\MJ><OR+Y^&CC%
M4V69'@3A9)HF55M4.#5KKSIBC_JM1VZ#FX0#TC,-9STEVQ?A* *@KJ*ZL0SA
M WG32"U3OWF^ *D#)]_M4:NPZ$&XU.$&U$C]<$V,KI4B(D42QMW_DZTD30#_
MP:?-Q1^>\N=5X!PNX"G_-Q5$S\I@K,ZI^]3H68$?W_6303AZC#-1"),G3GT9
M"#(GI"/DO,A4&:<TES(Z<X52#TQC4X>*/>V$3D4M:HLV;Q1?/D-S7XJ&TFAS
MMNLYJ8\N/6LOD@&LFKUY4FAYY70Q'Y_K4N,.]+(/JU.7&DM^2"/64BU"K3\>
M:"1A&HA">O_4GD-!CI.2TLC,T+53?8!&+5VM?*BI;^6P]D*Q.#R:&M+C5Y'-
MFKQ)/HN&^(Q.F6B2J5EW::"2*$?^,Y1?K#;TU\N;F$WK>.+W?WJ.!IGFW E(
MUW$W%/^)J02G,B(/;ZA(GUW?^KY:("PH^!W*@"N(TQ":"B/LHVCRYEL9?Q@J
MN+"=^U$;)<&93*-),G!43DJ:QO/S 177$JXK$W5HY(T_IRE ZO,HJ2A)_+%\
MU^7#4'P8_?&1I<E!U6JZ.?&+ZT>2BY,A,Y\DM# R4L.PO7 83H^DKN_:*X_"
MS<5%693"J$Y[YPL2PV3+;Z1)WU;"E<;;9* P-5+&55+I5+/)5&LK@>D*3A6E
M^63DK_V>I-TH7B-MO*:)6*%?G'D4>2J-RBY=[FVF)HO:9V-);9G;T!?0SD2S
MGGGLB^@&,0\>I3=EE!;&T%T_=7!LA\QAY),%Y;8_5/:5+I<WLM/!T/4?E82F
MA'7ZGU@B.@K6Z).,L8Z4KR1ER-X]$>I[9<(=&9UQF50D/:5  HO7(&[8)Y\N
MG Y4S+ESBJA*Y&U?1V2FCOE0=M]K===5^I(O?O!%\8:S4-+Q5PXB-@UJQ/9+
M(<R3DX@_M:K5$CUB/FI)"B\;UU)%I,Y&94S2VM*B)([)D]:2CA G:7ME]80^
MC7L)9^4$X[WR0.13AO+"D:B&4^!?BDV*UZQ^=";/%3]2OT3]9'R<). E;N<Y
M#VW^'PJJ0^75!K$KPL6%&V&"6,;P]%@W#M4\EJJ7?/FH;K+BJA+D,<4J33$I
MN3],'":9B9B2"X]&3M^1C?70]UE(G3KL.6(TZ4\=+4A=KB2$OZ-1DLP>C(NF
MO@IG*Z,JH7*<O.E+Q_%=VECTDT--$7-W0I;DC)1T"BF(F'1^!<ZF!E'2/O2P
M03B"8$\;*XU(J F\M.N'#FD,'HQ>/K[;CP,%'-1]E7DO;FYNBEDN11MD%:+^
MZ]GC*YB5QL;-RE:>NKIG_$S^_7Y.!=16F0K(IK%U]^O)(:VWEG;LGV^PN<&T
MWD*,[7CYV93IC$+EI$]TWNC\K]?LVX\$E&=R=G/Z[;9S>_SKT?DOI]>W9^>W
M)V?71[]<G9Y^.SV_N;[]Z^SFU]NCX^.#3\>3F1[I$9TX(;\+1&K<E'V16?.Q
M%REK1BY#^E':9'G#ES'1I%LMUP_E1-&*P8=LP*;^H.B<?JOD4I6L$M!"ERS0
M)4<[( E9:Y.CV^.+\YNKBZ_7MY=7%\>G)W]<G5Z3 J$[ M]-@/.EG%*S206$
MV]$!BSS%78E[HM_8,W5^+EMK3_3;7S(Q@$(,&?_8D\I:TY4=3BK[CJN%4&I>
MENZXDK%-,AR,&B\;C7<B";*-AIU^2D.2:V'%Z?S&Z8\TJ>?(4NL]C$ZM7E(!
M$AD@&0N^DS<<3%]V\/[]9,V)+4(:7^F2$T\5-UE"YDT2>=)PS4Y#M;1FDPFZ
M0 S]($H7LCP(UG-DSE @HZ2!$Z4!G+QPIK#.9*:O-)Y)IC_#>$!BE@B_E$[!
MR*>G64+I&R.2:YHF%3*9=^FHV#+]]?KT^/^%HU!1+LOQ94"6I!11"56FQG3]
M9&QNI7EJ<JY;92@-!K&<PDYG)60H1QV(_'%IUZ<GS>4OPX ^.T,RX>('B4:A
M$[_7<RR5@&5/_3Z9ODQ_3V0E.0!=1&\KJ1PNF6V1!-]448HP)9@(580=B#L>
MI+/UJ50F/2U\-MUQ7Z:2_DKSS^1<G92H'\NI(B;&F2BEJ>X4QM0%[E7#J&8>
M!_-#'D2.;' EWC02WY+XTB$YSDOP9/9=^F4RN-0SQK-*H^)L13\L'FKOGRRM
M9+.I\\*S1P5.AA05Z%X$25H/#;DP'8(5-K-P=2*3].Y0+%&ITKHMGO:/=+UK
M.J27;%"5\3')('EIP>G+(VFQPZ&+G?TV[NFD!J^4[*30QNG#J?%E%R3EJ? C
MN5(.BGVWPDJI3L:[E/*%9Z6UO^G32!P*ZG06]<8SSZJ4E"5,,N="1\8>4O6*
M4#I<3M@?!6HCTZX^VZ1]DY2%]+%IGV-RZ$SUVF#4J*I,RO1(/BAMSM30?LZ@
MRR$_,^)[[RL3.;[VR@0ZIZ9UQM*GI%BN[ []9!$Y#VGH*,8[,3%I>F*Z*:-:
MD[[H-:-DW2%]Q2=:;E&J3M*R/](*#.-@Z(=I[*R6EJL"*#T^FWUR1WHU4+"5
MKA,*D/-)&)VJ"\6WC[Q'%CZ&]#ZUM/U)6Y6HFZ1Y!:Q/-O:!(LEQRY14&H'C
MR>PPZC53B8[3%B--L*..DC1*XDJ-A6&1N2(GR7("\BCD/&*28RUE%*C4[Z0O
M.>%4HZ1)*G2%O))D&?#85CFF*DU;W2&S&Z3S)2+27BK1S0W]$GUE\33)?RKE
MU)(IH..2/^DNLZ9*ON5>3BBI7B3]C2?+_&4BO[+!8[WY?/,F,PFCWN5[:EYH
M01<;9RKZ*K.''CJVF7./3-\FA^A 1'OOX?SQ!O=E2Z[+@[*4,DE8>;WS%GW>
MJY'O7%KEO;RC0QR.1I-%JD].WR3*8=S-5GH/C6%Z3#=1IP=/3=UHTPBUB8U2
MH'>!<NV_!!0G/?C!]]*!FN0:.3UJ0HB&?R34T+J6EL%7:[$N@CON.7_S<9JL
MO/B&>KG]0"-)W14JD;Y3R6^]T0O>S[A/I)FG?=J'IQY-Z<6V*ZTHAP<^E5F]
MSY[-%&LMBC=S,\E5)M,UI>-7ZP+D (^&6X_N)$U#_DL@S2#U,C4>E4Y6SO5H
M-E5:6]5KI&FDH9EX2:DZ?QQG:_OS-ZS805=<I8<IK1<Y-##TVS'TYS4P])Y0
MZ,^W%U>W9^=?+JZ^'=V<79P??+I0J__.)D1LZ]-/,VEIF]SD;L6LY6D**!=4
MT2?2C%TA\9L3CK8#LIG4P0[9:?(-I&)+TEU*X_28-(Z1JC3Q?97&G?"(!,ND
M&3RRM[%VI6JH+PSC(TO:/TG/K8R2>>A97ZALK%W^_:7\\&6;79N=!"^F<]B:
MI32/[>R.FO(S!51>^)UBCLM^Y:0B(_(D8E7KHJ3/-%[8Q,/$2>L[HL<^2U=2
M.J@7J><[N^)YCOA\4QG]AIF\?!.MNX'TE6S>NM]),X;1T3]GYO6V?GN.5R;V
M4MF2RZ.KF]NSL[.#3_*OI,+T,;=.U3-C00^):.Y5K;=,X.T-OTNWRJC>GIQ=
MG1[?7%Q=WY[^Z_3XCYNS/T]OOYP=G](7QQ=7EQ=R CQ-R"ZQTS&N28U6,EEQ
M[),G(=$$^T4&2YY**-ZB-Z:-6W"V:+YY-/_D2)=IE*0L@TD^ N=JXD=R=$>U
MI=ROZ7&"F],):SD?/877IF"[;/(Q<)]B-_3_Z]':>J-^E")5+]UO0STI2>XU
M#7:4[+3R30@5:$M:)'.BDQ1OM6):OO12E>QZ5+)2NBFGY$!JF>IX=CTIK*2]
M<C8Z2!9#&V8U&4HVF3*F[-KTU)TL2\^1VY,PN8\(2V;^%TSW3>8'^X)+#1N.
MO-+Y_E@:>:*C*]RT^A)+C3ORDXNFQ7@U,X_P>;0JX62R*N&9#C]^J+P@??")
M(-\P69V3;GN2ZI;F._X^A3WAS(V)_SYZ_,B'EWTJD#LIR'T.*CDG <A(6\-H
M&?G/2#.,*5-U?/'M\O3\.F4"$WT@HRCAA5L' ]J8HJ=@8+$YFLR23F9>K*FF
MFM,_TXIGLDYE$7](TYC"T<9>D1-)FS"GJ:<E,])\J4U\8FZ@Z*#HGE5T9@$4
MG7E[37KNZNSFW[<7?YV32_[KV>4MN>8W1V?GMY]/ST^_''Q*_<)'=C&].]UQ
MNIXMV2Q%S5LDORLG8Y)JHSY>I?L83'F =(G:Q0"J<X'J#$=-/K,AX&@)87?2
MY/ZDR:?R>C:E8I]HV/4ZPBN:>!/I"WLA;\6YS:KQSE9YRQ0-J,T996A5_GU;
MHGN3<819A%F<-XNU IC%VM@&7IU^59Z_-(S7R:?3D]N;JX-/([VG;)OT1TD?
MAC/6[D86,%DA'Y;217!)C"\73XNAQ!%%X5BK6L"1K0OF6G>\)])4ZR;;4(T:
MUYEJW*V%&]/"3<C72.R7,DU-9J3/P9J%J&@\W3G=)T93=?-T:,QR9K>(1WP#
M1;ZB(J\70)'7;R^OSLZ/SRZ/OLI5R1=_G-\<G=_<?CD]O:;(Y^K/L^.#3Y?C
M7-#)@F3V1:08_%KFHEK;6G:XYUIZDD;+)TW7&S5=F#;=MIS:Y02W8MRQYS/_
M9G6UF?\M3\3O?NK]SYF9]S_S:_J6G/_5P]AE8-X:.YA<W[U!:]R>_NO7L\]G
M-]>W7\[.C\BTD66[OJ&H1.Z_<7M]_*N<H^@[7;F;Y^PV&F.=-Y[#W>%:^FR\
MG7?\?=(;3GPK3A=:J7ED>2PG#]*3 "<K.==*/M.GVD9ED=C#/*5+WBRS ?8+
M"QQ3^^!9%;41G'1*5':KVL5LVOU(TE+''27-:DA7CXX271=D%XQ7IB1_R#R#
M#YEF\Z]CZY)B?>!QY']\@]V;,74=LU(SY!53.GG6%E8ZYDN_-RJMUO3OZ:G.
M"ZWL:LV=?GSA;.L,7;M_<M8/Y"Z./UV=7EY<W9R=GYQ>GM(_YS=7I[^<7=^<
M7IV>7/[Q^>O9L=I_:<8@J_?8<EL)Y6$G+SKXE'3CI*?XO=&8&&&(](<K<2='
M"(4!R>?+N.LZ5GK2\'BQ:?+YBQ,,QF:7/V=ZTW/1-RT<;933_,GCKU1^RO,.
M9"E>=[SWJ#6^E(T%A[ 79[@>7\A!>GUZ(K<YNK[X>G:B&/+GHZ_DOIW>7O]Z
M>GISO=QX/9ZV>)^YJQ8-7_>%D,8=H^Z%43?7NW(^Y&I%'W*3@3:.CJYO+RY/
MKY+IG#>,M^M9OW)\' )&'D;>U,BK8^0M&'G'1]>_WG[Y>O'7^B/OF(=]]H6"
M-8P\C+SID=? R%LT\B[._SRE</'SU]/;RRN9T+?F^)M>QI%N(Y^>D(#QB/$X
M-1Z;A1Z/YQ<WI]>W-Q>WS\1_(WS_AO%X[D?)67V+*2\&(0;A>!"V%@S"S9[9
MM+'U_6_;8RF;*19SX13+9&8M9W,MH1@?JAQ.G83NJZW [/%N>U.'V-A/MQ(>
M;QHR.OIYX81-()=XBC YBE9N,!Q,/_Q1S<_(1:!\.'0=2TUG)/>,W_MB)KG>
MVWC5*FPT=[O?FW,=J4DUZ2R*T5RT/%-U/*^6;I6;5E9E/OY@SF @;+G7L_LH
MM\RTQ'B-K-SNA*MCM&4NRW@NCB=S<<%X)U>U,8Q1+?^^]$+7_*:'X&#&1>DA
M%!2-UD?GYXC&Y,@XND_NMO#[[;7:*/[QA3:?2"5I KGG53)NKO_X]NWHZM\Y
M/F8EPRWUM-QD9T_2&HV=;FB4A6YZQ?+G/DGD270Z:P#;E4[SOS^FA1JUA0J(
M6;72:@PC-O*3MP,3YK6Z;,3V,L-@S?ZP<G?0MT;GL4R,>L'>SLJ\6C'-EV6N
M7COD<E?RC\\&]<NF,K^AW9XTW'*)'[.5K+4K]3?U[-W4<$<]XT3M4JUVCURE
M\0K10QH5HU[X#B*]VUWU#$W[@6%4C#8Z@CQ#Z]RO0$W,>4@UJ(G49TI:[]Q'
M)WFJ0UJ5-GK)%[F?\AT[X9& ,SJK0UKH'=+"V(<;V*18XRK&@>>$?6'GNI:_
MBD#(C1F6S4)XB3C(VNX0-ZC&:;X^BI_34[J5ZDF4B]9<JU2S$>&2C;F]H9VW
MYGT2:*%]-URJV4@%NF"]SCKKT:,UU^R:+4T;<^RXC-[:3QPJ@RQK8SC*57C=
MH=E.T;.9SS4KAA;];?7)ME6<IFWE::IYN@SG=,>9LOTH&GXX/'QX>*B$PJK<
M^?>'1X'5EX>?'@K[C@>'-H_XH6$VJYU.]9 &H&%T:H;9,,RZ4>NT:X=VW:Q6
MS9HM?IA&I1\-EDNI/0IE0M)E3._BH6!'=X%(DOB2)-OD3*1K>:BN.BW ;,O3
M @R3=47T()/?9&92LC8ZX.D^M]?TYW<^/H11ODVF!U;^\9-IUC^RH.)67D_/
MS47G37S47;E(V>B?=OGWW0706Y+3HJZU=Y5(/7:]:K'IWD9ZK]RH-NJ=8LDV
MB1;TJH1NCDS6[?'6J$6O6FQ:JA=6Y$\V AKO V28Q9)U$E/I7XGG(BRSTLH\
MOLI;G+VMT":7C;7(E<Z^5'JVU4)/,/MBZ=E8BURK[$NE9ULM]%BR+Y:>C;7(
MY.^6DA:2AIK_L^?]9OMNP7Y1SFJ]V>@8G:I1,QOF(3<ZY4:G5;LUQ _37@5T
MCLFF9)27+E<'4'P3P9T(T@-+_.".>\[?ZK92"D"_J>/@U5'T1J<DUTW*:_G
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M.XPBZP8!@]M'!H=<N36,.G+ELJ_%IJ5Z%-_%890>/ENX48MDN>)&A@!_ '\
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M7JQ@MQ  DI11N5%MU L',@K!'PULYYA]+38MUV2*SU [G)C58@D8 ++($2H
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M]5#S)CVRV[KFD&[87<Z;Y+Z(;A#SX)$9ZLP8,W]BW"VEVP/7/F^1&D <0!Q
M7-:E H@#B .(RQ.(:VC1<9#0M].$/K/9:+:F(5UG]87>U\** R=RJ+:7,;U8
M;DHU3N^;WD[*Z"1I Z5Q:E_4%VQR\*4B=?*K8?J8(&0A"91'/D4LBM%%OFZ
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MS/$L-Y9:E=DBXHY+%]+U89Z')N"R+I4 7-:F$H#+NE0"<%F;2@ N RYOH%2
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M/=V6$OC+C)&7)JIJV&4SI_L>=IH#LJ6$!T0C3A(N$,T&,@,^$/,8%E2.6$&
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M99+SW#67A:@M<OD2?>V4RT)44[9^[30;[/TQ(Q[$^NEIM]4'N9;7F!'J;X8
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M3_8<+:QC>*LA"$UY"?"7@'UX1VSV.@5$."K]!OWM./W:,?WH^.S\^-W9VY?
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MIV]/3]\<+7U,?)@MO[Z!>1P%P!%9QA%P(,?R:K[0H!-Z":]=1NC7-P&:+>*
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MJ %!Z6K;#+\!!$/$\6M6Z\TQ,5]GM59%OY%ED^\%D*$Q #=QFVC(=G?(<!J
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MNR3!;E9TA^NXK=5;N.$SSP'L1J#6$_+?+$?\/"%%4VWO]3"[?B-<CZ>7U(5
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M#%0*Q+NQWO,7Y(P\+Z+74-L^@B=NO1V69"3M='BC5UCF&V;\CU9P7*<6$PC
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M?F*(FO%N)>PN9=K=R<0.]!'G;L==C2^Z*[]&R+\W,/*(])ZP3&GY[>JFO=H
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MC;#_BW=E;R4;8/;6BU.;G76K#30F1X'A"!@6$QBWJ;.C&R,^I8]1;%5[N(.
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M/>2L33PRTC8HSJTZK! AY(K-_4DNRE:[AHP^$HZ&U4TR2$B0[$19]0Q0 ##
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M%XD8>1@&WJ5Y.J 68%I6YLQHHT+)JUXEAXO<S(5BT2<[.65K JO&ONW?'QE
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M07>2T9#!@4PY]9SP"P^<[OB+Y8_1H]76L?V[;A&SC5:(EX(E%\39S#\A]0)
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M(']+=9 O\\B,[=>>L.L#+TM&81[BJ>)..R$%M]7&LH#%6KTL )8*[6P!=!0
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M_OX:]X8%HL,5O+;AO8H.ZP>\_O4JI3D6W:+83_=I]&C9LG*0CN/!X0#=(&?
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M\14:<35LWYE%[3O7(Y)N\W^SL ANO=_I0O'UE('=I]1S]ZCQ,8K?IX$PTT
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M%;.LBE=R%Y!G+6ZM,62,!+PZ&WR5(9Y3)-F5?.A8-2FY\!WGA2B^R='KS((
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M9%R\4P>Q-@_9.3I<'V'PCQL?$)=#@"5OV"NJY<Q,24-,3QK2_1KJ\%EF4'>
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MCHJ$U>(J^8;\CU3\^]?_#U!+ P04    "  QBVM2WD#D?T<+  !->0  $P
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M-$0NU_L6FOJ,(G^@CJ6J@Z:)N*9[2)J5]+\?U'F$1N>[JWD PW2H?<QW"&B
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MX6<_7'NNM*9-X*#O5;D4>P -.'FE<SG#W:9J!D.D(UX&(*-'K@G3&OX7L$7
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MBI8*DYZY5=P<?EM$ OXI\1]DU/ 3>/B.DP^#L.TX^0/EY,<[3CY43OZK+ $
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MI'#9YUCT3>Q11SO.;VQ6,57.>7_]1"<_2BO/*2Y4V&12=&MYA5C"#6SJW+7
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M-FPU"?5CN@AO=<[A0UQ@V.?@!KSF4[0@V0[<ND4;DJFJUAB(U.:QK;8)U)&
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M-- IJSFVXMD]O,T2FU/EL=P5<K"EQ)P%+'0;&03$7DM,O$#2RUW[YJC,+(=
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M<, 4Y%O624CB'7LVYT:+N!:%F6WQK?XI+%HU7M*@X):+4T:]JB1LMF5 M]?
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MJC*(&E]SX3_]\'.O^W+/E=PI=Q0H]C!)(O%RR[T(_GW$N(5 $B2#))^)(\?
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M>OT^5J=B^?P%WT+WH_(?\>Y'Y3_\_3]02P,$%     @ ,8MK4G*8V]Z;"
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M,'\?JU,Y??Z"I\[CJ/HON\=1]>]\_P]02P,$%     @ ,8MK4@RRNV &!@
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MN"^+5$[QFG]M[G=PGE7+LAE\E&J*-IKP_HHB\&O"/A(74*'/&ROEL;%PR+
MTS-0.N+ZC>59:*8T+7(6"CF9/^<LBMKG5NYZB1VJ-&5YP?OMCP&&0622ON]A
M@E8<-'U$<-%P1KVL=I.:M.?L;*T-I@G"@TVL*36F&*G6'=!)LG\9..^5?"BU
MTOT7K#3J_HF8<H,993=6NF+V99=T;[@$ZZ[H!['.$K#W+8:T=H=$VNIU?P2-
M>*@TH^RL&>ZS\.-$JU)&]J(:#Z*2[PQ=HMZ]V^>/--2O.?,.EWS6?;BT,=GB
M#LTRK_J'-'BBM<=>7*;I#(_'+$_IW)F?19I_*H7F&<)G<;U6H2(&CSA_:SW:
MF*/YU<DU/[4:2/=?]S8'=)[=]"5^:/H@),5O!-D'J6F>P/V[B/@G</^?@7OW
M"=S_/7 7DG2HEM+5QS AL207]>6A17XF-$)_KGE!(-^A:9:F@,OPYH+W'IS(
M$?6+3K4J%I+)D,9QPZAJK56W%*0JT_J,4'CE8?5-]_HMXI:KOQ_L_QJX;T*T
M;D58JP'_=I>&CTU!7NG:#IQ5D4PC]79;B(&;:X-&[M98A4I%!)[S:BO'*Q0%
M<\XTRCFPEC)P\S@7XKK%:6"UX+ZT]IO;CK_]S]I?9<2#:;[J1H9;N)^[SR\8
MUJV#:Y41]K@CA^1^[&%SBA@M2)(*L.]J_#Q%T?)1](B"9/U4"SS?<SS@;\7&
MQJW86.G1_3!=X0.L<Z(^O&<Z3,"OV[(W7RE]YYWUAS4@%9I(Q"<*,Z3I$XNP
M+CI% 0&GX;C44A0)5I^(LASK3:. A6%=%RZ6H_=J+R-\X<Y2F7;WJH%.'7=<
MGJN"7^]5[-RS/U$WKK.J57^-"\H24#6-=7A.I3@R"V98\L8<BZJ09D@=5 0%
M(7EN-L^G"<=GC35UA!4F)VM1[X3%]*+G1B._@_M.F(Y27E1:T+83+K&D3A<D
M(+U2E+]D$V(/18G16W-W8 \*Q#044FF!,8,+*X%0F2EJ;SB2TULD:NJT#9Y*
MH<7^?,+(=4B::W4AZ-T%JKB@5&6>J<"+0D!=HN9J$<QNT5QYOMG@/J\W- B\
M2Z"4<0QECB,D)B^,\_DTH:2HXOYVVJPF,X=N\[I^Z#;_+>!O4$L#!!0    (
M #&+:U+E=U'5$08  $0A   1    ;VYC="UE>#,R,E\Q-BYH=&WM6GM/&T<0
M_S]2O\/D(B*0?"\;"-@.$C$D14T @6E5J5*U=[?G6^5N][JWAW$_?6?N80R$
M!B<T)!2$;-_N[,[[M[-C#Y_O'8W&OQ_OP\_C#^_A^.S-^X,16+;K_M8;N>[>
M>*^>6'<\'\::R4(8H21+77?_T (K,2;ON^YT.G6F/4?IB3L^<1.3I>MNJE3!
MG<A$ULY/SX8T5KUS%M&[$2;E^$')T-C\HM?M_NEO.DB%<VX[.71;\N>V#8?O
M8*3D.=>&:SC?<#RGZVQX8-M$$*AHAN_/ACD49I;RUU;&]$1(.U#&J*SOY6;0
MC!B55X^&7QA;R(A+T_=6!K&2QHY9)M)9?RPR7L AG\*)RIBLYPKQ-^_[/JZT
M=E[*H,@'0S??6>!8;<A2,9%]+2;)G.%R(DPYK>T'*HT6^7:1_/,BDB!]J73&
MTGIS0SZ+<0!'):^ISID6##E"0VCM[%\D(A &>EVG>[M2(8K)]8^CU6C_9'SP
M]F"T.SXX.GP\:AV7NBAQ"(R"4QY2/L*VMPDJ!I-P.&4Z8)(7]M%%RF>P&QJ:
MZ7K>(_+LZFD9%+7J!:RR-6 R@M5@C31M3>+W-KP.C!*6$UYL]FAN3, "_E8'
MSJ0P/()3PPR*-5(17[MFGF^/'TMQ?.5L;J\L;?#&68TAO\H'!Q)")65C[:DP
M215^NU*6+(43GBN-D2?A+2X W[-_(0<<(=QSC><'C!.N6<Y+(\*B P<R=&"5
MUK]\L=7M>H.1RG(F9]63/U@#%*?:/N=:J @X&B&"/1[R+$#O]OP.1G@7_<T*
MB$6*<W.!,!Y*C:<6&H.B9/\B3)B<</1YEHFB(.'QGR@CC 5 L3@*NBA+K4LK
M"@K;@1.!N^@(WCGPJY"4/A7K42)X#&^%9#(4J.11'(L0Y6M2LU&J SAF1(P?
M\H5<]K?@S#EU1LZU$,9]6:1R"M?\2U._@_.L6I;-X*-44S31A/?O*0"_).HC
M<0X5^+RV4AX;"X<,"S [ Z4CKE];GH5F2M,B9Z&0D_ESSJ*H?6[EKI?8H4I3
MEA>\WWX88!1$)NG['N9GQ4'32P3G#6?4RVHWJ4E[SM;&RF":(#K8Q)HR8XJ!
M:MV"G"3[YW'S3KF'4BO=?\%*H^Z>ARDWF%!V8Z5+9I]W2?>:2[#LBGX0ZRR!
M>E]C2&MG2*2M7G<'T(B'2C/*SIKA&Q9^G&A5RLA>5.-!5/*=H4O4.[?[_)&&
M^A5GWN*23[H/ES8F6]RA6>95?TB#!UI[ZL5EFL[P=,SRE(Z=^5&D^5^ET#Q#
M^"RNEBI4P^ )YV^L1FMS-+\\N.:'5@/I_G9O?4#'V75?XHNF%T)2?$>0?9"2
MY@G<OXN(?P+W_QFX=Y_ _;\#=R%)AVHIW7P,$Q)+<E'?'5KD9T(C].>:%P3R
M'9IF:0JX#"\N>"/ B1Q1O^A4J^+Y30$WC*K66G5)0:HRK<\(A3<>5E]TK]XB
M;KCZ^\'^+X'[)D3K3H1U/^#?[M+PL2G(*UW;@9,JDFFDWFX#,7!]9=#(W1JK
M4*F(P'->;>1XA:)@SIE&.0?64@9N'N="7+4X#=PON"^M_?JFXV_^N_:7&?%@
MFM]W'\,MW$]<YQ?LZM:Q=9\!]K@#A^1^[%%S6Z?G*6Z6CYM'%!:KQQKQ0^08
M$3=B8^U&;-SK6?TP7> ]+&RB/GQ@.DS K]NP_H_527]8 U)EB41\HC!#FL:P
M".LJ4Q00<!J.2RU%D6"YB;C*L< T"E@8UH7@8OUYIWXR%IBXLU2FW;UJF%.'
M'9?GJN!7FQ-;=VQ(U)WJK&K-7^&"L@14/F/AG5/MC<R"&=:X,<<J*J094@<5
M04%(GNO=\FG"\5EC$1UA2<G)6M0L83%]L7.M<=_!?2=XE*>\J+2@;2=<8@V=
M+DA >J4H?\DFQ!Z*$J.WYN[ +A2(:2BDT@)C!A=6 J$R4]3><"2G;XVHB]-V
M="J%%AOR"2/7(6FNU;F@[RI0Q06E*O-,!=X, FH+-7>)8':#YM+SS09W^3I#
M@\#+ TH9QU#F.$)B\L(XGTX32HHJ[F^FS7>4F5O?.#'/3NV]H]'I'[ZWO?T*
MP[OG^#6 -S\U&+K-;QK^ 5!+ 0(4 Q0    ( #"+:U(PQJX"^O,  )-] 0 6
M              "  0    !G96YZ97)A9F)U9&PP,# P,#$N:G!G4$L! A0#
M%     @ ,(MK4NN;D6L>A ( G+<# !8              ( !+O0  &=E;GIE
M<F%F8G5D;# P,# P,BYJ<&=02P$"% ,4    "  PBVM2IW><RTBF  "Q 0$
M%@              @ & > , 9V5N>F5R869B=61L,# P,# S+FIP9U!+ 0(4
M Q0    ( #"+:U)[:4-LMZH  *?Q   6              "  ?P>! !G96YZ
M97)A9F)U9&PP,# P,#0N:G!G4$L! A0#%     @ ,(MK4D0YJ>\C3   Y&$
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M96YZ97)A9F)U9&PP,# P,3 N:G!G4$L! A0#%     @ ,(MK4C2:=B%1?
MI<H  !8              ( !E'L' &=E;GIE<F%F8G5D;# P,# Q,2YJ<&=0
M2P$"% ,4    "  PBVM2(CXK+,J9  !SPP  %@              @ $9^ <
M9V5N>F5R869B=61L,# P,#$R+FIP9U!+ 0(4 Q0    ( #"+:U*\.#^2UI(
M -*V   6              "  1>2" !G96YZ97)A9F)U9&PP,# P,3,N:G!G
M4$L! A0#%     @ ,(MK4O2Y%4ZU"00 H/ O !4              ( !(24)
M &]N8W0M,3!K7S(P,C Q,C,Q+FAT;5!+ 0(4 Q0    ( #&+:U)76NEG4Q<
M )/X   1              "  0DO#0!O;F-T+3(P,C Q,C,Q+GAS9%!+ 0(4
M Q0    ( #&+:U+$]^^*<0L   &9   5              "  8M&#0!O;F-T
M+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  QBVM2"\9?C:,H  !5H0(
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M>#$P,31?-#DV+FAT;5!+ 0(4 Q0    ( #&+:U(!CLL)^BX  +I8 0 3
M          "  ;DU#@!O;F-T+65X,3 S-U\U-S@N:'1M4$L! A0#%     @
M,8MK4H1-_48U P  !0X  !(              ( !Y&0. &]N8W0M97@R,S%?
M.#(V+FAT;5!+ 0(4 Q0    ( #&+:U)U%8Y'J @  &%8   0
M  "  4EH#@!O;F-T+65X,S$Q7S<N:'1M4$L! A0#%     @ ,8MK4G*8V]Z;
M"   /U@  !$              ( !'W$. &]N8W0M97@S,3)?,34N:'1M4$L!
M A0#%     @ ,8MK4@RRNV &!@  AR   !               ( !Z7D. &]N
M8W0M97@S,C%?."YH=&U02P$"% ,4    "  QBVM2Y7=1U1$&  !$(0  $0
M            @ $=@ X ;VYC="UE>#,R,E\Q-BYH=&U02P4&     !H &@"^
)!@  788.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
